Authors^Author full names^Author(s) ID^Title^Year^Source title^Volume^Issue^Art. No.^Page start^Page end^Page count^Cited by^DOI^Link^Affiliations^Authors with affiliations^Abstract^Author Keywords^Index Keywords^Molecular Sequence Numbers^Chemicals/CAS^Tradenames^Manufacturers^Funding Details^Funding Texts^References^Correspondence Address^Editors^Publisher^Sponsors^Conference name^Conference date^Conference location^Conference code^ISSN^ISBN^CODEN^PubMed ID^Language of Original Document^Abbreviated Source Title^Document Type^Publication Stage^Open Access^Source^EID
Xia Y.; Peng S.; Lin M.; Duan H.; Yuan F.; Shao M.; Tan W.; Luo H.^Xia, Yuan (58339820300); Peng, Shuai (57222312400); Lin, Mengjuan (57189383265); Duan, Houyu (57211590548); Yuan, Fangting (57219728258); Shao, Ming (57800815600); Tan, Wei (57199664684); Luo, Hesheng (24348352500)^58339820300; 57222312400; 57189383265; 57211590548; 57219728258; 57800815600; 57199664684; 24348352500^Apigenin attenuates visceral hypersensitivity in water avoidance stress rats by modulating the microbiota-gut-brain axis and inhibiting mast cell activation^2023^Biomedicine and Pharmacotherapy^167.0^^115562^^^^4^10.1016/j.biopha.2023.115562^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173045062&doi=10.1016%2fj.biopha.2023.115562&partnerID=40&md5=08240467a5d1ce830eda98163fd4b410^Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China^Xia Y., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Peng S., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Lin M., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Duan H., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Yuan F., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Shao M., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Tan W., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China; Luo H., Department of Gastroenterology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China, Key Laboratory of Hubei Province for Digestive System Diseases, Renmin Hospital of Wuhan University, Hubei Province, Wuhan, China^Visceral hypersensitivity (VH) and gut microbiota dysbiosis significantly contribute to the occurrence and development of irritable bowel syndrome (IBS), exacerbated by stress. Apigenin, a natural flavonoid derived from plants, possesses a range of beneficial properties. However, additional research is necessary to investigate its potential in alleviating symptoms of IBS and elucidating its underlying mechanisms of action. Our study confirms that apigenin effectively reverses mast cell and microglial activation, regulates the composition and abundance of the gut microbiota, improves intestinal barrier function in rats induced with water-avoidance stress, and mitigates VH and colonic hypermotility. Furthermore, in vitro studies suggest a potential role of dysbiotic gut microbiota in activating mast cells at the cellular level. Notably, apigenin inhibits mast cell degranulation through the toll-like receptor 4 (TLR4) / myeloid differentiation primary response gene 88 (MyD88) / nuclear factor-kappa B (NF-κB) pathway. In conclusion, this study discusses the potential therapeutic effects of apigenin in alleviating VH and modulating the gut-brain axis in water-avoidance stress rats, providing a novel or alternative treatment approach for IBS. © 2023 The Authors^Apigenin; Gut-brain axis; Irritable bowel syndrome; Mast cell; Toll-like receptors; Visceral hypersensitivity^Animals; Apigenin; Brain-Gut Axis; Irritable Bowel Syndrome; Mast Cells; Rats; Water; anesthetic agent; apigenin; beta n acetylhexosaminidase; immunoglobulin enhancer binding protein; myeloid differentiation factor 88; occludin; protein ZO1; toll like receptor 4; water; apigenin; water; abdominal reflex; abdominal wall musculature; Actinobacteria; anesthesia; animal cell; animal experiment; animal model; animal tissue; Article; Bifidobacterium; brain tissue; brain-gut axis; cell activation; cell viability; clinical feature; colon tissue; comparative study; controlled study; diarrhea; Enterococcus; enzyme linked immunosorbent assay; Escherichia; Firmicutes; immunofluorescence; in vitro study; intestinal dysmotility; intestine function; irritable colon; limit of quantitation; Limosilactobacillus; male; mast cell; mast cell degranulation; microbial diversity; microglia; nonhuman; operational taxonomic unit; pathogenesis; physiological stress; prophylaxis; Proteobacteria; rat; rat model; RBL-2H3 cell line; Shigella; signal transduction; Sprague Dawley rat; Streptococcus; visceral hyperalgesia; water avoidance stress; Western blotting; withdrawal reflex; animal; brain-gut axis; irritable colon; mast cell; metabolism^^apigenin, 520-36-5; beta n acetylhexosaminidase, 37211-57-7, 9012-33-3, 9027-52-5; occludin, 176304-61-3; toll like receptor 4, 203811-83-0; water, 7732-18-5; Apigenin, ; Water, ^^^National Natural Science Foundation of China, NSFC, (82000505)^This work was supported by the National Natural Science Foundation of China [NSFC: 82000505 ]. ^Melchior C., Colomier E., Trindade I.A., Khadija M., Hreinsson J.P., Tornblom H., Simren M., Irritable bowel syndrome: factors of importance for disease-specific quality of life, United European, Gastroenterol. J., 10, 7, pp. 754-764, (2022); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M., Rajilic-Stojanovic M., Schemann M., Schwille-Kiuntke J., Simren M., Zipfel S., Spiller R.C., Irritable bowel syndrome, Nat. Rev. Dis. Prim., 2, (2016); Uranga J.A., Martinez V., Abalo R., Mast cell regulation and irritable bowel syndrome: effects of food components with potential nutraceutical use, Molecules, 25, 18, (2020); Li Y.J., Li J., Dai C., The role of intestinal microbiota and mast cell in a rat model of visceral hypersensitivity, J. Neurogastroenterol. Motil., 26, 4, pp. 529-538, (2020); Sundin J., Nordlander S., Eutamene H., Alquier-Bacquie V., Cartier C., Theodorou V., Le Neve B., Tornblom H., Simren M., Ohman L., Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome, Neurogastroenterol. Motil., 31, 11, (2019); Barreau F., Salvador-Cartier C., Houdeau E., Bueno L., Fioramonti J., Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats, Gut, 57, 5, pp. 582-590, (2008); Guilarte M., Santos J., de Torres I., Alonso C., Vicario M., Ramos L., Martinez C., Casellas F., Saperas E., Malagelada J.R., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, 2, pp. 203-209, (2007); Guilarte M., Vicario M., Martinez C., de Torres I., Lobo B., Pigrau M., Gonzalez-Castro A., Rodino-Janeiro B.K., Salvo-Romero E., Fortea M., Pardo-Camacho C., Antolin M., Saperas E., Azpiroz F., Santos J., Alonso-Cotoner C., Peripheral corticotropin-releasing factor triggers jejunal mast cell activation and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 115, 12, pp. 2047-2059, (2020); Zhang J.D., Liu J., Zhu S.W., Fang Y., Wang B., Jia Q., Hao H.F., Kao J.Y., He Q.H., Song L.J., Liu F., Zhu B.L., Owyang C., Duan L.P., Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation, Acta Pharm. Sin., 42, 11, pp. 1821-1833, (2021); Shimbori C., De Palma G., Baerg L., Lu J., Verdu E.F., Reed D.E., Vanner S., Collins S.M., Bercik P., Gut bacteria interact directly with colonic mast cells in a humanized mouse model of IBS, Gut Microbes, 14, 1, (2022); Zhang L., Song J., Bai T., Wang R., Hou X., Sustained pain hypersensitivity in the stressed colon: role of mast cell-derived nerve growth factor-mediated enteric synaptic plasticity, Neurogastroenterol. Motil., 30, 9, (2018); Salehi B., Venditti A., Sharifi-Rad M., Kregiel D., Sharifi-Rad J., Durazzo A., Lucarini M., Santini A., Souto E.B., Novellino E., Antolak H., Azzini E., Setzer W.N., Martins N., The therapeutic potential of apigenin, Int J. Mol. Sci., 20, 6, (2019); Yao L., Fan Z., Han S., Sun N., Che H., Apigenin attenuates the allergic reactions by competitively binding to ER with estradiol, Front Pharm., 11, (2020); Shao H., Jing K., Mahmoud E., Huang H., Fang X., Yu C., apigenin sensitizes colon cancer cells to antitumor activity of ABT-263, Mol. Cancer Ther., 12, 12, pp. 2640-2650, (2013); Che D.N., Cho B.O., Shin J.Y., Kang H.J., Kim J.S., Oh H., Kim Y.S., Jang S.I., apigenin Inhibits IL-31 Cytokine in Human Mast Cell and Mouse Skin Tissues, Molecules, 24, 7, (2019); Grabauskas G., Wu X., Gao J., Li J.Y., Turgeon D.K., Owyang C., Prostaglandin E(2), produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice, Gastroenterology, 158, 8, pp. 2195-2207, (2020); Wang M., Firrman J., Zhang L., Arango-Argoty G., Tomasula P., Liu L., Xiao W., Yam K., Apigenin impacts the growth of the gut microbiota and alters the gene expression of enterococcus, Molecules, 22, 8, (2017); Yuan F., Tan W., Ren H., Yan L., Wang Y., Luo H., The effects of short-chain fatty acids on rat colonic hypermotility induced by water avoidance stress, Drug Des. Devel Ther., 14, pp. 4671-4684, (2020); Zhang T., Su J., Guo B., Wang K., Li X., Liang G., apigenin protects blood-brain barrier and ameliorates early brain injury by inhibiting TLR4-mediated inflammatory pathway in subarachnoid hemorrhage rats, Int Immunopharmacol., 28, 1, pp. 79-87, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N. Engl. J. Med, 376, 26, pp. 2566-2578, (2017); Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjorsvik B.R., Haleem N., Benitez-Paez A., Sanz Y., Hausken T., Lied G.A., Lundervold A., Berentsen B., Gut bless you: the microbiota-gut-brain axis in irritable bowel syndrome, World J. Gastroenterol., 28, 4, pp. 412-431, (2022); Spiller R., Impact of diet on symptoms of the irritable bowel syndrome, Nutrients, 13, 2, (2021); Xiao L., Liu Q., Luo M., Xiong L., Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome, Front Cell Infect. Microbiol, 11, (2021); Kim J.H., Jeun E.J., Hong C.P., Kim S.H., Jang M.S., Lee E.J., Moon S.J., Yun C.H., Im S.H., Jeong S.G., Park B.Y., Kim K.T., Seoh J.Y., Kim Y.K., Oh S.J., Ham J.S., Yang B.G., Jang M.H., Extracellular vesicle-derived protein from Bifidobacterium longum alleviates food allergy through mast cell suppression, J. Allergy Clin. Immunol., 137, 2, (2016); Garcia-Rodriguez K.M., Goenka A., Thomson D.D., Bahri R., Tontini C., Salcman B., Hernandez-Pando R., Bulfone-Paus S., Bacillus Calmette-Guerin-Induced Human Mast Cell Activation Relies on IL-33 Priming, Int J. Mol. Sci., 23, 14, (2022); Yue S.J., Liu J., Wang W.X., Wang A.T., Yang X.Y., Guan H.S., Wang C.Y., Yan D., Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis, Biomed. Pharm., 116, (2019); Zou Y.T., Zhou J., Zhu J.H., Wu C.Y., Shen H., Zhang W., Zhou S.S., Xu J.D., Mao Q., Zhang Y.Q., Long F., Li S.L., Gut Microbiota Mediates the Protective Effects of Traditional Chinese Medicine Formula Qiong-Yu-Gao against Cisplatin-Induced Acute Kidney Injury, Microbiol Spectr., 10, 3, (2022); Shang Q., Liu S., Liu H., Mahfuz S., Piao X., Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation, J. Anim. Sci. Biotechnol., 12, 1, (2021); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Reimund J.M., Ducrotte P., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am. J. Gastroenterol., 105, 5, pp. 1181-1188, (2010); Hou Q., Zhu S., Zhang C., Huang Y., Guo Y., Li P., Chen X., Wen Y., Han Q., Liu F., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice, Biomed. Pharm., 118, (2019); Lee K.J., Kim Y.B., Kim J.H., Kwon H.C., Kim D.K., Cho S.W., The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors, J. Gastroenterol. Hepatol., 23, 11, pp. 1689-1694, (2008); Pisipati S., Connor B.A., Riddle M.S., Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome, Curr. Opin. Infect. Dis., 33, 5, pp. 411-418, (2020); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, 7, pp. 923-929, (2008); Winston J.H., Xu G.Y., Sarna S.K., Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress, Gastroenterology, 138, 1, (2010); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study, Aliment Pharm. Ther., 45, 1, pp. 100-114, (2017); Imran M., Aslam Gondal T., Atif M., Shahbaz M., Batool Qaisarani T., Hanif Mughal M., Salehi B., Martorell M., Sharifi-Rad J., Apigenin as an anticancer agent, Phytother. Res, 34, 8, pp. 1812-1828, (2020); LoVerde D., Iweala O.I., Eginli A., Krishnaswamy G., Anaphylaxis, Chest, 153, 2, pp. 528-543, (2018); Folkerts J., Redegeld F., Folkerts G., Blokhuis B., van den Berg M.P.M., de Bruijn M.J.W., van IJcken W.F.J., Junt T., Tam S.Y., Galli S.J., Hendriks R.W., Standhouders R., Maurer M., Butyrate inhibits human mast cell activation via epigenetic regulation of FcepsilonRI-mediated signaling, Allergy, 75, 8, pp. 1966-1978, (2020); He-Yang J., Zhang W., Liu J., Xue P., Zhou X., Human breast milk oligosaccharides attenuate necrotizing enterocolitis in rats by suppressing mast cell accumulation, DPPI activity and TLR4 expression in ileum tissue, and regulating mitochondrial damage of Caco-2 cells, Int Immunopharmacol., 88, (2020)^W. Tan; Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China; email: tanwei_2000@163.com^^Elsevier Masson s.r.l.^^^^^^07533322^^BIPHE^37801900.0^English^Biomed. Pharmacother.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85173045062
Leite G.; de Freitas Germano J.; Morales W.; Weitsman S.; Barlow G.M.; Parodi G.; Pimentel M.L.; Villanueva-Millan M.J.; Sanchez M.; Ayyad S.; Rezaie A.; Mathur R.; Pimentel M.^Leite, Gabriela (57211561751); de Freitas Germano, Juliana (57194106499); Morales, Walter (57117524600); Weitsman, Stacy (56705105600); Barlow, Gillian M (55300614800); Parodi, Gonzalo (57211562499); Pimentel, Maya L (57217180122); Villanueva-Millan, Maria Jesus (54901742500); Sanchez, Maritza (57215506242); Ayyad, Sarah (57990747300); Rezaie, Ali (10044809800); Mathur, Ruchi (7202179697); Pimentel, Mark (7006799213)^57211561751; 57194106499; 57117524600; 56705105600; 55300614800; 57211562499; 57217180122; 54901742500; 57215506242; 57990747300; 10044809800; 7202179697; 7006799213^Cytolethal distending toxin B inoculation leads to distinct gut microtypes and IBS-D-like microRNA-mediated gene expression changes in a rodent model^2024^Gut Microbes^16.0^1^2293170^^^^1^10.1080/19490976.2023.2293170^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85180384970&doi=10.1080%2f19490976.2023.2293170&partnerID=40&md5=9c4aa0a9259c94bafc319b4ccd181fcc^Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States^Leite G., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; de Freitas Germano J., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Morales W., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Weitsman S., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Barlow G.M., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Parodi G., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Pimentel M.L., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Villanueva-Millan M.J., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Sanchez M., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Ayyad S., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States; Rezaie A., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States, Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States; Mathur R., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States; Pimentel M., Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, United States, Karsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai, Los Angeles, CA, United States^Diarrhea-predominant irritable bowel syndrome (IBS-D), associated with increased intestinal permeability, inflammation, and small intestinal bacterial overgrowth, can be triggered by acute gastroenteritis. Cytolethal distending toxin B (CdtB) is produced by gastroenteritis-causing pathogens and may underlie IBS-D development, through molecular mimicry with vinculin. Here, we examine the effects of exposure to CdtB alone on gut microbiome composition, host intestinal gene expression, and IBS-D-like phenotypes in a rat model. CdtB-inoculated rats exhibited increased anti-CdtB levels, which correlated with increased stool wet weights, pro-inflammatory cytokines (TNFα, IL2) and predicted microbial metabolic pathways including inflammatory responses, TNF responses, and diarrhea. Three distinct ileal microbiome profiles (microtypes) were identified in CdtB-inoculated rats. The first microtype (most like controls) had altered relative abundance (RA) of genera Bifidobacterium, Lactococcus, and Rothia. The second had lower microbial diversity, higher Escherichia-Shigella RA, higher absolute E. coli abundance, and altered host ileal tissue expression of immune-response and TNF-response genes compared to controls. The third microtype had higher microbial diversity, higher RA of hydrogen sulfide (H2S)-producer Desulfovibrio, and increased expression of H2S-associated pain/serotonin response genes. All CdtB-inoculated rats exhibited decreased ileal expression of cell junction component mRNAs, including vinculin-associated proteins. Significantly, cluster-specific microRNA-mRNA interactions controlling intestinal permeability, visceral hypersensitivity/pain, and gastrointestinal motility genes, including several previously associated with IBS were seen. These findings demonstrate that exposure to CdtB toxin alone results in IBS-like phenotypes including inflammation and diarrhea-like stool, decreased expression of intestinal barrier components, and altered ileal microtypes that influenced changes in microRNA-modulated gene expression and predicted metabolic pathways consistent with specific IBS-D symptoms. © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.^cytolethal distending toxin; gut microbiome; host gene expression; Irritable bowel syndrome; microRNAs^Animals; Diarrhea; Escherichia coli; Gastroenteritis; Gastrointestinal Microbiome; Gene Expression; Inflammation; Irritable Bowel Syndrome; Pain; Rats; Rodentia; Vinculin; cytolethal distending toxin; gamma interferon; interleukin 18; interleukin 2; interleukin 5; interleukin 8; lipopolysaccharide; messenger RNA; microRNA; occludin; RNA 16S; serotonin; tachykinin; tumor necrosis factor; cytolethal distending toxin; vinculin; animal model; animal tissue; Article; bacterial load; bacterial overgrowth; bacterial translocation; Bacteroides; Bifidobacterium; bioinformatics; blood sampling; cell junction; cluster analysis; cyanobacterium; cytotoxicity; Desulfovibrio; diarrhea; discriminant analysis; DNA extraction; DNA isolation; dysbiosis; enzyme linked immunosorbent assay; Escherichia; Escherichia coli; Eubacterium; feces analysis; feces microflora; gastroenteritis; gene expression; gene expression profiling; gene ontology; gene sequence; ileum; ileum tissue; immune response; inflammation; intestine flora; intestine mucosa permeability; irritable colon; Lactobacillus; Lactococcus; male; microbial diversity; microbiome; molecular mimicry; natural killer cell; nociception; nonhuman; principal component analysis; Pseudomonas; pyrosequencing; quality control; quality of life; rat; Rothia; Ruminococcus; Shigella; upregulation; animal; gastroenteritis; gene expression; genetics; pain; rodent^^gamma interferon, 82115-62-6; interleukin 18, 189304-55-0; interleukin 2, 85898-30-2; interleukin 8, 114308-91-7; occludin, 176304-61-3; serotonin, 50-67-9; cytolethal distending toxin, ; Vinculin, ^Agilent 210, Agilent; KAPA, Hoffmann La Roche, Switzerland; Luminex FlexMap 3D, Luminex, United States; MagAttract, Qiagen; MiSeq, Illumina; Qubit 4, Invitrogen^Agilent; Hoffmann La Roche, Switzerland; Illumina; Invitrogen; Luminex, United States; Qiagen^Bausch Health Inc.; Georgianna Atol Charitable Trust; John and Geraldine Cusenza Family Foundation; Monica Lester Charitable Trust; Thomas Wurster and David Allen; Tull Family Foundation; National Philanthropic Trust, NPT; Bausch Health, BHC^Funding text 1: This study was funded in part by funds from Bausch Health Companies Inc and the National Philanthropic Trust to MP. These sponsors played no role in the study design or in the collection, analysis, and interpretation of data. The authors would also like to thank the following donors for their support: The Gottesdiener foundation, Frank Lee, Joel Levine, the Monica Lester Charitable Trust, the Elias, Genevieve, and Georgianna Atol Charitable Trust, the Tull Family Foundation, Thomas Wurster and David Allen, and the John and Geraldine Cusenza Family Foundation.; Funding text 2: MP and AR are consultants for, and have received grant support from, Bausch Health Inc. The remaining authors have no relevant conflicts of interest to disclose. ^Ford A.C., Lacy B.E., Talley N.J., Longo D.L., Irritable bowel syndrome, N Engl J Med, 376, 26, pp. 2566-2525, (2017); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Et al., Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study, Gastroenterology, 160, pp. 99-114 e3, (2021); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Pimentel M., Saad R.J., Long M.D., Rao S.S.C., ACG clinical guideline: small intestinal bacterial overgrowth, Am J Gastroenterol, 115, pp. 165-178, (2020); Shah E.D., Riddle M.S., Chang C., Pimentel M., Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome, J Neurogastroenterol Motil, 18, pp. 200-204, (2012); Villanueva-Millan M.J., Leite G., Wang J., Morales W., Parodi G., Pimentel M.L., Barlow G.M., Mathur R., Rezaie A., Sanchez M., Et al., Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes, Am J Gastroenterol, 117, 12, pp. 2055-2066, (2022); Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., Singh S., Grover M., Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis, Gastroenterology, 152, pp. 1042-1054, (2017); Takakura W., Kudaravalli P., Chatterjee C., Pimentel M., Riddle M.S., Campylobacter infection and the link with irritable bowel syndrome: on the pathway towards a causal association, Pathog Dis, 80, (2022); Pimentel M., Chatterjee S., Chang C., Low K., Song Y., Liu C., Morales W., Ali L., Lezcano S., Conklin J., Et al., A new rat model links two contemporary theories in irritable bowel syndrome, Dig Dis Sci, 53, 4, pp. 982-989, (2008); Pokkunuri V., Pimentel M., Morales W., Jee S.-R., Alpern J., Weitsman S., Marsh Z., Low K., Hwang L., Khoshini R., Et al., Role of cytolethal distending toxin in altered stool form and bowel phenotypes in a rat model of post-infectious irritable bowel syndrome, J Neurogastroenterol Motil, 18, 4, pp. 434-442, (2012); Pimentel M., Morales W., Pokkunuri V., Brikos C., Kim S.M., Kim S.E., Triantafyllou K., Weitsman S., Marsh Z., Marsh E., Et al., Autoimmunity links vinculin to the pathophysiology of chronic functional bowel changes following Campylobacter jejuni infection in a rat model, Dig Dis Sci, 60, 5, pp. 1195-1205, (2015); Pickett C.L., Whitehouse C.A., The cytolethal distending toxin family, Trends Microbiol, 7, 7, pp. 292-297, (1999); Morales W., Triantafyllou K., Parodi G., Weitsman S., Park S.C., Rezaie A., Pichetshote N., Lin E., Pimentel M., Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J Neurogastroenterol Motil, 22, pp. 558-574, (2016); Sikander A., Rana S.V., Prasad K.K., Role of serotonin in gastrointestinal motility and irritable bowel syndrome, Clin Chim Acta, 403, 1-2, pp. 47-55, (2009); Hyland N.P., Quigley E.M., Brint E., Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions, World J Gastroenterol, 20, 27, pp. 8859-8866, (2014); Bravo-Vazquez L.A., Medina-Rios I., Marquez-Gallardo L.D., Reyes-Munoz J., Serrano-Cano F.I., Pathak S., Banerjee A., Bandyopadhyay A., Duttaroy A.K., Paul S., Et al., Functional implications and clinical potential of MicroRNAs in irritable bowel syndrome: a concise review, Dig Dis Sci, 68, 1, pp. 38-53, (2023); Leite G., Morales W., Weitsman S., Celly S., Parodi G., Mathur R., Barlow G.M., Sedighi R., Millan M.J.V., Rezaie A., Et al., The duodenal microbiome is altered in small intestinal bacterial overgrowth, Plos One, 15, 7, (2020); Fernandez-Calleja J.M.S., Konstanti P., Swarts H.J.M., Bouwman L.M.S., Garcia-Campayo V., Billecke N., Oosting A., Smidt H., Keijer J., van Schothorst E.M., Et al., Non-invasive continuous real-time in vivo analysis of microbial hydrogen production shows adaptation to fermentable carbohydrates in mice, Sci Rep, 8, 1, (2018); Klapholz B., Brown N.H., Talin - the master of integrin adhesions, J Cell Sci, 130, pp. 2435-2446, (2017); Parsanathan R., Jain S.K., Hydrogen sulfide regulates circadian-clock genes in C2C12 myotubes and the muscle of high-fat-diet-fed mice, Arch Biochem Biophys, 672, (2019); Kim D.S., Anantharam P., Padhi P., Thedens D.R., Li G., Transcriptomic profile analysis of brain inferior colliculus following acute hydrogen sulfide exposure, Toxicology, 430, (2020); Bravo-Vazquez L.A., Medina-Rios I., Marquez-Gallardo L.D., Reyes-Munoz J., Serrano-Cano F.I., Pathak S., Banerjee A., Bandyopadhyay A., Duttaroy A.K., Paul S., Et al., Functional implications and clinical potential of MicroRNAs in irritable bowel syndrome: a concise review, Dig Dis Sci, 68, pp. 38-53, (2022); Singh R., Zogg H., Ro S., Role of microRnas in disorders of gut–brain interactions: clinical insights and therapeutic alternatives, J Pers Med, 11, (2021); Park C., Lee M.Y., Slivano O.J., Park P.J., Ha S., Berent R.M., Fuchs R., Collins N.C., Yu T.J., Syn H., Park J., Loss of serum response factor induces microRNA-mediated apoptosis in intestinal smooth muscle cells, Cell Death Dis, 6, (2015); Hou Q., Huang Y., Zhang C., Zhu S., Li P., Chen X., Hou Z., Liu F., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J Neurogastroenterol Motil, 24, pp. 656-668, (2018); Chao G., Wang Y., Zhang S., Yang W., Ni Z., Zheng X., MicroRNA-29a increased the intestinal membrane permeability of colonic epithelial cells in irritable bowel syndrome rats, Oncotarget, 8, pp. 85828-85837, (2017); Nakata K., Sugi Y., Narabayashi H., Kobayakawa T., Nakanishi Y., Tsuda M., Hosono A., Kaminogawa S., Hanazawa S., Takahashi K., Et al., Commensal microbiota-induced microRNA modulates intestinal epithelial permeability through the small GTPase ARF4, J Biol Chem, 292, 37, pp. 15426-15433, (2017); Mahurkar-Joshi S., Rankin C.R., Videlock E.J., Soroosh A., Verma A., Khandadash A., Iliopoulos D., Pothoulakis C., Mayer E.A., Chang L., Et al., The colonic mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p are downregulated in irritable bowel syndrome and are associated with barrier function and MAPK signaling, Gastroenterology, 160, 7, pp. 2409-2422, (2021); Fourie N.H., Peace R.M., Abey S.K., Sherwin L.B., Rahim-Williams B., Smyser P.A., Wiley J.W., Henderson W.A., Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome, Exp Mol Pathol, 96, pp. 422-425, (2014); Ye D., Guo S., Al-Sadi R., Ma T.Y., MicroRNA regulation of intestinal epithelial tight junction permeability, Gastroenterology, 141, pp. 1323-1333, (2011); Zhu H., Xiao X., Shi Y., Wu Y., Huang Y., Li D., Xiong F., He G., Chai Y., Tang H., Et al., Inhibition of miRNA‑29a regulates intestinal barrier function in diarrhea‑predominant irritable bowel syndrome by upregulating ZO‑1 and CLDN1, Exp Ther Med, 20, (2020); Fei L., Wang Y., microRNA-495 reduces visceral sensitivity in mice with diarrhea-predominant irritable bowel syndrome through suppression of the PI3K/AKT signaling pathway via PKIB, Iubmb Life, 72, 7, pp. 1468-1480, (2020); Zhang Y., Wu X., Wu J., Li S., Han S., Lin Z., Ding S., Jia X., Gong W., Decreased expression of microRNA-510 in intestinal tissue contributes to post-infectious irritable bowel syndrome via targeting PRDX1, Am J Transl Res, 11, pp. 7385-7397, (2019); Tao W., Dong X., Kong G., Fang P., Huang X., Bo P., Elevated circulating hsa-miR-106b, hsa-miR-26a, and hsa-miR-29b in type 2 diabetes mellitus with diarrhea-predominant irritable bowel syndrome, Gastroenterol Res Pract, 2016, pp. 1-9, (2016); Guo J., Lu G., Chen L., Geng H., Wu X., Chen H., Li Y., Yuan M., Sun J., Pei L., Et al., Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome, Acupunct Med, 40, 1, pp. 34-42, (2022); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell–prostaglandin E2, Gastroenterology, 162, 7, pp. 1962-1974, (2022); Singh P., Lembo A., Emerging role of the gut microbiome in irritable bowel syndrome, Gastroenterol Clin North Am, 50, 3, pp. 523-545, (2021); Higashi T., Arnold T.R., Stephenson R.E., Dinshaw K., Miller A., Maintenance of the epithelial barrier and remodeling of cell-cell junctions during Cytokinesis, Curr Biol, 26, pp. 1829-1842, (2016); Goult B.T., Zacharchenko T., Bate N., Tsang R., Hey F., Gingras A.R., Elliott P.R., Roberts G.C.K., Ballestrem C., Critchley D.R., Et al., RIAM and vinculin binding to talin are mutually exclusive and regulate adhesion assembly and turnover, J Biol Chem, 288, 12, pp. 8238-8249, (2013); Konishi S., Yano T., Tanaka H., Mizuno T., Kanoh H., Tsukita K., Namba T., Tamura A., Yonemura S., Gotoh S., Et al., Vinculin is critical for the robustness of the epithelial cell sheet paracellular barrier for ions, Life Sci Alli, 2, (2019); Yao M., Qiu W., Liu R., Efremov A.K., Cong P., Seddiki R., Payre M., Lim C.T., Ladoux B., Mege R.-M., Et al., Force-dependent conformational switch of α-catenin controls vinculin binding, Nat Commun, 5, 1, (2014); Twiss F., Le Duc Q., Van Der Horst S., Tabdili H., Van Der Krogt G., Wang N., Rehmann H., Huveneers S., Leckband D.E., De Rooij J., Et al., Vinculin-dependent cadherin mechanosensing regulates efficient epithelial barrier formation, Biol Open, 1, 11, pp. 1128-1140, (2012); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study, BMC Gastroenterol, 18, (2018); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winte B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, (2021); Shefa U., Kim M.S., Jeong N.Y., Jung J., Antioxidant and cell-signaling functions of hydrogen sulfide in the central nervous System, Oxid Med Cell Longev, 2018, pp. 1-17, (2018); Koh S.J., Choi Y., Kim B.G., Lee K.L., Kim D.W., Kim J.H., Kim J.W., Kim J.S., Matricellular protein periostin mediates intestinal inflammation through the activation of nuclear factor κB signaling, Plos One, 11, (2016); Cui X.F., Zhou W.M., Yang Y., Zhou J., Li X.L., Lin L., Zhang H.J., Epidermal growth factor upregulates serotonin transporter and its association with visceral hypersensitivity in irritable bowel syndrome, World J Gastroenterol, 20, pp. 13521-13529, (2014); Crowell M.D., Role of serotonin in the pathophysiology of the irritable bowel syndrome, Br J Pharmacol, 141, 8, pp. 1285-1293, (2004); Pyleris E., Giamarellos-Bourboulis E.J., Tzivras D., Koussoulas V., Barbatzas C., Pimentel M., The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome, Dig Dis Sci, 57, pp. 1321-1329, (2012); Leite G., Rezaie A., Mathur R., Barlow G.M., Rashid M., Hosseini A., Wang J., Parodi G., Villanueva-Millan M.J., Sanchez M., Et al., Defining small intestinal bacterial overgrowth by culture and high throughput sequencing, Clin Gastroenterol Hepatol, (2023); Chassaing B., Raja S.M., Lewis J.D., Srinivasan S., Gewirtz A.T., Colonic microbiota encroachment correlates with dysglycemia in humans, Cell Mol Gastroenterol Hepatol, 4, pp. 205-221, (2017); Rolhion N., Chassaing B., When pathogenic bacteria meet the intestinal microbiota, Philos Trans R Soc Lond B Biol Sci, 371, (2016); Yang W., Xu H.W., Lu X.R., Xu Q.-F., Tao M.-H., Dai Y.-M., Overexpression of miR-122 impairs intestinal barrier function and aggravates acute pancreatitis by downregulating occludin expression, Biochem Genet, 60, pp. 382-394, (2022); Jingushi K., Kashiwagi Y., Ueda Y., Kitae K., Hase H., Nakata W., Fujita K., Uemura M., Nonomura N., Tsujikawa K., Et al., High miR-122 expression promotes malignant phenotypes in ccRCC by targeting occludin, Int J Oncol, 51, 1, pp. 289-297, (2017); Liu L., Zhu M., Liu X., Fei L., Shen J., Chen D., miR-122-5p regulates the tight junction of the blood-testis barrier of mice via occludin: miR-122-5p can regulate the tight junction, Basic Clin Androl, 31, (2021); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51 Suppl 1, pp. i41-i44, (2002); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); Holzer P., Holzer-Petsche U., Tachykinin receptors in the gut: physiological and pathological implications, Curr Opin Pharmacol, 1, 6, pp. 583-590, (2001); Tack J., Drossman D.A., What’s new in Rome IV?, Neurogastroenterol Motil, 29, (2017); Steinhoff M.S., von Mentzer B., Geppetti P., Pothoulakis C., Bunnett N.W., Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease, Physiol Rev, 94, pp. 265-301, (2014); Fritz N., Berens S., Dong Y., Martinez C., Schmitteckert S., Houghton L.A., Goebel-Stengel M., Wahl V., Kabisch M., Gotze D., Et al., The serotonin receptor 3E variant is a risk factor for female IBS-D, J Mol Med (Berl), 100, 11, pp. 1617-1627, (2022); Mogilyansky E., Rigoutsos I., The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease, Cell Death Differ, 20, 12, pp. 1603-1614, (2013); Wu S., Yuan C., Liu S., Zhang Q., Yang Z., Sun F., Zhan S., Zhu S., Zhang S., Irritable bowel syndrome and long-term risk of cancer: a prospective cohort study among 0.5 million adults in UK biobank, Am J Gastroenterol, 117, pp. 785-793, (2022); Morales W., Rezaie A., Barlow G., Pimentel M., Second-generation biomarker testing for irritable bowel syndrome using plasma anti-CdtB and anti-vinculin levels, Dig Dis Sci, 64, pp. 3115-3121, (2019); Klindworth A., Pruesse E., Schweer T., Peplies J., Quast C., Horn M., Glockner F.O., Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies, Nucleic Acids Res, 41, (2013); Leite G.G.S., Morales W., Weitsman S., Celly S., Parodi G., Mathur R., Sedighi R., Barlow G.M., Rezaie A., Pimentel M., Et al., Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study, BMC Microbiol, 19, 1, (2019); 16S metagenomic sequencing library preparation, (2013); CLC Genomics Workbench 23.0.5 product manual; Lu Y., Zhou G., Ewald J., Pang Z., Shiri T., Xia J., MicrobiomeAnalyst 2.0: comprehensive statistical, functional and integrative analysis of microbiome data, Nucleic Acids Res, 51, pp. W310-W318, (2023); Martin M., Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet Journal, 17, (2011); Andrews S., FastQC: a quality control tool for high throughput sequence data, (2010); Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R., STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, pp. 15-21, (2013); Anders S., Pyl P.T., Huber W., Htseq–a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, pp. 166-169, (2015); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, 12, (2014); Alexa A., Rahnenfuhrer J., topGO: enrichment analysis for gene ontology, R package version 1.38.1, (2019); Mitchell A.L., Attwood T.K., Babbitt P.C., Blum M., Bork P., Bridge A., Brown S.D., Chang H.-Y., El-Gebali S., Fraser M.I., Et al., InterPro in 2019: improving coverage, classification and access to protein sequence annotations, Nucleic Acids Res, 47, D1, pp. D351-D360, (2019); Geer L.Y., Marchler-Bauer A., Geer R.C., Han L., He J., He S., Liu C., Shi W., Bryant S.H., The NCBI BioSystems database, Nucleic Acids Res, 38, pp. D492-D496, (2010); Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci USA, 102, 43, pp. 15545-15550, (2005); Liberzon A., Subramanian A., Pinchback R., Thorvaldsdottir H., Tamayo P., Mesirov J.P., Molecular signatures database (MSigDB) 3.0, Bioinformatics, 27, pp. 1739-1740, (2011); Fabregat A., Jupe S., Matthews L., Sidiropoulos K., Gillespie M., Garapati P., Haw R., Jassal B., Korninger F., May B., Et al., The reactome pathway knowledgebase, Nucleic Acids Res, 46, D1, pp. D649-D655, (2018); Slenter D.N., Kutmon M., Hanspers K., Riutta A., Windsor J., Nunes N., Melius J., Cirillo E., Coort S.L., Digles D., Et al., WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research, Nucleic Acids Res, 46, D1, pp. D661-D667, (2018); Robinson M.D., Oshlack A., A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, 11, 3, (2010); Ge S.X., Jung D., Yao R., Valencia A., ShinyGO: a graphical gene-set enrichment tool for animals and plants, Bioinformatics, 36, 8, pp. 2628-2629, (2020); Svoronos A.A., Campbell S.G., Engelman D.M., MicroRNA function can be reversed by altering target gene expression levels, iScience, 24, (2021); Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P., A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?, Cell, 146, pp. 353-358, (2011)^M. Pimentel; Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, United States; email: mark.pimentel@cshs.org^^Taylor and Francis Ltd.^^^^^^19490976^^^38108386.0^English^Gut Microbes^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85180384970
Kang X.; Zhang H.; Li X.; Zhang K.; Huang Z.; Li Y.; Ren X.; Chai Y.^Kang, Xueling (58909753400); Zhang, Honglin (57211166289); Li, Xiaying (58910751800); Zhang, Kai (57212137034); Huang, Zhansheng (58909954300); Li, Yuanyuan (57884981400); Ren, Xiaoxuan (24473473500); Chai, Yemao (57817027600)^58909753400; 57211166289; 58910751800; 57212137034; 58909954300; 57884981400; 24473473500; 57817027600^Electroacupuncture Improving Intestinal Barrier Function in Rats with Irritable Bowel Syndrome Through Regulating Aquaporins^2024^Digestive Diseases and Sciences^69.0^4^^1143^1155^12.0^0^10.1007/s10620-024-08288-x^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85186190307&doi=10.1007%2fs10620-024-08288-x&partnerID=40&md5=27f9eaa35140c70b05a17c30f1c045f0^School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; School of Chinese Materia Medica, Beijing University of Chinese Medicine, No. 11 Beisanhuan East Road, Chaoyang District, Beijing, 100029, China^Kang X., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Zhang H., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Li X., School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Zhang K., School of Chinese Materia Medica, Beijing University of Chinese Medicine, No. 11 Beisanhuan East Road, Chaoyang District, Beijing, 100029, China; Huang Z., School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China; Li Y., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Ren X., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; Chai Y., School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China^Background: Intestinal mucosal barrier dysfunction plays a crucial role in the pathogenesis of irritable bowel syndrome with diarrhea (IBS-D). In order to explore the mechanism of electroacupuncture (EA) treatment on intestinal mucosal barrier, this study observed the effect of EA on aquaporins (AQPs), tight junctions (TJs), NF-κB pathway and the gut microbiota in IBS-D rats. Methods: The IBS-D model was established by acetic acid enema combined with chronic restraint method. The effects of EA on the treatment of IBS-D were examined by the abdominal withdrawal reflex score, Bristol's fecal character score, fecal water content, small intestine propulsion rate and HE staining. AQPs, TJs and inflammation-related molecular mechanisms were explored. The fecal samples were applied for 16S rRNA sequencing to assess the effect of EA intervention to the intestinal bacterial abundance. Results: EA reduced intestinal sensitization, restored intestinal motility and improved inflammatory cell infiltration. Furthermore, EA improved intestinal inflammation and flora environment significantly, inhibited NF-κB signaling and inflammatory factors (IL-1β and TNF-α). It can also increase the gene and protein expression of AQPs (AQP1, AQP3, and AQP8) and the gene levels of TJs (ZO-1 and Occludin). Conclusion: EA has an inhibitory effect on the NF-κB signaling pathway, and regulates the proteins of AQP1, AQP3, AQP8, and TJs to restore the balance of water metabolism and intestinal permeability in IBS-D, which also restored the function of the intestinal mucosa by regulating the intestinal flora. Graphical Abstract: Irritable bowel syndrome with predominant diarrhea (IBS-D) is a common gastrointestinal disease in clinical practice, which was affected by intestinal mucosal barrier dysfunction, intestinal mucosal inflammation production and abnormal intestinal flora, then there is currently no specific drug for treating IBS-D. Electroacupuncture (EA), as a non-pharmacological therapy, has good therapeutic effects in treating IBS-D. Aquaporins (AQPs) are distributed in the intestinal mucosa of the intestine and are important factors in mediating water–liquid transmembrane transport. Changes in AQPs expression have been identified as a common factor in the etiology of certain gastrointestinal diseases. AQP1, AQP3, and AQP8 are distributed in the distal colon. EA can inhibit NF-κB signaling pathway, and regulate the proteins of AQP1, AQP3, AQP8, and TJs to restore the balance of water metabolism and intestinal permeability in IBS-D, which also can restore the function of the intestinal mucosa by regulating the intestinal flora. (Figure presented.). © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.^Acupuncture; Aquaporins; Gut microbiota; Intestinal barrier function; Irritable bowel syndrome; NF-κB^Animals; Aquaporins; Diarrhea; Electroacupuncture; Inflammation; Intestinal Barrier Function; Irritable Bowel Syndrome; NF-kappa B; Rats; RNA, Ribosomal, 16S; Water; acetic acid; aquaporin; aquaporin 1; aquaporin 3; aquaporin 8; genomic DNA; immunoglobulin enhancer binding protein; interleukin 1beta; messenger RNA; occludin; protein ZO1; RNA 16S; tumor necrosis factor; aquaporin; immunoglobulin enhancer binding protein; RNA 16S; water; acupuncture; animal experiment; animal model; animal tissue; apical membrane; Article; Bacteroidaceae; cell infiltration; colon mucosa; controlled study; descending colon; diarrhea; electroacupuncture; enteritis; Enterococcaceae; enzyme linked immunosorbent assay; gene expression; immunohistochemistry; intestine; intestine flora; intestine function; intestine motility; intestine mucosa; intestine mucosa permeability; irritable colon; Lachnospiraceae; Lactobacillaceae; loose feces; male; microbial diversity; NF kB signaling; nonhuman; optical density; Prevotellaceae; protein expression; protein expression level; protein function; protein localization; rat; real time polymerase chain reaction; RNA sequencing; Ruminococcaceae; shangjuxu acupoint; small intestine; tianshu acupoint; water content; water metabolism; Western blotting; withdrawal reflex; animal; inflammation; metabolism^^acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; aquaporin, 215587-75-0; aquaporin 1, 146410-94-8, 149348-86-7; occludin, 176304-61-3; water, 7732-18-5; Aquaporins, ; NF-kappa B, ; RNA, Ribosomal, 16S, ; Water, ^^^Beijing University of Chinese Medicine, BUCM, (2020-JYB-XJSJJ-016); Beijing University of Chinese Medicine, BUCM^This research was supported by New Teacher Initiation Fund Project of Beijing University of Chinese Medicine (No. 2020-JYB-XJSJJ-016). ^Aziz I., Simren M., The overlap between irritable bowel syndrome and organic gastrointestinal diseases, Lancet Gastroenterol Hepatol, 6, pp. 139-148, (2021); Ghoshal U.C., Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: Pros, J Neurogastroenterol Motil, 23, pp. 334-340, (2017); Oka P., Parr H., Barberio B., Et al., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol, 5, pp. 908-917, (2020); Trinkley K.E., Nahata M.C., Medication management of irritable bowel syndrome, Digestion, 89, pp. 253-267, (2014); Canavan C., West J., Card T., Calculating total health service utilisation and costs from routinely collected electronic health records using the example of patients with irritable bowel syndrome before and after their first gastroenterology appointment, Pharmacoeconomics, 34, pp. 181-194, (2016); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Laforenza U., Water channel proteins in the gastrointestinal tract, Mol Aspects Med, 33, pp. 642-650, (2012); Kalita A., Das M., Baro M.R., Das B., Exploring the role of Aquaporins (AQPs) in LPS induced systemic inflammation and the ameliorative effect of Garcinia in male Wistar rat, Inflammopharmacology, 29, pp. 801-823, (2021); Zhao G.X., Dong P.P., Peng R., Et al., Expression, localization and possible functions of aquaporins 3 and 8 in rat digestive system, Biotech Histochem, 91, pp. 269-276, (2016); Singh S.K., Binder H.J., Boron W.F., Geibel J.P., Fluid absorption in isolated perfused colonic crypts, J Clin Investig, 96, pp. 2373-2379, (1995); Yano T., Kanoh H., Tamura A., Tsukita S., Apical cytoskeletons and junctional complexes as a combined system in epithelial cell sheets, Ann NY Acad Sci, 1405, pp. 32-43, (2017); Vermette D., Hu P., Canarie M.F., Funaro M., Glover J., Pierce R.W., Tight junction structure, function, and assessment in the critically ill: a systematic review, Intensive Care Med Exp, 6, (2018); Fischbarg J., Fluid transport across leaky epithelia: central role of the tight junction and supporting role of aquaporins, Physiol Rev, 90, pp. 1271-1290, (2010); Yuan Y., Wang X., Huang S., Wang H., Shen G., Low-level inflammation, immunity, and brain–gut axis in IBS: unraveling the complex relationships, Gut Microbes, 15, (2023); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Chao G., Zhang S., Aquaporins 1, 3 and 8 expression in irritable bowel syndrome rats' colon via NF-κB pathway, Oncotarget, 8, pp. 47175-47183, (2017); Rabitti S., Giovanardi C.M., Colussi D., Acupuncture and related therapies for the treatment of gastrointestinal diseases, J Clin Gastroenterol, 55, pp. 207-217, (2021); Zhu X., Liu Z., Qin Y., Et al., Analgesic effects of electroacupuncture at ST25 and CV12 in a rat model of postinflammatory irritable bowel syndrome visceral pain, Acupunct Med, 36, pp. 240-246, (2018); Li J., Lu J., Sun J., Et al., Acupuncture with regulating mind and spleen for diarrhea irritable bowel syndrome and sleep quality: a randomized controlled trial, Zhongguo Zhen Jiu, 37, pp. 9-13, (2017); Hou Y.J., Wang K., Jiang H.L., Et al., Study on the mechanism of electroacupuncture repairing intestinal barrier via regulating mast cell in rats with diarrhea-predominant irritable bowel syndrome, Zhen Ci Yan Jiu, 48, pp. 281-286, (2023); Mengzhu S., Yujie Z., Yafang S., Et al., Electroacupuncture alleviates water avoidance stress-induced irritable bowel syndrome in mice by improving intestinal barrier functions and suppressing the expression of inflammatory cytokines, J Tradit Chin Med, 43, pp. 494-500, (2023); Chao G., Wang Z., Yang Y., Zhang S., LncRNA H19 as a competing endogenous RNA to regulate AQP expression in the intestinal barrier of IBS-D patients, Front Physiol, 11, (2021); Williams C.L., Villar R.G., Peterson J.M., Burks T.F., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); La J.H., Kim T.W., Sung T.S., Et al., Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis, World J Gastroenterol, 9, pp. 2791-2795, (2003); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Camilleri M., Ford A.C., Irritable bowel syndrome: pathophysiology and current therapeutic approaches, Handb Exp Pharmacol, 239, pp. 75-113, (2017); Wu I.X.Y., Wong C.H.L., Ho R.S.T., Et al., Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis, Ther Adv Gastroenterol, 12, (2019); Huang J., Lu M., Zheng Y., Et al., Quality of evidence supporting the role of acupuncture for the treatment of irritable bowel syndrome, Pain Res Manag, 2021, (2021); Sun J.W., Sun M.L., Li D., Et al., Efficacy of acupuncture based on acupoint combination theory for irritable bowel syndrome: a study protocol for a multicenter randomized controlled trial, Trials, 22, (2021); Zhou Z.X., Ma H.F., Yang Y.C., Chen J.T., Feng Y.H., Effect of electroacupuncture on colonic motility and RhoA and ROCK protein expression in IBS-D rats, Zhen Ci Yan Jiu, 47, pp. 611-616, (2022); Li X., Ren K., Hong X., Et al., Ameliorating effects of electroacupuncture on the low-grade intestinal inflammation in rat model of diarrhea-predominant irritable bowel syndrome, J Gastroenterol Hepatol, 37, pp. 1963-1974, (2022); Su Q., Tun H.M., Liu Q., Et al., Gut microbiome signatures reflect different subtypes of irritable bowel syndrome, Gut Microbes, 15, (2023); Sun M.Z., Zhang Y.J., Song Y.F., Et al., Electroacupuncture at Tianshu (ST25) and Zusanli (ST36) alleviates stress-induced irritable bowel syndrome in mice by modulating gut microbiota and corticotropin-releasing factor, J Tradit Chin Med, 42, pp. 732-740, (2022); Piche T., Tight junctions and IBS—the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, pp. 296-302, (2014); Ivashkin V., Poluektov Y., Kogan E., Et al., Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome, PLoS ONE, 16, (2021); Martens E.C., Neumann M., Desai M.S., Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier, Nat Rev Microbiol, 16, pp. 457-470, (2018); Salman M.M., Kitchen P., Yool A.J., Bill R.M., Recent breakthroughs and future directions in drugging aquaporins, Trends Pharmacol Sci, 43, pp. 30-42, (2022); Wagner K., Unger L., Salman M.M., Et al., Signaling mechanisms and pharmacological modulators governing diverse aquaporin functions in human health and disease, Int J Mol Sci, 23, (2022); Camilleri M., Carlson P., Chedid V., Et al., Aquaporin expression in colonic mucosal biopsies from irritable bowel syndrome with diarrhea, Clin Transl Gastroenterol, 10, (2019); Wang J.P., Hou X.H., Expression of aquaporin 8 in colonic epithelium with diarrhoea-predominant irritable bowel syndrome, Chin Med J, 120, pp. 313-316, (2007); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb Perspect Biol, 10, (2018); Wang H.Y., Chi C., Xu Y.Q., Et al., Occludin endocytosis is involved in the disruption of the intestinal epithelial barrier in a mouse model of alcoholic steatohepatitis, J Dig Dis, 20, pp. 476-485, (2019); Zhang W., Xu Y., Chen Z., Xu Z., Xu H., Knockdown of aquaporin 3 is involved in intestinal barrier integrity impairment, FEBS Lett, 585, pp. 3113-3119, (2011); Dong L.W., Chen Y.Y., Chen C.C., Et al., Adenosine 2A receptor contributes to the facilitation of post-infectious irritable bowel syndrome by γδ T cells via the PKA/CREB/NF-κB signaling pathway, World J Gastroenterol, 29, pp. 1475-1491, (2023); Wang L., Lei J., Zhao Z., Jia J., Wang L., Therapeutic effects of paeoniflorin on irritable bowel syndrome in rats, J Vet Sci, 24, (2023); Zou L., Ruan J.R., Chen J.Y., Et al., Moxibustion relieves colonic inflammation by up-regulating expression of miR-345-3p/miR-216a-5p and down-regulating NF-κB p65 in colonic tissue of rats with diarrhea-predominant irritable bowel syndrome, Zhen Ci Yan Jiu, 48, pp. 226-232, (2023)^Y. Chai; School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, 100029, China; email: 201901020@bucm.edu.cn^^Springer^^^^^^01632116^^DDSCD^38421507.0^English^Dig. Dis. Sci.^Article^Final^^Scopus^2-s2.0-85186190307
Jin X.; Hu Y.; Lin T.; Gao F.; Xu Z.; Hou X.; Yin Y.; Kan S.; Zhu H.; Chen D.^Jin, Xueli (57736997800); Hu, Yongjia (57855175200); Lin, Ting (57855800900); Gao, Fei (57216622610); Xu, Ziqi (58099877800); Hou, Xiao (57856426700); Yin, Yu (56664962000); Kan, Shidong (35205618600); Zhu, Hui (57211883191); Chen, Daijie (35073629800)^57736997800; 57855175200; 57855800900; 57216622610; 58099877800; 57856426700; 56664962000; 35205618600; 57211883191; 35073629800^Selenium-enriched Bifidobacterium longum DD98 relieves irritable bowel syndrome induced by chronic unpredictable mild stress in mice^2023^Food and Function^14.0^11^^5355^5374^19.0^6^10.1039/d2fo03408e^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162818640&doi=10.1039%2fd2fo03408e&partnerID=40&md5=78fda1c68fadec17612b3f951f95342a^School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China^Jin X., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Hu Y., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Lin T., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Gao F., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Xu Z., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Hou X., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Yin Y., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Kan S., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Zhu H., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; Chen D., School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China, State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China^Irritable bowel syndrome (IBS) is a functional intestinal disorder without clear pathological mechanisms. Classical treatments for IBS are not always effective and are usually accompanied by side effects. Selenium-enriched Bifidobacterium longum DD98 (Se-B. longum DD98) is a selenized probiotic strain which has shown many beneficial effects on the gastrointestinal tract, but its effects on IBS and the underlying mechanism are unclear. This study aims to investigate the relieving effects of Se-B. longum DD98 on chronic unpredictable mild stress (CUMS)-induced IBS in mice. The model mice were treated with saline, B. longum DD98, or Se-B. longum DD98 while receiving CUMS. The results suggest that Se-B. longum DD98 significantly relieved the intestinal symptoms of IBS mice and reduced intestinal permeability and inflammation. The depression and anxiety-like behaviors of IBS mice were also improved by Se-B. longum DD98. In addition, the expression of serotonin (5-HT), γ-aminobutyric acid (GABA), neuropeptide Y (NPY), and brain-derived neurotrophic factor (BDNF), which are indicators closely related to mood and brain-gut axis, were up-regulated in mice treated with Se-B. longum DD98. Furthermore, the 16S rRNA sequencing study showed that Se-B. longum DD98 effectively restored the relative abundance of intestinal microbes (e.g., Lactobacillus, Desulfovibrio, Akkermansia) and regulated the impaired diversity of gut microbiota in IBS mice. These results suggest that Se-B. longum DD98 positively acts on the brain-gut axis by improving intestinal functions and regulating mood-associated behaviors and indicators of IBS mice. Therefore, this Se-enriched probiotic strain could be considered a promising candidate for the alleviation of CUMS-induced IBS. © 2023 The Royal Society of Chemistry.^^Animals; Bifidobacterium longum; Intestines; Irritable Bowel Syndrome; Mice; Probiotics; RNA, Ribosomal, 16S; Selenium; Amino acids; Mammals; Probiotics; RNA; Selenium compounds; probiotic agent; RNA 16S; selenium; Beneficial effects; Bifidobacterium longum; Gastrointestinal tract; Intestinal inflammation; Intestinal permeabilities; Irritable bowel syndromes; Probiotic strain; Side effect; Stress-induced; γ-Aminobutyric acid; animal; Bifidobacterium longum; intestine; irritable colon; metabolism; microbiology; mouse; Selenium^^selenium, 7782-49-2; RNA, Ribosomal, 16S, ; Selenium, ^^^Science and Technology Talent Project of Shanghai, (17XD1423200); National Natural Science Foundation of China, NSFC, (81872775); National Natural Science Foundation of China, NSFC; Ministry of Industry and Information Technology of the People's Republic of China, MIIT, (CEIEC-2020-ZM02-0165); Ministry of Industry and Information Technology of the People's Republic of China, MIIT; National Key Research and Development Program of China, NKRDPC, (2018YFA0901904); National Key Research and Development Program of China, NKRDPC^This work was supported by grants from the National Key Research and Development Program of China (No. 2018YFA0901904), the Science and Technology Talent Project of Shanghai (No. 17XD1423200), the National Natural Science Foundation of China (No. 81872775), and funding from the Consumer Products Group of Ministry of Industry and Information Technology of China (No. CEIEC-2020-ZM02-0165).^Foster J.A., Neufeld K.A.M., Gut-brain: how the microbiome influences anxiety and depression, Trends Neurosci., 36, pp. 305-312, (2013); Yu Y.B., Zhao D.Y., Qi Q.Q., Long X., Li X., Chen F.X., Zuo X.L., BDNF modulates intestinal barrier integrity through regulating the expression of tight junction proteins, Neurogastroenterol. Motil., 29, (2017); Lopez-Perez A.E., Nurgali K., Abalo R., Painful neurotrophins and their role in visceral pain, Behav. Pharmacol., 29, pp. 120-139, (2018); Rasmusson A.M., The gut peptide neuropeptide Y and post-traumatic stress disorder, Curr. Opin. Endocrinol., Diabetes Obes., 24, pp. 3-8, (2017); Abedpoor N., Taghian F., Hajibabaie F., Cross Brain-Gut Analysis Highlighted Hub Genes and LncRNA Networks Differentially Modified During Leucine Consumption and Endurance Exercise in Mice with Depression-Like Behaviors, Mol. Neurobiol., 59, pp. 4106-4123, (2022); Fetissov S.O., Neuropeptide-like signaling in the microbiota-gut-brain axis, Behav. Brain Sci., 42, (2019); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Peyton L., Greene J., Irritable bowel syndrome: current and emerging treatment options, P T, 39, pp. 567-578, (2014); Fitzgerald I., O'Dwyer S., Brooks M., Sahm L., Crowley E., Dhubhlaing C.N., Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine, Front. Mol. Psychiatry, 12, (2021); Bertholon F., Krajewski Y., el Allali A., Adverse effects: priapism caused by paroxetine, Ann. Med.-Psychol., 154, pp. 145-146, (1996); Mermi O., Atmaca M., Peripheral Edema Related to Paroxetine Discontinuation: A Case Report, Klin. Psikofarmakol. Bul., 25, pp. 291-294, (2015); Nicholson S.D., Extra pyramidal side effects associated with paroxetine, West Engl. Med. J., 107, pp. 90-91, (1992); Neve J., Vertongen F., Molle L., Selenium deficiency, Clin. Endocrinol. Metab., 14, pp. 629-656, (1985); Fairweather-Tait S.J., Bao Y., Broadley M.R., Collings R., Ford D., Hesketh J.E., Hurst R., Selenium in human health and disease, Antioxid. Redox Signal., 14, pp. 1337-1383, (2011); Mangiapane E., Pessione A., Pessione E., Selenium and selenoproteins: an overview on different biological systems, Curr. Protein Pept. Sci., 15, pp. 598-607, (2014); Rannem T., Ladefoged K., Hylander E., Hegnhoj J., Staun M., Selenium depletion in patients with gastrointestinal diseases: Are there any predictive factors?, Scand. J. Gastroenterol., 33, pp. 1057-1061, (1998); Ye R.H., Huang J.Q., Wang Z.X., Chen Y.X., Dong Y.L., Trace Element Selenium Effectively Alleviates Intestinal Diseases, Int. J. Mol. Sci., 22, (2021); Burk R.F., Hill K.E., Motley A.K., Winfrey V.P., Kurokawa S., Mitchell S.L., Zhang W.Q., Selenoprotein P and apolipoprotein E receptor-2 interact at the blood-brain barrier and also within the brain to maintain an essential selenium pool that protects against neurodegeneration, FASEB J., 28, pp. 3579-3588, (2014); Solovyev N., Drobyshev E., Blume B., Michalke B., Selenium at the Neural Barriers: A Review, Front. Neurosci., 15, (2021); Alim I., Caulfield J.T., Chen Y.X., Swarup V., Geschwind D.H., Ivanova E., Seravalli J., Ai Y.X., Sensing L.H., Ste Marie E.J., Hondal R.J., Mukherjee S., Cave J.W., Sagdullaev B.T., Karuppagounder S.S., Ratan R.R., Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke, Cell, 177, pp. 1262-1279, (2019); Amani H., Habibey R., Shokri F., Hajmiresmail S.J., Akhavans O., Mashaghi A., Pazoki-Toroudi H., Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling, Sci. Rep., 9, (2019); Malyar R.M., Naseri E., Li H., Ali I., Farid R.A., Liu D., Maroof K., Nasim M., Banuree S.A.H., Huang K., Waldron K.J., Chen X., Hepatoprotective Effects of Selenium-Enriched Probiotics Supplementation on Heat-Stressed Wistar Rat Through Anti-Inflammatory and Antioxidant Effects, Biol. Trace Elem. Res., 199, pp. 3445-3456, (2021); Darwish A.M., Khattab A.E.A., Abd El-Razik K.A., Othman S.I., Allam A.A., Abu-Taweel G.M., Effectiveness of new selenium-enriched mutated probiotics in reducing inflammatory effects of piroxicam medication in liver and kidney, Inflammopharmacology, 30, pp. 2097-2106, (2022); Ibrahim H.A., Zhu Y., Wu C., Lu C., Ezekwe M.O., Liao S.F., Huang K., Selenium-enriched probiotics improves murine male fertility compromised by high fat diet, Biol. Trace Elem. Res., 147, pp. 251-260, (2012); Yang J., Huang K., Qin S., Wu X., Zhao Z., Chen F., Antibacterial action of selenium-enriched probiotics against pathogenic Escherichia coli, Dig. Dis Sci., 54, pp. 246-254, (2009); Pophaly S.D., Poonam, Singh P., Kumar H., Tomar S.K., Singh R., Selenium enrichment of lactic acid bacteria and bifidobacteria: A functional food perspective, Trends Food Sci. Technol., 39, pp. 135-145, (2014); Lach G., Schellekens H., Dinan T.G., Cryan J.F., Anxiety, Depression, and the Microbiome: A Role for Gut Peptides, Neurotherapeutics, 15, pp. 36-59, (2018); Long-Smith C., O'Riordan K.J., Clarke G., Stanton C., Dinan T.G., Cryan J.F., Annual Review of Pharmacology and Toxicology, 60, pp. 477-502, (2020); Pittayanon R., Lau J.T., Yuan Y.H., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review, Gastroenterology, 157, pp. 97-108, (2019); El-Salhy M., Hatlebakk J.G., Hausken T., Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones, Nutrients, 11, (2019); Tian P.J., O'Riordan K.J., Lee Y.K., Wang G., Zhao J.X., Zhang H., Cryan J.F., Chen W., Towards a psychobiotic therapy for depression: Bifidobacterium breve CCFM1025 reverses chronic stress-induced depressive symptoms and gut microbial abnormalities in mice, Neurobiol. Stress, 12, (2020); Dale H.F., Rasmussen S.H., Asiller O.O., Lied G.A., Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review, Nutrients, 11, (2019); Kasaikina M.V., Kravtsova M.A., Lee B.C., Seravalli J., Peterson D.A., Walter J., Legge R., Benson A.K., Hatfield D.L., Gladyshev V.N., Dietary selenium affects host selenoproteome expression by influencing the gut microbiota, FASEB J., 25, pp. 2492-2499, (2011); Hui Z., Yan Z., Yan Q., Rui J., Junliang Z., Zhixiang Q., Chunzhen W., Jun T., Lei S., Daijie C., Preparation and characterization of selenium enriched-Bifidobacterium longum DD98, and its repairing effects on antibiotic-induced intestinal dysbacteriosis in mice, Food Funct., 10, pp. 4975-4984, (2019); Zhu H., Lu C.Y., Gao F., Qian Z.X., Yin Y., Kan S.D., Chen D.J., Selenium-enriched Bifidobacterium longum DD98 attenuates irinotecan-induced intestinal and hepatic toxicity in vitro and in vivo, Biomed. Pharmacother., 143, (2021); Hu Y.J., Jin X.L., Gao F., Lin T., Zhu H., Hou X., Yin Y., Kan S.D., Chen D.J., Selenium-enriched Bifidobacterium longum DD98 effectively ameliorates dextran sulfate sodium-induced ulcerative colitis in mice, Front. Microbiol., 13, (2022); Zhu H., Bierla K., Jin X., Szpunar J., Chen D., Lobinski R., Identification of γ-Glutamyl-Selenomethionine as the Principal Selenium Metabolite in a Selenium-Enriched Probiotic, Bifidobacterium longum, by Two-Dimensional HPLC-ICP MS and HPLC-ESI Orbitrap MS, J. Agric. Food Chem., 70, pp. 6726-6736, (2022); Antoniuk S., Bijata M., Ponimaskin E., Wlodarczyk J., Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability, Neurosci. Biobehav. Rev., 99, pp. 101-116, (2019); Shi H.L., Liu C.H., Ding L.L., Zheng Y., Fei X.Y., Lu L., Zhou X.M., Yuan J.Y., Xie J.Q., Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction, World J. Gastroenterol., 21, pp. 4852-4863, (2015); Zielinska M., Jarmuz A., Wasilewski A., Cami-Kobeci G., Husbands S., Fichna J., Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome, Pharmacol. Rep., 69, pp. 350-357, (2017); Christianson J.A., Gebhart G.F., Assessment of colon sensitivity by luminal distension in mice, Nat. Protoc., 2, pp. 2624-2631, (2007); Zhang C., Zhou X., Zhou X., Effect of Acute Brief Social Isolation on Visceral Pain, J. Pain. Res., 15, pp. 3547-3553, (2022); Kraeuter A.K., Guest P.C., Sarnyai Z., The Open Field Test for Measuring Locomotor Activity and Anxiety-Like Behavior, Methods Mol. Biol., 1916, pp. 99-103, (2019); Campos A.C., Fogaca M.V., Aguiar D.C., Guimaraes F.S., Animal models of anxiety disorders and stress, Rev. Bras. Psiquiatr., 35, pp. S101-S111, (2013); Planaguma J., Leypoldt F., Mannara F., Gutierrez-Cuesta J., Martin-Garcia E., Aguilar E., Titulaer M.J., Petit-Pedrol M., Jain A., Balice-Gordon R., Lakadamyali M., Graus F., Maldonado R., Dalmau J., Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice, Brain, 138, pp. 94-109, (2015); Schmittgen T.D., Livak K.J., Analyzing real-time PCR data by the comparative C(T) method, Nat. Protoc., 3, pp. 1101-1108, (2008); Zhang L., Wang Y., Xia X.Y., Shi C.H., Chen W., Song N., Fu X.J., Zhou R., Xu Y.F., Huang L., Zhu H., Han Y.L., Qin C., Altered Gut Microbiota in a Mouse Model of Alzheimer's Disease, J. Alzheimer's Dis., 60, pp. 1241-1257, (2017); Bruijstens A.L., Molenaar S., Wong Y.Y.M., Kraaij R., Neuteboom R.F., Gut microbiota analysis in pediatric-onset multiple sclerosis compared to pediatric monophasic demyelinating syndromes and pediatric controls, Eur. J. Neurol., (2022); Yanrong L., Xiangxiang Q., Huaijie J., Sirui C., Weiwei S., Xiaoxia W., The association between gut microbiota composition and BMI in Chinese male college students, as analysed by next-generation sequencing, Br. J. Nutr., 122, pp. 986-995, (2019); Brzozowski B., Mazur-Bialy A., Pajdo R., Kwiecien S., Bilski J., Zwolinska-Wcislo M., Mach T., Brzozowski T., Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis, Curr. Neuropharmacol., 14, pp. 892-900, (2016); Long Y., Du L., Kim J.J., Chen B., Zhu Y., Zhang Y., Yao S., He H., Zheng X., Huang Z., Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol. Motil., 30, (2018); Lambert G.P., Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects, J. Anim. Sci., 87, pp. E101-E108, (2009); Balmus I.M., Ciobica A., Cojocariu R., Luca A.C., Gorgan L., Irritable Bowel Syndrome and Neurological Deficiencies: Is There A Relationship? The Possible Relevance of the Oxidative Stress Status, Medicina, 56, (2020); Ghosh S., Whitley C.S., Haribabu B., Jala V.R., Regulation of Intestinal Barrier Function by Microbial Metabolites, Cell. Mol. Gastroenterol. Hepatol., 11, pp. 1463-1482, (2021); Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C., Regulation of Tight Junction Permeability by Intestinal Bacteria and Dietary Components1,2, J. Nutr., 141, pp. 769-776, (2011); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am. J. Physiol., 301, pp. G799-G807, (2011); Qiang-Song W., Yi-Lun W., Wen-Yan Z., Kuang-Dai L., Xiong-Fei L., Yuan-Lu C., Puerarin from Pueraria lobata alleviates the symptoms of irritable bowel syndrome-diarrhea, Food Funct., 12, pp. 2211-2224, (2021); Osadchiy V., Martin C.R., Mayer E.A., The Gut-Brain Axis and the Microbiome: Mechanisms and Clinical Implications, Clin. Gastroenterol. Hepatol., 17, pp. 322-332, (2019); Dinan T.G., Cryan J.F., The Microbiome-Gut-Brain Axis in Health and Disease, Gastroenterol. Clin. North Am., 46, pp. 77-89, (2017); Mayer E.A., Savidge T., Shulman R.J., Brain-Gut Microbiome Interactions and Functional Bowel Disorders, Gastroenterology, 146, pp. 1500-1512, (2014); Trinkley K.E., Nahata M.C., Medication Management of Irritable Bowel Syndrome, Digestion, 89, pp. 253-267, (2014); Avery J.C., Hoffmann P.R., Selenium, Selenoproteins, and Immunity, Nutrients, 10, (2018); Rayman M.P., Selenium intake, status, and health: a complex relationship, Hormones, 19, pp. 9-14, (2020); Bron P.A., Kleerebezem M., Brummer R.J., Cani P.D., Mercenier A., MacDonald T.T., Garcia-Rodenas C.L., Wells J.M., Can probiotics modulate human disease by impacting intestinal barrier function?, Br. J. Nutr., 117, pp. 93-107, (2017); Yan F., Polk D.B., Probiotics and Probiotic-Derived Functional Factors-Mechanistic Insights Into Applications for Intestinal Homeostasis, Front. Immunol., 11, (2020); Plaza-Diaz J., Ruiz-Ojeda F.J., Vilchez-Padial L.M., Gil A., Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases, Nutrients, 9, (2017); Li B., Liang L., Deng H., Guo J., Shu H., Zhang L., Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Front. Pharmacol., 11, (2020); Didari T., Mozaffari S., Nikfar S., Abdollahi M., Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis, World J. Gastroenterol., 21, pp. 3072-3084, (2015); Horvat I.B., Gobin I., Kresovic A., Hauser G., How can probiotic improve irritable bowel syndrome symptoms, World J. Gastrointest. Surg., 13, pp. 923-940, (2021); Xi L., Qingqing L., Jiaoyan Y., Ruitao Z., Ting S., Wei J., Na H., Peng Y., Li L., Jing R., Qinhui W., Yan W., Qi Y., Costunolide ameliorates intestinal dysfunction and depressive behaviour in mice with stress-induced irritable bowel syndrome via colonic mast cell activation and central 5-hydroxytryptamine metabolism, Food Funct., 12, pp. 4142-4151, (2021); Krammer L., Sowa A.S., Lorentz A., Mast Cells in Irritable Bowel Syndrome: A Systematic Review, J. Gastrointestin. Liver Dis., 28, pp. 463-472, (2019); Grabauskas G., Wu X.Y., Gao J., Li J.Y., Turgeon D.K., Owyang C., Prostaglandin E-2, Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice, Gastroenterology, 158, pp. 2195-2207, (2020); Feng B., La J.H., Schwartz E.S., Gebhart G.F., Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome, Am. J. Physiol.: Gastrointest. Liver Physiol., 302, pp. G1085-G1098, (2012); Brzozowski B., Mazur-Bialy A., Pajdo R., Kwiecien S., Bilski J., Zwolinska-Wcislo M., Mach T., Brzozowski T., Mechanisms by which Stress Affects the Experimental and Clinical Inflammatory Bowel Disease (IBD): Role of Brain-Gut Axis, Curr. Neuropharmacol., 14, pp. 892-900, (2016); Michielan A., D'Inca R., Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut, Mediators Inflammation, 2015, (2015); Long Y., Du L., Kim J.J., Chen B., Zhu Y., Zhang Y., Yao S., He H., Zheng X., Huang Z., Dai N., MLCK-mediated intestinal permeability promotes immune activation and visceral hypersensitivity in PI-IBS mice, Neurogastroenterol. Motil., 30, (2018); He Y., Yue Y., Zheng X., Zhang K., Chen S.H., Du Z.Y., Curcumin, Inflammation, and Chronic Diseases: How Are They Linked?, Molecules, 20, pp. 9183-9213, (2015); Balmus I.M., Ilie O.D., Ciobica A., Cojocariu R.O., Stanciu C., Trifan A., Cimpeanu M., Cimpeanu C., Gorgan L., Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise-Searching for Gap Fillers in the Oxidative Stress Way of Thinking, Medicina, 56, (2020); Miao L., St Clair D.K., Regulation of superoxide dismutase genes: implications in disease, Free Radicals Biol. Med., 47, pp. 344-356, (2009); De Luca C., Mikhal'chik E.V., Suprun M.V., Papacharalambous M., Truhanov A.I., Korkina L.G., Skin Antiageing and Systemic Redox Effects of Supplementation with Marine Collagen Peptides and Plant-Derived Antioxidants: A Single-Blind Case-Control Clinical Study, Oxid. Med. Cell. Longevity, 2016, (2016); Goyal M.M., Basak A., Human catalase: looking for complete identity, Protein Cell, 1, pp. 888-897, (2010); Vlasova I.I., Peroxidase Activity of Human Hemoproteins: Keeping the Fire under Control, Molecules, 23, (2018); Yang S.Y., Zhang C.Y., Xu W.Q., Li D.T., Feng Y., Wu J.Y., Luo W., Du X.G., Du Z.J., Huang X.L., Heat Stress Decreases Intestinal Physiological Function and Facilitates the Proliferation of Harmful Intestinal Microbiota in Sturgeons, Front. Microbiol., 13, (2022); Sinha A.K., Romano N., Shrivastava J., Monico J., Bishop W.M., Oxidative stress, histopathological alterations and anti-oxidant capacity in different tissues of largemouth bass (Micropterus salmoides) exposed to a newly developed sodium carbonate peroxyhydrate granular algaecide formulated with hydrogen peroxide, Aquat. Toxicol., 218, (2020); Jiang W.D., Feng L., Qu B., Wu P., Kuang S.Y., Jiang J., Tang L., Tang W.N., Zhang Y.A., Zhou X.Q., Liu Y., Changes in integrity of the gill during histidine deficiency or excess due to depression of cellular anti-oxidative ability, induction of apoptosis, inflammation and impair of cell-cell tight junctions related to Nrf2, TOR and NF-κB signaling in fish, Fish Shellfish Immunol., 56, pp. 111-122, (2016); Mete R., Tulubas F., Oran M., Yilmaz A., Avci B.A., Yildiz K., Turan C.B., Gurel A., The role of oxidants and reactive nitrogen species in irritable bowel syndrome: A potential etiological explanation, Med. Sci. Monit., 19, pp. 762-766, (2013); Chimienti G., Orlando A., Lezza A.M.S., D'Attoma B., Notarnicola M., Gigante I., Pesce V., Russo F., The Ketogenic Diet Reduces the Harmful Effects of Stress on Gut Mitochondrial Biogenesis in a Rat Model of Irritable Bowel Syndrome, Int. J. Mol. Sci., 22, (2021); Hardy G., Hardy I., Manzanares W., Selenium supplementation in the critically ill, Nutr. Clin. Pract., 27, pp. 21-33, (2012); Lackner J.M., Ma C.X., Keefer L., Brenner D.M., Gudleski G.D., Satchidanand N., Firth R., Sitrin M.D., Katz L., Krasner S.S., Ballou S.K., Naliboff B.D., Mayer E.A., Type, Rather Than Number, of Mental and Physical Comorbidities Increases the Severity of Symptoms in Patients With Irritable Bowel Syndrome, Clin. Gastroenterol. Hepatol., 11, pp. 1147-1157, (2013); Chen M.J., Ruan G.C., Chen L., Ying S.H., Li G.H., Xu F.H., Xiao Z.F., Tian Y.T., Lv L.L., Ping Y., Cheng Y., Wei Y.L., Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome, Front. Endocrinol., 13, (2022); Artigas F., Serotonin receptors involved in antidepressant effects, Pharmacol. Ther., 137, pp. 119-131, (2013); Fogaca M.V., Duman R.S., Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions, Front. Cell. Neurosci., 13, (2019); Castren E., Monteggia L.M., Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action, Biol. Psychiatry, 90, pp. 128-136, (2021); Sram R.J., Veleminsky M., Veleminsky M., Stejskalova J., The impact of air pollution to central nervous system in children and adults, Neuro. Endocrinol. Lett., 38, pp. 389-396, (2017); Cohen H., Liu T.M., Kozlovsky N., Kaplan Z., Zohar J., Mathe A.A., The Neuropeptide Y (NPY)-ergic System is Associated with Behavioral Resilience to Stress Exposure in an Animal Model of Post-Traumatic Stress Disorder, Neuropsychopharmacology, 37, pp. 350-363, (2012); Simren M., Stotzer P.O., Sjovall H., Abrahamsson H., Bjornsson E.S., Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome, Eur. J. Gastroenterol. Hepatol., 15, pp. 55-62, (2003); Naderi M., Puar P., Zonouzi-Marand M., Chivers D.P., Niyogi S., Kwong R.W.M., A comprehensive review on the neuropathophysiology of selenium, Sci. Total Environ., 767, (2021); Bogatov N.V., Selenium deficiency and its dietary correction in patients with irritable bowel syndrome and chronic catarrhal colitis, Vopr. Pitan., 76, pp. 35-39, (2007); Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjorsvik B.R., Haleem N., Benitez-Paez A., Sanz Y., Hausken T., Lied G.A., Lundervold A., Berentsen B., Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome, World J. Gastroenterol., 28, pp. 412-431, (2022); Ahluwalia B., Iribarren C., Magnusson M.K., Sundin J., Clevers E., Savolainen O., Ross A.B., Tornblom H., Simren M., Ohman L., A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome, Cells, 10, (2021); Hove H., Mortensen P.B., Colonic lactate metabolism and D-lactic acidosis, Dig. Dis. Sci., 40, pp. 320-330, (1995); Tana C., Umesaki Y., Imaoka A., Handa T., Kanazawa M., Fukudo S., Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome, Neurogastroenterol. Motil., 22, (2010); Wu Z., Liu H., Yan E., Zhang X., Wang Y., Huang C., He T., Miao L., Yang L., Jiang R., Qi C., Liu C., Wang D., Yang C., Desulfovibrio confers resilience to the comorbidity of pain and anxiety in a mouse model of chronic inflammatory pain, Psychopharmacology, 240, pp. 87-100, (2023); Hong Y., Sheng L., Zhong J., Tao X., Zhu W., Ma J., Yan J., Zhao A., Zheng X., Wu G., Li B., Han B., Ding K., Zheng N., Jia W., Li H., Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice, Gut Microbes, 13, (2021); Wouw M.V.D., Schellekens H., Dinan T.G., Cryan J.F., Microbiota-gut-brain axis: modulator of host metabolism and appetite, J. Nutr., 147, pp. 727-745, (2017); Woting A., Blaut M., The Intestinal Microbiota in Metabolic Disease, Nutrients, 8, (2016); Cheng D., Xie M.Z., A review of a potential and promising probiotic candidate-Akkermansia muciniphila, J. Appl. Microbiol., 130, pp. 1813-1822, (2021); Naito Y., Uchiyama K., Takagi T., A next-generation beneficial microbe: Akkermansia muciniphila, J. Clin. Biochem. Nutr., 63, pp. 33-35, (2018); Jiang H.Y., Ling Z.X., Zhang Y.H., Mao H.J., Ma Z.P., Yin Y., Wang W.H., Tang W.X., Tan Z.L., Shi J.F., Li L.J., Ruan B., Altered fecal microbiota composition in patients with major depressive disorder, Brain, Behav., Immun., 48, pp. 186-194, (2015); Valles-Colomer M., Falony G., Darzi Y., Tigchelaar E.F., Wang J., Tito R.Y., Schiweck C., Kurilshikov A., Joossens M., Wijmenga C., Claes S., Van Oudenhove L., Zhernakova A., Vieira-Silva S., Raes J., The neuroactive potential of the human gut microbiota in quality of life and depression, Nat. Microbiol., 4, pp. 623-632, (2019); Ait-Belgnaoui A., Colom A., Braniste V., Ramalho L., Marrot A., Cartier C., Houdeau E., Theodorou V., Tompkins T., Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice, Neurogastroenterol. Motil., 26, pp. 510-520, (2014); Xu Y., Wang N., Tan H.Y., Li S., Zhang C., Feng Y.B., Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems, Front. Microbiol., 11, (2020); Goodrich J.K., Waters J.L., Poole A.C., Sutter J.L., Koren O., Blekhman R., Beaumont M., Van Treuren W., Knight R., Bell J.T., Spector T.D., Clark A.G., Ley R.E., Human genetics shape the gut microbiome, Cell, 159, pp. 789-799, (2014); Lee J., d'Aigle J., Atadja L., Quaicoe V., Honarpisheh P., Ganesh B.P., Hassan A., Graf J., Petrosino J., Putluri N., Zhu L., Durgan D.J., Bryan R.M., McCullough L.D., Venna V.R., Gut Microbiota-Derived Short-Chain Fatty Acids Promote Poststroke Recovery in Aged Mice, Circ. Res., 127, pp. 453-465, (2020); Palmnas-Bedard M.S.A., Costabile G., Vetrani C., Aberg S., Hjalmarsson Y., Dicksved J., Riccardi G., Landberg R., The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs, Am. J. Clin. Nutr., 116, pp. 862-874, (2022)^H. Zhu; School of Pharmacy, Shanghai Jiao Tong, University, No. 800 Dongchuan Road, Minhang District, China; email: julie19930@sjtu.edu.cn; D. Chen; School of Pharmacy, Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, China; email: chen_lab@sjtu.edu.cn^^Royal Society of Chemistry^^^^^^20426496^^^37212199.0^English^Food. Funct.^Article^Final^^Scopus^2-s2.0-85162818640
Abdellah S.A.; Gal C.; Laterza L.; Velenza V.; Settanni C.R.; Napoli M.; Schiavoni E.; Mora V.; Petito V.; Gasbarrini A.^Abdellah, Samira Ait (57190169470); Gal, Caroline (57221644730); Laterza, Lucrezia (55428675300); Velenza, Venanzio (58299234600); Settanni, Carlo Romano (57189993230); Napoli, Marco (57203000868); Schiavoni, Elisa (57188980383); Mora, Vincenzina (57203530618); Petito, Valentina (41961464200); Gasbarrini, Antonio (58589716200)^57190169470; 57221644730; 55428675300; 58299234600; 57189993230; 57203000868; 57188980383; 57203530618; 41961464200; 58589716200^Effect of a Multistrain Probiotic on Leaky Gut in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study^2023^Digestive Diseases^41.0^3^^489^499^10.0^3^10.1159/000526712^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149019547&doi=10.1159%2f000526712&partnerID=40&md5=aa9815c5dcfb6df48e60a78932b5f8e6^PiLeJe Laboratoire, Paris, France; Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy^Abdellah S.A., PiLeJe Laboratoire, Paris, France; Gal C., PiLeJe Laboratoire, Paris, France; Laterza L., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Velenza V., Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Settanni C.R., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Napoli M., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Schiavoni E., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Mora V., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Petito V., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy; Gasbarrini A., Cemad, Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli Irccs, Università Cattolica Del Sacro Cuore, Roma, Italy^Background: A probiotic mixture prevented epithelial barrier impairment in various experimental models. The objective was to evaluate its effects in patients suffering from IBS with diarrhea (IBS-D) with confirmed leaky gut. Methods: IBS-D patients with increased intestinal permeability measured by radionuclide tracers were enrolled in this pilot, open-label, prospective, interventional, single-center, Phase IV study. Patients received two capsules of a multistrain probiotic a day for 30 days and were evaluated by repeated intestinal permeability tests, the Bristol Stool Scale, and patient-perceived quality of life and satisfaction. Results: Of the 30 enrolled patients (mean age: 42.1 [SD: 13.1] years; female: 60%), 27 completed the study (full analysis set [FAS]), and 18 had no major protocol violation (per protocol set [PPS]). On D30, an improvement of intestinal permeability was observed in 81.5% of patients in FAS, normalization being observed in 37% of the participants (44% in PPS). The mean intestinal permeability was significantly decreased: baseline minus D30, 3.4 (95% CI: 1.7, 5.2); the IBS-QOL total score was significantly increased: D30 minus baseline, 8.0 (95% CI: 3.0, 12.9); and stool consistency was significantly improved. On D15 and D30, 96.3% of patients claimed that their IBS symptoms had been satisfactory alleviated, and a significant improvement was reported for the following VAS-IBS items: abdominal pain, diarrhea, and impact of gastrointestinal problems in daily life. Compliance and tolerance were satisfactory. Conclusion: The multistrain probiotic tested may reduce intestinal permeability in a considerable proportion of patients and may improve abdominal pain, stool consistency, and quality of life. These results pave the way for larger, placebo-controlled clinical studies.  © 2023 S. Karger AG. All rights reserved.^Intestinal permeability; Irritable bowel syndrome; Leaky gut syndrome; Probiotics; Quality of life^Abdominal Pain; Adult; Diarrhea; Female; Humans; Irritable Bowel Syndrome; Pilot Projects; Probiotics; Prospective Studies; Quality of Life; Treatment Outcome; acetylsalicylic acid; C reactive protein; lactibiane tolrance; multistrain probiotics; nonsteroid antiinflammatory agent; probiotic agent; protein glutamine gamma glutamyltransferase antibody; radioisotope; tracer; unclassified drug; abdominal pain; adult; aged; Article; bacterial strain; bloating; blood pressure; blood sampling; body temperature; breathing rate; Bristol Stool Scale; colonoscopy; constipation; diarrhea; digestive system disease; disease assessment; drug safety; drug tolerability; enzyme linked immunosorbent assay; female; flatulence; follow up; gastrointestinal tumor; heart rate; human; Irritable Bowel Syndrome Quality of Life; irritable colon; lactose intolerance; leaky gut; leaky gut; major clinical study; male; open study; patient-reported outcome; pilot study; prospective study; psychological well-being; quality of life; satisfaction; urinary excretion; visual analog scale; young adult; clinical trial; complication; diarrhea; irritable colon; phase 4 clinical trial; treatment outcome^^acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; C reactive protein, 9007-41-4^lactibiane tolrance, PiLeJe Laboratoire^PiLeJe Laboratoire^PiLeJe Laboratoire^This study was sponsored by PiLeJe Laboratoire^Moayyedi P., Mearin F., Azpiroz F., Andresen V., Barbara G., Corsetti M., Et al., Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice, United European Gastroenterol J., 5, 6, pp. 773-788, (2017); Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol Hepatol., 5, 10, pp. 908-917, (2020); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., Et al., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J Clin Gastroenterol., 46, pp. S52-S55, (2012); Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P., A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-KultR) in the management of diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol., 18, 1, (2018); Quigley E.M.M., Fried M., Gwee K.-A., Khalif I., Hungin P., Lindberg G., Et al., Irritable bowel syndrome: a global perspective, (2015); Vasant D.H., Paine P.A., Black C.J., Houghton L.A., Everitt H.A., Corsetti M., Et al., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome, Gut., 70, 7, pp. 1214-1240, (2021); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion., 85, 1, pp. 40-46, (2012); La Fata G., Weber P., Mohajeri M.H., Probiotics and the gut immune system: indirect regulation, Probiotics Antimicrob Proteins., 10, 1, pp. 11-21, (2018); Nebot-Vivinus M., Harkat C., Bzioueche H., Cartier C., Plichon-Dainese R., Moussa L., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J Gastroenterol., 20, 22, pp. 6832-6843, (2014); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., Et al., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol., 14, (2021); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain., 146, 1-2, pp. 41-46, (2009); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Et al., Bowel disorders, Gastroenterology., 150, 6, pp. 1393e5-1407e5, (2016); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the visual analogue scale for irritable bowel syndrome (VAS-IBS), BMC Gastroenterol., 7, (2007); Patrick D.L., Drossman D.A., Frederick I.O., DiCesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: development and validation of a new measure, Dig Dis Sci., 43, 2, pp. 400-411, (1998); Andrae D.A., Patrick D.L., Drossman D.A., Covington P.S., Evaluation of the irritable bowel syndrome quality of life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients, Health Qual Life Outcomes., 11, (2013); Bjarnason I., Peters T.J., Veall N., A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test, Lancet., 1, 8320, pp. 323-325, (1983); Resnick R.H., Royal H., Marshall W., Barron R., Werth T., Intestinal permeability in gastrointestinal disorders, Use of oral [99mTc]DTPA. Dig Dis Sci., 35, 2, pp. 205-211, (1990); Scarpellini E., Valenza V., Gabrielli M., Lauritano E.C., Perotti G., Merra G., Et al., Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed?, Am J Gastroenterol., 105, 2, pp. 323-327, (2010); Fasano A., Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications, Clin Gastroenterol Hepatol., 10, pp. 1096-1100, (2012); Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci U S A., 106, 39, pp. 16799-16804, (2009); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Et al., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United European Gastroenterol J., 7, 5, pp. 709-715, (2019); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol., 32, 9, pp. 920-924, (1997); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Et al., The effectiveness and safety of multistrain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study, Nutrients., 13, 3, (2021); Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Et al., Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of Irritable Bowel Syndrome (IBS): a randomized, placebo-controlled study, Nutrients., 12, 4, (2020); Martoni C.J., Srivastava S., Leyer G.J., Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial, Nutrients., 12, 2, (2020); Zeng J., Li Y.-Q., Zuo X.-L., Zhen Y.-B., Yang J., Liu C.-H., Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther., 28, 8, pp. 994-1002, (2008); Boonma P., Shapiro J.M., Hollister E.B., Badu S., Wu Q., Weidler E.M., Et al., Probiotic VSL#3 treatment reduces colonic permeability and abdominal pain symptoms in patients with irritable bowel syndrome, Front Pain Res., 2, (2021); Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., Et al., Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients, Eur J Clin Invest., 50, 3, (2020); Caviglia G.P., Tucci A., Pellicano R., Fagoonee S., Rosso C., Abate M.L., Et al., Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with Bifidobacterium longum ES1 for 8 or 12 weeks: a preliminary report, J Clin Med., 9, (2020); Moser A.M., Spindelboeck W., Halwachs B., Strohmaier H., Kump P., Gorkiewicz G., Et al., Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome, Eur J Nutr., 58, 7, pp. 2767-2778, (2019); Talley N.J., Holtmann G.J., Jones M., Koloski N.A., Walker M.M., Burns G., Et al., Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity, Gut., 69, 9, pp. 1-3, (2020); Massier L., Chakaroun R., Kovacs P., Heiker J.T., Blurring the picture in leaky gut research: How shortcomings of zonulin as a biomarker mislead the field of intestinal permeability, Gut., 70, 9, pp. 1801-1802, (2021); Scheffler L., Crane A., Heyne H., Tonjes A., Schleinitz D., Ihling C.H., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front Endocrinol., 9, (2018); Ajamian M., Steer D., Rosella G., Gibson P.R., D'Auria S., Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems, PLoS One., 14, 1, (2019); Meira De-Faria F., Bednarska O., Strom M., Soderholm J.D., Walter S.A., Keita A.V., Colonic paracellular permeability and circulating zonulin-related proteins, Scand J Gastroenterol., 56, 4, pp. 424-431, (2021); Drouault-Holowacz S., Foligne B., Dennin V., Goudercourt D., Terpend K., Burckel A., Et al., Anti-inflammatory potential of the probiotic dietary supplement lactibiane tolerance: in vitro and in vivo considerations, Clin Nutr., 25, 6, pp. 994-1003, (2006); Rossi M., Sganga G., Mazzone M., Valenza V., Guarneri S., Portale G., Et al., Cardiopulmonary bypass in man: role of the intestine in a selflimiting inflammatory response with demonstrable bacterial translocation, Ann Thorac Surg., 77, 2, pp. 612-618, (2004)^S.A. Abdellah; PiLeJe Laboratoire, Paris, France; email: s.aitabdellah@pileje.com^^S. Karger AG^^^^^^02572753^^DIDIE^36007493.0^English^Dig. Dis.^Article^Final^All Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85149019547
Xu Y.; Yao R.; Zhao W.; Zhu J.; Yao J.; Zhang G.; Liu D.^Xu, Yan (58459840900); Yao, Ru (59029013100); Zhao, Wenxue (58423369300); Zhu, Jianguo (58366205200); Yao, Jingchun (57193604202); Zhang, Guimin (58297616700); Liu, Dongguang (58429640400)^58459840900; 59029013100; 58423369300; 58366205200; 57193604202; 58297616700; 58429640400^Spirocyclopiperazinium salt compound DXL-A-24 improves visceral sensation and gut microbiota in a rat model of irritable bowel syndrome^2023^Heliyon^9.0^6^e16544^^^^3^10.1016/j.heliyon.2023.e16544^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160690644&doi=10.1016%2fj.heliyon.2023.e16544&partnerID=40&md5=14b025ac6d1210617405024141b90d94^From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China^Xu Y., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Yao R., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Zhao W., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Zhu J., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Yao J., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Zhang G., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China; Liu D., From the Center for New Drug Pharmacology, Lunan Pharmaceutical Group Corporation, Linyi, China^Irritable bowel syndrome (IBS) is characterized by visceral pain, impaired intestinal barrier and a disorder of the microbiota. DXL-A-24 has analgesic and anti-inflammatory effects by inhibiting neuropeptides and inflammatory factors. In this study, we used chronic unpredictable mild stress (CUMS) induced IBS model, to assess the action of DXL-A-24 on visceral hypersensitivity, barrier function and microbiota. Visceral sensation was assessed by colorectal distension in a model of IBS. The expressions of substance P (SP) and calcitonin gene-related peptide (CGRP) were detected by immunohistochemistry and western blot, the contents of diamine oxidase (DAO) and D-lactic acid were detected by ELISA, and 16S rRNA to detect the diversity of gut microbiota. CUMS reduced visceral pain threshold and increased colonic permeability of rats. DXL-A-24 for 28 days inhibited these changes. DXL-A-24 also decreased the expression of SP, CGRP in colon and D-LA, DAO in serum. Besides, DXL-A-24 increased the richness and diversity of intestinal microbiota. In conclusions, DXL-A-24 reduced visceral sensitivity, improved intestinal barrier and regulated gut microbiota in rats with IBS. © 2023^Gut barrier; Irritable bowel syndrome; Microbiota; Visceral hypersensitivity^^^^^^Lunan Pharmaceutical Group Corporation^This work was supported by Lunan Pharmaceutical Group Corporation. ^Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N. Engl. J. Med., 376, 26, pp. 2566-2578, (2017); Raskov H., Burcharth J., Pommergaard H.C., Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 7, 5, pp. 365-383, (2016); Salvo Romero E., Alonso Cotoner C., Pardo Camacho C., Casado Bedmar M., Vicario M., The intestinal barrier function and its involvement in digestive disease, Rev. Esp. Enferm. Dig., 107, 11, pp. 686-696, (2015); Li N., Liu Q., Li R.T., Sun Q., Jiang Y.M., Ye J., Anti-arthritic effect of the spirocyclopiperazinium salt compound LXM-15 in rats and its underlying mechanism, Inflammation, 43, 3, pp. 903-915, (2020); Gao X., Sun Q., Zhang W., Jiang Y., Li R., Ye J., Anti-inflammatory effect and mechanism of the spirocyclopiperazinium salt compound LXM-15 in rats and mice, Inflamm. Res., 67, 4, pp. 363-370, (2018); Yang H., Sun Q., Liang Y., Jiang Y., Li R., Ye J., Antinociception of the spirocyclopiperazinium salt compound LXM-15 via activating α7 nAChR and M4 mAChR and inhibiting CaMKIIα/cAMP/CREB/CGRP signalling pathway in mice, Regul. Toxicol. Pharmacol., 94, pp. 108-114, (2018); Wang D., Yang H., Liang Y., Wang X., Du X., Li R., Jiang Y., Ye J., Antinociceptive Effect of spirocyclopiperazinium salt compound DXL-A-24 and the underlying mechanism, Neurochem. Res., 44, 12, pp. 2786-2795, (2019); Liu Q., Gao X., Wang T., Wang X., Li R., Jiang Y., Ye J., Effect and underlying mechanisms of spirocyclopiperazinium salt compound DXL-A-24 in rats following spinal nerve ligation, Brain Res., 1800, (2023); Fan J., Chang H., Dong S., Yan X., Wang J., Hong Y., Establishment and evaluation of a novel rat model of chronic stress-induced irritable bowel syndrome, Acta Labor. Anim. Sci. Sin., 18, 2, pp. 91-95+88, (2010); Yang J.P., Yao M., Jiang X.H., Wang L.N., Establishment of model of visceral pain due to colorectal distension and its behavioral assessment in rats, World J. Gastroenterol., 12, 17, pp. 2781-2784, (2006); Shi H.L., Liu C.H., Ding L.L., Zheng Y., Fei X.Y., Lu L., Zhou X.M., Yuan J.Y., Xie J.Q., Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction, World J. Gastroenterol., 21, 16, pp. 4852-4863, (2015); Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X., Impact of psychological stress on irritable bowel syndrome, World J. Gastroenterol., 20, 39, pp. 14126-14131, (2014); Sun H., Ma Y., An S., Wang Z., Altered gene expression signatures by calcitonin gene-related peptide promoted mast cell activity in the colon of stress-induced visceral hyperalgesia mice, Neurogastroenterol. Motil., 33, 6, (2021); Siiskonen H., Harvima I., Mast cells and sensory nerves contribute to neurogenic inflammation and pruritus in chronic skin inflammation, Front. Cell Neurosci., 13, (2019); Noor-Mohammadi E., Ligon C.O., Mackenzie K., Stratton J., Shnider S., Greenwood-Van Meerveld B., A Monoclonal Anti-Calcitonin Gene-Related Peptide Antibody Decreases Stress-Induced Colonic Hypersensitivity, J. Pharmacol. Exp. Ther., 379, 3, pp. 270-279, (2021); Al-Qudah M., Alkahtani R., Akbarali H.I., Murthy K.S., Grider J.R., Stimulation of synthesis and release of brain-derived neurotropic factor from intestinal smooth muscle cells by substance P and pituitary adenylate cyclase-activating peptide, Neurogastroenterol. Motil., 27, 8, pp. 1162-1174, (2015); Weinstock J.V., The role of substance P, hemokinin and their receptor in governing mucosal inflammation and granulomatous responses, Front. Biosci., 9, pp. 1936-1943, (2004); Holzer P., Holzer-Petsche U., Tachykinin receptors in the gut: physiological and pathological implications, Curr. Opin. Pharmacol., 1, 6, pp. 583-590, (2001); Galland L., The gut microbiome and the brain, J. Med. Food, 17, 12, pp. 1261-1272, (2014); Li H.C., Fan X.J., Chen Y.F., Tu J.M., Pan L.Y., Chen T., Yin P.H., Peng W., Feng D.X., Early prediction of intestinal mucosal barrier function impairment by elevated serum procalcitonin in rats with severe acute pancreatitis, Pancreatology, 16, 2, pp. 211-217, (2016); Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L., Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome, Front. Microbiol., 9, (2018); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, 6, pp. 521-30 e248, (2012); O'Mahony S.M., Marchesi J.R., Scully P., Codling C., Ceolho A.M., Quigley E.M., Cryan J.F., Dinan T.G., Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses, Biol. Psychiatry, 65, 3, pp. 263-267, (2009); Enqi W., Jingzhu S., Lingpeng P., Yaqin L., Comparison of the gut microbiota disturbance in rat models of irritable bowel syndrome induced by maternal separation and multiple early-life adversity, Front. Cell Infect. Microbiol., 10, (2021); Bennet S.M., Ohman L., Simren M., Gut microbiota as potential orchestrators of irritable bowel syndrome, Gut Liver, 9, 3, pp. 318-331, (2015); Chen W., Liu F., Ling Z., Tong X., Xiang C., Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer, PLoS One, 7, 6, (2012); Han Y.W., Redline R.W., Li M., Yin L., Hill G.B., McCormick T.S., Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth, Infect. Immun., 72, 4, pp. 2272-2279, (2004); Shang F.M., Liu H.L., Fusobacterium nucleatum and colorectal cancer: a review, World J. Gastrointest. Oncol., 10, 3, pp. 71-81, (2018); Shin N.R., Whon T.W., Bae J.W., Proteobacteria: microbial signature of dysbiosis in gut microbiota, Trends Biotechnol., 33, 9, pp. 496-503, (2015); Moratalla A., Gomez-Hurtado I., Santacruz A., A M., Peiro G., Zapater P., Gonzalez-Navajas J.M., Gimenez P., Such J., Sanz Y., Frances R., Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis, Liver Int., 34, 6, pp. 850-858, (2014); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Kerckhoffs A.P., Samsom M., van der Rest M.E., de Vogel J., Knol J., Ben-Amor K., Akkermans L.M., Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients, World J. Gastroenterol., 15, 23, pp. 2887-2892, (2009); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Rigsbee L., Agans R., Shankar V., Kenche H., Khamis H.J., Michail S., Paliy O., Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 107, 11, pp. 1740-1751, (2012); Malinen E., Rinttila T., Kajander K., Matto J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am. J. Gastroenterol., 100, 2, pp. 373-382, (2005); Duboc H., Rainteau D., Rajca S., Humbert L., Farabos D., Maubert M., Grondin V., Jouet P., Bouhassira D., Seksik P., Sokol H., Coffin B., Sabate J.M., Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, 6, pp. 513-520, (2012); O'Callaghan J., O'Toole P.W., Lactobacillus: host-microbe relationships, Curr. Top. Microbiol. Immunol., 358, pp. 119-154, (2013); Ponnusamy K., Choi J.N., Kim J., Lee S.Y., Lee C.H., Microbial community and metabolomic comparison of irritable bowel syndrome faeces, J. Med. Microbiol., 60, pp. 817-827, (2011); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Mack A., Bobardt J.S., Hass A., Nichols K.B., Schmid R.M., Stein-Thoeringer C.K., Changes in gut microbial metagenomic pathways associated with clinical outcomes after the elimination of malabsorbed sugars in an IBS cohort, Gut Microbes, 11, 3, pp. 620-631, (2020); Devriese S., Eeckhaut V., Geirnaert A., Van den Bossche L., Hindryckx P., Van de Wiele T., Van Immerseel F., Ducatelle R., De Vos M., Laukens D., Reduced mucosa-associated butyricicoccus activity in patients with ulcerative colitis correlates with aberrant claudin-1 expression, J. Crohns Colitis, 11, 2, pp. 229-236, (2017); Eeckhaut V., Machiels K., Perrier C., Romero C., Maes S., Flahou B., Steppe M., Haesebrouck F., Sas B., Ducatelle R., Vermeire S., Van Immerseel F., Butyricicoccus pullicaecorum in inflammatory bowel disease, Gut, 62, 12, pp. 1745-1752, (2013); Kong C., Gao R., Yan X., Huang L., Qin H., Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet, Nutrition, 60, pp. 175-184, (2019); Perez-Burillo S., Pastoriza S., Fernandez-Arteaga A., Luzon G., Jimenez-Hernandez N., D'Auria G., Francino M.P., Rufian-Henares J.A., Spent coffee grounds extract, rich in mannooligosaccharides, promotes a healthier gut microbial community in a dose-dependent manner, J. Agric. Food Chem., 67, 9, pp. 2500-2509, (2019); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut microbiota in patients with irritable bowel syndrome-a systematic review, Gastroenterology, 157, 1, pp. 97-108, (2019)^D. Liu; Lunan Pharmaceutical Group Corporation, Linyi, Shandong, 276000, China; email: liudongguang0176@163.com^^Elsevier Ltd^^^^^^24058440^^^^English^Heliyon^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85160690644
Sun J.; Zhang M.; Liu W.; Liu Y.; Zhang D.; Fan X.; Zhang J.; Li T.; Lu M.^Sun, Jing (58485206300); Zhang, Mengqiu (58302524500); Liu, Wei (58480217200); Liu, Youqian (57244836400); Zhang, Dongjian (56484812800); Fan, Xinyu (57226534707); Zhang, Jian (55922439400); Li, Tian (57217011478); Lu, Min (56553533900)^58485206300; 58302524500; 58480217200; 57244836400; 56484812800; 57226534707; 55922439400; 57217011478; 56553533900^Evaluation of the effectiveness and mechanism of action of the Chang-Kang-Fang formula combined with bifid triple viable capsules on diarrhea-predominant irritable bowel syndrome^2023^Frontiers in Microbiology^14.0^^1160783^^^^3^10.3389/fmicb.2023.1160783^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164749336&doi=10.3389%2ffmicb.2023.1160783&partnerID=40&md5=984338a5c1bb3f68e601d8edb0510c91^Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China; School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Suqian Hospital of Traditional Chinese Medicine, Suqian, China; Department of Gastroenterology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China^Sun J., Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China, Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China; Zhang M., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Suqian Hospital of Traditional Chinese Medicine, Suqian, China; Liu W., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Liu Y., Department of Gastroenterology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Zhang D., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Fan X., Department of Gastroenterology, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Zhang J., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Li T., Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Lu M., School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China^Introduction: The Chang-Kang-Fang (CKF) formula, a traditional Chinese herbal formula, can decrease serotonin (5-HT) levels and treat irritable bowel syndrome (IBS). Probiotics have a better synergistic effect on diarrhea-predominant IBS (IBS-D) when combined with 5-HT3 receptor antagonists. The present study aimed to elucidate the efficacy and the mechanisms of action of the CKF formula combined with bifid triple viable capsules (PFK) against IBS-D. Methods: The rat models of IBS-D were induced by gavage with senna decoction plus restraint stress. The CKF formula, PFK and their combination were administered to the rats. Their effects were evaluated based on general condition of the rats and the AWR score. The levels of 5-HT and fos protein in the colon and hippocampus were measured by immunohistochemistry. The levels of SP and VIP, as well as ZO-1 and occludin in the colon, were determined by enzyme-linked immunosorbent assay and immunohistochemistry. The intestinal microbiota in faeces was analyzed by 16S rRNA high-throughput sequencing. Results: The results showed that the oral CKF formula combined with PFK (CKF + PFK) could significantly relieve the symptoms of IBS-D, including elevating the weight rate and decreasing the AWR score. Compared with the MC group, administration of CKF + PFK significantly reduced the expression of fos in the colon and hippocampus and that of 5-HT, SP and VIP in the colon and increased the levels of 5-HT in the hippocampus and ZO-1 and occludin in the colon. The above indexes exhibited statistical significance in the CKF + PFK group relative to those in the other groups. Moreover, treatment with CKF + PFK improved the diversity of intestinal microbiota and the abundance of Firmicutes, Lachnospiraceae and Ruminococcaceae but decreased those of Bacteroidetes and Prevotellaceae. Conclusions: The CKF formula combined with PFK may have a synergistic effect on IBS-D by slowing gastrointestinal motility, lowering visceral hypersensitivity, enhancing the intestinal barrier function and modulating the composition of intestinal microbiota. Copyright © 2023 Sun, Zhang, Liu, Liu, Zhang, Fan, Zhang, Li and Lu.^bifid triple viable capsule; Chang-Kang-Fang; diarrhea-predominant irritable bowel syndrome; intestinal microbiota; serotonin^bifid triple viable capsule; occludin; probiotic agent; protein fos; protein ZO1; RNA 16S; serotonin; serotonin 3 antagonist; unclassified drug; vasoactive intestinal polypeptide; abdominal withdrawal reflex; animal experiment; animal model; animal tissue; Article; Bacteroidetes; Chang Kang Fang; comparative effectiveness; diarrhea; down regulation; enzyme linked immunosorbent assay; epithelium cell; feces; Firmicutes; gastrointestinal motility; gene sequence; high throughput sequencing; hippocampus; immobilization stress; immunohistochemistry; intestine flora; irritable colon; Lachnospiraceae; male; microbial community; microcapsule; monotherapy; nonhuman; operational taxonomic unit; physiological stress; polymerase chain reaction; Prevotellaceae; protein expression; Proteobacteria; quality control; rat; Ruminococcaceae; synergistic effect; visceral hyperalgesia^^occludin, 176304-61-3; serotonin, 50-67-9; vasoactive intestinal polypeptide, 37221-79-7^MiSeq, Illumina, United States^Illumina, United States^Jiangsu Cadre Health Research Project; Jiangsu Province Traditional Chinese Medicine Science and Technology Development Project, (ZD201708); Nanjing Hilshou Biotechnology Co.; Nanjing Lishui District Hospital of Traditional Chinese Medicine, (lzy2019yj002); Jiangsu Commission of Health, (BJ20026)^Funding text 1: This research was supported by Jiangsu Province Traditional Chinese Medicine Science and Technology Development Project (ZD201708) (design of the study, analysis of data, collection of data), Jiangsu Cadre Health Research Project, Jiangsu Commission of Health (BJ20026) (writing the manuscript), Nanjing Lishui District Hospital of Traditional Chinese Medicine (lzy2019yj002) (interpretation of data). ; Funding text 2: We thank Nanjing Hilshou Biotechnology Co., LTD for targeting capsule technology support.^Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea predominant-irritable bowel syndrome (ibs-d): effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, (2021); Bearcroft C.P., Perrett D., Farthing M.J.G., Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study, Gut, 42, pp. 42-46, (1998); Bu F.-L., Chen R.-L., Lin Z.-Y., Cao H.-J., Robinson N., Liang N., Et al., Chinese herbal medicine versus probiotics for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials, Eur. J. Integr. Med, 38, (2020); Chao G., Wang Z., Yang Y., Zhang S., LncRNA H19 as a Competing Endogenous RNA to Regulate AQP Expression in the Intestinal Barrier of IBS-D Patients, Front. Physiol, 11, (2021); Chapman C.M.C., Gibson G.R., Rowland I., Health benefits of probiotics: are mixtures more effective than single strains?, Eur. J. Nutr, 50, pp. 1-17, (2011); Chen M.-Y., Qiu Z.-W., Tang H.-M., Zhuang K.-H., Cai Q.-Q., Chen X.-L., Et al., Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: a systematic review and meta-analysis, Medicine, 98, (2019); Choi Y.-D., Sung T.-S., Kim H.-J., La J.-H., Kim T.-W., Yang I.-S., Increased 5-hydroxytryptamine mediates post-inflammatory visceral hypersensitivity via the 5-hydroxytryptamine 3 receptor in rats, Dig. Dis. Sci, 53, pp. 2909-2916, (2008); Choung R.S., Locke G.R., Epidemiology of IBS, Gastroenterol. Clin. N. Am, 40, pp. 1-10, (2011); Cibert-Goton V., Lam C., Lingaya M., Falcone Y., Wood J.N., Bulmer D.C., Et al., Pain severity correlates with biopsy-mediated colonic afferent activation but not psychological scores in patients with IBS-D, Clin. Transl. Gastroenterol, 12, (2021); Compare D., Rocco A., Coccoli P., Angrisani D., Sgamato C., Iovine B., Et al., Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome, BMC Gastroenterol, 17, (2017); Espley R.V., Butts C.A., Laing W.A., Martell S., Smith H., McGhie T.K., Et al., Dietary flavonoids from modified apple reduce inflammation markers and modulate gut microbiota in mice, J. Nutr, 144, pp. 146-154, (2014); Fan X., Lu M., Ren J., The effect of Chang-Kang-Fang formula on SERT and 5-HT3 receptors in the intestinal tissues of IBS-D rats, Acta Chin. Med. Pharmacol, 47, pp. 12-18, (2019); Flores-Ramos M., Moreno J., Heinze G., Aguilera-Perez R., Pellicer Graham F., Gonadal hormone levels and platelet tryptophan and serotonin concentrations in perimenopausal women with or without depressive symptoms, Gynecol. Endocrinol, 30, pp. 232-235, (2014); Foley S., Garsed K., Singh G., Duroudier N.P., Swan C., Hall I.P., Et al., Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation, Gastroenterology, 140, pp. 1434-1443.e1, (2011); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter (SERT) expression in IBS is modulated by gut microbiota via mast cell–prostaglandin E2, Gastroenterology, 162, pp. 1962-1974.e6, (2022); Geng Q., Yu Z., Shu-Kun, Serotonin transporter and cholecystokinin in diarrhea-predominant irritable bowel syndrome: associations with abdominal pain, visceral hypersensitivity and psychological performance, World J. Clin. Cases, 8, pp. 1632-1641, (2020); Ghoshal U.C., Srivastava D., Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype, World J. Gastroenterol, 20, pp. 2482-2491, (2014); Hou Q., Huang Y., Zhang C., Zhu S., Li P., Chen X., Et al., MicroRNA-200a targets cannabinoid receptor 1 and serotonin transporter to increase visceral hyperalgesia in diarrhea-predominant irritable bowel syndrome rats, J. Neurogastroenterol. Motil, 24, pp. 656-668, (2018); Hou Q., Huang Y., Zhu S., Li P., Chen X., Hou Z., Et al., MiR-144 increases intestinal permeability in ibs-d rats by targeting OCLN and ZO1, Cell. Physiol. Biochem, 44, pp. 2256-2268, (2017); Houghton L.A., Atkinson W., Whitaker R.P., Whorwell P.J., Rimmer M.J., Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome, Gut, 52, pp. 663-670, (2003); Houghton L.A., Brown H., Atkinson W., Morris J., Fell C., Whorwell P.J., Et al., 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status, Aliment. Pharmacol. Ther, 30, pp. 919-929, (2009); Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P., A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult(R)) in the management of diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 18, (2018); Jiang X., Yang S., Zhou X., Zhang Y., Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis, Eur. Rev. Med. Pharmacol. Sci, 24, pp. 935-942, (2020); Jie R., Xinyu F., Zhiwei F., Sheng J., Min L., Effect of Changkang formula on MC in rats with IBS-D, Information on Traditional Chinese Medicine, 37, (2020); Ko S.J., Ryu B., Kim J., Hong B.G., Park J.W., Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea study protocol for a randomized controlled trial, Trials, 12, (2011); Koloski N.A., Talley N.J., Huskic S.S., Boyce P.M., Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia, Aliment. Pharmacol. Ther, 17, pp. 841-851, (2003); Kruijer W., Schubert D., Verma I.M., Induction of the proto-oncogene fos by nerve growth factor, Proc. Natl. Acad. Sci. U. S. A, 82, pp. 7330-7334, (1985); Kwak D.S., Jun D.W., Seo J.G., Chung W.S., Park S.-E., Lee K.N., Et al., Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease, Eur. J. Gastroenterol. Hepatol, 26, pp. 1353-1359, (2014); Lacy B.E., Chey W.D., Cash B.D., Lembo A.J., Dove L.S., Covington P.S., Eluxadoline efficacy in IBS-D patients who report prior loperamide use, Am. J. Gastroenterol, 112, pp. 924-932, (2017); Lacy B.E., Harris L.A., Chang L., Lucak S., Gutman C., Dove L.S., Et al., Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials, Ther. Adv. Gastroenterol, 12, (2019); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Li J., Cui H., Cai Y., Lin J., Song X., Zhou Z., Et al., Tong-Xie-Yao-Fang regulates 5-ht level in diarrhea predominant irritable bowel syndrome through gut microbiota modulation, Front. Pharmacol, 9, (2018); Li L., Cui H., Li T., Qi J., Chen H., Gao F., Et al., Synergistic effect of berberine-based chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo, Front. Pharmacol, 11, (2020); Li X., Shen M., Effects of changkang prescription on SP and VIP in diarrheal irritable bowel syndrome rats, Chin. J. Exp. Tradit. Med. Formulae, 21, pp. 112-115, (2015); Liang S.-B., Liang C.-H., Yang S.-H., Li Y.-Q., Tian Z.-Y., Robinson N., Et al., Clinical effects and safety of compound glutamine entersoluble capsules for diarrhea-predominant irritable bowel syndrome: a systematic review and meta-analysis, Eur. J. Integr. Med, 32, (2019); Liang D., Longgui N., Guoqiang X., Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis, Medicine, 98, (2019); Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F., Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-ibs: an update, Dis. Markers, 2020, pp. 2886268-2886212, (2020); Liu L.S., Shenoy M., Pasricha P.J., The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia, Neurogastroenterol. Motil, 23, pp. 356-e161, (2011); Lu Z., Duan L., Liu Y., Leng Y., Wang K.J., A meta-analysis of the prevalence and risk factors of irritable bowel syndrome in Chinese community, Zhonghua Nei Ke Za Zhi, 53, pp. 969-975, (2014); Magzal F., Even C., Haimov I., Agmon M., Asraf K., Shochat T., Et al., Associations between fecal short-chain fatty acids and sleep continuity in older adults with insomnia symptoms, Sci. Rep, 11, (2021); Mao Q., Shi L., Wang Z.G., Luo Y.H., Wang Y.Y., Li X., Et al., Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome, J. Ethnopharmacol, 201, pp. 123-135, (2017); Marciani L., Wright J., Foley S., Hoad C.L., Totman J.J., Bush D., Et al., Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging, Aliment. Pharmacol. Ther, 32, pp. 655-663, (2010); Mayer E.A., Nance K., Chen S., The Gut–Brain Axis, Annu. Rev. Med, 73, pp. 439-453, (2022); Min Y.W., Rhee P.-L., The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D), Ther. Adv. Gastroenterol, 8, pp. 136-142, (2015); Moore N.A., Sargent B.J., Manning D.D., Guzzo P.R., Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-D, ACS Chem. Neurosci, 4, pp. 43-47, (2013); Nebot-Vivinus M., Harkat C., Bzioueche H., Cartier C., Plichon-Dainese R., Moussa L., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J. Gastroenterol, 20, pp. 6832-6843, (2014); Pham V.T., Calatayud M., Rotsaert C., Seifert N., Richard N., Van den Abbeele P., Et al., Antioxidant vitamins and prebiotic Fos and Xos differentially shift microbiota composition and function and improve intestinal epithelial barrier in vitro, Nutrients, 13, (2021); Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S., Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study, Benef Microbes, 9, pp. 697-706, (2018); Roberts A., Grafton G., Powell A.D., Brock K., Chen C., Xie D., Et al., CSTI-300 (SMP-100); a novel 5-HT3 receptor partial agonist with potential to treat patients with irritable bowel syndrome or carcinoid syndrome, J. Pharmacol. Exp. Ther, 373, pp. 122-134, (2020); Sabo C.M., Dumitrascu D.L., Microbiota and the irritable bowel syndrome, Minerva Gastroenterol, 67, pp. 377-384, (2021); Sadler R., Cramer J.V., Heindl S., Kostidis S., Betz D., Zuurbier K.R., Et al., Short-chain fatty acids improve poststroke recovery via immunological mechanisms, J. Neurosci, 40, pp. 1162-1173, (2020); Sanchez B., Delgado S., Blanco-Miguez A., Lourenco A., Gueimonde M., Margolles A., Probiotics, gut microbiota, and their influence on host health and disease, Mol. Nutr. Food Res, 61, (2017); Schnadower D., Finkelstein Y., Freedman S.B., Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries, Curr. Opin. Gastroenterol, 31, pp. 1-6, (2015); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Et al., The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled study, Nutrients, 13, (2021); Spiller R., Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease, Neurogastroenterol. Motil, 19, pp. 25-31, (2007); Su T., Liu R., Lee A., Long Y., Du L., Lai S., Et al., Altered intestinal microbiota with increased abundance of prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome, Gastroenterol. Res. Pract, 2018, (2018); Sun J., Wu X., Meng Y., Cheng J., Ning H., Peng Y., Et al., Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome(D-IBS), BMC Complement. Altern. Med, 15, (2015); Tang X.-D., Lu B., Li Z.-H., Wei W., Meng L.-N., Li B.-S., Et al., Therapeutic effect of chang’an i recipe on irritable bowel syndrome with diarrhea: a multicenter randomized double-blind placebo-controlled clinical trial, Chin. J. Integr. Med, 24, pp. 645-652, (2018); Tarrerias A.L., Costil V., Vicari F., Letard J.C., Adenis-Lamarre P., Aisene A., Et al., The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome, Dig. Dis, 29, pp. 588-591, (2011); Vacca M., Celano G., Calabrese F.M., Portincasa P., Gobbetti M., De Angelis M., The controversial role of human gut lachnospiraceae, Microorganisms, 8, (2020); van Tilburg M.A., Palsson O.S., Levy R.L., Feld A.D., Turner M.J., Drossman D.A., Et al., Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO, BMC Complement. Altern. Med, 8, (2008); Wu K.-Q., Sun W.-J., Li N., Chen Y.-Q., Wei Y.-L., Chen D.-F., Small intestinal bacterial overgrowth is associated with Diarrhea-predominant irritable bowel syndrome by increasing mainly Prevotella abundance, Scand. J. Gastroenterol, 54, pp. 1419-1425, (2019); Wu H., Zhan K., Rao K., Zheng H., Qin S., Tang X., Et al., Comparison of five diarrhea-predominant irritable bowel syndrome (IBS-D) rat models in the brain-gut-microbiota axis, Biomed. Pharmacother, 149, (2022); Xie S.-Z., Liu B., Ye H.-Y., Li Q.-M., Pan L.-H., Zha X.-Q., Et al., Dendrobium huoshanense polysaccharide regionally regulates intestinal mucosal barrier function and intestinal microbiota in mice, Carbohydr. Polym, 206, pp. 149-162, (2019); Xu X.J., Liu L., Yao S.K., Nerve growth factor and diarrhea-predominant irritable bowel syndrome (IBS-D): a potential therapeutic target?, J Zhejiang Univ Sci B, 17, pp. 1-9, (2016); Yu F.-Y., Huang S.-G., Zhang H.-Y., Ye H., Chi H.-G., Zou Y., Et al., Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis, World J. Gastroenterol, 22, pp. 3451-3459, (2016); Zaleski A., Banaszkiewicz A., Walkowiak J., Butyric acid in irritable bowel syndrome, Prz. Gastroenterol, 6, pp. 350-353, (2013); Zhang X., Zhao Y., Zhang M., Pang X., Xu J., Kang C., Et al., Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats, PLoS One, 7, (2012); Zhao J., Observation and research on the effect of probiotics in the treatment of ulcerative colitis, China Pract Med, 13, pp. 84-85, (2018); Zheng Y., Ching J., Cheng C.W., Lam W.C., Chan K.L., Zhang X., Et al., Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial, Chin. Med, 16, (2021); Zheng Y., Yu T., Tang Y., Xiong W., Shen X., Jiang L., Et al., Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials, PLoS One, 12, (2017); Zhou Y., Han S., He Y., Clinical effects and safety of tongxieyaofang on diarrhea predominant irritable bowel syndrome: a meta-analysis of randomized trails, Evid. Based Complement. Alternat. Med, 2019, pp. 4893876-4893811, (2019); Zhu X., Liu Z., Niu W., Wang Y., Zhang A., Qu H., Et al., Effects of Electroacupuncture at St25 and Bl25 in a Sennae-induced rat model of diarrhoea-predominant irritable bowel syndrome, Acupunct. Med, 35, pp. 216-223, (2017)^T. Li; Department of Central laboratory, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; email: littian26@163.com; M. Lu; School of Third Clinical Medicine, Nanjing University of Chinese Medicine, Nanjing, China; email: lumin@jsatcm.com^^Frontiers Media SA^^^^^^1664302X^^^^English^Front. Microbiol.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85164749336
Marchix J.; Quénéhervé L.; Bordron P.; Aubert P.; Durand T.; Oullier T.; Blondeau C.; Ait Abdellah S.; Bruley des Varannes S.; Chaffron S.; Coron E.; Neunlist M.^Marchix, Justine (54929796800); Quénéhervé, Lucille (55342915000); Bordron, Philippe (37078852500); Aubert, Philippe (56652397900); Durand, Tony (56059320200); Oullier, Thibauld (54420888000); Blondeau, Claude (55607676300); Ait Abdellah, Samira (57190169470); Bruley des Varannes, Stanislas (57193752746); Chaffron, Samuel (15759198300); Coron, Emmanuel (22134096900); Neunlist, Michel (6701416352)^54929796800; 55342915000; 37078852500; 56652397900; 56059320200; 54420888000; 55607676300; 57190169470; 57193752746; 15759198300; 22134096900; 6701416352^Could the Microbiota Be a Predictive Factor for the Clinical Response to Probiotic Supplementation in IBS-D? A Cohort Study^2023^Microorganisms^11.0^2^277^^^^3^10.3390/microorganisms11020277^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149025268&doi=10.3390%2fmicroorganisms11020277&partnerID=40&md5=3889aa29d40a282fa8b43b48c4319c21^Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Gastroenterology Department, University Hospital of Brest, Brest, 29200, France; PiLeJe Laboratoire, 31-35 rue de la Fédération, Paris, 75015, France; Nantes Université, CHU Nantes, INSERM, Département de Gastroentérologie, CIC 1413, IMAD, Nantes, F-44000, France; Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France; Gastroenterology and Hepatology Department, University Hospital of Geneva (HUG), Geneva, 1211, Switzerland^Marchix J., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Quénéhervé L., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France, Gastroenterology Department, University Hospital of Brest, Brest, 29200, France; Bordron P., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Aubert P., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Durand T., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Oullier T., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; Blondeau C., PiLeJe Laboratoire, 31-35 rue de la Fédération, Paris, 75015, France; Ait Abdellah S., PiLeJe Laboratoire, 31-35 rue de la Fédération, Paris, 75015, France; Bruley des Varannes S., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France, Nantes Université, CHU Nantes, INSERM, Département de Gastroentérologie, CIC 1413, IMAD, Nantes, F-44000, France; Chaffron S., Nantes Université, École Centrale Nantes, CNRS, LS2N, UMR 6004, Nantes, F-44000, France; Coron E., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France, Nantes Université, CHU Nantes, INSERM, Département de Gastroentérologie, CIC 1413, IMAD, Nantes, F-44000, France, Gastroenterology and Hepatology Department, University Hospital of Geneva (HUG), Geneva, 1211, Switzerland; Neunlist M., Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France^Background: Increasing evidence suggests the beneficial effects of probiotics in irritable bowel syndrome (IBS), but little is known about how they can impact the gut microbiota. Our objective was to evaluate the effects of a multistrain probiotic on IBS symptoms, gut permeability and gut microbiota in patients with diarrhoea-predominant IBS (IBS-D). Methods: Adults with IBS-D were enrolled in an open-label trial to receive a multistrain probiotic for 4 weeks. Abdominal pain, stool frequency, quality of life, gut permeability, and the luminal and adherent microbiota from colonic biopsies were evaluated before and after supplementation. Results: Probiotics significantly improved symptoms and quality of life, despite having no impact on permeability in the global population. In the population stratified by the response, the diarrhoea responders displayed reduced colonic permeability after supplementation. The luminal and adherent microbiota were specifically altered depending on the patients’ clinical responses regarding pain and diarrhoea. Interestingly, we identified a microbial signature in IBS-D patients that could predict a response or lack of response to supplementation. Conclusions: The multistrain probiotic improved the symptoms of IBS-D patients and induced distinct effects on the gut microbiota according to the patient’s clinical response and initial microbiota composition. Our study further supports the need to develop individualised probiotic-based approaches regarding IBS. © 2023 by the authors.^diarrhoea; intestinal permeability; irritable bowel syndrome; microbiota; probiotics^^^^^^Conseil Régional des Pays de la Loire, (ANR-19-CE14-0024)^This study was funded by PiLeJe Laboratoire and supported in part by the Région Pays de la Loire (MibioGate) and ANR Microbiautism (ANR-19-CE14-0024).^Ducrotte P., Sawant P., Jayanthi V., Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome, World J. Gastroenterol, 18, pp. 4012-4018, (2012); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Et al., Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study, Gastroenterology, 160, pp. 99-114.e3, (2021); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.-H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol, 301, pp. G799-G807, (2011); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 24, (2012); Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C., Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome, Sci. Rep, 5, (2015); Liu H.-N., Wu H., Chen Y.-Z., Chen Y.-J., Shen X.-Z., Liu T.-T., Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis, Dig. Liver Dis, 49, pp. 331-337, (2017); Lee B.J., Bak Y.-T., Irritable bowel syndrome, gut microbiota and probiotics, J. Neurogastroenterol. Motil, 17, pp. 252-266, (2011); Alard J., Peucelle V., Boutillier D., Breton J., Kuylle S., Pot B., Holowacz S., Grangette C., New probiotic strains for inflammatory bowel disease management identified by combining in vitro and in vivo approaches, Benef. Microbes, 9, pp. 317-331, (2018); Carco C., Young W., Gearry R.B., Talley N.J., McNabb W.C., Roy N.C., Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis, Front. Cell. Infect. Microbiol, 10, (2020); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., de Giorgio R., Corinaldesi R., Stanghellini V., Mucosal Permeability and Immune Activation as Potential Therapeutic Targets of Probiotics in Irritable Bowel Syndrome, J. Clin. Gastroenterol, 46, pp. S52-S55, (2012); Ishaque S.M., Khosruzzaman S.M., Ahmed D.S., Sah M.P., A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult<sup>®</sup>) in the management of diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 18, (2018); Tiequn B., Guanqun C., Shuo Z., Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: A meta-analysis, Intern Med, 54, pp. 243-249, (2015); Li B., Liang L., Deng H., Guo J., Shu H., Zhang L., Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Front. Pharmacol, 11, (2020); Sun J.-R., Kong C.-F., Qu X.-K., Deng C., Lou Y.-N., Jia L.-Q., Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis, Saudi J. Gastroenterol, 26, pp. 66-77, (2020); Zhang T., Zhang C., Zhang J., Sun F., Duan L., Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis, Front. Cell. Infect. Microbiol, 12, (2022); Hungin A.P., Mulligan C., Pot B., Whorwell P., Agreus L., Fracasso P., Lionis C., Mendive J., Philippart de Foy J.M., Rubin G., Et al., Systematic review: Probiotics in the management of lower gastrointestinal symptoms in clinical practice—An evidence-based international guide, Aliment. Pharmacol. Ther, 38, pp. 864-886, (2013); Murakami K., Habukawa C., Nobuta Y., Moriguchi N., Takemura T., The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: A placebo-controlled double-blind crossover trial, Biopsychosoc. Med, 6, (2012); Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B., A double blind, placebo-controlled, randomized clinical trial that breast milk derived-Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome, J. Clin. Biochem. Nutr, 62, pp. 179-186, (2018); Lewis E.D., Antony J.M., Crowley D.C., Piano A., Bhardwaj R., Tompkins T.A., Evans M., Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study, Nutrients, 12, (2020); Martoni C.J., Srivastava S., Leyer G.J., Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial, Nutrients, 12, (2020); Clinical Decision Support Tool: IBS Treatment, Gastroenterology, 163, (2022); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an Intestinal Microbiota Signature Associated with Severity of Irritable Bowel Syndrome, Gastroenterology, 152, pp. 111-123.e8, (2017); Nebot-Vivinus M., Harkat C., Bzioueche H., Cartier C., Plichon-Dainese R., Moussa L., Eutamene H., Pishvaie D., Holowacz S., Seyrig C., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J. Gastroenterol, 20, pp. 6832-6843, (2014); Slim K., Bousquet J., Kwiatkowski F., Lescure G., Pezet D., Chipponi J., Première validation de la version française de l’index de qualité de vie pour les maladies digestives (GIQLI), Gastroenterol. Clin. Biol, 23, pp. 25-31, (1999); Pimentel M., Cash B.D., Lembo A., Wolf R.A., Israel R.J., Schoenfeld P., Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity, Dig. Dis. Sci, 62, pp. 2455-2463, (2017); Sequeira I.R., Lentle R.G., Kruger M.C., Hurst R.D., Hogan S.P., Standardising the Lactulose Mannitol Test of Gut Permeability to Minimise Error and Promote Comparability, PLoS ONE, 9, (2014); Meurette G., Blanchard C., Duchalais-Dassonneville E., Coquenlorge S., Aubert P., Wong M., Lehur P.-A., Neunlist M., Sacral nerve stimulation enhances epithelial barrier of the rectum: Results from a porcine model, Neurogastroenterol. Motil, 24, (2012); Queneherve L., David G., Bourreille A., Hardouin J.B., Rahmi G., Neunlist M., Bregeon J., Coron E., Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases, Gastrointest. Endosc, 89, pp. 626-636, (2019); Bolyen E., Rideout J.R., Dillon M.R., Bokulich N.A., Abnet C.C., Al-Ghalith G.A., Alexander H., Alm E.J., Arumugam M., Asnicar F., Et al., Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, Nat. Biotechnol, 37, pp. 852-857, (2019); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, (2014); Sisson G., Ayis S., Sherwood R.A., Bjarnason I., Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—A 12 week double-blind study, Aliment. Pharmacol. Ther, 40, pp. 51-62, (2014); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kanarek E., Sowinska A., Cukrowska B., The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study, Nutrients, 13, (2021); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., de Man J.G., Hassett L.C., de Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, (2021); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Nagy F., Molnar T., Szepes Z., Pavics L., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, pp. 40-46, (2012); Boonma P., Shapiro J.M., Hollister E.B., Badu S., Wu Q., Weidler E.M., Abraham B.P., Devaraj S., Luna R.A., Versalovic J., Et al., Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients with Irritable Bowel Syndrome, Front. Pain Res, 2, (2021); Zeng J., Li Y.-Q., Zuo X.-L., Zhen Y.-B., Yang J., Liu C.-H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 28, pp. 994-1002, (2008); Caviglia G.P., Tucci A., Pellicano R., Fagoonee S., Rosso C., Abate M.L., Olivero A., Armandi A., Vanni E., Saracco G.M., Et al., Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report, J. Clin. Med, 9, (2020); Ait Abdellah S., Gal C., Laterza L., Velenza V., Settanni C.R., Napoli M., Schiavoni E., Mora V., Petito V., Gasbarrini A., Effect of a multistrain probiotic on leaky gut in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): A pilot study, Dig. Dis, (2022); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Hod K., Dekel R., Aviv Cohen N., Sperber A., Ron Y., Boaz M., Berliner S., Maharshak N., The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 30, (2018); Michail S., Kenche H., Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome, Probiotics Antimicrob. Proteins, 3, pp. 1-7, (2011); Shin S.Y., Park S., Moon J.M., Kim K., Kim J.W., Chun J., Lee T.H., Choi C.H., Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients with Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial, J. Neurogastroenterol. Motil, 28, pp. 642-654, (2022); Wang T., Teng K., Liu Y., Shi W., Zhang J., Dong E., Zhang X., Tao Y., Zhong J., Lactobacillus plantarum PFM 105 Promotes Intestinal Development Through Modulation of Gut Microbiota in Weaning Piglets, Front. Microbiol, 10, (2019); Deleu S., Machiels K., Raes J., Verbeke K., Vermeire S., Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?, EBioMedicine, 66, (2021); Mazzawi T., Hausken T., Hov J.R., Valeur J., Sangnes D.A., El-Salhy M., Gilja O.H., Hatlebakk J.G., Lied G.A., Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels, Scand. J. Gastroenterol, 54, pp. 690-699, (2019); El-Salhy M., Mazzawi T., Hausken T., Hatlebakk J.G., Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation, Neurogastroenterol. Motil, 34, (2022); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut Microbiota in Patients with Irritable Bowel Syndrome-A Systematic Review, Gastroenterology, 157, pp. 97-108, (2019); Janda J.M., Abbott S.L., The Genus Hafnia: From Soup to Nuts, Clin. Microbiol. Rev, 19, pp. 12-28, (2006)^M. Neunlist; Nantes Université, CHU Nantes, INSERM, The Enteric Nervous System in Gut and Brain Diseases, IMAD, Nantes, F-44000, France; email: michel.neunlist@univ-nantes.fr^^MDPI^^^^^^20762607^^^^English^Microorg.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85149025268
Lu M.; Fan X.; Zheng Y.; Kong W.; Ji R.; Xie H.^Lu, Min (56553533900); Fan, Xinyu (57226534707); Zheng, Yuanyuan (57473427500); Kong, Weiqian (57473427600); Ji, Ruyi (57473427700); Xie, Hui (57473692400)^56553533900; 57226534707; 57473427500; 57473427600; 57473427700; 57473692400^Chang-Kang-Fang ameliorates irritable bowel syndrome with diarrhea in rat by regulating gut microbiota and improving intestinal barrier^2022^ScienceAsia^48.0^2^^151^158^7.0^0^10.2306/scienceasia1513-1874.2022.021^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125600878&doi=10.2306%2fscienceasia1513-1874.2022.021&partnerID=40&md5=170967d06d2362f0e6e50d031b057d63^Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210023, China; Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, 210023, China; Clinical College of Jiangsu Health Vocational College, Nanjing, 210023, China; Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China^Lu M., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210023, China; Fan X., Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, 210023, China, Clinical College of Jiangsu Health Vocational College, Nanjing, 210023, China; Zheng Y., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Kong W., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Ji R., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Xie H., Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China^Chang-Kang-Fang formula (CKF), a multi-herb traditional Chinese medicinal formula, has been clinically used for treatment of irritable bowel syndrome with diarrhea (IBS-D). Though we have reported the compounds of CKF and their therapeutic effect on IBS-D rats, the exact underlying mechanism is still not clear. The aim of this study was to clearly define the effect of CKF on IBS-D by regulating gut microbiota and promoting intestinal barrier. IBS-D rats were established by psychosocial stress (restraint) combined with the peripheral stimulation (senna leaf gavage) stress. The changes of body weight and the number of fecal pellets were investigated during the experiment. The effect on intestinal sensitivity was assessed based on the abdominal withdrawal reflex (AWR) scores and the intestinal permeability, the expression of zona occludens 1 (ZO-1), measured by immunohistochemistry. The composition of gut microbiota was detected through 16S rRNA. The administration of CKF significantly had therapeutic effects on IBS-D rats based on the decreased AWR scores and the increased number of pellets. However, the changes of body weight were not observed. In addition, CKF could up-regulate the expression of ZO-1 in the colon and rebalance the gut microbiota of IBS-D by increasing the abundance of Lactobacillus, Allobaculum, Roseburia, and Lachnospiraceae_NK4A136. CKF potentially alleviated IBS-D through regulating gut microbiota and improving the intestinal barrier function. © 2022 Science Society of Thailand under Royal Patronage. All rights reserved.^Diarrhea predominant irritable bowel syndrome; Gut microbiota; TCM^^^^^^Jiangsu Health Vocational College University, (JKC201958); Jiangsu Provincial ?; Major Science and Technology Project of Jiangsu Province Administration of Traditional Chinese Medicine, (WSN-040, ZD201708); Natural Science Foundation of Jiangsu Province, (BK20161608)^Funding text 1: Acknowledgements: This work was supported by Major Science and Technology Project of Jiangsu Province Administration of Traditional Chinese Medicine (ZD201708); the Jiangsu Provincial “six talent peaks” High talents the fourteenth batch (WSN-040); the Natural Science Foundation of Jiangsu Province (BK20161608); Jiangsu Health Vocational College University level scientific research projects(JKC201958).; Funding text 2: Acknowledgements: This work was supported by Major Science and Technology Project of Jiangsu Province Administration of Traditional Chinese Medicine (ZD201708); the Jiangsu Provincial ?six talent peaks? High talents the fourteenth batch (WSN-040); the Natural Science Foundation of Jiangsu Province (BK20161608); Jiangsu Health Vocational College University level scientific research projects(JKC201958).^Lovell RM, Ford AC, Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Ford AC, Sperber AD, Corsetti M, Camilleri M, Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Ford AC, Lacy BE, Talley NJ, Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Zhu HM, Li L, Li SY, Yan Q, Li F, Effect of water extract from Berberis heteropoda Schrenk roots on diarrhea-predominant irritable bowel syndrome by adjusting intestinal flora, J Ethnopharmacol, 237, pp. 182-191, (2019); Turner JR, Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Yu C, Xi L, Zhao Y, Feng A, Zha L, Yang H, Chen M, Zhang Y, Et al., Artificial cultivation and nutritional evaluation of proteins from a wild Ganoderma gibbosum strain, ScienceAsia, 46, pp. 548-556, (2020); Mao Q, Shi L, Wang ZG, Luo YH, Wang YY, Li X, Lu M, Ju JM, Et al., Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome, J Ethnopharmacol, 201, pp. 123-135, (2017); Vila VA, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, Kurilshikov A, Bonder MJ, Et al., Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome, Sci Transl Med, 10, (2018); Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT, Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis, Dig Liver Dis, 49, pp. 331-337, (2017); Arzani M, Jahromi SR, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A, Sacco S, TOgha M, Et al., Gut-brain axis and migraine headache: a comprehensive review, J Headache Pain, 21, (2020); Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Irritable bowel syndrome: a microbiome-gut-brain axis disorder?, World J Gastroenterol, 20, pp. 14105-14125, (2014); Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B, Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroenterol, 95, pp. 1231-1238, (2000); Martoni CJ, Srivastava S, Leyer GJ, Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial, Nutrients, 12, (2020); Labus JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Yoon BC, Choi HS, Et al., Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial, J Gastroenterol Hepatol, 29, pp. 52-59, (2014); Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, Acosta J, Luna RA, Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, (2017); Li J, Cui H, Cai Y, Lin J, Song X, Zhou Z, Xiong W, Zhou H, Et al., Tong-Xie-Yao-Fang regulates 5-HT level in diarrhea predominant irritable bowel syndrome through gut microbiota modulation, Front Pharmacol, 9, (2018)^H. Xie; Third Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, 210023, China; email: xiehuitcm@163.com^^Science Society of Thailand under Royal Patronage^^^^^^15131874^^^^English^ScienceAsia^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85125600878
Torres-Maravilla E.; Holowacz S.; Delannoy J.; Lenoir L.; Jacouton E.; Gervason S.; Meynier M.; Boucard A.-S.; Carvalho F.A.; Barbut F.; Bermúdez-Humarán L.G.; Langella P.; Waligora-Dupriet A.-J.^Torres-Maravilla, Edgar (56922108200); Holowacz, Sophie (56200615700); Delannoy, Johanne (57186421200); Lenoir, Loïc (56801539100); Jacouton, Elsa (56641711900); Gervason, Sandie (57209348857); Meynier, Maëva (57217062090); Boucard, Anne-Sophie (57208299895); Carvalho, Frédéric A. (16041688200); Barbut, Frédéric (7005710294); Bermúdez-Humarán, Luis G. (6602243913); Langella, Philippe (7003598187); Waligora-Dupriet, Anne-Judith (6506915359)^56922108200; 56200615700; 57186421200; 56801539100; 56641711900; 57209348857; 57217062090; 57208299895; 16041688200; 7005710294; 6602243913; 7003598187; 6506915359^Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome^2022^Scientific Reports^12.0^1^19776^^^^4^10.1038/s41598-022-21746-8^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142172749&doi=10.1038%2fs41598-022-21746-8&partnerID=40&md5=f264846ad4c81d0a219480059c3d4b44^INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; National Reference Laboratory for C. Difficile, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, 75012, France^Torres-Maravilla E., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France, Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; Holowacz S., PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; Delannoy J., Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; Lenoir L., PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; Jacouton E., PiLeJe Laboratoire, 37 Quai de Grenelle, Paris Cedex 15, 75015, France; Gervason S., INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Meynier M., INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Boucard A.-S., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Carvalho F.A., INSERM UMR 1107 NeuroDol, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Barbut F., Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France, National Reference Laboratory for C. Difficile, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, 75012, France; Bermúdez-Humarán L.G., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Langella P., INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; Waligora-Dupriet A.-J., Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France^Probiotic supplementation can help to mitigate the pathogenesis of irritable bowel syndrome (IBS) by reinforcing the intestinal barrier, and reducing both inflammation and proteolytic activity. Here, a combination of in vitro tests was performed on 33 Bifidobacterium strains as probiotic candidates for IBS. In addition to the classical tests performed, the detection of the serine protease inhibitor (serpin) enzyme capable of decreasing the high proteolytic activity found in IBS patients was included. Three serpin-positive strains were selected: Bifidobacterium breve CNCM I-5644, Bifidobacterium longum subsp. infantis CNCM I-5645 and B. longum CNCM I-5646 for their immunomodulation properties and protection of intestinal epithelial integrity in vitro. Furthermore, we found that B. breve CNCM I-5644 strain prevented intestinal hyperpermeability by upregulating Cingulin and Tight Junction Protein 1 mRNA levels and reducing pro-inflammatory markers. The ability of CNCM I-5644 strain to restore intestinal hyperpermeability (FITC-dextran) was shown in the murine model of low-grade inflammation induced by dinitrobenzene sulfonic acid (DNBS). This effect of this strain was corroborated in a second model of IBS, the neonatal maternal separation model in mice. Altogether, these data suggest that serpin-positive B. breve CNCM I-5644 may partially prevent disorders associated with increased barrier permeability such as IBS. © 2022, The Author(s).^^Animals; Bifidobacterium breve; Bifidobacterium longum subspecies infantis; Inflammation; Irritable Bowel Syndrome; Maternal Deprivation; Mice; Permeability; Serpins; serine proteinase inhibitor; animal; Bifidobacterium breve; Bifidobacterium longum subsp. infantis; inflammation; irritable colon; maternal deprivation; mouse; permeability^^Serpins, ^^^INRAE Infectiology of Fishes and Rodents Facility, (IERP-UE907); Jouy-en-Josas Research Center; National Distributed Research Infrastructure for the Control of Animal and Zoonotic Emerging Infectious Diseases; Université de Paris; Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, INRAE^Funding text 1: The reported study was supported by the National Research Institute for Agriculture, Food and Environment (INRAE), Paris University and a contract with PiLeJe Laboratoire. ; Funding text 2: We would like to thank Claude Blondeau for his help for the writing assistance, technical editing, language editing, and proofreading of the manuscript. We wish to thank the staff of the INRAE Infectiology of Fishes and Rodents Facility (IERP-UE907, Jouy-en-Josas Research Center, France) in which animal experiments have been performed. IERP Facility belongs to the National Distributed Research Infrastructure for the Control of Animal and Zoonotic Emerging Infectious Diseases through In vivo Investigation.^Lacy B.E., Et al., ACG clinical guideline: Management of irritable bowel syndrome, Am. Coll. Gastroenterol., 116, pp. 17-44, (2021); Qin H.-Y., Cheng C.-W., Tang X.-D., Bian Z.-X., Impact of psychological stress on irritable bowel syndrome, World J. Gastroenterol., 20, pp. 14126-14131, (2014); Jeffery I.B., Et al., Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption, Gastroenterology, 158, pp. 1016-1028.e1018, (2020); Ticho A.L., Malhotra P., Dudeja P.K., Gill R.K., Alrefai W.A., Bile acid receptors and gastrointestinal functions, Liver Res., 3, pp. 31-39, (2019); Chong P.P., Et al., The microbiome and irritable bowel syndrome—A review on the pathophysiology, current research and future therapy, Front. Microbiol., 10, (2019); Wang L., Et al., Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and meta-analysis of case-control studies, J. Acad. Nutr. Diet., 120, pp. 565-586, (2020); Distrutti E., Monaldi L., Ricci P., Fiorucci S., Gut microbiota role in irritable bowel syndrome: New therapeutic strategies, World J. Gastroenterol., 22, pp. 2219-2241, (2016); Rodino-Janeiro B.K., Vicario M., Alonso-Cotoner C., Pascua-Garcia R., Santos J., A review of microbiota and irritable bowel syndrome: Future in therapies, Adv. Ther., 35, pp. 289-310, (2018); Thevaranjan N., Et al., Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction, Cell Host Microbe, 21, pp. 455-466.e454, (2017); Bischoff S.C., Et al., Intestinal permeability—A new target for disease prevention and therapy, BMC Gastroenterol., 14, (2014); Edogawa S., Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, pp. 62-73, (2020); Jablaoui A., Et al., Fecal serine protease profiling in inflammatory bowel diseases, Front. Cell. Infect. Microbiol., 10, (2020); Rolland-Fourcade C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, Gut, 66, pp. 1767-1778, (2017); Burns G., Et al., Immune activation in functional gastrointestinal disorders, Gastroenterol. Hepatol., 15, pp. 539-548, (2019); Alessandri G., Ossiprandi M.C., MacSharry J., van Sinderen D., Ventura M., Bifidobacterial dialogue with its human host and consequent modulation of the immune system, Front. Immunol., (2019); McCarville J.L., Et al., A commensal Bifidobacterium longum strain prevents gluten-related immunopathology in mice through expression of a serine protease inhibitor, Appl. Environ. Microbiol., 83, pp. e01323-e1317, (2017); Ivanov D., Et al., A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases, J. Biol. Chem., 281, pp. 17246-17252, (2006); Marshall N.C., Finlay B.B., Overall C.M., Sharpening host defenses during infection: Proteases cut to the chase, Mol. Cell. Proteom., 16, pp. S161-S171, (2017); Martin R., Et al., The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models, Inflamm. Bowel Dis., 20, pp. 417-430, (2014); Martin R., Et al., Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model, BMC Microbiol., 15, (2015); Larauche M., Mulak A., Tache Y., Stress and visceral pain: From animal models to clinical therapies, Exp. Neurol., 233, pp. 49-67, (2012); Schell M.A., Et al., The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract, Proc. Natl. Acad. Sci. U.S.A., 99, pp. 14422-14427, (2002); Buhner S., Et al., Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients, PLoS ONE, 13, (2018); Liebregts T., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Cremon C., Et al., Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms, Am. J. Gastroenterol., 104, pp. 392-400, (2009); Barbara G., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barbara G., Et al., Rome foundation working team report on post-infection irritable bowel syndrome, Gastroenterology, 156, pp. 46-58.e47, (2019); Bermudez-Humaran L.G., Et al., Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci, Microb. Cell Factories, 14, (2015); Ceuleers H., Et al., Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome, Br. J. Pharmacol., 175, pp. 3516-3533, (2018); Ruiz L., Delgado S., Ruas-Madiedo P., Sanchez B., Margolles A., Bifidobacteria and their molecular communication with the immune system, Front. Microbiol., 8, (2017); Levy M., Thaiss C.A., Elinav E., Metabolites: Messengers between the microbiota and the immune system, Genes Dev., 30, pp. 1589-1597, (2016); Haub S., Et al., Enhancement of intestinal inflammation in mice lacking interleukin 10 by deletion of the serotonin reuptake transporter, Neurogastroenterol. Motil., 22, pp. 826-e229, (2010); Mauras A., Et al., A new Bifidobacteria Expression SysTem (BEST) to produce and deliver interleukin-10 in Bifidobacterium bifidum, Front. Microbiol., 9, (2018); Biancheri P., Di Sabatino A., Corazza G.R., MacDonald T.T., Proteases and the gut barrier, Cell Tissue Res., 351, pp. 269-280, (2013); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, (2009); Engevik M.A., Et al., Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways, MBio, (2019); Martin R., Et al., The infant-derived Bifidobacterium bifidum strain CNCM I-4319 strengthens gut functionality, Microorganisms, 8, (2020); Martin R., Et al., Bifidobacterium animalis ssp. lactis CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice, Front. Microbiol., 7, (2016); Schossleitner K., Et al., Evidence that cingulin regulates endothelial barrier function in vitro and in vivo, Arterioscler. Thromb. Vasc. Biol., 36, pp. 647-654, (2016); Soroosh A., Et al., miR-24 Is elevated in ulcerative colitis patients and regulates intestinal epithelial barrier function, Am. J. Pathol., 189, pp. 1763-1774, (2019); Sultana R., McBain A.J., O'Neill C.A., Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates, Appl. Environ. Microbiol., 79, pp. 4887-4894, (2013); Kiu R., Et al., Bifidobacterium breve UCC2003 induces a distinct global transcriptomic programme in neonatal murine intestinal epithelial cells, bioRxiv, (2020); Din A.U., Et al., Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism, J. Nutr. Biochem., 79, (2020); O'Malley D., Dinan T.G., Cryan J.F., Interleukin-6 modulates colonic transepithelial ion transport in the stress-sensitive wistar kyoto rat, Front. Pharmacol., 3, (2012); Stallhofer J., Et al., Lipocalin-2 Is a disease activity marker in inflammatory bowel disease regulated by IL-17A, IL-22, and TNF-α and modulated by IL23R genotype status, Inflamm. Bowel Dis., 21, pp. 2327-2340, (2015); Roka R., Et al., A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., 5, pp. 550-555, (2007); Van Spaendonk H., Et al., Regulation of intestinal permeability: The role of proteases, World J. Gastroenterol., 23, pp. 2106-2123, (2017); Zhao J., Et al., A protease inhibitor against acute stress-induced visceral hypersensitivity and paracellular permeability in rats, Eur. J. Pharmacol., 654, pp. 289-294, (2011); Sinagra E., Et al., Inflammation in irritable bowel syndrome: Myth or new treatment target?, World J. Gastroenterol., 22, pp. 2242-2255, (2016); Larauche M., Mulak A., Tache Y., Stress-related alterations of visceral sensation: Animal models for irritable bowel syndrome study, J. Neurogastroenterol. Motil., 17, pp. 213-234, (2011); Lo Presti A., Et al., Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease, Front. Microbiol., 10, (2019); Fukui H., Et al., Effect of probiotic Bifidobacterium bifidum G9–1 on the relationship between gut microbiota profile and stress sensitivity in maternally separated rats, Sci. Rep., 8, (2018); Miquel S., Et al., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci. Rep., 6, (2016); Ait-Belgnaoui A., Et al., Bifidobacterium longum and Lactobacillus helveticus synergistically suppress stress-related visceral hypersensitivity through hypothalamic-pituitary-adrenal axis modulation, J. Neurogastroenterol. Motil., 24, pp. 138-146, (2018); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb Perspect. Biol., 10, (2018); Amasheh M., Et al., Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: A novel model for studying the pathomechanisms of inflammatory bowel disease cytokines, Scand. J. Gastroenterol., 44, pp. 1226-1235, (2009); Zheng G., Et al., Corticosterone mediates stress-related increased intestinal permeability in a region-specific manner, Neurogastroenterol. Motil., 25, pp. e127-e139, (2013); Neau E., Et al., Three novel candidate probiotic strains with prophylactic properties in a murine model of cow's milk allergy, Appl. Environ. Microbiol., 82, pp. 1722-1733, (2016); Kechaou N., Et al., Identification of one novel candidate probiotic Lactobacillus plantarum strain active against influenza virus infection in mice by a large-scale screening, Appl. Environ. Microbiol., 79, pp. 1491-1499, (2013); Laval L., Et al., Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2–165 exhibit similar protective effects to induced barrier hyper-permeability in mice, Gut Microb., 6, pp. 1-9, (2015); Prisciandaro L.D., Et al., Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage, Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer, 20, pp. 3205-3210, (2012); Barone M., Et al., A versatile new model of chemically induced chronic colitis using an outbred murine strain, Front. Microbiol., 9, (2018); Maeda S., Et al., Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression, J. Vet. Med. Sci., 76, pp. 1119-1127, (2014)^P. Langella; INRAE, AgroParisTech, Micalis Institute, Université Paris-Saclay, Jouy-en-Josas, 78350, France; email: philippe.langella@inrae.fr; A.-J. Waligora-Dupriet; Université Paris Cité, INSERM, 3PHM, Paris, F-75006, France; email: anne-judith.waligora@u-paris.fr^^Nature Research^^^^^^20452322^^^36396717.0^English^Sci. Rep.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85142172749
Iribarren C.; Nordlander S.; Sundin J.; Isaksson S.; Savolainen O.; Törnblom H.; Magnusson M.K.; Simrén M.; Öhman L.^Iribarren, Cristina (57200549137); Nordlander, Sofia (24780774900); Sundin, Johanna (56332687100); Isaksson, Stefan (21639681500); Savolainen, Otto (56011360600); Törnblom, Hans (7801453693); Magnusson, Maria K. (35248805000); Simrén, Magnus (57202571330); Öhman, Lena (14820629200)^57200549137; 24780774900; 56332687100; 21639681500; 56011360600; 7801453693; 35248805000; 57202571330; 14820629200^Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids^2022^Neurogastroenterology and Motility^34.0^10^e14390^^^^6^10.1111/nmo.14390^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128884996&doi=10.1111%2fnmo.14390&partnerID=40&md5=895e7637fc93563dcb19b6ff523f39be^Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Chalmers Mass Spectrometry Infrastructure, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden; Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States^Iribarren C., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Nordlander S., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Sundin J., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Isaksson S., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Savolainen O., Chalmers Mass Spectrometry Infrastructure, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden; Törnblom H., Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Magnusson M.K., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Simrén M., Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States; Öhman L., Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden^Background: Alteration of the host-microbiota cross talk at the intestinal barrier may participate in the pathophysiology of irritable bowel syndrome (IBS). Therefore, we aimed to determine effects of fecal luminal factors from IBS patients on the colonic epithelium using colonoids. Methods: Colon-derived organoid monolayers, colonoids, generated from a healthy subject, underwent stimulation with fecal supernatants from healthy subjects and IBS patients with predominant diarrhea, phosphate-buffered saline (PBS), or lipopolysaccharide (LPS). Cytokines in cell cultures and fecal LPS were measured by ELISA and mRNA gene expression of monolayers was analyzed using Qiagen RT2 Profiler PCR Arrays. The fecal microbiota profile was determined by the GA-map™ dysbiosis test and the fecal metabolite profile was analyzed by untargeted liquid chromatography/mass spectrometry. Key results: Colonoid monolayers stimulated with fecal supernatants from healthy subjects (n = 7), PBS (n = 4) or LPS (n = 3) presented distinct gene expression profiles, with some overlap (R2Y = 0.70, Q2= 0.43). Addition of fecal supernatants from healthy subjects and IBS patients (n = 9) gave rise to different gene expression profiles of the colonoid monolayers (R2Y = 0.79, Q2= 0.64). Genes (n = 22) related to immune response (CD1D, TLR5) and barrier integrity (CLDN15, DSC2) contributed to the separation. Levels of proinflammatory cytokines in colonoid monolayer cultures were comparable when stimulated with fecal supernatants from either donor types. Fecal microbiota and metabolite profiles, but not LPS content, differed between the study groups. Conclusions: Fecal luminal factors from IBS patients induce a distinct colonic epithelial gene expression, potentially reflecting the disease pathophysiology. The culture of colonoids from healthy subjects with fecal supernatants from IBS patients may facilitate the exploration of IBS related intestinal micro-environmental and barrier interactions. © 2022 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.^colonoids; epithelial barrier; host-microbiota cross talk; intestinal microenvironment; irritable bowel syndrome^Cytokines; Diarrhea; Feces; Gene Expression; Humans; Irritable Bowel Syndrome; Lipopolysaccharides; Phosphates; RNA, Messenger; Toll-Like Receptor 5; CD1d antigen; cytokine; lipopolysaccharide; messenger RNA; phosphate buffered saline; toll like receptor 5; cytokine; lipopolysaccharide; messenger RNA; phosphate; toll like receptor 5; adult; Article; clinical article; colon epithelium; colonoid; controlled study; cytokine release; diarrhea; digestive system disease assessment; DNA determination; enzyme linked immunosorbent assay; feces microflora; female; gene expression; gene expression profiling; human; immune response; immunofluorescence; irritable bowel syndrome severity scoring system; irritable colon; liquid chromatography-mass spectrometry; male; metabolite; microenvironment; monolayer culture; protein expression; scoring system; supernatant; chemistry; feces; gene expression; metabolism^^phosphate, 14066-19-4, 14265-44-2; Cytokines, ; Lipopolysaccharides, ; Phosphates, ; RNA, Messenger, ; Toll-Like Receptor 5, ^^^Centre for Cellular Imaging at the University of Gothenburg, (VR‐RFI 2016‐00968); Faculty of Medicine at University of Gothenburg; Hubrecht Institute for Developmental Biology and Stem Cell Research; Menarini; Regional Executive Board; Sahlgrenska Academy at University of Gothenburg; Swedish government, (ALFGBG‐722331, ALFGBG‐723921); AstraZeneca; AbbVie; Västra Götalandsregionen, (VGFOUREG-931919); Västra Götalandsregionen; Baylor College of Medicine; Takeda Pharmaceutical Company, TPC; Universiteit Utrecht, UU; Kyowa Hakko Kirin; Shire; Ferring Pharmaceuticals; Medicinska Forskningsrådet, MFR, (2018‐02566, 2019‐01052); Medicinska Forskningsrådet, MFR^Funding text 1: The study was funded by Swedish Medical Research Council (grants no. 2019-01052 (LÖ) and 2018-02566 (MS)), Sahlgrenska Academy at University of Gothenburg (LÖ), Faculty of Medicine at University of Gothenburg (MS), grants from the Swedish state under the agreement between the Swedish government and the county councils; the ALF-agreement (ALFGBG-723921 (LÖ), ALFGBG-722331 (MS)) and Regional Executive Board, Region Västra Götaland (grant no. VGFOUREG-931919 (LÖ)) and Swedish Fund for Research without Animal Experiments (LÖ)Key points Cross talk between the luminal factors and the epithelial layer likely participates in the pathogenesis of irritable bowel syndrome (IBS). It may be explored in vitro using human colon crypt-derived organoid monolayers and fecal supernatants. Fecal luminal factors from healthy subjects and IBS induce distinct gene expression profiles of colon crypt-derived organoid monolayers. Here, we present a unique model of colonoid monolayers to evaluate IBS-specific regulation of colonic epithelium, which may provide improved understanding of the pathophysiology of IBS. Cross talk between the luminal factors and the epithelial layer likely participates in the pathogenesis of irritable bowel syndrome (IBS). It may be explored in vitro using human colon crypt-derived organoid monolayers and fecal supernatants. Fecal luminal factors from healthy subjects and IBS induce distinct gene expression profiles of colon crypt-derived organoid monolayers. Here, we present a unique model of colonoid monolayers to evaluate IBS-specific regulation of colonic epithelium, which may provide improved understanding of the pathophysiology of IBS. The authors gratefully acknowledge Daisy Jonkers and Pan Xu for sharing their knowledge isolating colonic crypts and passaging colonoids; and Gaelle Noel and Julie In, for their help regarding the expansion of colonoids, transwell cultures and immunofluorescence staining. Further, the authors acknowledge the contribution of Inga Rimkute and Baylor College of Medicine (Houston, Texas, USA) for specific advice on growing colonoids into monolayers. Additionally, the authors thank Hans Clevers group from Hubrecht Institute for Developmental Biology and Stem Cell Research (Utrecht University, Utrecht, Netherlands) for providing Noggin and Wnt-3A cell lines together with protocols for conditioned media. Chalmers Mass Spectrometry Infrastructure is acknowledged for performing on the metabolomics analyses. Last, the authors acknowledge the Centre for Cellular Imaging at the University of Gothenburg and the National Microscopy Infrastructure, NMI (VR-RFI 2016-00968) for the support and assistance in microscopy.; Funding text 2: The authors gratefully acknowledge Daisy Jonkers and Pan Xu for sharing their knowledge isolating colonic crypts and passaging colonoids; and Gaelle Noel and Julie In, for their help regarding the expansion of colonoids, transwell cultures and immunofluorescence staining. Further, the authors acknowledge the contribution of Inga Rimkute and Baylor College of Medicine (Houston, Texas, USA) for specific advice on growing colonoids into monolayers. Additionally, the authors thank Hans Clevers group from Hubrecht Institute for Developmental Biology and Stem Cell Research (Utrecht University, Utrecht, Netherlands) for providing Noggin and Wnt‐3A cell lines together with protocols for conditioned media. Chalmers Mass Spectrometry Infrastructure is acknowledged for performing on the metabolomics analyses. Last, the authors acknowledge the Centre for Cellular Imaging at the University of Gothenburg and the National Microscopy Infrastructure, NMI (VR‐RFI 2016‐00968) for the support and assistance in microscopy. ; Funding text 3: The study was funded by Swedish Medical Research Council (grants no. 2019‐01052 (LÖ) and 2018‐02566 (MS)), Sahlgrenska Academy at University of Gothenburg (LÖ), Faculty of Medicine at University of Gothenburg (MS), grants from the Swedish state under the agreement between the Swedish government and the county councils; the ALF‐agreement (ALFGBG‐723921 (LÖ), ALFGBG‐722331 (MS)) and Regional Executive Board, Region Västra Götaland (grant no. VGFOUREG‐931919 (LÖ)) and Swedish Fund for Research without Animal Experiments (LÖ) Key points ; Funding text 4: CI, SN, JS, SI, OS and MKM do not have conflict of interest to declare. HT has served as advisory board member for Almirall, Allergan, and Shire. MS has received unrestricted research grants from Danone, Ferring Pharmaceuticals and Glycom (now DSM); served as advisory board member for Almirall, Allergan, Albireo, AstraZeneca, Danone, Nestlé, Glycom (now part of DSM), Menarini, and Shire, as well as a speaker for AlfaSigma, Allergan, Almirall, Alimentary Health, Biocodex, Kyowa Kirin, Menarini, Tillotts, Takeda and Shire. LÖ has received a financial support for research by Genetic Analysis AS, Biocodex, Danone Research and AstraZeneca and served as Consultant/Advisory Board member for Genetic Analysis AS, and as a speaker for Biocodex, Ferring Pharmaceuticals, Takeda, AbbVie, and Meda. ^Ohman L., Tornblom H., Simren M., Crosstalk at the mucosal border: importance of the gut microenvironment in IBS, Nat Rev Gastroenterol Hepatol, 12, 1, pp. 36-49, (2015); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liv, 6, 3, pp. 305-315, (2012); Vancamelbeke M., Vermeire S., The intestinal barrier: a fundamental role in health and disease, Expert Rev Gastroenterol Hepatol, 11, 9, pp. 821-834, (2017); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J Gastroenterol, 49, 11, pp. 1467-1476, (2014); Bennet S.M.P., Sundin J., Magnusson M.K., Et al., Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation, Neurogastroenterol Motil, 30, 12, (2018); Tap J., Derrien M., Tornblom H., Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, 1, pp. 111-123 e8, (2017); Sundin J., Aziz I., Nordlander S., Et al., Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome, Sci Rep, 10, 1, (2020); Zhang W.-X., Zhang Y.U., Qin G., Et al., Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome, World J Gastroenterol, 25, 43, pp. 6416-6429, (2019); Lee J.S., Kim S.-Y., Chun Y.S., Et al., Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using 1H-NMR coupled with multivariate statistical analysis, Neurogastroenterol Motil, 3, (2020); Ahluwalia B., Iribarren C., Magnusson M.K., Et al., A distinct faecal microbiota and metabolite profile linked to bowel habits in patients with irritable bowel syndrome, Cells, 10, 6, (2021); Ludidi S., Jonkers D., Elamin E., Et al., The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model, PLoS One, 10, 5, (2015); Edogawa S., Edwinson A.L., Peters S.A., Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, 1, pp. 62-73, (2020); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Wilms E., Troost F.J., Elizalde M., Et al., Intestinal barrier function is maintained with aging – a comprehensive study in healthy subjects and irritable bowel syndrome patients, Sci Rep, 10, 1, (2020); Altay G., Larranaga E., Tosi S., Et al., Self-organized intestinal epithelial monolayers in crypt and villus-like domains show effective barrier function, Sci Rep, 9, 1, (2019); Castellanos-Gonzalez A., Cabada M.M., Nichols J., Gomez G., White A.C., Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection, Infect Immun, 81, 6, pp. 1996-2001, (2013); Noel G., Baetz N.W., Staab J.F., Et al., A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions, Sci Rep, 7, 1, (2017); In J.G., Foulke-Abel J., Clarke E., Kovbasnjuk O., Human colonoid monolayers to study interactions between pathogens, commensals, and host intestinal epithelium, J Vis Exp, 146, (2019); Sato T., Stange D.E., Ferrante M., Et al., Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium, Gastroenterology, 141, 5, pp. 1762-1772, (2011); George M.M., Rahman M., Connors J., Stadnyk A.W., Opinion: are organoids the end of model evolution for studying host intestinal epithelium/microbe interactions?, Microorganisms, 7, 10, (2019); Kashfi S.M.H., Almozyan S., Jinks N., Koo B.K., Nateri A.S., Morphological alterations of cultured human colorectal matched tumour and healthy organoids, Oncotarget, 9, 12, pp. 10572-10584, (2018); Heaton K.W., O'Donnell L.J., An office guide to whole-gut transit time. Patients’ recollection of their stool form, J Clin Gastroenterol, 19, 1, pp. 28-30, (1994); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); Iribarren C., Tornblom H., Aziz I., Et al., Human milk oligosaccharide supplementation in irritable bowel syndrome patients: a parallel, randomized, double-blind, placebo-controlled study, Neurogastroenterol Motil, 32, 10, (2020); Lacy B.E., Mearin F., Chang L., Et al., Bowel disorders, Gastroenterology, 150, 6, pp. 1393-1407.e5, (2016); In J., Foulke-Abel J., Zachos N.C., Et al., Enterohemorrhagic Escherichia coli reduces mucus and intermicrovillar bridges in human stem cell-derived colonoids, Cell Mol Gastroenterol Hepatol, 2, 1, pp. 48-62.e3, (2016); Haileselassie Y., Johansson M.A., Zimmer C.L., Et al., Lactobacilli regulate Staphylococcus aureus 161:2-induced pro-inflammatory T-cell responses in vitro, PLoS One, 8, 10, (2013); Zheng R., Brunius C., Shi L., Et al., Prediction and evaluation of the effect of pre-centrifugation sample management on the measurable untargeted LC-MS plasma metabolome, Anal Chim Acta, 1182, (2021); Klavus A., Kokla M., Noerman S., Et al., “Notame”: workflow for non-targeted LC–MS metabolic profiling, Metabolites, 10, 4, (2020); Casen C., Vebo H.C., Sekelja M., Et al., Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD, Aliment Pharmacol Ther, 42, 1, pp. 71-83, (2015); James S.C., Fraser K., Young W., McNabb W.C., Roy N.C., Gut microbial metabolites and biochemical pathways involved in irritable bowel syndrome: effects of diet and nutrition on the microbiome, J Nutr, 150, 5, pp. 1012-1021, (2019); d'Aldebert E., Quaranta M., Sebert M., Et al., Characterization of human colon organoids from inflammatory bowel disease patients, Front Cell Dev Biol, 8, (2020); Liu L., Saitz-Rojas W., Smith R., Et al., Mucus layer modeling of human colonoids during infection with enteroaggragative E. coli, Sci Rep, 10, 1, (2020); Zhang J., Huang Y.-J., Yoon J.Y., Et al., Primary human colonic mucosal barrier crosstalk with super oxygen-sensitive Faecalibacterium prausnitzii in continuous culture, Med, 2, 1, pp. 74-98.e9, (2021); Aguilera-Lizarraga J., Florens M.V., Van Brussel T., Et al., Expression of immune-related genes in rectum and colon descendens of irritable bowel syndrome patients is unrelated to clinical symptoms, Neurogastroenterol Motil, 31, 6, (2019); Zhen Y., Chu C., Zhou S., Qi M., Shu R., Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea, Mol Med Rep, 12, 4, pp. 5239-5245, (2015); Huang X., Yang Y., Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses, Expert Opin Ther Targets, 14, 8, pp. 787-796, (2010); Bel S., Pendse M., Wang Y., Et al., Paneth cells secrete lysozyme via secretory autophagy during bacterial infection of the intestine, Science, 357, 6355, pp. 1047-1052, (2017); Olszak T., Neves J.F., Dowds C.M., Et al., Protective mucosal immunity mediated by epithelial CD1d and IL-10, Nature, 509, 7501, pp. 497-502, (2014); Wang Y., Liu L., Moore D.J., Et al., An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells, Mucosal Immunol, 10, 2, pp. 373-384, (2017); Luissint A.-C., Parkos C.A., Nusrat A., Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair, Gastroenterology, 151, 4, pp. 616-632, (2016); Han X., Lee A., Huang S., Gao J., Spence J.R., Owyang C., Lactobacillus rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids, Gut Microbes, 10, 1, pp. 59-76, (2019); Menard S., Cerf-Bensussan N., Heyman M., Multiple facets of intestinal permeability and epithelial handling of dietary antigens, Mucosal Immunol, 3, 3, pp. 247-259, (2010); Serena G., Huynh D., Lima R.S., Et al., Intestinal epithelium modulates macrophage response to gliadin in celiac disease, Front Nutr, 6, (2019); Wang Y., Kim R., Hwang S.-H.J., Dutton J., Sims C.E., Allbritton N.L., Analysis of interleukin 8 secretion by a stem-cell-derived human-intestinal-epithelial-monolayer platform, Anal Chem, 90, 19, pp. 11523-11530, (2018); Maasfeh L., Hartlova A., Isaksson S., Et al., Impaired luminal control of intestinal macrophage maturation in patients with ulcerative colitis during remission, Cell Mol Gastroenterol Hepatol, 12, 4, pp. 1415-1432, (2021); Pittayanon R., Lau J.T., Yuan Y., Et al., Gut microbiota in patients with irritable bowel syndrome - a systematic review, Gastroenterology, 157, 1, pp. 97-108, (2019); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol, 9, (2009); Mei L., Zhou J., Su Y., Et al., Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 21, 1, (2021); Kerckhoffs A.P.M., Ben-Amor K., Samsom M., Et al., Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome, J Med Microbiol, 60, pp. 236-245, (2011); Maharshak N., Ringel Y., Katibian D., Et al., Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Dig Dis Sci, 63, 7, pp. 1890-1899, (2018); Leclercq S., Matamoros S., Cani P.D., Et al., Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity, Proc Natl Acad Sci USA, 111, 42, pp. E4485-E4493, (2014); Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, 5, (2021); Tailford L.E., Crost E.H., Kavanaugh D., Juge N., Mucin glycan foraging in the human gut microbiome, Front Genet, 6, (2015); Taverniti V., Guglielmetti S., Methodological issues in the study of intestinal microbiota in irritable bowel syndrome, World J Gastroenterol, 20, 27, pp. 8821-8836, (2014); Lee J.S., Wang R.X., Alexeev E.E., Et al., Hypoxanthine is a checkpoint stress metabolite in colonic epithelial energy modulation and barrier function, J Biol Chem, 293, 16, pp. 6039-6051, (2018); Zhou S.-Y., Gillilland M., Wu X., Et al., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J Clin Invest, 128, 1, pp. 267-280, (2018)^L. Öhman; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; email: lena.ohman@microbio.gu.se^^John Wiley and Sons Inc^^^^^^13501925^^NMOTE^35485994.0^English^Neurogastroenterol. Motil.^Article^Final^All Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85128884996
Omarova S.; Awad K.; Moos V.; Püning C.; Gölz G.; Schulzke J.-D.; Bücker R.^Omarova, Sholpan (58163484800); Awad, Karem (57188694305); Moos, Verena (6602224334); Püning, Christoph (57216042644); Gölz, Greta (12647649300); Schulzke, Jörg-Dieter (35502556700); Bücker, Roland (10043068400)^58163484800; 57188694305; 6602224334; 57216042644; 12647649300; 35502556700; 10043068400^Intestinal Barrier in Post-Campylobacter jejuni Irritable Bowel Syndrome^2023^Biomolecules^13.0^3^449^^^^8^10.3390/biom13030449^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151221533&doi=10.3390%2fbiom13030449&partnerID=40&md5=76988cd8cc2619e91c8cd6610d39b029^Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Department of Veterinary Medicine, Center for Veterinary Public Health, Institute of Food Safety and Food Hygiene, Freie Universität Berlin, Berlin, 14163, Germany^Omarova S., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Awad K., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Moos V., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Püning C., Department of Veterinary Medicine, Center for Veterinary Public Health, Institute of Food Safety and Food Hygiene, Freie Universität Berlin, Berlin, 14163, Germany; Gölz G., Department of Veterinary Medicine, Center for Veterinary Public Health, Institute of Food Safety and Food Hygiene, Freie Universität Berlin, Berlin, 14163, Germany; Schulzke J.-D., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany; Bücker R., Clinical Physiology, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, 12203, Germany^Background: Campylobacter jejuni (C. jejuni) is one of the most common causes of bacterial gastroenteritis worldwide. One sequela of this infection is the development of post-infectious irritable bowel syndrome (PI-IBS). It has been suggested that a dysfunctional intestinal barrier may promote IBS development. We aimed to test this hypothesis against the background of the leaky gut concept for low-grade inflammation in PI-IBS. Methods: We identified patients with persistent PI-IBS symptoms after C. jejuni infection. During sigmoidoscopy, forceps biopsies were obtained for electrophysiological measurements of epithelial transport and barrier function in miniaturized Ussing devices. C. jejuni absence was checked by PCR and cytokine production with immunohistochemistry. Results: In PI-IBS, the epithelial resistance of the colon epithelium was unaltered, reflecting an intact paracellular pathway. In contrast, temperature-dependent horseradish peroxidase (HRP, 44 kDa) permeation increased. Short-circuit current (Isc) reflecting active anion secretion and ENaC-dependent electrogenic sodium absorption was unaffected. Early endosome antigen-1 (EEA1) and IL-4 levels increased. C. jejuni is not incorporated into the resident microbiota of the colon mucosa in PI-IBS. Conclusions: In PI-IBS after C. jejuni infection, macromolecule uptake via endocytosis was enhanced, leading to low-grade inflammation with pro-inflammatory cytokine release. The findings will allow C. jejuni-induced pathomechanisms to be targeted during infection and, thereafter to reduce sequelae such as PI-IBS. © 2023 by the authors.^antigen entry; barrier function; Campylobacter jejuni; cytokine; endocytosis; irritable bowel syndrome; leaky gut; permeability; post-infectious irritable bowel syndrome; tight junction; transcytosis^Campylobacter Infections; Campylobacter jejuni; Cytokines; Humans; Inflammation; Irritable Bowel Syndrome; aldosterone; amiloride; early endosome antigen 1; epithelial sodium channel; gamma interferon; horseradish peroxidase; interleukin 10; interleukin 1beta; interleukin 22; interleukin 4; interleukin 6; tumor necrosis factor; cytokine; antigen entry; Article; biological functions; biopsy technique; Campylobacter enteritis; clinical feature; colon biopsy; colon epithelium; colon mucosa; colonoscopy; controlled study; DNA extraction; electric resistance; electrogenic anion secretion; electrogenic sodium absorption; electrophysiology; endocytosis; epithelial resistance; forceps biopsies; human; human tissue; immunohistochemistry; impedance spectroscopy; inflamed subepithelium; intestinal barrier; intestine cell; irritable colon; leaky gut; low grade inflammation; microflora; multiplex polymerase chain reaction; overall resistance defect; paracellular pathway; pathological anatomy; permeability barrier; post campylobacter jejuni irritable bowel syndrome; resident microbiota; short circuit current; sigmoidoscopy; signal transduction; sodium absorption; tight junction; transcytosis; transepithelial resistance; Campylobacter jejuni; campylobacteriosis; complication; inflammation; metabolism; microbiology^^aldosterone, 52-39-1, 6251-69-0; amiloride, 2016-88-8, 2609-46-3; gamma interferon, 82115-62-6; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; Cytokines, ^CFX96, Biorad, United States; DNeasy, Qiagen, Germany; QIAamp, Qiagen, Germany^Biorad, United States; Qiagen, Germany; Qiagen, Germany^Sonnenfeld-Stiftung Berlin; Deutsche Forschungsgemeinschaft, DFG, (559/11-5–175142815, GRK 2318–318905415); Bundesministerium für Bildung und Forschung, BMBF, (IP2/01KI2007A, IP8/01KI2007D)^This research was funded by the Deutsche Forschungsgemeinschaft (Schu 559/11-5–175142815 and GRK 2318–318905415 (C01)) and the Sonnenfeld-Stiftung Berlin. This research was partly supported by the German Federal Ministry of Education and Research (BMBF) in frame of the zoonoses research consortium PAC-Campylobacter (project IP2/01KI2007A and project IP8/01KI2007D).^Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Kaakoush N.O., Castano-Rodriguez N., Global Epidemiology of Campylobacter Infection, Clin. Microbiol. Rev, 28, pp. 687-720, (2015); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin. Gastroenterol. Hepatol, 10, pp. 712-721, (2012); Scallan Walter E.J., Crim S.M., Bruce B.B., Griffin P.M., Postinfectious Irritable Bowel Syndrome After Campylobacter Infection, Am. J. Gastroenterol, 114, pp. 1649-1656, (2019); Bucker R., Krug S.M., Moos V., Bojarski C., Schweiger M.R., Kerick M., Fromm A., Janssen S., Fromm M., Hering N.A., Et al., Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon, Mucosal. Immunol, 11, pp. 474-485, (2018); de Sa F.D.L., Heimesaat M.M., Bereswill S., Nattramilarasu P.K., Schulzke J.D., Bucker R., Resveratrol prevents Campylobacter jejuni-induced leaky gut by restoring occludin and claudin-5 in the paracellular leak pathway, Front. Pharmacol, 12, (2021); Lobo de Sa F.D., Butkevych E., Nattramilarasu P.K., Fromm A., Mousavi S., Moos V., Golz J.C., Stingl K., Kittler S., Seinige D., Et al., Curcumin Mitigates Immune-Induced Epithelial Barrier Dysfunction by Campylobacter jejuni, Int. J. Mol. Sci, 20, (2019); Lobo de Sa F.D., Backert S., Nattramilarasu P.K., Mousavi S., Sandle G.I., Bereswill S., Heimesaat M.M., Schulzke J.D., Bucker R., Vitamin D Reverses Disruption of Gut Epithelial Barrier Function Caused by Campylobacter jejuni, Int. J. Mol. Sci, 22, (2021); Mayr A.M., Lick S., Bauer J., Tharigen D., Busch U., Huber I., Rapid detection and differentiation of Campylobacter jejuni, Campylobacter coli and Campylobacter lari in food, using multiplex real-time PCR, J. Food Prot, 73, pp. 241-250, (2010); Burgel N., Bojarski C., Mankertz J., Zeitz M., Fromm M., Schulzke J.D., Mechanisms of diarrhea in collagenous colitis, Gastroenterology, 123, pp. 433-443, (2002); Barmeyer C., Erko I., Fromm A., Bojarski C., Loddenkemper C., Dames P., Kerick M., Siegmund B., Fromm M., Schweiger M.R., Et al., ENaC dysregulation through activation of MEK1/2 contributes to impaired sodium absorption in lymphocytic colitis, Inflamm. Bowel Dis, 22, pp. 539-547, (2016); Bucker R., Schulz E., Gunzel D., Bojarski C., Lee I.F., John L.J., Wiegand S., Janssen T., Wieler L.H., Dobrindt U., Et al., α-Haemolysin of Escherichia coli in IBD: A potentiator of inflammatory activity in the colon, Gut, 63, pp. 1893-1901, (2014); John L., Mechanisms of Macromolecular Transcytosis during Crohn’s Disease: Investigations on the Cell Model T84 and Human Colon Biopsies, Ph.D. Dissertation, (2014); Berin M.C., Yang P.C., Ciok L., Waserman S., Perdue M.H., Role for IL-4 in macromolecular transport across human intestinal epithelium, Am. J. Physiol, 276, pp. C1046-C1052, (1999); Cohen E., Ophir I., Henis Y.I., Bacher A., Ben Shaul Y., Effect of temperature on the assembly of tight junctions and on the mobility of lipids in membranes of HT29 cells, J. Cell Sci, 97, pp. 119-125, (1990); Punnonen E.L., Ryhanen K., Marjomaki V.S., At reduced temperature, endocytic membrane traffic is blocked in multivesicular carrier endosomes in rat cardiac myocytes, Eur. J. Cell Biol, 75, pp. 344-352, (1998); Schinnerling K., Geelhaar-Karsch A., Allers K., Friebel J., Conrad K., Loddenkemper C., Kuhl A., Erben U., Ignatius R., Moos V., Et al., Role of dendritic cells in the pathogenesis of Whipple’s disease, Infect. Immun, 83, pp. 482-491, (2015); Buschmann M.M., Shen L., Rajapakse H., Raleigh D.R., Wang Y., Wang Y., Lingaraju A., Zha J., Abbott E., McAuley E.M., Et al., Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux, Mol. Biol. Cell, 24, pp. 3056-3068, (2013); Krug S.M., Amasheh S., Richter J.F., Milatz S., Gunzel D., Westphal J.K., Huber O., Schulzke J.D., Fromm M., Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability, Mol. Biol. Cell, 20, pp. 3713-3724, (2009); Bellono N.W., Bayrer J.R., Leitch D.B., Castro J., Zhang C., O'Donnell T.A., Brierley S.M., Ingraham H.A., Julius D., Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways, Cell, 170, pp. 185-198, (2017); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res, 11, pp. 345-349, (2018); Lobo de Sa F.D., Schulzke J.D., Bucker R., Diarrheal Mechanisms and the Role of Intestinal Barrier Dysfunction in Campylobacter Infections, Curr. Top. Microbiol. Immunol, 431, pp. 203-231, (2021); Miner-Williams W.M., Stevens B.R., Moughan P.J., Are intact peptides absorbed from the healthy gut in the adult human?, Nutr. Res. Rev, 27, pp. 308-329, (2014); Matysiak-Budnik T., Candalh C., Dugave C., Namane A., Cellier C., Cerf-Bensussan N., Heyman M., Alterations of the intestinal transport and processing of gliadin peptides in celiac disease, Gastroenterology, 125, pp. 696-707, (2003); Krug S.M., Bojarski C., Fromm A., Lee I.M., Dames P., Richter J.F., Turner J.R., Fromm M., Schulzke J.D., Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis, Mucosal Immunol, 11, pp. 345-356, (2018); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand. J. Gastroenterol, 43, pp. 1467-1476, (2008); Awad K., Epitheliale Barrierefunktion des Kolons Beim DIARRHOE-Dominanten und Beim Mischtyp-Reizdarmsyndrom, Ph.D. Dissertation, (2022); Brooks P.T., Brakel K.A., Bell J.A., Bejcek C.E., Gilpin T., Brudvig J.M., Mansfield L.S., Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice, Microbiome, 5, (2017); Parthasarathy G., Mansfield L.S., Recombinant interleukin-4 enhances Campylobacter jejuni invasion of intestinal pig epithelial cells (IPEC-1), Microb. Pathog, 47, pp. 38-46, (2009); Edwards L.A., Nistala K., Mills D.C., Stephenson H.N., Zilbauer M., Wren B.W., Dorrell N., Lindley K.J., Wedderburn L.R., Bajaj-Elliott M., Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection, PLoS ONE, 5, (2010); Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., Diepolder H., Marquardt A., Jagla W., Popp A., Et al., IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration, Am. J. Physiol. Gastrointest Liver Physiol, 290, pp. G827-G838, (2006); Yuki N., Kuwabara S., Axonal Guillain-Barré syndrome: Carbohydrate mimicry and pathophysiology, J. Peripher. Nerv. Syst, 12, pp. 239-249, (2007); Morales W., Triantafyllou K., Parodi G., Weitsman S., Park S.C., Rezaie A., Pichetshote N., Lin E., Pimentel M., Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome, Neurogastroenterol. Motil, 32, (2020); Pimentel M., Morales W., Pokkunuri V., Brikos C., Kim S.M., Kim S.E., Triantafyllou K., Weitsman S., Marsh Z., Marsh E., Et al., Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model, Dig Dis. Sci, 60, pp. 1195-1205, (2015); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007)^R. Bücker; Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Campus Benjamin Franklin, 12203, Germany; email: roland-felix.buecker@charite.de^^MDPI^^^^^^2218273X^^^36979384.0^English^Biomolecules^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85151221533
Meynier M.; Daugey V.; Mallaret G.; Gervason S.; Meleine M.; Barbier J.; Aissouni Y.; Lolignier S.; Bonnet M.; Ardid D.; De Vos W.M.; Van Hul M.; Suenaert P.; Brochot A.; Cani P.D.; Carvalho F.A.^Meynier, Maëva (57217062090); Daugey, Valentine (58793530700); Mallaret, Geoffroy (57221844941); Gervason, Sandie (57209348857); Meleine, Mathieu (53464003400); Barbier, Julie (57195961481); Aissouni, Youssef (6508190769); Lolignier, Stéphane (24076257000); Bonnet, Mathilde (36051650700); Ardid, Denis (6603953203); De Vos, Willem M. (35495729400); Van Hul, Matthias (24400419500); Suenaert, Peter (6506787503); Brochot, Amandine (57191440247); Cani, Patrice D. (6507917827); Carvalho, Frédéric A. (16041688200)^57217062090; 58793530700; 57221844941; 57209348857; 53464003400; 57195961481; 6508190769; 24076257000; 36051650700; 6603953203; 35495729400; 24400419500; 6506787503; 57191440247; 6507917827; 16041688200^Pasteurized akkermansia muciniphila improves irritable bowel syndrome-like symptoms and related behavioral disorders in mice^2024^Gut Microbes^16.0^1^2298026^^^^2^10.1080/19490976.2023.2298026^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181520039&doi=10.1080%2f19490976.2023.2298026&partnerID=40&md5=43d31eb54593dfd3eb60043bcff3b1fa^NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; M2iSH, UMR 1071 INSERM, UMR1382 INRAé, University of Clermont Auvergne, Clermont-Ferrand, France; Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands; Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium; WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO department, WEL Research Institute, Wavre, Belgium; Institute of Experimental and Clinical Research (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium^Meynier M., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France, M2iSH, UMR 1071 INSERM, UMR1382 INRAé, University of Clermont Auvergne, Clermont-Ferrand, France; Daugey V., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Mallaret G., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Gervason S., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Meleine M., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Barbier J., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Aissouni Y., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Lolignier S., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; Bonnet M., M2iSH, UMR 1071 INSERM, UMR1382 INRAé, University of Clermont Auvergne, Clermont-Ferrand, France; Ardid D., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France; De Vos W.M., Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands, Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland, The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Van Hul M., Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium, WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO department, WEL Research Institute, Wavre, Belgium; Suenaert P., The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Brochot A., The Akkermansia Company™, Mont-Saint-Guibert, Belgium; Cani P.D., Metabolism and Nutrition Research group, Louvain Drug Research Institute (LDRI), UCLouvain, Université Catholique de Louvain, Brussels, Belgium, WELBIO-Walloon Excellence in Life Sciences and Biotechnology, WELBIO department, WEL Research Institute, Wavre, Belgium, Institute of Experimental and Clinical Research (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium; Carvalho F.A., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, France^Gut–brain communications disorders in irritable bowel syndrome (IBS) are associated with intestinal microbiota composition, increased gut permeability, and psychosocial disturbances. Symptoms of IBS are difficult to medicate, and hence much research is being made into alternative approaches. This study assesses the potential of a treatment with pasteurized Akkermansia muciniphila for alleviating IBS-like symptoms in two mouse models of IBS with different etiologies. Two clinically relevant animal models were used to mimic IBS-like symptoms in C57BL6/J mice: the neonatal maternal separation (NMS) paradigm and the Citrobacter rodentium infection model. In both models, gut permeability, colonic sensitivity, fecal microbiota composition and colonic IL-22 expression were evaluated. The cognitive performance and emotional state of the animals were also assessed by several tests in the C. rodentium infection model. The neuromodulation ability of pasteurized A. muciniphila was assessed on primary neuronal cells from mice dorsal root ganglia using a ratiometric calcium imaging approach. The administration of pasteurized A. muciniphila significantly reduced colonic hypersensitivity in both IBS mouse models, accompanied by a reinforcement of the intestinal barrier function. Beneficial effects of pasteurized A. muciniphila treatment have also been observed on anxiety-like behavior and memory defects in the C. rodentium infection model. Finally, a neuroinhibitory effect exerted by pasteurized A. muciniphila was observed on neuronal cells stimulated with two algogenic substances such as capsaicin and inflammatory soup. Our findings demonstrate novel anti-hyperalgesic and neuroinhibitory properties of pasteurized A. muciniphila, which therefore may have beneficial effects in relieving pain and anxiety in subjects with IBS. © 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.^anxiety-like disorders; colonic hypersensitivity; IBS; memory impairment; neuroinhibition; Pasteurized akkermansia muciniphila^Akkermansia muciniphila; Animals; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Maternal Deprivation; Mice; Verrucomicrobia; calcium; capsaicin; claudin 2; fluorescein isothiocyanate dextran; interleukin 22; occludin; protein ZO1; RNA 16S; acclimatization; Akkermansia muciniphila; animal experiment; animal model; animal tissue; anxiety disorder; area under the curve; Article; behavior disorder; Citrobacter rodentium; colony forming unit; colorectal distension test; controlled study; diagnostic test; diagnostic test accuracy study; elevated plus maze test; female; fluorometry; hole board test; hypersensitivity; irritable colon; male; memory disorder; mouse; nerve cell inhibition; nonhuman; novel object recognition test; Y-maze test; Akkermansia muciniphila; animal; human; intestine flora; irritable colon; maternal deprivation; physiology; Verrucomicrobia^^calcium, 7440-70-2, 14092-94-5; capsaicin, 404-86-4; fluorescein isothiocyanate dextran, 60842-46-8; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; occludin, 176304-61-3^C1000, Biorad, United States; CFX96, Biorad, United States; Distender Series II, GJ Electronics; Ethovision XT 15, Noldus; GraphPad Prism version 10.1.1, Graphpad, United States; LabChart 7, AdInstruments, France; PCU-2000, Millar, United States; QIAamp, Qiagen, Germany; QX manager software 2.1, Biorad, United States; model 600, Millar, United States^AdInstruments, France; Biorad, United States; Biorad, United States; Biorad, United States; GJ Electronics; Graphpad, United States; Millar, United States; Millar, United States; Noldus; Qiagen, Germany^Akkermansia Company™; Clermont Auvergne Métropole; French Ministère de la Recherche et de la Technologie; Waalse Gewest, (8206); Institut National de la Santé et de la Recherche Médicale, Inserm; Fonds De La Recherche Scientifique - FNRS, FNRS, (40007505, WELBIO-CR-2022A-02); European Regional Development Fund, ERDF, (16-IDEX-0001-CAP 20-25); Région Auvergne-Rhône-Alpes^This work was supported by co-financing from The Akkermansia Company™ (Belgium) and supported by a research agreement from the Walloon Region (agreement 8206), the French Ministère de la Recherche et de la Technologie (NeuroDol laboratory [INSERM 1107]), the Region Auvergne-Rhône-Alpes and FEDER, No. Thématiques émergentes, Pack Ambition Recherche; the French Government IDEX-ISITE Initiative, No. 16-IDEX-0001-CAP 20-25, and the Clermont Auvergne Métropole, No “Recherche-Action” project. P.D.C. is research director for the FNRS and recipient of a Projet de Recherche PDR-convention: FNRS T.0030.21 and FRFS-WELBIO: WELBIO-CR-2022A-02, EOS: program no. 40007505. Abdelkrim Alloui (Animal Facilities) for animal care.^Drossman D.A., Hasler W.L., Rome IV—functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, 6, pp. 1257-1221, (2016); Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjorsvik B.R., Haleem N., Benitez-Paez A., Sanz Y., Hausken T., Lied G.A., Lundervold A., Et al., Gut bless you: the microbiota-gut-brain axis in irritable bowel syndrome, World J Gastroentero, 28, 4, pp. 412-431, (2022); Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M., Rome foundation working team report on post-infection irritable bowel syndrome, Gastroenterology, 156, 1, pp. 46-58, (2019); Nicholl B.I., Halder S.L., Macfarlane G.J., Thompson D.G., O'Brien S., Musleh M., McBeth J., Psychosocial risk markers for new onset irritable bowel syndrome–results of a large prospective population-based study, Pain, 137, 1, pp. 147-155, (2008); Camilleri M., Boeckxstaens G., Irritable bowel syndrome: treatment based on pathophysiology and biomarkers, Gut, 72, 3, pp. 590-599, (2023); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, 3, pp. 240-245, (2007); Mallaret G., Lashermes A., Meleine M., Boudieu L., Barbier J., Aissouni Y., Gelot A., Chassaing B., Gewirtz A.T., Ardid D., Et al., Involvement of toll-like receptor 5 in mouse model of colonic hypersensitivity induced by neonatal maternal separation, World J Gastroenterol, 28, 29, pp. 3903-3916, (2022); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap Adv Gastroenterol, 14, (2021); Mondelaers S.U., Theofanous S.A., Florens M.V., Perna E., Aguilera-Lizarraga J., Boeckxstaens G., Wouters M., Effect of genetic background and postinfectious stress on visceral sensitivity in citrobacter rodentium-infected mice, Neurogastroent Motil, 28, 5, pp. 647-658, (2016); Collins J.W., Keeney K.M., Crepin V.F., Rathinam V.A.K., Fitzgerald K.A., Finlay B.B., Frankel G., Citrobacter rodentium: infection, inflammation and the microbiota, Nat Rev Microbiol, 12, 9, pp. 612-623, (2014); Meynier M., Baudu E., Rolhion N., Defaye M., Daugey V., Modoux M., Wawrzyniak I., Villeger R., Meleine M., Borras Nogues E., Et al., AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms, Gut Microbes, 14, 1, (2022); Ibeakanma C., Miranda-Morales M., Richards M., Bautista-Cruz F., Martin N., Hurlbut D., Vanner S., Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons, J Physiol, 587, 14, pp. 3505-3521, (2009); Dinan T.G., Cryan J.F., The microbiome-gut-brain axis in health and disease, Gastroenterol Clin North Am, 46, 1, pp. 77-89, (2017); Derrien M., Vaughan E.E., Plugge C.M., de Vos W.M., Akkermansia municiphila gen. Nov., sp. Nov., a human intestinal mucin-degrading bacterium, Int J Syst Evol Microbiol, 54, 5, pp. 1469-1476, (2004); Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., Guiot Y., Derrien M., Muccioli G.G., Delzenne N.M., Et al., Cross-talk between akkermansia muciniphila and intestinal epithelium controls diet-induced obesity, Proceedings of the National Academy of Sciences of the United States of America, 110, pp. 9066-9071, (2013); Cani P.D., Depommier C., Derrien M., Everard A., de Vos W.M., Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms, Nat Rev Gastroenterol Hepatol, 19, 10, pp. 625-637, (2022); Karlsson C.L.J., Onnerfalt J., Xu J., Molin G., Ahrne S., Thorngren-Jerneck K., The microbiota of the gut in preschool children with normal and excessive body weight, Obesity, 20, 11, pp. 2257-2261, (2012); Everard A., Lazarevic V., Derrien M., Girard M., Muccioli G.M., Neyrinck A.M., Possemiers S., Van Holle A., Francois P., De Vos W.M., Et al., Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice, Diabetes, 60, 11, pp. 2775-2786, (2011); Plovier H., Everard A., Druart C., Depommier C., Van Hul M., Geurts L., Chilloux J., Ottman N., Duparc T., Lichtenstein L., Et al., A purified membrane protein from akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nat Med, 23, 1, pp. 107-113, (2017); Depommier C., Van Hul M., Everard A., Delzenne N.M., De Vos W.M., Cani P.D., Pasteurized akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice, Gut Microbes, 11, 5, pp. 1231-1245, (2020); Depommier C., Everard A., Druart C., Plovier H., Van Hul M., Vieira-Silva S., Falony G., Raes J., Maiter D., Delzenne N.M., Et al., Supplementation with akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study, Nat Med, 25, 7, pp. 1096-1103, (2019); Xu D., Chen V.L., Steiner C.A., Berinstein J.A., Eswaran S., Waljee A.K., Higgins P.D.R., Owyang C., Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis, Am J Gastroenterol, 114, 7, pp. 1043-1050, (2019); Ford A.C., Harris L.A., Lacy B.E., Quigley E.M.M., Moayyedi P., Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment Pharmacol Ther, 48, 10, pp. 1044-1060, (2018); Cruz-Aguliar R.M., Wantia N., Clavel T., Vehreschild M.J.G.T., Buch T., Bajbouj M., Haller D., Busch D., Schmid R.M., Stein-Thoeringer C.K., An open-labeled study on fecal microbiota transfer in irritable bowel syndrome patients reveals improvement in abdominal pain associated with the relative abundance of akkermansia muciniphila, Digestion, 100, 2, pp. 127-138, (2019); Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Eschalier A., Ardid D., Bermudez-Humaran L.G., Sokol H., Et al., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci Rep, 6, 1, (2016); Xin Y., Wang J., Chu T., Zhou Y., Liu C., Xu A., Electroacupuncture alleviates neuroinflammation by inhibiting the HMGB1 signaling pathway in rats with sepsis-associated encephalopathy, Brain Sci, 12, 12, (2022); Iban-Arias R., Trageser K.J., Yang E.-J., Griggs E., Radu A., Naughton S., Al Rahim M., Tatsunori O., Raval U., Palmieri J., Et al., Exposure to world trade center dust exacerbates cognitive impairment and evokes a central and peripheral pro-inflammatory transcriptional profile in an animal model of alzheimer’s disease, J Alzheimers Dis, 91, 2, pp. 779-794, (2022); Perez-Berezo T., Pujo J., Martin P., Le Faouder P., Galano J.-M., Guy A., Knauf C., Tabet J.C., Tronnet S., Barreau F., Et al., Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain nissle 1917, Nat Commun, 8, 1, (2017); Perez-Burgos A., Wang L., McVey Neufeld K.-A., Mao Y.-K., Ahmadzai M., Janssen L.J., Stanisz A.M., Bienenstock J., Kunze W.A., The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic lactobacillus reuteri DSM 17938, J Physiol, 593, pp. 3943-3957, (2015); Simren M., Tornblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts, Gut, 67, pp. 255-262, (2018); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Drossman D.A., Tack J., Ford A.C., Szigethy E., Tornblom H., Van Oudenhove L., Neuromodulators for functional gastrointestinal disorders (disorders of gut−brain interaction): a Rome foundation working team report, Gastroenterology, 154, 4, pp. 1140-1171, (2018); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, 5, pp. 966-974, (2017); Wilmes L., Collins J.M., O'Riordan K.J., O'Mahony S.M., Cryan J.F., Clarke G., Of bowels, brain and behavior: a role for the gut microbiota in psychiatric comorbidities in irritable bowel syndrome, Neurogastroenterol Motil, 33, 3, (2021); Coutinho S.V., Plotsky P.M., Sablad M., Miller J.C., Zhou H., Bayati A.I., McRoberts J.A., Mayer E.A., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, 2, pp. G307-G316, (2002); Meleine M., Boudieu L., Gelot A., Muller E., Lashermes A., Matricon J., Silberberg C., Theodorou V., Eschalier A., Ardid D., Et al., Comparative effects of α2δ-1 ligands in mouse models of colonic hypersensitivity, World J Gastroenterol, 22, 31, pp. 7111-7123, (2016); Chen Y., Xiao S., Gong Z., Zhu X., Yang Q., Li Y., Gao S., Dong Y., Shi Z., Wang Y., Et al., Wuji wan formula ameliorates diarrhea and disordered colonic motility in post-inflammation irritable bowel syndrome rats by modulating the gut microbiota, Front Microbiol, 8, (2017); Jacobs J.P., Gupta A., Bhatt R.R., Brawer J., Gao K., Tillisch K., Lagishetty V., Firth R., Gudleski G.D., Ellingson B.M., Et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement, Microbiome, 9, 1, (2021); Morais L.H., Schreiber H.L., Mazmanian S.K., The gut microbiota–brain axis in behaviour and brain disorders, Nat Rev Microbiol, 19, 4, pp. 241-255, (2021); Ji N.-N., Jiang H., Xia M., The influence of the enriched environment in different periods on neonatal maternal separation-induced visceral pain, anxiousness, and depressive behaviors, Transl Pediatr, 11, 9, pp. 1562-1569, (2022); Pontifex M.G., Connell E., Le Gall G., Pourtau L., Gaudout D., Angeloni C., Zallocco L., Ronci M., Giusti L., Muller M., Et al., Saffron extract (Safr’inside™) improves anxiety related behaviour in a mouse model of low-grade inflammation through the modulation of the microbiota and gut derived metabolites, Food Funct, 13, 23, pp. 12219-12233, (2022); Sun Y., Zhu H., Cheng R., Tang Z., Zhang M., Outer membrane protein Amuc_1100 of akkermansia muciniphila alleviates antibiotic-induced anxiety and depression-like behavior in mice, Physiol Behavior, 258, (2023); Bae M., Cassilly C.D., Liu X., Park S.-M., Tusi B.K., Chen X., Kwon J., Filipcik P., Bolze A.S., Liu Z., Et al., Akkermansia muciniphila phospholipid induces homeostatic immune responses, Nature, 608, 7921, pp. 168-173, (2022); Gu Z., Pei W., Shen Y., Wang L., Zhu J., Zhang Y., Fan S., Wu Q., Li L., Zhang Z., Akkermansia muciniphila and its outer protein Amuc_1100 regulates tryptophan metabolism in colitis, Food Funct, 12, 20, pp. 10184-10195, (2021); Bachmann R., Van Hul M., Baldin P., Leonard D., Delzenne N.M., Belzer C., Ouwerkerk J.P., Repsilber D., Rangel I., Kartheuser A., Et al., Akkermansia muciniphila reduces peritonitis and improves intestinal tissue wound healing after a colonic transmural defect by a MyD88-dependent mechanism, Cells, 11, 17, (2022); Lapointe T.K., Basso L., Iftinca M.C., Flynn R., Chapman K., Dietrich G., Vergnolle N., Altier C., TRPV1 sensitization mediates postinflammatory visceral pain following acute colitis, Am J Physiol-Gastr L, 309, 2, pp. G87-G99, (2015); Akbar A., Yiangou Y., Facer P., Walters J.R.F., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, 7, pp. 923-929, (2008); Najjar S.A., Davis B.M., Albers K.M., Epithelial–neuronal communication in the colon: implications for visceral pain, Trends Neurosci, 43, 3, pp. 170-181, (2020); Jalanka J., Lam C., Bennett A., Hartikainen A., Crispie F., Finnegan L.A., Cotter P.D., Spiller R., Colonic gene expression and fecal microbiota in diarrhea-predominant irritable bowel syndrome: increased toll-like receptor 4 but minimal inflammation and no response to Mesalazine, J Neurogastroenterol Motil, 27, 2, pp. 279-291, (2021); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); Sugiuar T., Bielefeldt K., Gebhart G.F., TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation, J Neurosci, 24, 43, pp. 9521-9530, (2004); Mistry S., Paule C.C., Varga A., Photiou A., Jenes A., Avelino A., Buluwela L., Nagy I., Prolonged exposure to bradykinin and prostaglandin E2 increases TRPV1 mRNA but does not alter TRPV1 and TRPV1b protein expression in cultured rat primary sensory neurons, Neurosci Lett, 564, pp. 89-93, (2014); Wouters M.M., Balemans D., Van Wanrooy S., Dooley J., Cibert-Goton V., Alpizar Y.A., Valdez-Morales E.E., Nasser Y., Van Veldhoven P.P., Vanbrabant W., Et al., Histamine receptor H1–mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome, Gastroenterology, 150, 4, pp. 875-887, (2016); Shen W., Shen M., Zhao X., Zhu H., Yang Y., Lu S., Tan Y., Li G., Li M., Wang J., Et al., Anti-obesity effect of capsaicin in mice fed with high-fat diet is associated with an increase in population of the gut bacterium akkermansia muciniphila, Front Microbiol, 8, (2017); Gong T., Wang H., Liu S., Zhang M., Xie Y., Liu X., Capsaicin regulates lipid metabolism through modulation of bile acid/gut microbiota metabolism in high-fat-fed SD rats, Food Nutr Res, 66, (2022); Fried D.E., Gulbransen B.D., In situ Ca2+ imaging of the enteric nervous system, J Vis Exp, (2015); Dinan T.G., Cryan J.F., The impact of gut microbiota on brain and behaviour: implications for psychiatry, Curr Opin Clin Nutr Metab Care, 18, 6, pp. 552-558, (2015); Zimmermann M., Ethical guidelines for investigations of experimental pain in conscious animals, Pain, 16, 2, pp. 109-110, (1983); Larauche M., Gourcerol G., Million M., Adelson D.W., Tache Y., Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: influence of surgery and postoperative single housing on visceromotor responses, Stress, 13, 4, pp. 344-355, (2010); Picard E., Carvalho F.A., Agosti F., Bourinet E., Ardid D., Eschalier A., Daulhac L., Mallet C., Inhibition of cav 3.2 calcium channels: a new target for colonic hypersensitivity associated with low-grade inflammation, Br J Pharmacol, 176, 7, pp. 950-963, (2019); Rodriguez Echandia E.L., Broitman S.T., Foscolo M.R., Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats, Pharmacol Biochem Behav, 26, 2, pp. 207-210, (1987); Sierksma A.S.R., Van Den Hove D.L.A., Pfau F., Philippens M., Bruno O., Fedele E., Ricciarelli R., Steinbusch H.W.M., Vanmierlo T., Prickaerts J., Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D, Neuropharmacology, 77, pp. 120-130, (2014); Barre A., Berthoux C., De Bundel D., Valjent E., Bockaert J., Marin P., Becamel C., Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning, Proceedings of the National Academy of Sciences of the United States of America, 113, pp. E1382-E1391, (2016); Bolyen E., Rideout J.R., Dillon M.R., Bokulich N.A., Abnet C.C., Al-Ghalith G.A., Alexander H., Alm E.J., Arumugam M., Asnicar F., Et al., Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2, Nat Biotechnol, 37, 8, pp. 852-857, (2019); Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J.A., Holmes S.P., DADA2: High-resolution sample inference from Illumina amplicon data, Nat Methods, 13, 7, pp. 581-583, (2016); Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glockner F.O., The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res, 41, D1, pp. D590-D596, (2013)^F.A. Carvalho; NeuroDol UMR 1107 INSERM, University of Clermont-Auvergne, Clermont-Ferrand, 28 place Henri Dunant, BP 38, 63000, France; email: frederic.carvalho@inserm.fr^^Taylor and Francis Ltd.^^^^^^19490976^^^38170633.0^English^Gut Microbes^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85181520039
Langlois L.D.; Oddoux S.; Aublé K.; Violette P.; Déchelotte P.; Noël A.; Coëffier M.^Langlois, Ludovic D. (58869571200); Oddoux, Sarah (57225291827); Aublé, Kanhia (58222029100); Violette, Paul (57734216600); Déchelotte, Pierre (57201760610); Noël, Antoine (57221445829); Coëffier, Moïse (6603081357)^58869571200; 57225291827; 58222029100; 57734216600; 57201760610; 57221445829; 6603081357^Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model^2023^International Journal of Molecular Sciences^24.0^8^7220^^^^3^10.3390/ijms24087220^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85156197877&doi=10.3390%2fijms24087220&partnerID=40&md5=92df7794dce22002e73d1fbd68ad7435^Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France; Laboratoire DIELEN, Tourlaville, F-50110, France; Nutrition Department, CHU Rouen, Rouen, 76000, France^Langlois L.D., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France, Laboratoire DIELEN, Tourlaville, F-50110, France; Oddoux S., Laboratoire DIELEN, Tourlaville, F-50110, France; Aublé K., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France; Violette P., Laboratoire DIELEN, Tourlaville, F-50110, France; Déchelotte P., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France, Nutrition Department, CHU Rouen, Rouen, 76000, France; Noël A., Laboratoire DIELEN, Tourlaville, F-50110, France; Coëffier M., Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France, Nutrition Department, CHU Rouen, Rouen, 76000, France^Irritable bowel syndrome (IBS), a multifactorial intestinal disorder, is often associated with a disruption in intestinal permeability as well as an increased expression of pro-inflammatory markers. The aim of this study was to first test the impact of treatment with glutamine (Gln), a food supplement containing natural curcumin extracts and polyunsaturated n-3 fatty acids (Cur); bioactive peptides from a fish protein hydrolysate (Ga); and a probiotic mixture containing Bacillus coagulans, Lactobacillus acidophilus, Lactobacillus gasseri and Lactobacillus helveticus. These compounds were tested alone on a stress-based IBS model, the chronic-restraint stress model (CRS). The combination of Gln, Cur and Ga (GCG) was also tested. Eight-week-old C57Bl/6 male mice were exposed to restraint stress for two hours every day for four days and received different compounds every day one week before and during the CRS procedure. Plasma corticosterone levels were measured as a marker of stress, and colonic permeability was evaluated ex vivo in Ussing chambers. Changes in the gene expression of tight junction proteins (occludin, claudin-1 and ZO 1) and inflammatory cytokines (IL1β, TNFα, CXCL1 and IL10) were assessed using RT-qPCR. The CRS model led to an increase in plasma corticosterone and an increase in colonic permeability compared with unstressed animals. No change in plasma corticosterone concentrations was observed in response to CRS with the different treatments (Gln, Cur, Ga or GCG). Stressed animals treated with Gln, Cur and Ga alone and in combination showed a decrease in colonic permeability when compared to the CRS group, while the probiotic mixture resulted in an opposite response. The Ga treatment induced an increase in the expression of the anti-inflammatory cytokine IL-10, and the GCG treatment was able to decrease the expression of CXCL1, suggesting the synergistic effect of the combined mixture. In conclusion, this study demonstrated that a combined administration of glutamine, a food supplement containing curcumin and polyunsaturated n-3 fatty acids, and bioactive peptides from a fish hydrolysate was able to reduce colonic hyperpermeability and reduce the inflammatory marker CXCL1 in a stress-based model of IBS and could be of interest to patients suffering from IBS. © 2023 by the authors.^curcumin; fish bioactive peptides; glutamine; intestinal permeability; stress^Animals; Corticosterone; Curcumin; Cytokines; Fatty Acids, Omega-3; Glutamine; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Permeability; alpha tocopherol; claudin 1; colecalciferol; corticosterone; curcumega; curcumin; CXCL1 chemokine; docosahexaenoic acid; fish protein; gabolysat; glutamine; icosapentaenoic acid; interleukin 10; interleukin 1beta; interleukin 8; isoflurane; messenger RNA; occludin; probiotic agent; protein hydrolysate; protein ZO1; tight junction protein; tumor necrosis factor; unclassified drug; corticosterone; curcumin; cytokine; glutamine; omega 3 fatty acid; adult; animal experiment; animal model; animal tissue; Article; Bacillus coagulans; blood sampling; colon mucosa; combination drug therapy; controlled study; corticosterone blood level; dietary supplement; drug potentiation; human; immobilization stress; intestine mucosa permeability; irritable colon; Lactobacillus acidophilus; Lactobacillus gasseri; Lactobacillus helveticus; male; mouse; nonhuman; real time polymerase chain reaction; animal; intestine mucosa; irritable colon; metabolism; permeability^^alpha tocopherol, 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; claudin 1, 329338-06-9; colecalciferol, 1406-16-2, 67-97-0; corticosterone, 50-22-6; curcumin, 458-37-7; docosahexaenoic acid, 25167-62-8, 32839-18-2; glutamine, 56-85-9, 6899-04-3; icosapentaenoic acid, 10417-94-4, 1553-41-9, 25378-27-2, 32839-30-8; interleukin 8, 114308-91-7; isoflurane, 26675-46-7; occludin, 176304-61-3; protein hydrolysate, 76773-71-2, 9015-54-7; Corticosterone, ; Curcumin, ; Cytokines, ; Fatty Acids, Omega-3, ; Glutamine, ^curcumega; gabolysat^^Laboratoire Dielen; Region Normandy, (21E00021)^This work was funded by the Region Normandy via the program Impulsion Innovation, grant no. 21E00021, and by Laboratoire Dielen.^Canavan C., West J., Card T., The Epidemiology of Irritable Bowel Syndrome, Clin. Epidemiol, 6, pp. 71-80, (2014); Le Pluart D., Sabate J.-M., Bouchoucha M., Hercberg S., Benamouzig R., Julia C., Functional Gastrointestinal Disorders in 35,447 Adults and Their Association with Body Mass Index. Aliment, Pharmacol. Ther, 41, pp. 758-767, (2015); Kopczynska M., Mokros L., Pietras T., Malecka-Panas E., Quality of Life and Depression in Patients with Irritable Bowel Syndrome, Przeglad Gastroenterol, 13, pp. 102-108, (2018); Talley N.J., Zinsmeister A.R., Melton L.J., Irritable Bowel Syndrome in a Community: Symptom Subgroups, Risk Factors, and Health Care Utilization, Am. J. Epidemiol, 142, pp. 76-83, (1995); Longstreth G.F., Irritable Bowel Syndrome: A Multibillion-Dollar Problem, Gastroenterology, 109, pp. 2029-2031, (1995); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased Rectal Mucosal Enteroendocrine Cells, T Lymphocytes, and Increased Gut Permeability Following Acute Campylobacter Enteritis and in Post-Dysenteric Irritable Bowel Syndrome, Gut, 47, pp. 804-811, (2000); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Antonietti M., Savoye G., Bole-Feysot C., Dechelotte P., Et al., Increased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome, Am. J. Gastroenterol, 105, pp. 1181-1188, (2010); Zhou Q., Zhang B., Verne G.N., Intestinal Membrane Permeability and Hypersensitivity in the Irritable Bowel Syndrome, Pain, 146, pp. 41-46, (2009); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.-M., Dechelotte P., Menard J.-F., Ducrotte P., Et al., The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients with Differences According to the Disease Subtype, Am. J. Gastroenterol, 106, pp. 2165-2173, (2011); Collins S.M., Denou E., Verdu E.F., Bercik P., The Putative Role of the Intestinal Microbiota in the Irritable Bowel Syndrome, Dig. Liver Dis, 41, pp. 850-853, (2009); De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Umeh G., Miranda P.M., Pigrau Pastor M., Sidani S., Et al., Transplantation of Fecal Microbiota from Patients with Irritable Bowel Syndrome Alters Gut Function and Behavior in Recipient Mice, Sci. Transl. Med, 9, (2017); Walter S.A., Aardal-Eriksson E., Thorell L.H., Bodemar G., Hallbook O., Pre-Experimental Stress in Patients with Irritable Bowel Syndrome: High Cortisol Values Already before Symptom Provocation with Rectal Distensions, Neurogastroenterol. Motil, 18, pp. 1069-1077, (2006); Vanuytsel T., van Wanrooy S., Vanheel H., Vanormelingen C., Verschueren S., Houben E., Salim Rasoel S., Tomicronth J., Holvoet L., Farre R., Et al., Psychological Stress and Corticotropin-Releasing Hormone Increase Intestinal Permeability in Humans by a Mast Cell-Dependent Mechanism, Gut, 63, pp. 1293-1299, (2014); Ghouzali I., Lemaitre C., Bahlouli W., Azhar S., Bole-Feysot C., Meleine M., Ducrotte P., Dechelotte P., Coeffier M., Targeting Immunoproteasome and Glutamine Supplementation Prevent Intestinal Hyperpermeability, Biochim. Biophys. Acta Gen. Subj, 1861, pp. 3278-3288, (2017); Barreau F., Cartier C., Leveque M., Ferrier L., Moriez R., Laroute V., Rosztoczy A., Fioramonti J., Bueno L., Pathways Involved in Gut Mucosal Barrier Dysfunction Induced in Adult Rats by Maternal Deprivation: Corticotrophin-Releasing Factor and Nerve Growth Factor Interplay, J. Physiol, 580, pp. 347-356, (2007); L'Huillier C., Jarbeau M., Achamrah N., Belmonte L., Amamou A., Nobis S., Goichon A., Salameh E., Bahlouli W., do Rego J.-L., Et al., Glutamine, but Not Branched-Chain Amino Acids, Restores Intestinal Barrier Function during Activity-Based Anorexia, Nutrients, 11, (2019); Achamrah N., Dechelotte P., Coeffier M., Glutamine and the Regulation of Intestinal Permeability: From Bench to Bedside, Curr. Opin. Clin. Nutr. Metab. Care, 20, pp. 86-91, (2017); Zhou Q., Costinean S., Croce C.M., Brasier A.R., Merwat S., Larson S.A., Basra S., Verne G.N., MicroRNA 29 Targets Nuclear Factor-ΚB–Repressing Factor and Claudin 1 to Increase Intestinal Permeability, Gastroenterology, 148, pp. 158-169.e8, (2015); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised Placebo-Controlled Trial of Dietary Glutamine Supplements for Postinfectious Irritable Bowel Syndrome, Gut, 68, pp. 996-1002, (2019); Lubbad A., Oriowo M.A., Khan I., Curcumin Attenuates Inflammation through Inhibition of TLR-4 Receptor in Experimental Colitis, Mol. Cell. Biochem, 322, pp. 127-135, (2009); Ng Q.X., Soh A.Y.S., Loke W., Venkatanarayanan N., Lim D.Y., Yeo W.-S., A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS), J. Clin. Med, 7, (2018); Freret T., Largilliere S., Nee G., Coolzaet M., Corvaisier S., Boulouard M., Fast Anxiolytic-Like Effect Observed in the Rat Conditioned Defensive Burying Test, after a Single Oral Dose of Natural Protein Extract Products, Nutrients, 13, (2021); Bernet F., Montel V., Noel B., Dupouy J.P., Diazepam-like Effects of a Fish Protein Hydrolysate (Gabolysat PC60) on Stress Responsiveness of the Rat Pituitary-Adrenal System and Sympathoadrenal Activity, Psychopharmacology, 149, pp. 34-40, (2000); Oddoux S., Violette P., Cornet J., Akkoyun-Farinez J., Besnier M., Noel A., Rouillon F., Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice, Nutrients, 14, (2022); Colomier E., Algera J., Melchior C., Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome with Diarrhea, Front. Pharmacol, 11, (2020); Asfaha S., Dubeykovskiy A.N., Tomita H., Yang X., Stokes S., Shibata W., Friedman A.N., Ariyama H., Dubeykovskaya Z.A., Muthupalani S., Et al., Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis, Gastroenterology, 144, pp. 155-166, (2013); Hol J., Wilhelmsen L., Haraldsen G., The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies, J. Leukoc. Biol, 87, pp. 501-508, (2010); Larauche M., Moussaoui N., Biraud M., Bae W.K., Duboc H., Million M., Tache Y., Brain Corticotropin-Releasing Factor Signaling: Involvement in Acute Stress-Induced Visceral Analgesia in Male Rats, Neurogastroenterol. Motil, 31, (2019); Greenwood-Van Meerveld B., Johnson A.C., Stress-Induced Chronic Visceral Pain of Gastrointestinal Origin, Front. Syst. Neurosci, 11, (2017); Saw C.L.L., Huang Y., Kong A.-N., Synergistic Anti-Inflammatory Effects of Low Doses of Curcumin in Combination with Polyunsaturated Fatty Acids: Docosahexaenoic Acid or Eicosapentaenoic Acid, Biochem. Pharmacol, 79, pp. 421-430, (2010); Rastgoo S., Ebrahimi-Daryani N., Agah S., Karimi S., Taher M., Rashidkhani B., Hejazi E., Mohseni F., Ahmadzadeh M., Sadeghi A., Et al., Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management, Front. Nutr, 8, (2021); Cao W., Wang C., Chin Y., Chen X., Gao Y., Yuan S., Xue C., Wang Y., Tang Q., DHA-Phospholipids (DHA-PL) and EPA-Phospholipids (EPA-PL) Prevent Intestinal Dysfunction Induced by Chronic Stress, Food Funct, 10, pp. 277-288, (2019); Lobo de Sa F.D., Backert S., Nattramilarasu P.K., Mousavi S., Sandle G.I., Bereswill S., Heimesaat M.M., Schulzke J.-D., Bucker R., Vitamin D Reverses Disruption of Gut Epithelial Barrier Function Caused by Campylobacter Jejuni, Int. J. Mol. Sci, 22, (2021); Thomson A., Smart K., Somerville M.S., Lauder S.N., Appanna G., Horwood J., Sunder Raj L., Srivastava B., Durai D., Scurr M.J., Et al., The Ussing Chamber System for Measuring Intestinal Permeability in Health and Disease, BMC Gastroenterol, 19, (2019); Fitzgerald A.J., Rai P.S., Marchbank T., Taylor G.W., Ghosh S., Ritz B.W., Playford R.J., Reparative Properties of a Commercial Fish Protein Hydrolysate Preparation, Gut, 54, pp. 775-781, (2005); Gupta A.K., Maity C., Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant], Medicine, 100, (2021); Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., Grillasca J.-P., Pons O., Maixent J.-M., A 2-Strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial, Dig. Liver Dis, 52, pp. 534-540, (2020); Kim J.Y., Park Y.J., Lee H.J., Park M.Y., Kwon O., Effect of Lactobacillus Gasseri BNR17 on Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial, Food Sci. Biotechnol, 27, pp. 853-857, (2018); Ait-Belgnaoui A., Payard I., Rolland C., Harkat C., Braniste V., Theodorou V., Tompkins T.A., Bifidobacterium Longum and Lactobacillus Helveticus Synergistically Suppress Stress-Related Visceral Hypersensitivity through Hypothalamic-Pituitary-Adrenal Axis Modulation, J. Neurogastroenterol. Motil, 24, pp. 138-146, (2018); Ligaarden S.C., Axelsson L., Naterstad K., Lydersen S., Farup P.G., A Candidate Probiotic with Unfavourable Effects in Subjects with Irritable Bowel Syndrome: A Randomised Controlled Trial, BMC Gastroenterol, 10, (2010); Zhu F., He H., Fan L., Ma C., Xu Z., Xue Y., Wang Y., Zhang C., Zhou G., Blockade of CXCR2 Suppresses Proinflammatory Activities of Neutrophils in Ulcerative Colitis, Am. J. Transl. Res, 12, pp. 5237-5251, (2020); Faucher P., Dries A., Mousset P.Y., Leboyer M., Dore J., Beracochea D., Synergistic Effects of Lacticaseibacillus Rhamnosus GG, Glutamine, and Curcumin on Chronic Unpredictable Mild Stress-Induced Depression in a Mouse Model, Benef. Microbes, 13, pp. 253-264, (2022); Moreno-Martinez S., Tendilla-Beltran H., Sandoval V., Flores G., Terron J.A., Chronic Restraint Stress Induces Anxiety-like Behavior and Remodeling of Dendritic Spines in the Central Nucleus of the Amygdala, Behav. Brain Res, 416, (2022); Kilkenny C., Parsons N., Kadyszewski E., Festing M.F.W., Cuthill I.C., Fry D., Hutton J., Altman D.G., Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals, PLoS ONE, 4, (2009); Tian L., Zeng K., Shao W., Yang B.B., Fantus I.G., Weng J., Jin T., Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice, J. Nutr, 145, pp. 2300-2307, (2015); Nair A.B., Jacob S., A Simple Practice Guide for Dose Conversion between Animals and Human, J. Basic Clin. Pharm, 7, pp. 27-31, (2016); Coeffier M., Claeyssens S., Hecketsweiler B., Lavoinne A., Ducrotte P., Dechelotte P., Enteral Glutamine Stimulates Protein Synthesis and Decreases Ubiquitin MRNA Level in Human Gut Mucosa, Am. J. Physiol. Gastrointest. Liver Physiol, 285, pp. G266-G273, (2003)^M. Coëffier; Univ Rouen Normandie, Inserm, ADEN UMR1073 “Nutrition, Inflammation and Microbiota-Gut-Brain Axis”, Rouen, 76000, France; email: moise.coeffier@univ-rouen.fr^^Multidisciplinary Digital Publishing Institute (MDPI)^^^^^^16616596^^^37108383.0^English^Int. J. Mol. Sci.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85156197877
Kovaleva A.; Poluektova E.; Maslennikov R.; Karchevskaya A.; Shifrin O.; Kiryukhin A.; Tertychnyy A.; Kovalev L.; Kovaleva M.; Lobanova O.; Kudryavtseva A.; Krasnov G.; Fedorova M.; Ivashkin V.^Kovaleva, Aleksandra (57224547897); Poluektova, Elena (57205199117); Maslennikov, Roman (57204125411); Karchevskaya, Anna (57845159500); Shifrin, Oleg (6507547844); Kiryukhin, Andrey (57212314548); Tertychnyy, Aleksandr (57209460072); Kovalev, Leonid (7004540939); Kovaleva, Marina (6701467064); Lobanova, Olga (57484405500); Kudryavtseva, Anna (35083706800); Krasnov, George (24492185500); Fedorova, Maria (58098836200); Ivashkin, Vladimir (57201595785)^57224547897; 57205199117; 57204125411; 57845159500; 6507547844; 57212314548; 57209460072; 7004540939; 6701467064; 57484405500; 35083706800; 24492185500; 58098836200; 57201595785^Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial^2023^Journal of Clinical Medicine^12.0^18^6064^^^^4^10.3390/jcm12186064^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172813571&doi=10.3390%2fjcm12186064&partnerID=40&md5=8fc5b2a8a46ed7412ce9c949242c491e^Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Laboratory of General and Clinical Neurophysiology, Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5A Butlerova Str, Moscow, 117485, Russian Federation; N.N. Burdenko National Medical Research Center of Neurosurgery, 16, 4th Tverskaya-Yamskaya St, Moscow, 125047, Russian Federation; Endoscopy Unit, The Second University Clinic, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Institute of Clinical Morphology and Digital Pathology, Sechenov University, Trubetskaya Str., 8, Bld. 2, Moscow, 119048, Russian Federation; Laboratory of Structural Biochemistry of Protein, A.N. Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation^Kovaleva A., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Poluektova E., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Maslennikov R., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Karchevskaya A., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, Laboratory of General and Clinical Neurophysiology, Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5A Butlerova Str, Moscow, 117485, Russian Federation, N.N. Burdenko National Medical Research Center of Neurosurgery, 16, 4th Tverskaya-Yamskaya St, Moscow, 125047, Russian Federation; Shifrin O., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Kiryukhin A., Endoscopy Unit, The Second University Clinic, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation; Tertychnyy A., Institute of Clinical Morphology and Digital Pathology, Sechenov University, Trubetskaya Str., 8, Bld. 2, Moscow, 119048, Russian Federation; Kovalev L., Laboratory of Structural Biochemistry of Protein, A.N. Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Kovaleva M., Laboratory of Structural Biochemistry of Protein, A.N. Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Lobanova O., Institute of Clinical Morphology and Digital Pathology, Sechenov University, Trubetskaya Str., 8, Bld. 2, Moscow, 119048, Russian Federation; Kudryavtseva A., Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation; Krasnov G., Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation; Fedorova M., Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova Str., 32, Bld. 1, Moscow, 119991, Russian Federation; Ivashkin V., Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation, The Scientific Community for Human Microbiome Research, Pogodinskaya Str., 1, Bld. 1, Moscow, 119435, Russian Federation^Treatment of functional digestive disorders is not always effective. Therefore, a search for new application points for potential drugs is perspective. Our aim is to evaluate the effect of rebamipide on symptom severity, intestinal barrier status, and intestinal microbiota composition and function in patients with diarrheal variant of irritable bowel syndrome overlapping with functional dyspepsia (D-IBSoFD). Sixty patients were randomized to receive trimebutine (TRI group), trimebutine + rebamipide (T + R group), or rebamipide (REB group) for 2 months. At the beginning and end of the study, patients were assessed for general health (SF-36), severity of digestive symptoms (Gastrointestinal Symptom Rating and 7 × 7 scales), state of the intestinal barrier, and composition (16S rRNA gene sequencing) and function (short-chain fatty acid fecal content) of the gut microbiota. The severity of most digestive symptoms was reduced in the REB and T + R groups to levels similar to that observed in the TRI group. The duodenal and sigmoidal lymphocytic and sigmoidal eosinophilic infiltration was decreased only in the REB and T + R groups, not in the TRI group. Serum zonulin levels were significantly decreased only in the REB group. A decrease in intraepithelial lymphocytic infiltration in the duodenum correlated with a decrease in the severity of rumbling and flatulence, while a decrease in infiltration within the sigmoid colon correlated with improved stool consistency and decreased severity of the sensation of incomplete bowel emptying. In conclusion, rebamipide improves the intestinal barrier condition and symptoms in D-IBSoFD. The rebamipide effects are not inferior to those of trimebutine. © 2023 by the authors.^dysbiosis; functional bowel disease; gut microbiota; intestinal permeability; minimal inflammation^biological marker; fatty acid binding protein; fatty acid binding protein 1; haptoglobin; mucin 2; placebo; rebagit; rebamipide; RNA 16S; short chain fatty acid; trimebutine; unclassified drug; zonulin; abdominal discomfort; abdominal pain; adult; Article; clinical outcome; controlled study; diarrhea; digestive system function disorder; disease severity; drug effect; drug efficacy; duodenum; dysbiosis; dyspepsia; enzyme linked immunosorbent assay; eosinophil; eructation; feces; female; flatulence; gastrointestinal symptom; gastrointestinal symptom rating scale; gene sequence; heartburn; human; human tissue; incomplete bowel emptying; inflammation; intestine flora; intestine mucosa; intestine mucosa permeability; intraepithelial lymphocyte; irritable colon; liquid feces; loose feces; lymphocytic infiltration; major clinical study; male; nonhuman; outcome assessment; permeability barrier; protein blood level; randomized controlled trial; Short Form 36; sigmoid; treatment response^^haptoglobin, 9087-69-8; rebamipide, 111911-87-6; trimebutine, 39133-31-8^2100 Bioanalyzer, Agilent, United States; Agencourt AMPure XP, Beckman Coulter, United States; Applied Biosystems 2720, Thermo, United States; BenchMark XT, Ventana, United States; DNA 1000 Kit, Agilent, United States; I-view detection kit, Ventana, United States; MagNA Pure Compact Nucleic Acid Isolation Kit I, Hoffmann La Roche; MagNA Pure LC, Hoffmann La Roche; MiSeq Reagent Kit v3, Illumina, United States; MiSeq, Illumina, United States; NanoDrop 1000, Thermo, United States; Nextera XT Index Kit, Illumina, United States; QuantiT dsDNA High-Sensitivity Assay Kit; Qubit 2.0, Invitrogen, United States; rebagit^Agilent, United States; Agilent, United States; Beckman Coulter, United States; Hoffmann La Roche; Hoffmann La Roche; Illumina, United States; Illumina, United States; Illumina, United States; Invitrogen, United States; Thermo, United States; Thermo, United States; Ventana, United States; Ventana, United States^^^Enck P., Azpiroz F., Boeckxstaens G., Elsenbruch S., Feinle-Bisset C., Holtmann G., Lackner J.M., Ronkainen J., Schemann M., Stengel A., Et al., Functional Dyspepsia, Nat. Rev. Dis. Primers, 3, (2017); Talley N.J., Walker M.M., Holtmann G., Functional Dyspepsia, Curr. Opin. Gastroenterol, 32, pp. 467-473, (2016); Stanghellini V., Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV, Dig. Dis, 35, pp. 14-17, (2017); von Wulffen M., Talley N.J., Hammer J., McMaster J., Rich G., Shah A., Koloski N., Kendall B.J., Jones M., Holtmann G., Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors, Dig. Dis. Sci, 64, pp. 480-486, (2018); Choi Y.J., Kim N., Yoon H., Shin C.M., Park Y.S., Kim J.-W., Kim Y.S., Lee D.H., Jung H.C., Overlap between Irritable Bowel Syndrome and Functional Dyspepsia Including Subtype Analyses, J. Gastroenterol. Hepatol, 32, pp. 1553-1561, (2017); Yao X., Yang Y.S., Cui L.H., Sun G., Peng L.H., Wang W.F., Hyder Q., Zhang X.L., The Overlap of Upper Functional Gastrointestinal Disorders with Irritable Bowel Syndrome in Chinese Outpatients: A Multicenter Study, J. Gastroenterol. Hepatol, 31, pp. 1584-1593, (2016); Ford A.C., Marwaha A., Lim A., Moayyedi P., Systematic Review and Meta-Analysis of the Prevalence of Irritable Bowel Syndrome in Individuals with Dyspepsia, Clin. Gastroenterol. Hepatol, 8, pp. 401-409, (2010); Mekhdiyev S.N., Mekhdieva O.A., Berko O.M., Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy, Russ. J. Gastroenterol. Hepatol. Coloproctol, 32, pp. 95-103, (2022); Fan K., Talley N.J., Functional Dyspepsia and Duodenal Eosinophilia: A New Model, J. Dig. Dis, 18, pp. 667-677, (2017); Sarkar M.A.M., Akhter S., Khan M.R., Saha M., Roy P.K., Association of Duodenal Eosinophilia with Helicobacter Pylori-Negative Functional Dyspepsia, Arab. J. Gastroenterol, 21, pp. 19-23, (2020); Wauters L., Burns G., Ceulemans M., Walker M.M., Vanuytsel T., Keely S., Talley N.J., Duodenal Inflammation: An Emerging Target for Functional Dyspepsia?, Expert Opin. Ther. Targets, 24, pp. 511-523, (2020); Lee K.J., Tack J., Duodenal Implications in the Pathophysiology of Functional Dyspepsia, J. Neurogastroenterol. Motil, 16, pp. 251-257, (2010); Ivashkin V.T., Maev I.V., Trukhmanov A.S., Sheptulin A.A., Lapina T.L., Simanenkov V.I., Sokolov K.A., Inflammation, Impaired Motor Function and Visceral Hypersensitivity: The Main Mechanisms of Functional Disorders of the Gastrointestinal Tract (Materials of the Expert Council and Literature Review), Russ. J. Gastroenterol. Hepatol. Coloproctol, 32, pp. 7-14, (2022); Puthanmadhom Narayanan S., O'Brien D.R., Sharma M., Smyrk T.C., Graham R.P., Grover M., Bharucha A.E., Duodenal Mucosal Barrier in Functional Dyspepsia, Clin. Gastroenterol. Hepatol, 20, pp. 1019-1028.e3, (2022); Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita A.V., Pardon N., Santos J., Soderholm J.D., Tack J., Et al., Impaired Duodenal Mucosal Integrity and Low-Grade Inflammation in Functional Dyspepsia, Gut, 63, pp. 262-271, (2013); Nojkov B., Zhou S.-Y., Dolan R.D., Davis E.M., Appelman H.D., Guo X., Jackson K., Sturm M.B., Wang T.D., Owyang C., Et al., Evidence of Duodenal Epithelial Barrier Impairment and Increased Pyroptosis in Patients with Functional Dyspepsia on Confocal Laser Endomicroscopy and “Ex Vivo” Mucosa Analysis, Am. J. Gastroenterol, 115, pp. 1891-1901, (2020); Wauters L., Ceulemans M., Schol J., Farre R., Tack J., Vanuytsel T., The Role of Leaky Gut in Functional Dyspepsia, Front. Neurosci, 16, (2022); Farre R., Vicario M., Abnormal Barrier Function in Gastrointestinal Disorders, Gastrointest. Pharmacol, 239, pp. 193-217, (2016); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A.M., Kruimel J.W., Lenaerts K., Hanssen N.M.J., Conchillo J.M., Jonkers D.M.A.E., Masclee A.A.M., Small Intestinal Permeability Is Increased in Diarrhoea Predominant IBS, While Alterations in Gastroduodenal Permeability in All IBS Subtypes Are Largely Attributable to Confounders, Aliment. Pharmacol. Ther, 40, pp. 288-297, (2014); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive Biomarkers of Gut Barrier Function Identify Two Subtypes of Patients Suffering from Diarrhoea Predominant-IBS: A Case-Control Study, BMC Gastroenterol, 18, (2018); Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F., Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update, Dis. Markers, 2020, (2020); Iakupova A.A., Abdulkhakov S.R., Zalyalov R.K., Safin A.G., Abdulkhakov R.A., Intestinal Permeability Assays: A Review, Russ. J. Gastroenterol. Hepatol. Coloproctol, 31, pp. 20-30, (2021); Jakobsson H.E., Rodriguez-Pineiro A.M., Schutte A., Ermund A., Boysen P., Bemark M., Sommer F., Backhed F., Hansson G.C., Johansson M.E.V., The Composition of the Gut Microbiota Shapes the Colon Mucus Barrier, EMBO Rep, 16, pp. 164-177, (2015); Grondin J.A., Kwon Y.H., Far P.M., Haq S., Khan W.I., Mucins in Intestinal Mucosal Defense and Inflammation: Learning from Clinical and Experimental Studies, Front. Immunol, 11, (2020); Shin A., Preidis G.A., Shulman R., Kashyap P.C., The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders, Clin. Gastroenterol. Hepatol, 17, pp. 256-274, (2019); Ma W., Drew D.A., Staller K., The Gut Microbiome and Colonic Motility Disorders: A Practical Framework for the Gastroenterologist, Curr. Gastroenterol. Rep, 24, pp. 115-126, (2022); Singh R., Zogg H., Wei L., Bartlett A., Ghoshal U.C., Rajender S., Ro S., Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders, J. Neurogastroenterol. Motil, 27, pp. 19-34, (2021); Ivashkin V.T., Maev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., Zolnikova O.Y., Ivashkina N.Y., Korochanskaya N.V., Mammayev S.N., Et al., Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults, Russ. J. Gastroenterol. Hepatol. Coloproctol, 31, pp. 65-91, (2021); Maslennikov R., Ivashkin V., Efremova I., Poluektova E., Shirokova E., Probiotics in Hepatology: An Update, World J. Hepatol, 13, pp. 1154-1166, (2021); Arakawa T., Higuchi K., Fujiwara Y., Watanabe T., Tominaga K., Sasaki E., Oshitani N., Yoshikawa T., Tarnawski A.S., 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications, Dig. Dis. Sci, 50, pp. S3-S11, (2005); Kleine A., Kluge S., Peskar B.M., Stimulation of Prostaglandin Biosynthesis Mediates Gastroprotective Effect of Rebamipide in Rats, Dig. Dis. Sci, 38, pp. 1441-1449, (1993); Gweon T.-G., Park J.-H., Kim B.-W., Choi Y.K., Kim J.S., Park S.M., Kim C.W., Kim H.-G., Chung J.-W., Incheon and Western Kyonggi Gastrointestinal Study Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease, Gut Liver, 12, pp. 46-50, (2018); Jaafar M.H., Safi S.Z., Tan M.-P., Rampal S., Mahadeva S., Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis, Dig. Dis. Sci, 63, pp. 1250-1260, (2017); Naryzhny S.N., Legina O.K., Zonulin—Regulation of Tight Contacts in the Brain and Intestine—Facts and Hypotheses, Biomeditsinskaya Khimiya, 68, pp. 309-320, (2022); Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., Kim D.J., Prokinetics for the Treatment of Functional Dyspepsia: Bayesian Network Meta-Analysis, BMC Gastroenterol, 17, (2017); Kountouras J., Doulberis M., Papaefthimiou A., Polyzos S.A., Gastroesophageal Reflux Disease, Irritable Bowel Syndrome and Functional Dyspepsia as Overlapping Conditions: Focus on Effect of Trimebutine, Ann. Gastroenterol, 32, (2019); Salvioli B., Trimebutine: A State-of-the-Art Review, Minerva Gastroenterol. Dietol, 65, pp. 229-238, (2019); Moayyedi P.M., Lacy B.E., Andrews C.N., Enns R.A., Howden C.W., Vakil N., ACG and CAG Clinical Guideline: Management of Dyspepsia, Am. J. Gastroenterol, 112, pp. 988-1013, (2017); Fukudo S., Kaneko H., Akiho H., Inamori M., Endo Y., Okumura T., Kanazawa M., Kamiya T., Sato K., Chiba T., Et al., Evidence-Based Clinical Practice Guidelines for Irritable Bowel Syndrome, J. Gastroenterol, 50, pp. 11-30, (2014); Brazier J.E., Harper R., Jones N.M., O'Cathain A., Thomas K.J., Usherwood T., Westlake L., Validating the SF-36 Health Survey Questionnaire: New Outcome Measure for Primary Care, BMJ, 305, pp. 160-164, (1992); Ivashkin V., Sheptulin A., Shifrin O., Poluektova E., Pavlov C., Ivashkin K., Drozdova A., Lyashenko O., Korolev A., Clinical Validation of the “7 × 7” Questionnaire for Patients with Functional Gastrointestinal Disorders, J. Gastroenterol. Hepatol, 34, pp. 1042-1048, (2018); Svedlund J., Sjdin I., Dotevall G., GSRS—A Clinical Rating Scale for Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease, Dig. Dis. Sci, 33, pp. 129-134, (1988); Fouhy F., Deane J., Rea M.C., O'Sullivan O., Ross R.P., O'Callaghan G., Plant B.J., Stanton C., The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations, PLoS ONE, 10, (2015); Zheng W., Tsompana M., Ruscitto A., Sharma A., Genco R., Sun Y., Buck M.J., An accurate and efficient experimental approach for characterization of the complex oral microbiota, Microbiome, 3, (2015); Parikh H.I., Koparde V.N., Bradley S.P., Buck G.A., Sheth N.U., MeFiT: Merging and filtering tool for illumina paired-end reads for 16S rRNA amplicon sequencing, BMC Bioinform, 17, (2016); Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J., Holmes S.P., DADA2: High-resolution sample inference from Illumina amplicon data, Nat. Methods, 13, pp. 581-583, (2016); Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glockner F.O., The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools, Nucleic Acids Res, 41, pp. D590-D596, (2013); Fernandes A.D., Macklaim J.M., Linn T.G., Reid G., Gloor G.B., ANOVA-like differential expression (ALDEx) analysis for mixed population RNA-Seq, PLoS ONE, 8, (2013); Funaoka H., Kanda T., Kajiura S., Ohkaru Y., Fujii H., Development of a High-Specificity Sandwich ELISA System for the Quantification of Human Intestinal Fatty Acid-Binding Protein (I-FABP) Concentrations, Immunol. Investig, 40, pp. 223-242, (2011); Poynard T., Regimbeau C., Benhamou Y., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, Aliment. Pharmacol. Ther, 15, pp. 355-361, (2001); Ruepert L., Quartero A.O., de Wit N.J., van der Heijden G.J., Rubin G., Muris J.W., Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome, Cochrane Database Syst. Rev, 2013, (2011)^R. Maslennikov; Department of Introduction to Internal Diseases, Gastroenterology and Hepatology, Sechenov University, Moscow, Pogodinskaya Str., 1, Bld. 1, 119435, Russian Federation; email: maslennikov_r_v@staff.sechenov.ru^^Multidisciplinary Digital Publishing Institute (MDPI)^^^^^^20770383^^^^English^J. Clin. Med.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85172813571
Kovaleva A.; Poluektova E.; Maslennikov R.; Karchevskaya A.; Shifrin O.; Kiryukhin A.; Tertychnyy A.; Kovalev L.; Kovaleva M.; Lobanova O.; Kudryavtseva A.; Krasnov G.; Ivashkin V.^Kovaleva, Aleksandra (57224547897); Poluektova, Elena (57205199117); Maslennikov, Roman (57204125411); Karchevskaya, Anna (57845159500); Shifrin, Oleg (6507547844); Kiryukhin, Andrey (57212314548); Tertychnyy, Aleksandr (57209460072); Kovalev, Leonid (7004540939); Kovaleva, Marina (6701467064); Lobanova, Olga (57484405500); Kudryavtseva, Anna (35083706800); Krasnov, George (24492185500); Ivashkin, Vladimir (57201595785)^57224547897; 57205199117; 57204125411; 57845159500; 6507547844; 57212314548; 57209460072; 7004540939; 6701467064; 57484405500; 35083706800; 24492185500; 57201595785^Intestinal Barrier and Gut Microbiota in Patients with Overlapping Irritable Bowel Syndrome and Functional Dyspepsia^2023^Digestive Diseases and Sciences^68.0^11^^4166^4174^8.0^1^10.1007/s10620-023-08117-7^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172406139&doi=10.1007%2fs10620-023-08117-7&partnerID=40&md5=5130ccd8d21e2f08b49f8e1c7b765c52^Sechenov University, Moscow, 119435, Russian Federation; A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, 119991, Russian Federation^Kovaleva A., Sechenov University, Moscow, 119435, Russian Federation; Poluektova E., Sechenov University, Moscow, 119435, Russian Federation; Maslennikov R., Sechenov University, Moscow, 119435, Russian Federation; Karchevskaya A., Sechenov University, Moscow, 119435, Russian Federation; Shifrin O., Sechenov University, Moscow, 119435, Russian Federation; Kiryukhin A., Sechenov University, Moscow, 119435, Russian Federation; Tertychnyy A., Sechenov University, Moscow, 119435, Russian Federation; Kovalev L., A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Kovaleva M., A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, 119071, Russian Federation; Lobanova O., Sechenov University, Moscow, 119435, Russian Federation; Kudryavtseva A., Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, 119991, Russian Federation; Krasnov G., Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, 119991, Russian Federation; Ivashkin V., Sechenov University, Moscow, 119435, Russian Federation^Background: Disturbances in the intestinal barrier and gut dysbiosis have been observed in patients with functional bowel diseases. Aims: To investigate the correlation between biomarkers of intestinal barrier disorders at different layers and the severity of symptoms in patients with overlapping diarrhea-predominant irritable bowel syndrome and functional dyspepsia (IDFO), as well as with gut microbiota taxa. Methods: This study included 45 patients with IDFO and 16 healthy controls. Endoscopy with biopsy of the duodenum and sigmoid colon (SC) was performed to count intraepithelial lymphocytes (IELs) and mucosal eosinophils (subepithelial layer), assess fatty acid binding protein (FABP; epithelial layer) level, and stain for mucin-2 (MUC-2; pre-epithelial layer). Composition of the gut microbiota was evaluated using 16S rRNA gene sequencing. Results: Patients with IDFO exhibited an increase in biomarkers of intestinal barrier disorders at all layers studied. IEL count in the duodenum was correlated with the severity of bloating (r = 0.336; p = 0.024) and, in the SC, was correlated with tenesmus severity (r = 0.303; p = 0.042). FABP-1 level in the SC was correlated with the severity of diarrhea (r = 0.577; p = 0.001), and FABP-5 concentration in the SC was correlated with abdominal distension (r = 0.477; p = 0.010). MUC-2 concentration in the duodenum was correlated with the severity of heartburn (r = 0.572; p = 0.025) and burning sensation in the epigastrium (r = 0.518; p = 0.048). All biomarkers of intestinal barrier permeability were correlated with the abundance of some gut microbiota taxa. Conclusion: Patients with IDFO exhibited disrupted intestinal barrier function in all layers, which was associated with clinical symptom severity and changes in the gut microbiota. Graphical Abstract: [Figure not available: see fulltext.]. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.^Diarrhea; Dysbiosis; Functional digestive disease; Gut barrier; Microbiome; Microbiota^Biomarkers; Diarrhea; Dysbiosis; Dyspepsia; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; RNA, Ribosomal, 16S; fatty acid binding protein; fatty acid binding protein 1; fatty acid binding protein 5; mucin 2; RNA 16S; unclassified drug; biological marker; RNA 16S; abdominal distension; adult; Article; bloating; burning sensation; clinical article; colon biopsy; colon mucosa; controlled study; diarrhea; disease severity; duodenum biopsy; dyspepsia; endoscopy; eosinophil; female; gastrointestinal symptom rating scale; heartburn; human; human cell; intestine endoscopy; intestine epithelium; intestine flora; intestine mucosa permeability; intraepithelial lymphocyte; irritable colon; male; nonhuman; observational study; retrospective study; RNA sequencing; sigmoid; stain; tenesmus; dysbiosis; genetics^^Biomarkers, ; RNA, Ribosomal, 16S, ^^^^^Lacy B.E., Mearin F., Chang L., Chey W.D., Et al., Bowel disorders, Gastroenterology., 150, pp. 1393-1407, (2016); Ivashkin V.T., Maev I.V., Shelygin Y.A., Et al., Diagnosis and treatment of irritable bowel syndrome: clinical recommendations of the Russian gastroenterological association and association of coloproctologists of Russia, Russ J Gastroenterol Hepatol Coloproctol., 31, pp. 74-95, (2021); Enck P., Azpiroz F., Boeckxstaens G., Et al., Functional dyspepsia, Nat Rev Dis Primers., 3, (2017); Scaldaferri F., Pizzoferrato M., Gerardi V., Lopetuso L., Gasbarrini A., The gut barrier: new acquisitions and therapeutic approaches, J Clin Gastroenterol., 46, pp. S12-S17, (2012); Schneeberger E.E., Lynch R.D., The tight junction: a multifunctional complex, Am J Physiol Cell Physiol., 286, pp. C1213-C1228, (2004); Fukui H., Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation?, Inflamm Intest Dis., 1, pp. 135-145, (2016); Salim S.Y., Soderholm J.D., Importance of disrupted intestinal barrier in inflammatory bowel diseases, Inflamm Bowel Dis., 17, pp. 362-381, (2011); Jakobsson H.E., Rodriguez-Pineiro A.M., Schutte A., Et al., The composition of the gut microbiota shapes the colon mucus barrier, EMBO Rep., 16, pp. 164-177, (2015); Groschwitz K.R., Hogan S.P., Intestinal barrier function: molecular regulation and disease pathogenesis, J Allergy Clin Immunol., 124, pp. 3-20, (2009); Simanenkov V.I., Maev I.V., Tkacheva O.N., Et al., Increased epithelial permeability syndrome in clinical practice multidisciplinary national consensus, Cardiovasc Ther Prev., 20, (2021); Kovaleva A.L., Poluektova E.A., Shifrin O.S., Intestinal barrier, intestinal permeability, nonspecific inflammation and their role in forming functional diseases of gastrointestinal tract, Russ J Gastroenterol Hepatol Coloproctol., 30, pp. 52-59, (2020); Schoultz I., Keita A.V., The Intestinal barrier and current techniques for the assessment of gut permeability, Cells., 9, (2020); Sinagra E., Pompei G., Tomasello G., Et al., Inflammation in irritable bowel syndrome: myth or new treatment target?, World J Gastroenterol., 22, pp. 2242-2255, (2016); Wibowo A.A., Pardjianto B., Sumitro S.B., Kania N., Handono K., Decreased expression of MUC2 due to a decrease in the expression of lectins and apoptotic defects in colitis patients, Biochem Biophys Rep., 19, (2019); Du L., Chen B., Kim J.J., Chen X., Dai N., Micro-inflammation in functional dyspepsia: a systematic review and meta-analysis, Neurogastroenterol Motil., 30, (2018); Taki M., Oshima T., Li M., Et al., Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia, Neurogastroenterol Motil., 31, (2019); Lee J.Y., Kim N., Choi Y.J., Et al., Expression of tight junction proteins according to functional dyspepsia subtype and sex, J Neurogastroenterol Motil., 26, pp. 248-258, (2020); Ivashkin V.T., Mayev I.V., Sheptulin A.A., Et al., Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association, Russ J Gastroenterol Hepatol Coloproctol\., 27, pp. 50-61, (2017); Humes D.J., Changing epidemiology: does it increase our understanding?, Dig Dis., 30, pp. 6-11, (2012); Ivashkin V.T., Sheptulin A.A., Poluektova E.A., Et al., Opportunities of 7x7 Scale (7 symptoms per 7 Days) to evaluate dynamics in symptoms of functional dyspepsia and irritable bowel syndrome, Russ J Gastroenterol Hepatol Coloproctol., 26, pp. 24-33, (2016); Revicki D.A., Wood M., Wiklund I., Crawley J., Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease, Qual Life Res., 7, pp. 75-83, (1998); Jung H.K., Talley N.J., Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift, J Neurogastroenterol Motil., 24, pp. 345-354, (2018); Lacy B.E., Cangemi D.J., Updates in functional dyspepsia and bloating, Curr Opin Gastroenterol., 38, pp. 613-619, (2022); Adriaanse M.P., Tack G.J., Passos V.L., Et al., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Aliment Pharmacol Ther., 37, pp. 482-490, (2013); Adriaanse M.P.M., Mubarak A., Riedl R.G., Et al., Progress towards non-invasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP, Sci Rep., 7, (2017); Shi H., Wan J., Liu W., Su B., An analysis for the clinical difference between post infectious irritable bowel syndrome and non post infectious irritable bowel syndrome, Zhonghua Nei Ke Za Zhi., 54, pp. 326-329, (2015); Li B., Reynolds J.M., Stout R.D., Bernlohr D.A., Suttles J., Regulation of Th17 differentiation by epidermal fatty acid-binding protein, J Immunol., 182, pp. 7625-7633, (2009); Grondin J.A., Kwon Y.H., Far P.M., Haq S., Khan W.I., Mucins in intestinal mucosal defense and inflammation: learning from clinical and experimental studies, Front Immunol., 11, (2020); Ivashkin V.T., Trukhmanov A.S., Gonik M.I., Using rebamipide in treating gastroesophageal reflux disease, Therapeutic Archive., 92, pp. 98-104, (2020); Arakawa T., Higuchi K., Fujiwara Y., Et al., 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications, Dig Dis Sci., 50, pp. S3-S11, (2005); Kleine A., Kluge S., Peskar B.M., Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats, Dig Dis Sci., 38, pp. 1441-1449, (1993); Gweon T.G., Park J.H., Kim B.W., Et al., Additive Effects of rebamipide plus proton pump inhibitors on the expression of tight junction proteins in a rat model of gastro-esophageal reflux disease, Gut Liver., 12, pp. 46-50, (2018)^R. Maslennikov; Sechenov University, Moscow, 119435, Russian Federation; email: maslennikov_r_v@staff.sechenov.ru^^Springer^^^^^^01632116^^DDSCD^37752368.0^English^Dig. Dis. Sci.^Article^Final^^Scopus^2-s2.0-85172406139
Tao E.; Wu Y.; Hu C.; Zhu Z.; Ye D.; Long G.; Chen B.; Guo R.; Shu X.; Zheng W.; Zhang T.; Jia X.; Du X.; Fang M.; Jiang M.^Tao, Enfu (57188721251); Wu, Yuhao (58136887300); Hu, Chenmin (57559943700); Zhu, Zhenya (57480252000); Ye, Diya (57219930107); Long, Gao (57201640175); Chen, Bo (55673224900); Guo, Rui (57194716253); Shu, Xiaoli (14519820600); Zheng, Wei (57201637334); Zhang, Ting (57198705875); Jia, Xinyi (57205193870); Du, Xiao (57218300356); Fang, Marong (8664493500); Jiang, Mizu (7401861132)^57188721251; 58136887300; 57559943700; 57480252000; 57219930107; 57201640175; 55673224900; 57194716253; 14519820600; 57201637334; 57198705875; 57205193870; 57218300356; 8664493500; 7401861132^Early life stress induces irritable bowel syndrome from childhood to adulthood in mice^2023^Frontiers in Microbiology^14.0^^1255525^^^^0^10.3389/fmicb.2023.1255525^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174277827&doi=10.3389%2ffmicb.2023.1255525&partnerID=40&md5=c3ee2a6d587308ca22e2a5106853ef46^Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Department of Neonatology and NICU, Wenling Maternal and Child Health Care Hospital, Wenling, China; Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Institute of Neuroscience and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China^Tao E., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Neonatology and NICU, Wenling Maternal and Child Health Care Hospital, Wenling, China; Wu Y., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Hu C., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Zhu Z., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Ye D., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Long G., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Chen B., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Guo R., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Shu X., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Zheng W., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Zhang T., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Jia X., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Du X., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; Fang M., Institute of Neuroscience and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China; Jiang M., Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China, Department of Gastroenterology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China^Background: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorder. Traditionally, early life stress (ELS) is predisposed to IBS in adult. However, whether ELS induces IBS in early life remains unclear. Methods: Separated cohort studies were conducted in neonatal male pups of C57BL/6 mice by maternal separation (MS) model. MS and non-separation mice were scheduled to be evaluated for prime IBS-phenotypes, including visceral hypersensitivity, intestinal motility, intestinal permeability, and anxiety-like behavior. Ileal contents and fecal samples were collected and analyzed by 16S rRNA gene sequencing and bacterial community analyses. Subcellular structures of intestinal epithelial, such as epithelial tight junctions and mitochondria, were observed under transmission electron microscopy. Results: MS induced visceral hypersensitivity and decreased total intestinal transit time from childhood to adulthood. In addition, MS induced intestinal hyperpermeability and anxiety-like behavior from adolescence to adulthood. Besides, MS affected intestinal microbial composition from childhood to adulthood. Moreover, MS disrupted intestinal mitochondrial structure from childhood to adulthood. Conclusion: The study showed for the first time that MS induced IBS from early life to adulthood in mice. The disrupted intestinal mitochondrial structure and the significant dysbiosis of intestinal microbiota in early life may contribute to the initiation and progress of IBS from early life to adulthood. Copyright © 2023 Tao, Wu, Hu, Zhu, Ye, Long, Chen, Guo, Shu, Zheng, Zhang, Jia, Du, Fang and Jiang.^brain-gut-microbiota axis; early life stress; irritable bowel syndrome; maternal separation; visceral hypersensitivity^RNA 16S; Actinobacteria; adolescence; adulthood; animal experiment; animal model; anxiety; Article; Blautia; brain-gut axis; childhood; Clostridiales; cohort analysis; decapitation; dysbiosis; early life stress; elevated plus maze test; feces; female; fluorescence intensity; gastrointestinal disease; gene sequence; gestational age; intestine epithelium cell; intestine flora; intestine motility; intestine transit time; irritable colon; Lachnospiraceae; Lactobacillus; male; maternal deprivation; microbial community; microbial diversity; mitochondrion; mouse; newborn; nonhuman; open field test; physiological stress; tight junction; transmission electron microscopy; visceral hyperalgesia^^^EM UC7, Leica, United States; G2 Spirit^Leica, United States^National Clinical Research Center for Child Health, (G20A0008Z)^The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a project from the National Clinical Research Center for Child Health (G20A0008Z). ^Black C.J., Ford A.C., Global burden of irritable bowel syndrome: trends, predictions and risk factors, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 473-486, (2020); Borre Y.E., O'keeffe G.W., Clarke G., Stanton C., Dinan T.G., Cryan J.F., Microbiota and neurodevelopmental windows: implications for brain disorders, Trends Mol. Med, 20, pp. 509-518, (2014); Botschuijver S., Van Diest S.A., Van Thiel I.A.M., Saia R.S., Strik A.S., Yu Z., Et al., Miltefosine treatment reduces visceral hypersensitivity in a rat model for irritable bowel syndrome via multiple mechanisms, Sci. Rep, 9, (2019); Bradford K., Shih W., Videlock E.J., Presson A.P., Naliboff B.D., Mayer E.A., Et al., Association between early adverse life events and irritable bowel syndrome, Clin. Gastroenterol. Hepatol, 10, (2012); Brandsma E., Kloosterhuis N.J., Koster M., Dekker D.C., Gijbels M.J.J., Van Der Velden S., Et al., A Proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis, Circ. Res, 124, pp. 94-100, (2019); Brierley S.M., Greenwood-Van Meerveld B., Sarnelli G., Sharkey K.A., Storr M., Tack J., Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome, Nat. Rev. Gastroenterol. Hepatol, 20, pp. 5-25, (2023); Bulbul M., Sinen O., Centrally administered neuropeptide-S alleviates gastrointestinal Dysmotility induced by neonatal maternal separation, Neurogastroenterol. Motil, 34, (2021); Burke N.N., Finn D.P., Mcguire B.E., Roche M., Psychological stress in early life as a predisposing factor for the development of chronic pain: clinical and preclinical evidence and neurobiological mechanisms, J. Neurosci. Res, 95, pp. 1257-1270, (2017); Canakis A., Haroon M., Weber H.C., Irritable bowel syndrome and gut microbiota, Curr. Opin. Endocrinol. Diabetes Obes, 27, pp. 28-35, (2020); Cao H., Liu X., An Y., Zhou G., Liu Y., Xu M., Et al., Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine, Sci. Rep, 7, (2017); Chang C.S., Liao Y.C., Huang C.T., Lin C.M., Cheung C.H.Y., Ruan J.W., Et al., Identification of a gut microbiota member that ameliorates DSS-induced colitis in intestinal barrier enhanced Dusp6-deficient mice, Cell Rep, 37, (2021); Chen S., Chen F., Amin N., Ren Q., Ye S., Hu Z., Et al., Defects of parvalbumin-positive interneurons in the ventral dentate gyrus region are implicated depression-like behavior in mice, Brain Behav. Immun, 99, pp. 27-42, (2021); Chen M., Ruan G., Chen L., Ying S., Li G., Xu F., Et al., Neurotransmitter and intestinal interactions: focus on the microbiota-gut-brain Axis in irritable bowel syndrome, Front. Endocrinol, 13, (2022); Chen S., Wang J., Dong N., Fang Q., Zhang Y., Chen C., Et al., Polysaccharides from natural Cordyceps sinensis attenuated dextran sodium sulfate-induced colitis in C57BL/6J mice, Food Funct, 14, pp. 720-733, (2023); Collins J.M., Hyland N.P., Clarke G., Fitzgerald P., Julio-Pieper M., Bulmer D.C., Et al., Beta 3-adrenoceptor agonism ameliorates early-life stress-induced visceral hypersensitivity in male rats, J. Neurochem, (2023); Cruz B., Conceicao L.L.D., Mendes T.A.O., Ferreira C., Goncalves R.V., Peluzio M., Use of the synbiotic VSL#3 and yacon-based concentrate attenuates intestinal damage and reduces the abundance of Candidatus Saccharimonas in a colitis-associated carcinogenesis model, Food Res. Int, 137, (2020); Egerton S., Donoso F., Fitzgerald P., Gite S., Fouhy F., Whooley J., Et al., Investigating the potential of fish oil as a nutraceutical in an animal model of early life stress, Nutr. Neurosci, 25, pp. 356-378, (2020); Eisner V., Cupo R.R., Gao E., Csordas G., Slovinsky W.S., Paillard M., Et al., Mitochondrial fusion dynamics is robust in the heart and depends on calcium oscillations and contractile activity, Proc. Natl. Acad. Sci. U. S. A, 114, pp. E859-E868, (2017); Emami N.K., White M.B., Calik A., Kimminau E.A., Dalloul R.A., Managing broilers gut health with antibiotic-free diets during subclinical necrotic enteritis, Poult. Sci, 100, (2021); Favoretto C.A., Bertagna N.B., Righi T., Rodolpho B.T., Anjos-Santos A., Silva F.B.R., Et al., Impacts of maternal separation stress on ethanol-related responses, anxiety-and depressive-like behaviors in adolescent mice, Neurosci. Lett, 809, (2023); Gao Y., Ding P., Wang J., Zhang C., Ji G., Wu T., Application of metabolomics in irritable bowel syndrome in recent 5 years, Int. Immunopharmacol, 124, (2023); Gu Z., Zhu Y., Jiang S., Xia G., Li C., Zhang X., Et al., Tilapia head glycolipids reduce inflammation by regulating the gut microbiota in dextran sulphate sodium-induced colitis mice, Food Funct, 11, pp. 3245-3255, (2020); Guerbette T., Boudry G., Lan A., Mitochondrial function in intestinal epithelium homeostasis and modulation in diet-induced obesity, Mol. Metab, 63, (2022); Han L., Zhao L., Zhou Y., Yang C., Xiong T., Lu L., Et al., Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity, ISME J, 16, pp. 983-996, (2022); Han H., Zhou Y., Liu Q., Wang G., Feng J., Zhang M., Effects of Ammonia on gut microbiota and growth performance of broiler chickens, Animals (Basel), 11, (2021); Hollis F., Van Der Kooij M.A., Zanoletti O., Lozano L., Canto C., Sandi C., Mitochondrial function in the brain links anxiety with social subordination, Proc. Natl. Acad. Sci. U. S. A, 112, pp. 15486-15491, (2015); Hu L., Jin L., Xia D., Zhang Q., Ma L., Zheng H., Et al., Nitrate ameliorates dextran sodium sulfate-induced colitis by regulating the homeostasis of the intestinal microbiota, Free Radic. Biol. Med, 152, pp. 609-621, (2020); Huang J., Huang J., Li Y., Wang Y., Wang F., Qiu X., Et al., Sodium alginate modulates immunity, intestinal mucosal barrier function, and gut microbiota in cyclophosphamide-induced immunosuppressed BALB/c mice, J. Agric. Food Chem, 69, pp. 7064-7073, (2021); Huang S.T., Song Z.J., Liu Y., Luo W.C., Yin Q., Zhang Y.M., BNST (AV) (GABA)-PVN (CRF) circuit regulates visceral hypersensitivity induced by maternal separation in Vgat-Cre mice, Front. Pharmacol, 12, (2021); Ibrahim A., Hugerth L.W., Hases L., Saxena A., Seifert M., Thomas Q., Et al., Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity, Int. J. Cancer, 144, pp. 3086-3098, (2019); Ju T., Naliboff B.D., Shih W., Presson A.P., Liu C., Gupta A., Et al., Risk and protective factors related to early adverse life events in irritable bowel syndrome, J. Clin. Gastroenterol, 54, pp. 63-69, (2020); Kan L., Guo F., Liu Y., Pham V.H., Guo Y., Wang Z., Probiotics Bacillus licheniformis improves intestinal health of subclinical necrotic enteritis-challenged broilers, Front. Microbiol, 12, (2021); Kasahara T., Takata A., Kato T.M., Kubota-Sakashita M., Sawada T., Kakita A., Et al., Depression-like episodes in mice harboring mtDNA deletions in paraventricular thalamus, Mol. Psychiatry, 21, pp. 39-48, (2016); Khorjahani A., Peeri M., Azarbayjani M.A., The therapeutic effect of exercise on anxiety and bowel oxidative stress in the maternal separation animal model, Basic Clin. Neurosci, 11, pp. 69-78, (2020); Kuti D., Winkler Z., Horvath K., Juhasz B., Paholcsek M., Stagel A., Et al., Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior, Brain Behav. Immun, 84, pp. 218-228, (2020); Lacy B.E., Pimentel M., Brenner D.M., Chey W.D., Keefer L.A., Long M.D., Et al., ACG clinical guideline: Management of Irritable Bowel Syndrome, Am. J. Gastroenterol, 116, pp. 17-44, (2021); Lam J., Katti P., Biete M., Mungai M., Ashshareef S., Neikirk K., Et al., A universal approach to analyzing transmission Electron microscopy with ImageJ, Cells, 10, (2021); Laursen M.F., Bahl M.I., Licht T.R., Settlers of our inner surface - factors shaping the gut microbiota from birth to toddlerhood, FEMS Microbiol. Rev, 45, (2021); Lee S.H., Jung E.-M., Adverse effects of early-life stress: focus on the rodent neuroendocrine system, Neural Regen. Res, 19, pp. 336-341, (2024); Leyrolle Q., Decoeur F., Briere G., Amadieu C., Quadros A.R.A.A., Voytyuk I., Et al., Maternal dietary omega-3 deficiency worsens the deleterious effects of prenatal inflammation on the gut-brain axis in the offspring across lifetime. Neuropsychopharmacology: official publication of the American college of, Neuropsychopharmacology, 46, pp. 579-602, (2021); Li Y.-C., Wang Q., Li M.-G., Hu S.-F., Xu G.-Y., A paraventricular hypothalamic nucleus input to ventral of lateral septal nucleus controls chronic visceral pain, Pain, 164, pp. 625-637, (2023); Litvak Y., Byndloss M.X., Baumler A.J., Colonocyte metabolism shapes the gut microbiota, Science, 362, (2018); Liu L., Cheng S., Qi X., Meng P., Yang X., Pan C., Et al., Mitochondria-wide association study observed significant interactions of mitochondrial respiratory and the inflammatory in the development of anxiety and depression, Transl. Psychiatry, 13, (2023); Liu X.L., Zhao Y.C., Zhu H.Y., Wu M., Zheng Y.N., Yang M., Et al., Taxifolin retards the D-galactose-induced aging process through inhibiting Nrf2-mediated oxidative stress and regulating the gut microbiota in mice, Food Funct, 12, pp. 12142-12158, (2021); Low E.X.S., Mandhari M., Herndon C.C., Loo E.X.L., Tham E.H., Siah K.T.H., Parental, perinatal, and childhood risk factors for development of irritable bowel syndrome: a systematic review, J Neurogastroenterol. Motil, 26, pp. 437-446, (2020); Maltz R.M., Keirsey J., Kim S.C., Mackos A.R., Gharaibeh R.Z., Moore C.C., Et al., Prolonged restraint stressor exposure in outbred CD-1 mice impacts microbiota, colonic inflammation, and short chain fatty acids, PLoS One, 13, (2018); Martin-Gallausiaux C., Marinelli L., Blottiere H.M., Larraufie P., Lapaque N., SCFA: mechanisms and functional importance in the gut, Proc. Nutr. Soc, 80, pp. 37-49, (2021); Matsumoto H., Shiotani A., Katsumata R., Fukushima S., Handa Y., Osawa M., Et al., Mucosa-associated microbiota in patients with irritable bowel syndrome: a comparison of subtypes, Digestion, 102, pp. 49-56, (2021); Mcnamara M.P., Singleton J.M., Cadney M.D., Ruegger P.M., Borneman J., Garland T., Early-life effects of juvenile Western diet and exercise on adult gut microbiome composition in mice, J. Exp. Biol, 224, (2021); Mishima Y., Ishihara S., Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome, Int. J. Mol. Sci, 22, (2021); Oh J.K., Vasquez R., Hwang I.C., Oh Y.N., Kim S.H., Kang S.H., Et al., Cudrania tricuspidata combined with Lacticaseibacillus rhamnosus modulate gut microbiota and alleviate obesity-associated metabolic parameters in obese mice, Microorganisms, 9, (2021); Osadchiy V., Martin C.R., Mayer E.A., The gut-brain Axis and the microbiome: mechanisms and clinical implications, Clin. Gastroenterol. Hepatol, 17, pp. 322-332, (2019); Pagliai G., Russo E., Niccolai E., Dinu M., Di Pilato V., Magrini A., Et al., Influence of a 3-month low-calorie Mediterranean diet compared to the vegetarian diet on human gut microbiota and SCFA: the CARDIVEG study, Eur. J. Nutr, 59, pp. 2011-2024, (2020); Park H.J., Kim S.A., Kang W.S., Kim J.W., Early-life stress modulates gut microbiota and peripheral and central inflammation in a sex-dependent manner, Int. J. Mol. Sci, 22, (2021); Park S.H., Videlock E.J., Shih W., Presson A.P., Mayer E.A., Chang L., Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity, Neurogastroenterol. Motil, 28, pp. 1252-1260, (2016); Petitfils C., Maurel S., Payros G., Hueber A., Agaiz B., Gazzo G., Et al., Identification of bacterial lipopeptides as key players in IBS, Gut, 72, pp. 939-950, (2023); Picard M., Mcewen B.S., Psychological stress and mitochondria: a systematic review, Psychosom. Med, 80, pp. 141-153, (2018); Rashidi A., Peled J.U., Ebadi M., Rehman T.U., Elhusseini H., Marcello L.T., Et al., Protective effect of intestinal Blautia against neutropenic fever in allogeneic transplant recipients, Clin. Infect. Dis. Off. Public. Infect. Dis. Soc. Am, 75, pp. 1912-1920, (2022); Rath E., Moschetta A., Haller D., Mitochondrial function - gatekeeper of intestinal epithelial cell homeostasis, Nat. Rev. Gastroenterol. Hepatol, 15, pp. 497-516, (2018); Ratsika A., Codagnone M.C., O'mahony S., Stanton C., Cryan J.F., Priming for life: early life nutrition and the microbiota-gut-brain Axis, Nutrients, 13, (2021); Riba A., Olier M., Lacroix-Lamande S., Lencina C., Bacquie V., Harkat C., Et al., Early life stress in mice is a suitable model for irritable bowel syndrome but does not predispose to colitis nor increase susceptibility to enteric infections, Brain Behav. Immun, 73, pp. 403-415, (2018); Rincel M., Darnaudery M., Maternal separation in rodents: a journey from gut to brain and nutritional perspectives, Proc. Nutr. Soc, 79, pp. 113-132, (2020); Rosario D., Bidkhori G., Lee S., Bedarf J., Hildebrand F., Le Chatelier E., Et al., Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease, Cell Rep, 34, (2021); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Schmitt C.C., Aranias T., Viel T., Chateau D., Le Gall M., Waligora-Dupriet A.J., Et al., Intestinal invalidation of the glucose transporter GLUT2 delays tissue distribution of glucose and reveals an unexpected role in gut homeostasis, Mol. Metab, 6, pp. 61-72, (2017); Song Y.F., Pei L.X., Chen L., Geng H., Yuan M.Q., Xu W.L., Et al., Electroacupuncture relieves irritable bowel syndrome by regulating IL-18 and gut microbial Dysbiosis in a Trinitrobenzene sulfonic acid-induced post-inflammatory animal model, Am. J. Chin. Med, 48, pp. 77-90, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Et al., Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study, Gastroenterology, 160, pp. 99-114.e3, (2021); Sun D., Ge X., Tang S., Liu Y., Sun J., Zhou Y., Et al., Bacterial characteristics of intestinal tissues from patients with Crohn's disease, Front. Cell. Infect. Microbiol, 11, (2021); Takihara H., Okuda S., Glycan-related genes in human gut microbiota exhibit differential distribution and diversity in carbohydrate degradation and glycan synthesis, Front. Mol. Biosci, 10, (2023); Tao E., Long G., Yang T., Chen B., Guo R., Ye D., Et al., Maternal separation induced visceral hypersensitivity evaluated via novel and small size distention balloon in post-weaning mice, Front. Neurosci, 15, (2022); Tao E., Zhu Z., Hu C., Long G., Chen B., Guo R., Et al., Potential roles of Enterochromaffin cells in early life stress-induced irritable bowel syndrome, Front. Cell. Neurosci, 16, (2022); Tesfaye M., Jaholkowski P., Hindley G.F.L., Shadrin A.A., Rahman Z., Bahrami S., Et al., Shared genetic architecture between irritable bowel syndrome and psychiatric disorders reveals molecular pathways of the gut-brain axis, Genome Med, 15, (2023); Torres-Maravilla E., Holowacz S., Delannoy J., Lenoir L., Jacouton E., Gervason S., Et al., Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome, Sci. Rep, 12, (2022); Toubal A., Kiaf B., Beaudoin L., Cagninacci L., Rhimi M., Fruchet B., Et al., Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity, Nat. Commun, 11, (2020); Van Orten-Luiten A.C.B., De Roos N.M., Majait S., Witteman B.J.M., Witkamp R.F., Effects of Cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with symptom-driven dosing, Cann. Cannab. Res, 7, pp. 436-444, (2022); Vicario M., Alonso C., Guilarte M., Serra J., Martinez C., Gonzalez-Castro A.M., Et al., Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction, Psychoneuroendocrinology, 37, pp. 65-77, (2012); Wang J., Duan G., Zhan T., Dong Z., Zhang Y., Chen Y., Et al., Upregulation of Netrin-1 in the hippocampus mediates the formation of visceral hypersensitivity induced by maternal separation, Front. Mol. Neurosci, 15, (2022); Wang J., Zhang C., Guo C., Li X., Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora, Int. J. Mol. Sci, 20, (2019); Wei W., Jiang W., Tian Z., Wu H., Ning H., Yan G., Et al., Fecal g. Streptococcus and g. Eubacterium_coprostanoligenes_group combined with sphingosine to modulate the serum dyslipidemia in high-fat diet mice, Clin. Nutr, 40, pp. 4234-4245, (2021); Wong H.L.X., Qin H.Y., Tsang S.W., Zuo X., Che S., Chow C.F.W., Et al., Early life stress disrupts intestinal homeostasis via NGF-TrkA signaling, Nat. Commun, 10, (2019); Wu K., Gao J.H., Hua R., Peng X.H., Wang H., Zhang Y.M., Predisposition of neonatal maternal separation to visceral hypersensitivity via downregulation of small-conductance calcium-activated Potassium Channel subtype 2 (SK2) in mice, Neural Plast, 2020, pp. 8876230-8876215, (2020); Wu F., Lei H., Chen G., Chen C., Song Y., Cao Z., Et al., In vitro and in vivo studies reveal that Hesperetin-7-O-glucoside, a naturally occurring Monoglucoside, exhibits strong anti-inflammatory capacity, J. Agric. Food Chem, 69, pp. 12753-12762, (2021); Wu Y., Ran L., Yang Y., Gao X., Peng M., Liu S., Et al., Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota, Life Sci, 314, (2023); Xiao L., Liu Q., Luo M., Xiong L., Gut microbiota-derived metabolites in irritable bowel syndrome, Front. Cell. Infect. Microbiol, 11, (2021); Xie X.Q., Geng Y., Guan Q., Ren Y., Guo L., Lv Q., Et al., Influence of short-term consumption of Hericium erinaceus on serum biochemical markers and the changes of the gut microbiota: a pilot study, Nutrients, 13, (2021); Xu Y., Yu Y., Shen Y., Li Q., Lan J., Wu Y., Et al., Effects of Bacillus subtilis and Bacillus licheniformis on growth performance, immunity, short chain fatty acid production, antioxidant capacity, and cecal microflora in broilers, Poult. Sci, 100, (2021); Yang D.-F., Huang W.-C., Wu C.W., Huang C.-Y., Yang Y.C.S.H., Tung Y.-T., Acute sleep deprivation exacerbates systemic inflammation and psychiatry disorders through gut microbiota dysbiosis and disruption of circadian rhythms, Microbiol. Res, 268, (2023); Yao Y., Cai X., Fei W., Ye Y., Zhao M., Zheng C., The role of short-chain fatty acids in immunity, inflammation and metabolism, Crit. Rev. Food Sci. Nutr, 62, pp. 1-12, (2020); Ye D., Hu Y., Zhu N., Gu W., Long G., Tao E., Et al., Exploratory investigation of intestinal structure and function after stroke in mice, Mediat. Inflamm, 2021, pp. 1315797-1315712, (2021); Yi L., Zhang H., Sun H., Zhou L., Chen Y., Xuan L., Et al., Maternal separation induced visceral hypersensitivity from childhood to adulthood, J. Neurogastroenterol. Motil, 23, pp. 306-315, (2017); Yoon C.H., Ryu J.S., Moon J., Kim M.K., Association between aging-dependent gut microbiome dysbiosis and dry eye severity in C57BL/6 male mouse model: a pilot study, BMC Microbiol, 21, (2021); Yu Y.B., Zuo X.L., Zhao Q.J., Chen F.X., Yang J., Dong Y.Y., Et al., Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome, Gut, 61, pp. 685-694, (2012); Yuan Y., Lu L., Bo N., Chaoyue Y., Haiyang Y., Allicin ameliorates intestinal barrier damage via microbiota-regulated short-chain fatty acids-TLR4/MyD88/NF-κB Cascade response in acrylamide-induced rats, J. Agric. Food Chem, 69, pp. 12837-12852, (2021); Zhang Z.-W., Gao C.-S., Zhang H., Yang J., Wang Y.-P., Pan L.-B., Et al., Morinda officinalis oligosaccharides increase serotonin in the brain and ameliorate depression via promoting 5-hydroxytryptophan production in the gut microbiota, Acta Pharm. Sin. B, 12, pp. 3298-3312, (2022); Zhang H., Geng X., Li Z., Li Y., Xu K., Wu H., Et al., Paeonol at certain doses alleviates aggressive and anxiety-like behaviours in two premenstrual dysphoric disorder rat models, Front. Psych, 11, (2020); Zhang J.D., Liu J., Zhu S.W., Fang Y., Wang B., Jia Q., Et al., Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation, Acta Pharmacol. Sin, 42, pp. 1821-1833, (2021); Zhang Y., Zhang J., Duan L., The role of microbiota-mitochondria crosstalk in pathogenesis and therapy of intestinal diseases, Pharmacol. Res, 186, (2022); Zhang Y., Zhang H., Zhang W., Zhang Y., Wang W., Nie L., LncRNA XIST modulates 5-hydroxytrytophan-induced visceral hypersensitivity by epigenetic silencing of the SERT gene in mice with diarrhea-predominant IBS, Cell. Signal, 73, (2020); Zhang Q., Zhong D., Sun R., Zhang Y., Pegg R.B., Zhong G., Prevention of loperamide induced constipation in mice by KGM and the mechanisms of different gastrointestinal tract microbiota regulation, Carbohydr. Polym, 256, (2021); Zhao X., Jiang L., Fang X., Guo Z., Wang X., Shi B., Et al., Host-microbiota interaction-mediated resistance to inflammatory bowel disease in pigs, Microbiome, 10, (2022); Zhou L., Wu Z., Li Y., Xiao L., Wang H., Wang G., Brief maternal separation promotes resilience to anxiety-like and depressive-like behaviors in female C57BL/6J offspring with Imiquimod-induced psoriasis, Brain Sci, 12, (2022); Zhou Y., Zhang F., Mao L., Feng T., Wang K., Xu M., Et al., Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines, Eur. J. Nutr, 62, pp. 139-155, (2023); Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L., Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome, Front. Microbiol, 9, (2018); Zitkovsky E.K., Daniels T.E., Tyrka A.R., Mitochondria and early-life adversity, Mitochondrion, 57, pp. 213-221, (2021)^M. Jiang; Pediatric Endoscopy Center and Gastrointestinal Laboratory, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China; email: mizu@zju.edu.cn^^Frontiers Media SA^^^^^^1664302X^^^^English^Front. Microbiol.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85174277827
Rodríguez-Sojo M.J.; Garcia-Garcia J.; Ruiz-Malagón A.J.; Diez-Echave P.; Hidalgo-García L.; Molina-Tijeras J.A.; González-Lozano E.; López-Escanez L.; Rodríguez-Cabezas M.E.; Rodríguez-Sánchez M.J.; Rodríguez-Nogales A.; Mediavilla C.; Galvez J.^Rodríguez-Sojo, María Jesús (57219963817); Garcia-Garcia, Jorge (57222272619); Ruiz-Malagón, Antonio Jesús (57211626330); Diez-Echave, Patricia (57203976100); Hidalgo-García, Laura (56957125300); Molina-Tijeras, José Alberto (57205398368); González-Lozano, Elena (58025289200); López-Escanez, Laura (58047074200); Rodríguez-Cabezas, María Elena (6602880894); Rodríguez-Sánchez, Maria José (57893513100); Rodríguez-Nogales, Alba (55603925700); Mediavilla, Cristina (6603428888); Galvez, Julio (7102940760)^57219963817; 57222272619; 57211626330; 57203976100; 56957125300; 57205398368; 58025289200; 58047074200; 6602880894; 57893513100; 55603925700; 6603428888; 7102940760^Beneficial Effects of Limosilactobacillus fermentum in the DCA Experimental Model of Irritable Bowel Syndrome in Rats^2023^Nutrients^15.0^1^24^^^^1^10.3390/nu15010024^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145914602&doi=10.3390%2fnu15010024&partnerID=40&md5=b6c6f1e70316a2f31b8068a242d1178a^Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, Granada, 18071, Spain; Department of Psychobiology, Mind, Brain, and Behavior Research Center (CIMCYC), University of Granada, Granada, 18071, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, 08036, Spain^Rodríguez-Sojo M.J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Garcia-Garcia J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain; Ruiz-Malagón A.J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Diez-Echave P., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Hidalgo-García L., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Molina-Tijeras J.A., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; González-Lozano E., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; López-Escanez L., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Rodríguez-Cabezas M.E., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Rodríguez-Sánchez M.J., Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain, Servicio de Digestivo, Hospital Universitario Virgen de las Nieves, Granada, 18071, Spain; Rodríguez-Nogales A., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; Mediavilla C., Department of Psychobiology, Mind, Brain, and Behavior Research Center (CIMCYC), University of Granada, Granada, 18071, Spain; Galvez J., Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, 08036, Spain^Limosilactobacillus fermentum CECT5716, a probiotic strain isolated from human milk, has reported beneficial effects on different gastrointestinal disorders. Moreover, it has shown its ability to restore altered immune responses, in association with microbiome modulation in different pathological conditions. Therefore, our aim was to assess the effects of a Limosilacbacillus fermentum CECT5716 in a rat experimental model of irritable bowel syndrome (IBS) that resembles human IBS. The experimental IBS was induced by deoxycholic acid (DCA) in rats and then, Limosilactobacillus fermentum CECT5716 (109 CFU/day/rat) was administered. Behavioral studies, hyperalgesia and intestinal hypersensitivity determinations were performed and the impact of the probiotic on the inflammatory and intestinal barrier integrity was evaluated. Additionally, the gut microbiota composition was analyzed. Limosilactobacillus fermentum CECT5716 attenuated the anxiety-like behavior as well as the visceral hypersensitivity and referred pain. Moreover, this probiotic ameliorated the gut inflammatory status, re-establishing the altered intestinal permeability, reducing the mast cell degranulation and re-establishing the gut dysbiosis in experimental IBS. Therefore, our results suggest a potential use of Limosilactobacillus fermentum CECT5716 in clinical practice for the management of IBS patients. © 2022 by the authors.^IBS rat model; Intestine anti-inflammatory activity; Limosilactobacillus fermentum CECT5716; probiotic; visceral analgesia^Animals; Humans; Hyperalgesia; Irritable Bowel Syndrome; Limosilactobacillus fermentum; Milk, Human; Probiotics; Rats; deoxycholic acid; gabapentin; probiotic agent; rifaximin; probiotic agent; adult; animal cell; animal experiment; animal model; animal tissue; antiinflammatory activity; anxiety disorder; Article; behavior assessment; colony forming unit; controlled study; gene expression profiling; human; human cell; intestine flora; intestine mucosa permeability; irritable colon; Lactobacillus fermentum; male; mast cell degranulation; nonhuman; rat; referred pain; species composition; visceral hyperalgesia; animal; breast milk; hyperalgesia; irritable colon^^deoxycholic acid, 83-44-3; gabapentin, 60142-96-3; rifaximin, 80621-81-4, 88747-56-2^^^CIBER-EHD; Instituto de Salud Carlos III, ISCIII, (PI19/01058, PI20/01447); Junta de Andalucía, (A-CTS-447-UGR18, CTS 164)^This study was supported by the Junta de Andalucía (A-CTS-447-UGR18 and CTS 164), and by the Instituto de Salud Carlos III (ISCIII) (PI19/01058, PI20/01447; CIBER-EHD).^Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N. Engl. J. Med, 376, pp. 2566-2578, (2017); Black C.J., Ford A.C., Global burden of irritable bowel syndrome: Trends, predictions and risk factors, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 473-486, (2020); Lee Y.J., Park K.S., Irritable bowel syndrome: Emerging paradigm in pathophysiology, World J. Gastroenterol, 20, pp. 2456-2469, (2014); Uranga J.A., Martinez V., Abalo R., Mast Cell Regulation and Irritable Bowel Syndrome: Effects of Food Components with Potential Nutraceutical Use, Molecules, 25, (2020); Zamani M., Alizadeh-Tabari S., Zamani V., Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome, Aliment. Pharm, 50, pp. 132-143, (2019); Van Oudenhove L., Crowell M.D., Drossman D.A., Halpert A.D., Keefer L., Lackner J.M., Murphy T.B., Naliboff B.D., Levy R.L., Biopsychosocial Aspects of Functional Gastrointestinal Disorders, Gastroenterology, 150, pp. 1355-1367.e2, (2016); Coss-Adame E., Rao S.S., Brain and gut interactions in irritable bowel syndrome: New paradigms and new understandings, Curr. Gastroenterol. Rep, 16, (2014); Foster J.A., Rinaman L., Cryan J.F., Stress & the gut-brain axis: Regulation by the microbiome, Neurobiol. Stress, 7, pp. 124-136, (2017); Bellini M., Gambaccini D., Stasi C., Urbano M.T., Marchi S., Usai-Satta P., Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy, World J. Gastroenterol, 20, pp. 8807-8820, (2014); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, pp. 966-974, (2017); Bordbar G., Miri M.B., Omidi M., Shoja S., Akhavan M., Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial, Gastroenterol. Res. Pr, 2020, (2020); Camilleri M., Diagnosis and Treatment of Irritable Bowel Syndrome: A Review, Jama, 325, pp. 865-877, (2021); Bond D.M., Morris J.M., Nassar N., Study protocol: Evaluation of the probiotic Lactobacillus Fermentum CECT5716 for the prevention of mastitis in breastfeeding women: A randomised controlled trial, BMC Pregnancy Childbirth, 17, (2017); Pastor-Villaescusa B., Blanco-Rojo R., Olivares M., Evaluation of the Effect of Limosilactobacillus fermentum CECT5716 on Gastrointestinal Infections in Infants: A Systematic Review and Meta-Analysis, Microorganisms, 9, (2021); Rodriguez-Nogales A., Algieri F., Vezza T., Garrido-Mesa N., Olivares M., Comalada M., Riccardi C., Utrilla M.P., Rodriguez-Cabezas M.E., Galvez J., The viability of Lactobacillus fermentum CECT5716 is not essential to exert intestinal anti-inflammatory properties, Food Funct, 6, pp. 1176-1184, (2015); Rodriguez-Nogales A., Algieri F., Garrido-Mesa J., Vezza T., Utrilla M.P., Chueca N., Garcia F., Olivares M., Rodriguez-Cabezas M.E., Galvez J., Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: Impact on microRNAs expression and microbiota composition, Mol. Nutr. Food Res, 61, (2017); Molina-Tijeras J.A., Diez-Echave P., Vezza T., Hidalgo-Garcia L., Ruiz-Malagon A.J., Rodriguez-Sojo M.J., Romero M., Robles-Vera I., Garcia F., Plaza-Diaz J., Et al., Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis, Pharm. Res, 167, (2021); Robles-Vera I., Toral M., de la Visitacion N., Sanchez M., Romero M., Olivares M., Jimenez R., Duarte J., The Probiotic Lactobacillus fermentum Prevents Dysbiosis and Vascular Oxidative Stress in Rats with Hypertension Induced by Chronic Nitric Oxide Blockade, Mol. Nutr. Food Res, 62, (2018); Lee K.J., Kim J.H., Cho S.W., Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharm, 22, pp. 981-988, (2005); Pimentel M., Park S., MIrocha J., Kane S.V., Kong Y., The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial, Ann. Intern. Med, 145, pp. 557-563, (2006); Menees S.B., Maneerattannaporn M., Kim H.M., Chey W.D., The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis, Am. J. Gastroenterol, 107, pp. 28-35, (2012); Rodriguez-Nogales A., Algieri F., Vezza T., Garrido-Mesa J., Molina-Tijeras J.A., ROdriguez-Cabezas M.E., Utrilla M.P., Pischel I., Galvez J., Calcium Pyruvate Exerts Beneficial Effects in an Experimental Model of Irritable Bowel Disease Induced by DCA in Rats, Nutrients, 11, (2019); Keszthelyi D., Troost F.J., Masclee A.A., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol, 303, pp. G141-G154, (2012); Zhang C., Rui Y.-Y., Zhou Y.-Y., Ju Z., Zhang H.-H., Hu C.-Y., Xiao Y., Xu G.-Y., Adrenergic β2-receptors mediates visceral hypersensitivity induced by heterotypic intermittent stress in rats, PLoS ONE, 9, (2014); Vezza T., Algieri F., Rodriguez-Nogales A., Garrido-Mesa J., Utrilla M.P., Talhaoui N., Gomez-Caravaca A.M., Segura-Carretero A., Rodriguez-Cabezas M.E., Monteleone G., Immunomodulatory properties of Olea europaea leaf extract in intestinal inflammation, Mol. Nutr. Food Res, 61, (2017); Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., Fiji: An open-source platform for biological-image analysis, Nat. Methods, 9, pp. 676-682, (2012); Mane J., Loren V., Pedrosa E., Ojanguren I., Xaus J., Cabre E., Domenech E., Gassull M.A., Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice, Inflamm. Bowel Dis, 15, pp. 1155-1163, (2009); (2019); Lucak S., Chang L., Halpert A., Harris L.A., Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: Evidence-based treatment in practice, Ther. Adv. Gastroenterol, 10, pp. 253-275, (2017); Patel S., Doerfler B., Boutros K., Ng S., Manuel M., DeSimone E., Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation, Int. J. Gen. Med, 14, pp. 1457-1468, (2021); Nee J., Lembo A., Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M), Aliment. Pharm, 54, pp. S63-S74, (2021); Jiang H.-Y., Zhang X., Yu Z.-H., Zhang Z., Deng M., Zhao J.-H., Ruan B., Altered gut microbiota profile in patients with generalized anxiety disorder, J. Psychiatr. Res, 104, pp. 130-136, (2018); Elsenbruch S., Abdominal pain in Irritable Bowel Syndrome: A review of putative psychological, neural and neuro-immune mechanisms, Brain Behav. Immun, 25, pp. 386-394, (2011); Traub R.J., Tang B., Ji Y., Pandya S., Yfnatis H., Sun Y., A rat model of chronic postinflammatory visceral pain induced by deoxycholic acid, Gastroenterology, 135, pp. 2075-2083, (2008); Guthrie E., Barlow J., Fernandes L., Ratcliffe J., Read N., Thompson D.G., Tomenson B., Creed F., Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome, Psychosom. Med, 66, pp. 578-582, (2004); Trinkley K.E., Nahata M.C., Medication management of irritable bowel syndrome, Digestion, 89, pp. 253-267, (2014); Ait-Belgnaoui A., Payard I., Rolland C., Harkat C., Braniste V., Theodorou V., Tompkins T.A., Bifidobacterium longum and Lactobacillus helveticus Synergistically Suppress Stress-related Visceral Hypersensitivity Through Hypothalamic-Pituitary-Adrenal Axis Modulation, J. Neurogastroenterol. Motil, 24, pp. 138-146, (2018); Eutamene H., Lamine F., Chabo C., Theodorou V., Rochat F., Bergonzelli G.E., Corthesy-Theulaz I., Fioramonti J., Bueno L., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J. Nutr, 137, pp. 1901-1907, (2007); McGrath J.C., Drummond G.B., McLachlan E.M., Kilkenny C., Wainwright C.L., Guidelines for reporting experiments involving animals: The ARRIVE guidelines, Br. J. Pharm, 160, pp. 1573-1576, (2010); Wang B., Mao Y.-K., Diorio C., Wang L., Huizinga J.D., Bienenstock J., Kunze W., Lactobacillus reuteri ingestion and IK(Ca) channel blockade have similar effects on rat colon motility and myenteric neurones, Neurogastroenterol. Motil, 22, pp. 98-107, (2010); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.-S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res, 11, pp. 345-349, (2018); Hassanin T.M., Fouad Y., Mohamed F.E., Abdel-Hafeez E.H., Hassnine A., Colonic mucosal eosinophilia and immunohistochemical expression of COX-2 and NF-kB in patients with irritable bowel syndrome, Eur. J. Gastroenterol. Hepatol, 34, pp. 512-517, (2022); Holzer P., TRPV1: A new target for treatment of visceral pain in IBS?, Gut, 57, pp. 882-884, (2008); Dasgupta Y., Golovine K., Nieborowska-Skorska M., Luo L., Matlawska-Wasowska K., Mullighan C.G., Skorski T., Drugging DNA repair to target T-ALL cells, Leuk. Lymphoma, 59, pp. 1746-1749, (2018); Lee J., Lee B.J., Lee Y.M., Park H., Kim J.H., Kim W.J., Self-Assembled Nanoconstructs Modified with Amplified Aptamers Inhibited Tumor Growth and Retinal Vascular Hyperpermeability via Vascular Endothelial Growth Factor Capturing, Mol. Pharm, 14, pp. 1460-1468, (2017); Grabauskas G., Wu X., Gao J., Li J.-Y., Turgeon D.K., Owyang C., Prostaglandin E(2), Produced by Mast Cells in Colon Tissues From Patients With Irritable Bowel Syndrome, Contributes to Visceral Hypersensitivity in Mice, Gastroenterology, 158, pp. 2195-2207.e6, (2020); Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S., Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain, Gut, 57, pp. 923-929, (2008); Perez-Burgos A., Wang L., Neufeld K.-A.M., Mao Y.-K., Ahmadzai M., Janssen L.J., Stanisz A.M., Bienenstock J., Kunze W.A., The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938, J. Physiol, 593, pp. 3943-3957, (2015); Yang C.Q., Guo X.-S., Wei Z.-B., Zhao L., Zhao G.-T., Sheng S.-T., Rifaximin Improves Visceral Hyperalgesia via TRPV1 by Modulating Intestinal Flora in the Water Avoidance Stressed Rat, Gastroenterol. Res. Pr, 2020, (2020); Ribatti D., Vacca A., Dammacco F., The role of the vascular phase in solid tumor growth: A historical review, Neoplasia, 1, pp. 293-302, (1999); Chen L., Deng H., Cui H., Fang J., Zuo Z., Deng J., Li Y., Wang X., Zhao L., Inflammatory responses and inflammation-associated diseases in organs, Oncotarget, 9, pp. 7204-7218, (2018); Casado-Bedmar M., Keita A.V., Potential neuro-immune therapeutic targets in irritable bowel syndrome, Ther. Adv. Gastroenterol, 13, (2020); Carabotti M., Scirocco A., Maselli M.A., Severi C., The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems, Ann. Gastroenterol, 28, pp. 203-209, (2015); Bischoff S.C., Kramer S., Human mast cells, bacteria, and intestinal immunity, Immunol. Rev, 217, pp. 329-337, (2007); O'Sullivan M., Clayton N., Breslin N.P., Harman I., Bountra C., McLaren A., O'morain C.A., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol. Motil, 12, pp. 449-457, (2000); Camilleri M., Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome, Expert Opin Pharm, 14, pp. 1151-1160, (2013); Klooker T.K., Braak B., Koopman K.E., Welting O., Wouters M.M., van der Heide S., Schemann M., Bischoff S.C., van den Wijingaard E.M., Boeckxstaerns G.E., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Buhner S., Li Q., Vignali S., Barbara G., De Giorgio R., Stanghellini V., Cremon C., Zeller F., Langer R., Daniel H., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Harata G., He F., Takahashi K., Hosono A., Miyazawa K., Yoda K., Hiramatsu M., Kaminogawa S., Human Lactobacillus Strains from the Intestine can Suppress IgE-Mediated Degranulation of Rat Basophilic Leukaemia (RBL-2H3) Cells, Microorganisms, 4, (2016); Forsythe P., Wang B., Khambati I., Kunze W.A., Systemic effects of ingested Lactobacillus rhamnosus: Inhibition of mast cell membrane potassium (IKCa) current and degranulation, PLoS ONE, 7, (2012); Kawahara T., Inhibitory effect of heat-killed Lactobacillus strain on immunoglobulin E-mediated degranulation and late-phase immune reactions of mouse bone marrow-derived mast cells, Anim. Sci. J, 81, pp. 714-721, (2010); Piche T., Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol. Motil, 26, pp. 296-302, (2014); Zeng H., Umar S., Rust B., Lazarova D., Bordonario M., Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer, Int. J. Mol. Sci, 20, (2019); Vancamelbeke M., Vermeire S., The intestinal barrier: A fundamental role in health and disease, Expert Rev. Gastroenterol. Hepatol, 11, pp. 821-834, (2017); Chen X., Oshima T., Tomita T., Fukui H., Watari J., Matsumoto T., Miwa H., Acidic bile salts modulate the squamous epithelial barrier function by modulating tight junction proteins, Am. J. Physiol. Gastrointest. Liver Physiol, 301, pp. G203-G209, (2011); Ghosh S., Whitley C.S., Haribabu B., Jala V.R., Regulation of Intestinal Barrier Function by Microbial Metabolites, Cell Mol. Gastroenterol. Hepatol, 11, pp. 1463-1482, (2021); Duan R., Zhu S., Wang B., Duan L., Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review, Clin. Transl. Gastroenterol, 10, (2019); Jeffery I.B., Das A., OHerlihy E., Coughlan S., Cisek K., Moore M., Bradley F., Carty T., Pradhan M., Dwibedi C., Et al., Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption, Gastroenterology, 158, pp. 1016-1028.e8, (2020); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome, Gastroenterology, 152, pp. 111-123.e8, (2017); Su T., Liu R., Lee A., Long Y., Du L., LAi S., Chen X., Wang L., Si J., Owyang C., Et al., Altered Intestinal Microbiota with Increased Abundance of Prevotella Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome, Gastroenterol. Res. Pr, 2018, (2018); Kovatcheva-Datchary P., Nilsson A., Akrami R., Lee Y.S., De Vadder F., Arora T., Hallen A., Martens E., Bjorck I., Backhed F., Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella, Cell Metab, 22, pp. 971-982, (2015); Staudacher H.M., Irving P.M., Lomer M.C.E., Whelan K., Mechanisms and efficacy of dietary FODMAP restriction in IBS, Nat. Rev. Gastroenterol. Hepatol, 11, pp. 256-266, (2014); Chen J., Wright K., Davis J.M., Jeraldo P., Marietta E.V., Murray J., Nelson H., Matteson E.L., Taneja V., An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis, Genome Med, 8, (2016); Menees S., Chey W., The gut microbiome and irritable bowel syndrome, F1000Res, 7, (2018); Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation, Brain Behav. Immun, 25, pp. 397-407, (2011); Kuti D., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Gastrointestinal (non-systemic) antibiotic rifaximin differentially affects chronic stress-induced changes in colon microbiome and gut permeability without effect on behavior, Brain Behav. Immun, 84, pp. 218-228, (2020); Bercik P., The microbiota-gut-brain axis: Learning from intestinal bacteria?, Gut, 60, pp. 288-289, (2011); Smith K.B., Murray E., Gregory J.G., Liang J., Ismail N., Pubertal probiotics mitigate lipopolysaccharide-induced programming of the hypothalamic-pituitary-adrenal axis in male mice only, Brain Res. Bull, 177, pp. 111-118, (2021)^A. Rodríguez-Nogales; Departamento de Farmacología, Centro de Investigación Biomédica (CIBM), Universidad de Granada, Granada, 18071, Spain; email: albarn@ugr.es; M.J. Rodríguez-Sánchez; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, 18071, Spain; email: mjrs2188@gmail.com^^MDPI^^^^^^20726643^^^36615683.0^English^Nutrients^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85145914602
Bootz-Maoz H.; Pearl A.; Melzer E.; Malnick S.; Sharon E.; Bennet Y.; Tsentsarevsky R.; Abuchatzera S.; Amidror S.; Aretz E.; Azriel S.; Gam Ze Letova C.; Naama M.; Shoval I.; Yaron O.; Karako-Lampert S.; Bel S.; Yissachar N.^Bootz-Maoz, Hadar (57970591500); Pearl, Ayelet (57266289300); Melzer, Ehud (7006188330); Malnick, Stephen (7005572437); Sharon, Efrat (57265949600); Bennet, Yifat (57969661500); Tsentsarevsky, Rotem (57970360600); Abuchatzera, Shlomi (57266061200); Amidror, Sivan (57215692576); Aretz, Elana (57266635600); Azriel, Shalhevet (55362650600); Gam Ze Letova, Chen (57321224600); Naama, Maria (57969901100); Shoval, Irit (25634529400); Yaron, Orly (57220352504); Karako-Lampert, Sarit (8221376300); Bel, Shai (37025474200); Yissachar, Nissan (13008478500)^57970591500; 57266289300; 7006188330; 7005572437; 57265949600; 57969661500; 57970360600; 57266061200; 57215692576; 57266635600; 55362650600; 57321224600; 57969901100; 25634529400; 57220352504; 8221376300; 37025474200; 13008478500^Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome^2022^Cell Reports^41.0^7^111657^^^^10^10.1016/j.celrep.2022.111657^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142157389&doi=10.1016%2fj.celrep.2022.111657&partnerID=40&md5=d686a7ed7a255ceabc805c2ae3263668^The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel; Department of Internal Medicine, Kaplan Medical Center, Rehovot, Israel; Hadassah Medical Center, the Hebrew University, Jerusalem, Israel; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel^Bootz-Maoz H., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Pearl A., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Melzer E., Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel, Hadassah Medical Center, the Hebrew University, Jerusalem, Israel; Malnick S., Department of Internal Medicine, Kaplan Medical Center, Rehovot, Israel, Hadassah Medical Center, the Hebrew University, Jerusalem, Israel; Sharon E., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Bennet Y., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Tsentsarevsky R., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Abuchatzera S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Amidror S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Aretz E., Department of Gastroenterology and Liver Disease, Kaplan Medical Center, Rehovot, Israel; Azriel S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Gam Ze Letova C., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Naama M., Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; Shoval I., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Yaron O., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Karako-Lampert S., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; Bel S., Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; Yissachar N., The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, 5290002, Israel^Changes in microbiome composition are associated with a wide array of human diseases, turning the human microbiota into an attractive target for therapeutic intervention. Yet, clinical translation of these findings requires the establishment of causative connections between specific microbial taxa and their functional impact on host tissues. Here, we infuse gut organ cultures with longitudinal microbiota samples collected from therapy-naive patients with irritable bowel syndrome (IBS) under a low-fermentable oligo-, di-, mono-saccharides and polyols (FODMAP) diet. We show that post-diet microbiota regulates intestinal expression of inflammatory and neuro-muscular gene sets. Specifically, we identify Bifidobacterium adolescentis as a diet-sensitive pathobiont that alters tight junction integrity and disrupts gut barrier functions. Collectively, we present a pathway discovery platform for mechanistic dissection and identification of functional diet-host-microbiota modules. Our data support the hypothesis that the gut microbiota mediates the beneficial effects of a low-FODMAP diet and reinforce the potential feasibility of microbiome-based therapies in IBS. © 2022 The Author(s)^CP: Microbiology; gut microbiota; intestinal epithelial barrier; irritable bowel syndrome; low-FODMAP diet^Diet, Carbohydrate-Restricted; Gastrointestinal Microbiome; Homeostasis; Humans; Irritable Bowel Syndrome; adult; animal cell; animal experiment; animal model; animal tissue; Article; Bifidobacterium adolescentis; clinical article; cohort analysis; colon; controlled study; enteritis; female; gene control; gene expression; gene set analysis; genetic association; homeostasis; human; human cell; intestine flora; irritable colon; longitudinal study; low FODMAP diet; male; microbial identification; microdissection; mouse; neuromuscular function; nonhuman; organ culture; regulator gene; signal transduction; species composition; tight junction; homeostasis; low carbohydrate diet^^^^^Gassner Fund for Medical Research, Israel; Broad Institute, (2615/18); Israel Science Foundation, ISF, (1384/18)^We thank Ron Unger for helpful advice, Sara Gerstein for assistance with organ cultures, the Mathis/Benoist lab for microbial strains, Shani Brown and Sondra Turjeman for critical editing of the manuscript, and members of the Yissachar lab for insightful discussions. This work was supported by the Israel Science Foundation (grant no. 1384/18 ), the Israel Science Foundation —Broad Institute Joint Program (grant no. 2615/18 ), and the Gassner Fund for Medical Research, Israel. ^Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajilic-Stojanovic M., Schemann M., Et al., Irritable bowel syndrome, Nat. Rev. Dis. Primers, 2, (2016); Palsson O.S., Whitehead W.E., van Tilburg M.A.L., Chang L., Chey W., Crowell M.D., Keefer L., Lembo A.J., Parkman H.P., Rao S.S., Et al., Rome IV diagnostic questionnaires and tables for investigators and clinicians, Gastroenterology, (2016); Mars R.A.T., Yang Y., Ward T., Houtti M., Priya S., Lekatz H.R., Tang X., Sun Z., Kalari K.R., Korem T., Et al., Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome, Cell, 182, pp. 1460-1473.e17, (2020); Moayyedi P., Simren M., Bercik P., Evidence-based and mechanistic insights into exclusion diets for IBS, Nat. Rev. Gastroenterol. Hepatol., 17, pp. 406-413, (2020); Altobelli E., Del Negro V., Angeletti P.M., Latella G., Low-FODMAP diet improves irritable bowel syndrome symptoms: a meta-analysis, Nutrients, 9, (2017); Staudacher H.M., Irving P.M., Lomer M.C.E., Whelan K., Mechanisms and efficacy of dietary FODMAP restriction in IBS, Nat. Rev. Gastroenterol. Hepatol., 11, pp. 256-266, (2014); Staudacher H.M., Whelan K., The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS, Gut, 66, pp. 1517-1527, (2017); Nanayakkara W.S., Skidmore P.M., O'Brien L., Wilkinson T.J., Gearry R.B., Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date, Clin. Exp. Gastroenterol., 9, pp. 131-142, (2016); Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G., Diets that differ in their FODMAP content alter the colonic luminal microenvironment, Gut, 64, pp. 93-100, (2015); Hustoft T.N., Hausken T., Ystad S.O., Valeur J., Brokstad K., Hatlebakk J.G., Lied G.A., Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome, Neuro Gastroenterol. Motil., 29, (2017); McIntosh K., Reed D.E., Schneider T., Dang F., Keshteli A.H., De Palma G., Madsen K., Bercik P., Vanner S., FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial, Gut, 66, pp. 1241-1251, (2017); Bennet S.M.P., Bohn L., Storsrud S., Liljebo T., Collin L., Lindfors P., Tornblom H., Ohman L., Simren M., Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs, Gut, 67, pp. 872-881, (2018); Yissachar N., Zhou Y., Ung L., Lai N.Y., Mohan J.F., Ehrlicher A., Weitz D.A., Kasper D.L., Chiu I.M., Mathis D., Benoist C., An intestinal organ culture system uncovers a role for the nervous system in microbe-immune crosstalk, Cell, 168, pp. 1135-1148.e12, (2017); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut microbiota in patients with irritable bowel syndrome-A systematic review, Gastroenterology, 157, pp. 97-108, (2019); Staudacher H.M., Lomer M.C.E., Anderson J.L., Barrett J.S., Muir J.G., Irving P.M., Whelan K., Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome, J. Nutr., 142, pp. 1510-1518, (2012); Staudacher H.M., Lomer M.C.E., Farquharson F.M., Louis P., Fava F., Franciosi E., Scholz M., Tuohy K.M., Lindsay J.O., Irving P.M., Whelan K., A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and A probiotic restores Bifidobacterium species: a randomized controlled trial, Gastroenterology, 153, pp. 936-947, (2017); Duscha A., Gisevius B., Hirschberg S., Yissachar N., Stangl G.I., Eilers E., Bader V., Haase S., Kaisler J., David C., Et al., Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism, Cell, 180, pp. 1067-1080.e16, (2020); Zhou Y., Zhou B., Pache L., Chang M., Khodabakhshi A.H., Tanaseichuk O., Benner C., Chanda S.K., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets, Nat. Commun., 10, (2019); Tan T.G., Sefik E., Geva-Zatorsky N., Kua L., Naskar D., Teng F., Pasman L., Ortiz-Lopez A., Jupp R., Wu H.-J.J., Et al., Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice, Proc. Natl. Acad. Sci. USA, 113, pp. E8141-E8150, (2016); Eftychi C., Schwarzer R., Vlantis K., Wachsmuth L., Basic M., Wagle P., Neurath M.F., Becker C., Bleich A., Pasparakis M., Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment, Immunity, 51, pp. 367-380.e4, (2019); Atarashi K., Tanoue T., Ando M., Kamada N., Nagano Y., Narushima S., Suda W., Imaoka A., Setoyama H., Nagamori T., Et al., Th17 cell induction by adhesion of microbes to intestinal epithelial cells, Cell, 163, pp. 367-380, (2015); Zhou S.-Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J. Clin. Invest., 128, pp. 267-280, (2018); Mazmanian S.K., Round J.L., Kasper D.L., A microbial symbiosis factor prevents intestinal inflammatory disease, Nature, 453, pp. 620-625, (2008); Tsai P.-Y., Zhang B., He W.-Q., Zha J.-M., Odenwald M.A., Singh G., Tamura A., Shen L., Sailer A., Yeruva S., Et al., IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance, Cell Host Microbe, 21, pp. 671-681.e4, (2017); Johansson M.E.V., Phillipson M., Petersson J., Velcich A., Holm L., Hansson G.C., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Proc. Natl. Acad. Sci. USA, 105, pp. 15064-15069, (2008); Yu R., Zuo F., Ma H., Chen S., Exopolysaccharide-producing Bifidobacterium adolescentis strains with similar adhesion property induce differential regulation of inflammatory immune response in Treg/Th17 Axis of DSS-colitis mice, Nutrients, 11, (2019); Fanning S., Hall L.J., Cronin M., Zomer A., MacSharry J., Goulding D., Motherway M.O., Shanahan F., Nally K., Dougan G., van Sinderen D., Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection, Proc. Natl. Acad. Sci. USA, 109, pp. 2108-2113, (2012); Hughes K.R., Harnisch L.C., Alcon-Giner C., Mitra S., Wright C.J., Ketskemety J., van Sinderen D., Watson A.J.M., Hall L.J., Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner, Open Biol., 7, (2017); Kaminsky L.W., Al-Sadi R., Ma T.Y., IL-1β and the intestinal epithelial tight junction barrier, Front. Immunol., 12, (2021); Cox S.R., Lindsay J.O., Fromentin S., Stagg A.J., McCarthy N.E., Galleron N., Ibraim S.B., Roume H., Levenez F., Pons N., Et al., Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial, Gastroenterology, 158, pp. 176-188.e7, (2020); Zeevi D., Korem T., Zmora N., Israeli D., Rothschild D., Weinberger A., Ben-Yacov O., Lador D., Avnit-Sagi T., Lotan-Pompan M., Et al., Personalized nutrition by prediction of glycemic responses, Cell, 163, pp. 1079-1094, (2015); Rothschild D., Weissbrod O., Barkan E., Kurilshikov A., Korem T., Zeevi D., Costea P.I., Godneva A., Kalka I.N., Bar N., Et al., Environment dominates over host genetics in shaping human gut microbiota, Nature, 555, pp. 210-215, (2018); El-Salhy M., Hatlebakk J.G., Gilja O.H., Brathen Kristoffersen A., Hausken T., Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study, Gut, 69, pp. 859-867, (2020); Valdez-Palomares F., Nambo-Venegas R., Uribe-Garcia J., Mendoza-Vargas A., Granados-Portillo O., Meraz-Cruz N., Palacios-Gonzalez B., Intestinal microbiota fingerprint in subjects with irritable bowel syndrome responders to a low FODMAP diet, Food Funct., 12, pp. 3206-3218, (2021); Santacruz A., Marcos A., Warnberg J., Marti A., Martin-Matillas M., Campoy C., Moreno L.A., Veiga O., Redondo-Figuero C., Garagorri J.M., Et al., Interplay between weight loss and gut microbiota composition in overweight adolescents, Obesity, 17, pp. 1906-1915, (2009); Modesto M., Checcucci A., Mattarelli P., Identification of bifidobacteria by the phosphoketolase assay, Methods Mol. Biol., 2278, pp. 141-148, (2021); Febbraio M.A., Karin M., “Sweet death”: fructose as a metabolic toxin that targets the gut-liver axis, Cell Metab., 33, pp. 2316-2328, (2021); Herman M.A., Birnbaum M.J., Molecular aspects of fructose metabolism and metabolic disease, Cell Metab., 33, pp. 2329-2354, (2021); Todoric J., Di Caro G., Reibe S., Henstridge D.C., Green C.R., Vrbanac A., Ceteci F., Conche C., McNulty R., Shalapour S., Et al., Fructose stimulated de novo lipogenesis is promoted by inflammation, Nat. Metab., 2, pp. 1034-1045, (2020); Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N., Costa F.R.C., Tiniakou E., Greiling T., Ruff W., Et al., Translocation of a gut pathobiont drives autoimmunity in mice and humans, Science, 359, pp. 1156-1161, (2018); Thaiss C.A., Levy M., Grosheva I., Zheng D., Soffer E., Blacher E., Braverman S., Tengeler A.C., Barak O., Elazar M., Et al., Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection, Science, 359, pp. 1376-1383, (2018); Buckley A., Turner J.R., Cell biology of tight junction barrier regulation and mucosal disease, Cold Spring Harb. Perspect. Biol., 10, (2018); Luissint A.-C., Parkos C.A., Nusrat A., Inflammation and the intestinal barrier: leukocyte-epithelial cell interactions, cell junction remodeling, and mucosal repair, Gastroenterology, 151, pp. 616-632, (2016); Khor B., Gardet A., Xavier R.J., Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, pp. 307-317, (2011); Clemente M.G., De Virgiliis S., Kang J.S., Macatagney R., Musu M.P., Di Pierro M.R., Drago S., Congia M., Fasano A., Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function, Gut, 52, pp. 218-223, (2003); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Aguilera-Lizarraga J., Florens M.V., Viola M.F., Jain P., Decraecker L., Appeltans I., Cuende-Estevez M., Fabre N., Van Beek K., Perna E., Et al., Local immune response to food antigens drives meal-induced abdominal pain, Nature, 590, pp. 151-156, (2021); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., Et al., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Umeh G., Miranda P.M., Pigrau Pastor M., Sidani S., Et al., Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice, Sci. Transl. Med., 9, (2017); DeSantis T.Z., Hugenholtz P., Larsen N., Rojas M., Brodie E.L., Keller K., Huber T., Dalevi D., Hu P., Andersen G.L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Appl. Environ. Microbiol., 72, pp. 5069-5072, (2006); Parks D.H., Chuvochina M., Rinke C., Mussig A.J., Chaumeil P.-A., Hugenholtz P., GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy, Nucleic Acids Res., 50, pp. D785-D794, (2022); Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P., Peplies J., Glockner F.O., The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res., 41, pp. D590-D596, (2013); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, (2014); Drossman D.A., Hasler W.L., Rome IV—functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther., 11, pp. 395-402, (1997); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol., 32, pp. 920-924, (1997); Matsuki T., Watanabe K., Tanaka R., Oyaizu H., Rapid identification of human intestinal bifidobacteria by 16S rRNA-targeted species- and group-specific primers, FEMS Microbiol. Lett., 167, pp. 113-121, (1998); Salter S.J., Cox M.J., Turek E.M., Calus S.T., Cookson W.O., Moffatt M.F., Turner P., Parkhill J., Loman N.J., Walker A.W., Reagent and laboratory contamination can critically impact sequence-based microbiome analyses, BMC Biol., 12, (2014); Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R., STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, pp. 15-21, (2013); Anders S., Pyl P.T., Huber W., HTSeq–a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, pp. 166-169, (2015); Howe K.L., Achuthan P., Allen J., Allen J., Alvarez-Jarreta J., Amode M.R., Armean I.M., Azov A.G., Bennett R., Bhai J., Et al., Ensembl 2021, Nucleic Acids Res., 49, pp. D884-D891, (2021); Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, pp. 15545-15550, (2005)^N. Yissachar; The Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel; email: nissan.yissachar@biu.ac.il^^Elsevier B.V.^^^^^^22111247^^^36384106.0^English^Cell Rep.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85142157389
Xu W.; Zhang Z.; Lu Y.; Li M.; Li J.; Tao W.^Xu, Weidong (57454238900); Zhang, Zhiyi (57453877000); Lu, Ye (57979814700); Li, Mengxi (57979262800); Li, Jiayao (57216911717); Tao, Wenhua (57219926856)^57454238900; 57453877000; 57979814700; 57979262800; 57216911717; 57219926856^Traditional Chinese medicine Tongxie Yaofang treating irritable bowel syndrome with diarrhea and type 2 diabetes mellitus in rats with liver-depression and spleen-deficiency: A preliminary study^2022^Frontiers in Nutrition^9.0^^968930^^^^9^10.3389/fnut.2022.968930^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142520790&doi=10.3389%2ffnut.2022.968930&partnerID=40&md5=686ba5df33f554a46f381d62279875fb^Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China; School of Pharmacy, Jiangsu University, Zhenjiang, China^Xu W., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China, School of Pharmacy, Jiangsu University, Zhenjiang, China; Zhang Z., School of Pharmacy, Jiangsu University, Zhenjiang, China; Lu Y., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China, School of Pharmacy, Jiangsu University, Zhenjiang, China; Li M., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China; Li J., School of Pharmacy, Jiangsu University, Zhenjiang, China; Tao W., Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China^Tongxie Yaofang (TXYF), a Traditional Chinese Medicine (TCM) with four components as follows: Rhizoma Atractylodis Macrocephalae (baizhu), Radix Paeoniae Alba (baishao), Pericarpium Citri Reticulatae (chenpi) and Radix Saposhnikovia Divaricata (fangfeng), benefits irritable bowel syndrome (IBS). Nonetheless, proofs of this formula ameliorating D-IBS and T2DM are required. This research aimed at investigating the efficacy of TXYF in treating inflammation in rats with D-IBS and T2DM using animal models. In this study, gavage with high-fat diet, fasciculation, and senna was given to develop rat models with target diseases. To determine intestinal inflammations, major inflammatory factors, and intestinal permeability proteins, H&E staining, ELISA, and immunohistochemistry methods were employed, respectively. This study also utilized Western blot to discover potential inflammatory targets. Results of this research illustrates that TXYF treatment reduced the level of TNF-α, IL-1β, and IL-6, and raised the IL-10 concentration in liver-depressed spleende ficient rats with D-IBS and T2DM, indicating controlled inflammatory reactions. Staining analysis also showed improved disease states of animal models. Furthermore, efficient rebounds of claudin-1, an intestinal permeability-associated protein, were detected. Moreover, TXYF may treat D-IBS and T2DM in rats via the rage pathway. Copyright © 2022 Xu, Zhang, Lu, Li, Li and Tao.^D-IBS; inflammation; RAGE; T2DM; TXYF^^^^^^National Natural Science Foundation of China, NSFC, (81904166)^This study was funded by the National Natural Science Foundation of China (81904166). ^Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea predominant-irritable bowel syndrome (IBS-D): effects of different nutritional patterns on intestinal dysbiosis and symptoms, Nutrients, 13, 1506, (2021); Wang H., Zhou G., Luo L., Crusius J.B.A., Yuan A., Kou J., Et al., Serological screening for celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome, Medicine (Baltimore), 94, e1779, (2015); Devanarayana N.M., Rajindrajith S., Pathmeswaran A., Abegunasekara C., Gunawardena N.K., Benninga M.A., Epidemiology of irritable bowel syndrome in children and adolescents in Asia, J Pediatr Gastroenterol Nutr, 60, pp. 792-798, (2015); Wei X., Chen M., Wang J., The epidemiology of irritable bowel syndrome and functional constipation of Guangzhou residents, Zhonghua Nei Ke Za Zhi, 40, pp. 517-520, (2001); Gao H.X., Regier E.E., Close K.L., International diabetes federation world diabetes congress 2015, J Diabetes, 8, pp. 300-302, (2016); Gulcan E., Taser F., Toker A., Korkmaz U., Alcelik A., Increased frequency of prediabetes in patients with irritable bowel syndrome, Am J Med Sci, 338, pp. 116-119, (2009); Tao W.-H., Correlation between irritable bowel syndrome and diabetes, World Chin J Dig, 24, pp. 1770-1774, (2016); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Inai T., Kobayashi J., Shibata Y., Claudin-1 contributes to the epithelial barrier function in MDCK cells, Eur J Cell Biol, 78, pp. 849-855, (1999); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Et al., Intestinal permeability–a new target for disease prevention and therapy, BMC Gastroenterol, 14, 189, (2014); Coeffier M., Dechelotte P., Ducrotte P., Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation?, Gastroenterology, 148, pp. 1079-1080, (2015); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Et al., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment Pharmacol Ther, 40, pp. 288-297, (2014); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, J Gastroenterol, 49, pp. 1467-1476, (2014); Hirabara S.M., Gorjao R., Vinolo M.A., Rodrigues A.C., Nachbar R.T., Curi R., Molecular targets related to inflammation and insulin resistance and potential interventions, J Biomed Biotechnol, 2012, (2012); Maynard C.L., Weaver C.T., Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation, Immunol Rev, 226, pp. 219-233, (2008); Wang H., Shi P., Zuo L., Dong J., Zhao J., Liu Q., Et al., Dietary non-digestible polysaccharides ameliorate intestinal epithelial barrier dysfunction in IL-10 knockout mice, J Crohns Colitis, 10, pp. 1076-1086, (2016); Boontanrart M., Hall S.D., Spanier J.A., Hayes C.E., Olson J.K., Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism, J Neuroimmunol, 292, pp. 126-136, (2016); Hua M.C., Lai M.W., Kuo M.L., Yao T.C., Huang J.L., Chen S.M., Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 52, pp. 376-381, (2011); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Martinez-Garcia R., Gutierrez-Ruiz M.C., Et al., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am J Gastroenterol, 107, pp. 747-753, (2012); Acharya A.B., Thakur S., Muddapur M.V., Evaluation of serum interleukin-10 levels as a predictor of glycemic alteration in chronic periodontitis and type 2 diabetes mellitus, J Indian Soc Periodontol, 19, pp. 388-392, (2015); Wang S.S., Wang X.R., Yang R.Y., Xu Y., Li M.Y., [Efficacy and mechanism of acupuncture combined with tongxieyaofang for diarrhea-type irritable bowel syndrome of liver depression and spleen deficiency], Zhongguo Zhen Jiu, 40, pp. 605-609, (2020); Zhang J., Deng H., Bai J., Zhou X., Zhao Y., Zhu Y., Et al., Health-promoting properties of barley: a review of nutrient and nutraceutical composition, functionality, bioprocessing, and health benefits, Crit Rev Food Sci Nutr, (2022); Li M., Bao X., Zhang X., Ren H., Cai S., Hu X., Et al., Exploring the phytochemicals and inhibitory effects against α-glucosidase and dipeptidyl peptidase-IV in Chinese pickled chili pepper: insights into mechanisms by molecular docking analysis, LWT, 162, (2022); Aziz M.N.M., Kumar J., Muhammad Nawawi K.N., Raja Ali R.A., Mokhtar N.M., Irritable bowel syndrome, depression, and neurodegeneration: a bidirectional communication from gut to Brain, Nutrients, 13, 3061, (2021); Vahora I.S., Tsouklidis N., Kumar R., Soni R., Khan S., How serotonin level fluctuation affects the effectiveness of treatment in irritable bowel syndrome, Cureus, 12, e9871, (2020); Vincenzi A., Goettert M.I., Volken de Souza C.F., An evaluation of the effects of probiotics on tumoral necrosis factor (TNF-alpha) signaling and gene expression, Cytokine Growth Factor Rev, 57, pp. 27-38, (2021); Yang W.L., Chen S.Y., Ho C.Y., Yen G.C., Citrus flavonoids suppress IL-5 and ROS through distinct pathways in PMA/ionomycin-induced EL-4 cells, Food Funct, 11, pp. 824-833, (2020); Cai H., Xu Y., Xie L., Duan Y., Zhou J., Liu J., Et al., Investigation on spectrum-effect correlation between constituents absorbed into blood and bioactivities of baizhu shaoyao San before and after processing on ulcerative colitis rats by UHPLC/Q-TOF-MS/MS coupled with gray correlation analysis, Molecules, 24, 940, (2019); Zhou Y., Tao H., Wang A., Zhong Z., Wu X., Wang M., Et al., Chinese herb pair paeoniae radix alba and atractylodis macrocephalae rhizoma suppresses LPS-induced inflammatory response through inhibiting MAPK and NF-kappaB pathway, Chin Med, 14, 2, (2019); Shang Z., Li M., Zhang W., Cai S., Hu X., Yi J., Analysis of phenolic compounds in pickled chayote and their effects on antioxidant activities and cell protection, Food Res Int, 157, (2022); Body-Malapel M., Djouina M., Waxin C., Langlois A., Gower-Rousseau C., Zerbib P., Et al., The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for inflammatory bowel diseases, Mucosal Immunol, 12, pp. 468-478, (2019); Schmidt A.M., Yan S.D., Yan S.F., Stern D.M., The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses, J Clin Investig, 108, pp. 949-955, (2001)^W. Tao; Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China; email: taowh@ujs.edu.con^^Frontiers Media S.A.^^^^^^2296861X^^^^English^Front. Nutr.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85142520790
Linsalata M.; Riezzo G.; Orlando A.; D’Attoma B.; Prospero L.; Ignazzi A.; Losurdo G.; Di Leo A.; Giannelli G.; Russo F.^Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); Orlando, Antonella (23767683100); D’Attoma, Benedetta (57205751185); Prospero, Laura (57207799778); Ignazzi, Antonia (57206193613); Losurdo, Giuseppe (56516483500); Di Leo, Alfredo (56962705200); Giannelli, Gianluigi (7005015716); Russo, Francesco (59133987100)^6603600075; 7004144336; 23767683100; 57205751185; 57207799778; 57206193613; 56516483500; 56962705200; 7005015716; 59133987100^The Role of Intestinal Barrier Function in Overweight Patients with IBS with Diarrhea Undergoing a Long-Term Low Fermentable Oligo-, Di-, and Monosaccharide and Polyol Diet^2023^Nutrients^15.0^21^4683^^^^0^10.3390/nu15214683^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176903096&doi=10.3390%2fnu15214683&partnerID=40&md5=1ec6663ab1a7417938956356e76afd22^Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, 70124, Italy; Scientific Direction, National Institute of Gastroenterology IRCCS “S. de Bellis”, Metropolitan, 70013, Italy^Linsalata M., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Riezzo G., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Orlando A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; D’Attoma B., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Prospero L., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Ignazzi A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; Losurdo G., Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, 70124, Italy; Di Leo A., Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, 70124, Italy; Giannelli G., Scientific Direction, National Institute of Gastroenterology IRCCS “S. de Bellis”, Metropolitan, 70013, Italy; Russo F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy^Overweight and obesity have been suggested as significant factors in irritable bowel syndrome (IBS) development. However, the relationship between overweight/obesity and IBS is unclear. It is known that a modified intestinal barrier, especially the permeability of the small intestine (s-IP), can play a significant role in the pathogenesis of both obesity and IBS. Moreover, dietary interventions are essential for treating both pathologies. We evaluated the gastrointestinal (GI) symptoms and the urinary and circulating markers of GI barrier function and integrity, the markers of intestinal dysbiosis and bacterial translocation, in 40 IBS patients with predominant diarrhea (IBS-D) (32 females and 8 males; mean age = 43.5 ± 1.4 years), categorized using their Body Mass Index levels as normal (NW) and overweight (OW). Evaluations were performed before and after 12 weeks of a Low FODMAP Diet (LFD). At the baseline, OW patients showed a significantly higher s-IP than NW. After an LFD, a significant improvement of s-IP in OW patients occurred, along with a significant decrease in markers of epithelial integrity and bacterial translocation. Our findings highlight the close relationship between overweight and the intestinal barrier and support their involvement in IBS-D pathophysiology. Furthermore, the positive role of an LFD in managing overweight IBS-D was highlighted. © 2023 by the authors.^gastrointestinal symptoms; intestinal barrier; irritable bowel syndrome; low FODMAP diet; overweight^Adult; Diarrhea; Diet; Disaccharides; Female; Fermentation; Humans; Irritable Bowel Syndrome; Male; Monosaccharides; Obesity; Oligosaccharides; Overweight; amine oxidase (copper containing); biological marker; fatty acid binding protein 2; indican; lipopolysaccharide; tight junction protein; unclassified drug; zonulin; disaccharide; monosaccharide; oligosaccharide; polyol; abdominal distension; abdominal pain; adult; age; Article; attitude assessment; bacterial translocation; body mass; Bristol stool form scale; caloric intake; case control study; clinical evaluation; cohort analysis; comparative study; controlled clinical trial; controlled study; defecation habit; diarrhea; digestive system disease assessment; disease severity assessment; dysbiosis; energy expenditure; female; gastrointestinal symptom; gastrointestinal symptom rating scale; gender; human; IBS diet adherence report scale; IBS symptom severity scale; intestine function; intestine mucosa permeability; irritable bowel syndrome with diarrhea; irritable colon; long term care; low FODMAP diet; major clinical study; male; obese patient; obesity; pain intensity; quality of life; small intestine; complication; diarrhea; diet; fermentation; irritable colon; microbiology; obesity^^amine oxidase (copper containing), 9001-53-0, 9014-75-9; indican, 1336-79-4, 487-94-5; Disaccharides, ; Monosaccharides, ; Oligosaccharides, ; polyol, ^2005 Stata Statistical software release 9, StataCorp, United States; Bodygram PLUS Software v. 1.0, akern, Italy; SECA mod. 220, Intermed, Italy; SECA mod. 700, Intermed, Italy; mod-201 SECA tape^Intermed, Italy; Intermed, Italy; StataCorp, United States; akern, Italy^Italian Ministry of Health RC 2020, (2020012064, 700/2020)^This research was funded by the Italian Ministry of Health RC 2020–2021, Prog. N° 16 (DDG n. 700/2020) Workflow ID n. 2020012064—1 December 2020.^Camilleri M., Diagnosis and Treatment of Irritable Bowel Syndrome: A Review, JAMA, 325, pp. 865-877, (2021); Yanping W., Gao X., Cheng Y., Liu M., Liao S., Zhou J., Hao J., Jiang G., Lu Y., Qu T., Et al., The interaction between obesity and visceral hypersensitivity, J. Gastroenterol. Hepatol, 38, pp. 370-377, (2023); Pickett-Blakely O., Obesity and irritable bowel syndrome: A comprehensive review, Gastroenterol Hepatol, 10, pp. 411-416, (2014); Pugliese G., Muscogiuri G., Barrea L., Laudisio D., Savastano S., Colao A., Irritable bowel syndrome: A new therapeutic target when treating obesity?, Hormones, 18, pp. 395-399, (2019); Rusu F., Obesity and irritable bowel syndrome: Coincidence or association?, J. Gastrointest. Liver Dis, 27, (2018); Svedberg P., Johansson S., Wallander M., Hamelin B., Pedersen N.L., Extra-intestinal manifestations associated with irritable bowel syndrome: A twin study, Aliment. Pharmacol. Ther, 16, pp. 975-983, (2002); Aasbrenn M., Hogestol I., Eribe I., Kristinsson J., Lydersen S., Mala T., Farup P.G., Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: A cross-sectional study, BMC Obes, 4, (2017); Sherwin L.B., Ozoji O.M., Boulineaux C.M., Joseph P.V., Fourie N.H., Abey S.K., Zhang X., Henderson W.A., Gender and Weight Influence Quality of Life in Irritable Bowel Syndrome, J. Clin. Med, 6, (2017); Akhondi N., Montazerin S.M., Soltani S., Saneei P., Keshteli A.H., Esmaillzadeh A., Adibi P., General and abdominal obesity in relation to the prevalence of irritable bowel syndrome, Neurogastroenterol. Motil, 31, (2019); Seethaler B., Basrai M., Neyrinck A.M., Nazare J.-A., Walter J., Delzenne N.M., Bischoff S.C., Biomarkers for assessment of intestinal permeability in clinical practice, Am. J. Physiol. Liver Physiol, 321, pp. G11-G17, (2021); Farre R., Fiorani M., Abdu Rahiman S., Matteoli G., Intestinal Permeability, Inflammation and the Role of Nutrients, Nutrients, 12, (2020); Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., Ardid D., Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment. Pharmacol. Ther, 36, pp. 1009-1031, (2012); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: A systematic review, Ther. Adv. Gastroenterol, 14, (2021); Linsalata M., Riezzo G., Clemente C., D'attoma B., Russo F., Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update, Dis. Markers, 2020, (2020); Chelakkot C., Ghim J., Ryu S.H., Mechanisms regulating intestinal barrier integrity and its pathological implications, Exp. Mol. Med, 50, pp. 1-9, (2018); Damms-Machado A., Louis S., Schnitzer A., Volynets V., Rings A., Basrai M., Bischoff S.C., Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction, Am. J. Clin. Nutr, 105, pp. 127-135, (2017); Sadik R., Bjornsson E., Simren M., The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome, Eur. J. Gastroenterol. Hepatol, 22, pp. 102-108, (2010); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Fasano A., Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer, Physiol. Rev, 91, pp. 151-175, (2011); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid–binding protein with severity of disease in patient with heat stroke, Am. J. Emerg. Med, 33, pp. 867-871, (2015); Inczefi O., Bacsur P., Resal T., Keresztes C., Molnar T., The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease, Front. Nutr, 9, (2022); Aasbrenn M., Lydersen S., Farup P.G., A Conservative Weight Loss Intervention Relieves Bowel Symptoms in Morbidly Obese Subjects with Irritable Bowel Syndrome: A Prospective Cohort Study, J. Obes, 2018, (2018); Linsalata M., Riezzo G., Orlando A., D'attoma B., Prospero L., Tutino V., Notarnicola M., Russo F., The Relationship between Low Serum Vitamin D Levels and Altered Intestinal Barrier Function in Patients with IBS Diarrhoea Undergoing a Long-Term Low-FODMAP Diet: Novel Observations from a Clinical Trial, Nutrients, 13, (2021); Svedlund J., Sjodin I., Dotevall G., GSRS–A Clinical Rating Scale for Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease, Dig. Dis. Sci, 33, pp. 129-134, (1988); Schmulson M.J., A Drossman D., What Is New in Rome IV, J. Neurogastroenterol. Motil, 23, pp. 151-163, (2017); Verdu E.F., Armstrong D., A Murray J., Between Celiac Disease and Irritable Bowel Syndrome: The “No Man’s Land” of Gluten Sensitivity, Am. J. Gastroenterol, 104, pp. 1587-1594, (2009); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 44, pp. 693-703, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Minguez Perez M., Benages Martinez A., The Bristol scale—A useful system to assess stool form?, Rev. Esp. Enferm. Dig, 101, pp. 305-311, (2009); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D'attoma B., De Nunzio V., Et al., Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective, Nutrients, 12, (2020); Khalil S.F., Mohktar M.S., Ibrahim F., The Theory and Fundamentals of Bioimpedance Analysis in Clinical Status Monitoring and Diagnosis of Diseases, Sensors, 14, pp. 10895-10928, (2014); Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Munkholm P., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet, World J. Gastroenterol, 22, pp. 4009-4019, (2016); The Monash University Low FODMAP App, (2017); Hilsden R., Meddings J., Sutherland L., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease, Gastroenterology, 110, pp. 1395-1403, (1996); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur. J. Nutr, 58, pp. 2145-2156, (2018); Emerenziani S., Guarino M.P.L., Asensio L.M.T., Altomare A., Ribolsi M., Balestrieri P., Cicala M., Role of Overweight and Obesity in Gastrointestinal Disease, Nutrients, 12, (2019); Mansueto P., Soresi M., La Blasca F., Fayer F., D'alcamo A., Carroccio A., Body Mass Index and Associated Clinical Variables in Patients with Non-Celiac Wheat Sensitivity, Nutrients, 11, (2019); Gasmi A., Mujawdiya P.K., Pivina L., Dosa A., Semenova Y., Benahmed A.G., Bjorklund G., Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity, Curr. Med. Chem, 28, pp. 827-839, (2021); Bashir M., Meddings J., Alshaikh A., Jung D., Le K., Amin R., Ratakonda S., Sharma S., Granja I., Satti M., Et al., Enhanced gastrointestinal passive paracellular permeability contributes to the obesity-associated hyperoxaluria, Am. J. Physiol. Liver Physiol, 316, pp. G1-G14, (2019); Bull M.J., Plummer N.T., Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis, Integr. Med, 14, pp. 25-33, (2015); Sarmiento-Andrade Y., Suarez R., Quintero B., Garrochamba K., Chapela S.P., Gut microbiota and obesity: New insights, Front. Nutr, 9, (2022); Ajamian M., Rosella G., Newnham E.D., Biesiekierski J.R., Muir J.G., Gibson P.R., Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity, Mol. Nutr. Food Res, 65, (2020); Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M., Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs, World J. Gastroenterol, 23, pp. 4632-4643, (2017); Tahapary D.L., Fatya A.I., Kurniawan F., Marcella C., Rinaldi I., Tarigan T.J.E., Harbuwono D.S., Yunir E., Soewondo P., Purnamasari D., Increased intestinal-fatty acid binding protein in obesity-associated type 2 diabetes mellitus, PLoS ONE, 18, (2023); Altomare A., Di Rosa C., Imperia E., Emerenziani S., Cicala M., Guarino M.P.L., Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms, Nutrients, 13, (2021)^F. Russo; Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “S. de Bellis, Metropolitan, 70013, Italy; email: francesco.russo@irccsdebellis.it^^Multidisciplinary Digital Publishing Institute (MDPI)^^^^^^20726643^^^37960336.0^English^Nutrients^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85176903096
Peruhova M.; Mihova A.; Altankova I.; Velikova T.^Peruhova, Milena (57219107674); Mihova, Antoaneta (6507547182); Altankova, Iskra (6603179662); Velikova, Tsvetelina (55987966500)^57219107674; 6507547182; 6603179662; 55987966500^Specific Immunoglobulin E and G to Common Food Antigens and Increased Serum Zonulin in IBS Patients: A Single-Center Bulgarian Study^2022^Antibodies^11.0^2^23^^^^2^10.3390/antib11020023^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128463512&doi=10.3390%2fantib11020023&partnerID=40&md5=f6980f266827285d7d2aa9d560389a32^Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria^Peruhova M., Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Mihova A., Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Altankova I., Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; Velikova T., Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria^Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder whose pathogenesis is considered multifactorial, including abnormal gut motility, visceral hyperreactivity, psychological factors, disturbances in the brain-gut axis, leaky gut, oxidative stress, etc. We aimed to investigate serum levels of specific immunoglobulin E and G to common food antigens and zonulin and to assess their use in clinical practice for patients with IBS. Material and methods. We included 23 participants, 15 with IBS (diagnosed according to the Rome IV criteria) and 8 healthy controls. We investigated serum levels of specific IgG antibodies to 24 food antigens, specific IgE antibodies to 20 food antigens, anti-celiac antibodies, fecal calprotectin and serum zonulin by ELISA. Results. Food-specific positive IgG antibodies were significantly higher in patients with IBS than in controls (p = 0.007). IgE-mediated allergic reactions were found in five patients with IBS; no one had anti-TG antibodies. One-third of IBS patients demonstrated a low degree of chronic inflammation (positive fecal calprotectin test > 50 ng/mL) without specific bacterial infection. Serum levels of zonulin in IBS patients were higher than in healthy controls (0.378 ± 0.13 vs. 0.250 ± 0.14 ng/mL, p = 0.0315). However, no correlations between clinical symptoms and zonulin levels were found. Conclusion. The mechanisms of IgG hypersensitivity and low degree inflammation in IBS and elevated zonulin may contribute to multifactor pathogenesis in IBS. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.^IgE-mediated hypersensitivity; IgG-mediated hypersensitivity; irritable bowel syndrome; leaky gut; zonulin^calgranulin; Clostridium difficile toxin A; Clostridium difficile toxin B; food antigen; gliadin; gliadin antibody; immunoglobulin E; immunoglobulin G; probiotic agent; protein; unclassified drug; Zonulin; abdominal pain; adult; anxiety; Article; bacterial infection; blood sampling; brain-gut axis; clinical article; constipation; diarrhea; enzyme linked immunosorbent assay; fatigue; female; flatulence; headache; Helicobacter pylori; human; immune deficiency; immunoaffinity chromatography; immunoblotting; immunoglobulin blood level; insomnia; irritable colon; male; migraine; nausea and vomiting; oxidative stress; pruritus; questionnaire; rash; retrospective study; urticaria^^gliadin, 9007-90-3; immunoglobulin E, 37341-29-0; immunoglobulin G, 97794-27-9, 308067-58-5; protein, 67254-75-5^^^University Hospitals, UH, (80-10-160/25.04.2018); Sofia University^Funding: This research was funded by Sofia University St. Kliment Ohridski and supported by the University Hospital “Lozenetz”, grant number № 80-10-160/25.04.2018.^Balmus I.-M., Ilie O.-D., Ciobica A., Cojocariu R.-O., Stanciu C., Trifan A., Cimpeanu M., Cimpeanu C., Gorgan L., Irritable Bowel Syndrome between Molecular Approach and Clinical Expertise—Searching for Gap Fillers in the Oxidative Stress Way of Thinking, Medicina, 56, (2020); Li F.X., Patten S.B., Hilsden R.J., Sutherland L.R., Irritable bowel syndrome and health-related quality of life: A population-based study in Calgary, Alberta, Can. J. Gastroenterol. Hepatol, 17, pp. 259-263, (2003); Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis, Clin. Gastroenterol. Hepatol, 10, pp. 712-721, (2012); Foxx-Orenstein A.E., New and emerging therapies for the treatment of irritable bowel syndrome: An update for gastroenterologists, Ther. Adv. Gastroenterol, 9, pp. 354-375, (2016); Adriani A., Ribaldone D.G., Astegiano M., Durazzo M., Saracco G.M., Pellicano R., Irritable bowel syndrome: The clinical approach, Panminerva Med, 60, pp. 213-222, (2018); Choung R.S., Talley N.J., Food Allergy and Intolerance in IBS, Gastroenterol. Hepatol, 2, pp. 756-760, (2006); Elsenbruch S., Abdominal pain in irritable bowel syndrome: A review of putative psychological, neural and neuro-immune mechanisms, Brain Behav. Immun, 25, pp. 386-394, (2011); Velikova T., Kukov A., Georgieva V., Peruhova M., Yurukova N., Mihova A., Mehandziyska-Marinova T., Mizgova G., Terzieva V., Zhelezova G., Et al., Methods for detection of food intolerance, Recent Adv. Food Sci, 1, pp. 106-119, (2018); Dainese R., Galliani E.A., De Lazzari F., Leo V.D., Naccarato R., Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients, Am. J. Gastroenterol, 94, pp. 1892-1897, (1999); Gwynn C.M., Smith J.M., Leon G.L., Stanworth D.R., Role of IgG4 subclass in childhood allergy, Lancet, 1, pp. 910-911, (1978); Husby S., Oxelius V.A., Teisner B., Jensenius J.C., Svehag S.-E., Humoral immunity to dietary antigens in healthy adults. Occurrence, isotype and IgG subclass distribution of serum antibodies to protein antigens, Int. Arch. Allergy Appl. Immunol, 77, pp. 416-422, (1985); Barnes R.M., Harvey M.M., Blears J., Finn R., Johnson P., IgG subclass of human serum antibodies reactive with dietary proteins, Int. Arch. Allergy Appl. Immunol, 81, pp. 141-147, (1986); Hunter J.O., Food elimination in IBS: The case for IgG testing remains doubtful, Gut, 54, (2005); Barnes R.M., Lewis-Jones M.S., Allan S., Dixon T.A., Vickers C.F.H., Development and isotype diversity of antibodies to inhalant and dietary antigens in childhood atopic eczema, Clin. Exp. Dermatol, 18, pp. 211-216, (1993); Ishikawa R., Tsujimura Y., Obata K., Dixon T.A., Vickers C.F.H., IgG-mediated systemic anaphylaxis to protein antigen can be induced even under conditions of limited amounts of antibody and antigen, Biochem. Biophys. Res. Commun, 402, pp. 742-746, (2010); Tsujimura Y., Obata K., Mukai K., Shindou H., Shindou M., Nishikado H., Kawano Y., Kawano Y., Shimizu T., Karasuyama H., Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis, Immunity, 28, pp. 581-589, (2008); Brandtzaeg P., Food allergy: Separating the science from the mythology, Nat. Rev. Gastroenterol. Hepatol, 7, pp. 380-400, (2010); Vojdani A., Detection of IgE, IgG, IgA and IgM antibodies against raw and processed food antigens, Nutr. Metab, 6, (2009); Bock S.A., AAAAI Support of the EAACI Position Paper on IgG4; Position Statement, J. Allergy Clin. Immunol, 125, (2010); Fasano A., All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000Research, 9, (2020); Fasano A., Zonulin, regulation of tight junctions, and autoimmune diseases, Ann. N. Y. Acad. Sci, 1258, pp. 25-33, (2012); Stevens B.R., Goel R., Seungbum K., Richards E.M., Holbert R.C., Pepine C.J., Raizada M.K., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Paterson B.M., Lammers K.M., Arrieta M.C., Fasano A., Meddings J.B., The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: A proof of concept study, Aliment. Pharmacol. Ther, 26, pp. 757-766, (2007); Sturgeon C., Lan J., Fasano A., Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model, Ann. N. Y. Acad. Sci, 1397, pp. 130-142, (2017); Velikova T.V., Altankova I., Peruhova M., Mihova A., Kukov A., Georgieva V., Yurukova N., Mizgova G., Mehandzhiyska-Marinova T., Terzieva V., Et al., Prevalence of Specific IgG to Food Antigens in Bulgarian IBS Patients: A Preliminary Study, Mathews J. Nutr. Diet, 3, (2018); Velikova T.V., Altankova I., Mihova A., Terzieva V., Georgieva V., Kukov A., Yurukova N., Mehandzhiyska-Marinova T., Mizgova G., Zhelezova G., Et al., IgG-mediated immune reactivity in patients with Irritable Bowel Syndrome: A pilot study, Yearbook of Bulgarian Association for Clinical Immunology, 12, pp. 31-71, (2018); Schur P.H., Rosen F., Norman M.E., Immunoglobulin subclasses in normal children, Pediatr. Res, 13, pp. 181-183, (1979); Bentley S.J., Pearson D.J., Rix K.J., Food hypersensitivity in irritable bowel syndrome, Lancet, 2, pp. 295-297, (1983); Zar S., Mincher L., Benson M.J., Kumar D., Food-specific IgG4 antibodyguided exclusion diet improves symptoms and rectal compliance in irritable bowel syndrome, Scand. J. Gastroenterol, 40, pp. 800-807, (2005); Zeng Q., Dong S.Y., Wu L.X., Li H., Sun Z.-J., Li J.-B., Jiang H.-X., Chen Z.-H., Wang Q.-B., Chen W.-W., Variable food-specific IgG antibody levels in healthy and symptomatic Chinese adults, PLoS ONE, 8, (2013); Ligaarden S.C., Lydersen S., Farup P.G., IgG and IgG4 antibodies in subjects with irritable bowel syndrome: A case control study in the general population, BMC Gastroenterol, 12, (2012); Kvehaugen A.S., Tveiten D., Farup P.G., Is perceived intolerance to milk and wheat associated with the corresponding IgG and IgA food antibodies? A cross sectional study in subjects with morbid obesity and gastrointestinal symptoms, BMC Gastroenterol, 18, (2018); Wilders-Truschnig M., Mangge H., Lieners C., Gruber H.-J., Mayer C., Marz W., IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles, Exp. Clin. Endocrinol. Diabetes, 116, pp. 241-245, (2008); Aydinlar E.I., Dikmen P.Y., Tiftikci A., Saruc M., Aksu M., Gunsoy H.G., Tozun N., IgG-based elimination diet in migraine plus irritable bowel syndrome, Headache, 53, pp. 514-525, (2013); Drisko J., Bischoff B., Hall M., McCallum R., Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics, J. Am. Coll. Nutr, 25, pp. 514-522, (2006); Atkinson W., Sheldon T.A., Shaath N., Whorwell P.J., Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial, Gut, 53, pp. 1459-1464, (2004); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in, I.B.S.; correlates with stool frequency in, I.B.S.-D, United Eur. Gastroenterol. J, 7, pp. 709-715, (2019); Caviglia G.P., Rosso C., Ribaldone D.G., Dughera F., Fagoonee S., Astegiano M., Pellicano R., Physiopathology of intestinal barrier and the role of zonulin, Minerva Biotecnol, 31, pp. 83-92, (2019); Barbaro M.R., Cremon C., Caio G., de Giorgio R., Volta U., Stanghellini V., Barbara G., 247 Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, (2015); Prospero L., Riezzo G., Linsalata M., Orlando A., D'Attoma B., Russo F., Psychological and Gastrointestinal Symptoms of Patients with Irritable Bowel Syndrome Undergoing a Low-FODMAP Diet: The Role of the Intestinal Barrier, Nutrients, 13, (2021); Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., Antalis T.M., Vogel S.N., Zhao A., Yang S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc. Natl. Acad. Sci. USA, 106, pp. 16799-16804, (2009); Koch W., Latz W., Eichinger M., Gschwendner C., Teige B., Schomig A., Kastrati A., Haptoglobin gene subtyping by restriction enzyme analysis, Clin. Chem, 49, pp. 1937-1940, (2003); Meira de-Faria F., Bednarska O., Strom M., Soderholm J.D., Walter S.A., Keita A.V., Colonic paracellular permeability and circulating zonulin-related proteins, Scand. J. Gastroenterol, 56, pp. 424-431, (2021); Scheffler L., Crane A., Heyne H., Tonjes A., Schleinitz D., Ihling C.H., Stumvoll M., Freire R., Fiorentino M., Fasano A., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front. Endocrinol, 9, (2018); Ajamian M., Steer D., Rosella G., Gibson P.R., Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems, PLoS ONE, 14, (2019); Talley N.J., Holtmann G.J., Jones M., Koloski N.A., Walker M.M., Burns G., Potter M.D.E., Shah A., Keely S., Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity, Gut, 69, pp. 1719-1722, (2020)^T. Velikova; Laboratory of Clinical Immunology, University Hospital Lozenetz, Sofia University St. Kliment Ohridski, Sofia, 1407, Bulgaria; email: tsvelikova@medfac.mu-sofia.bg^^MDPI^^^^^^20734468^^^^English^Antibodies^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85128463512
Valibouze C.; Dubuquoy C.; Chavatte P.; Genin M.; Maquet V.; Modica S.; Desreumaux P.; Rousseaux C.^Valibouze, Caroline (57216955115); Dubuquoy, Caroline (16678426600); Chavatte, Philippe (7004730680); Genin, Michaël (55627397100); Maquet, Veronique (6603820646); Modica, Salvatore (57208187463); Desreumaux, Pierre (54978202100); Rousseaux, Christel (8415396600)^57216955115; 16678426600; 7004730680; 55627397100; 6603820646; 57208187463; 54978202100; 8415396600^Chitin-glucan improves important pathophysiological features of irritable bowel syndrome^2024^World Journal of Gastroenterology^30.0^16^^2258^2271^13.0^0^10.3748/wjg.v30.i16.2258^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85191863150&doi=10.3748%2fwjg.v30.i16.2258&partnerID=40&md5=331eab2a4e4138298b4d785da318cf0a^Department of Digestive Surgery and Transplantation, Lille University, Lille, 59037, France; Intestinal Biotech Development, Faculté de Médicine, Lille, 59045, France; U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, 59000, France; ULR 2694-METRICS, Évaluation des Technologies de Santé et des Pratiques Médicales, University of Lille, Lille, 59000, France; KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal, 4040, Belgium; Hepato-Gastroenterology Department, Lille University Hospital, Lille, 59037, France^Valibouze C., Department of Digestive Surgery and Transplantation, Lille University, Lille, 59037, France; Dubuquoy C., Intestinal Biotech Development, Faculté de Médicine, Lille, 59045, France; Chavatte P., U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, Lille, 59000, France; Genin M., ULR 2694-METRICS, Évaluation des Technologies de Santé et des Pratiques Médicales, University of Lille, Lille, 59000, France; Maquet V., KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal, 4040, Belgium; Modica S., KitoZyme SA, Institution Société Anonyme, Zone 2, Parc des Hauts Sarts, Rue de Milmort, Herstal, 4040, Belgium; Desreumaux P., Hepato-Gastroenterology Department, Lille University Hospital, Lille, 59037, France; Rousseaux C., Intestinal Biotech Development, Faculté de Médicine, Lille, 59045, France^BACKGROUND Irritable bowel syndrome (IBS) is one of the most frequent and debilitating conditions leading to gastroenterological referrals. However, recommended treatments remain limited, yielding only limited therapeutic gains. Chitin-glucan (CG) is a novel dietary prebiotic classically used in humans at a dosage of 1.5-3.0 g/d and is considered a safe food ingredient by the European Food Safety Authority. To provide an alternative approach to managing patients with IBS, we performed preclinical molecular, cellular, and animal studies to evaluate the role of chitin-glucan in the main pathophysiological mechanisms involved in IBS. AIM To evaluate the roles of CG in visceral analgesia, intestinal inflammation, barrier function, and to develop computational molecular models. METHODS Visceral pain was recorded through colorectal distension (CRD) in a model of long-lasting colon hypersensitivity induced by an intra-rectal administration of TNBS [15 milligrams (mg)/kilogram (kg)] in 33 Sprague-Dawley rats. Intracolonic pressure was regularly assessed during the 9 wk-experiment (weeks 0, 3, 5, and 7) in animals receiving CG (n = 14) at a human equivalent dose (HED) of 1.5 g/d or 3.0 g/d and compared to negative control (tap water, n = 11) and positive control (phloroglucinol at 1.5 g/d HED, n = 8) groups. The anti-inflammatory effect of CG was evaluated using clinical and histological scores in 30 C57bl6 male mice with colitis induced by dextran sodium sulfate (DSS) administered in their drinking water during 14 d. HT-29 cells under basal conditions and after stimulation with lipopolysaccharide (LPS) were treated with CG to evaluate changes in pathways related to analgesia (µ-opioid receptor (MOR), cannabinoid receptor 2 (CB2), peroxisome proliferator-activated receptor alpha, inflammation [interleukin (IL)-10, IL-1b, and IL-8] and barrier function [mucin 2-5AC, claudin-2, zonula occludens (ZO)-1, ZO-2] using the real-time PCR method. Molecular modelling of CG, LPS, lipoteichoic acid (LTA), and phospholipomannan (PLM) was developed, and the ability of CG to chelate microbial pathogenic lipids was evaluated by docking and molecular dynamics simulations. Data were expressed as the mean ± SEM. RESULTS Daily CG orally-administered to rats or mice was well tolerated without including diarrhea, visceral hypersensitivity, or inflammation, as evaluated at histological and molecular levels. In a model of CRD, CG at a dosage of 3 g/d HED significantly decreased visceral pain perception by 14% after 2 wk of administration (P < 0.01) and reduced inflammation intensity by 50%, resulting in complete regeneration of the colonic mucosa in mice with DSS-induced colitis. To better reproduce the characteristics of visceral pain in patients with IBS, we then measured the therapeutic impact of CG in rats with TNBS-induced inflammation to long-lasting visceral hypersensitivity. CG at a dosage of 1.5 g/d HED decreased visceral pain perception by 20% five weeks after colitis induction (P < 0.01). When the CG dosage was increased to 3.0 g/d HED, this analgesic effect surpassed that of the spasmolytic agent phloroglucinol, manifesting more rapidly within 3 wk and leading to a 50% inhibition of pain perception (P < 0.0001). The underlying molecular mechanisms contributing to these analgesic and anti-inflammatory effects of CG involved, at least in part, a significant induction of MOR, CB2 receptor, and IL-10, as well as a significant decrease in pro-inflammatory cytokines IL-1b and IL-8. CG also significantly upregulated barrier-related genes including muc5AC, claudin-2, and ZO-2. Molecular modelling of CG revealed a new property of the molecule as a chelator of microbial pathogenic lipids, sequestering gram-negative LPS and gram-positive LTA bacterial toxins, as well as PLM in fungi at the lowesr energy conformations. CONCLUSION CG decreased visceral perception and intestinal inflammation through master gene regulation and direct binding of microbial products, suggesting that CG may constitute a new therapeutic strategy for patients with IBS or IBS-like symptoms. © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.^Abdominal pain; Chitin-glucan; Inflammation; Intestinal barrier; Irritable bowel syndrome; Microbial cell walls chelation; Molecular modelling^Animals; Chitin; Colitis; Colon; Disease Models, Animal; Glucans; HT29 Cells; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Prebiotics; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid; Visceral Pain; cannabinoid 2 receptor; chitin glucan; claudin 2; dextran sulfate; interleukin 10; interleukin 1beta; interleukin 8; lipopolysaccharide; lipoteichoic acid; mu opiate receptor; mucin 2; mucin 5AC; phloroglucinol; phospholipid; phospholipomannan; polysaccharide; protein ZO1; protein ZO2; unclassified drug; chitin; glucan; prebiotic agent; trinitrobenzenesulfonic acid; analgesic activity; animal experiment; animal model; animal tissue; antiinflammatory activity; Article; colitis; colon mucosa; controlled study; drug tolerability; gene expression; histopathology; human; human cell; hypersensitivity; inflammation; intestinal barrier function; irritable colon; male; molecular docking; molecular model; nonhuman; pathophysiology; rat; real time polymerase chain reaction; tissue regeneration; upregulation; visceral pain; animal; colon; disease model; drug effect; HT-29 cell line; intestine mucosa; irritable colon; metabolism; mouse; pathology; Sprague Dawley rat; visceral pain^^dextran sulfate, 9011-18-1, 9042-14-2; interleukin 8, 114308-91-7; lipoteichoic acid, 56411-57-5; phloroglucinol, 108-73-6; chitin, 1398-61-4; glucan, 9012-72-0, 9037-91-6; trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; Chitin, ; Glucans, ; Prebiotics, ; Trinitrobenzenesulfonic Acid, ^^^^^Camilleri M, Choi MG., Review article: irritable bowel syndrome, Aliment Pharmacol Ther, 11, pp. 3-15, (1997); Fortea J, Prior M., Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden, J Med Econ, 16, pp. 329-341, (2013); Sethi S, Wadhwa V, LeClair J, Mikami S, Park R, Jones M, Sethi N, Brown A, Lembo A., In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010, Aliment Pharmacol Ther, 38, pp. 1338-1346, (2013); Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B., ACG Clinical Guideline: Management of Irritable Bowel Syndrome, Am J Gastroenterol, 116, pp. 17-44, (2021); Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, Agrawal A, Aziz I, Farmer AD, Eugenicos MP, Moss-Morris R, Yiannakou Y, Ford AC., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome, Gut, 70, pp. 1214-1240, (2021); Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S., Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS), J Can Assoc Gastroenterol, 2, pp. 6-29, (2019); Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, Sato K, Shiotani A, Naito Y, Fujikawa Y, Hokari R, Masaoka T, Fujimoto K, Kaneko H, Torii A, Matsueda K, Miwa H, Enomoto N, Shimosegawa T, Koike K., Evidence-based clinical practice guidelines for irritable bowel syndrome 2020, J Gastroenterol, 56, pp. 193-217, (2021); Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN., AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea, Gastroenterology, 163, pp. 137-151, (2022); Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ., AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation, Gastroenterology, 163, pp. 118-136, (2022); Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simren M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G., Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility, United European Gastroenterol J, 10, pp. 556-584, (2022); Jakobsson Ung E, Ringstrom G, Sjovall H, Simren M., How patients with long-term experience of living with irritable bowel syndrome manage illness in daily life: a qualitative study, Eur J Gastroenterol Hepatol, 25, pp. 1478-1483, (2013); Bertram S, Kurland M, Lydick E, Locke GR, Yawn BP., The patient's perspective of irritable bowel syndrome, J Fam Pract, 50, pp. 521-525, (2001); Scientific opinion on the safety of ‘Chitin-glucan’ as a novel food ingredient, EFSA J, 8, (2010); Berecochea-Lopez A, Decorde K, Ventura E, Godard M, Bornet A, Teissedre PL, Cristol JP, Rouanet JM., Fungal chitin-glucan from Aspergillus niger efficiently reduces aortic fatty streak accumulation in the high-fat fed hamster, an animal model of nutritionally induced atherosclerosis, J Agric Food Chem, 57, pp. 1093-1098, (2009); Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM., Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice, J Nutr Biochem, 23, pp. 51-59, (2012); Calatayud M, Verstrepen L, Ghyselinck J, Van den Abbeele P, Marzorati M, Modica S, Ranjanoro T, Maquet V., Chitin Glucan Shifts Luminal and Mucosal Microbial Communities, Improve Epithelial Barrier and Modulates Cytokine Production In Vitro, Nutrients, 13, (2021); Rodriguez J, Neyrinck AM, Zhang Z, Seethaler B, Nazare JA, Robles Sanchez C, Roumain M, Muccioli GG, Bindels LB, Cani PD, Maquet V, Laville M, Bischoff SC, Walter J, Delzenne NM., Metabolite profiling reveals the interaction of chitin-glucan with the gut microbiota, Gut Microbes, 12, (2020); Martin R, Rios-Covian D, Huillet E, Auger S, Khazaal S, Bermudez-Humaran LG, Sokol H, Chatel JM, Langella P., Faecalibacterium: a bacterial genus with promising human health applications, FEMS Microbiol Rev, 47, (2023); Johnson AC, Farmer AD, Ness TJ, Greenwood-Van Meerveld B., Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Brenna O, Furnes MW, Drozdov I, van Beelen Granlund A, Flatberg A, Sandvik AK, Zwiggelaar RT, Marvik R, Nordrum IS, Kidd M, Gustafsson BI., Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD, PLoS One, 8, (2013); Zimmermann M., Ethical guidelines for investigations of experimental pain in conscious animals, Pain, 16, pp. 109-110, (1983); Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D., Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats, Gastroenterology, 128, pp. 1996-2008, (2005); Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, pp. 35-37, (2007); Cooper HS, Murthy SN, Shah RS, Sedergran DJ., Clinicopathologic study of dextran sulfate sodium experimental murine colitis, Lab Invest, 69, pp. 238-249, (1993); Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP., Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines, Clin Exp Immunol, 114, pp. 385-391, (1998); Funakoshi T, Yamashita K, Ichikawa N, Fukai M, Suzuki T, Goto R, Oura T, Kobayashi N, Katsurada T, Ichihara S, Ozaki M, Umezawa K, Todo S., A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice, J Crohns Colitis, 6, pp. 215-225, (2012); Clark M, Cramer RD, Van Opdenbosch N., Validation of the general purpose Tripos 5.2 force field, J Comput Chem, 10, pp. 982-1012, (1989); Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R., Bowel Disorders, Gastroenterology, (2016); Drossman DA., Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV, Gastroenterology, (2016); Esquerre N, Basso L, Dubuquoy C, Djouina M, Chappard D, Blanpied C, Desreumaux P, Vergnolle N, Vignal C, Body-Malapel M., Aluminum Ingestion Promotes Colorectal Hypersensitivity in Rodents, Cell Mol Gastroenterol Hepatol, 7, pp. 185-196, (2019); Jafri W, Yakoob J, Hussain S, Jafri N, Islam M., Phloroglucinol in irritable bowel syndrome, J Pak Med Assoc, 56, pp. 5-8, (2006); Annahazi A, Roka R, Rosztoczy A, Wittmann T., Role of antispasmodics in the treatment of irritable bowel syndrome, World J Gastroenterol, 20, pp. 6031-6043, (2014); Shin SY, Cha BK, Kim WS, Park JY, Kim JW, Choi CH., The Effect of Phloroglucinol in Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled Trial, J Neurogastroenterol Motil, 26, pp. 117-127, (2020); Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, Bulois P, Breisse M, Vorng H, Gay J, Colombel JF, Desreumaux P, Chamaillard M., Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation, Gut, 55, pp. 815-823, (2006); Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P., Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation, J Clin Invest, 111, pp. 1329-1338, (2003); Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S., Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing, Gastroenterology, 129, pp. 437-453, (2005); Kasatkina LA, Rittchen S, Sturm EM., Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation, Int J Mol Sci, 22, (2021); Xu B, Zhang Q, Chen D, Zhang M, Zhang R, Zhao W, Qiu Y, Xu K, Xiao J, Niu J, Shi Y, Li N, Fang Q., OCP002, a Mixed Agonist of Opioid and Cannabinoid Receptors, Produces Potent Antinociception With Minimized Side Effects, Anesth Analg, 136, pp. 373-386, (2023); Luo Y, Xie C, Brocker CN, Fan J, Wu X, Feng L, Wang Q, Zhao J, Lu D, Tandon M, Cam M, Krausz KW, Liu W, Gonzalez FJ., Intestinal PPARα Protects Against Colon Carcinogenesis via Regulation of Methyltransferases DNMT1 and PRMT6, Gastroenterology, 157, pp. 744-759, (2019); Drewes AM, Olesen AE, Farmer AD, Szigethy E, Rebours V, Olesen SS., Gastrointestinal pain, Nat Rev Dis Primers, 6, (2020); Ford AC, Talley NJ., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Bugbee E, Wang AA, Gommerman JL., Under the influence: environmental factors as modulators of neuroinflammation through the IL-10/IL-10R axis, Front Immunol, 14, (2023); Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Rao AS, Camilleri M, Eckert DJ, Busciglio I, Burton DD, Ryks M, Wong BS, Lamsam J, Singh R, Zinsmeister AR., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Inaba R, Vujakovic S, Bergstrom K., The gut mucus network: A dynamic liaison between microbes and the immune system, Semin Immunol, 69, (2023); Martinez-Maqueda D, Miralles B, Recio I., HT29 Cell Line, The Impact of Food Bioactives on Health: in vitro and ex vivo models [Internet], (2015); Bentzer P, Russell JA, Walley KR., Advances in Sepsis Research, Clin Chest Med, 36, pp. 521-530, (2015); Cinel I, Opal SM., Molecular biology of inflammation and sepsis: a primer, Crit Care Med, 37, pp. 291-304, (2009); Howell CA, Kemppinen A, Allgar V, Dodd M, Knowles CH, McLaughlin J, Pandya P, Whorwell P, Markaryan E, Yiannakou Y., Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D), Gut, 71, pp. 2430-2438, (2022); Rosa RD, Vergnes A, de Lorgeril J, Goncalves P, Perazzolo LM, Saune L, Romestand B, Fievet J, Gueguen Y, Bachere E, Destoumieux-Garzon D., Functional divergence in shrimp anti-lipopolysaccharide factors (ALFs): from recognition of cell wall components to antimicrobial activity, PLoS One, 8, (2013); Yang Y, Boze H, Chemardin P, Padilla A, Moulin G, Tassanakajon A, Pugniere M, Roquet F, Destoumieux-Garzon D, Gueguen Y, Bachere E, Aumelas A., NMR structure of rALF-Pm3, an anti-lipopolysaccharide factor from shrimp: model of the possible lipid A-binding site, Biopolymers, 91, pp. 207-220, (2009); Perez S, Wertz JL., Chitin and Chitosans in the bioeconomy, (2022); Ngo DH, Kim SK., Antioxidant effects of chitin, chitosan, and their derivatives, Adv Food Nutr Res, 73, pp. 15-31, (2014); Gonzalez-Fernandez C, Basauri A, Fallanza M, Bringas E, Oostenbrink C, Ortiz I., Fighting Against Bacterial Lipopolysaccharide-Caused Infections through Molecular Dynamics Simulations: A Review, J Chem Inf Model, 61, pp. 4839-4851, (2021)^C. Rousseaux; Intestinal Biotech Development, Faculté de Médicine, Pole Recherche Amphi JK, Lille, Bd du Pr Jules Leclercq, 59045, France; email: crousseaux@ibd-biotech.com^^Baishideng Publishing Group Inc^^^^^^10079327^^WJGAF^38690023.0^English^World J. Gastroenterol.^Article^Final^All Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85191863150
Ciriza de Los Ríos C.; Aparicio Cabezudo M.; Zatarain Vallés A.; Rey E.^Ciriza de Los Ríos, Constanza (6602108091); Aparicio Cabezudo, Marta (56113649600); Zatarain Vallés, Ana (57205761877); Rey, Enrique (7103353498)^6602108091; 56113649600; 57205761877; 7103353498^Practical approach to irritable bowel syndrome-diarrhea beyond low-FODMAP diet^2022^Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva^114.0^8^^481^488^7.0^0^10.17235/reed.2022.8749/2022^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135419412&doi=10.17235%2freed.2022.8749%2f2022&partnerID=40&md5=fbe215b182a6da2de6922ef9fb486871^Aparato Digestivo, Hospital Clínico San Carlos, Spain; Aparato Digestivo, Hospital Clínico San Carlos, Spain^Ciriza de Los Ríos C., Aparato Digestivo, Hospital Clínico San Carlos, Spain; Aparicio Cabezudo M., Aparato Digestivo, Hospital Clínico San Carlos, Spain; Zatarain Vallés A., Aparato Digestivo, Hospital Clínico San Carlos, Spain; Rey E., Aparato Digestivo, Hospital Clínico San Carlos, Spain^Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered defecation, usually accompanied by abdominal bloating or distension. The integrated model of bidirectional interaction between the central, autonomic, enteric nervous system, the microbiome, and the gut barrier allows a better understanding of the pathophysiology of IBS, as well as consideration of potential therapeutic strategies. IBS with predominant diarrhea (IBS-D) represents a therapeutic challenge. Dietary changes or restrictions are most commonly used by patients in an attempt at symptom control. Therefore, a number of diets, especially low-FODMAP diet, have increasingly gained interest as a therapy for IBS-D or mixed IBS. However, this kind of diet, while effective, is not exempt of problems. It is therefore necessary that other therapeutic options be considered while bearing pathophysiological mechanisms and general symptom management in mind.^^Diarrhea; Diet; Fermentation; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Monosaccharides; Oligosaccharides; monosaccharide; oligosaccharide; complication; diarrhea; diet; fermentation; gastrointestinal disease; human; irritable colon^^Monosaccharides, ; Oligosaccharides, ^^^^^^^^NLM (Medline)^^^^^^11300108^^^35694883.0^English^Rev Esp Enferm Dig^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85135419412
Nozu T.; Okumura T.^Nozu, Tsukasa (12765917900); Okumura, Toshikatsu (7202327796)^12765917900; 7202327796^Pathophysiological Commonality Between Irritable Bowel Syndrome and Metabolic Syndrome: Role of Corticotropin-releasing Factor–Toll-like Receptor 4–Proinflammatory Cytokine Signaling^2022^Journal of Neurogastroenterology and Motility^28.0^2^^173^184^11.0^9^10.5056/jnm21002^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128625983&doi=10.5056%2fjnm21002&partnerID=40&md5=d3033a4e3eeef46d1541a966cb616760^Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Center for Medical Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Department of General Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan^Nozu T., Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan, Center for Medical Education, Asahikawa Medical University, Hokkaido, Asahikawa, Japan; Okumura T., Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan, Department of General Medicine, Asahikawa Medical University, Hokkaido, Asahikawa, Japan^Irritable bowel syndrome (IBS) displays chronic abdominal pain with altered defecation. Most of the patients develop visceral hypersensitivity possibly resulting from impaired gut barrier and altered gut microbiota. We previously demonstrated that colonic hyperpermeability with visceral hypersensitivity in animal IBS models, which is mediated via corticotropin-releasing factor (CRF)–Toll-like receptor 4 (TLR4)–proinflammatory cytokine signaling. CRF impairs gut barrier via TLR4. Leaky gut induces bacterial translocation resulting in dysbiosis, and increases lipopolysaccharide (LPS). Activation of TLR4 by LPS increases the production of proinflammatory cytokines, which activate visceral sensory neurons to induce visceral hypersensitivity. LPS also activates CRF receptors to further increase gut permeability. Metabolic syndrome (MS) is a cluster of cardiovascular risk factors, including insulin resistance, obesity, dyslipidemia, and hypertension, and recently several researchers suggested the possibility that impaired gut barrier and dysbiosis with low-grade systemic inflammation are involved in MS. Moreover, TLR4–proinflammatory cytokine contributes to the development of insulin resistance and obesity. Thus, the existence of pathophysiological commonality between IBS and MS is expected. This review discusses the potential mechanisms of IBS and MS with reference to gut barrier and microbiota, and explores the possibility of existence of a pathophysiological link between these diseases with a focus on CRF, TLR4, and proinflammatory cytokine signaling. We also review epidemiological data supporting this possibility, and discuss the potential of therapeutic application of the drugs used for MS to IBS treatment. This notion may pave the way for exploring novel therapeutic approaches for these disorders. © 2022 The Korean Society of Neurogastroenterology and Motility.^Gut barrier; Irritable bowel syndrome; Metabolic syndrome; Microbiota; Toll-like receptor 4^corticotropin releasing factor; fatty acid; oxidized low density lipoprotein; toll like receptor 4; Article; brain-gut axis; cytokine signaling; epidemiological data; human; immune system; intestine flora; irritable colon; metabolic syndrome X; nonhuman; pathophysiology^^corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; toll like receptor 4, 203811-83-0^^^^^Drossman DA, Camilleri M, Mayer EA, Whitehead WE., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Tache Y, Kiank C, Stengel A., A role for corticotropin-releasing factor in functional gastrointestinal disorders, Curr Gastroenterol Rep, 11, pp. 270-277, (2009); Nozu T, Okumura T., Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome, J Gastroenterol, 50, pp. 819-830, (2015); Tache Y, Million M., Role of corticotropin-releasing factor signaling in stress-related alterations of colonic motility and hyperalgesia, J Neurogastroenterol Motil, 21, pp. 8-24, (2015); Lozano R, Naghavi M, Foreman K, Et al., Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet, 380, pp. 2095-2128, (2012); Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A., Gut microbiota and metabolic syndrome, World J Gastroenterol, 20, pp. 16079-16094, (2014); Wellen KE, Hotamisligil GS., Inflammation, stress, and diabetes, J Clin Invest, 115, pp. 1111-1119, (2005); Cani PD, Amar J, Iglesias MA, Et al., Metabolic endotoxemia initiates obesity and insulin resistance, Diabetes, 56, pp. 1761-1772, (2007); Mayer EA, Savidge T, Shulman RJ., Brain-gut microbiome interactions and functional bowel disorders, Gastroenterology, 146, pp. 1500-1512, (2014); Camilleri M, Lasch K, Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1, J Endocrinol, 239, pp. 241-252, (2018); Cryan JF, O'Mahony SM., The microbiome-gut-brain axis: from bowel to behavior, Neurogastroenterol Motil, 23, pp. 187-192, (2011); Fukudo S, Nomura T, Muranaka M, Taguchi F., Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study, J Clin Gastroenterol, 17, pp. 133-141, (1993); Mayer EA, Naliboff BD, Chang L, Coutinho SV. V., Stress and irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 280, pp. G519-G524, (2001); Fukudo S, Nomura T, Hongo M., Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome, Gut, 42, pp. 845-849, (1998); Lee C, Doo E, Choi JM, Et al., The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis, J Neurogastroenterol Motil, 23, pp. 349-362, (2017); Fond G, Loundou A, Hamdani N, Et al., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis, Eur Arch Psychiatry Clin Neurosci, 264, pp. 651-660, (2014); Kellow JE, Delvaux M, Azpiroz F, Camilleri M, Quigley EM, Thompson DG., Principles of applied neurogastroenterology: physiology/motility-sensation, Gut, 45, pp. II17-II24, (1999); Delvaux M., Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome, Gut, 51, pp. i67-i71, (2002); Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA., Altered rectal perception is a biological marker of patients with irritable bowel syndrome, Gastroenterology, 109, pp. 40-52, (1995); Bouin M, Plourde V, Boivin M, Et al., Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds, Gastroenterology, 122, pp. 1771-1777, (2002); Kanazawa M, Hongo M, Fukudo S., Visceral hypersensitivity in irritable bowel syndrome, J Gastroenterol Hepatol, 26, pp. 119-121, (2011); Nozu T, Kudaira M, Kitamori S, Uehara A., Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome, J Gastroenterol, 41, pp. 217-222, (2006); Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J Neurogastroenterol Motil, 22, pp. 558-574, (2016); Camilleri M, Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Dlugosz A, Nowak P, D'Amato M, Et al., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol Motil, 27, pp. 1747-1754, (2015); Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ., Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines, Rev Esp Enferm Dig, 102, pp. 711-717, (2010); Sinagra E, Pompei G, Tomasello G, Et al., Inflammation in irritable bowel syndrome: myth or new treatment target?, World J Gastroenterol, 22, pp. 2242-2255, (2016); Liebregts T, Adam B, Bredack C, Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats, J Gastroenterol, 52, pp. 72-80, (2017); Avila M, Gonzalez-Espinosa C., Signaling through toll-like receptor 4 and mast cell-dependent innate immunity responses, IUBMB Life, 63, pp. 873-880, (2011); Boyer J, Saint-Paul MC, Dadone B, Et al., Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: a promising pilot study, Neurogastroenterol Motil, 30, (2018); Creekmore AL, Hong S, Zhu S, Xue J, Wiley JW., Chronic stress-associated visceral hyperalgesia correlates with severity of intestinal barrier dysfunction, Pain, 159, pp. 1777-1789, (2018); Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T., Lovastatin inhibits visceral allodynia and increased colonic permeability induced by lipopolysaccharide or repeated water avoidance stress in rats, Eur J Pharmacol, 818, pp. 228-234, (2017); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome, J Pharmacol Sci, 139, pp. 46-49, (2018); Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J Gastroenterol Hepatol, 34, pp. 186-193, (2019); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Eur J Pharmacol, 852, pp. 198-206, (2019); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome, Sci Rep, 9, (2019); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome, Neurogastroenterol Motil, 32, (2020); Nozu T, Kudaira M., Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans, J Gastroenterol, 41, pp. 740-744, (2006); Barreau F, Cartier C, Leveque M, Et al., Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin-releasing factor and nerve growth factor interplay, J Physiol, 580, pp. 347-356, (2007); Santos J, Saunders PR, Hanssen NP, Et al., Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat, Am J Physiol, 277, pp. G391-G399, (1999); Saunders PR, Santos J, Hanssen NP, Yates D, Groot JA, Perdue MH., Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH, Dig Dis Sci, 47, pp. 208-215, (2002); Soderholm JD, Yates DA, Gareau MG, Yang PC, MacQueen G, Perdue MH., Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress, Am J Physiol Gastrointest Liver Physiol, 283, pp. G1257-G1263, (2002); Hillhouse EW, Grammatopoulos DK., The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology, Endocr Rev, 27, pp. 260-286, (2006); Perrin MH, Vale WW., Corticotropin releasing factor receptors and their ligand family, Ann N Y Acad Sci, 885, pp. 312-328, (1999); Nozu T, Takakusaki K, Okumura T., A balance theory of peripheral corticotropin-releasing factor receptor type 1 and type 2 signaling to induce colonic contractions and visceral hyperalgesia in rats, Endocrinology, 155, pp. 4655-4664, (2014); Nozu T, Miyagishi S, Nozu R, Takakusaki K, Okumura T., Repeated water avoidance stress induces visceral hypersensitivity: role of IL-1, IL-6 and peripheral corticotropin-releasing factor, J Gastroenterol Hepatol, 32, pp. 1958-1965, (2017); Overman EL, Rivier JE, Moeser AJ., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha, PLoS One, 7, (2012); Barbara G, Wang B, Stanghellini V, Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Bhattarai Y, Muniz Pedrogo DA, Kashyap PC., Irritable bowel syndrome: a gut microbiota-related disorder?, Am J Physiol Gastrointest Liver Physiol, 312, pp. G52-G62, (2017); Tap J, Derrien M, Tornblom H, Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); O'Mahony SM, Marchesi JR, Scully P, Et al., Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses, Biol Psychiatry, 65, pp. 263-267, (2009); Xu D, Gao J, Gillilland M, Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, pp. 484-496, (2014); Salguero MV, Al-Obaide MAI, Singh R, Siepmann T, Vasylyeva TL., Dysbiosis of gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease, Exp Ther Med, 18, pp. 3461-3469, (2019); Bailey MT, Dowd SE, Galley JD, Hufnagle AR, Allen RG, Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation, Brain Behav Immun, 25, pp. 397-407, (2011); Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH., Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat, Gut, 48, pp. 630-636, (2001); Ait-Belgnaoui A, Durand H, Cartier C, Et al., Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats, Psychoneuroendocrinology, 37, pp. 1885-1895, (2012); Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP., Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders, Front Cell Neurosci, 9, (2015); Ploger S, Stumpff F, Penner GB, Et al., Microbial butyrate and its role for barrier function in the gastrointestinal tract, Ann N Y Acad Sci, 1258, pp. 52-59, (2012); Zhang J, Song L, Wang Y, Et al., Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats, J Gastroenterol Hepatol, 34, pp. 1368-1376, (2019); Crouzet L, Gaultier E, Del'Homme C, Et al., The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota, Neurogastroenterol Motil, 25, pp. e272-e282, (2013); Zong Y, Zhu S, Zhang S, Zheng G, Wiley JW, Hong S., Chronic stress and intestinal permeability: lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human, Neurogastroenterol Motil, (2019); Cryan JF, Dinan TG., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour, Nat Rev Neurosci, 13, pp. 701-712, (2012); Audhya T, Jain R, Hollander CS., Receptor-mediated immunomodulation by corticotropin-releasing factor, Cell Immunol, 134, pp. 77-84, (1991); Hojo M, Ohkusa T, Tomeoku H, Et al., Corticotropin-releasing factor secretion from dendritic cells stimulated by commensal bacteria, World J Gastroenterol, 17, pp. 4017-4022, (2011); Zheng PY, Feng BS, Oluwole C, Et al., Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, pp. 1473-1479, (2009); Yu Y, Liu ZQ, Liu XY, Et al., Stress-derived corticotropin releasing factor breaches epithelial endotoxin tolerance, PLoS One, 8, (2013); Obreja O, Rathee PK, Lips KS, Distler C, Kress M., IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C, FASEB J, 16, pp. 1497-1503, (2002); Suzuki T, Yoshinaga N, Tanabe S., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J Biol Chem, 286, pp. 31263-31271, (2011); Liu L, Zhu G., Gut-brain axis and mood disorder, Front Psychiatry, 9, (2018); Calarge CA, Devaraj S, Shulman RJ., Gut permeability and depressive symptom severity in unmedicated adolescents, J Affect Disord, 246, pp. 586-594, (2019); Uehara A, Gottschall PE, Dahl RR, Arimura A., Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor, Endocrinology, 121, pp. 1580-1582, (1987); Dabke K, Hendrick G, Devkota S., The gut microbiome and metabolic syndrome, J Clin Invest, 129, pp. 4050-4057, (2019); Araujo JR, Tomas J, Brenner C, Sansonetti PJ., Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity, Biochimie, 141, pp. 97-106, (2017); Jakobsdottir G, Xu J, Molin G, Ahrne S, Nyman M., High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects, PLoS One, 8, (2013); Gao F, Lv YW, Long J, Et al., Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet, Front Pharmacol, 10, (2019); Rogero MM, Calder PC., Obesity, inflammation, toll-like receptor 4 and fatty acids, Nutrients, 10, (2018); Kim KA, Gu W, Lee IA, Joh EH, Kim DH., High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway, PLoS One, 7, (2012); Rehman K, Akash MS., Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?, J Biomed Sci, 23, (2016); Gregor MF, Hotamisligil GS., Inflammatory mechanisms in obesity, Annu Rev Immunol, 29, pp. 415-445, (2011); Kallio KA, Hatonen KA, Lehto M, Salomaa V, Mannisto S, Pussinen PJ., Endotoxemia, nutrition, and cardiometabolic disorders, Acta Diabetol, 52, pp. 395-404, (2015); Jialal I, Kaur H, Devaraj S., Toll-like receptor status in obesity and metabolic syndrome: a translational perspective, J Clin Endocrinol Metab, 99, pp. 39-48, (2014); Miura K, Ishioka M, Iijima K., The roles of the gut microbiota and toll-like receptors in obesity and nonalcoholic fatty liver disease, J Obes Metab Syndr, 26, pp. 86-96, (2017); Ahmad R, Al-Mass A, Atizado V, Et al., Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation, J Inflamm (Lond), 9, (2012); Nakarai H, Yamashita A, Nagayasu S, Et al., Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications, Innate Immun, 18, pp. 164-170, (2012); Hotamisligil GS, Shargill NS, Spiegelman BM., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science, 259, pp. 87-91, (1993); Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, pp. 1796-1808, (2003); Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE., The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes, J Biol Chem, 275, pp. 24255-24263, (2000); Daemen S, Schilling JD., The interplay between tissue niche and macrophage cellular metabolism in obesity, Front Immunol, 10, (2019); Farrell GC, van Rooyen D, Gan L, Chitturi S., NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications, Gut Liver, 6, pp. 149-171, (2012); Frost RA, Nystrom GJ, Lang CH., Lipopolysaccharide stimulates nitric oxide synthase-2 expression in murine skeletal muscle and C<sub>2</sub>C<sub>12</sub> myoblasts via toll-like receptor-4 and c-Jun NH(2)-terminal kinase pathways, Am J Physiol Cell Physiol, 287, pp. C1605-C1615, (2004); Frost RA, Nystrom GJ, Lang CH., Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH<sub>2</sub>-terminal kinase, Am J Physiol Regul Integr Comp Physiol, 285, pp. R1153-R1164, (2003); Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM., Diabetes and nonalcoholic fatty liver disease: a pathogenic duo, Endocr Rev, 34, pp. 84-129, (2013); Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E., The role of the microbiome in NAFLD and NASH, EMBO Mol Med, 11, (2019); Rocha DM, Caldas AP, Oliveira LL, Bressan J, Hermsdorff HH., Saturated fatty acids trigger TLR4-mediated inflammatory response, Atherosclerosis, 244, pp. 211-215, (2016); Suganami T, Tanimoto-Koyama K, Nishida J, Et al., Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages, Arterioscler Thromb Vasc Biol, 27, pp. 84-91, (2007); Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS., TLR4 links innate immunity and fatty acid-induced insulin resistance, J Clin Invest, 116, pp. 3015-3025, (2006); Fessler MB, Rudel LL, Brown JM., Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome, Curr Opin Lipidol, 20, pp. 379-385, (2009); Zhang N, Liang H, Farese RV, Li J, Musi N, Hussey SE., Pharmacological TLR4 inhibition protects against acute and chronic fat-induced insulin resistance in rats, PLoS One, 10, (2015); Hopps E, Noto D, Caimi G, Averna MR., A novel component of the metabolic syndrome: the oxidative stress, Nutr Metab Cardiovasc Dis, 20, pp. 72-77, (2010); Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R, Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk, J Mol Endocrinol, 51, pp. R51-R64, (2013); Linna MS, Ahotupa M, Kukkonen-Harjula K, Fogelholm M, Vasankari TJ., Co-existence of insulin resistance and high concentrations of circulating oxidized LDL lipids, Ann Med, 47, pp. 394-398, (2015); Liu HQ, Qiu Y, Mu Y, Et al., A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats, Nutr Res, 33, pp. 849-858, (2013); Barreau F, Ferrier L, Fioramonti J, Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, pp. 501-506, (2004); Yi L, Zhang H, Sun H, Et al., Maternal separation induced visceral hypersensitivity from childhood to adulthood, J Neurogastroenterol Motil, 23, pp. 306-315, (2017); Clarke G, O'Mahony SM, Hennessy AA, Et al., Chain reactions: early-life stress alters the metabolic profile of plasma polyunsaturated fatty acids in adulthood, Behav Brain Res, 205, pp. 319-321, (2009); Chua CS, Huang SY, Cheng CW, Et al., Fatty acid components in Asian female patients with irritable bowel syndrome, Medicine (Baltimore), 96, (2017); Bale TL, Anderson KR, Roberts AJ, Lee KF, Nagy TR, Vale WW., Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold, Endocrinology, 144, pp. 2580-2587, (2003); Tache Y, Bonaz B., Corticotropin-releasing factor receptors and stress-related alterations of gut motor function, J Clin Invest, 117, pp. 33-40, (2007); Li C, Chen P, Vaughan J, Lee KF, Vale W., Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis, Proc Natl Acad Sci USA, 104, pp. 4206-4211, (2007); Kuperman Y, Issler O, Regev L, Et al., Perifornical urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis, Proc Natl Acad Sci USA, 107, pp. 8393-8398, (2010); Chrousos GP., The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes, Int J Obes Relat Metab Disord, 24, pp. S50-S55, (2000); Rosmond R., Role of stress in the pathogenesis of the metabolic syndrome, Psychoneuroendocrinology, 30, pp. 1-10, (2005); Tramullas M, Finger BC, Dinan TG, Cryan JF., Obesity takes its toll on visceral pain: high-fat diet induces toll-like receptor 4-dependent visceral hypersensitivity, PLoS One, 11, (2016); Pickett-Blakely O., Obesity and irritable bowel syndrome: a comprehensive review, Gastroenterol Hepatol (NY), 10, pp. 411-416, (2014); Aasbrenn M, Lydersen S, Farup PG., A conservative weight loss intervention relieves bowel symptoms in morbidly obese subjects with irritable bowel syndrome: a prospective cohort study, J Obes, 2018, (2018); Lee CG, Lee JK, Kang YS, Et al., Visceral abdominal obesity is associated with an increased risk of irritable bowel syndrome, Am J Gastroenterol, 110, pp. 310-319, (2015); Despres JP, Lemieux I., Abdominal obesity and metabolic syndrome, Nature, 444, pp. 881-887, (2006); Guo Y, Niu K, Momma H, Et al., Irritable bowel syndrome is positively related to metabolic syndrome: a population-based cross-sectional study, PLoS One, 9, (2014); Cholongitas E, Pipili C, Dasenaki M., Gastro-oesophageal reflux disease and irritable bowel syndrome significantly associated with metabolic syndrome, Scand J Gastroenterol, 43, pp. 1405-1406, (2008); Basilisco G, Camboni G, Bozzani A, Vita P, Doldi S, Bianchi PA., Orocecal transit delay in obese patients, Dig Dis Sci, 34, pp. 509-512, (1989); Sadik R, Bjornsson E, Simren M., The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome, Eur J Gastroenterol Hepatol, 22, pp. 102-108, (2010); Eswaran S, Tack J, Chey WD., Food: the forgotten factor in the irritable bowel syndrome, Gastroenterol Clin North Am, 40, pp. 141-162, (2011); Chirila I, Petrariu FD, Ciortescu I, Mihai C, Drug VL., Diet and irritable bowel syndrome, J Gastrointestin Liver Dis, 21, pp. 357-362, (2012); Kaptoge S, Seshasai SR, Gao P, Et al., Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis, Eur Heart J, 35, pp. 578-589, (2014); Nozu T, Miyagishi S, Kumei S, Nozu R, Takakusaki K, Okumura T., Glucagon-like peptide-1 analog, liraglutide improves visceral sensation and gut permeability in rats, J Gastroenterol Hepatol, 33, pp. 232-239, (2018)^T. Nozu; Department of Regional Medicine and Education, Asahikawa Medical University, Hokkaido, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, 078-8510, Japan; email: tnozu@sea.plala.or.jp^^Korean Society of Neurogastroenterology and Motility^^^^^^20930879^^^^English^J. Neurogastroenterology Motil.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85128625983
Cui L.; Hua Y.; Zou S.; Gu C.; Li H.^Cui, Li (55189436500); Hua, Yongzhi (57223416459); Zou, Shuting (58731982700); Gu, Chao (57226658841); Li, Hui (57196364139)^55189436500; 57223416459; 58731982700; 57226658841; 57196364139^Combination of fenchone and sodium hyaluronate ameliorated constipation-predominant irritable bowel syndrome and underlying mechanisms^2024^Chemical Biology and Drug Design^103.0^1^e14397^^^^0^10.1111/cbdd.14397^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178242854&doi=10.1111%2fcbdd.14397&partnerID=40&md5=9f457953cac4b58f9c843ec43012e906^Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Digestive Department, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China^Cui L., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Hua Y., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Digestive Department, Nanjing Lishui District Hospital of Traditional Chinese Medicine, Nanjing, China; Zou S., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Gu C., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Li H., Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China^We sought to explore the protective effect of the combination of fenchone (FE) and sodium hyaluronate (SH) on ice water-induced IBS-C rats and the potential mechanism. The neurotransmitter levels, including substance P (SP), motilin (MTL), 5-hydroxytryptamine (5-HT), and vasoactive intestinal peptide (VIP), were determined by ELISA methods. The stem cell factors (SCF)/c-Kit signaling pathway-related protein and mRNA levels were determined by western blot and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analyses, respectively. The expressions of tight ZO-1, Occludin, and Claudin-1 were also measured by western blot assay and immunofluorescence staining. The 16S rRNA gene sequence was used to measure the composition of gut microbiota. The co-administration of FE and SH improved the body weight, number of fecal pellets, fecal moisture, abdominal with drawal reflex score, and gastrointestinal transit rate in IBS-C rats. The unique efficacy of combination depended on the regulation of balance between excitatory and inhibitory neurotransmitters, enhancement of intestinal barrier function, and activation of SCF/c-Kit pathway. The gut microbiota structure was also restored. The ability of FE combined with SH to regulate SCF/c-Kit signaling pathway, enhance intestinal barrier function, and modulate gut microbiota contributes to their efficacy in managing IBS-C in rats. © 2023 John Wiley & Sons Ltd.^constipation-predominant irritable bowel syndrome; fenchone; gut microbiota; SCF/c-kit signaling pathway; sodium hyaluronate^Animals; Camphanes; Constipation; Hyaluronic Acid; Irritable Bowel Syndrome; Norbornanes; Rats; RNA, Ribosomal, 16S; activated carbon; bicyclic monoterpenoid; claudin 1; cytokine; essential oil; fenchone; glycerol; hyaluronic acid; interleukin 18; interleukin 1beta; linaclotide; messenger RNA; motilin; neurotransmitter; occludin; RNA 16S; serotonin; stem cell factor; substance P; tight junction protein; tumor necrosis factor; unclassified drug; vasoactive intestinal polypeptide; camphane derivative; fenchone; hyaluronic acid; norbornane derivative; abdominal wall musculature; animal experiment; animal model; Article; body weight; cell nucleus; chemical structure; clinical practice; colon motility; colon tissue; constipation; controlled study; enzyme linked immunosorbent assay; fluid intake; food intake; gastrointestinal transit; gene sequence; genetic profile; homeostasis; ileocecal valve; immune response; immunofluorescence; immunohistochemistry; intestine flora; intestine motility; irritable colon; male; microbial diversity; myoelectricity; nonhuman; population abundance; protein expression level; quantitative analysis; rat; real time polymerase chain reaction; real time reverse transcription polymerase chain reaction; remission; signal transduction; Simpson index; species diversity; Sprague Dawley rat; upregulation; visceral hyperalgesia; water content; water treatment; Western blotting; withdrawal reflex; animal; constipation; irritable colon^^activated carbon, 64365-11-3, 82228-96-4; claudin 1, 329338-06-9; glycerol, 56-81-5; hyaluronic acid, 31799-91-4, 9004-61-9, 9067-32-7; interleukin 18, 189304-55-0; linaclotide, 851199-59-2, 851199-60-5; motilin, 52906-92-0; occludin, 176304-61-3; serotonin, 50-67-9; substance P, 33507-63-0; vasoactive intestinal polypeptide, 37221-79-7; Camphanes, ; fenchone, ; Hyaluronic Acid, ; Norbornanes, ; RNA, Ribosomal, 16S, ^^^Jiangsu Provincial TCM Science and Technology Development Plan Project, (MS2021025); National Administration of Traditional Chinese Medicine, (2022GJJZDYJS‐01); Social Development Project of Jiangsu Province, (BE2022817); National Natural Science Foundation of China, NSFC, (81403121); National Natural Science Foundation of China, NSFC^This work was financially supported by the National Natural Science Foundation of China (81403121), Jiangsu Provincial TCM Science and Technology Development Plan Project (MS2021025), Social Development Project of Jiangsu Province (BE2022817), and Central government financial transfer payment for local projects from National Administration of Traditional Chinese Medicine (2022GJJZDYJS‐01). ^"Bai Y., Liu F., Zheng L., Wan Y., Fan J., Deng J., Li Q., Xie Y., Guo P., Yajieshaba"" prevents acute alcoholic liver injury and repairs the intestinal mucosal barrier, Journal of Ethnopharmacology, 318, (2023); Bonetti A., Piva A., Grilli E., Botanicals as a zinc oxide alternative to protect intestinal cells from an Escherichia coli F4 infection in vitro by modulation of enterocyte inflammatory response and bacterial virulence, Frontiers in Veterinary Science, 10, (2023); Chen I.J., Wong C.S., Shea nut oil extracts enhance the intra-articular sodium hyaluronate effectiveness on surgically induced OA progression in rats, Nutrients, 12, 4, (2020); DuPont A.W., Jiang Z.D., Harold S.A., Snyder N., Galler G.W., Garcia-Torres F., DuPont H.L., Motility abnormalities in irritable bowel syndrome, Digestion, 89, 2, pp. 119-123, (2014); Faghihi A., Zohalinezhad M.E., Najafi Kalyani M., Comparison of the effects of abdominal massage and Oral Administration of Sweet Almond oil on constipation and quality of life among elderly individuals: A single-blind clinical trial, BioMed Research International, 2022, (2022); Feng J., Gao J., Zhou S., Liu Y., Zhong Y., Shu Y., Meng M.S., Yan J., Sun D., Fang Q., Sun D., Role of stem cell factor in the regulation of ICC proliferation and detrusor contraction in rats with an underactive bladder, Molecular Medicine Reports, 16, 2, pp. 1516-1522, (2017); Filippone A., Ardizzone A., Bova V., Lanza M., Casili G., Cuzzocrea S., Esposito E., Campolo M., Paterniti I., A combination of xyloglucan, pea protein and Chia seed ameliorates intestinal barrier integrity and mucosa functionality in a rat model of constipation-predominant irritable bowel syndrome, Journal of Clinical Medicine, 11, 23, (2022); Fiorino G., Gilardi D., Naccarato P., Sociale O.R., Danese S., Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis, Digestive and Liver Disease, 46, 4, pp. 330-334, (2014); Furgala A., Ciesielczyk K., Przybylska-Felus M., Jablonski K., Gil K., Zwolinska-Wcislo M., Postprandial effect of gastrointestinal hormones and gastric activity in patients with irritable bowel syndrome, Scientific Reports, 13, 1, (2023); Ge C., Luo X., Wu L., Lv Y., Hu Z., Yu D., Liu B., Plant essential oils improve growth performance by increasing antioxidative capacity, enhancing intestinal barrier function, and modulating gut microbiota in Muscovy ducks, Poultry Science, 102, 8, (2023); Gong Y., Liang X., Dai Y., Huang X., Su Q., Ma Y., Chen F., Wang S., Prokinetic effects of Citrus reticulata and Citrus aurantium extract with/without Bupleurum chinense using multistress-induced delayed gastric emptying models, Pharmaceutical Biology, 61, 1, pp. 345-355, (2023); Hao M., Song J., Zhai X., Cheng N., Xu C., Gui S., Chen J., Improvement of loperamide-hydrochloride-induced intestinal motility disturbance by Platycodon grandiflorum polysaccharides through effects on gut microbes and colonic serotonin, Frontiers in Cellular and Infection Microbiology, 13, (2023); Hollister E.B., Cain K.C., Shulman R.J., Jarrett M.E., Burr R.L., Ko C., Zia J., Han C.J., Heitkemper M.M., Relationships of microbiome markers with extraintestinal, psychological distress and gastrointestinal symptoms, and quality of life in women with irritable bowel syndrome, Journal of Clinical Gastroenterology, 54, 2, pp. 175-183, (2020); Hou Y., Dong L., Lu X., Shi H., Xu B., Zhong W., Ma L., Wang S., Yang C., He X., Zhao Y., Wang S., Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome, Digestive Diseases and Sciences, 67, 12, pp. 5580-5592, (2022); Hu J., Gao W.Y., Gao Y., Ling N.S., Huang L.Q., Liu C.X., M3 muscarinic receptor- and Ca2+ influx-mediated muscle contractions induced by croton oil in isolated rabbit jejunum, Journal of Ethnopharmacology, 129, 3, pp. 377-380, (2010); Hu L., Nomura S., Sato Y., Takagi K., Ishii T., Honma Y., Watanabe K., Mizukami Y., Muto J., Anti-inflammatory effects of differential molecular weight hyaluronic acids on UVB-induced calprotectin-mediated keratinocyte inflammation, Journal of Dermatological Science, 107, 1, pp. 24-31, (2022); Jacobs J.P., Lagishetty V., Hauer M.C., Labus J.S., Dong T.S., Toma R., Vuyisich M., Naliboff B.D., Lackner J.M., Gupta A., Tillisch K., Mayer E.A., Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes, Microbiome, 11, 1, (2023); Jung S.M., Ha A.W., Choi S.J., Kim S.Y., Kim W.K., Effect of Bacillus coagulans SNZ 1969 on the improvement of bowel movement in loperamide-treated SD rats, Nutrients, 14, 18, pp. 1-13, (2022); Karaus M., Sarna S.K., Ammon H.V., Wienbeck M., Effects of oral laxatives on colonic motor complexes in dogs, Gut, 28, 9, pp. 1112-1119, (1987); Keskin I., Gunal Y., Ayla S., Kolbasi B., Sakul A., Kilic U., Gok O., Koroglu K., Ozbek H., Effects of Foeniculum vulgare essential oil compounds, fenchone and limonene, on experimental wound healing, Biotechnic & Histochemistry, 92, 4, pp. 274-282, (2017); Kim M., Sowndhararajan K., Kim S., The chemical composition and biological activities of essential oil from Korean native thyme Bak-Ri-hyang (Thymus quinquecostatus Celak.), Molecules, 27, 13, (2022); Kojima R., Doihara H., Nozawa K., Kawabata-Shoda E., Yokoyama T., Ito H., Characterization of two models of drug-induced constipation in mice and evaluation of mustard oil in these models, Pharmacology, 84, 4, pp. 227-233, (2009); Lee J.W., Kim H.H., Hyaluronic acid solution injection for upper and lower gastrointestinal bleeding after failed conventional endoscopic therapy, Digestive Endoscopy, 26, 2, pp. 285-290, (2014); Meligy A.M.A., El-Hamid M.I.A., Yonis A.E., Elhaddad G.Y., Abdel-Raheem S.M., El-Ghareeb W.R., Mohamed M.H.A., Ismail H., Ibrahim D., Liposomal encapsulated oregano, cinnamon, and clove oils enhanced the performance, bacterial metabolites antioxidant potential, and intestinal microbiota of broiler chickens, Poultry Science, 102, 6, (2023); Meunier M., Scandolera A., Chapuis E., Lapierre L., Sandre J., Brunner G., Lovchik M., Reynaud R., The anti-wrinkles properties of sodium acetylated hyaluronate, Journal of Cosmetic Dermatology, 21, 7, pp. 2749-2762, (2022); Parthasarathy G., Chen J., Chen X., Chia N., O'Connor H.M., Wolf P.G., Gaskins H.R., Bharucha A.E., Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation, Gastroenterology, 150, 2, pp. 367-379 e361, (2016); Pessoa M.L.S., Silva L.M.O., Araruna M.E.C., Serafim C.A.L., Junior E.B.A., Silva A.O., Pessoa M.M.B., Neto H.D., Lima E.O., Batista L.M., Antifungal activity and antidiarrheal activity via antimotility mechanisms of (−)-fenchone in experimental models, World Journal of Gastroenterology, 26, 43, pp. 6795-6809, (2020); Picon P.D., Picon R.V., Costa A.F., Sander G.B., Amaral K.M., Aboy A.L., Henriques A.T., Randomized clinical trial of a phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for chronic constipation, BMC Complementary and Alternative Medicine, 10, (2010); Rangan V., Ballou S., Shin A., Camilleri M., Nee J., Iturrino J., Singh P., Patel R., Lembo A., Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey, Gastroenterology, 158, 3, pp. 786-788 e781, (2020); Reigstad C.S., Salmonson C.E., Rainey J.F., Szurszewski J.H., Linden D.R., Sonnenburg J.L., Farrugia G., Kashyap P.C., Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells, The FASEB Journal, 29, 4, pp. 1395-1403, (2015); Saravanaperumal S.A., Gibbons S.J., Malysz J., Sha L., Linden D.R., Szurszewski J.H., Farrugia G., Extracellular Cl(−) regulates electrical slow waves and setting of smooth muscle membrane potential by interstitial cells of Cajal in mouse jejunum, Experimental Physiology, 103, 1, pp. 40-57, (2018); Sedky A.A., Magdy Y., Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome, Life Sciences, 256, (2020); Shang X.E.F.F., Guo K.L., Li Y.F., Zhao H.L., Wang Y., Chen N., Nian T., Yang C.Q., Yang K.H., Li X.X., Effectiveness and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis of 10 randomized controlled trials, Nutrients, 14, 12, (2022); Slavchev I., Dobrikov G.M., Valcheva V., Ugrinova I., Pasheva E., Dimitrov V., Antimycobacterial activity generated by the amide coupling of (−)-fenchone derived aminoalcohol with cinnamic acids and analogues, Bioorganic & Medicinal Chemistry Letters, 24, 21, pp. 5030-5033, (2014); Tan W., Lee G., Chen J.H., Huizinga J.D., Relationships between distention-, butyrate- and pellet-induced stimulation of peristalsis in the mouse colon, Frontiers in Physiology, 11, (2020); Tang S., Liu W., Zhao Q., Li K., Zhu J., Yao W., Gao X., Combination of polysaccharides from Astragalus membranaceus and Codonopsis pilosula ameliorated mice colitis and underlying mechanisms, Journal of Ethnopharmacology, 264, (2021); Tian H., Cui J., Ye C., Zhao J., Yang B., Xu Y., Ji S., Wang L., Lv X., Ma C., Zhou S., Li N., Wang X., Qin H., Chen Q., Depletion of butyrate-producing microbes of the firmicutes predicts nonresponse to FMT therapy in patients with recurrent Clostridium difficile infection, Gut Microbes, 15, 1, (2023); van Muijlwijk G.H., van Mierlo G., Jansen P., Vermeulen M., Bleumink-Pluym N.M.C., Palm N.W., van Putten J.P.M., de Zoete M.R., Identification of Allobaculum mucolyticum as a novel human intestinal mucin degrader, Gut Microbes, 13, 1, (2021); Vanuytsel T., Bercik P., Boeckxstaens G., Understanding neuroimmune interactions in disorders of gut-brain interaction: From functional to immune-mediated disorders, Gut, 72, 4, pp. 787-798, (2023); Vedantam G., Viswanathan V.K., Unlocking the gates to inflammatory bowel disease: The role of Enterococcus faecalis gelatinase, Gastroenterology, 141, 3, pp. 795-798, (2011); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut microbial dysbiosis in the irritable bowel syndrome: A systematic review and meta-analysis of case-control studies, Journal of the Academy of Nutrition and Dietetics, 120, 4, pp. 565-586, (2020); Wang X., Xiao Y., Xu X., Guo L., Yu Y., Li N., Xu C., Characteristics of fecal microbiota and machine learning strategy for fecal invasive biomarkers in pediatric inflammatory bowel disease, Frontiers in Cellular and Infection Microbiology, 11, (2021); Wen Y., Li J., Long Q., Yue C.C., He B., Tang X.G., The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials, International Journal of Surgery, 79, pp. 111-119, (2020); Yokoi A., Kamata N., The usefulness of olive oil enema in children with severe chronic constipation, Journal of Pediatric Surgery, 56, 7, pp. 1141-1144, (2021); Zhang D., Lu R., Wang M., Ji J., Zhang S., Wang S., Zhang D., Chen M., Effects of Banxia Xiexin decoction on apoptosis of interstitial cells of Cajal via regulation of MiR-451-5p: An in vivo and in vitro study, Journal of Ethnopharmacology, 314, (2023); Zhao Y., Zou D.W., Gut microbiota and irritable bowel syndrome, Journal of Digestive Diseases, 24, pp. 312-320, (2023); Zhu Y., Yang Y., Guo J., Zhang W., Zhu Z., Xie B., Yu J., Cheng J., Abdominal manual therapy repairs interstitial cells of Cajal and increases colonic c-kit expression when treating bowel dysfunction after spinal cord injury, BioMed Research International, 2017, (2017)"^C. Gu; Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; email: gcsunny@163.com; H. Li; Department of Gastroenterology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; email: jessica20110215@163.com^^John Wiley and Sons Inc^^^^^^17470277^^CBDDA^38030381.0^English^Chem. Biol. Drug Des.^Article^Final^^Scopus^2-s2.0-85178242854
Fan X.; Shi J.; Liu Y.; Zhang M.; Lu M.; Qu D.^Fan, Xinyu (57226534707); Shi, Jiachen (58127241100); Liu, Ye (58302577000); Zhang, Mengqiu (58302524500); Lu, Min (56553533900); Qu, Ding (55924162600)^57226534707; 58127241100; 58302577000; 58302524500; 56553533900; 55924162600^Cannabidiol-Decorated Berberine-Loaded Microemulsions Improve IBS-D Therapy Through Ketogenic Diet-Induced Cannabidiol Receptors Overexpression^2023^International Journal of Nanomedicine^18.0^^^2839^2853^14.0^2^10.2147/IJN.S402871^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160973727&doi=10.2147%2fIJN.S402871&partnerID=40&md5=d050cd4bbaa1ab488595f44337d92d88^Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China; The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China^Fan X., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China; Shi J., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Liu Y., The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Zhang M., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China; Lu M., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China; Qu D., Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China^Background: Berberine (BR) shows promise as a candidate for treating irritable bowel syndrome with diarrhea (IBS-D). However, the undesired physicochemical properties and poor oral absorption limit its clinical translation. A ketogenic diet (KD) can induce intestinal overexpression of cannabidiol (CB) receptors, which may offer a potential target for IBS-D-specific delivery of BR. Methods: The microemulsions loaded with BR and decorated with cannabidiol (CBD/BR-MEs) were developed through a one-step emulsion method. The pharmaceutical behaviors of the CBD/BR-MEs were measured using dynamic light scattering and high-performance liquid chromatography. The efficacy of the anti-IBS-D therapy was evaluated by assessing fecal water content, Bristol score, and AWR score. The intestinal permeability were assessed through immunofluorescent staining of CB1 and ZO-1, respectively. The signaling of CREB/BDNF/c-Fos was also studied along with immunofluorescent and immunohistochemical examination of brain sections. Results: The CBD/BR-MEs, which had a particle size of approximately 30 nm and a surface density of 2% (wt%) CBD, achieved greater than 80% (wt%) encapsulation efficiency of BR. The pharmacokinetics performance of CBD/BR-MEs was significantly improved in the KD-fed IBS-D rats than the standard diet-fed ones, which is highly related to intestinal expression of CB1 receptors. The treatment with CBD/BR-MEs and KD exhibited evident comprehensive advantages over the other groups in terms of anti-IBS-D efficacy. CBD/BR-MEs and KD synergistically decreased intestinal permeability. Moreover, the treatment with CBD/BR-MEs and KD not only blocked the CREB/BDNF/c-Fos signaling in the brain but also decreased the levels of neurotrophic factors, neurotransmitters, and inflammatory cytokines in the serum of IBS-D model rats. Conclusion: Such a design represents the first attempt at IBS-D-targeted drug delivery for improved oral absorption and efficacy through KD-induced target exposure, which holds promising potential for the treatment of IBS-D. © 2023 Fan et al.^berberine; CB1 receptors; irritable bowel syndrome-diarrhea; ketogenic diet; microemulsion^Animals; Berberine; Brain-Derived Neurotrophic Factor; Cannabidiol; Diarrhea; Diet, Ketogenic; Irritable Bowel Syndrome; Rats; berberine; cannabidiol; cannabinoid 1 receptor; neurotransmitter; neurotrophic factor; berberine; brain derived neurotrophic factor; cannabidiol; animal cell; animal experiment; animal model; Article; diarrhea; drug absorption; drug delivery system; drug distribution; drug efficacy; drug formulation; high performance liquid chromatography; intestine mucosa permeability; irritable colon; male; microemulsion; nanoencapsulation; nonhuman; particle size; photon correlation spectroscopy; rat; water content; animal; diarrhea; ketogenic diet; metabolism^^berberine, 2086-83-1, 633-65-8; cannabidiol, 13956-29-1; brain derived neurotrophic factor, 218441-99-7; Berberine, ; Brain-Derived Neurotrophic Factor, ; Cannabidiol, ^^^Jiangsu Provincial Cadre Health Research Project, (BJ20026); National Natural Science Foundation of China, NSFC, (81873017, 82173980); Natural Science Foundation of Jiangsu Province, (BK20211389); Six Talent Peaks Project in Jiangsu Province, (WSN-040, YY-028-2019); Graduate Research and Innovation Projects of Jiangsu Province, (SJCX22-0841)^Funding text 1: This work was also supported by Graduate Research and Practice Innovation Project of Jiangsu Province (SJCX22-0841).; Funding text 2: This work was supported by National Natural Science Foundation of China (82173980 and 81873017), Natural Science Foundation of Jiangsu Province of China (BK20211389), the Six Talent Peak Project of Jiangsu Province (WSN-040; YY-028-2019), and the Jiangsu Provincial Cadre Health Research Project (BJ20026).^Chey WD, Kurlander J, Eswaran S., Irritable bowel syndrome: a clinical review, JAMA, 313, 9, pp. 949-958, (2015); Enck P, Aziz Q, Barbara G, Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Singh P, Staller K, Barshop K, Et al., Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation, World j Gastroenterol, 21, 26, pp. 8103-8109, (2015); Gracie DJ, Hamlin PJ, Ford AC., The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment, lancet Gastroenterol Hepatol, 4, 8, pp. 632-642, (2019); Shi C, Dawulieti J, Shi F, Et al., A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease, Sci Adv, 8, 4, (2022); Barbaro MR, Cremon C., Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders, Nutrients, 12, 12, (2020); Martin CR, Osadchiy V, Kalani A, Mayer EA., The Brain-Gut-Microbiome Axis, Cell Mol Gastroenterol Hepatol, 6, 2, pp. 133-148, (2018); Pinto-Sanchez MI, Hall GB, Ghajar K, Et al., Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: a Pilot Study in Patients With Irritable Bowel Syndrome, Gastroenterology, 153, 2, pp. 448-459, (2017); Xu J, Xu J, Shi T, Et al., Restores Intestinal Homeostasis in Colitis by Regulating Redox Balance, Immune Responses, and the Gut Microbiome, Adv Mater, 35, 3, (2023); Zhang W, Xu JH, Yu T, Chen QK., Effects of berberine and metformin on intestinal inflammation and gut microbiome composition in db/db mice, Biomed Pharmacother, 118, (2019); Lu Y, Huang J, Zhang Y, Et al., Therapeutic Effects of Berberine Hydrochloride on Stress-Induced Diarrhea-Predominant Irritable Bowel Syndrome Rats by Inhibiting Neurotransmission in Colonic Smooth Muscle, Front Pharmacol, 12, (2021); Wang Y, Tong Q, Ma SR, Et al., Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota, Signal Transduction and Targeted Therapy, 6, 1, (2021); Qu D, Wang L, Qin Y, Et al., Non-triggered sequential-release liposomes enhance anti-breast cancer efficacy of STS and celastrol-based microemulsion, Biomaterials sci, 6, 12, pp. 3284-3299, (2018); Su X, Gao C, Shi F, Et al., A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance, Drug Deliv, 24, 1, pp. 10-19, (2017); Gui SY, Wu L, Peng DY, Liu QY, Yin BP, Shen JZ., Preparation and evaluation of a microemulsion for oral delivery of berberine, Die Pharmazie, 63, 7, pp. 516-519, (2008); Ang QY, Alexander M, Newman JC, Et al., Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells, Cell, 181, 6, pp. 1263-1275, (2020); Gigante I, Tutino V, Russo F., Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet, International Journal of Molecular Sciences, 22, 6, (2021); Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, Br J Pharmacol, 172, 20, pp. 4790-4805, (2015); Pertwee RG., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin, Br J Pharmacol, 153, 2, pp. 199-215, (2008); Fathalipour S, Ataei B, Janati F., Aqueous suspension of biocompatible reduced graphene oxide-Au NPs composite as an effective recyclable catalyst in a Betti reaction, Mater Sci Eng C Mater Biol Appl, 97, pp. 356-366, (2019); Zhong L, Xu L, Liu Y, Et al., Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy, Acta pharmaceutica Sinica B, 9, 2, pp. 397-409, (2019); Zuo Z, Li M, Han T, Et al., A platelet-cloaking tetramethylprazine-loaded microemulsion for improved therapy of myocardial ischaemia/reperfusion injury, J Drug Target, 30, 6, pp. 646-656, (2022); Chen Y, Wang S, Hu Q, Zhou L., Self-Emulsifying System Coloaded with Paclitaxel and Coix Seed Oil Deeply Penetrated to Enhance Efficacy of Cervical Cancer, Curr Drug Deliv, 2, (2022); Maulvi FA, Desai AR, Choksi HH, Et al., Effect of surfactant chain length on drug release kinetics from microemulsion-laden contact lenses, Int J Pharm, 524, 1–2, pp. 193-204, (2017); Bao CH, Wang CY, Li GN, Et al., Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome, World j Gastroenterol, 25, 32, pp. 4696-4714, (2019); Al-Chaer ED, Kawasaki M, Pasricha PJ., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Zhou Q, Verne ML, Fields JZ, Et al., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, 6, pp. 996-1002, (2019); Pleguezuelos-Manzano C, Puschhof J, van den Brink S, Geurts V, Beumer J, Clevers H., Establishment and Culture of Human Intestinal Organoids Derived from Adult Stem Cells, Curr Protocols Immunol, 130, 1, (2020); Mohammadi S, Morell-Perez C, Wright CW, Et al., Assessing donor-to-donor variability in human intestinal organoid cultures, Stem Cell Reports, 16, 9, pp. 2364-2378, (2021); Lin J, Huang L, Xiang R, Et al., Blood compatibility evaluations of CaCO<sub>3</sub> particles, Biomed Mater, 16, 5, (2021); Mohamed AS, Fahmy SR, Soliman AM, Gaafar KM., Effects of 3 Rodent Beddings on Biochemical Measures in Rats and Mice, J Am Assoc Lab Anim Sci, 57, 5, pp. 443-446, (2018); Chen Y, Qu D, Fu R, Et al., A Tf-modified tripterine-loaded coix seed oil microemulsion enhances anti-cervical cancer treatment, Int J Nanomedicine, 13, pp. 7275-7287, (2018); Cheng MB, Wang JC, Li YH, Et al., Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme, J Controlled Release, 129, 1, pp. 41-48, (2008); Raskov H, Burcharth J, Pommergaard HC, Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 7, 5, pp. 365-383, (2016); Ford AC, Sperber AD, Corsetti M, Camilleri M., Irritable bowel syndrome, Lancet, 396, 10263, pp. 1675-1688, (2020); Li H, Wang T, Shi C, Et al., Inhibition of GALR1 in PFC Alleviates Depressive-Like Behaviors in Postpartum Depression Rat Model by Upregulating CREB-BNDF and 5-HT Levels, Front Psychiatry, 9, (2018); Rosa K, Delgado-Herrera L, Zeiher B, Et al., Psychometric assessment of the IBS-D Daily Symptom Diary and Symptom Event Log, Quality Res, 25, 12, pp. 3197-3208, (2016)^M. Lu; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 100 Shizi Street, Hongshan Road, 210028, China; email: lmxlsr6666@163.com; D. Qu; Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 100 Shizi Street, Hongshan Road, 210028, China; email: quding1985@hotmail.com^^Dove Medical Press Ltd^^^^^^11769114^^^37273286.0^English^Int. J. Nanomed.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85160973727
Zhao Y.; Zhan J.; Sun C.; Zhu S.; Zhai Y.; Dai Y.; Wang X.; Gao X.^Zhao, Yucui (57929201600); Zhan, Jiaguo (58284590300); Sun, Congying (57929138600); Zhu, Shixiao (58857940200); Zhai, Yue (58857745400); Dai, Yongna (57217080459); Wang, Xiaoying (56013824000); Gao, Xiumei (7403872165)^57929201600; 58284590300; 57929138600; 58857940200; 58857745400; 57217080459; 56013824000; 7403872165^Sishen Wan enhances intestinal barrier function via regulating endoplasmic reticulum stress to improve mice with diarrheal irritable bowel syndrome^2024^Phytomedicine^129.0^^155541^^^^0^10.1016/j.phymed.2024.155541^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189512466&doi=10.1016%2fj.phymed.2024.155541&partnerID=40&md5=7be350af59dbc075b906cb01496b87da^Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China^Zhao Y., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Zhan J., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Sun C., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Zhu S., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Zhai Y., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Dai Y., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Wang X., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China, State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; Gao X., Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China^Background: Diarrheal irritable bowel syndrome (IBS-D), characterized primarily by the presence of diarrhea and abdominal pain, is a clinical manifestation resulting from a multitude of causative factors. Furthermore, Sishen Wan (SSW) has demonstrated efficacy in treating IBS-D. Nevertheless, its mechanism of action remains unclear. Methods: A model of IBS-D was induced by a diet containing 45 % lactose and chronic unpredictable mild stress. Additionally, the impact of SSW was assessed by measuring body weight, visceral sensitivity, defecation parameters, intestinal transport velocity, intestinal neurotransmitter levels, immunohistochemistry, and transmission electron microscopy analysis. Immunofluorescent staining was used to detect the expression of Mucin 2 (MUC2) and Occludin in the colon. Western blotting was used to detect changes in proteins related to tight junction (TJ), autophagy, and endoplasmic reticulum (ER) stress in the colon. Finally, 16S rRNA amplicon sequencing was used to monitor the alteration of gut microbiota after SSW treatment. Results: Our study revealed that SSW administration resulted in reduced visceral sensitivity, improved defecation parameters, decreased intestinal transport velocity, and reduced intestinal permeability in IBS-D mice. Furthermore, SSW promotes the secretion of colonic mucus by enhancing autophagy and inhibiting ER stress. SSW treatment caused remodeling of the gut microbiome by increasing the abundance of Blautia, Muribaculum and Ruminococcus torques group. Conclusion: SSW can improve intestinal barrier function by promoting autophagy and inhibiting ER stress, thus exerting a therapeutic effect on IBS-D. © 2024 Elsevier GmbH^Colonic mucus; Diarrheal irritable bowel syndrome; Endoplasmic reticulum stress; Sishen Wan^Animals; Autophagy; Colon; Diarrhea; Disease Models, Animal; Drugs, Chinese Herbal; Endoplasmic Reticulum Stress; Gastrointestinal Microbiome; Intestinal Barrier Function; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred C57BL; Mucin-2; Occludin; Permeability; Tight Junctions; beclin 1; Chinese medicinal formula; claudin 2; digestive tract agent; Evodia fruit; lactose; microtubule associated protein; microtubule associated protein 1A 1B light chain; mucin 2; neurotransmitter; occludin; RNA 16S; Schisandra chinensis extract; sequestosome 1; sishen wan; unclassified drug; herbaceous agent; mucin 2; occludin; abdominal pain; abdominal wall musculature; Akkermansia; amplicon; animal experiment; animal model; animal tissue; Article; autophagy (cellular); Bacteroides; Bifidobacterium; Blautia; body weight; chronic unpredictable stress; colon tissue; controlled study; Cullen corylifolium; defecation; diarrhea; drug efficacy; drug mechanism; drug synthesis; endoplasmic reticulum stress; enzyme linked immunosorbent assay; feces microflora; immunofluorescence assay; immunohistochemistry; intestinal barrier function; intestine absorption; intestine brush border; intestine flora; intestine motility; intestine mucosa permeability; intestine transit time; irritable colon; Lactobacillus; male; metabolic disorder; microbial community; mouse; mucus secretion; Muribaculum; muscle contraction; neutrophil chemotaxis; nonhuman; nutmeg; protein expression; Ruminococcus; Shannon index; tight junction; transmission electron microscopy; viscera; Western blotting; animal; C57BL mouse; colon; disease model; drug effect; drug therapy; intestinal barrier function; intestine flora; intestine mucosa; metabolism; permeability^^lactose, 10039-26-6, 16984-38-6, 63-42-3, 64044-51-5; occludin, 176304-61-3; Drugs, Chinese Herbal, ; Mucin-2, ; Occludin, ^^^National Natural Science Foundation of China, NSFC, (82192914); National Natural Science Foundation of China, NSFC^This work was supported by the National Natural Science Foundation of China under Grant No. 82192914 . ^Alvarado D.M., Chen B., Iticovici M., Thaker A.I., Dai N., VanDussen K.L., Shaikh N., Lim C.K., Guillemin G.J., Tarr P.I., Ciorba M.A., Epithelial indoleamine 2,3-dioxygenase 1 modulates aryl hydrocarbon receptor and notch signaling to increase differentiation of secretory cells and alter mucus-associated microbiota, Gastroenterology, 157, pp. 1093-1108.e1011, (2019); Annahazi A., Roka R., Rosztoczy A., Wittmann T., Role of antispasmodics in the treatment of irritable bowel syndrome, World J. Gastroenterol., 20, pp. 6031-6043, (2014); Camilleri M., Magnus Y., Carlson P., Wang X.J., Chedid V., Maselli D., Taylor A., McKinzie S., Kengunte Nagaraj N., Busciglio I., Nair A., Differential mRNA expression in ileal and colonic biopsies in irritable bowel syndrome with diarrhea or constipation, Am. J. Physiol. Gastrointest. Liver. Physiol., 323, pp. G88-g101, (2022); Canavan C., West J., Card T., Review article: the economic impact of the irritable bowel syndrome, Aliment. Pharmacol. Ther., 40, pp. 1023-1034, (2014); Cantero-Recasens G., Burballa C., Ohkawa Y., Fukuda T., Harada Y., Curwin A.J., Brouwers N., Thun G.A., Gu J., Gut I., Taniguchi N., Malhotra V., The ulcerative colitis-associated gene FUT8 regulates the quantity and quality of secreted mucins, Proc. Natl. Acad. Sci. U S A, 119, (2022); Chen Q., Zhang H., Sun C.Y., He Q.Y., Zhang R.R., Luo B.F., Zhou Z.H., Chen X.F., Evaluation of two laboratory model methods for diarrheal irritable bowel syndrome, Mol. Med., 29, (2023); Cheng S., Ma X., Geng S., Jiang X., Li Y., Hu L., Li J., Wang Y., Han X., Fecal microbiota transplantation beneficially regulates intestinal mucosal autophagy and alleviates gut barrier injury, mSystems, 3, (2018); Chi L., Khan I., Lin Z., Zhang J., Lee M.Y.S., Leong W., Hsiao W.L.W., Zheng Y., Fructo-oligosaccharides from Morinda officinalis remodeled gut microbiota and alleviated depression features in a stress rat model, Phytomedicine, 67, (2020); Donohoe D.R., Garge N., Zhang X., Sun W., O'Connell T.M., Bunger M.K., Bultman S.J., The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon, Cell Metab., 13, pp. 517-526, (2011); Flacco M.E., Manzoli L., De Giorgio R., Gasbarrini A., Cicchetti A., Bravi F., Altini M., Caio G.P., Ursini F., Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis, Eur. Rev. Med. Pharmacol. Sci., 23, pp. 2986-3000, (2019); Ford A.C., Sperber A.D., Corsetti M., Camilleri M., Irritable bowel syndrome, Lancet, 396, pp. 1675-1688, (2020); Gao J., Xiong T., Grabauskas G., Owyang C., Mucosal serotonin reuptake transporter expression in irritable bowel syndrome is modulated by gut microbiota via mast cell-prostaglandin E2, Gastroenterology, 162, pp. 1962-1974.e1966, (2022); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Goodoory V.C., Ng C.E., Black C.J., Ford A.C., Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom, Aliment. Pharmacol. Ther., 56, pp. 110-120, (2022); Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G., A diet low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, pp. 67-75.e65, (2014); Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., De Winter B.Y., Grover M., Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review, Therap. Adv. Gastroenterol., 14, (2021); Hu W.D., Hong L.L., Wang W., Wang H.D., Jiang M.T., Li X.H., Xu X.Y., Hu Y., Wang S.Y., Wang Y., Zou Y.D., Wang X.Y., Gao X.M., Yang W.Z., Unveiling the chemical components variation of Sishen formula induced by different prescription ratios by the advanced liquid chromatography/mass spectrometry approaches, Arab. J. Chem., 17, (2024); Imhann F., Vich Vila A., Bonder M.J., Fu J., Gevers D., Visschedijk M.C., Spekhorst L.M., Alberts R., Franke L., van Dullemen H.M., Ter Steege R.W.F., Huttenhower C., Dijkstra G., Xavier R.J., Festen E.A.M., Wijmenga C., Zhernakova A., Weersma R.K., Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease, Gut, 67, pp. 108-119, (2018); Jacobs J.P., Lagishetty V., Hauer M.C., Labus J.S., Dong T.S., Toma R., Vuyisich M., Naliboff B.D., Lackner J.M., Gupta A., Tillisch K., Mayer E.A., Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes, Microbiome, 11, (2023); Jin X., Hu Y., Lin T., Gao F., Xu Z., Hou X., Yin Y., Kan S., Zhu H., Chen D., Selenium-enriched Bifidobacterium longum DD98 relieves irritable bowel syndrome induced by chronic unpredictable mild stress in mice, Food Funct., 14, pp. 5355-5374, (2023); Kamphuis J.B.J., Guiard B., Leveque M., Olier M., Jouanin I., Yvon S., Tondereau V., Riviere P., Gueraud F., Chevolleau S., Noguer-Meireles M.H., Martin J.F., Debrauwer L., Eutamene H., Theodorou V., Lactose and fructo-oligosaccharides increase visceral sensitivity in mice via glycation processes, increasing mast cell density in colonic mucosa, Gastroenterology, 158, pp. 652-663.e656, (2020); Kaser A., Lee A.H., Franke A., Glickman J.N., Zeissig S., Tilg H., Nieuwenhuis E.E., Higgins D.E., Schreiber S., Glimcher L.H., Blumberg R.S., XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease, Cell, 134, pp. 743-756, (2008); Ke X., You K., Pichaud M., Haiser H.J., Graham D.B., Vlamakis H., Porter J.A., Xavier R.J., Gut bacterial metabolites modulate endoplasmic reticulum stress, Genome Biol., 22, (2021); Kennelly J.P., Carlin S., Ju T., van der Veen J.N., Nelson R.C., Buteau J., Thiesen A., Richard C., Willing B.P., Jacobs R.L., Intestinal phospholipid disequilibrium initiates an ER stress response that drives goblet cell necroptosis and spontaneous colitis in mice, Cell Mol. Gastroenterol. Hepatol., 11, pp. 999-1021, (2021); Larabi A., Barnich N., Nguyen H.T.T., New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD, Autophagy, 16, pp. 38-51, (2020); Lembo A., Sultan S., Chang L., Heidelbaugh J.J., Smalley W., Verne G.N., AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea, Gastroenterology, 163, pp. 137-151, (2022); Linsalata M., Riezzo G., Orlando A., D'Attoma B., Prospero L., Tutino V., Notarnicola M., Russo F., The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with ibs diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial, Nutrients, 13, (2021); Liu L., Saitz-Rojas W., Smith R., Gonyar L., In J.G., Kovbasnjuk O., Zachos N.C., Donowitz M., Nataro J.P., Ruiz-Perez F., Mucus layer modeling of human colonoids during infection with enteroaggragative E. coli, Sci. Rep., 10, (2020); Liu S., Zhao S., Cheng Z., Ren Y., Shi X., Mu J., Ge X., Dai Y., Li L., Zhang Z., Akkermansia muciniphila protects against antibiotic-associated diarrhea in mice, Probiotics. Antimicrob. Proteins, (2023); Liu X., Mao B., Gu J., Wu J., Cui S., Wang G., Zhao J., Zhang H., Chen W., Blautia-a new functional genus with potential probiotic properties?, Gut. Microbes, 13, pp. 1-21, (2021); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Martinon F., Chen X., Lee A.H., Glimcher L.H., TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages, Nat. Immunol., 11, pp. 411-418, (2010); Mayer E.A., Ryu H.J., Bhatt R.R., The neurobiology of irritable bowel syndrome, Mol. Psychiatry, 28, pp. 1451-1465, (2023); Naama M., Telpaz S., Awad A., Ben-Simon S., Harshuk-Shabso S., Modilevsky S., Rubin E., Sawaed J., Zelik L., Zigdon M., Asulin N., Turjeman S., Werbner M., Wongkuna S., Feeney R., Schroeder B.O., Nyska A., Nuriel-Ohayon M., Bel S., Autophagy controls mucus secretion from intestinal goblet cells by alleviating ER stress, Cell Host. Microbe, 31, pp. 433-446.e434, (2023); Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C., Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, Lancet Gastroenterol. Hepatol., 5, pp. 908-917, (2020); Paton A.W., Beddoe T., Thorpe C.M., Whisstock J.C., Wilce M.C., Rossjohn J., Talbot U.M., Paton J.C., AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP, Nature, 443, pp. 548-552, (2006); Petitfils C., Maurel S., Payros G., Hueber A., Agaiz B., Gazzo G., Marrocco R., Auvray F., Langevin G., Motta J.P., Floch P., Tremblay-Franco M., Galano J.M., Guy A., Durand T., Lachambre S., Durbec A., Hussein H., Decraecker L., Bertrand-Michel J., Saoudi A., Oswald E., Poisbeau P., Dietrich G., Melchior C., Boeckxstaens G., Serino M., Le Faouder P., Cenac N., Identification of bacterial lipopeptides as key players in IBS, Gut, 72, pp. 939-950, (2023); Seewoo B.J., Chua E.G., Arena-Foster Y., Hennessy L.A., Gorecki A.M., Anderton R., Rodger J., Changes in the rodent gut microbiome following chronic restraint stress and low-intensity rTMS, Neurobiol. Stress., 17, (2022); Skrzydlo-Radomanska B., Prozorow-Krol B., Cichoz-Lach H., Majsiak E., Bierla J.B., Kosikowski W., Szczerbinski M., Gantzel J., Cukrowska B., The effectiveness of synbiotic preparation containing lactobacillus and bifidobacterium probiotic strains and short chain fructooligosaccharides in patients with diarrhea predominant irritable bowel syndrome-a randomized double-blind, placebo-controlled study, Nutrients, 12, pp. 1-19, (2020); Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., Whitehead W.E., Dumitrascu D.L., Fang X., Fukudo S., Kellow J., Okeke E., Quigley E.M.M., Schmulson M., Whorwell P., Archampong T., Adibi P., Andresen V., Benninga M.A., Bonaz B., Bor S., Fernandez L.B., Choi S.C., Corazziari E.S., Francisconi C., Hani A., Lazebnik L., Lee Y.Y., Mulak A., Rahman M.M., Santos J., Setshedi M., Syam A.F., Vanner S., Wong R.K., Lopez-Colombo A., Costa V., Dickman R., Kanazawa M., Keshteli A.H., Khatun R., Maleki I., Poitras P., Pratap N., Stefanyuk O., Thomson S., Zeevenhooven J., Palsson O.S., Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study, Gastroenterology, 160, pp. 99-114.e113, (2021); Wang H.Y., Zhao H.M., Wang Y., Liu Y., Lu X.Y., Liu X.K., Chen F., Ge W., Zuo Z.Y., Liu D.Y., Sishen Wan(®) Ameliorated trinitrobenzene-sulfonic-acid-induced chronic colitis via NEMO/NLK signaling pathway, Front. Pharmacol., 10, (2019); Wang L., Chai M., Wang J., Yu Q., Wang G., Zhang H., Zhao J., Chen W., Bifidobacterium longum relieves constipation by regulating the intestinal barrier of mice, Food Funct., 13, pp. 5037-5049, (2022); Wang L.X., Zhao Q., Zhang Y., Xue R., Li S., Li Y., Yu J.J., Li J.C., Zhang Y.Z., Network pharmacology and pharmacological evaluation for deciphering novel indication of Sishen Wan in insomnia treatment, Phytomedicine, 108, (2023); Wang Q., Wang C., Abdullah, Tian W., Qiu Z., Song M., Cao Y., Xiao J., Hydroxytyrosol alleviates dextran sulfate sodium-induced colitis by modulating inflammatory responses, intestinal barrier, and microbiome, J. Agric. Food Chem., 70, pp. 2241-2252, (2022); Wei Y., Fan Y., Huang S., Lv J., Zhang Y., Hao Z., Baizhu shaoyao decoction restores the intestinal barrier and brain-gut axis balance to alleviate diarrhea-predominant irritable bowel syndrome via FoxO1/FoxO3a, Phytomedicine, 122, (2024); Xia X., Lin H., Luo F., Wu X., Zhu L., Chen S., Luo H., Ye F., Peng X., Zhang Y., Yang G., Lin Q., Oryzanol ameliorates DSS-stimulated gut barrier damage via targeting the gut microbiota accompanied by the TLR4/NF-κB/NLRP3 cascade response in vivo, J. Agric. Food Chem., 70, pp. 15747-15762, (2022); Xie Y., Zhan X., Tu J., Xu K., Sun X., Liu C., Ke C., Cao G., Zhou Z., Liu Y., Atractylodes oil alleviates diarrhea-predominant irritable bowel syndrome by regulating intestinal inflammation and intestinal barrier via SCF/c-kit and MLCK/MLC2 pathways, J. Ethnopharmacol., 272, (2021); Xiong R., Li W., Li Y., Zheng K., Zhang T., Gao M., Li Y., Hu L., Hu C., Er Shen Wan extract reduces diarrhea and regulates AQP 4 and NHE 3 in a rat model of spleen-kidney Yang deficiency-induced diarrhea, Biomed. PharmacOther, 98, pp. 834-846, (2018); Yao D., Dai W., Dong M., Dai C., Wu S., MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis, EBioMedicine, 74, (2021); Zhai L., Huang C., Ning Z., Zhang Y., Zhuang M., Yang W., Wang X., Wang J., Zhang L., Xiao H., Zhao L., Asthana P., Lam Y.Y., Chow C.F.W., Huang J.D., Yuan S., Chan K.M., Yuan C.S., Lau J.Y., Wong H.L.X., Bian Z.X., Ruminococcus gnavus plays a pathogenic role in diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis, Cell Host. Microbe, 31, pp. 33-44.e35, (2023)^Y. Dai; Key Laboratory of Pharmacology of Traditional Chinese Medical Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, inghai District, No.10 Poyanghu Road, Tianjin, 301617, China; email: daiyongna@tjutcm.edu.cn^^Elsevier GmbH^^^^^^09447113^^PYTOE^38579640.0^English^Phytomedicine^Article^Final^^Scopus^2-s2.0-85189512466
Maqoud F.; Orlando A.; Tricarico D.; Antonacci M.; Di Turi A.; Giannelli G.; Russo F.^Maqoud, Fatima (57189688787); Orlando, Antonella (23767683100); Tricarico, Domenico (7003562407); Antonacci, Marina (57468115900); Di Turi, Annamaria (56180925800); Giannelli, Gianluigi (7005015716); Russo, Francesco (57201476097)^57189688787; 23767683100; 7003562407; 57468115900; 56180925800; 7005015716; 57201476097^Anti-Inflammatory Effects of a Novel Acetonitrile–Water Extract of Lens Culinaris against LPS-Induced Damage in Caco-2 Cells^2024^International Journal of Molecular Sciences^25.0^7^3802^^^^0^10.3390/ijms25073802^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85190364768&doi=10.3390%2fijms25073802&partnerID=40&md5=854905ef63177c43adfb00b1b3e1982d^Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Scientific Direction, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy^Maqoud F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Orlando A., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Tricarico D., Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Antonacci M., Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Di Turi A., Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari ‘Aldo Moro’, BA, Bari, 70121, Italy; Giannelli G., Scientific Direction, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy; Russo F., Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, BA, Castellana Grotte, 70013, Italy^Natural compounds like flavonoids preserve intestinal mucosal integrity through their antioxidant, anti-inflammatory, and antimicrobial properties. Additionally, some flavonoids show prebiotic abilities, promoting the growth and activity of beneficial gut bacteria. This study investigates the protective impact of Lens culinaris extract (LE), which is abundant in flavonoids, on intestinal mucosal integrity during LPS-induced inflammation. Using Caco-2 cells as a model for the intestinal barrier, the study found that LE did not affect cell viability but played a cytoprotective role in the presence of LPS. LE improved transepithelial electrical resistance (TEER) and tight junction (TJ) protein levels, which are crucial for barrier integrity. It also countered the upregulation of pro-inflammatory genes TRPA1 and TRPV1 induced by LPS and reduced pro-inflammatory markers like TNF-α, NF-κB, IL-1β, and IL-8. Moreover, LE reversed the LPS-induced upregulation of AQP8 and TLR-4 expression. These findings emphasize the potential of natural compounds like LE to regulate the intestinal barrier and reduce inflammation’s harmful effects on intestinal cells. More research is required to understand their mechanisms and explore therapeutic applications, especially for gastrointestinal inflammatory conditions. © 2024 by the authors.^aquaporin; ATP-sensitive K<sup>+</sup> channels; calcium-activated K<sup>+</sup> channels; functional gastrointestinal disorders; intestinal dismicrobism; ion channels; irritable bowel syndrome (IBS); transient receptor potential; transporters; voltage-dependent sodium channels^Acetonitriles; Caco-2 Cells; Flavonoids; Humans; Inflammation; Lens Plant; Lipopolysaccharides; acetonitrile; cytoprotective agent; immunoglobulin enhancer binding protein; interleukin 1beta; interleukin 8; lipopolysaccharide; occludin; plant extract; protein ZO1; tight junction protein; toll like receptor 4; tumor necrosis factor; acetonitrile; acetonitrile derivative; flavonoid; lipopolysaccharide; antiinflammatory activity; Article; Caco-2 cell line; cell protection; cell viability; controlled study; electric resistance; human; human cell; intestinal barrier function; intestine mucosa; lentil; lipopolysaccharide-induced inflammation; mRNA expression level; MTT assay; nonhuman; protein expression; tight junction; upregulation; Western blotting; Caco-2 cell line; inflammation^^acetonitrile, 75-05-8; interleukin 8, 114308-91-7; occludin, 176304-61-3; toll like receptor 4, 203811-83-0; acetonitrile, ; Acetonitriles, ; Flavonoids, ; Lipopolysaccharides, ^^^Ministero della Salute, (RC 2022–2024, DDG_661_23.12.2022); Ministero della Salute^This research was funded by the Italian Ministry of Health RC 2022\u20132024, Prog. N. 19 (DDG_661_23.12.2022).^Barrett K.E., New ways of thinking about (and teaching about) intestinal epithelial function, Adv. Physiol. Educ, 32, pp. 25-34, (2008); Runkle E.A., Mu D., Tight junction proteins: From barrier to tumorigenesis, Cancer Lett, 337, pp. 41-48, (2013); Hodges K., Gill R., Infectious diarrhea: Cellular and molecular mechanisms, Gut Microbes, 1, pp. 4-21, (2010); Maqoud F., Tricarico D., Mallamaci R., Orlando A., Russo F., The Role of Ion Channels in Functional Gastrointestinal Disorders (FGID): Evidence of Channelopathies and Potential Avenues for Future Research and Therapeutic Targets, Int. J. Mol. Sci, 24, (2023); Ikarashi N., Kon R., Sugiyama K., Aquaporins in the Colon as a New Therapeutic Target in Diarrhea and Constipation, Int. J. Mol. Sci, 17, (2016); Putt K.K., Pei R., White H.M., Bolling B.W., Yogurt inhibits intestinal barrier dysfunction in Caco-2 cells by increasing tight junctions, Food Funct, 8, pp. 406-414, (2017); Holst O., Ulmer A.J., Brade H., Flad H.-D., Rietschel E.T., Biochemistry and cell biology of bacterial endotoxins, FEMS Immunol. Med. Microbiol, 16, pp. 83-104, (1996); Straub R.H., TRPV1, TRPA1, and TRPM8 channels in inflammation, energy redirection, and water retention: Role in chronic inflammatory diseases with an evolutionary perspective, J. Mol. Med, 92, pp. 925-937, (2014); Ciesielska A., Matyjek M., Kwiatkowska K., TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling, Cell. Mol. Life Sci, 78, pp. 1233-1261, (2021); Kanda Y., Yamasaki Y., Sasaki-Yamaguchi Y., Ida-Koga N., Kamisuki S., Sugawara F., Nagumo Y., Usui T., TRPA1-dependent reversible opening of tight junction by natural compounds with an α,β-unsaturated moiety and capsaicin, Sci. Rep, 8, (2018); Noda S., Tanabe S., Suzuki T., Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells, Mol. Nutr. Food Res, 57, pp. 2019-2028, (2013); Mahmoud A.M., Yang W., Bosland M.C., Soy isoflavones and prostate cancer: A review of molecular mechanisms, J. Steroid Biochem. Mol. Biol, 140, pp. 116-132, (2014); Toschi A., Rossi B., Tugnoli B., Piva A., Grilli E., Nature-Identical Compounds and Organic Acids Ameliorate and Prevent the Damages Induced by an Inflammatory Challenge in Caco-2 Cell Culture, Molecules, 25, (2020); Bialkowski S., Toschi A., Yu L.-E., Schlitzkus L., Mann P., Grilli E., Li Y., Effects of microencapsulated blend of organic acids and botanicals on growth performance, intestinal barrier function, inflammatory cytokines, and endocannabinoid system gene expression in broiler chickens, Poult. Sci, 102, (2023); Di Turi A., Antonacci M., Dibenedetto J.R., Maqoud F., Leonetti F., Centoducati G., Colonna N., Tricarico D., Molecular Composition and Biological Activity of a Novel Acetonitrile–Water Extract of Lens Culinaris Medik in Murine Native Cells and Cell Lines Exposed to Different Chemotherapeutics Using Mass Spectrometry, Cells, 12, (2023); Antonacci M., Dibenedetto J.R., Maqoud F., Centoducati G., Colonna N., Leonetti F., Tricarico D., Counteractions of a Novel Hydroalcoholic Extract from Lens Culinaria against the Dexamethasone-Induced Osteoblast Loss of Native Murine Cells, Cells, 11, (2022); Bueno L., Fioramonti J., Protease-activated receptor 2 and gut permeability: A review, Neurogastroenterol. Motil, 20, pp. 580-587, (2008); Fan J., Li B.-R., Zhang Q., Zhao X.-H., Wang L., Pretreatment of IEC-6 cells with quercetin and myricetin resists the indomethacin-induced barrier dysfunction via attenuating the calcium-mediated JNK/Src activation, Food Chem. Toxicol, 147, (2021); Felix K., Tobias S., Jan H., Nicolas S., Michael M., Measurements of transepithelial electrical resistance (TEER) are affected by junctional length in immature epithelial monolayers, Histochem. Cell Biol, 156, pp. 609-616, (2021); An L., Wirth U., Koch D., Schirren M., Drefs M., Koliogiannis D., Niess H., Andrassy J., Guba M., Bazhin A.V., Et al., The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases, J. Gastrointest. Surg, 26, pp. 671-683, (2022); Ghosh S.S., Wang J., Yannie P.J., Ghosh S., Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development, J. Endocr. Soc, 4, (2020); Maleki S.J., Crespo J.F., Cabanillas B., Anti-inflammatory effects of flavonoids, Food Chem, 299, (2019); Serafini M., Peluso I., Raguzzini A., Flavonoids as anti-inflammatory agents, Proc. Nutr. Soc, 69, pp. 273-278, (2010); Joo M., Kim H.S., Kwon T.H., Palikhe A., Zaw T.S., Jeong J.H., Sohn U.D., Anti-inflammatory Effects of Flavonoids on TNBS-induced Colitis of Rats, Korean J. Physiol. Pharmacol. Off. J. Korean Physiol. Soc. Korean Soc. Pharmacol, 19, pp. 43-50, (2015); Amasheh M., Schlichter S., Amasheh S., Mankertz J., Zeitz M., Fromm M., Schulzke J.D., Quercetin Enhances Epithelial Barrier Function and Increases Claudin-4 Expression in Caco-2 Cells, J. Nutr, 138, pp. 1067-1073, (2008); DiGuilio K.M., Rybakovsky E., Valenzano M.C., Nguyen H.H., Del Rio E.A., Newberry E., Spadea R., Mullin J.M., Quercetin improves and protects Calu-3 airway epithelial barrier function, Front. Cell Dev. Biol, 11, (2023); Junyuan Z., Hui X., Chunlan H., Junjie F., Qixiang M., Yingying L., Lihong L., Xingpeng W., Yue Z., Quercetin protects against intestinal barrier disruption and inflammation in acute necrotizing pancreatitis through TLR4/MyD88/p38 MAPK and ERS inhibition, Pancreatology, 18, pp. 742-752, (2018); Li J., Tian R., Liang G., Shi R., Hu J., Jiang Z., Interaction mechanism of flavonoids with whey protein isolate: A spectrofluorometric and theoretical investigation, Food Chem, 355, (2021); Wang R., Tu L., Pan D., Gao X., Du L., Cai Z., Wu J., Dang Y., A Comparative Study of Binding Interactions between Proteins and Flavonoids in Angelica Keiskei: Stability, α-Glucosidase Inhibition and Interaction Mechanisms, Int. J. Mol. Sci, 24, (2023); Tunisi L., Forte N., Fernandez-Rilo A.C., Mavaro I., Capasso R., D'Angelo L., Milic N., Cristino L., Di Marzo V., Palomba L., Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier, Front. Endocrinol, 10, (2019); He C., Deng J., Hu X., Zhou S., Wu J., Xiao D., Darko K.O., Huang Y., Tao T., Peng M., Et al., Vitamin A inhibits the action of LPS on the intestinal epithelial barrier function and tight junction proteins, Food Funct, 10, pp. 1235-1242, (2019); Al-Sadi R., Boivin M., Ma T., Mechanism of cytokine modulation of epithelial tight junction barrier, Front. Biosci. (Landmark Ed.), 14, pp. 2765-2778, (2009); Capaldo C.T., Nusrat A., Cytokine regulation of tight junctions, Biochim. Biophys. Acta (BBA) Biomembr, 1788, pp. 864-871, (2009); Zhu C., Chen Z., Jiang Z., Expression, Distribution and Role of Aquaporin Water Channels in Human and Animal Stomach and Intestines, Int. J. Mol. Sci, 17, (2016); Kruger C., Jorns A., Kaynert J., Waldeck-Weiermair M., Michel T., Elsner M., Lenzen S., The importance of aquaporin-8 for cytokine-mediated toxicity in rat insulin-producing cells, Free Radic. Biol. Med, 174, pp. 135-143, (2021); Safe S., Jayaraman A., Chapkin R.S., Howard M., Mohankumar K., Shrestha R., Flavonoids: Structure–function and mechanisms of action and opportunities for drug development, Toxicol. Res, 37, pp. 147-162, (2021); Scala R., Maqoud F., Zizzo N., Passantino G., Mele A., Camerino G.M., McClenaghan C., Harter T.M., Nichols C.G., Tricarico D., Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome, Cells, 10, (2021); Scala R., Maqoud F., Antonacci M., Dibenedetto J.R., Perrone M.G., Scilimati A., Castillo K., Latorre R., Conte D., Bendahhou S., Et al., Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects, Front. Pharmacol, 13, (2022); Conte E., Romano A., De Bellis M., de Ceglia M., Carratu M.R., Gaetani S., Maqoud F., Tricarico D., Camerino C., Oxtr/TRPV1 expression and acclimation of skeletal muscle to cold-stress in male mice, J. Endocrinol, 249, pp. 135-148, (2021); Maqoud F., Scala R., Tragni V., Pierri C.L., Perrone M.G., Scilimati A., Tricarico D., Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K<sup>+</sup> Channels: Role in the Adverse Drug Reactions, Pharmaceutics, 13, (2021); Maqoud F., Cetrone M., Mele A., Tricarico D., Molecular structure and function of big calcium-activated potassium channels in skeletal muscle: Pharmacological perspectives, Physiol. Genom, 49, pp. 306-317, (2017); Maqoud F., Vacca E., Tommaseo-Ponzetta M., From Morocco to Italy: How Women’s Bodies Reflect their Change of Residence, Coll. Antropol, 40, pp. 9-15, (2016)^F. Russo; Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS “Saverio de Bellis”, Castellana Grotte, BA, 70013, Italy; email: francesco.russo@irccsdebellis.it^^Multidisciplinary Digital Publishing Institute (MDPI)^^^^^^16616596^^^38612611.0^English^Int. J. Mol. Sci.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85190364768
Frieling T.; Gjini B.; Melchior I.; Euler P.; Kreysel C.; Kalde S.; Krummen B.; Kiesslich R.; Hemmerlein B.^Frieling, Thomas (56253543400); Gjini, Besmir (57999111300); Melchior, Ilka (37081575200); Euler, Philipp (57219446514); Kreysel, Christian (35170027600); Kalde, Sigrid (6507669661); Krummen, Britta (57209271853); Kiesslich, Ralf (22234423500); Hemmerlein, Bernhard (55951725600)^56253543400; 57999111300; 37081575200; 57219446514; 35170027600; 6507669661; 57209271853; 22234423500; 55951725600^Endoscopic laser endomicroscopy and leaky gut in patients with functional gastrointestinal symptoms and food intolerance^2022^Zeitschrift fur Gastroenterologie^61.0^11^^1465^1471^6.0^4^10.1055/a-1959-3200^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144742507&doi=10.1055%2fa-1959-3200&partnerID=40&md5=cc15ec687d0ba37c5fc38b604ee903bb^Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Helios Dr. Horst Schmidt Kliniken Wiesbaden GmbH, Wiesbaden, Germany; Institut für Pathologie, HELIOS Klinikum Krefeld, Krefeld, Germany^Frieling T., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Gjini B., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Melchior I., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Euler P., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Kreysel C., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Kalde S., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Krummen B., Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Germany; Kiesslich R., Helios Dr. Horst Schmidt Kliniken Wiesbaden GmbH, Wiesbaden, Germany; Hemmerlein B., Institut für Pathologie, HELIOS Klinikum Krefeld, Krefeld, Germany^Background Intestinal epithelial barrier dysfunction (leaky gut syndrome, LGS) is thought to play a major role in the pathogenesis of disorders of the gut brain axis. Endoscopic confocal laser endomicroscopy (eCLE) is an objective measure to test duodenal permeability. We applied this technique in patients with functional gastrointestinal symptoms and food intolerance to characterize the proportion of patients with LGS. Material and Methods In an observational study, we evaluated 85 patients with functional gastrointestinal symptoms and food intolerance. Gastrointestinal symptoms were classified according to Rom IV into functional abdominal pain (FAP), irritable bowel syndrome (IBS), irritable bowel syndrome diarrhea dominant (IBS-D), irritable bowel syndrome constipation dominant (IBS-C), irritable bowel syndrome with mixed stool (IBS-M), functional abdominal bloating (FAB), functional diarrhea (FD) and unclassified (NC). During eCLE, spontaneous transfer of intravenously applied fluorescein into duodenal lumen (LGS) and following duodenal food challenge (DFC) were analyzed. Blood analysis comprised parameters of mast cell function, histology of duodenal mucosal biopsies analysis of mucosal inflammation, intraepithelial lymphocytes (IELs) as well as number, distribution and morphology of mast cells. Results 24 patients (9 IBS, 9 FAP, 3 FAB, 1 FD, 2 NC), showed LGS, 50 patients (14 IBS-D, 4 IBS-C, 3 IBS-M, 23 FAP, 3 FAB, 3 NC) had no LGS but responded to DFC and 11 patients (6 NC, 3 FAP, 1 FAB, 1 FD) had no LGS and no response to DFC. The proportion of subgroups with/or without spontaneous leakage of fluorescein (+LGS/-LGS) were IBS-LGS/IBS+LGS 67%/33%, FAP-LGS/FAP+LGS 72%/28%,FAB-LGS/FAB+LGS 50%/50%, NC-LGS/NC+LGS 60%/40%. Subgroup analysis revealed no significant differences for all parameters tested. Conclusion As a proof of concept, the results of our study indicate that eCLE is a clinical useful tool to evaluate patients with disorders of the gut brain axis and those suspicious of LGS. However, the clinical significance of LGS remains unclear. The study should be an incentive to perform a randomized study including healthy controls. © 2022 Georg Thieme Verlag. All rights reserved.^disorders of the gut-brain-axis; Endoscopic laser endomicroscopy (eCLE); food intolerance; functional gastrointestinal symptoms; irritable bowel syndrome (IBS); leaky gut syndrome^Abdominal Pain; Diarrhea; Fluoresceins; Food Intolerance; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; fluorescein; fluorescein derivative; abdominal pain; Article; bloating; blood analysis; cell function; confocal laser scanning microscopy; constipation; diarrhea; endoscopic laser endomicroscopy; female; gastrointestinal symptom; human; human tissue; immunohistochemistry; intraepithelial lymphocyte; irritable colon; major clinical study; male; mast cell; microscopy; mucosa inflammation; nutritional intolerance; observational study; complication; diarrhea; gastrointestinal disease; irritable colon; nutritional intolerance^^fluorescein, 2321-07-5, 91316-42-6; Fluoresceins, ^^^^^Fukui H., Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation?, Inflamm Intest Dis, 1, pp. 135-145, (2016); Yoshimoto T., Oshima T., Huang X., Microinflammation in the intestinal mucosa and symptoms of irritable bowel syndrome, J Gastroenterol, 57, pp. 62-69, (2022); Vanuytsel T., Van Wanrooy S., Vanheel H., Psychological stress and corticotropin-releasuing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism, Gut, 63, pp. 1293-1299, (2014); Wauters L., Talley N.J., Walker M.M., Novel concepts in the pathophysiology and treatment of functional dyspepsia, Gut, 69, pp. 591-600, (2020); Vanheel H., Vicario M., Vanuytsel T., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, pp. 262-271, (2014); Talley N.J., Walker M.M., Aro P., Non-ulcer dyspepsia and duodenal eosinophilia: An adult endoscopic population-based case-control study, Clin Gastroenterol Hepatol, 5, pp. 1175-1183, (2007); Vanheel H., Vicario M., Boesmans W., Activation of eosinophils and mast cells in functional dyspepsia: An ultrastructural evaluation, Sci Rep, 8, (2018); Cirillo C., Bessissow T., Desmet A.S., Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia, Am J Gastroenterol, 110, pp. 1205-1215, (2015); Kindt S., Tertychnyy A., De Hertogh G., Intestinal immune activation in presumed post-infectious functional dyspepsia, Neurogastroenterol Motil, 21, (2009); Taki M., Oshima T., Li M., Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia, Neurogastroenterol Motil, 31, (2019); Miglietta S., Borghini R., Relucenti M., New insights into intestinal permeability in irritable Bowel syndrome-like disorders: Histological and ultrastructural findings of duodenal biopsies, Cells, 10, (2021); Obrenovich M.E.M., Leaky gut, leaky brain?, Microorganisms, 6, (2018); Tack J., Schol J., Van Den Houte K., Pradigm shift. Functional dyspepsia-a leaky gut disorder?, Am J Gastroenterol, 116, pp. 274-275, (2020); Nojkov B., Zhou S.Y., Dolan R.D., Evidence of duodenal epithelial barrier impairment and increased pyroptosis in patients with functional dyspepsia on confocal laser endomicroscopy and ex vivo mucosa analysis, Am J Gastroenterol, 115, pp. 1891-1901, (2020); Wauters L., Ceulemans M., Schol J., The Role of Leaky Gut in Functional Dyspepsia, Front. Neurosci, (2022); Beeckmans D., Farre R., Riethorst D., Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia, Neurogastroenterol Motil, 32, (2020); Vanheel H., Carbone F., Valvekens L., Pathophysiological abnormalities in functional dyspepsia subgroups according to the rome III criteria, Am J Gastroenterol, 112, pp. 132-140, (2017); Binienda A., Twardowska A., Makaro A., Dietary Carbohydrates and Lipids in the Pathogenesis of Leaky Gut Syndrome: An Overview, Int J Mol Sci, 21, (2020); Fritscher-Ravens A., Schuppan D., Ellrichmann M., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Fritscher-Ravens A., Pflaum T., Mosinger M., Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin e, Gastroenterology, 157, pp. 109-118, (2019); Drossman D.A., Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV, Gastroenterology, (2016); Wyatt J., Oberhuber G., Pongratz S., Increased gastric and intestinal permeability in patients with Crohn's disease, Am J Gastroenterol, 92, pp. 1891-1896, (1997); Oriishi T., Sata M., Toyonaga A., Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A, Gut, 36, pp. 891-896, (1995); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Buning C., Geissler N., Prager M., Increased small intestinal permeability in ulcerative colitis: Rather genetic than environmental and a risk factor for extensive disease?, Inflamm Bowel Dis, 18, pp. 1932-1939, (2012); Gerova V.A., Stoynov S.G., Katsarov D.S., Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test, World J Gastroenterol, 17, pp. 2211-2215, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, pp. G775-G785, (2012); Piche T., Barbara G., Aubert P., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-220, (2009); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Waugh E., Waugh N., Cummins E., Faecal Calprotectin Testing for Differentiating Amongst Inflammatory and Non-inflammatory Bowel Diseases: Systematic Review and Economic EvaluationHealth Technology Assessment, 17, (2013)^T. Frieling; Medizinische Klinik II, HELIOS Klinikum Krefeld, Krefeld, Lutherplatz 40, 47805, Germany; email: thomas.frieling@helios-gesundheit.de^^Georg Thieme Verlag^^^^^^00442771^^ZGASA^36417920.0^English^Z. Gastroenterol.^Article^Final^^Scopus^2-s2.0-85144742507
Olyaiee A.; Yadegar A.; Mirsamadi E.S.; Sadeghi A.; Mirjalali H.^Olyaiee, Alireza (57789669300); Yadegar, Abbas (26658798500); Mirsamadi, Elnaz Sadat (50761257100); Sadeghi, Amir (57746270700); Mirjalali, Hamed (35311420300)^57789669300; 26658798500; 50761257100; 57746270700; 35311420300^Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study^2023^European Journal of Medical Research^28.0^1^483^^^^1^10.1186/s40001-023-01441-8^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175822681&doi=10.1186%2fs40001-023-01441-8&partnerID=40&md5=1376bb45611e1fa8468c9ef047e242da^Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Microbiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran^Olyaiee A., Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Yadegar A., Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Mirsamadi E.S., Department of Microbiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Sadeghi A., Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Mirjalali H., Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran^Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to modulate the relative expression of microRNAs to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization. © 2023, The Author(s).^Blastocystis; Fecal microbiota; IBS; MicroRNA; mir-16^Blastocystis; Blastocystis Infections; Case-Control Studies; Circulating MicroRNA; Humans; Irritable Bowel Syndrome; Microbiota; MicroRNAs; microRNA 16; circulating microRNA; microRNA; MIRN16 microRNA, human; Actinobacteria; adult; Alistipes; Article; bacterial colonization; Bifidobacteriaceae; Blastocystis; blastocystosis; blood sampling; clinical article; controlled study; disease association; DNA extraction; Faecalibacterium; feces analysis; feces microflora; female; Firmicutes; gene expression; gene function; genetic association; genetic code; human; irritable colon; Lactobacillus; male; molecular pathology; nonhuman; phylum; population abundance; real time polymerase chain reaction; RNA extraction; Blastocystis; case control study; microbiology; microflora^^Circulating MicroRNA, ; MicroRNAs, ; MIRN16 microRNA, human, ^^^^^Olyaiee A., Sadeghi A., Yadegar A., Mirsamadi E.S., Mirjalali H., Gut microbiota shifting in irritable bowel syndrome: the mysterious role of Blastocystis sp, Front Med (Lausanne), 9, (2022); Mei L., Zhou J., Su Y., Mao K., Wu J., Zhu C., He L., Cui Y., Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome, BMC Gastroenterol, 21, (2021); Johnsen P.H., Hilpusch F., Valle P.C., Goll R., The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial, EBioMedicine, 51, (2020); Nagel R., Traub R.J., Allcock R.J., Kwan M.M., Bielefeldt-Ohmann H., Comparison of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel syndrome patients, Microbiome, 4, (2016); Dale H.F., Lied G.A., Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives, Turk J Med Sci, 50, pp. 1632-1641, (2020); Zhao L., Yang W., Chen Y., Huang F., Lu L., Lin C., Huang T., Ning Z., Zhai L., Zhong L.L., Et al., A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome, J Clin Invest, 130, pp. 438-450, (2020); Gasbarrini A., Lauritano E.C., Garcovich M., Sparano L., Gasbarrini G., New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility, Eur Rev Med Pharmacol Sci, 12, pp. 111-117, (2008); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Shankar V., Reo N.V., Paliy O., Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome, Microbiome, 3, (2015); Fagoonee S., Pellicano R., Does the microbiota play a pivotal role in the pathogenesis of irritable bowel syndrome?, J Clin Med, 8, (2019); Nieves-Ramirez M., Partida-Rodriguez O., Laforest-Lapointe I., Reynolds L., Brown E., Valdez-Salazar A., Moran-Silva P., Rojas-Velazquez L., Morien E., Parfrey L., Asymptomatic intestinal colonization with protist Blastocystis is strongly associated with distinct microbiome ecological patterns, Msystems, 3, pp. e00007-e00018, (2018); Nemati S., Zali M.R., Johnson P., Mirjalali H., Karanis P., Molecular prevalence and subtype distribution of Blastocystis sp. in Asia and in Australia, J Water Health, 19, pp. 687-704, (2021); Cifre S., Gozalbo M., Ortiz V., Soriano J.M., Merino J.F., Trelis M., Blastocystis subtypes and their association with Irritable Bowel Syndrome, Med Hypotheses, 116, pp. 4-9, (2018); Dogruman-Al F., Simsek Z., Boorom K., Ekici E., Sahin M., Tuncer C., Kustimur S., Altinbas A., Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey PLoS One, 5, (2010); Beghini F., Pasolli E., Truong T.D., Putignani L., Caccio S.M., Segata N., Large-scale comparative metagenomics of Blastocystis, a common member of the human gut microbiome, ISME J, 11, pp. 2848-2863, (2017); Asnicar F., Berry S.E., Valdes A.M., Nguyen L.H., Piccinno G., Drew D.A., Leeming E., Gibson R., Le Roy C., Khatib H.A., Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals, Nat Med, 27, pp. 321-332, (2021); Karamati S.A., Mirjalali H., Niyyati M., Yadegar A., Asadzadeh Aghdaei H., Haghighi A., Seyyed Tabaei S.J., Association of Blastocystis ST6 with higher protease activity among symptomatic subjects, BMC Microbiol, 21, (2021); Mirza H., Wu Z., Teo J.D., Tan K.S., Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by Blastocystis cysteine proteases, Cell Microbiol, 14, pp. 1474-1484, (2012); Mohammad Rahimi H., Yadegar A., Asadzadeh Aghdaei H., Mirjalali H., Zali M.R., Modulation of microRNAs and claudin-7 in Caco-2 cell line treated with Blastocystis sp., subtype 3 soluble total antigen, BMC Microbiol, 22, (2022); Chatterjee B., Sarkar M., Bose S., Alam M.T., Chaudhary A.A., Dixit A.K., Tripathi P.P., Srivastava A.K., MicroRNAs: Key modulators of inflammation-associated diseases, Seminars in Cell & Developmental Biology, (2023); Martinez C., Rodino-Janeiro B.K., Lobo B., Stanifer M.L., Klaus B., Granzow M., Gonzalez-Castro A.M., Salvo-Romero E., Alonso-Cotoner C., Pigrau M., miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea, Gut, 66, pp. 1537-1538, (2017); Norouzi M., Pirestani M., Arefian E., Dalimi A., Sadraei J., Mirjalali H., Exosomes secreted by Blastocystis subtypes affect the expression of proinflammatory and anti-inflammatory cytokines (TNFα, IL-6, IL-10, IL-4), Front Med (Lausanne), 9, (2022); Gholam-Mostafaei F.S., Azimirad M., Naseri K., Nabavi-Rad A., Asadzadeh Aghdaei H., Shahrokh S., Ebrahimi Daryani N., Yadegar A., Zali M.R., Intestinal microbiota changes pre-and post-fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection among Iranian patients with concurrent inflammatory bowel disease, Front Microbiol, 14, (2023); De Gregoris T.B., Aldred N., Clare A.S., Burgess J.G., Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa, J Microbiol Method, 86, pp. 351-356, (2011); Moszak M., Szulinska M., Bogdanski P., You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review, Nutrients, 12, (2020); Thursby E., Juge N., Introduction fo the human gut flora, Biochem J, 474, pp. 1823-1836, (2017); Hermann-Bank M.L., Skovgaard K., Stockmarr A., Larsen N., Molbak L., The gut microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity, BMC Genomic, 14, pp. 1-14, (2013); Springham N., Robert G., Experience based co-design reduces formal complaints on an acute mental health ward, BMJ Open Qual, 4, u209153, (2015); Keshavarz Azizi Raftar S., Ashrafian F., Yadegar A., Lari A., Moradi H.R., Shahriary A., Azimirad M., Alavifard H., Mohsenifar Z., Davari M., The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD/CCl4-induced liver injury, Microbiol Spect, 9, pp. e00484-e1421, (2021); Wang I.-K., Lai H.-C., Yu C.-J., Liang C.-C., Chang C.-T., Kuo H.-L., Yang Y.-F., Lin C.-C., Lin H.-H., Liu Y.-L., Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients, Appl Environ Microbiol, 78, pp. 1107-1112, (2012); Quigley E.M., Gut bacteria in health and disease, Gastroenterol Hepatol, 9, (2013); Vigsnaes L.K., Brynskov J., Steenholdt C., Wilcks A., Licht T.R., Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls, Beneficial Microb, 3, pp. 287-297, (2012); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); Zhuang X., Tian Z., Li L., Zeng Z., Chen M., Xiong L., Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome, Front Microbiol, 9, (2018); Deng L., Wojciech L., Gascoigne N.R., Peng G., Tan K.S., New insights into the interactions between Blastocystis, the gut microbiota, and host immunity, PLoS Pathog, 17, (2021); Kim M.J., Lee Y.J., Kim T.J., Won E.J., Gut microbiome profiles in colonizations with the enteric protozoa Blastocystis in Korean populations, Microorganisms, 10, (2021); Stensvold C.R., Sorland B.A., Berg R., Andersen L.O., van der Giezen M., Bowtell J.L., El-Badry A.A., Belkessa S., Kurt O., Nielsen H.V., Stool microbiota diversity analysis of Blastocystis-positive and Blastocystis-negative individuals, Microorganisms, 10, (2022); Olivo-Diaz A., Romero-Valdovinos M., Gudino-Ramirez A., Reyes-Gordillo J., Jimenez-Gonzalez D.E., Ramirez-Miranda M.E., Martinez-Flores W.A., Martinez-Hernandez F., Flisser A., Maravilla P., Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis, Parasitol Res, 111, pp. 487-491, (2012); Ismail M.H., Molan A.L., Abbas S.K., Serological levels of cytokines in irritable bowel syndrome (IBS) patients and non-IBS subjects with and without Blastocystis spp. infection, Ann Parasitol, 68, pp. 77-85, (2022); Nagel R., Traub R.J., Kwan M.M., Bielefeldt-Ohmann H., Blastocystis specific serum immunoglobulin in patients with irritable bowel syndrome (IBS) versus healthy controls, Parasit Vectors, 8, (2015); Chen H., Ou R., Tang N., Su W., Yang R., Yu X., Zhang G., Jiao J., Zhou X., Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data, J Transl Med, 21, (2023); Lee S.M., Kim N., Yoon H., Kim Y.S., Choi S.I., Park J.H., Lee D.H., Compositional and functional changes in the gut microbiota in irritable bowel syndrome patients, Gut Liver, 15, pp. 253-261, (2021); Lopetuso L.R., Petito V., Graziani C., Schiavoni E., Paroni Sterbini F., Poscia A., Gaetani E., Franceschi F., Cammarota G., Sanguinetti M., Et al., Gut microbiota in health, diverticular disease, irritable bowel syndrome, and inflammatory bowel diseases: time for microbial marker of gastrointestinal disorders, Dig Dis, 36, pp. 56-65, (2018); Barandouzi Z.A., Lee J., Maas K., Starkweather A.R., Cong X.S., Altered gut microbiota in irritable bowel syndrome and its association with food components, J Pers Med, 11, (2021); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 301, pp. G799-G807, (2011); Parker B.J., Wearsch P.A., Veloo A.C.M., Rodriguez-Palacios A., The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health, Front Immunol, 11, (2020); O'Riordan K.J., Collins M.K., Moloney G.M., Knox E.G., Aburto M.R., Fulling C., Morley S.J., Clarke G., Schellekens H., Cryan J.F., Short chain fatty acids: microbial metabolites for gut-brain axis signalling, Mol Cell Endocrinol, 546, (2022); Oliphant K., Allen-Vercoe E., Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health, Microbiome, 7, (2019); Jiang W., Wu J., Zhu S., Xin L., Yu C., Shen Z., The role of short chain fatty acids in irritable bowel syndrome, J Neurogastroenterol Motil, 28, pp. 540-548, (2022); Sun Q., Jia Q., Song L., Duan L., Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis, Medicine (Baltimore), 98, (2019); Gargari G., Taverniti V., Gardana C., Cremon C., Canducci F., Pagano I., Barbaro M.R., Bellacosa L., Castellazzi A.M., Valsecchi C., Et al., Fecal clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome, Environ Microbiol, 20, pp. 3201-3213, (2018); Dalile B., Van Oudenhove L., Vervliet B., Verbeke K., The role of short-chain fatty acids in microbiota-gut-brain communication, Nat Rev Gastroenterol Hepatol, 16, pp. 461-478, (2019); Deng L., Wojciech L., Png C.W., Kioh D.Y.Q., Gu Y., Aung T.T., Malleret B., Chan E.C.Y., Peng G., Zhang Y., Et al., Colonization with two different Blastocystis subtypes in DSS-induced colitis mice is associated with strikingly different microbiome and pathological features, Theranostics, 13, pp. 1165-1179, (2023); Deng L., Wojciech L., Png C.W., Koh E.Y., Aung T.T., Kioh D.Y.Q., Chan E.C.Y., Malleret B., Zhang Y., Peng G., Et al., Experimental colonization with Blastocystis ST4 is associated with protective immune responses and modulation of gut microbiome in a DSS-induced colitis mouse model, Cell Mol Life Sci, 79, (2022); Mayneris-Perxachs J., Arnoriaga-Rodriguez M., Garre-Olmo J., Puig J., Ramos R., Trelis M., Burokas A., Coll C., Zapata-Tona C., Pedraza S., Et al., Presence of Blastocystis in gut microbiota is associated with cognitive traits and decreased executive function, Isme J, 16, pp. 2181-2197, (2022); Schoultz I., Keita A.V., The intestinal barrier and current techniques for the assessment of gut permeability, Cells, 2020, (1909); Lee S.H., Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases, Intestin Res, 13, (2015); Koziel M.J., Ziaja M., Piastowska-Ciesielska A.W., Intestinal barrier, claudins and mycotoxins, Toxins, 13, (2021); Zhao X., Zeng H., Lei L., Tong X., Yang L., Yang Y., Li S., Zhou Y., Luo L., Huang J., Tight junctions and their regulation by non-coding RNAs, Int J Biol Sci, 17, (2021); Xi M., Zhao P., Li F., Bao H., Ding S., Ji L., Yan J., MicroRNA-16 inhibits the TLR4/NF-κB pathway and maintains tight junction integrity in irritable bowel syndrome with diarrhea, J Biol Chem, 298, 11, (2022)^H. Mirjalali; Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; email: hamed_mirjalali@hotmail.com^^BioMed Central Ltd^^^^^^09492321^^^37932792.0^English^Eur. J. Med. Res.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85175822681
Torres-Maravilla E.; Carvalho F.A.; Holowacz S.; Delannoy J.; Lenoir L.; Jacouton E.; Barbut F.; Langella P.; Bermúdez-Humarán L.G.; Waligora-Dupriet A.-J.^Torres-Maravilla, E. (56922108200); Carvalho, F.A. (16041688200); Holowacz, S. (56200615700); Delannoy, J. (57186421200); Lenoir, L. (56801539100); Jacouton, E. (56641711900); Barbut, F. (7005710294); Langella, P. (7003598187); Bermúdez-Humarán, L.G. (6602243913); Waligora-Dupriet, A-J (6506915359)^56922108200; 16041688200; 56200615700; 57186421200; 56801539100; 56641711900; 7005710294; 7003598187; 6602243913; 6506915359^Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches^2024^Beneficial microbes^15.0^3^^293^310^17.0^0^10.1163/18762891-bja00006^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195227914&doi=10.1163%2f18762891-bja00006&partnerID=40&md5=fcc1a66a38cfe6c67d7e7ecbf898604e^AgroParisTech, Micalis Institute, Université Paris-Saclay, France; INSERM, UMRS 1139, Paris, 75006, France; INSERM U1107 NeuroDol, Université Clermont Auvergne, Clermont-Ferrand, France; PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Service de Microbiologie de l'environnement, UHLIN (Unité d'Hygiène et de Lutte contre les Infections Nosocomiales), National Reference Laboratory for Clostridium difficile, Groupe Hospitalier de l'Est Parisien (HUEP) Site Saint-Antoine, Paris, 75012, France^Torres-Maravilla E., AgroParisTech, Micalis Institute, Université Paris-Saclay, France, INSERM, UMRS 1139, Paris, 75006, France; Carvalho F.A., INSERM U1107 NeuroDol, Université Clermont Auvergne, Clermont-Ferrand, France; Holowacz S., PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Delannoy J., INSERM, UMRS 1139, Paris, 75006, France; Lenoir L., PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Jacouton E., PiLeJe Laboratoire, 31-35 Rue de la Fédération, Paris, 75015, France; Barbut F., INSERM, UMRS 1139, Paris, 75006, France, Service de Microbiologie de l'environnement, UHLIN (Unité d'Hygiène et de Lutte contre les Infections Nosocomiales), National Reference Laboratory for Clostridium difficile, Groupe Hospitalier de l'Est Parisien (HUEP) Site Saint-Antoine, Paris, 75012, France; Langella P., AgroParisTech, Micalis Institute, Université Paris-Saclay, France; Bermúdez-Humarán L.G., AgroParisTech, Micalis Institute, Université Paris-Saclay, France; Waligora-Dupriet A.-J., INSERM, UMRS 1139, Paris, 75006, France^Oral administration of probiotics has been proposed as a promising biotherapy to prevent and treat different diseases related to gastrointestinal disorders, such as irritable bowel syndrome (IBS). Due to the increasing research area on the characterisation of new probiotic bacterial strains, it is necessary to perform suitable in vitro experiments, using pertinent cellular models, in order to establish appropriate readout profiles based on IBS symptoms and subtypes. In this work, a collection of 30 candidate strains, belonging mainly to the Lactobacillus and Bifidobacterium genera, were screened using three different sets of in vitro experiments with different readouts to identify promising probiotic strains with: (1) the ability to inhibit the synthesis of IL-8 production by TNF-α stimulated HT-29 cells, (2) immunomodulatory properties quantified as increased IL-10 levels in peripheral blood mononuclear cell (PBMCs), and (3) the ability to maintain epithelial barrier integrity by increasing the trans-epithelial/endothelial electrical resistance (TEER) values in Caco-2 cells. Based on these criteria, three strains were selected: Lactobacillus gasseri PI41, Lacticaseibacillus rhamnosus PI48 and Bifidobacterium animalis subsp. lactis PI50, and tested in a murine model of low-grade inflammation induced by dinitrobenzene sulfonic acid (DNBS), which mimics some of the symptoms of IBS. Among the three strains, L. gasseri PI41 improved overall host well-being by preventing body weight loss in DNBS-treated mice and restored gut homeostasis by normalising the intestinal permeability and reducing pro-inflammatory markers. Therefore, the potential of this strain was confirmed in a second murine model known to reproduce IBS symptoms: the neonatal maternal separation (NMS) model. The PI41 strain was effective in preventing intestinal permeability and reducing colonic hypersensitivity. In conclusion, the set of in vitro experiments combined with in vivo assessments allowed us to identify a promising probiotic candidate strain, L. gasseri PI41, in the context of IBS.^^Animals; Bifidobacterium; Bifidobacterium animalis; Caco-2 Cells; Disease Models, Animal; HT29 Cells; Humans; Interleukin-10; Interleukin-8; Irritable Bowel Syndrome; Lacticaseibacillus rhamnosus; Lactobacillus; Lactobacillus gasseri; Leukocytes, Mononuclear; Male; Mice; Probiotics; interleukin 10; interleukin 8; probiotic agent; animal; Bifidobacterium; Bifidobacterium animalis; Caco-2 cell line; disease model; HT-29 cell line; human; immunology; irritable colon; Lactobacillus; Lactobacillus gasseri; Lactobacillus rhamnosus; male; metabolism; microbiology; mononuclear cell; mouse; physiology; therapy^^interleukin 8, 114308-91-7; Interleukin-10, ; Interleukin-8, ^^^^^^^^^^^^^^18762891^^^38677716.0^English^Benef Microbes^Article^Final^^Scopus^2-s2.0-85195227914
Cui L.; Zou S.; Liu J.; Lv H.; Li H.; Zhang Z.^Cui, Li (55189436500); Zou, Shuting (58731982700); Liu, Jing (59062363500); Lv, Huixia (35364715600); Li, Hui (57196364139); Zhang, Zhenhai (55658029100)^55189436500; 58731982700; 59062363500; 35364715600; 57196364139; 55658029100^Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome^2024^International Immunopharmacology^127.0^^111404^^^^0^10.1016/j.intimp.2023.111404^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85180612456&doi=10.1016%2fj.intimp.2023.111404&partnerID=40&md5=781ed588099957e204192fe429660b5b^Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China^Cui L., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Zou S., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Liu J., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Lv H., School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China; Li H., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China; Zhang Z., Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, 210028, China^Treatment strategies for constipation-predominant irritable bowel syndrome (IBS-C) continue to improve. However, effective drugs are still lacking. Herein, we explored whether sodium hyaluronate (SH) could be used to treat IBS-C. The effects of SH with different molecular weights were compared in a rat model of IBS-C. Low-molecular-weight SH (LMW-SH, 5 ∼ 10 kDa), medium-molecular-weight SH (MMW-SH, 200 ∼ 400 kDa), and high-molecular-weight SH (HMW-SH, 1300 ∼ 1500 kDa) were screened for efficacy in IBS-C using the following indicators: body weight, number of fecal pellets, fecal moisture, visceral hypersensitivity, and gastrointestinal transit rate. H-HMW-SH was the most effective in improving IBS-C symptoms. The ELISA kits indicated that H-HMW-SH reduced the levels of pro-inflammatory cytokines IL-1β, IL-18, and TNF-α in IBS-C rats. In addition, both western blot and immunofluorescence analyses showed that H-HMW-SH increased the protein expressions of claudin-1, occludin and zonula occludens-1. Furthermore, H-HMW-SH restored the balance of intestinal flora in different intestinal contents (duodenum, jejunum, ileum, and colon) and feces of rats with IBS-C. Overall, our study illustrates the therapeutic potential of H-HMW-SH in the treatment of IBS-C. © 2023 Elsevier B.V.^Constipation-predominant irritable bowel syndrome; Gut barrier; Gut microbiota; Inflammatory cytokines; Molecular weight; Sodium hyaluronate^Animals; Claudin-1; Constipation; Cytokines; Diarrhea; Hyaluronic Acid; Irritable Bowel Syndrome; Rats; claudin 1; hyaluronic acid; interleukin 18; interleukin 1beta; linaclotide; occludin; protein ZO1; tumor necrosis factor; ultraha; claudin 1; cytokine; hyaluronic acid; animal experiment; animal model; Article; body weight; colon; constipation; controlled study; digestive tract parameters; drug efficacy; drug megadose; duodenum; fecal moisture; fecal pellet; gastrointestinal transit; ileum; immunofluorescence; intestine flora; irritable colon; jejunum; low drug dose; male; microbial community; microbial diversity; molecular weight; nonhuman; protein expression; rat; rat model; species richness; visceral hyperalgesia; Western blotting; animal; constipation; diarrhea; irritable colon; metabolism^^claudin 1, 329338-06-9; hyaluronic acid, 31799-91-4, 9004-61-9, 9067-32-7; interleukin 18, 189304-55-0; linaclotide, 851199-59-2, 851199-60-5; occludin, 176304-61-3; Claudin-1, ; Cytokines, ; Hyaluronic Acid, ^ultraha, Bloomage Biotech, China^Bloomage Biotech, China^Jiangsu Provincial TCM Science and Technology Development Plan Project, (MS2021025); Natural Science Foundation of Nanjing University of Chinese Medicine, (XZR2020025); Social Development Project of Jiangsu Province, (BE2022817); National Natural Science Foundation of China, NSFC, (81403121); National Natural Science Foundation of China, NSFC^This work was financially supported by the National Natural Science Foundation of China ( 81403121 ), Social Development Project of Jiangsu Province ( BE2022817 ), Jiangsu Provincial TCM Science and Technology Development Plan Project ( MS2021025 ), and the Natural Science Foundation of Nanjing University of Chinese Medicine ( XZR2020025 ).^Liu J., Lv C., Wang W., Huang Y., Wang B., Tian J., Sun C., Yu Y., Slow, deep breathing intervention improved symptoms and altered rectal sensitivity in patients with constipation-predominant irritable bowel syndrome, Front. Neurosci., 16, (2022); Xiao L., Liu Q., Luo M., Xiong L., Gut microbiota-derived metabolites in irritable bowel syndrome, Front. Cell. Infect. Microbiol., 11, (2021); Pimentel M., Lembo A., Microbiome and its role in irritable bowel syndrome, Dig. Dis. Sci., 65, 3, pp. 829-839, (2020); Mertz H., Morgan V., Tanner G., Pickens D., Price R., Shyr Y., Kessler R., Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention, Gastroenterology, 118, 5, pp. 842-848, (2000); Attaluri A., Jackson M., Valestin J., Rao S.S., Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS, Am. J. Gastroenterol., 105, 6, pp. 1407-1411, (2010); Wen Y., Li J., Long Q., Yue C.C., He B., Tang X.G., The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials, Int. J. Surg., 79, pp. 111-119, (2020); Filippone A., Ardizzone A., Bova V., Lanza M., Casili G., Cuzzocrea S., Esposito E., Campolo M., Paterniti I., A combination of xyloglucan, pea protein and chia seed ameliorates intestinal barrier integrity and mucosa functionality in a rat model of constipation-predominant irritable bowel syndrome, J. Clin. Med., 11, 23, (2022); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Martinez-Garcia R., Gutierrez-Ruiz M.C., Lopez-Alvarenga J.C., Robles-Diaz G., Gutierrez-Reyes G., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am. J. Gastroenterol., 107, 5, pp. 747-753, (2012); Bashashati M., Moradi M., Sarosiek I., Interleukin-6 in irritable bowel syndrome: a systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels, Cytokine, 99, pp. 132-138, (2017); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Quigley E.M., Mucosal cytokine imbalance in irritable bowel syndrome, Scand. J. Gastroenterol., 43, 12, pp. 1467-1476, (2008); Ohman L., Isaksson S., Lundgren A., Simren M., Sjovall H., A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 3, 10, pp. 980-986, (2005); Lazaridis N., Germanidis G., Current insights into the innate immune system dysfunction in irritable bowel syndrome, Ann. Gastroenterol., 31, 2, pp. 171-187, (2018); Wojdasiewicz P., Poniatowski L.A., Szukiewicz D., The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis, Mediators Inflamm., 2014, (2014); Korner E., Lorentz A., Fecal microbiota transplantation in patients with irritable bowel syndrome: an overview of current studies, J. Appl. Microbiol., (2023); Chen H., Ou R., Tang N., Su W., Yang R., Yu X., Zhang G., Jiao J., Zhou X., Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data, J. Transl. Med., 21, 1, (2023); Kim G.H., Lee K., Shim J.O., Gut bacterial dysbiosis in irritable bowel syndrome: a case-control study and a cross-cohort analysis using publicly available data sets, Microbiol. Spectr., 11, 1, (2023); Jacobs J.P., Lagishetty V., Hauer M.C., Labus J.S., Dong T.S., Toma R., Vuyisich M., Naliboff B.D., Lackner J.M., Gupta A., Tillisch K., Mayer E.A., Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes, Microbiome, 11, 1, (2023); Rangan V., Ballou S., Shin A., Camilleri M., Gastroenterology, 158, 3, pp. 786-788, (2020); Chircov C., Grumezescu A.M., Bejenaru L.E., Hyaluronic acid-based scaffolds for tissue engineering, Rom. J. Morphol. Embryol., 59, 1, pp. 71-76, (2018); Hu L., Nomura S., Sato Y., Takagi K., Ishii T., Honma Y., Watanabe K., Mizukami Y., Muto J., Anti-inflammatory effects of differential molecular weight Hyaluronic acids on UVB-induced calprotectin-mediated keratinocyte inflammation, J. Dermatol. Sci., 107, 1, pp. 24-31, (2022); Jiang D., Liang J., Noble P.W., Hyaluronan as an immune regulator in human diseases, Physiol. Rev., 91, 1, pp. 221-264, (2011); Noble P.W., Hyaluronan and its catabolic products in tissue injury and repair, Matrix Biol., 21, 1, pp. 25-29, (2002); Cyphert J.M., Trempus C.S., Garantziotis S., Size matters: molecular weight specificity of hyaluronan effects in cell biology, Int J Cell Biol, 2015, (2015); Heldin P., Lin C.Y., Kolliopoulos C., Chen Y.H., Skandalis S.S., Regulation of hyaluronan biosynthesis and clinical impact of excessive hyaluronan production, Matrix Biol., 78-79, pp. 100-117, (2019); Fiorino G., Gilardi D., Naccarato P., Sociale O.R., Danese S., Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis, Dig. Liver Dis., 46, 4, pp. 330-334, (2014); Lee J.W., Kim H.H., Hyaluronic acid solution injection for upper and lower gastrointestinal bleeding after failed conventional endoscopic therapy, Dig. Endosc., 26, 2, pp. 285-290, (2014); Witting M., Boreham A., Brodwolf R., Vavrova K., Alexiev U., Friess W., Hedtrich S., Interactions of hyaluronic Acid with the skin and implications for the dermal delivery of biomacromolecules, Mol. Pharm., 12, 5, pp. 1391-1401, (2015); Sedky A.A., Magdy Y., Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome, Life Sci., 256, (2020); Sharman S.K., Islam B.N., Hou Y., Usry M., Bridges A., Singh N., Sridhar S., Rao S., Browning D.D., Sildenafil normalizes bowel transit in preclinical models of constipation, PLoS One, 12, 4, (2017); Pecundo M.H., Chang A.C.G., Chen T., Dela Cruz T.E.E., Ren H., Li N., Full-Length 16S rRNA and ITS gene sequencing revealed rich microbial flora in roots of Cycas spp. in China, Evol Bioinform Online, 17, (2021); Zhang D., Li H., Luo X., Liu D., Wei Q., Ye X., Integrated 16S rDNA, metabolomics, and TNF-alpha/NF-kappaB signaling pathway analyses to explain the modulatory effect of Poria cocos aqueous extract on anxiety-like behavior, Phytomedicine, 104, (2022); Diop K., Diop A., Levasseur A., Mediannikov O., Robert C., Armstrong N., Couderc C., Bretelle F., Raoult D., Fournier P.E., Fenollar F., Microbial culturomics broadens human vaginal flora diversity: genome sequence and description of Prevotella lascolaii sp. nov. isolated from a patient with bacterial vaginosis, OMICS, 22, 3, pp. 210-222, (2018); Cui L., Guan X., Ding W., Luo Y., Wang W., Bu W., Song J., Tan X., Sun E., Ning Q., Liu G., Jia X., Feng L., Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota, Int. J. Biol. Macromol., 166, pp. 1035-1045, (2021); Li X., Lv H., Shi F., Song J., Zhang Z., The potential therapeutic effects of hydroxypropyl cellulose on acute murine colitis induced by DSS, Carbohydr. Polym., 289, (2022); Ng S.C., Lam E.F., Lam T.T., Chan Y., Law W., Tse P.C., Kamm M.A., Sung J.J., Chan F.K., Wu J.C., Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome, J. Gastroenterol. Hepatol., 28, 10, pp. 1624-1631, (2013); Giamarellos-Bourboulis E., Tang J., Pyleris E., Pistiki A., Barbatzas C., Brown J., Lee C.C., Harkins T.T., Kim G., Weitsman S., Barlow G.M., Funari V.A., Pimentel M., Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome, Scand. J. Gastroenterol., 50, 9, pp. 1076-1087, (2015); Maharshak N., Ringel Y., Katibian D., Lundqvist A., Sartor R.B., Carroll I.M., Ringel-Kulka T., Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome, Dig. Dis. Sci., 63, 7, pp. 1890-1899, (2018); Liu M., Yang Y., Zhu W., Wu J., Yu X., Li W., Specific TLR-mediated HSP70 activation plays a potential role in host defense against the intestinal parasite Giardia duodenalis, Front. Microbiol., 14, (2023); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, 12, pp. 2165-2173, (2011); Annahazi A., Ferrier L., Bezirard V., Leveque M., Eutamene H., Ait-Belgnaoui A., Coeffier M., Ducrotte P., Roka R., Inczefi O., Gecse K., Rosztoczy A., Molnar T., Ringel-Kulka T., Ringel Y., Piche T., Theodorou V., Wittmann T., Bueno L., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am. J. Gastroenterol., 108, 8, pp. 1322-1331, (2013); Wu Y., Zheng Y., Wang X., Tang P., Guo W., Ma H., Zhang A., Li D., Xie Y., Wang C.Z., Yao H., Wan J.Y., Yuan C.S., Ginseng-containing Sijunzi decoction ameliorates ulcerative colitis by orchestrating gut homeostasis in microbial modulation and intestinal barrier integrity, Am. J. Chin. Med., pp. 1-23, (2023); Loayza J.J.J., Kang S., Schooth L., Teh J.J., de Klerk A., Noon E.K., Zhang J., Hu J., Hamilton A.L., Wilson-O'Brien A., Trakman G.L., Lin W., Ching J., Or L., Sung J.J.Y., Yu J., Ng S.C., Kamm M.A., Morrison M., Effect of food additives on key bacterial taxa and the mucosa-associated microbiota in Crohn's disease. The ENIGMA study, Gut Microbes, 15, 1, (2023); Qi B., Zhang Y., Ren D., Qin X., Wang N., Yang X., Fu brick tea alleviates constipation via regulating the aquaporins-mediated water transport system in association with gut microbiota, J. Agric. Food Chem., 71, 8, pp. 3862-3875, (2023); Yang Y., Li M., Liu Q., Zhao Q., Zeng J., Wang Q., Zhao Y., Du F., Chen Y., Shen J., Luo H., Wang S., Li W., Chen M., Li X., Wang F., Sun Y., Gu L., Xiao Z., Du Y., Wu X., Starch from Pueraria lobata and the amylose fraction alleviates dextran sodium sulfate induced colitis in mice, Carbohydr. Polym., 302, (2023); Llewellyn S.R., Britton G.J., Contijoch E.J., Vennaro O.H., Mortha A., Colombel J.F., Grinspan A., Clemente J.C., Merad M., Faith J.J., Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in Mice, Gastroenterology, 154, 4, pp. 1037-1046, (2018); Brierley S.M., Linden D.R., Neuroplasticity and dysfunction after gastrointestinal inflammation, Nat. Rev. Gastroenterol. Hepatol., 11, 10, pp. 611-627, (2014); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, 7, pp. 997-1006, (2012); Hou Y., Dong L., Lu X., Shi H., Xu B., Zhong W., Ma L., Wang S., Yang C., He X., Zhao Y., Wang S., Distinctions between fecal and intestinal mucosal microbiota in subgroups of irritable bowel syndrome, Dig. Dis. Sci., 67, 12, pp. 5580-5592, (2022); Gomaa E.Z., Human gut microbiota/microbiome in health and diseases: a review, Antonie Van Leeuwenhoek, 113, 12, pp. 2019-2040, (2020); Sinn D.H., Song J.H., Kim H.J., Lee J.H., Son H.J., Chang D.K., Kim Y.H., Kim J.J., Rhee J.C., Rhee P.L., Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome, Dig. Dis. Sci., 53, 10, pp. 2714-2718, (2008); Ouwehand A.C., Invernici M.M., Furlaneto F.A.C., Messora M.R., (2018); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies, J. Acad. Nutr. Diet., 120, 4, pp. 565-586, (2020); Ji M., Huang H., Lan X., Correlation between intestinal microflora in irritable bowel syndrome and severity, Dis. Markers, 2022, (2022); Guardado R., Asensi V., Torres J.M., Perez F., Blanco A., Maradona J.A., Carton J.A., Post-surgical enterococcal meningitis: clinical and epidemiological study of 20 cases, Scand. J. Infect. Dis., 38, 8, pp. 584-588, (2006); Zhao J., Bai M., Ning X., Qin Y., Wang Y., Yu Z., Dong R., Zhang Y., Sun S., Expansion of Escherichia-Shigella in gut is associated with the onset and response to immunosuppressive therapy of IgA nephropathy, J Am Soc Nephrol, 33, 12, pp. 2276-2292, (2022); Chen J., Wright K., Davis J.M., Jeraldo P., Marietta E.V., Murray J., Nelson H., Matteson E.L., Taneja V., An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis, Genome Med., 8, 1, (2016); Sheh A., The gastrointestinal microbiota of the common marmoset (Callithrix jacchus), ILAR J., 61, 2-3, pp. 188-198, (2020); Belzer C., Chia L.W., Aalvink S., Chamlagain B., Piironen V., Knol J., de Vos W.M., Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B(12) production by intestinal symbionts, MBio, 8, 5, (2017); Kang C., Wang B., Kaliannan K., Wang X., Lang H., Hui S., Huang L., Zhang Y., Zhou M., Chen M., Mi M., Gut microbiota mediates the protective effects of dietary capsaicin against chronic low-grade inflammation and associated obesity induced by high-fat diet, MBio, 8, 3, (2017); Quigley E.M.M., Markinson L., Stevenson A., Treasure F.P., Lacy B.E., Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome, Aliment. Pharmacol. Ther., 57, 1, pp. 81-93, (2023); Kocak E., Akbal E., Koklu S., Ergul B., Can M., The colonic tissue levels of TLR2, TLR4 and nitric oxide in patients with irritable bowel syndrome, Intern. Med., 55, 9, pp. 1043-1048, (2016); Wood J.D., Neuropathophysiology of irritable bowel syndrome, J. Clin. Gastroenterol., 35, 1, pp. S11-S22, (2002)^H. Lv; School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China; email: lvhuixia@163.com^^Elsevier B.V.^^^^^^15675769^^IINMB^38128311.0^English^Int. Immunopharmacol.^Article^Final^^Scopus^2-s2.0-85180612456
Ozaka S.; Sonoda A.; Ariki S.; Minata M.; Kamiyama N.; Hidano S.; Sachi N.; Ito K.; Kudo Y.; Dewayani A.; Chalalai T.; Ozaki T.; Soga Y.; Fukuda C.; Mizukami K.; Ishizawa S.; Nishiyama M.; Fujitsuka N.; Mogami S.; Kubota K.; Murakami K.; Kobayashi T.^Ozaka, Sotaro (56094787900); Sonoda, Akira (7004117592); Ariki, Shimpei (57218213616); Minata, Mizuki (57226804532); Kamiyama, Naganori (57188694955); Hidano, Shinya (6508296343); Sachi, Nozomi (57195370979); Ito, Kanako (57226796472); Kudo, Yoko (35332411600); Dewayani, Astri (57218165232); Chalalai, Thanyakorn (57194543524); Ozaki, Takashi (57195284895); Soga, Yasuhiro (57216298878); Fukuda, Chiaki (57195366124); Mizukami, Kazuhiro (7005239531); Ishizawa, Shiori (57202194061); Nishiyama, Mitsue (24339049800); Fujitsuka, Naoki (7005396694); Mogami, Sachiko (54883734200); Kubota, Kunitsugu (35074382700); Murakami, Kazunari (57214336895); Kobayashi, Takashi (36067140500)^56094787900; 7004117592; 57218213616; 57226804532; 57188694955; 6508296343; 57195370979; 57226796472; 35332411600; 57218165232; 57194543524; 57195284895; 57216298878; 57195366124; 7005239531; 57202194061; 24339049800; 7005396694; 54883734200; 35074382700; 57214336895; 36067140500^Saireito, a Japanese herbal medicine, alleviates leaky gut associated with antibiotic-induced dysbiosis in mice^2022^PLoS ONE^17.0^6 June^e0269698^^^^2^10.1371/journal.pone.0269698^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85132155385&doi=10.1371%2fjournal.pone.0269698&partnerID=40&md5=946f7c15bac947270ed7289371f82e7e^Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Tsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan; Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan^Ozaka S., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Sonoda A., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Ariki S., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Minata M., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Kamiyama N., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Hidano S., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Sachi N., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Ito K., Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Kudo Y., Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Dewayani A., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Chalalai T., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Ozaki T., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Soga Y., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Fukuda C., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; Mizukami K., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan, Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Ishizawa S., Tsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan; Nishiyama M., Tsumura Advanced Technology Research Laboratories, Tsumura & Co., Ibaraki, Japan; Fujitsuka N., Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan; Mogami S., Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan; Kubota K., Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, Japan; Murakami K., Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Kobayashi T., Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan^Antibiotics disrupt normal gut microbiota and cause dysbiosis, leading to a reduction in intestinal epithelial barrier function. Disruption of the intestinal epithelial barrier, which is known as “leaky gut”, results in increased intestinal permeability and contributes to the development or exacerbation of gastrointestinal diseases such as inflammatory bowel disease and irritable bowel syndrome. We have previously reported on a murine model of intestinal epithelial barrier dysfunction associated with dysbiosis induced by the administration of ampicillin and vancomycin. Saireito, a traditional Japanese herbal medicine, is often used to treat autoimmune disorders including ulcerative colitis; the possible mechanism of action and its efficacy, however, remains unclear. In this study, we examined the efficacy of Saireito in our animal model for leaky gut associated with dysbiosis. C57BL/6 mice were fed a Saireito diet for the entirety of the protocol (day1-28). To induce colitis, ampicillin and vancomycin were administered in drinking water for the last seven consecutive days (day22-28). As previously demonstrated, treatment with antibiotics caused fecal occult bleeding, cecum enlargement with black discoloration, colon inflammation with epithelial cell apoptosis, and upregulation of pro-inflammatory cytokines. Oral administration of Saireito significantly improved antibiotics-induced fecal occult bleeding and cecum enlargement by suppressing inflammation in the colon. Furthermore, Saireito treatment ensured the integrity of the intestinal epithelial barrier by suppressing apoptosis and inducing cell adhesion proteins including ZO-1, occludin, and E-cadherin in intestinal epithelial cells, which in turn decreased intestinal epithelial permeability. Moreover, the reduced microbial diversity seen in the gut of mice treated with antibiotics was remarkably improved with the administration of Saireito. In addition, Saireito altered the composition of gut microbiota in these mice. These results suggest that Saireito alleviates leaky gut caused by antibiotic-induced dysbiosis. Our findings provide a potentially new therapeutic strategy for antibiotic-related gastrointestinal disorders. Copyright: © 2022 Ozaka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.^^Ampicillin; Animals; Anti-Bacterial Agents; Colitis; Colitis, Ulcerative; Disease Models, Animal; Drugs, Chinese Herbal; Dysbiosis; Herbal Medicine; Inflammation; Intestinal Mucosa; Japan; Mice; Mice, Inbred C57BL; Vancomycin; acetic acid; ampicillin; antibiotic agent; butyric acid; daikenchuto; fluorescein isothiocyanate dextran; genomic DNA; interleukin 12p40; interleukin 13; interleukin 1beta; interleukin 6; lactoferrin; occludin; propionic acid; protein ZO1; RNA 16S; sairei to; secretory leukocyte proteinase inhibitor; short chain fatty acid; uvomorulin; valeric acid; vancomycin; antiinfective agent; herbaceous agent; vancomycin; animal cell; animal experiment; animal model; animal tissue; apoptosis; Article; blood sampling; cell adhesion; cell culture; cell infiltration; cervical spine dislocation; controlled study; DNA extraction; dysbiosis; female; herbal medicine; histology; immunohistochemistry; inflammatory bowel disease; intestine flora; irritable colon; mass fragmentography; metagenome; mouse; mRNA expression level; nonhuman; occult blood; real time reverse transcription polymerase chain reaction; RNA extraction; scoring system; sequence analysis; TUNEL assay; ulcerative colitis; animal; C57BL mouse; colitis; disease model; dysbiosis; herbal medicine; inflammation; intestine mucosa; Japan; metabolism; ulcerative colitis^^acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; butyric acid, 107-92-6, 156-54-7, 461-55-2; daikenchuto, 110445-34-6; fluorescein isothiocyanate dextran, 60842-46-8; interleukin 13, 148157-34-0; lactoferrin, 55599-62-7; occludin, 176304-61-3; propionic acid, 72-03-7, 79-09-4; sairei to, 308068-64-6; uvomorulin, 112956-45-3; valeric acid, 10023-74-2, 109-52-4; vancomycin, 1404-90-6, 1404-93-9; Ampicillin, ; Anti-Bacterial Agents, ; Drugs, Chinese Herbal, ; sairei-to, ; Vancomycin, ^EnVision, Agilent; Infinite 200 PRO, Tecan, Switzerland; LightCycler 96, Hoffmann La Roche, Switzerland; MiSeq, Illumina, United States; PureLink, Thermo, United States; QuantStudio 7, Thermo, United States; TQ8040, Shimadzu, Japan^Agilent; Hoffmann La Roche, Switzerland; Illumina, United States; Shimadzu, Japan; Tecan, Switzerland; Thermo, United States; Thermo, United States^Four Seasons Ladies Clinic; Tsumura & Co.; Taiju Life Social Welfare Foundation; Japan Society for the Promotion of Science, KAKEN, (17K08889, 20K07394, 20K16028, 20K16499, 20K17025, 20K18482, 21K07984); Oita University^This work was supported by Oita University President’s Strategic Discretionary Fund to S.O., S.A., N.K., and N.S., Taiju Life Social Welfare Foundation (http://www.kousei-zigyodan. or.jp/igakukenkyu_zyosei.html) (to N.K.), Four Seasons Ladies Clinic Research Grant (https:// fourseasons096.com/) (to T.K.), Tsumura & Co. (https://www.tsumura.co.jp/) (to K.M.) and Japan Society for the Promotion of Science [grant number (17K08889, 21K07984 to T.K.), (20K18482 to N.K.), (20K17025 to S.A.), (20K16499 to N.S.), (20K16028 to S.O.), (20K07394 to K.M.)]. In this study, we received the financial support from Tsumura & Co. Co-authors include employees of the company (Shiori Ishizawa, Mitsue Nishiyama, Naoki, Fujitsuka, Sachiko Mogami, and Kunitsugu Kubota) that solely provide Saireito and contribute data analysis of gut microbiota (Fig. 6, S2 Fig). We thank Ms. Aiko Yasuda (Oita University), Ms. Mami Koya (Oita University) and Ms. Kumiko Sakai (Oita University) for excellent technical assistance.^"Strati F, Pujolassos M, Burrello C, Giuffre MR, Lattanzi G, Caprioli F, Et al., Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models, Microbiome, 9, 1, (2021); Kamada N, Seo S, Chen G, Nunez G., Role of the gut microbiota in immunity and inflammatory disease, Nature Reviews Immunology, 13, 5, pp. 321-335, (2013); Keeney K, Yurist-Doutsch S, Arrieta M, Finlay B., Effects of Antibiotics on Human Microbiota and Subsequent Disease, Annual Review of Microbiology, 68, pp. 217-235, (2014); Sturgeon C, Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Pakravan N, Kermanian F, Mahmoudi E., Filtered Kombucha tea ameliorates the leaky gut syndrome in young and old mice model of colitis, Iran J Basic Med Sci, 22, 10, pp. 1158-1165, (2019); Zhu L, Li J, Wei C, Luo T, Deng Z, Fan Y, Et al., A polysaccharide from Fagopyrum esculentum Moench bee pollen alleviates microbiota dysbiosis to improve intestinal barrier function in antibiotic-treated mice, Food Funct, 11, 12, pp. 10519-10533, (2020); Mu Q, Kirby J, Reilly CM, Luo XM., Leaky Gut As a Danger Signal for Autoimmune Diseases, Front Immunol, 8, (2017); Paray BA, Albeshr MF, Jan AT, Rather IA., Leaky Gut and Autoimmunity: An Intricate Balance in Individuals Health and the Diseased State, Int J Mol Sci, 21, 24, (2020); Camilleri M., Leaky gut: mechanisms, measurement and clinical implications in humans, Gut, 68, 8, pp. 1516-1526, (2019); Fukui H., Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?, Inflamm Intest Dis, 1, 3, pp. 135-145, (2016); Fasano A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer, Physiol Rev, 91, 1, pp. 151-175, (2011); Sonoda A, Kamiyama N, Ozaka S, Gendo Y, Ozaki T, Hirose H, Et al., Oral administration of antibiotics results in fecal occult bleeding due to metabolic disorders and defective proliferation of the gut epithelial cell in mice, Genes Cells, 23, 12, pp. 1043-1055, (2018); Ohno S., Roles of Kampo medicine in treating rheumatic diseases, J Trad Med, 24, pp. 73-80, (2007); Kimura K, Nanba S, Tojo A, Matsuoka H, Sugimoto T., Effects of sairei-to on the relapse of steroid-dependent nephrotic syndrome, Am J Chin Med, 18, pp. 45-50, (1990); Endo M, Oikawa T, Hoshino T, Hatori T, Matsumoto T, Hanawa T., Supression of murine colitis by Kampo medicines, with special reference to the efficacy of saireito, J Trad Med, 26, pp. 110-121, (2009); Kato S, Hayashi S, Kitahara Y, Nagasawa K, Aono H, Shibata J, Et al., Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells, PLoS One, 10, 1, (2015); Watanabe T, Yamamoto T, Yoshida M, Fujiwara K, Kageyama-Yahara N, Kuramoto H, Et al., The traditional herbal medicine saireito exerts its inhibitory effect on murine oxazolone-induced colitis via the induction of Th1-polarized immune responses in the mucosal immune system of the colon, Int Arch Allergy Immunol, 151, 2, pp. 98-106, (2010); Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, Et al., Therapeutic potential of follistatin for colonic inflammation in mice, Gastroenterology, 128, 2, pp. 411-423, (2005); Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Et al., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells, Nature, 504, 7480, pp. 446-450, (2013); Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Et al., QIIME allows analysis of high-throughput community sequencing data, Nat Methods, 7, 5, pp. 335-336, (2010); Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas-Silva P, Turnbaugh PJ, Et al., Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome, Diabetes, 64, 8, pp. 2847-2858, (2015); Martini E, Krug SM, Siegmund B, Neurath MF, Becker C., Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease, Cell Mol Gastroenterol Hepatol, 4, 1, pp. 33-46, (2017); Chelakkot C, Ghim J, Ryu SH., Mechanisms regulating intestinal barrier integrity and its pathological implications, Exp Mol Med, 50, 8, pp. 1-9, (2018); Ho S, Pothoulakis C, Koon HW., Antimicrobial peptides and colitis, Curr Pharm Des, 19, 1, pp. 40-47, (2013); Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC., The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Proc Natl Acad Sci U S A, 105, 39, pp. 15064-15069, (2008); Vancamelbeke M, Vanuytsel T, Farre R, Verstockt S, Ferrante M, Van Assche G, Et al., Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease, Inflamm Bowel Dis, 23, 10, pp. 1718-1729, (2017); Luissint AC, Parkos CA, Nusrat A., Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair, Gastroenterology, 151, 4, pp. 616-632, (2016); Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L, Et al., RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis, Nature, 513, 7516, pp. 90-94, (2014); Shi Y, Kellingray L, Zhai Q, Gall GL, Narbad A, Zhao J, Et al., Structural and Functional Alterations in the Microbial Community and Immunological Consequences in a Mouse Model of Antibiotic-Induced Dysbiosis, Front Microbiol, 9, (2018); Shi Y, Zhai Q, Li D, Mao B, Liu X, Zhao J, Et al., Restoration of cefixime-induced gut microbiota changes by Lactobacillus cocktails and fructooligosaccharides in a mouse model, Microbiol Res, 200, pp. 14-24, (2017); Ravisankar S, Tatum R, Garg PM, Herco M, Shekhawat PS, Chen YH., Necrotizing enterocolitis leads to disruption of tight junctions and increase in gut permeability in a mouse model, BMC Pediatr, 18, 1, (2018); Kim SW, Peck KR, Jung SI, Kim YS, Kim S, Lee NY, Et al., Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea, J Korean Med Sci, 16, 6, pp. 742-744, (2001); Chuang CH, Wang YH, Chang HJ, Chen HL, Huang YC, Lin TY, Et al., Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease, Gut, 63, 5, pp. 736-743, (2014); Alnabhani Z, Montcuquet N, Biaggini K, Dussaillant M, Roy M, Ogier-Denis E, Et al., Pseudomonas fluorescens alters the intestinal barrier function by modulating IL-1β expression through hematopoietic NOD2 signaling, Inflamm Bowel Dis, 21, 3, pp. 543-555, (2015); von Klitzing E, Ekmekciu I, Kuhl AA, Bereswill S, Heimesaat MM., Multidrug-resistant Pseudomonas aeruginosa aggravates inflammatory responses in murine chronic colitis, Sci Rep, 8, 1, (2018); Tao S, Xiong Y, Han D, Pi Y, Zhang H, Wang J., N-(3-oxododecanoyl)-l-homoserine lactone disrupts intestinal epithelial barrier through triggering apoptosis and collapsing extracellular matrix and tight junction, J Cell Physiol, 236, 8, pp. 5771-5784, (2021); Tian P, Zhu H, Qian X, Chen Y, Wang Z, Zhao J, Et al., Consumption of Butylated Starch Alleviates the Chronic Restraint Stress-Induced Neurobehavioral and Gut Barrier Deficits Through Reshaping the Gut Microbiota, Front Immunol, 12, (2021); Wu T, Wang X, Xiong H, Deng Z, Peng X, Xiao L, Et al., Bioactives and their metabolites from Tetra-stigma hemsleyanum leaves ameliorate DSS-induced colitis via protecting the intestinal barrier, mitigating oxidative stress and regulating the gut microbiota, Food Funct, 12, 23, pp. 11760-11776, (2021); Luciano L, Hass R, Busche R, von Engelhardt W, Reale E., Withdrawal of butyrate from the colonic mucosa triggers ""mass apoptosis"" primarily in the G0/G1 phase of the cell cycle, Cell Tissue Res, 286, 1, pp. 81-92, (1996); Hass R, Busche R, Luciano L, Reale E, Engelhardt WV., Lack of butyrate is associated with induction of Bax and subsequent apoptosis in the proximal colon of guinea pig, Gastroenterology, 112, 3, pp. 875-881, (1997)"^T. Kobayashi; Department of Infectious Disease Control, Faculty of Medicine, Oita University, Yufu, Japan; email: takashik@oita-u.ac.jp^^Public Library of Science^^^^^^19326203^^POLNC^35704618.0^English^PLoS ONE^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85132155385
Wu H.; Zhan K.; Rao K.; Zheng H.; Qin S.; Tang X.; Huang S.^Wu, Haomeng (57211081140); Zhan, Kai (57220068150); Rao, Kehan (57491348600); Zheng, Huan (57210640207); Qin, Shumin (57189902334); Tang, Xudong (24339251100); Huang, Shaogang (56346213200)^57211081140; 57220068150; 57491348600; 57210640207; 57189902334; 24339251100; 56346213200^Comparison of five diarrhea-predominant irritable bowel syndrome (IBS-D) rat models in the brain-gut-microbiota axis^2022^Biomedicine and Pharmacotherapy^149.0^^112811^^^^10^10.1016/j.biopha.2022.112811^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126529037&doi=10.1016%2fj.biopha.2022.112811&partnerID=40&md5=fc7a8943b11ed4b62caf8e9ad10ce460^Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan, 523000, China^Wu H., Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Zhan K., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Rao K., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Zheng H., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Qin S., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China; Tang X., Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China; Huang S., The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China, Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, Guangzhou, 510120, China, Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan, 523000, China^The brain-gut-microbiota (BGM) axis is known to be essential for diarrhea-predominant irritable bowel syndrome (IBS-D). In order to evaluate the effects of IBS-D rat models (the central sensitization model, the peripheral sensitization model and the compound model) on the BGM axis, five models were induced in Wistar rats with 4% acetic acid (AD, dissolved 0.4 ml of AD in 9.6 ml of ultrapure water) + wrap restrain stress (WRS), 4% AD, colorectal distention (CRD), WRS, and neonatal maternal separation (NMS). Abdominal withdrawal reflex (AWR) scale scores and the moisture content of feces (MCF) were evaluated on the day of completing modeling. Body weight was measured every 7 days during modeling. Brain gut peptides, cytokine levels, the activity of spinal cord neurons, intestinal mucosal barrier function, and gut microbiota were determined after induction of IBS-D. We found intervention with 4% AD + WRS, 4% AD, CRD, WRS, and NMS induced a similar course of effects on the BGM axis. Among the five models, AWR scores (60 mmHg, 80 mmHg) were all increased. The levels of 5-hydroxytryptamine, corticotropin-releasing factor, substance P, and calcitonin gene-related protein in serum rapidly increased, whereas that of neuropeptide Y decreased. C-fos in the spinal cord showed increased neuronal activity. The intestinal permeability was increased and the composition and structure of gut microbiota were changed. In conclusion, the five models could cause changes in BGM axis, but the 4% AD + WRS model was closer to the changes BGM axis of post-inflammatory models of IBS-D. © 2022 The Authors^Acetic acid; Brain-gut-microbiota axis; Colorectal distention; Diarrhea predominant-irritable bowel syndrome; Neonatal maternal separation; Rat models; Wrap restrain stress^Animals; Brain; Diarrhea; Gastrointestinal Microbiome; Irritable Bowel Syndrome; Maternal Deprivation; Rats; Rats, Wistar; acetic acid; calcitonin; calcitonin gene related peptide; corticotropin releasing factor; interleukin 10; interleukin 2; interleukin 4; nuclear factor Y; serotonin; substance P; tumor necrosis factor; animal experiment; animal model; animal tissue; Article; body weight; brain-gut axis; controlled study; diarrhea; DNA extraction; enzyme linked immunosorbent assay; feces; immobilization stress; immunohistochemistry; irritable colon; male; maternal deprivation; moisture; newborn; nonhuman; rat; Western blotting; withdrawal reflex; animal; brain; diarrhea; intestine flora; metabolism; Wistar rat^^acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1, 6131-90-4; calcitonin, 12321-44-7, 21215-62-3, 9007-12-9; calcitonin gene related peptide, 83652-28-2; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; interleukin 2, 85898-30-2; serotonin, 50-67-9; substance P, 33507-63-0^GeneAmp 9700, ABI, United States; NanoDrop 2000, Thermo, United States^ABI, United States; Thermo, United States^City School-College Union-Fundamentals and Application Fundamentals, (202102010207, 202102010226); Guangdong Medical Science and Technology Research Fund Project, (A2017394, A2020181); Traditional Chinese Medicine Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine, (20192024, 20222074); Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases, (2021xk63); National Natural Science Foundation of China, NSFC, (81703992, 81974563); Natural Science Foundation of Beijing Municipality, (7192184); Guangzhou Municipal Science and Technology Project^Funding text 1: This work was supported by the National Natural Science Foundation of China (Grant nos. 81974563 and 81703992 ), Natural Science Foundation of Beijing Municipality ( 7192184 )， Guangzhou Science and Technology Project, City School-College Union-Fundamentals and Application Fundamentals ( 202102010226 , 202102010207 ), Guangdong Medical Science and Technology Research Fund Project (No. A2017394 , A2020181 ), and Traditional Chinese Medicine Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine ( 20192024 , 20222074 ). Project of Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases ( 2021xk63 ). ; Funding text 2: This work was supported by the National Natural Science Foundation of China (Grant nos. 81974563 and 81703992), Natural Science Foundation of Beijing Municipality (7192184)?Guangzhou Science and Technology Project, City School-College Union-Fundamentals and Application Fundamentals (202102010226, 202102010207), Guangdong Medical Science and Technology Research Fund Project (No. A2017394, A2020181), and Traditional Chinese Medicine Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20192024, 20222074). Project of Collaborative Innovation Team of Traditional Chinese Medicine in Prevention and Treatment of Functional Gastrointestinal Diseases (2021xk63).^Zhan K., Zheng H., Li J., Wu H., Qin S., Luo L., Huang S., Gut microbiota-bile acid crosstalk in diarrhea-irritable bowel syndrome, Biomed. Res. Int., 2020, (2020); Garsed K., Chernova J., Hastings M., Lam C., Et al., A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut, 63, pp. 1617-1625, (2014); Black C.J., Burr N.E., Camilleri M., Earnest D.L., Et al., Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis, Gut, 69, pp. 74-82, (2020); Johnson A.C., Greenwood-Van Meerveld B., Critical evaluation of animal models of gastrointestinal disorders, Handb. Exp. Pharm., 239, pp. 289-317, (2017); Mayer E.A., Naliboff B.D., Chang L., Basic pathophysiologic mechanisms in irritable bowel syndrome, Dig. Dis., 19, pp. 212-218, (2001); Tsang S.W., Zhao M., Wu J., Sung J.J., Et al., Nerve growth factor-mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation-induced visceral hypersensitivity in rats, Eur. J. Pain, 16, pp. 463-472, (2012); Williams C.L., Villar R.G., Peterson J.M., Burks T.F., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); Vannucchi M.G., Evangelista S., Experimental models of irritable bowel syndrome and the role of the enteric neurotransmission, J. Clin. Med., 7, (2018); Qin H.Y., Wu J.C., Tong X.D., Sung J.J., Et al., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, J. Gastroenterol., 46, pp. 164-174, (2011); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Zhao L., Yang W., Chen Y., Huang F., Et al., A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome, J. Clin. Invest., 130, pp. 438-450, (2020); La J.H., Kim T.W., Sung T.S., Kang J.W., Et al., Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis, World J. Gastroenterol., 9, pp. 2791-2795, (2003); Zou B.C., Dong L., Wang Y., Wang S.H., Et al., Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome, Chin. Med. J., 120, pp. 2069-2074, (2007); Zhang B., Xue H., Wang W., Chen T., Et al., Comparative proteomic analysis of the brain and colon in three rat models of irritable bowel syndrome, Proteome Sci., 18, 1, (2020); Ma J., Li J.H., Qian M.R., He N., Et al., The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity, Faseb J., 33, pp. 13560-13571, (2019); Quigley E.M.M., The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS), J. Clin. Med., 7, (2018); Moloney R.D., Johnson A.C., O'Mahony S.M., Dinan T.G., Et al., Stress and the microbiota-gut-brain axis in visceral pain: relevance to irritable bowel syndrome, Cns Neurosci. Ther., 22, pp. 102-117, (2016); Martin C.R., Osadchiy V., Kalani A., Mayer E.A., The brain-gut-microbiome axis, Cell. Mol. Gastroenterol., 6, pp. 133-148, (2018); Holzer P., Farzi A., Neuropeptides and the microbiota-gut-brain axis, Adv. Exp. Med. Biol., 817, pp. 195-219, (2014); Monnikes H., Lauer G., Arnold R., Peripheral administration of cholecystokinin activates c-fos expression in the locus coeruleus/subcoeruleus nucleus, dorsal vagal complex and paraventricular nucleus via capsaicin-sensitive vagal afferents and CCK-A receptors in the rat, Brain Res., 770, pp. 277-288, (1997); Zhang R., Zou N., Li J., Lv H., Et al., Elevated expression of c-fos in central nervous system correlates with visceral hypersensitivity in irritable bowel syndrome (IBS): a new target for IBS treatment, Int. J. Colorectal Dis., 26, pp. 1035-1044, (2011); Darkoh C., Comer L., Zewdie G., Harold S., Et al., Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome, PLoS One, 9, (2014); Schmulson M., Pulido-London D., Rodriguez O., Morales-Rochlin N., Et al., Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico, Am. J. Gastroenterol., 107, pp. 747-753, (2012); Sun J.H., Wu X.L., Meng Y.F., Cheng J., Et al., Electro-acupuncture decreases 5-HT, CGRP and increases NPY in the brain-gut axis in two rat models of Diarrhea-predominant irritable bowel syndrome (D-IBS), Bmc Complement. Altern. Med., (2015); Sohnn W., Lee O.Y., Lee S.P., Lee K.N., Et al., Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea, Scand. J. Gastroenterol., 49, pp. 43-51, (2014); Martinez C., Lobo B., Pigrau M., Ramos L., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat. Rev. Immunol., 9, pp. 799-809, (2009); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Hou Q., Huang Y., Zhu Z., Liao L., Et al., Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways, BMC Complement. Altern. Med., 19, (2019); Piche T., Barbara G., Aubert P., des Varannes S.B., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Vicario M., Ramos L., Lobo B., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol., 107, pp. 736-746, (2012); Zhao L., Huang Y., Lu L., Yang W., Et al., Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats, Microbiome, 6, (2018); Traini C., Evangelista S., Girod V., Faussone-Pellegrini M.S., Et al., Changes of excitatory and inhibitory neurotransmitters in the colon of rats underwent to the wrap partial restraint stress, Neurogastroenterol. Motil., 28, pp. 1172-1185, (2016); Drossman D.A., Hasler W.L., Rome IV-functional GI disorders: disorders of gut-brain interaction introduction, Gastroenterology, 150, pp. 1257-1261, (2016); Ma X.X., Wang X.G., Kang N., Chen T., Et al., The effect of Tong-Xie-Yao-Fang on intestinal mucosal mast cells in postinfectious irritable bowel syndrome rats, Evid.-Based Complement. Altern. Med., 2017, (2017); Zhang C.R., Huang Y.Q., Li P.W., Chen X.L., Et al., Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction, Bmc Complement. Med., 20, (2020); Hou Q.K., Zhu S.L., Zhang C.R., Huang Y.Q., Et al., Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice (vol. 118, 109206, 2019), Biomed. Pharmcother., (2019); Greenwood-Van Meerveld B., Prusator D.K., Johnson A.C., Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges, Am. J. Physiol.-Gastrointest. Liver, 308, pp. G885-G903, (2015); Fan M., Zhang X., Liu J., Wang S., Research progress in functional dyspepsia relevant to traditional Chinese medicine based on the theory of brain-gut axis, Zhong Nan Da Xue Xue Bao Yi Xue Ban., 44, pp. 1300-1305, (2019); Wu Y., He H.X., Cheng Z.B., Bai Y.Y., Et al., The role of neuropeptide Y and peptide YY in the development of obesity via gut-brain axis, Curr. Protein Pept. Sci., 20, pp. 750-758, (2019); Huang W., Jiang S.M., Jia L., You L.Q., Et al., Effect of amitriptyline on gastrointestinal function and brain-gut peptides: a double-blind trial, World J. Gastroenterol., 19, pp. 4214-4220, (2013); Camilleri M., Boeckxstaens G., Dietary and pharmacological treatment of abdominal pain in IBS, Gut, 66, pp. 966-974, (2017); Welgan P., Meshkinpour H., Hoehler F., The effect of stress on colon motor and electrical activity in irritable bowel syndrome, Psychosom. Med., 47, pp. 139-149, (1985); Schou W.S., Ashina S., Amin F.M., Goadsby P.J., Et al., Calcitonin gene-related peptide and pain: a systematic review, J. Headache Pain, (2017); Barreau F., Salvador-Cartier C., Houdeau E., Bueno L., Et al., Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats, Gut, 57, pp. 582-590, (2008); Chatoo M., Li Y., Ma Z., Coote J., Et al., Involvement of corticotropin-releasing factor and receptors in immune cells in irritable bowel syndrome, Front. Endocrinol., 9, (2018); Chang L., The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome, Gastroenterology, 140, pp. 761-U124, (2011); Kiank C., Tache Y., Larauche M., Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors, Brain Behav. Immun., 24, pp. 41-48, (2010); Gong Z.P., Chen Y., Zhang R.J., Yang Q., Et al., Pharmacokinetic difference of berberine between normal and chronic visceral hypersensitivity irritable bowel syndrome rats and its mechanism, Arch. Pharm. Res., 38, pp. 1888-1896, (2015); Ren T.H., Wu J., Yew D., Ziea E., Et al., Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome, Am. J. Physiol.-Gastrointest. Liver, 292, pp. G849-G856, (2007); Bercik P., Verdu E.F., Collins S.M., Is irritable bowel syndrome a low-grade inflammatory bowel disease?, Gastroenterol. Clin. N. Am., 34, (2005); Ohman L., Simren M., Pathogenesis of IBs: role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepat., 7, pp. 163-173, (2010); Ivashkin V., Poluektov Y., Kogan E., Shifrin O., Et al., Disruption of the pro-inflammatory, anti-inflammatory cytokines and tight junction proteins expression, associated with changes of the composition of the gut microbiota in patients with irritable bowel syndrome, PLoS One, 16, (2021); Hughes P.A., Zola H., Penttila I.A., Blackshaw L.A., Et al., Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?, Am. J. Gastroenterol., 108, pp. 1066-1074, (2013); Dinan T.G., Quigley E.M., Ahmed S.M., Scully P., Et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?, Gastroenterology, 130, pp. 304-311, (2006); Scully P., McKernan D.P., Keohane J., Groeger D., Et al., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am. J. Gastroenterol., 105, pp. 2235-2243, (2010); Chang L., Adeyemo M., Karagiannidis I., Videlock E.J., Et al., Serum and colonic mucosal immune markers in irritable bowel syndrome, Am. J. Gastroenterol., 107, pp. 262-272, (2012); Hughes P.A., Harrington A.M., Castro J., Liebregts T., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Swan C., Duroudier N.P., Campbell E., Zaitoun A., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα, Gut, 62, pp. 985-994, (2013); Malkin C.J., Pugh P.J., Jones R.D., Kapoor D., Et al., The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men, J. Clin. Endocr. Metab., 89, pp. 3313-3318, (2004); Lee J.Y., Kim N., Park J.H., Nam R.H., Et al., Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex, J. Neurogastroenterol., 26, pp. 106-116, (2020); Ganci M., Suleyman E., Butt H., Ball M., The role of the brain-gut-microbiota axis in psychology: the importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders, Brain Behav., 9, (2019); Deng Y.Y., Zhou M.F., Wang J.F., Yao J.X., Et al., Involvement of the microbiota-gut-brain axis in chronic restraint stress: disturbances of the kynurenine metabolic pathway in both the gut and brain, Gut Microbes, (2021); Duan R.Q., Zhu S.W., Wang B., Duan L.P., Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review, Clin. Transl. Gastroenterol., 10, (2019); Zhou C., Fang X., Xu J., Gao J., Et al., Bifidobacterium longum alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation, Gut Microbes, 12, (2020); Zhou X.Y., Li M., Li X., Long X., Et al., Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients, World J. Gastroenterol., 22, pp. 5211-5227, (2016); Labus J.S., Hollister E.B., Jacobs J., Kirbach K., Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, (2017); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Yi W., Cheng J., Wei Q., Pan R., Et al., Effect of temperature stress on gut-brain axis in mice: regulation of intestinal microbiome and central NLRP3 inflammasomes, Sci. Total Environ., 772, (2021); Shin N.R., Whon T.W., Bae J.W., Proteobacteria: microbial signature of dysbiosis in gut microbiota, Trends Biotechnol., 33, pp. 496-503, (2015); Becerra-Castro C., Macedo G., Silva A.M.T., Manaia C.M., Et al., Proteobacteria become predominant during regrowth after water disinfection, Sci. Total Environ., 573, pp. 313-323, (2016); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Et al., Gut microbiota in patients with irritable bowel syndrome–a systematic review, Gastroenterology, 157, pp. 97-108, (2019); Bonfrate L., Di Palo D.M., Celano G., Albert A., Et al., Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients, Eur. J. Clin. Invest., 50, (2020); Johnson A.C., Farmer A.D., Ness T.J., Greenwood-Van Meerveld B., Critical evaluation of animal models of visceral pain for therapeutics development: a focus on irritable bowel syndrome, Neurogastroenterol. Motil., 32, (2020)^X. Tang; Xiyuan Hospital China Academy of Chinese Medical Sciences, Beijing, 100091, China; email: txdly@sina.com; S. Huang; The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; email: huangshaogang@gzucm.edu.cn^^Elsevier Masson s.r.l.^^^^^^07533322^^BIPHE^35303570.0^English^Biomed. Pharmacother.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85126529037
Filippone A.; Ardizzone A.; Bova V.; Lanza M.; Casili G.; Cuzzocrea S.; Esposito E.; Campolo M.; Paterniti I.^Filippone, Alessia (57200369301); Ardizzone, Alessio (57216888911); Bova, Valentina (57876785600); Lanza, Marika (57200363172); Casili, Giovanna (57189218376); Cuzzocrea, Salvatore (35492552100); Esposito, Emanuela (56417262900); Campolo, Michela (55364236100); Paterniti, Irene (26041018000)^57200369301; 57216888911; 57876785600; 57200363172; 57189218376; 35492552100; 56417262900; 55364236100; 26041018000^A Combination of Xyloglucan, Pea Protein and Chia Seed Ameliorates Intestinal Barrier Integrity and Mucosa Functionality in a Rat Model of Constipation-Predominant Irritable Bowel Syndrome^2022^Journal of Clinical Medicine^11.0^23^7073^^^^4^10.3390/jcm11237073^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143588426&doi=10.3390%2fjcm11237073&partnerID=40&md5=7d01dfe4e75e7b61cf2ebe7c9757657d^Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy^Filippone A., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Ardizzone A., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Bova V., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Lanza M., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Casili G., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Cuzzocrea S., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Esposito E., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Campolo M., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy; Paterniti I., Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’ Alcontres, 31, Messina, 98166, Italy^Irritable Bowel Syndrome is a gastrointestinal disorder that affects the large intestine, which encompasses several symptoms including, but not limited to, abdominal pain, bloating and dysmotility. In particular, IBS associated with constipation (IBS-C) is characterized by hard and dry stools and inadequate evacuation and difficulty in defecation. Although several drugs ameliorate intestinal modifications and constipation-associated features, management of IBS is still a challenge. Natural compounds including Xyloglucan and pea protein (XP) and Chia seed powder (CS) are widely known to possess beneficial effects in counteracting several gastrointestinal disorders. Here, we aimed to assess the combined effects of XP and CS to treat constipation-related alterations in an IBS-C rat model. IBS-C was induced by gastric instillation of 2 mL of cold water (0–4 °C) for 14 days and Xiloglucan, Pea protein and Chia seeds (XP + CS) treatment was orally administered for 7 days. On day 22, colon tissues were collected for histological analysis. Our results showed that XP + CS administration attenuated constipation-related parameters by increasing body weight and food and water intake. Upon XP + CS treatment, from day 14 to 22, stool moisture content was restored to physiological level. Colonic tissues from IBS-C rats depicted a disruption of the organ architecture accompanied by edema. Loss of colonic structure was reflected by the marked reduction of tight junction protein expression, Occludin and zona occludens-1 (ZO-1). Administration of XP + CS treatment in IBS-C rats significantly ameliorated the colonic histological parameters and exerted a positive effect on barrier integrity by restoring the expression of Occludin and zona occludens-1 (ZO-1). Our findings demonstrated that the efficacy of XP and CS in managing constipation in rats is due to the ability of these compounds to form a protective barrier fortifying intestinal integrity and gut functionality. © 2022 by the authors.^constipation; intestinal barrier; irritable bowel syndrome (IBS); natural compounds^laxative; occludin; pea protein; protein ZO1; tight junction protein; unclassified drug; xyloglucan; abdominal pain; adult; animal experiment; animal model; animal tissue; Article; body weight gain; chia; colon tissue; combination drug therapy; constipation; controlled study; drug efficacy; drug instillation; edema; fluid intake; food intake; intestine mucosa; irritable colon; male; moisture; nonhuman; protein expression; rat; urine volume; visceral sensitivity index^^occludin, 176304-61-3^^^^^Ardizzone A., Filippone A., Mannino D., Scuderi S.A., Casili G., Lanza M., Cucinotta L., Campolo M., Esposito E., Ulva pertusa, a Marine Green Alga, Attenuates DNBS-Induced Colitis Damage via NF-kappaB/Nrf2/SIRT1 Signaling Pathways, J. Clin. Med, 11, (2022); Li C., Nie S.P., Zhu K.X., Xiong T., Li C., Gong J., Xie M.Y., Effect of Lactobacillus plantarum NCU116 on loperamide-induced constipation in mice, Int. J. Food Sci. Nutr, 66, pp. 533-538, (2015); Lacy B.E., Patel N.K., Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome, J. Clin. Med, 6, (2017); Kopczynska M., Mokros L., Pietras T., Malecka-Panas E., Quality of life and depression in patients with irritable bowel syndrome, Przegląd Gastroenterol, 13, pp. 102-108, (2018); Gillman P.K., Tricyclic antidepressant pharmacology and therapeutic drug interactions updated, Br. J. Pharmacol, 151, pp. 737-748, (2007); Marlicz W., Skonieczna-Zydecka K., Krynicka P., Loniewski I., Rydzewska G., Probiotics in irritable bowel syndrome—Is the quest for the right strain over? Rapid review of existing guidelines and recommendations, Przegląd Gastroenterol, 16, pp. 369-382, (2021); Roudsari N.M., Lashgari N.A., Momtaz S., Farzaei M.H., Marques A.M., Abdolghaffari A.H., Natural polyphenols for the prevention of irritable bowel syndrome: Molecular mechanisms and targets; a comprehensive review, Daru, 27, pp. 755-780, (2019); Cao P.Q., Li X.P., Ou-Yang J., Jiang R.G., Huang F.F., Wen B.B., Zhang X.N., Huang J.A., Liu Z.H., The protective effects of yellow tea extract against loperamide-induced constipation in mice, Food Funct, 12, pp. 5621-5636, (2021); Lanza M., Filippone A., Ardizzone A., Casili G., Paterniti I., Esposito E., Campolo M., SCFA Treatment Alleviates Pathological Signs of Migraine and Related Intestinal Alterations in a Mouse Model of NTG-Induced Migraine, Cells, 10, (2021); Soltanian N., Janghorbani M., Effect of flaxseed or psyllium vs. placebo on management of constipation, weight, glycemia, and lipids: A randomized trial in constipated patients with type 2 diabetes, Clin. Nutr. ESPEN, 29, pp. 41-48, (2019); Oh S.J., Fuller G., Patel D., Khalil C., Spalding W., Nag A., Spiegel B.M.R., Almario C.V., Chronic Constipation in the United States: Results From a Population-Based Survey Assessing Healthcare Seeking and Use of Pharmacotherapy, Am. J. Gastroenterol, 115, pp. 895-905, (2020); Campolo M., Casili G., Paterniti I., Filippone A., Lanza M., Ardizzone A., Scuderi S.A., Cuzzocrea S., Esposito E., Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis, Int. J. Mol. Sci, 21, (2020); de Los Rios C.C., Falcon B.S., Arguelles-Arias F., Perez E., Teruel C., Geijo F., Rey E., Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome, Ther. Adv. Gastroenterol, 14, (2021); Emkani M., Oliete B., Saurel R., Pea Protein Extraction Assisted by Lactic Fermentation: Impact on Protein Profile and Thermal Properties, Foods, 10, (2021); Bellini M., Berti G., Bonfrate L., Ciranni F., Di Ciaula A., Di Ruscio M., Dell'Era A., Lambiase C., Noto A., Pancetti A., Et al., Use of GELSECTAN((R)) in Patients with Irritable Bowel Syndrome (IBS): An Italian Experience, Patient Prefer. Adherence, 15, pp. 1763-1774, (2021); Garland V., Herlitz L., Regunathan-Shenk R., Diet-induced oxalate nephropathy from excessive nut and seed consumption, BMJ Case Rep, 13, (2020); Kulczynski B., Kobus-Cisowska J., Taczanowski M., Kmiecik D., Gramza-Michalowska A., The Chemical Composition and Nutritional Value of Chia Seeds-Current State of Knowledge, Nutrients, 11, (2019); Ardizzone A., Lanza M., Casili G., Campolo M., Paterniti I., Cuzzocrea S., Esposito E., Efficacy of a Novel Therapeutic, Based on Natural Ingredients and Probiotics, in a Murine Model of Multiple Food Intolerance and Maldigestion, Nutrients, 14, (2022); Xu J.R., Luo J.Y., Shang L., Kong W.M., Effect of change in an inhibitory neurotransmitter of the myenteric plexus on the pathogenetic mechanism of irritable bowel syndrome subgroups in rat models, Chin. J. Dig. Dis, 7, pp. 89-96, (2006); Lee H.Y., Kim J.H., Jeung H.W., Lee C.U., Kim D.S., Li B., Lee G.H., Sung M.S., Ha K.C., Back H.I., Et al., Effects of Ficus carica paste on loperamide-induced constipation in rats, Food Chem. Toxicol, 50, pp. 895-902, (2012); Xie N., Cui Y., Yin Y.N., Zhao X., Yang J.W., Wang Z.G., Fu N., Tang Y., Wang X.H., Liu X.W., Et al., Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet, BMC Complement. Altern. Med, 11, (2011); Campolo M., Crupi R., Cordaro M., Cardali S.M., Ardizzone A., Casili G., Scuderi S.A., Siracusa R., Esposito E., Conti A., Et al., Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury, Int. J. Mol. Sci, 22, (2021); Filippone A., Casili G., Ardizzone A., Lanza M., Mannino D., Paterniti I., Esposito E., Campolo M., Inhibition of Prolyl Oligopeptidase Prevents Consequences of Reperfusion following Intestinal Ischemia, Biomedicines, 9, (2021); Scuderi S.A., Casili G., Lanza M., Ardizzone A., Pantaleo L., Campolo M., Paterniti I., Cucinotta L., Cuzzocrea S., Esposito E., Efficacy of a Product Containing Xyloglucan and Pea Protein on Intestinal Barrier Function in a Partial Restraint Stress Animal Model, Int. J. Mol. Sci, 23, (2022); Lucarini E., Nocentini A., Bonardi A., Chiaramonte N., Parisio C., Micheli L., Toti A., Ferrara V., Carrino D., Pacini A., Et al., Carbonic Anhydrase IV Selective Inhibitors Counteract the Development of Colitis-Associated Visceral Pain in Rats, Cells, 10, (2021); Saha L., Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine, World J. Gastroenterol, 20, pp. 6759-6773, (2014); Qian Y., Suo H., Du M., Zhao X., Li J., Li G.J., Song J.L., Liu Z., Preventive effect of Lactobacillus fermentum Lee on activated carbon-induced constipation in mice, Exp. Ther. Med, 9, pp. 272-278, (2015); Meng J., Yu H., Ma J., Wang J., Banerjee S., Charboneau R., Barke R.A., Roy S., Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner, PLoS ONE, 8, (2013); Sharma A., Rao S., Constipation: Pathophysiology and Current Therapeutic Approaches, Handb. Exp. Pharmacol, 239, pp. 59-74, (2017); Vriesman M.H., Koppen I.J.N., Camilleri M., Di Lorenzo C., Benninga M.A., Management of functional constipation in children and adults, Nat. Rev. Gastroenterol. Hepatol, 17, pp. 21-39, (2020); Hossen I., Hua W., Ting L., Mehmood A., Jingyi S., Duoxia X., Yanping C., Hongqing W., Zhipeng G., Kaiqi Z., Et al., Phytochemicals and inflammatory bowel disease: A review, Crit. Rev. Food Sci. Nutr, 60, pp. 1321-1345, (2020); Hagan M., Hayee B.H., Rodriguez-Mateos A., (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review, Molecules, 26, (2021); Pique N., Gomez-Guillen M.D.C., Montero M.P., Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview, Int. J. Mol. Sci, 19, (2018); Campolo M., Lanza M., Filippone A., Paterniti I., Casili G., Scuderi S.A., Ardizzone A., Cuzzocrea S., Esposito E., Evaluation of a Product Containing Xyloglucan and Pea Protein on Skin Barrier Permeability, Skin Pharmacol. Physiol, 33, pp. 231-236, (2020); Gnessi L., Bacarea V., Marusteri M., Pique N., Xyloglucan for the treatment of acute diarrhea: Results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial, BMC Gastroenterol, 15, (2015); Cong L., Ma J.T., Jin Z.J., Duan L.W., Su W.P., Zheng J., Zhang L.J., Xu J., Li D.F., Efficacy and Safety of High Specific Volume Polysaccharide-A New Type of Dietary Fiber for Treatment of Functional Constipation and IBS-C, J. Nutr. Sci. Vitaminol. (Tokyo), 61, pp. 326-331, (2015); Tamargo A., Cueva C., Laguna L., Moreno-Arribas M.V., Munoz L.A., Understanding the impact of chia seed mucilage on human gut microbiota by using the dynamic gastrointestinal model simgi<sup>®</sup>, J. Funct. Foods, 50, pp. 104-111, (2018); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat. Rev. Immunol, 9, pp. 799-809, (2009)^M. Campolo; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Viale Ferdinando Stagno D’ Alcontres, 31, 98166, Italy; email: campolom@unime.it^^MDPI^^^^^^20770383^^^^English^J. Clin. Med.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85143588426
Maëva M.; Elodie B.; Nathalie R.; Manon D.; Marjolène S.; Valentine D.; Morgane M.; Ivan W.; Frédéric D.; Romain V.; Mathieu M.; Esther B.N.; Catherine G.; Nicolas B.; Denis A.; Philippe P.; Harry S.; Jean-Marc C.; Philippe L.; Valérie L.; Mathilde B.; Frédéric Antonio C.^Maëva, Meynier (57434423400); Elodie, Baudu (57434537800); Nathalie, Rolhion (57434460300); Manon, Defaye (57434479700); Marjolène, Straube (57434423500); Valentine, Daugey (57434479800); Morgane, Modoux (57434557400); Ivan, Wawrzyniak (57434537900); Frédéric, Delbac (57434557500); Romain, Villéger (57223197063); Mathieu, Méleine (57434423600); Esther, Borras Nogues (57434499900); Catherine, Godfraind (57434460400); Nicolas, Barnich (7801564380); Denis, Ardid (57434500000); Philippe, Poirier (57434479900); Harry, Sokol (57189696121); Jean-Marc, Chatel (57434519700); Philippe, Langella (57434423700); Valérie, Livrelli (57434460500); Mathilde, Bonnet (57223179033); Frédéric Antonio, Carvalho (16041688200)^57434423400; 57434537800; 57434460300; 57434479700; 57434423500; 57434479800; 57434557400; 57434537900; 57434557500; 57223197063; 57434423600; 57434499900; 57434460400; 7801564380; 57434500000; 57434479900; 57189696121; 57434519700; 57434423700; 57434460500; 57223179033; 16041688200^AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms^2022^Gut Microbes^14.0^1^2022997^^^^26^10.1080/19490976.2021.2022997^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123814767&doi=10.1080%2f19490976.2021.2022997&partnerID=40&md5=6293a6285a81e4ddecf194d6aa62683a^M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France; Paris Centre for Microbiome Medicine FHU, Paris, France; Department of Physiology and Pharmacology, Inflammation Research Network, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, T2N 4N1, AB, Canada; LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; CHU Clermont-Ferrand, Neuropathology Unit, Clermont-Ferrand, France; CHU Clermont-Ferrand, Laboratoire de Parasitologie et de Mycologie, Clermont-Ferrand, France^Maëva M., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Elodie B., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Nathalie R., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France, Paris Centre for Microbiome Medicine FHU, Paris, France; Manon D., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France, Department of Physiology and Pharmacology, Inflammation Research Network, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, T2N 4N1, AB, Canada, LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Marjolène S., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France; Valentine D., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Morgane M., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France; Ivan W., LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Frédéric D., LMGE, CNRS 6023, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Romain V., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; Mathieu M., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Esther B.N., Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Catherine G., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, CHU Clermont-Ferrand, Neuropathology Unit, Clermont-Ferrand, France; Nicolas B., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; Denis A., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France; Philippe P., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, CHU Clermont-Ferrand, Laboratoire de Parasitologie et de Mycologie, Clermont-Ferrand, France; Harry S., Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris, F-75012, France, Paris Centre for Microbiome Medicine FHU, Paris, France, Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Jean-Marc C., Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Philippe L., Université Paris-Saclay, Institut National de la Recherche Agronomique et Environnementale (INRAE), AgroParisTech UMR 1319 MICALIS, Jouy-en-Josas, France; Valérie L., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France, CHU Clermont-Ferrand, Laboratoire de Parasitologie et de Mycologie, Clermont-Ferrand, France; Mathilde B., M2iSH, UMR 1071 INSERM, University of Clermont Auvergne, INRAE USC 2018, Clermont-Ferrand, 63001, France; Frédéric Antonio C., NeuroDol, UMR 1107 INSERM, University of Clermont Auvergne, Clermont-Ferrand, 63001, France^Alterations in brain/gut/microbiota axis are linked to Irritable Bowel Syndrome (IBS) physiopathology. Upon gastrointestinal infection, chronic abdominal pain and anxio-depressive comorbidities may persist despite pathogen clearance leading to Post-Infectious IBS (PI-IBS). This study assesses the influence of tryptophan metabolism, and particularly the microbiota-induced AhR expression, on intestinal homeostasis disturbance following gastroenteritis resolution, and evaluates the efficacy of IL-22 cytokine vectorization on PI-IBS symptoms. The Citrobacter rodentium infection model in C57BL6/J mice was used to mimic Enterobacteria gastroenteritis. Intestinal homeostasis was evaluated as low-grade inflammation, permeability, mucosa-associated microbiota composition, and colonic sensitivity. Cognitive performances and emotional state of animals were assessed using several tests. Tryptophan metabolism was analyzed by targeted metabolomics. AhR activity was evaluated using a luciferase reporter assay method. One Lactococcus lactis strain carrying an eukaryotic expression plasmid for murine IL-22 (L. lactis IL−22) was used to induce IL-22 production in mouse colonic mucosa. C. rodentium-infected mice exhibited persistent colonic hypersensitivity and cognitive impairments and anxiety-like behaviors after pathogen clearance. These post-infectious disorders were associated with low-grade inflammation, increased intestinal permeability, decrease of Lactobacillaceae abundance associated with the colonic layer, and increase of short-chain fatty acids (SCFAs). During post-infection period, the indole pathway and AhR activity were decreased due to a reduction of tryptophol production. Treatment with L. lactis IL−22 restored gut permeability and normalized colonic sensitivity, restored cognitive performances and decreased anxiety-like behaviors. Data from the video-tracking system suggested an upgrade of welfare for mice receiving the L.lactis IL−22 strain. Our findings revealed that AhR/IL-22 signaling pathway is altered in a preclinical PI-IBS model. IL-22 delivering alleviate PI-IBS symptoms as colonic hypersensitivity, cognitive impairments, and anxiety-like behaviors by acting on intestinal mucosa integrity. Thus, therapeutic strategies targeting this pathway could be developed to treat IBS patients suffering from chronic abdominal pain and associated well-being disorders. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.^ahr; citrobacter rodentium; colonic-associated microbiota; il-22; lactococcus lactis; Post-infectious ibs; tryptophan; well-being disorders^Animals; Bacteria; Cognition; Depression; Fatty Acids, Volatile; Gastrointestinal Microbiome; Humans; Interleukins; Intestines; Irritable Bowel Syndrome; Mice; Mice, Inbred C57BL; Receptors, Aryl Hydrocarbon; aromatic hydrocarbon receptor; interleukin 22; short chain fatty acid; aromatic hydrocarbon receptor; interleukin derivative; interleukin-22; volatile fatty acid; abdominal pain; animal experiment; animal model; animal tissue; anxiety; Article; behavioral test parameters; Citrobacter rodentium; cognitive function test; colorectal disease; controlled study; edema; enteropathy; epithelium lesion; forced swim test; gas chromatography; gastroenteritis; gastrointestinal infection; goblet cell; histopathology; hole board test; hyperplasia; infection complication; intestine mucosa; Lactobacillaceae; liquid chromatography; low grade inflammation; luciferase assay; male; mass spectrometry; mental performance; microflora; mouse; nonhuman; novel object recognition test; pathogen clearance; real time polymerase chain reaction; tail suspension test; tryptophan metabolism; Y-maze test; animal; bacterium; C57BL mouse; classification; cognition; complication; depression; genetics; human; intestine; intestine flora; irritable colon; isolation and purification; metabolism; microbiology; psychology^^interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; Fatty Acids, Volatile, ; interleukin-22, ; Interleukins, ; Receptors, Aryl Hydrocarbon, ^^^CPER; Ministère de la Recherche et de la Technologie; Plateforme Scientifique et Technologique; Institut National de la Santé et de la Recherche Médicale, Inserm, (UMR1071, UMR1107); Institut National de la Santé et de la Recherche Médicale, Inserm; Centre National de la Recherche Scientifique, CNRS, (UMR6023); Centre National de la Recherche Scientifique, CNRS; European Regional Development Fund, ERDF, (16-IDEX-0001-CAP 20-25); European Regional Development Fund, ERDF; Région Auvergne-Rhône-Alpes; Université Clermont-Auvergne, UCA; Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, INRAE, (USC-2018); Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, INRAE^This work was supported by co-financing from the Region Auvergne-Rhône-Alpes and FEDER in 2015 (“Thématiques émergentes”) and in 2018 (“Pack Ambition Recherche” CNSBACT and CPER Nex-N-Mob). It has also been funded by the French government IDEX-ISITE initiative (Grant number: 16-IDEX-0001-CAP 20-25) of the University of Clermont Auvergne. Maëva Meynier, Elodie Baudu, Romain Villéger and Manon Defaye received grants from the Auvergne-Rhône-Alpes Region, CPER and the FEDER. This work was supported by the « Ministère de la Recherche et de la Technologie », INSERM and University of Clermont Auvergne [UMR1071, UMR1107]; INRAE [USC-2018]; CNRS [UMR6023]. Virginie Bonnin, Gwenaelle Roche and Pierre Sauvanet for their technical assistance, the CICS platform from University of Clermont Auvergne for assistance with histopathology technics Abdelkrim Alloui (Animal Facilities) for animal care and Patrick Emond and Antoine Lefèvre (Plateforme Scientifique et Technologique, analyse des systèmes biologiques, Tours) for metabolomics analyses.^Drossman D.A., Hasler W.L., Rome IV - Functional GI disorders: disorders of gut-brain interaction, Gastroenterology, 150, 6, pp. 1257-1220, (2016); Cryan J.F., O'Riordan K.J., Cowan C.S.M., Sandhu K.V., Bastiaanssen T.F.S., Boehme M., Codagnone M.G., Cussotto S., Fulling C., Golubeva A.V., The microbiota-gut-brain axis, Physiol Rev, 99, 4, pp. 1877-2013, (2019); Card T., Enk P., Barbara G., Boeckxstaens G., Santos J., Azpiroz F., Mearin F., Aziz Q., Marshall J., Spiller R., Post-infectious IBS: defining its clinical features and prognosis using an internet-based survey, J United European Gastroenterology, 6, 8, pp. 1245-1253, (2018); Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M., Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome, Gastroenterology, 156, 1, pp. 46-58, (2019); Wang L., Alammar N., Singh R., Nanavati J., Song Y., Chaudhary R., Mullin G.E., Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: a Systematic Review and Meta-Analysis of Case-Control Studies, Journal of the Academy of Nutrition and Dietetics, 120, 4, pp. 565-586, (2020); Crouzet L., Gaultier E., Del'Homme C., Cartier C., Delmas E., Dapoigny M., Fioramonti J., Bernalier-Donadille A., The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota, Neurogastroenterology & Motility, 25, 4, pp. 272-282, (2013); Zhou L., Zhang M., Wang Y., Dorfman R.G., Liu H., Yu T., Chen X., Tang D., Xu L., Yin Y., Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1, Inflamm Bowel Dis, 24, 9, pp. 1926-1940, (2018); Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermudez-Humaran L.G., Gratadoux J.J., Blugeon S., Bridonneau C., Furet J.P., Corthier G., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, J PNAS, 162, pp. 323-327, (2008); Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Eschalier A., Ardid D., Bermudez-Humaran L.G., Sokol H., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci Rep, 6, 1, pp. 1-8, (2016); Agus A., Planchais J., Sokol H., Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease, Cell Host Microbe, 23, 6, pp. 716-724, (2018); Obata Y., Castano A., Boeing S., Bon-Frauches A.C., Fung C., Fallesen T., de Aguero M.G., Yilmaz B., Lopes R., Huseynova A., Neuronal programming by microbiota regulates intestinal physiology, Nature, 578, 7794, pp. 284-289, (2020); Benech N., Rolhion N., Sokol H., Tryptophan metabolites get the gut moving, Cell Host Microbe, 29, 2, pp. 145-147, (2021); Zhang L.S., Davies S.S., Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions, Genome Med, 8, 1, pp. 1-18, (2016); Lee J.S., Cella M., McDonald K.G., Garlanda C., Kennedy G.D., Nukaya M., Mantovani A., Kopan R., Bradfield C.A., Newberry R.D., AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch, J Nat Immunol, 13, pp. 144-151, (2012); Qiu J., Heller J., Guo X., Chen Z.-M., Fish K., Fu Y.-X., Zhou L., The Aryl Hydrocarbon Receptor Regulates Gut Immunity through Modulation of Innate Lymphoid Cells, Immunity, 36, 1, pp. 92-104, (2012); Lamas B., Adolph T.E., Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence, Gut, 67, 1, pp. 1-9, (2018); Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage F.J., Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens, Nat Med, 14, 3, pp. 282-289, (2008); Zenewicz L.A., Yin X., Wang G., Elinav E., Hao L., Zhao L., Flavell R.A., Interleukin-22 deficiency alters colonic microbiota to be transmissible and colitogenic, Journal of Immunology (Baltimore, Md. : 1950), 190, 10, pp. 5306-5312, (2013); Brawner K.M., Yeramilli V.A., Duck L.W., Van Der Pol W., Smythies L.E., Morrow C.D., Elson C.O., Martin C.A., Depletion of dietary aryl hydrocarbon receptor ligands alters microbiota composition and function, Sci Rep, 9, 1, pp. 1-12, (2019); Lupp C., Robertson M.L., Wickham M.E., Sekirov I., Champion O.L., Gaynor E.C., Finlay B.B., Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae, Cell Host Microbe, 2, 2, pp. 119-129, (2007); Enck P., Aziz Q., Barbara G., Farmer A.D., Fukudo S., Mayer E.A., Niesler B., Quigley E.M.M., Rajilic-Stojanovic M., Schemann M., Irritable bowel syndrome, J Nat Rev Dis Prim, 2, (2016); Mondelaers S.U., Theofanous S.A., Florens M.V., Perna E., Aguilera-Lizarraga J., Boeckxstaens G.E., Wouters M.M., Effect of genetic background and postinfectious stress on visceral sensitivity in Citrobacter rodentium -infected mice, Neurogastroenterol Motil, 28, 5, pp. 647-658, (2016); Ibeakanma C., Miranda-Morales M., Richards M., Bautista-Cruz F., Martin N., Hurlbut D., Vanner S., Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons, J Physiol, 587, 14, pp. 3505-3521, (2009); Hoffmann C., Hill D.A., Minkah N., Kirn T., Troy A., Artis D., Bushman F., Community-Wide Response of the Gut Microbiota to Enteropathogenic Citrobacter rodentium Infection Revealed by Deep Sequencing, Infect Immun, 77, 10, pp. 4668-4678, (2009); Wiles S., Clare S., Harker J., Huett A., Young D., Dougan G., Frankel G., Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium, J Cell Microbiol, 6, 10, pp. 963-972, (2004); Spreadbury I., Ochoa-Cortes F., Ibeakanma C., Martin N., Hurlbut D., Vanner S.J., Concurrent psychological stress and infectious colitis is key to sustaining enhanced peripheral sensory signaling, Neurogastroenterol Motil, 27, 3, pp. 347-355, (2015); Moloney R.D., Johnson A.C., O'Mahony S.M., Dinan T.G., Greenwood-Van Meerveld B., Cryan J.F., Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome, J CNS Neurosci Ther, 22, 2, pp. 102-117, (2016); Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Behavioral phenotypes of inbred mouse strains, J Psychopharmacology (Berl), 132, 2, pp. 107-124, (1997); Lyte M., Li W., Opitz N., Gaykema R.P.A., Goehler L.E., Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia Citrobacter rodentium, Physiol Behav, 89, 3, pp. 350-357, (2006); Salameh E., Meleine M., Gourcerol G., do Rego J.C., do Rego J.L., Legrand R., Breton J., Aziz M., Guerin C., Coeffier M., Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase, Am J Physiol - Gastrointest Liver Physiol, 316, 6, pp. G692-G700, (2019); Wei D., Zhao N., Xie L., Huang B., Zhuang Z., Tang Y., Yu S., Wu Q., Electroacupuncture and moxibustion improved anxiety behavior in DSS-induced colitis mice, Gastroenterol Res Pract, 2019, pp. 1-12, (2019); Gareau M.G., Wine E., Rodrigues D.M., Cho J.H., Whary M.T., Philpott D.J., MacQueen G., Sherman P.M., Bacterial infection causes stress-induced memory dysfunction in mice, Gut, 60, 3, pp. 307-317, (2011); Midenfjord I., Polster A., Sjovall H., Tornblom H., Simren M., Anxiety and depression in irritable bowel syndrome: exploring the interaction with other symptoms and pathophysiology using multivariate analyses, Neurogastroenterol Motil, 31, 8, pp. 1-14, (2019); Romero-Sandoval E.A., Depression and Pain, Anesthesiology, 115, 4, pp. 687-688, (2011); Yalcin I., Bohren Y., Waltisperger E., Sage-Ciocca D., Yin J.C., Freund-Mercier M.-J., Barrot M., A time-dependent history of mood disorders in a murine model of neuropathic pain, Biological Psychiatry, 70, 10, pp. 946-953, (2011); Gareau M.G., Gareau M.G., Lyte M., Cryan J.F., Microbiota-Gut-Brain Axis and Cognitive Function Abbreviations 5-HT Serotonin ANS Autonomic nervous system BDNF Brain derived neurotropic factor CD Crohn’s disease CREB cAMP response element binding protein CRF Corticotrophin-releasing factor DA Dopamine, Adv Exp Med Biol, 817, pp. 357-371, (2014); Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q., Kynurenines in the mammalian brain: when physiology meets pathology, Nat Rev Neurosci, 13, 7, pp. 465-477, (2012); Stone T.W., Darlington L.G., The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders, Br J Pharmacol, 169, 6, pp. 1211-1227, (2013); McKernan D.P., Fitzgerald P., Dinan T.G., Cryan J.F., The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat, Neurogastroenterol Motil, 22, 9, pp. 1029-1036, (2010); Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M., Neurology of Depression, Neuron, 34, 1, pp. 13-25, (2002); O'Mahony S.M., Felice V.D., Nally K., Savignac H.M., Claesson M.J., Scully P., Woznicki J., Hyland N.P., Shanahan F., Quigley E.M., Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats, J Neuroscience, 277, pp. 885-901, (2014); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, 7, pp. 997-1006, (2012); Rodino-Janeiro B.K., Vicario M., Alonso-Cotoner C., Pascua-Garcia R., Santos J., A Review of Microbiota and Irritable Bowel Syndrome: future in Therapies, Adv Ther, 35, 3, pp. 289-310, (2018); Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., Makivuokko H., Kajander K., Pavla A., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, J BMC Gastroenterol, 9, 1, pp. 1-11, (2009); Osbelt L., Thiemann S., Smit N., Lesker T.R., Schroter M., Galvez E.J.C., Schmidt-Hohagen K., Pils M.C., Muhlen S., Dersch P., Variations in microbiota composition of laboratory mice influence Citrobacter rodentium infection via variable short-chain fatty acid production, PLoS Pathog, 16, 3, pp. 1-27, (2020); Brugiroux S., Beutler M., Pfann C., Garzetti D., Ruscheweyh H.-J., Ring D., Diehl M., Herp S., Lotscher Y., Hussain S., Genome-guided design of a defined mouse microbiota that confers colonization resistance against Salmonella enterica serovar Typhimurium, Nat Microbiol, 2, (2016); Chassaing B., Srinivasan G., Delgado M.A., Young A.N., Gewirtz A.T., Vijay-Kumar M., Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal Inflammation, J PLoS One, 7, 9, pp. 3-10, (2012); Collins J.W., Keeney K.M., Crepin V.F., Rathinam V.A.K., Fitzgerald K.A., Finlay B.B., Frankel G., Citrobacter rodentium: infection, inflammation and the microbiota, J Nat Rev Microbiol, 12, 9, pp. 612-623, (2014); Simpson C.A., Diaz-Arteche C., Eliby D., Schwartz O.S., Simmons J.G., Cowan C.S.M., The gut microbiota in anxiety and depression–a systematic review, J Clin Psychol Rev, 83, (2021); Farmer A.D., Aziz Q., Mechanisms of visceral pain in health and functional gastrointestinal disorders, Scand J Pain, 5, 2, pp. 51-60, (2014); Fitzgerald P., Cassidy Eugene M., Clarke G., Scully P., Barry S., Quigley Eamonn M.M., Shanahan F., Cryan J., Dinan Timothy G., Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity, Neurogastroenterol Motil, 20, 12, pp. 1291-1297, (2008); Clarke G., Fitzgerald P., Cryan J.F., Cassidy E.M., Quigley E.M., Dinan T.G., Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort, BMC Gastroenterol, 9, 1, pp. 1-7, (2009); Burr R.L., Gu H., Cain K., Djukovic D., Zhang X., Han C., Callan N., Raftery D., Heitkemper M., Tryptophan Metabolites in Irritable Bowel Syndrome: an Overnight Time-course Study, J Neurogastroenterol Motil, 25, 4, pp. 551-562, (2019); Berstad A., Raa J., Valeur J.T., Essential’ for the pathogenesis of irritable bowel syndrome?, Scand J Gastroenterol, 49, 12, pp. 1493-1498, (2014); Lamas B., Natividad J.M., Sokol H., Aryl hydrocarbon receptor and intestinal immunity review-article, Mucosal Immunol, 11, 4, pp. 1024-1038, (2018); De Moreno De Leblanc A., Del Carmen S., Chatel J.-M., Miyoshi A., Azevedo V., Langella P., Bermudez-Humaran L.G., LeBlanc J.G., Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models, Gastroenterol Res Pract, 2015, pp. 1-8, (2015); Mariat D., Robert V., Langella P., Chatel J.M., Plasmid transfer efficiency using Lactoccocus lactis strains depends on invasiveness status but also on plasmid copy number, FEMS Microbiol Lett, 364, 14, (2017); Guttman J.A., Li Y., Wickham M.E., Deng W., Vogl A.W., Finlay B.B., Attaching and effacing pathogen-induced tight junction disruption in vivo, Cell Microbiol, 8, 4, pp. 634-645, (2006); Dudakov J.A., Hanash A.M., van den Brink M.R.M., Interleukin-22: immunology and pathology, J Annu Rev Immunol, pp. 747-785, (2015); Prevot T.D., Misquitta K.A., Fee C., Newton D.F., Chatterjee D., Nikolova Y.S., Sibille E., Banasr M., Residual avoidance: a new, consistent and repeatable readout of chronic stress-induced conflict anxiety reversible by antidepressant treatment, Neuropharmacology, 153, pp. 98-110, (2019); Alameh M.-G., Weissman D., Pardi N., Messenger RNA-Based Vaccines Against Infectious Diseases, (2020); Zimmermann M., Ethical guidelines for invetigations of experimental pain in conscious animals, Pain, 16, 2, pp. 109-110, (1983); Defaye M., Nourrisson C., Baudu E., Lashermes A., Meynier M., Meleine M., Wawrzyniak I., Bonnin V., Barbier J., Chassaing B., Fecal dysbiosis associated with colonic hypersensitivity and behavioral alterations in chronically Blastocystis-infected rats, Sci Rep, 10, 1, pp. 1-12, (2020); Lefevre A., Mavel S., Nadal-Desbarats L., Galineau L., Attucci S., Dufour D., Sokol H., Emond P., Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS, Talanta, 195, pp. 593-598, (2019); Rodriguez Echandia E.L., Broitman S.T., Foscolo M.R., Effect of the chronic ingestion of chlorimipramine and desipramine on the hole board response to acute stresses in male rats, Pharmacol Biochem Behav, 26, 2, pp. 207-210, (1987); Sierksma A.S.R., van Den Hove D.L.A., Pfau F., Philippens M., Bruno O., Fedele E., Ricciarelli R., Steinbusch H.W.M., Vanmierlo T., Prickaerts J., Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D, Neuropharmacology, 77, pp. 120-130, (2014); Barre A., Berthoux C., De Bundel D., Valjent E., Bockaert J., Marin P., Becamel C., Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning, J Proc Natl Acad Sci USA, 113, 10, pp. E1382-E1391, (2016); Steru L., Chermat R., Thierry B., Simon P., The tail suspension test: a new method for screening antidepressants in mice, Psychopharmacology (Berl), 85, 3, pp. 367-370, (1985); Porsolt R.D., Anton G., Blavet N., Jalfre M., Behavioural despair in rats: a new model sensitive to antidepressant treatments, Eur J Pharmacol, 47, 4, pp. 379-391, (1978); Larauche M., Gourcerol G., Million M., Adelson D.W., Tache Y., Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: influence of surgery and postoperative single housing on visceromotor responses, Stress, 13, 4, pp. 343-354, (2010)^B. Mathilde; University of Clermont Auvergne, INSERM, 1071 M2iSH, INRAE USC 2018, Clermont-Ferrand, 28, place Henri Dunant, BP38, F-63001, France; email: mathilde.bonnet@uca.fr; C. Frédéric Antonio; UMR 1107 INSERM, University of Clermont Auvergne, 28 Place Henri, Dunant, BP38, F-63001, France; email: frederic.carvalho@inserm.fr^^Taylor and Francis Ltd.^^^^^^19490976^^^35090380.0^English^Gut Microbes^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85123814767
Edogawa S.; Edwinson A.L.; Peters S.A.; Chikkamenahalli L.L.; Sundt W.; Graves S.; Gurunathan S.V.; Breen-Lyles M.; Johnson S.; Dyer R.; Graham R.; Chen J.; Kashyap P.; Farrugia G.; Grover M.^Edogawa, Shoko (49861248700); Edwinson, Adam L (57207580613); Peters, Stephanie A (57193683015); Chikkamenahalli, Lakshmikanth L (57200100953); Sundt, Wendy (57148557200); Graves, Sara (58360669200); Gurunathan, Sakteesh V (57204856638); Breen-Lyles, Margaret (57195807544); Johnson, Stephen (57190584123); Dyer, Roy (7202532150); Graham, Rondell (53979541600); Chen, Jun (56640742100); Kashyap, Purna (24178249300); Farrugia, Gianrico (7006024784); Grover, Madhusudan (23012057300)^49861248700; 57207580613; 57193683015; 57200100953; 57148557200; 58360669200; 57204856638; 57195807544; 57190584123; 7202532150; 53979541600; 56640742100; 24178249300; 7006024784; 23012057300^Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS^2020^Gut^69.0^1^^62^73^11.0^61^10.1136/gutjnl-2018-317416^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063578049&doi=10.1136%2fgutjnl-2018-317416&partnerID=40&md5=7808ee1b2b729c760673135255233e30^Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States; Immunochemical Core Laboratory, Mayo Clinic, Rochester, MN, United States; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States^Edogawa S., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Edwinson A.L., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Peters S.A., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Chikkamenahalli L.L., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Sundt W., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Graves S., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Gurunathan S.V., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Breen-Lyles M., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Johnson S., Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States; Dyer R., Immunochemical Core Laboratory, Mayo Clinic, Rochester, MN, United States; Graham R., Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Chen J., Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Kashyap P., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Farrugia G., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States; Grover M., Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, United States^Objective The intestinal lumen contains several proteases. Our aim was to determine the role of faecal proteases in mediating barrier dysfunction and symptoms in IBS. Design 39 patients with IBS and 25 healthy volunteers completed questionnaires, assessments of in vivo permeability, ex vivo colonic barrier function in Ussing chambers, tight junction (TJ) proteins, ultrastructural morphology and 16 s sequencing of faecal microbiota rRNA. A casein-based assay was used to measure proteolytic activity (PA) in faecal supernatants (FSNs). Colonic barrier function was determined in mice (ex-germ free) humanised with microbial communities associated with different human PA states. Results Patients with IBS had higher faecal PA than healthy volunteers. 8/20 postinfection IBS (PI-IBS) and 3/19 constipation- predominant IBS had high PA (>95th percentile). High-PA patients had more and looser bowel movements, greater symptom severity and higher in vivo and ex vivo colonic permeability. High-PA FSNs increased paracellular permeability, decreased occludin and increased phosphorylated myosin light chain (pMLC) expression. Serine but not cysteine protease inhibitor significantly blocked high-PA FSN effects on barrier. The effects on barrier were diminished by pharmacological or siRNA inhibition of protease activated receptor-2 (PAR-2). Patients with high-PA IBS had lower occludin expression, wider TJs on biopsies and reduced microbial diversity than patients with low PA. Mice humanised with high-PA IBS microbiota had greater in vivo permeability than those with low-PA microbiota. Conclusion A subset of patients with IBS, especially in PI-IBS, has substantially high faecal PA, greater symptoms, impaired barrier and reduced microbial diversity. Commensal microbiota affects luminal PA that can influence host barrier function. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.^Campylobacter; gastroenteritis; germ-free mice; microbiome; trypsin^Adult; Animals; Biopsy; Caco-2 Cells; Case-Control Studies; Colon; Dysbiosis; Feces; Female; Gastrointestinal Microbiome; Humans; Intestinal Absorption; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Mice; Middle Aged; Permeability; Prospective Studies; Proteolysis; Serine Proteases; Severity of Illness Index; Tight Junction Proteins; bacterial RNA; cysteine proteinase; myosin light chain; occludin; proteinase activated receptor 2; ribosome RNA; serine proteinase; tight junction protein; serine proteinase; adult; animal experiment; animal model; animal tissue; Article; clinical article; colon; colon biopsy; constipation; controlled study; diarrhea; disease severity; enteropathy; ex vivo study; feces microflora; female; human; human cell; human tissue; in vivo study; intestinal barrier dysfunction; intestine mucosa permeability; irritable colon; male; microbial community; nonhuman; priority journal; protein degradation; protein expression; questionnaire; RNA sequence; supernatant; animal; biopsy; Caco-2 cell line; case control study; dysbiosis; enzymology; feces; intestine absorption; intestine flora; intestine mucosa; irritable colon; metabolism; microbiology; middle aged; mouse; pathology; pathophysiology; permeability; physiology; prospective study; severity of illness index^^cysteine proteinase, 37353-41-6; mucosa associated lymphoid tissue lymphoma translocation protein 1, ; occludin, 176304-61-3; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; Serine Proteases, ; Tight Junction Proteins, ^^^National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (K23DK103911); Mayo Clinic; Center for Individualized Medicine, Mayo Clinic, CIM^Funding text 1: Funding this project was funded by niDDK K23 DK103911 to Dr. Madhusudan grover. Dr. Jun chen is supported by Mayo clinic center for individualized Medicine.; Funding text 2: This project was funded by NIDDK K23 DK103911 to Dr. Madhusudan Grover. Dr. Jun Chen is supported by Mayo Clinic Center for Individualized Medicine.^Vergnolle N., Protease inhibition as new therapeutic strategy for GI diseases, Gut, 65, pp. 1215-1224, (2016); Olland-Fourcade C.R., Denadai-Souza A., Cirillo C., Et al., Epithelial expression and function of trypsin-3 in irritable bowel syndrome, Gut, 66, pp. 1767-1778, (2017); Biancheri P., Di Sabatino A., Corazza G.R., Et al., Proteases and the gut barrier, Cell Tissue Res, 351, pp. 269-280, (2013); Maharshak N., Huh E.Y., Paiboonrungruang C., Et al., Enterococcus faecalis gelatinase mediates intestinal permeability via protease-activated receptor 2, Infect Immun, 83, pp. 2762-2770, (2015); Ao M.B.R., Tanksale A.M., Ghatge M.S., Et al., Molecular and biotechnological aspects of microbial proteases, Microbiol Mol Biol Rev, 62, pp. 597-635, (1998); Pruteanu M., Hyland N.P., Clarke D.J., Et al., Degradation of the extracellular matrix components by bacterial-derived metalloproteases: Implications for inflammatory bowel diseases, Inflamm Bowel Dis, 17, pp. 1189-1200, (2011); Shen W., Matsui T., Current knowledge of intestinal absorption of bioactive peptides, Food Funct, 8, pp. 4306-4314, (2017); Awlings N.D.R., Barrett A.J., Thomas P.D., Et al., The merops database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the panther database, Nucleic Acids Res, 46, 1 D, pp. D624-D632, (2018); Alipeau H.J.G., Wiepjes M., Motta J.P., Et al., Novel role of the serine protease inhibitor elafin in gluten-related disorders, Am J Gastroenterol, 109, pp. 748-756, (2014); Motta J.P., Magne L., Descamps D., Et al., Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis, Gastroenterology, 140, pp. 1272-1282, (2011); Schmid M., Fellermann K., Fritz P., Et al., Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease, J Leukoc Biol, 81, pp. 907-915, (2007); Macfarlane G.T., Allison C., Gibson S.A., Et al., Contribution of the microflora to proteolysis in the human large intestine, J Appl Bacteriol, 64, pp. 37-46, (1988); Ibson S.A.G., McFarlan C., Hay S., Et al., Significance of microflora in proteolysis in the colon, Appl Environ Microbiol, 55, pp. 679-683, (1989); Enell S.G., Gustafsson B.E., Ohlsson K., Immunochemical quanitation of pancreatic endopeptidases in the intestinal contents of germfree and conventional rats, Scand J Gastroenterol, 12, pp. 811-820, (1977); Enell S.G., Gustafsson B.E., Impaired enteric degradation of pancreatic endopeptidases in antibiotic-treated rats, Scand J Gastroenterol, 12, pp. 801-809, (1977); Enac N.C., Andrews C.N., Holzhausen M., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Desormeaux C., Bautzova T., Garcia-Caraballo S., Et al., Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators-induced signaling to thoracic human sensory neurons, Pain, 159, pp. 1257-1267, (2018); Nnahazi A.A., Ferrier L., Bezirard V., Et al., Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS, Am J Gastroenterol, 108, pp. 1322-1331, (2013); Buhner S., Hahne H., Hartwig K., Et al., Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients, PLoS One, 13, (2018); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Nnahazi A.A., Gecse K., Dabek M., Et al., Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice, Pain, 144, 1-2, pp. 209-217, (2009); Ecse K.G., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Beakanma C.I., Ochoa-Cortes F., Miranda-Morales M., Et al., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108, (2011); Klem F., Wadhwa A., Prokop L.J., Et al., Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis, Gastroenterology, 152, pp. 1042-1054, (2017); Rover M.G., Camilleri M., Smith K., Et al., On the fiftieth anniversary, Postinfectious Irritable Bowel Syndrome: Mechanisms Related to Pathogens. Neurogastroenterol Motil, 26, pp. 156-167, (2014); Vnin L.B.E., Vasquez J.R., Craik C.S., Substrate specificity of trypsin investigated by using a genetic selection, Proc Natl Acad Sci U S A, 87, pp. 6659-6663, (1990); DelMar E.G., Largman C., Brodrick J.W., Et al., A sensitive new substrate for chymotrypsin, Anal Biochem, 99, pp. 316-320, (1979); Dwards J.V.E., Prevost N.T., French A.D., Et al., Kinetic and structural analysis of fluorescent peptides on cotton cellulose nanocrystals as elastase sensors, Carbohydr Polym, 116, pp. 278-285, (2015); Sabotic J., Bleuler-Martinez S., Renko M., Et al., Structural basis of trypsin inhibition and entomotoxicity of cospin, serine protease inhibitor involved in defense of Coprinopsis cinerea fruiting bodies, J Biol Chem, 287, pp. 3898-3907, (2012); Morita T., Kato H., Iwanaga S., Et al., New fluorogenic substrates for alpha-thrombin, factor xa, kallikreins, and urokinase, J Biochem, 82, pp. 1495-1498, (1977); Euleers H.C., Hanning N., Heirbaut J., Et al., Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome, Br J Pharmacol, 175, pp. 3516-3533, (2018); Denadai-Souza A., Bonnart C., Tapias N.S., Et al., Functional proteomic profiling of secreted serine proteases in health and inflammatory bowel disease, Sci Rep, 8, (2018); Dgington-Mitchell L.E.E., Barlow N., Aurelio L., Et al., Fluorescent diphenylphosphonate-based probes for detection of serine protease activity during inflammation, Bioorg Med Chem Lett, 27, pp. 254-260, (2017); Wegener J., Abrams D., Willenbrink W., Et al., Automated multi-well device to measure transepithelial electrical resistances under physiological conditions, Biotechniques, 37, 4, pp. 590-597, (2004); Rover M.G., Camilleri M., Hines J., Et al., 13) C mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Szarka L.A., Camilleri M., Methods for the assessment of small-bowel and colonic transit, Semin Nucl Med, 42, pp. 113-123, (2012); Sai P.Y.T., Zhang B., He W.Q., Et al., IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance, Cell Host Microbe, 21, pp. 671-681, (2017); Baldwin E.A., Walther-Antonio M., MacLean A.M., Et al., Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery, PeerJ, 3, (2015); Jeraldo P., Kalari K., Chen X., Et al., Im-tornado: A tool for comparison of 16s reads from paired-end libraries, PLoS One, 9, (2014); Arroll I.M.C., Ringel-Kulka T., Ferrier L., Et al., Fecal protease activity is associated with compositional alterations in the intestinal microbiota, PLoS One, 8, (2013); Oka R.R., Rosztoczy A., Leveque M., Et al., A pilot study of fecal serine-protease activity: A pathophysiologic factor in diarrhea-predominant irritable bowel syndrome, Clin Gastroenterol Hepatol, 5, pp. 550-555, (2007); Ooth D.T., Garsed K., Singh G., Et al., Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: Origin and effect of gut transit, Gut, 63, pp. 753-760, (2014); Wilcz-Villega E.M., McClean S., O'Sullivan M.A., Mast cell tryptase reduces junctional adhesion molecule-A (jam-A ) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Oeffier M.C., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Shen L., Weber C.R., Raleigh D.R., Et al., Tight junction pore and leak pathways: A dynamic duo, Annu Rev Physiol, 73, pp. 283-309, (2011); Oka R.R., Ait-Belgnaoui A., Salvador-Cartier C., Et al., Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats, Gut, 56, pp. 1072-1078, (2007); Reed D.E., Barajas-Lopez C., Cottrell G., Et al., Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of Guinea-pig submucosal neurons, J Physiol, 547, pp. 531-542, (2003); Sessenwein J.L., Baker C.C., Pradhananga S., Et al., Protease-mediated suppression of drg neuron excitability by commensal bacteria, J Neurosci, 37, pp. 11758-11768, (2017); McCarville J.L., Dong J., Caminero A., Et al., A commensal Bifidobacterium longum strain improves gluten-related immunopathology in mice through expression of a serine protease inhibitor, Appl Environ Microbiol, (2017); Mkaouar H., Akermi N., Mariaule V., Et al., Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases, Microb Cell Fact, 15, (2016); Arcia-Ferrer I.G., Arede P., Gomez-Blanco J., Et al., Structural and functional insights into Escherichia coli α2-macroglobulin endopeptidase snap-trap inhibition, Proc Natl Acad Sci U S A, 112, pp. 8290-8295, (2015); Oulas T.G., Ksiazek M., Garcia-Ferrer I., Et al., A structure-derived snap-trap mechanism of a multispecific serpin from the dysbiotic human oral microbiome, J Biol Chem, 292, pp. 10883-10898, (2017); Ibson S.A.G., Macfarlane G.T., Characterization of proteases formed by Bacteroides fragilis, J Gen Microbiol, 134, pp. 2231-2240, (1988); Hornton R.F.T., Murphy E.C., Kagawa T.F., Et al., The effect of environmental conditions on expression of Bacteroides fragilis and Bacteroides thetaiotaomicron C10 protease genes, BMC Microbiol, 12, (2012); Uo C.J.G., Chang F.Y., Wyche T.P., Et al., Discovery of reactive microbiota-derived Metabolites that inhibit host proteases, Cell, 168, pp. 517-526, (2017); Leynen I.C., Vazeille E., Artieda M., Et al., Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease, Gut, 63, pp. 1265-1274, (2014); Motta J.P., Bermudez-Humaran L.G., Deraison C., Et al., Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis, Sci Transl Med, 4, (2012); Kobayashi H., Prevention of cancer and inflammation by soybean protease inhibitors, Front Biosci, 5, pp. 966-973, (2013); De Santis S., Galleggiante V., Scandiffio L., Et al., Secretory leukoprotease inhibitor (Slpi) expression is required for educating murine dendritic cells inflammatory response following quercetin exposure, Nutrients, 9, (2017)^M. Grover; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, 200 First Street SW, 55905, United States; email: grover.madhusudan@mayo.edu^^BMJ Publishing Group^^^^^^00175749^^GUTTA^30923071.0^English^Gut^Article^Final^All Open Access; Bronze Open Access; Green Open Access^Scopus^2-s2.0-85063578049
Liu Y.; Xiao W.; Yu L.; Tian F.; Wang G.; Lu W.; Narbad A.; Chen W.; Zhai Q.^Liu, Yang (57208195491); Xiao, Wei (57222007753); Yu, Leilei (56510578800); Tian, Fengwei (19337981000); Wang, Gang (56190334700); Lu, Wenwei (55484329700); Narbad, Arjan (6603867601); Chen, Wei (55613230694); Zhai, Qixiao (55241436100)^57208195491; 57222007753; 56510578800; 19337981000; 56190334700; 55484329700; 6603867601; 55613230694; 55241436100^Evidence from comparative genomic analyses indicating that: Lactobacillus -mediated irritable bowel syndrome alleviation is mediated by conjugated linoleic acid synthesis^2021^Food and Function^12.0^3^^1121^1134^13.0^16^10.1039/d0fo02616f^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100945293&doi=10.1039%2fd0fo02616f&partnerID=40&md5=aed827bf8af5aa1cd478b28ab7e007b6^State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China; (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, 225004, China; National Engineering Research Center for Functional Food, Jiangnan University, Wuxi Jiangsu, 214122, China; Gut Health and Food Safety Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom; Beijing Innovation Center of Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, 100048, China^Liu Y., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; Xiao W., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; Yu L., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; Tian F., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China; Wang G., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China, (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, 225004, China; Lu W., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, (Yangzhou) Institute of Food Biotechnology, Jiangnan University, Yangzhou, 225004, China, National Engineering Research Center for Functional Food, Jiangnan University, Wuxi Jiangsu, 214122, China; Narbad A., International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China, Gut Health and Food Safety Programme, Quadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom; Chen W., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, National Engineering Research Center for Functional Food, Jiangnan University, Wuxi Jiangsu, 214122, China, Beijing Innovation Center of Food Nutrition and Human Health, Beijing Technology and Business University (BTBU), Beijing, 100048, China; Zhai Q., State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, School of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China, International Joint Research Laboratory for Pharmabiotics and Antibiotic Resistance, Jiangnan University, Wuxi Jiangsu, 214122, China^Irritable bowel syndrome (IBS) is a chronic intestinal disorder accompanied by low-grade inflammation, visceral hypersensitivity, and gut microbiota dysbiosis. Several studies have indicated that Lactobacillus supplementation can help to alleviate IBS symptoms and that these effects are strain-specific. Therefore, this study aimed to investigate the key physiological characteristics and functional genes contributing to the IBS-alleviating effects of Lactobacillus. An IBS model was established by subjecting C57BL/6 mice to Citrobacter rodentium ingestion and water avoidance stress. Lactobacillus strains with different physiological characteristics were administered to mice intragastrically for 4 weeks (5 × 109 CFU/0.2 mL per mouse per day). Indicators of colonic inflammation, visceral hypersensitivity, and gut microbiota were also evaluated. Finally, differences in functional genes between Lactobacillus strains were analyzed by a comparative genomic analysis, and the relationships between the physiological characteristics, functional genes, and IBS-alleviating effects of the strains were quantified using correlation analysis. Among the eight tested Lactobacillus strains, only Lactobacillus plantarum CCFM8610 significantly inhibited the expression of IL-1β, IL-6, PAR-2, and mast cell tryptase. L. plantarum CCFM8610 also significantly increased the intestinal barrier function, inhibited visceral hypersensitivity symptoms, and modulated the gut microbiota diversity and composition. The correlation analysis of factors associated with the IBS-alleviating effects of Lactobacillus revealed the ability to synthesize conjugated linoleic acid as the most strongly associated physiological characteristic and COG1028-related genes as the most strongly associated functional genes. In conclusion, these findings can facilitate the rapid screening of Lactobacillus strains with IBS-alleviating effects and lay a foundation for studies of the related mechanisms. © The Royal Society of Chemistry.^^Animals; Citrobacter rodentium; Colon; Corticosterone; Enterobacteriaceae Infections; Humans; Inflammation; Irritable Bowel Syndrome; Lactobacillus; Linoleic Acids, Conjugated; Male; Mice; Mice, Inbred C57BL; Probiotics; Receptor, PAR-2; Tryptases; Correlation methods; Genes; Immunology; Mammals; Pathology; Physiology; Strain; conjugated linoleic acid; corticosterone; F2rl1 protein, mouse; probiotic agent; proteinase activated receptor 2; tryptase; Conjugated linoleic acid; Correlation analysis; Intestinal barriers; Irritable bowel syndromes; Lactobacillus plantarum; Lactobacillus strains; Physiological characteristics; Water avoidance stress; animal; blood; C57BL mouse; Citrobacter rodentium; colon; Enterobacteriaceae infection; genetics; human; inflammation; irritable colon; Lactobacillus; male; metabolism; microbiology; mouse; pathology; physiology; Linoleic acid^^corticosterone, 50-22-6; tryptase, 97501-93-4; Corticosterone, ; F2rl1 protein, mouse, ; Linoleic Acids, Conjugated, ; Receptor, PAR-2, ; Tryptases, ^^^National First-Class Discipline Program of Food Science and Technology, (JUFSTR20180102); Projects of Innovation and Development Pillar Program for Key Industries in Southern Xinjiang of Xinjiang Production and Construction Corps, (2018DB002); Biotechnology and Biological Sciences Research Council, BBSRC; National Key Research and Development Program of China, NKRDPC, (31820103010, 31871773); National Key Research and Development Program of China, NKRDPC; Collaborative Innovationcenter of Food Safety and Quality Control in Jiangsu Province^This work was supported by the National Natural Science Foundation of China Program [No. 31820103010 and No. 31871773]; the Projects of Innovation and Development Pillar Program for Key Industries in Southern Xinjiang of Xinjiang Production and Construction Corps [2018DB002]; the National First-Class Discipline Program of Food Science and Technology [JUFSTR20180102]; the BBSRC Newton Fund Joint Centre Award; and the Collaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province.^Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N. Engl. J. Med., 376, pp. 2566-2578, (2017); Buono J.L., Carson R.T., Flores N.M., Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea, Health. Qual. Life. Outcomes, 15, (2017); Canavan C., West J., Card T., Review article: The economic impact of the irritable bowel syndrome, Aliment. Pharmacol. Ther., 40, pp. 1023-1034, (2014); Gwee K.A., Ghoshal U.C., Chen M., Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management, J. Gastroenterol. Hepatol., 33, pp. 99-110, (2018); Staudacher H.M., Whelan K., The low FODMAP diet: Recent advances in understanding its mechanisms and efficacy in IBS, Gut, 66, pp. 1517-1527, (2017); Akehurst R.L., Brazier J.E., Mathers N., O'Keefe C., Kaltenthaler E., Morgan A., Platts M., Walters S.J., Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting, Pharmacoeconomics, 20, pp. 455-462, (2002); Ballou S., McMahon C., Lee H.-N., Katon J., Shin A., Rangan V., Singh P., Nee J., Camilleri M., Lembo A., Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey, Clin. Gastroenterol. Hepatol., 17, pp. 2471-2478, (2019); Brenner D.M., Sayuk G.S., Current US Food and Drug Administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea, Adv. Ther., 37, pp. 83-96, (2020); Sayuk G.S., Wolf R., Chang L., Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome, Am. J. Gastroenterol., 112, pp. 892-899, (2017); Sanders M.E., Merenstein D.J., Reid G., Gibson G.R., Rastall R.A., Probiotics and prebiotics in intestinal health and disease: From biology to the clinic, Nat. Rev. Gastroenterol. Hepatol., 16, pp. 605-616, (2019); De Filippis F., Pasolli E., Ercolini D., The food-gut axis: Lactic acid bacteria and their link to food, the gut microbiome and human health, FEMS Microbiol. Rev., 44, pp. 454-489, (2020); Do Carmo M.S., Itapary Dos Santos C., Araujo M.C., Giron J.A., Fernandes E.S., Monteiro-Neto V., Probiotics, mechanisms of action, and clinical perspectives for diarrhea management in children, Food Funct., 9, pp. 5074-5095, (2018); Zhao Q., Yang W.-R., Wang X.-H., Li G.-Q., Xu L.-Q., Cui X., Liu Y., Zuo X.-L., Clostridium butyricum alleviates intestinal low-grade inflammation in TNBS-induced irritable bowel syndrome in mice by regulating functional status of lamina propria dendritic cells, World J. Gastroenterol., 25, pp. 5469-5482, (2019); Ding R., Goh W., Wu R., Yue X., Luo X., Khine W.W.T., Wu J., Lee Y., Revisit gut microbiota and its impact on human health and disease, J. Food Drug Anal., 27, pp. 623-631, (2019); Ait-Belgnaoui A., Payard I., Rolland C., Harkat C., Braniste V., Theodorou V., Tompkins T.A., Bifidobacterium longum and Lactobacillus helveticus synergistically suppress stress-related visceral hypersensitivity through hypothalamic-pituitary-adrenal axis modulation, J. Neurogastroenterol., 24, pp. 138-146, (2018); Martoni C.J., Srivastava S., Leyer G.J., Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial, Nutrients, 12, (2020); Cremon C., Guglielmetti S., Gargari G., Taverniti V., Castellazzi A.M., Valsecchi C., Tagliacarne C., Fiore W., Bellini M., Bertani L., Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial, United Eur. Gastroenterol. J., 6, pp. 604-613, (2018); Shin S.P., Choi Y.M., Kim W.H., Hong S.P., Park J.-M., Kim J., Kwon O., Lee E.H., Hahm K.B., A double blind, placebo-controlled, randomized clinical trial that breast milk derived- Lactobacillus gasseri BNR17 mitigated diarrhea-dominant irritable bowel syndrome, J. Clin. Biochem. Nutr., 62, pp. 179-186, (2018); Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S., Randomized clinical trial: Effect of Lactobacillus plantarum, 299v on symptoms of irritable bowel syndrome, Nutrition, 30, pp. 1151-1157, (2014); Hod K., Dekel R., Aviv Cohen N., Sperber A., Ron Y., Boaz M., Berliner S., Maharshak N., The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 30, (2018); Begtrup L.M., De Muckadell O.B.S., Kjeldsen J., Jarbol D.E., Long-term treatment with probiotics in primary care patients with irritable bowel syndrome-a randomised, double-blind, placebo controlled trial, Scand. J. Gastroenterol., 48, pp. 1127-1135, (2013); Romijn A.R., Rucklidge J.J., Kuijer R.G., Frampton C., A double-blind, randomized, placebo-controlled trial of Lactobacillus helveticus and Bifidobacterium longum for the symptoms of depression, Aust. N. Z. J. Psychiat., 51, pp. 810-821, (2017); Dunne C., O'Mahony L., Murphy L., Thornton G., Morrissey D., O'Halloran S., Feeney M., Flynn S., Fitzgerald G., Daly C., In vitro selection criteria for probiotic bacteria of human origin: Correlation with in vivo findings, Am. J. Clin. Nutr., 73, pp. 386s-392s, (2001); Li R., Zhang Y., Polk D.B., Tomasula P.M., Yan F., Liu L., Preserving viability of Lactobacillus rhamnosus GG in vitro and in vivo by a new encapsulation system, J. Controlled Release, 230, pp. 79-87, (2016); Yan S., Yang B., Zhao J., Zhao J., Stanton C., Ross R.P., Zhang H., Chen W., A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation, Food Funct., 10, pp. 1595-1608, (2019); Wang J., Chen H., Yang B., Gu Z., Zhang H., Chen W., Chen Y.Q., Lactobacillus plantarum ZS2058 produces CLA to ameliorate DSS-induced acute colitis in mice, RSC Adv., 6, pp. 14457-14464, (2016); Subramaniyan V., Gurumurthy K., Diversity of probiotic adhesion genes in the gastrointestinal tract of goats, J. Cell. Biochem., 120, pp. 12422-12428, (2019); Lee I.-C., Caggianiello G., Van Swam I.I., Taverne N., Meijerink M., Bron P.A., Spano G., Kleerebezem M., Strain-specific features of extracellular polysaccharides and their impact on Lactobacillus plantarum -host interactions, Appl. Environ. Microbiol., 82, pp. 3959-3970, (2016); Ibeakanma C., Cortes F.O., Morales M.M., McDonald T., Spreadbury I., Cenac N., Cattaruzza F., Hurlbut D.J., Vanner S., Bunnett N.W., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108, (2011); Chen Q., Ren Y., Lu J., Bartlett M., Chen L., Zhang Y., Guo X., Liu C., A novel prebiotic blend product prevents irritable bowel syndrome in mice by improving gut microbiota and modulating immune response, Nutrients, 9, (2017); Liu Y., Sheng Y., Pan Q., Xue Y., Yu L., Tian F., Zhao J., Zhang H., Zhai Q., Chen W., Identification of the key physiological characteristics of Lactobacillus plantarum strains for ulcerative colitis alleviation, Food Funct., 11, pp. 1279-1291, (2020); Zhao J., Tian F., Yan S., Zhai Q., Zhang H., Chen W., Lactobacillus plantarum CCFM10 alleviating oxidative stress and restoring the gut microbiota in d-galactose-induced aging mice, Food Funct., 9, pp. 917-924, (2018); Cen S., Yin R., Mao B., Zhao J., Zhang H., Zhai Q., Chen W., Comparative genomics shows niche-specific variations of Lactobacillus plantarum strains isolated from human, Drosophila melanogaster, vegetable and dairy sources, Food Biosci., 35, (2020); Liu Y., Li Y., Yu X., Yu L., Tian F., Zhao J., Zhang H., Zhai Q., Chen W., Physiological characteristics of Lactobacillus casei strains and their alleviation effects against inflammatory bowel disease, J. Microbiol. Biotechnol., 30, (2020); Choghakhori R., Abbasnezhad A., Hasanvand A., Amani R., Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life, Cytokine, 93, pp. 34-43, (2017); Bertiauxvandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J., Ducrotte P., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Duan R., Zhu S., Wang B., Duan L., Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: A systematic review, Clin. Transl. Gastroenterol., 10, (2019); Ringelkulka T., McRorie J.W., Ringel Y., Multi-Center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic Bifidobacte rium infantis, 35624 in non-patients with symptoms of abdominal discomfort and bloating, Am. J. Gastroenterol., 112, pp. 145-151, (2017); Ludidi S., Jonkers D., Koning C.J.M., Kruimel J.W., Mulder L., Der Vaart I.B.V., Conchillo J.M., Masclee A.A.M., Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients, Neurogastroenterol. Motil., 26, pp. 705-714, (2014); Cui Y., Wei H., Lu F., Liu X., Liu D., Gu L., Ouyang C., Different effects of three selected Lactobacillus strains in dextran sulfate sodium-induced colitis in BALB/c mice, PLoS One, 11, (2016); Zheng B., Van Bergenhenegouwen J., Van De Kant H.J.G., Folkerts G., Garssen J., Vos A.P., Morgan M.E., Kraneveld A.D., Specific probiotic dietary supplementation leads to different effects during remission and relapse in murine chronic colitis, Benefic. Microbes, 7, pp. 205-213, (2016); Perezberezo T., Pujo J., Martin P., Faouder P.L., Galano J., Guy A., Knauf C., Tabet J., Tronnet S., Barreau F., Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917, Nat. Commun., 8, (2017); Zhang J., Song L., Wang Y., Liu C., Zhang L., Zhu S., Liu S., Duan L., Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats, J. Gastroenterol. Hepatol., 34, pp. 1368-1376, (2018); Yang B., Qi H., Gu Z., Zhang H., Chen W., Chen H., Chen Y., Characterization of the triple-component linoleic acid isomerase in Lactobacillus plantarum ZS2058 by genetic manipulation, J. Appl. Microbiol., 123, pp. 1263-1273, (2017); Evans N.P., Misyak S.A., Schmelz E.M., Guri A.J., Hontecillas R., Bassaganya-Riera J., Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARγ, J. Nutr., 140, pp. 515-521, (2010); Borniquel S., Jadert C., Lundberg J.O., Dietary conjugated linoleic acid activates PPARγ and the intestinal trefoil factor in SW480 cells and mice with dextran sulfate sodium-induced colitis, J. Nutr., 142, pp. 2135-2140, (2012); Delerive P., Gervois P., Fruchart J.-C., Staels B., Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators, J. Biol. Chem., 275, pp. 36703-36707, (2000); Belury M.A., Dietary conjugated linoleic acid in health: Physiological effects and mechanisms of action, Annu. Rev. Nutr., 22, pp. 505-531, (2002); Chen Y., Jin Y., Stanton C., Ross R.P., Zhao J., Zhan H., Yang B., Chen W., Alleviation effects of Bifidobacterium breve on DSS-induced colitis depends on intestinal tract barrier maintenance and gut microbiota modulation, Eur. J. Nutr., (2020); Bassaganya-Riera J., Viladomiu M., Pedragosa M., De Simone C., Carbo A., Shaykhutdinov R., Jobin C., Arthur J.C., Corl B.A., Vogel H., Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPARγ to suppress colitis, PLoS One, 7, (2012); Cole M., Augustin M.A., Food Safety and Health, Engineering, 6, pp. 391-392, (2020); Den Hartigh L.J., Conjugated linoleic acid effects on cancer, obesity, and atherosclerosis: A review of pre-clinical and human trials with current perspectives, Nutrients, 11, (2019); Marques T.M., Wall R., O'Sullivan O., Fitzgerald G.F., Shanahan F., Quigley E.M., Cotter P.D., Cryan J.F., Dinan T.G., Ross R.P., Dietary trans-10, cis-12-conjugated linoleic acid alters fatty acid metabolism and microbiota composition in mice, Br. J. Nutr., 113, pp. 728-738, (2015); Chen Y., Yang B., Ross R.P., Jin Y., Stanton C., Zhao J., Zhang H., Chen W., Orally administered CLA ameliorates DSS-induced colitis in mice via intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokine and gut microbiota modulation, J. Agric. Food Chem., 67, pp. 13282-13298, (2019); Queiroz M.P., Lima M.S., Melo M.F.F.T., Bertozzo C.C.D.S., Araujo D.F., Guerra G.C.B., Queiroga R.C.R.E., Soares J.K.B., Maternal suppplementation with conjugated linoleic acid reduce anxiety and lipid peroxidation in the offspring brain, J. Affective Disord., 243, pp. 75-82, (2019); Soares J.K.B., Melo A.P.R., Medeiros M.C., Queiroga R.C.R.E., Bomfim M.A.D., Santiago E.C.A., Guedes R.A., Anxiety behavior is reduced, and physical growth is improved in the progeny of rat dams that consumed lipids from goat milk: An elevated plus maze analysis, Neurosci. Lett., 552, pp. 25-29, (2013); Cigliano L., Spagnuolo M.S., Boscaino F., Ferrandino I., Monaco A., Capriello T., Cocca E., Iannotta L., Treppiccione L., Luongo D., Dietary supplementation with fish oil or conjugated linoleic acid relieves depression markers in mice by modulation of the Nrf2 pathway, Mol. Nutr. Food Res., 63, (2019); Cryan J.F., O'Riordan K.J., Cowan C.S., Sandhu K.V., Bastiaanssen T.F., Boehme M., Codagnone M.G., Cussotto S., Fulling C., Golubeva A.V., The microbiota-gut-brain axis, Physiol. Rev., 99, pp. 1877-2013, (2019); Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci., 264, pp. 651-660, (2014); Adam B., Liebregts T., Gschossmann J.M., Krippner C., Scholl F., Ruwe M., Holtmann G., Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model, Pain, 123, pp. 179-186, (2006)^Q. Zhai; State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi Jiangsu, 214122, China; email: zhaiqixiao@sina.com^^Royal Society of Chemistry^^^^^^20426496^^^33427835.0^English^Food. Funct.^Article^Final^^Scopus^2-s2.0-85100945293
Ajamian M.; Rosella G.; Newnham E.D.; Biesiekierski J.R.; Muir J.G.; Gibson P.R.^Ajamian, Mary (55675396400); Rosella, Gennaro (57193555101); Newnham, Evan D. (15835231300); Biesiekierski, Jessica R. (36184914800); Muir, Jane G. (7202728581); Gibson, Peter R. (57226032608)^55675396400; 57193555101; 15835231300; 36184914800; 7202728581; 57226032608^Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity^2021^Molecular Nutrition and Food Research^65.0^5^1901275^^^^21^10.1002/mnfr.201901275^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092933215&doi=10.1002%2fmnfr.201901275&partnerID=40&md5=17728620114819d435d92d16ecc115eb^Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia; Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia^Ajamian M., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia; Rosella G., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia; Newnham E.D., Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia; Biesiekierski J.R., Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia; Muir J.G., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia, Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia; Gibson P.R., Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, VIC, Australia, Department of Gastroenterology and Hepatology, Eastern Health, 3128, VIC, Australia^Scope: Since epithelial barrier dysfunction has been associated with gluten and fermentable oligosaccharide, disaccharide, monosaccharide, and polyols (FODMAPs), the effect of alterations in FODMAP a gluten intake on epithelial barrier function in patients with irritable bowel syndrome (IBS) who self-reported gluten sensitivity. Methods and results: Circulating concentrations of markers of epithelial injury (syndecan-1 and intestinal fatty acid-binding protein) and bacterial translocation (lipopolysaccharide-binding protein and soluble CD14) are measured while consuming habitual gluten-free diet and during blinded challenges with gluten or placebo on a background of low FODMAP intake. In 33 patients, only syndecan-1 concentrations during their habitual diet are elevated (median 43 ng mL−1) compared with 23 ng mL−1 in 49 healthy subjects (p < 0.001). On a low FODMAP diet, symptoms are reduced and levels of syndecan-1 (but not other markers) fell by a median 3335% (p < 0.001) irrespective of whether gluten is present or not. Conclusion: Gluten ingestion has no specific effect on epithelial integrity or symptoms in this cohort, but reducing FODMAP intake concomitantly reduces symptoms and reverses apparent colonic epithelial injury. These findings highlight the heterogeneity of populations self-reporting gluten sensitivity and implicate FODMAPs in colonic injury in IBS. © 2020 Wiley-VCH GmbH^bacterial translocation; functional bowel disorders; gluten-free diet; intestinal epithelium^Acute-Phase Proteins; Adult; Carrier Proteins; Celiac Disease; Diet, Carbohydrate-Restricted; Double-Blind Method; Female; Glutens; Humans; Irritable Bowel Syndrome; Lipopolysaccharide Receptors; Malabsorption Syndromes; Male; Membrane Glycoproteins; Middle Aged; Self Report; Syndecan-1; Treatment Outcome; Young Adult; acute phase protein; carrier protein; CD14 protein, human; gluten; lipopolysaccharide receptor; lipopolysaccharide-binding protein; membrane protein; SDC1 protein, human; syndecan 1; adult; blood; celiac disease; controlled study; double blind procedure; female; human; irritable colon; low carbohydrate diet; malabsorption; male; middle aged; randomized controlled trial; self report; treatment outcome; young adult^^carrier protein, 80700-39-6; gluten, 8002-80-0; syndecan 1, 128559-86-4; Acute-Phase Proteins, ; Carrier Proteins, ; CD14 protein, human, ; Glutens, ; Lipopolysaccharide Receptors, ; lipopolysaccharide-binding protein, ; Membrane Glycoproteins, ; SDC1 protein, human, ; Syndecan-1, ^^^^^Catassi C., Elli L., Bonaz B., Bouma G., Carroccio A., Castillejo G., Cellier C., Cristofori F., de Magistris L., Dolinsek J., Dieterich W., Francavilla R., Hadjivassiliou M., Holtmeier W., Korner U., Leffler D.A., Lundin K.E.A., Mazzarella G., Mulder C.J., Pellegrini N., Rostami K., Sanders D., Skodje G.I., Schuppan D., Ullrich R., Volta U., Williams M., Zevallos V.F., Zopf Y., Fasano A., Nutrients, 7, (2015); Di Sabatino A., Volta U., Salvatore C., Biancheri P., Caio G., De Giorgio R., Di Stefano M., Corazza G.R., Clin. Gastroenterol. Hepatol., 13, (2015); Elli L., Tomba C., Branchi F., Roncoroni L., Lombardo V., Bardella M.T., Ferretti F., Conte D., Valiante F., Fini L., Forti E., Cannizzaro R., Maiero S., Londoni C., Lauri A., Fornaciari G., Lenoci N., Spagnuolo R., Basilisco G., Somalvico F., Borgatta B., Leandro G., Segato S., Barisani D., Morreale G., Buscarini E., Nutrients, 8, (2016); Zanini B., Basche R., Ferraresi A., Ricci C., Lanzarotto F., Marullo M., Villanacci V., Hidalgo A., Lanzini A., Aliment. Pharmacol. Ther., 42, (2015); Francavilla R., Cristofori F., Verzillo L., Gentile A., Castellaneta S., Polloni C., Giorgio V., Verduci E., D'Angelo E., Dellatte S., Indrio F., Am. J. Gastroenterol., 113, (2018); Skodje G.I., Sarna V.K., Minelle I.H., Rolfsen K.L., Muir J.G., Gibson P.R., Veierod M.B., Henriksen C., Lundin K.E.A., Gastroenterology, 154, (2018); Uhde M., Ajamian M., Caio G., De Giorgio R., Indart A., Green P.H., Verna E.C., Volta U., Alaedini A., Gut, 65, (2016); Biesiekierski J.R., Peters S.L., Newnham E.D., Rosella O., Muir J.G., Gibson P.R., Gastroenterology, 145, (2013); Gibson P.R., Halmos E.P., Muir J.G., Aliment. Pharmacol. Ther., 52, (2020); Argenzio R.A., Meuten D.J., Dig. Dis. Sci., 36, (1991); Bovee-Oudenhoven I.M., Ten Bruggencate S.J., Lettink-Wissink M.L., Van der Meer R., J. Nutr., 135, (2005); Ten Bruggencate S.J., Bovee-Oudenhoven I.M., Lettink-Wissink M.L., Van der Meer R., J. Nutr., 136, (2006); Petersen A., Heegaard P.M., Pedersen A.L., Andersen J.B., Sorensen R.B., Frokiaer H., Lahtinen S.J., Ouwehand A.C., Poulsen M., Licht T.R., BMC Microbiol., 9, (2009); Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., J. Clin. Invest., 128, (2017); Chen B.R., Du L.J., He H.Q., Kim J.J., Yan Zhao Y., Zhang Y., Luo L., Dai N., World J. Gastroenterol., 23, (2017); Palaiologou M., Delladetsima I., Tiniakos D., Histol. Histopathol., 29, (2014); Xu H., Diolintzi A., Storch J., Curr. Opin. Clin. Nutr. Metab. Care, 22, (2019); Alexopoulou A., Agiasotelli D., Vasilieva L.E., Dourakis S.P., Ann. Gastroenterol., 30, (2017); Gibson P.R., Skodje G.I., Lundin K.E., J. Gastroenterol. Hepatol., 32, (2017); Carroccio A., Giannone G., Mansueto P., Soresi M., La Blasca F., Fayer F., Iacobucci R., Porcasi R., Catalano T., Geraci G., Arini A., D'Alcamo A., Villanacci V., Florena A.M., Clin. Gastroenterol. Hepatol., 17, (2019); Furuhashi M., Hotamisligil G.S., Nat. Rev. Drug Discovery, 7, (2008); Derikx J.P., Schellekens D.H., Acosta S., Best Pract. Res. Clin. Gastroenterol., 31, (2017); Derikx J.P., Vreugdenhil A.C., Van den Neucker A.M., Grootjans J., van Bijnen A.A., Damoiseaux J.G.M.C., van Heurn L.W.E., Heineman E., Buurman W.A., J. Clin. Gastroenterol., 43, (2009); Adriaanse M.P., Tack G.J., Passos V.L., Damoiseaux J.G.M.C., Schreurs M.W.J., van Wijck K., Riedl R.G., Masclee A.A.M., Buurman W.A., Mulder C.J.J., Vreugdenhil A.C.E., Aliment. Pharmacol. Ther., 37, (2013); Hoffmanova I., Sanchez D., Habova V., Andel M., Tuckova L., Tlaskalova-Hogenova H., Physiol. Res., 64, (2015); B. Arias N.M., Garcia M., Bondar C., Guzman L., Redondo A., Chopita N., Corsico B., Chirdo F.G., Mediators Inflammation, 2015, (2015); Vreugdenhil A.C., Wolters V.M., Adriaanse M.P., Van den Neucker A.M., van Bijnen A.A., Houwen R., Buurman W.A., Scand. J. Gastroenterol., 46, (2011); Adriaanse M.P.M., Mubarak A., Riedl R.G., Ten Kate F.J.W., Damoiseaux J.G.M.C., Buurman W.A., Houwen R.H.J., Vreugdenhil A.C.E., Sci. Rep., 7, (2017); Oldenburger I.B., Wolters V.M., Kardol-Hoefnagel T., Houwen R.H.J., Otten H.G., APMIS, 126, (2018); Adriaanse M.P., Leffler D.A., Kelly C.P., Schuppan D., Najarian R.M., Goldsmith J.D., Buurman W.A., Vreugdenhil A.C.E., Am. J. Gastroenterol., 111, (2016); Bodelier A.G., Pierik M.J., Lenaerts K., de Boer E., Damink S.W.O., Hameeteman W.M., Masclee A.A.M., Jonkers D.M., Eur. J. Gastroenterol. Hepatol., 28, (2016); Wiercinska-Drapalo A., Jaroszewicz J., Siwak E., Pogorzelska J., Prokopowicz D., Regul. Pept., 147, (2008); Wang Z., Li R., Tan J., Peng L., Wang P., Liu J., Xiong H., Jiang B., Chen Y., Inflammatory Bowel Dis., 21, (2015); Alexopoulou A.N., Multhaupt H.A., Couchman J.R., Int. J. Biochem. Cell Biol., 39, (2007); Bode L., Salvestrini C., Park P.W., Li J.-P., Esko J.D., Yamaguchi Y., Murch S., Freeze H.H., J. Clin. Invest., 118, (2008); Gan X., Wong B., Wright S.D., Cai T.Q., J. Interferon Cytokine Res., 21, (2001); Klein R.D., Borchers A.H., Sundareshan P., Bougelet C., Berkman M.R., Nagle R.B., Bowden G.T., J. Biol. Chem., 272, (1997); Yablecovitch D., Stein A., Shabat-Simon M., Naftali T., Gabay G., Laish I., Oren A., Konikoff F.M., Dig. Dis. Sci., 60, (2015); Cekic C., Kirci A., Vatansever S., Aslan F., Yilmaz H.E., Alper E., Arabul M., Yuksel E.S., Unsal B., Gastroenterol. Res. Pract., 2015, (2015); Ierardi E., Giorgio F., Zotti M., Rosania R., Principi M., Marangi S., Valle N.D., De Francesco V., Di Leo A., Ingrosso M., Panella C., J. Clin. Pathol., 64, (2011); Tursi A., Elisei W., Principi M., Inchingolo D.D., Nenna R., Picchio M., Giorgio F., Ierardi E., Brandimarte G., J. Gastrointest. Liver Dis., 23, (2014); Grube B.J., Cochane C.G., Ye R.D., McPhail M.E., Ulevitch R.J., Tobias P.S., J. Biol. Chem., 269, (1994); Klein R.D., Su G.L., Aminlari A., Alarcon W.H., Wang S.C., J. Surg. Res., 78, (1998); Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., Mathison J.C., Science, 249, (1990); Tapping R.I., Tobias P.S., J. Biol. Chem., 272, (1997); Landmann R., Knopf H.P., Link S., Sansano S., Schumann R., Zimmerli W., Infect. Immun., 64, (1996); P. Rojo O., Lopez San Roman A., Arbizu E.A., de la Hera Martinez A., Sevillano E.R., Martinez A.A., Inflammatory Bowel Dis., 13, (2007); Sandler N.G., Douek D.C., Nat. Rev. Microbiol., 10, (2012); Benjamini Y., Hochberg Y., J. R. Stat. Soc., Ser. B, 57, (1995)^P.R. Gibson; Department of Gastroenterology, Monash University and Alfred Health, Melbourne, 3004, Australia; email: peter.gibson@monash.edu; P.R. Gibson; Department of Gastroenterology and Hepatology, Eastern Health, 3128, Australia; email: peter.gibson@monash.edu^^Wiley-VCH Verlag^^^^^^16134125^^^32902928.0^English^Mol. Nutr. Food Res.^Article^Final^^Scopus^2-s2.0-85092933215
Fritscher-Ravens A.; Pflaum T.; Mösinger M.; Ruchay Z.; Röcken C.; Milla P.J.; Das M.; Böttner M.; Wedel T.; Schuppan D.^Fritscher-Ravens, Annette (7003556738); Pflaum, Theresa (57209284188); Mösinger, Marie (57209284049); Ruchay, Zino (57209284428); Röcken, Christoph (57194578639); Milla, Peter J. (7006184499); Das, Melda (57209278870); Böttner, Martina (6602507256); Wedel, Thilo (56253065500); Schuppan, Detlef (35448732000)^7003556738; 57209284188; 57209284049; 57209284428; 57194578639; 7006184499; 57209278870; 6602507256; 56253065500; 35448732000^Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E^2019^Gastroenterology^157.0^1^^109^118.e5^^163^10.1053/j.gastro.2019.03.046^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067204898&doi=10.1053%2fj.gastro.2019.03.046&partnerID=40&md5=23dde4a9c36f7655cf66522888f2c9d8^Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; UCL Institute of Child Health, University College London, London, United Kingdom; Department of Anatomy, Christian Albrecht University, Kiel, Germany; Institute of Translational Immunology, University Medical Center, Mainz, Germany; Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States^Fritscher-Ravens A., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Pflaum T., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Mösinger M., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Ruchay Z., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Röcken C., Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Milla P.J., UCL Institute of Child Health, University College London, London, United Kingdom; Das M., Unit Experimental Endoscopy, Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Böttner M., Department of Anatomy, Christian Albrecht University, Kiel, Germany; Wedel T., Department of Anatomy, Christian Albrecht University, Kiel, Germany; Schuppan D., Institute of Translational Immunology, University Medical Center, Mainz, Germany, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States^Background & Aims: Confocal laser endomicroscopy (CLE) is a technique that permits real-time detection and quantification of changes in intestinal tissues and cells, including increases in intraepithelial lymphocytes and fluid extravasation through epithelial leaks. Using CLE analysis of patients with irritable bowel syndrome (IBS), we found that more than half have responses to specific food components. Exclusion of the defined food led to long-term symptom relief. We used the results of CLE to detect reactions to food in a larger patient population and analyzed duodenal biopsy samples and fluid from patients to investigate mechanisms of these reactions. Methods: In a prospective study, 155 patients with IBS received 4 challenges with each of 4 common food components via the endoscope, followed by CLE, at a tertiary medical center. Classical food allergies were excluded by negative results from immunoglobulin E serology analysis and skin tests for common food antigens. Duodenal biopsy samples and fluid were collected 2 weeks before and immediately after CLE and were analyzed by histology, immunohistochemistry, reverse transcription polymerase chain reaction, and immunoblots. Results from patients who had a response to food during CLE (CLE+) were compared with results from patients who did not have a reaction during CLE (CLE–) or healthy individuals (controls). Results: Of the 108 patients who completed the study, 76 were CLE+ (70%), and 46 of these (61%) reacted to wheat. CLE+ patients had a 4-fold increase in prevalence of atopic disorders compared with controls (P =.001). Numbers of intraepithelial lymphocytes were significantly higher in duodenal biopsy samples from CLE+ vs CLE– patients or controls (P =.001). Expression of claudin-2 increased from crypt to villus tip (P <.001) and was up-regulated in CLE+ patients compared with CLE– patients or controls (P =.023). Levels of occludin were lower in duodenal biopsy samples from CLE+ patients vs controls (P =.022) and were lowest in villus tips (P <.001). Levels of messenger RNAs encoding inflammatory cytokines were unchanged in duodenal tissues after CLE challenge, but eosinophil degranulation increased, and levels of eosinophilic cationic protein were higher in duodenal fluid from CLE+ patients than controls (P =.03). Conclusions: In a CLE analysis of patients with IBS, we found that more than 50% of patients could have nonclassical food allergy, with immediate disruption of the intestinal barrier upon exposure to food antigens. Duodenal tissues from patients with responses to food components during CLE had immediate increases in expression of claudin-2 and decreases in occludin. CLE+ patients also had increased eosinophil degranulation, indicating an atypical food allergy characterized by eosinophil activation. © 2019 AGA Institute^Diet; Eosinophil; Food Allergy; Tight Junction^Adolescent; Adult; Aged; Allergens; Animals; Biopsy; Cell Degranulation; Claudin-2; Cytokines; Duodenum; Egg Hypersensitivity; Egg White; Endoscopy, Digestive System; Eosinophil Cationic Protein; Eosinophils; Female; Food Hypersensitivity; Humans; Immunoglobulin E; Intestinal Mucosa; Intraepithelial Lymphocytes; Irritable Bowel Syndrome; Male; Microscopy, Confocal; Middle Aged; Milk; Milk Hypersensitivity; Occludin; Permeability; Prospective Studies; RNA, Messenger; Soybeans; Tight Junctions; Triticum; Wheat Hypersensitivity; Yeasts; Young Adult; claudin 2; eosinophil cationic protein; immunoglobulin E; messenger RNA; occludin; tryptase; allergen; claudin 2; cytokine; egg white; eosinophil cationic protein; immunoglobulin E; messenger RNA; occludin; adult; aged; Article; atopy; confocal laser scanning microscopy; controlled study; degranulation; duodenum biopsy; duodenum tissue; egg; eosinophil; female; food allergy; histopathology; human; human tissue; immunoblotting; immunohistochemistry; intestine crypt; intestine villus; intraepithelial lymphocyte; irritable colon; major clinical study; male; milk; priority journal; protein expression; provocation test; quantitative analysis; randomized controlled trial (topic); retrospective study; reverse transcription polymerase chain reaction; soy food; upregulation; wheat; yeast; adolescent; animal; biopsy; confocal microscopy; digestive tract endoscopy; duodenum; egg allergy; food allergy; intestine mucosa; irritable colon; metabolism; middle aged; milk allergy; pathology; permeability; prospective study; soybean; tight junction; wheat allergy; young adult^^immunoglobulin E, 37341-29-0; occludin, 176304-61-3; tryptase, 97501-93-4; egg white, 9006-50-2; Allergens, ; Claudin-2, ; Cytokines, ; Eosinophil Cationic Protein, ; Immunoglobulin E, ; Occludin, ; RNA, Messenger, ^^^Deutsche Forschungsgemeinschaft, DFG, (646/17-1, 646/20-1)^Funding The work was supported by the Rashid Hussein Charity Trust, Kuala Lumpur, Malaysia to Annette Fritscher-Ravens and by research grants from the German Research Foundation (DFG Schu 646/17-1, DFG Schu 646/20-1) and from the Leibniz Foundation (Wheatscan, SAW-2016-DFA-2) to Detlef Schuppan. The sponsor has no involvement in the study. Author contributions: Annette Fritscher-Ravens: study concept and design, oversaw study, performed endoscopies, wrote manuscript; Theresa Pflaum: immunohistochemistry and histology, clinical assessment of patients; Marie Mösinger: clinical patient assessment; performed eosinophil count, tryptase, ECP measurements; statistics: Zino Ruchai: clinical patient evaluation and follow-up, CLE image interpretation, questionnaire evaluation, statistics; Chirstoph Röcken: oversaw all histology, guided correlation CLE histology, corrected manuscript; Peter Milla: helped with study design and writing of manuscript; Melda Das: clinical patient evaluation and follow-up, oversaw all diets and follow-up; Martina Böttner: helped with study design and all immunohistochemistry; Thilo Wedel: corrected manuscript; Detlef Schuppan: study concept/design, wrote manuscript, provided conceptual strategy.^Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, pp. 712-721, (2012); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Soares R.L., Irritable bowel syndrome: a clinical review, World J Gastroenterol, 20, pp. 12144-12160, (2014); Bohn L., Storsrud S., Tornblom H., Et al., Self-reported food related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life, Am J Gastroenterol, 108, pp. 634-641, (2013); Halmos E.P., Power V.A., Shepherd S.J., Et al., A diet low in FODMAPS reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, pp. 67-75, (2014); Bohn L., Storsrud S., Liljebo T., Et al., Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, pp. 1399-1407, (2015); Eswaran S., Goel A., Chey W.D., What role does wheat play in the symptoms of irritable bowel syndrome?, Gastroenterol Hepatol, 9, pp. 85-91, (2013); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function, Gastroenterology, 144, pp. 903-911, (2013); Fritscher-Ravens A., Schuppan D., Erichmann M., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Guidelines—Rome III diagnostic criteria for functional gastrointestinal disorders, J Gastrointest Liver Dis, 15, pp. 307-312, (2006); Walker M.M., Murray J.A., Ronkainen J., Et al., Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study, Gastroenterology, 139, pp. 112-119, (2010); Phillips A.D., Rice S.J., France N.E., Et al., Small intestinal intraepithelial lymphocyte levels in cow's milk protein intolerance, Gut, 20, pp. 509-512, (1979); Hayat M., Cairns A., Dixon M.F., Et al., Quantitation of intraepithelial lymphocytes in human duodenum: what is normal?, J Clin Pathol, 55, pp. 393-394, (2002); Hofmann S.R., Laass M.W., Fehrs A., Et al., IL10 promoter haplotypes may contribute to altered cytokine expression and systemic inflammation in celiac disease, Clin Immunol, 190, pp. 15-21, (2018); Rothenburg M.E., Eosinophilia. N Engl J Med, 338, pp. 1592-1600, (1998); Neumann H., Vieth M., Atreya R., Et al., Assessment of Crohn's disease activity by confocal laser endomicroscopy, Inflamm Bowel Dis, 12, pp. 2261-2269, (2012); Queneherve L., David G., Bourreille A., Et al., Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel disease, Gastrointest Endosc, 89, pp. 626-636, (2019); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., Association of permeability measurements bowel transit, barrier function and inﬂammation in irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 303, pp. G1262-G1269, (2012); Martinez C., Lobo B., Pigrau M., Et al., Diarrhea-predominant irritable bowel syndrome. An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Gunzel D., Yu A.S.L., Claudins and the modulation of tight junction permeability, Physiol Rev, 93, pp. 525-569, (2013); Al-Sadi R., Khatib K., Guo S., Et al., Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier, Am J Physiol Gastrointest Liver Physiol, 300, pp. G1054-G1064, (2011); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Zeissig S., Burgel N., Gunzel D., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Landy J., Ronde E., English N., Et al., Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer, World J Gastroenterol, 22, pp. 3117-3126, (2016); Rauhavirta T., Lindfors K., Koskinen O., Et al., Impaired epithelial integrity in the duodenal mucosa in early stages of celiac disease, Transl Res, 164, pp. 223-231, (2014); Wang F., Graham W.V., Wang Y., Et al., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Travers J., Rothenburg M.E., Eosinophils in mucosal immune responses, Mucosal Immunol, 8, pp. 464-475, (2015); Furuta G.T., Nieuwenhuis E.E., Karhausen J., Et al., Eosinophils alter colonic epithelial barrier function: role for major basic protein, Am J Physiol Gastrointest Liver Physiol, 289, pp. G890-G897, (2005); O'Shea K.M., Aceves S.S., Dellon E.S., Et al., Pathophysiology of eosinophilic esophagitis, Gastroenterology, 154, pp. 333-345, (2018); Kalach N., Kapel N., Waligora-Dupriet A.J., Et al., Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow's milk allergy in toddlers, Clin Chem Lab Med, 51, pp. 351-361, (2013); Warners M.J., Vlieg-Boerstra B.J., Verheij J., Et al., Esophageal and small intestinal mucosal integrity in eosinophilic esophagitis and response to an elemental diet, Am J Gastroenterol, 112, pp. 1061-1071, (2017); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Vanheel H., Vicario M., Vanuytsel T., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, pp. 262-271, (2014); Gibson P.G., Inflammatory phenotypes in adult asthma: clinical applications, Clin Respir J, 3, pp. 198-206, (2009); Saitoh O., Kojima K., Sugi K., Et al., Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease, Am J Gastroenterol, 94, pp. 3513-3520, (1999); Zevallos V.F., Raker V.K., Maxeiner J., Et al.; Junker Y., Zeissig S., Kim S.J., Et al., Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4, J Exp Med, 209, pp. 2395-2408, (2012); Bellinghausen I., Weigmann B., Zevallos V., Et al., Wheat amylase-trypsin inhibitors exacerbate intestinal and airway allergic immune responses in humanized mice, J Allergy Clin Immunol, 143, pp. 201-212, (2019); Fritscher-Ravens A., Schuppan D., Erichmann M., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Alimentary Pharmacol Ther, 11, pp. 395-402, (2007); Coffin B., Dapoigny M., Cloarec D., Et al., Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome, Gastroenterol Clin Biol, 28, pp. 11-15, (2004); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS), BMC Gastroenterol, 7, (2007)^A. Fritscher-Ravens; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Arnold Heller Strasse 3, 24105, Germany; email: fri.rav@btopenworld.com^^W.B. Saunders^^^^^^00165085^^GASTA^31100380.0^English^Gastroenterology^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-85067204898
Linsalata M.; Riezzo G.; Orlando A.; D’attoma B.; Prospero L.; Tutino V.; Notarnicola M.; Russo F.^Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); Orlando, Antonella (23767683100); D’attoma, Benedetta (57205751185); Prospero, Laura (57207799778); Tutino, Valeria (25646829800); Notarnicola, Maria (6701314744); Russo, Francesco (59133987400)^6603600075; 7004144336; 23767683100; 57205751185; 57207799778; 25646829800; 6701314744; 59133987400^The relationship between low serum vitamin d levels and altered intestinal barrier function in patients with ibs diarrhoea undergoing a long-term low-fodmap diet: Novel observations from a clinical trial^2021^Nutrients^13.0^3^1011^1^18^17.0^23^10.3390/nu13031011^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102709617&doi=10.3390%2fnu13031011&partnerID=40&md5=c4cb806f04caa475a0fd4d09c63053d1^Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy^Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; D’attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Tutino V., Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Notarnicola M., Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy^Decreased serum vitamin D (VD) levels have been associated with gastrointestinal (GI) disorders, including irritable bowel syndrome (IBS). VD can also modulate the intestinal barrier. Given the link between the GI barrier’s alterations and diet, attention has aroused the positive effects of the Low FODMAP Diet (LFD) on IBS patients’ symptom profile. We evaluated the GI symptoms and the urinary and circulating markers of GI barrier function, the markers of inflammation and intestinal dysbiosis in 36 IBS patients with predominant diarrhea (IBS-D) (5 men and 31 women, 43.1 ± 1.7 years) categorized for their circulating VD levels in low (L-VD) and normal (N-VD) (cutoff = 20 ng/mL). Evaluations were performed before and after 12 weeks of LFD. At the baseline, L-VD patients showed a significantly worse symptom profile and altered small intestinal permeability (s-IP) than N-VD. After LFD, a significant increase in the circulating VD levels in both the subgroups and a significant improvement of s-IP in L-VD patients occurred. Finally, VD levels negatively correlated with the symptom score and fecal zonulin. These data highlight the close relationship between VD and the intestinal barrier and support their involvement in IBS-D pathophysiology. Moreover, the potentially positive role of LFD in the management of IBS-D was confirmed. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.^Intestinal barrier; Irritable bowel syndrome; Low FODMAP diet; Symptom profile; Vitamin D^Adult; Biomarkers; Body Mass Index; Diarrhea; Diet, Carbohydrate-Restricted; Feces; Female; Fermentation; Gastrointestinal Diseases; Haptoglobins; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Protein Precursors; Vitamin D; HLA DQ2 antigen; HLA DQ8 antigen; interleukin 6; interleukin 8; vitamin D; biological marker; haptoglobin; protein precursor; vitamin D; zonulin; abdominal circumference; abdominal distension; abdominal pain; adult; Article; bacterial translocation; basal metabolic rate; body mass; clinical article; clinical trial; colorimetry; comparative study; controlled study; diarrhea; disease duration; energy consumption; enzyme linked immunosorbent assay; feeding behavior; female; follicular phase; high performance liquid chromatography; human; human tissue; irritable colon; lifestyle; low FODMAP diet; male; nutrient intake; pain severity; physical activity; physical examination; questionnaire; vitamin blood level; waist circumference; blood; chemistry; complication; diarrhea; feces; fermentation; gastrointestinal disease; irritable colon; low carbohydrate diet; middle aged; pathophysiology; procedures^^interleukin 8, 114308-91-7; haptoglobin, 9087-69-8; Biomarkers, ; Haptoglobins, ; Protein Precursors, ; Vitamin D, ; zonulin, ^ELISA kits, Becton Dickinson Biosciences, United States; ELISA kits, Cloud-Clone, United States; ELISA kits, Thermo, United States; UltiMate 3000^Becton Dickinson Biosciences, United States; Cloud-Clone, United States; Thermo, United States^Italian Ministry of Health RC 2020, (700/2020); Italian Ministry of Health RC 2020?^Funding text 1: Funding: This research was funded by the Italian Ministry of Health RC 2020–2021, Prog. (D.D.G. n. 700/2020).; Funding text 2: This research was funded by the Italian Ministry of Health RC 2020?2021, Prog. N? 16 (D.D.G. n. 700/2020).^Brett N.R., Lavery P., Agellon S., Vanstone C.A., Goruk S., Field C.J., Weiler H.A., Vitamin D Status and Immune Health Outcomes in a Cross-Sectional Study and a Randomized Trial of Healthy Young Children, Nutrients, 10, (2018); Sassi F., Tamone C., D'Amelio P., Vitamin D: Nutrient, Hormone, and Immunomodulator, Nutrients, 10, (2018); Panarese A., Pesce F., Porcelli P., Riezzo G., Iacovazzi P.A., Leone C.M., De Carne M., Rinaldi C.M., Shahini E., Chronic functional constipation is strongly linked to vitamin D deficiency, World J. Gastroenterol, 25, pp. 1729-1740, (2019); Tazzyman S., Richards N., Trueman A.R., Evans A.L., Grant V.A., Garaiova I., Plummer S.F., Williams E.A., Corfe B.M., Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: Outcomes from a pilot trial, BMJ Open Gastroenterol, 2, (2015); Abbasnezhad A., Amani R., Hajiani E., Alavinejad P., Cheraghian B., Ghadiri A., Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: A randomized double-blind clinical trial, Neurogastroenterol. Motil, 28, pp. 1533-1544, (2016); Gil A., Plaza-Diaz J., Mesa M.D., Vitamin D: Classic and Novel Actions, Ann. Nutr. Metab, 72, pp. 87-95, (2018); Williams C.E., Williams E.A., Corfe B.M., Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: What do we know and what do we need to know?, Eur. J. Clin. Nutr, 72, pp. 1358-1363, (2018); Katrinaki M., Kampa M., Margioris A., Castanas E., Malliaraki N., Vitamin D levels in a large Mediterranean cohort: Reconsidering normal cut-off values, Hormones (Athens), 15, pp. 205-223, (2016); Khalighi Sikaroudi M., Mokhtare M., Janani L., Faghihi Kashani A.H., Masoodi M., Agah S., Abbaspour N., Dehnad A., Shidfar F., Vitamin d3 supplementation in diarrhea-predominant irritable bowel syndrome patients: The effects on symptoms improvement, serum corticotropin-releasing hormone, and interleukin-6—A randomized clinical trial, Complementary Med. Res, 27, pp. 302-309, (2020); Silva M.C., Furlanetto T.W., Intestinal absorption of vitamin D: A systematic review, Nutr. Rev, 76, pp. 60-76, (2018); Assa A., Vong L., Pinnell L.J., Avitzur N., Johnson-Henry K.C., Sherman P.M., Vitamin d deficiency promotes epithelial barrier dysfunction and intestinal inflammation, J. Infect. Dis, 210, pp. 1296-1305, (2014); Fakhoury H.M.A., Kvietys P.R., Al Kattan W., Anouti F.A., Elahi M.A., Karras S.N., Grant W.B., Vitamin D and intestinal homeostasis: Barrier, microbiota, and immune modulation, J. Steroid Biochem. Mol. Biol, 200, (2020); Akimbekov N.S., Digel I., Sherelkhan D.K., Lutfor A.B., Razzaque M.S., Vitamin D and the Host-Gut Microbiome: A Brief Overview, Acta Histochem. Cytochem, 53, pp. 33-42, (2020); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-ibs: A case-control study, BMC Gastroenterol, 18, (2018); Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Meheust A., de Vos W.M., Et al., Homeostasis of the gut barrier and potential biomarkers, Am. J. Physiol. Gastrointest. Liver Physiol, 312, pp. G171-G193, (2017); Linsalata M., Riezzo G., Clemente C., D'Attoma B., Russo F., Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-ibs: An update, Dis. Markers, 2020, (2020); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiol. Rev, 91, pp. 151-175, (2011); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clin. Chim. Acta, 352, pp. 15-35, (2005); Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Wang Y.Y., Ji H.L., Ma L., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease, World J. Gastroenterol, 15, pp. 3916-3919, (2009); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke, Am. J. Emerg. Med, 33, pp. 867-871, (2015); Tuck C.J., Reed D.E., Muir J.G., Vanner S.J., Implementation of the low FODMAP diet in functional gastrointestinal symptoms: A real-world experience, Neurogastroenterol. Motil, 32, (2020); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D'Attoma B., De Nunzio V., Et al., Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective, Nutrients, 12, (2020); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Kulich K.R., Madisch A., Pacini F., Pique J.M., Regula J., Van Rensburg C.J., Ujszaszy L., Carlsson J., Halling K., Wiklund I.K., Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study, Health Qual. Life Outcomes, 6, (2008); Schmulson M.J., Drossman D.A., What Is New in Rome IV, J. Neurogastroenterol. Motil, 23, pp. 151-163, (2017); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: The “no man’s land” of gluten sensitivity, Am. J. Gastroenterol, 104, pp. 1587-1594, (2009); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol. Ther, 44, pp. 693-703, (2016); Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Munkholm P., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet, World J. Gastroenterol, 22, pp. 4009-4019, (2016); The Monash University Low FODMAP App, (2017); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin. Chem. Lab. Med, 52, pp. e61-e64, (2014); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn’s disease, Gastroenterology, 110, pp. 1395-1403, (1996); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur. J. Nutr, 58, pp. 2145-2156, (2019); Meeker S., Seamons A., Maggio-Price L., Paik J., Protective links between vitamin D, inflammatory bowel disease and colon cancer, World J. Gastroenterol, 22, pp. 933-948, (2016); Barbalho S.M., Goulart R.A., Araujo A.C., Guiguer E.L., Bechara M.D., Irritable bowel syndrome: A review of the general aspects and the potential role of vitamin D, Expert Rev. Gastroenterol. Hepatol, 13, pp. 345-359, (2019); Eslamian G., Ardehali S.H., Hajimohammadebrahim-Ketabforoush M., Vahdat Shariatpanahi Z., Association of intestinal permeability with admission vitamin D deficiency in patients who are critically ill, J. Investig. Med, 68, pp. 397-402, (2020); Kong J., Zhang Z., Musch M.W., Ning G., Sun J., Hart J., Bissonnette M., Li Y.C., Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier, Am. J. Physiol. Gastrointest. Liver Physiol, 294, pp. G208-G216, (2008); Zhu T., Liu T.J., Shi Y.Y., Zhao Q., Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis, Int. J. Mol. Med, 35, pp. 1213-1218, (2015); Raftery T., Martineau A.R., Greiller C.L., Ghosh S., McNamara D., Bennett K., Meddings J., O'Sullivan M., Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study, United Eur. Gastroenterol. J, 3, pp. 294-302, (2015); McCabe P.S., Pye S.R., Beth J.M., Lee D.M., Tajar A., Bartfai G., Boonen S., Bouillon R., Casanueva F., Finn J.D., Et al., Low vitamin D and the risk of developing chronic widespread pain: Results from the European male ageing study, BMC Musculoskelet. Disord, 17, (2016); Jalili M., Vahedi H., Poustchi H., Hekmatdoost A., Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Int. J. Prev. Med, 10, (2019); Bicikova M., Duskova M., Vitku J., Kalvachova B., Ripova D., Mohr P., Starka L., Vitamin D in anxiety and affective disorders, Physiol. Res, 64, pp. S101-S103, (2015); Ajamian M., Rosella G., Newnham E.D., Biesiekierski J.R., Muir J.G., Gibson P.R., Effect of Gluten Ingestion and FODMAP Restriction on Intestinal Epithelial Integrity in Patients with Irritable Bowel Syndrome and Self-Reported Non-Coeliac Gluten Sensitivity, Mol. Nutr. Food Res, (2020); Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J. Clin. Investig, 128, pp. 267-280, (2018); Harvie R.M., Chisholm A.W., Bisanz J.E., Burton J.P., Herbison P., Schultz K., Schultz M., Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs, World J. Gastroenterol, 23, pp. 4632-4643, (2017); Gibson P.R., Shepherd S.J., Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach, J. Gastroenterol. Hepatol, 25, pp. 252-258, (2010); Bascunan K.A., Elli L., Pellegrini N., Scricciolo A., Lombardo V., Doneda L., Vecchi M., Scarpa C., Araya M., Roncoroni L., Impact of FODMAP Content Restrictions on the Quality of Diet for Patients with Celiac Disease on a Gluten-Free Diet, Nutrients, 11, (2019); Vincenzi M., Del Ciondolo I., Pasquini E., Gennai K., Paolini B., Effects of a Low FODMAP Diet and Specific Carbohydrate Diet on Symptoms and Nutritional Adequacy of Patients with Irritable Bowel Syndrome: Preliminary Results of a Single-blinded Randomized Trial, J. Transl. Int. Med, 5, pp. 120-126, (2017); Maes M., Kubera M., Leunis J.C., The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression, Neuro Endocrinol. Lett, 29, pp. 117-124, (2008)^F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte (Ba), 70013, Italy; email: francesco.russo@irccsdebellis.it^^MDPI AG^^^^^^20726643^^^33801020.0^English^Nutrients^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85102709617
Jalili M.; Vahedi H.; Poustchi H.; Hekmatdoost A.^Jalili, Mahsa (54398609400); Vahedi, Homayoon (6602272096); Poustchi, Hossein (8622806500); Hekmatdoost, Azita (7801320384)^54398609400; 6602272096; 8622806500; 7801320384^Soy isoflavones and cholecalciferol reduce inflammation, and gut permeability, without any effect on antioxidant capacity in irritable bowel syndrome: A randomized clinical trial^2019^Clinical Nutrition ESPEN^34.0^^^50^54^4.0^20^10.1016/j.clnesp.2019.09.003^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072757376&doi=10.1016%2fj.clnesp.2019.09.003&partnerID=40&md5=f9825ed6d170b79776d3b52b84c7f283^Cell, Molecular Biology Group (CMBG), Department of Biology, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Digestive Disease Research Center, Digestive Disease Research Institute (DDRI), Tehran, Iran; Liver and Pancreatobiliary Research Group, Digestive Disease Research Institute (DDRI), Tehran, Iran; National Nutrition and Food Technology Research Institute (NFTRI), Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran^Jalili M., Cell, Molecular Biology Group (CMBG), Department of Biology, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Vahedi H., Digestive Disease Research Center, Digestive Disease Research Institute (DDRI), Tehran, Iran; Poustchi H., Liver and Pancreatobiliary Research Group, Digestive Disease Research Institute (DDRI), Tehran, Iran; Hekmatdoost A., National Nutrition and Food Technology Research Institute (NFTRI), Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran^Background & aims: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that is more prevalent in women. Vitamin D deficiency and hormonal disorders are also prevalent in Iranian women, and may influence the severity of clinical outcomes mediated by microinflammation, oxidative stress and intestinal permeability pathways. Our objective was to investigate the effects of co-administration of soy and vitamin D on some inflammatory, antioxidant and gut permeability markers in women with IBS. Methods: In a randomized clinical trial, women (18–75 years of age) were randomly allocated into four groups to receive soy isoflavones (40 mg/day), cholecalciferol (50,000 IU/15 days), both soy isoflavones and cholecalciferol, or placebo for six weeks. The outcomes were plasma inflammatory markers, antioxidant status and fecal protease activity at week 0 and week 6. Results: After the intervention, plasma inflammatory markers and fecal protease activity were reduced significantly in all treatment groups compared to the placebo group; however, there was no significant effect on antioxidant status. Conclusion: This study suggests combined supplementation of soy isoflavones and active vitamin D can improve some biochemical parameters regarding inflammation and intestinal permeability of IBS in women. Trial registration: Clinical.Trials.gov NCT02026518. © 2019 European Society for Clinical Nutrition and Metabolism^Antioxidant; Cholecalciferol; Inflammation; Irritable bowel syndrome; Permeability; Soy; Women^Adolescent; Adult; Aged; Antioxidants; Biomarkers; Cholecalciferol; Dietary Supplements; Feces; Female; Gastrointestinal Tract; Humans; Inflammation; Iran; Irritable Bowel Syndrome; Isoflavones; Middle Aged; Permeability; Serine Proteases; Tumor Necrosis Factor-alpha; Vitamin D; Vitamin D Deficiency; Young Adult; 25 hydroxyvitamin D; antioxidant; biological marker; colecalciferol; daidzein; genistein; glycetin; immunoglobulin enhancer binding protein; isoflavone derivative; serine proteinase; tumor necrosis factor; unclassified drug; antioxidant; biological marker; colecalciferol; isoflavone derivative; serine proteinase; tumor necrosis factor; vitamin D; adult; aged; Article; clinical article; clinical outcome; controlled study; drug effect; enzyme activity; feces level; female; human; inflammation; intestine mucosa permeability; irritable colon; leukocyte; oxidative stress; protein blood level; randomized controlled trial; soybean; supplementation; vitamin blood level; adolescent; dietary supplement; feces; gastrointestinal tract; inflammation; Iran; irritable colon; metabolism; middle aged; permeability; vitamin D deficiency; young adult^^25 hydroxyvitamin D, 64719-49-9; colecalciferol, 1406-16-2, 67-97-0; daidzein, 486-66-8; genistein, 446-72-0; proprotein convertase 9, ; serine protease HTRA1, ; serine proteinase, 37259-58-8; Antioxidants, ; Biomarkers, ; Cholecalciferol, ; Isoflavones, ; Serine Proteases, ; Tumor Necrosis Factor-alpha, ; Vitamin D, ^^^National Nutrition and Food Technology Research Institute, NNFTRI^This study was financially supported by National Nutrition and Food Science Technology Research Institute, Tehran, Iran . ^Taft T., Guadagnoli L., Abbasi R., Ibrahim A., Doerfler B., Brenner D.M., Et al., Food related quality of life in patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Gastroenterology, 152, (2017); Holtmann G.J., Ford A.C., Talley N.J., Pathophysiology of irritable bowel syndrome, Lancet Gastroenterol Hepatol, 1, pp. 133-146, (2016); Mulak A., Tache Y., Larauche M., Sex hormones in the modulation of irritable bowel syndrome, World J Gastroenterol: WJG, 20, (2014); Van Der Veek P.P., Van Den Berg M., De Kroon Y.E., Verspaget H.W., Masclee A.A., Role of tumor necrosis factor-α and interleukin-10 gene polymorphisms in irritable bowel syndrome, Am J Gastroenterol, 100, pp. 2510-2516, (2005); Beutler B., The role of tumor necrosis factor in health and disease, J Rheumatol Suppl, 57, pp. 16-21, (1999); Rogler G., Brand K., Vogl D., Page S., Hofmeister R., Andus T., Et al., Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa, Gastroenterology, 115, pp. 357-369, (1998); Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., Et al., TNF-α-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation, Am J Physiol Gastrointest Liver Physiol, 286, pp. G367-G376, (2004); Neurath M.F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., Meyer zum Buschenfelde K.H., Et al., Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice, Eur J Immunol, 27, pp. 1743-1750, (1997); A P., Caso J.R., Alou L., Colon A., Sevillano D., Moro M.A., Et al., The role of PPARγ on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction, Gastroenterology, 132, pp. 1791-1803, (2007); Asadi-Shahmirzadi A., Mozaffari S., Sanei Y., Baeeri M., Hajiaghaee R., Monsef-Esfahani H.R., Et al., Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: combination of antioxidant and spasmolytic effects, Chin J Integr Med, pp. 1-9, (2012); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Et al., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Investig, 117, pp. 636-647, (2007); Al-Sadi R., Boivin M., Ma T., Mechanism of cytokine modulation of epithelial tight junction barrier, Front Biosci – J Vis Lit, 14, (2009); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Heitkemper M.M., Cain K.C., Jarrett M.E., Burr R.L., Hertig V., Bond E.F., Symptoms across the menstrual cycle in women with irritable bowel syndrome, Am J Gastroenterol, 98, pp. 420-430, (2003); Braniste V., Leveque M., Buisson-Brenac C., Bueno L., Fioramonti J., Houdeau E., Oestradiol decreases colonic permeability through oestrogen receptor β-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells, J Physiol, 587, pp. 3317-3328, (2009); Somjen D., Kohen F., Gayer B., Knoll E., Limor R., Baz M., Et al., A non-calcemic Vitamin D analog modulates both nuclear and putative membranal estrogen receptors in cultured human vascular smooth muscle cells, J Steroid Biochem Mol Biol, 89, pp. 397-399, (2004); Jalili M., Hekmatdoost A., Vahedi H., Poustchi H., Khademi B., Saadi M., Et al., Co-administration of soy isoflavones and vitamin D in management of irritable bowel disease, PLoS One, 11, (2016); Drossman D.A., Dumitrascu D.L., Rome III: new standard for functional gastrointestinal disorders, J Gastrointest Liver Dis, 15, (2006); Suh K.S., Koh G., Park C.Y., Woo J.T., Kim S.W., Kim J.W., Et al., Soybean isoflavones inhibit tumor necrosis factor-α-induced apoptosis and the production of interleukin-6 and prostaglandin E2 in osteoblastic cells, Phytochemistry, 63, pp. 209-215, (2003); Satsu H., Hyun J.S., Shin H.S., Shimizu M., Suppressive effect of an isoflavone fraction on tumor necrosis factor-α-induced interleukin-8 production in human intestinal epithelial Caco-2 cells, J Nutr Sci Vitaminol, 55, pp. 442-446, (2009); Moussa L., Bezirard V., Salvador-Cartier C., Bacquie V., Houdeau E., Theodorou V., A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats, Clin Nutr, 32, pp. 51-58, (2013); Amani R., Abbasnezhad A., Hajiani E., Cheraghian B., Abdoli Z., RJIjoiI C., Vitamin D3 induced decrease in IL-17 and malondialdehyde, and increase in IL-10 and total antioxidant capacity levels in patients with irritable bowel syndrome, 15, pp. 186-196, (2018)^M. Jalili; Trondheim, Høgskoleringen 5, 7034, Norway; email: mahsa.jalili@ntnu.no^^Elsevier Ltd^^^^^^24054577^^^31677711.0^English^Clin. Nutr. ESPEN^Article^Final^^Scopus^2-s2.0-85072757376
Miglietta S.; Borghini R.; Relucenti M.; Sorrentino V.; Chen R.; Li X.; Fazi F.; Donato G.; Familiari G.; Petrozza V.; Picarelli A.^Miglietta, Selenia (56940649200); Borghini, Raffaele (39960970700); Relucenti, Michela (14011954100); Sorrentino, Veronica (57200959131); Chen, Rui (24824111000); Li, Xiaobo (35741076500); Fazi, Francesco (6505950816); Donato, Giuseppe (56396394000); Familiari, Giuseppe (35514590400); Petrozza, Vincenzo (6603788886); Picarelli, Antonio (7004609330)^56940649200; 39960970700; 14011954100; 57200959131; 24824111000; 35741076500; 6505950816; 56396394000; 35514590400; 6603788886; 7004609330^New insights into intestinal permeability in irritable bowel syndrome-like disorders: Histological and ultrastructural findings of duodenal biopsies^2021^Cells^10.0^10^2593^^^^10^10.3390/cells10102593^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85115852842&doi=10.3390%2fcells10102593&partnerID=40&md5=70fa57b55e6027e4326fe17eea557b7c^Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 00161, Italy; Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, 218889, China^Miglietta S., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Borghini R., Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; Relucenti M., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Sorrentino V., Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 00161, Italy; Chen R., Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, 218889, China; Li X., Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing, 218889, China; Fazi F., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Donato G., Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; Familiari G., Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; Petrozza V., Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, 00161, Italy; Picarelli A., Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy^Background and Aim: Diarrhea, abdominal pain, and bloating are frequent in irritable bowel syndrome (IBS)-like disorders, although little is known about their intestinal ultrastructural alterations. The aim of the present study was to study duodenal biopsies from IBS-like patients to find ultrastructural alterations. Materials and Methods: Study design: descriptive comparative pilot study. Thirty outpatients (9 male and 21 female; median age 37.7 years; range, 20 to 65 years) complaining of IBS-like symptoms were enrolled between January 2015 to May 2019 and were divided into 6 groups, each equally consisting of 5 patients: (A) untreated celiac disease (uCD); (B) treated celiac disease (tCD); (C) wheat allergy (WA); (D) Non-celiac gluten sensitivity (NCGS); (E) Nickel allergic contact mucositis (Ni ACM); (F) controls affected by GERD. Transmission electron microscopy (TEM) morphological characteristics were: microvilli length, intermicrovillar distance, junctional complexes (JC) gap width, autophagic bodies, apoptosis, altered mitochondria, lipid/chylomicron droplets, and mast cells. Regarding JC, we focused on tight junctions (TJ), adherens junctions (AJ), and desmosomes. Results: Major alterations in microvilli length and intermicrovillar distance have been observed in the subjects affected by uCD. Microvilli of tCD patients showed marked recovery after adequate GFD, although not comparable to controls. Intermediate microvillar alterations were instead observed in NCGS and Ni ACM, while characteristics of WA subjects appeared more similar to tCD. Regarding JC, TJ did not show significant differences between all groups studied, including controls. The AJ were significantly more dilated in all groups compared to controls, while no significant differences were found between the pathological groups. The distance between desmosomes was greater in uCD, NCGS, and Ni ACM than in tCD, WA, and controls. Finally, intracellular alterations have been detected in most of the groups studied although they seemed more unspecific. Conclusions: TEM analysis confirmed damages to the intestinal barrier and defense mechanisms by enterocytes in IBS-like patients, probably linked to low-grade inflammation or adverse reactions triggered by food allergens, heavy metals, or other unknown. On the other hand, our study needs confirmation and further investigations with larger populations to facilitate diagnosis, therapy, and prevention of IBS-like disorders in the future. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.^Celiac disease; Diagnosis; Duodenal biopsies; IBS-like disorders; Intestinal permeability; Nickel allergy; Non-celiac gluten sensitivity; Transmission electron microscopy (TEM); Ultrastructure; Wheat allergy^Adult; Aged; Biopsy; Duodenum; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Pilot Projects; Young Adult; allergen; chylomicron; epoxy resin; heavy metal; immunoglobulin A; immunoglobulin E; nickel; propylene oxide; abdominal pain; adherens junction; adult; anemia; apoptosis; Article; asthenia; atopic dermatitis; autophagosome; bloating; capsule endoscopy; celiac disease; clinical article; colonoscopy; Creutzfeldt Jakob disease; defense mechanism; desmosome; diarrhea; duodenum biopsy; duodenum mucosa; dyspepsia; dysphagia; endoscopy; female; flow cytometry; gastroesophageal reflux; genetic polymorphism; gluten free diet; heartburn; histology; human; immunohistochemistry; inflammation; intestine cell; intestine flora; irritable colon; lamina propria; lymphocytosis; male; mast cell; mitochondrion; morphological trait; mucosa inflammation; nickel hypersensitivity; observational study; outpatient; pilot study; psoriasis; swelling; tight junction; transmission electron microscopy; ulcerative colitis; ultrastructure; wheat allergy; aged; biopsy; complication; duodenum; irritable colon; middle aged; procedures; surgery; ultrastructure; young adult^^immunoglobulin E, 37341-29-0; nickel, 7440-02-0; propylene oxide, 75-56-9^^^Ministry of Foreign Affairs and International Cooperation of Italy, (CN18GR10)^This research was funded by Ministry of Foreign Affairs and International Cooperation of Italy, grant number CN18GR10.^Spiller R., Irritable bowel syndrome: New insights into symptom mechanisms and advances in treatment, F1000Research, 29, (2016); Borghini R., Donato G., Alvaro D., Picarelli A., New insights in IBS-like disorders: Pandora’s box has been opened; a review, Gastroenterol. Hepatol. Bed Bench, 10, pp. 79-89, (2017); Elli L., Branchi F., Tomba C., Villalta D., Norsa L., Ferretti F., Roncoroni L., Bardella M.T., Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity, World J. Gastroenterol, 21, pp. 7110-7119, (2015); Goswami P., Das P., Verma A.K., Prakash S., Das T.K., Nag T.C., Ahuja V., Gupta S.D., Makharia G.K., Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn’s disease?, Virchows Arch, 465, pp. 521-530, (2014); Valitutti F., Fasano A., Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments, Dig. Dis. Sci, 64, pp. 1748-1758, (2019); Anderson J.M., Van Itallie C.M., Fanning A.S., Setting up a selective barrier at the apical junction complex, Curr. Opin. Cell Biol, 16, pp. 140-145, (2004); Visser J., Rozing J., Sapone A., Lammers K., Fasano A., Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms, Ann. N. Y. Acad. Sci, 1165, pp. 195-205, (2009); Cukrowska B., Sowinska A., Bierla J.B., Czarnowska E., Rybak A., Grzybowska-Chlebowczyk U., Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota-Key players in the pathogenesis of celiac disease, World J. Gastroenterol, 23, pp. 7505-7518, (2017); Schumann M., Siegmund B., Schulzke J.D., Fromm M., Celiac Disease: Role of the Epithelial Barrier, Cell Mol. Gastroenterol. Hepatol, 3, pp. 150-162, (2017); Schoultz I., Keita A.V., The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability, Cells, 9, (2020); Cardoso-Silva D., Delbue D., Itzlinger A., Moerkens R., Withoff S., Branchi F., Schumann M., Intestinal Barrier Function in Gluten-Related Disorders, Nutrients, 11, (2019); Hollon J., Puppa E.L., Greenwald B., Goldberg E., Guerrerio A., Fasano A., Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity, Nutrients, 7, pp. 1565-1576, (2015); Lebwohl B., Sanders D.S., Green P.H.R., Coeliac disease, Lancet, 391, pp. 70-81, (2018); Picarelli A., Borghini R., Isonne C., Di Tola M., Reactivity to dietary gluten: New insights into differential diagnosis among gluten-related gastrointestinal disorders, Pol. Arch. Med. Wewn, 123, pp. 708-712, (2013); Borghini R., Di Tola M., Salvi E., Isonne C., Puzzono M., Marino M., Donato G., Picarelli A., Impact of gluten-free diet on quality of life in celiac patients, Acta Gastroenterol. Belg, 79, pp. 447-453, (2016); Shiner M., Birbeck M.S., The microvilli of the small intestinal surface epithelium in coeliac disease and in idiopathic steatorrhoea, Gut, 2, pp. 277-284, (1961); Serena G., D'Avino P., Fasano A., Celiac Disease and Non-celiac Wheat Sensitivity: State of Art of Non-dietary Therapies, Front. Nutr, 7, (2020); Picarelli A., Borghini R., Di Tola M., Marino M., Urciuoli C., Isonne C., Puzzono M., Porowska B., Rumi G., Lonardi S., Et al., Intestinal, Systemic, and Oral Gluten-related Alterations in Patients with Nonceliac Gluten Sensitivity, J. Clin. Gastroenterol, 50, pp. 849-858, (2016); Biesiekierski J.R., Peters S.L., Newnham E.D., Rosella O., Muir J.G., Gibson P.R., No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates, Gastroenterology, 145, pp. 320-328, (2013); Catassi C., Elli L., Bonaz B., Bouma G., Carroccio A., Castillejo G., Cellier C., Cristofori F., de Magistris L., Dolinsek J., Et al., Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts’ Criteria, Nutrients, 7, pp. 4966-4977, (2015); Carroccio A., Giannone G., Mansueto P., Soresi M., La Blasca F., Fayer F., Iacobucci R., Porcasi R., Catalano T., Geraci G., Et al., Duodenal and Rectal Mucosa Inflammation in Patients with Non-celiacWheatSensitivity, Clin. Gastroenterol. Hepatol, 17, pp. 682-690, (2019); Pizzutelli S., Systemic nickel hypersensitivity and diet: Myth or reality?, Eur. Ann. Allergy Clin. Immunol, 43, pp. 5-18, (2011); Borghini R., Porpora M.G., Casale R., Marino M., Palmieri E., Greco N., Donato G., Picarelli A., Irritable Bowel Syndrome-Like Disorders in Endometriosis: Prevalence of Nickel Sensitivity and Effects of a Low-Nickel Diet. An Open-Label Pilot Study, Nutrients, 28, (2020); Borghini R., Puzzono M., Rosato E., Di Tola M., Marino M., Greco F., Picarelli A., Nickel-Related Intestinal Mucositis in IBS-Like Patients: Laser Doppler Perfusion Imaging and Oral Mucosa Patch Test in Use, Biol. Trace Elem. Res, 173, pp. 55-61, (2016); Di Tola M., Marino M., Amodeo R., Tabacco F., Casale R., Portaro L., Borghini R., Cristaudo A., Manna F., Rossi A., Et al., Immunologicalcharacterization of the allergiccontactmucositisrelated to the ingestion of nickel-richfoods, Immunobiology, 219, pp. 522-530, (2014); Al-Toma A., Volta U., Auricchio R., Castillejo G., Sanders D.S., Cellier C., Mulder C.J., Lundin K.E.A., European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders, United Eur. Gastroenterol. J, 7, pp. 583-613, (2019); Vitalone A., Di Sotto A., Mammola C.L., Heyn R., Miglietta S., Mariani P., Sciubba F., Passarelli F., Nativio P., Mazzanti G., Phytochemicalanalysis and effects on ingestivebehaviour of a Caralluma fimbriata extract, Food Chem. Toxicol, 108, pp. 63-73, (2017); Nabi A., Khalili M.A., Talebi A.R., Mangoli E., Yari N., Nottola S.A., Miglietta S., Taheri F., In-Vitro Application of Pentoxifylline Preserved Ultrastructure of Spermatozoa After Vitrification in Asthenozoospermic Patients, Urol. J, 14, pp. 4038-4043, (2017); Sowinska A., Morsy Y., Czarnowska E., Oralewska B., Konopka E., Woynarowski M., Szymanska S., Ejmont M., Scharl M., Bierla J.B., Et al., Transcriptional and Ultrastructural Analyses Suggest Novel Insightsinto Epithelial Barrier Impairment in Celiac Disease, Cells, 9, (2020); Canavan C., West J., Card T., The epidemiology of irritable bowel syndrome, Clin. Epidemiol, 6, pp. 71-80, (2014); Catassi C., Alaedini A., Bojarski C., Bonaz B., Bouma G., Carroccio A., Castillejo G., De Magistris L., Dieterich W., Di Liberto D., Et al., The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update, Nutrients, 9, (2017); Granger B., Baker R.F., Electron microscope investigation of the striated border of intestinal epithelium, Anat. Rec, 107, pp. 423-441, (1950); Yardley J.H., Bayless T.M., Norton J.H., Hendrix T.R., Celiac disease. A study of the jejunal epithelium before and after a gluten-free diet, N. Engl. J. Med, 267, pp. 1173-1179, (1962); Trier J.S., Rubin C.E., Electron microscopy of the small intestine: A review, Gastroenterology, 49, pp. 574-603, (1965); Trier J.S., Structure of the mucosa of the small intestine as it relates to intestinal function, Fed. Proc, 26, pp. 1391-1404, (1967); Wehman H.J., Plantholt B.A., Lifshitz F., Microvillous anomalies induced by various conditions of stress in the small intestine of the rat, Exp. Mol. Pathol, 17, pp. 296-306, (1972); Borghini R., De Amicis N., Bella A., Greco N., Donato G., Picarelli A., Beneficial Effects of a Low-Nickel Diet on Relapsing IBS-Like and Extraintestinal Symptoms of Celiac Patients during a Proper Gluten-Free Diet: Nickel Allergic Contact Mucositis in Suspected Non-Responsive Celiac Disease, Nutrients, 12, (2020); Jing K., Lim K., Why is autophagy important in human diseases?, Exp. Mol. Med, 44, pp. 69-72, (2012); Klionsky D.J., Autophagy: From phenomenology to molecular understanding in less than a decade, Nat. Rev. Mol. Cell Biol, 8, pp. 931-937, (2007); Huett A., Xavier R.J., Autophagy at the gut interface: Mucosal responses to stress and the consequences for inflammatory bowel diseases, Inflamm. Bowel. Dis, 16, pp. 152-174, (2010); Barone M.V., Troncone R., Auricchio S., Gliadin Peptides as Triggers of the Proliferative and Stress/Innate Immune Response of the Celiac Small Intestinal Mucosa, Int. J. Mol. Sci, 15, pp. 20518-20537, (2014); Buret A.G., Bhargava A., Modulatory mechanisms of enterocyte apoptosis by viral, bacterial and parasitic pathogens, Crit. Rev. Microbiol, 40, pp. 1-17, (2014); Shalimar D.M., Das P., Sreenivas V., Gupta S.D., Panda S.K., Makharia G.K., Mechanism of villous atrophy in celiac disease: Role of apoptosis and epithelial regeneration, Arch. Pathol. Lab. Med, 137, pp. 1262-1269, (2013); Mazzarella G., Stefanile R., Camarca A., Giliberti P., Cosentini E., Marano C., Iaquinto G., Giardullo N., Auricchio S., Sette A., Et al., Gliadinactivates HLA class I-restricted CD8+ T cells in celiacdiseaseintestinal mucosa and induces the enterocyteapoptosis, Gastroenterology, 134, pp. 1017-1027, (2008); Novak E.A., Mollen K.P., Mitochondrial dysfunction in inflammatory bowel disease, Front. Cell Dev. Biol, 3, (2015); Bhonchal S., Nain C.K., Prasad K.K., Nada R., Sharma A.K., Sinha S.K., Singh K., Functional and morphological alterations in small intestine mucosa of chronic alcoholics, J. Gastroenterol. Hepatol, 23, pp. e43-e48, (2008); Beilstein F., Carriere V., Leturque A., Demignot S., Characteristics and functions of lipid droplets and associated proteins in enterocytes, Exp. Cell Res, 340, pp. 172-179, (2016); Demignot S., Beilstein F., Morel E., Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: Key players in intestinal physiology and metabolic disorders, Biochimie, 96, pp. 48-55, (2014); Magrone T., Magrone M., Jirillo E., Mast Cells as a Double Edged Sword in Immunity: Disorders of Mast Cell Activation and Therapeutic Management. Second of Two Parts, Endocr. Metab. Immune Disord. Drug Targets, 20, pp. 670-686, (2019); Albert-Bayo M., Paracuellos I., Gonzalez-Castro A.M., Rodriguez-Urrutia A., Rodriguez-Lagunas M.J., Alonso-Cotoner C., Santos J., Vicario M., Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis, Cells, 8, (2019); Frossi B., De Carli M., Calabro A., Coeliac Disease and Mast Cells, Int. J. Mol. Sci, 20, (2019); Hiatt R.B., Katz L., Mast cells in inflammatory conditions of the gastrointestinal tract, Am. J. Gastroenterol, 37, pp. 541-545, (1962); Robles A., Perez Ingles D., Myneedu K., Deoker A., Sarosiek I., Zuckerman M.J., Schmulson M.J., Bashashati M., Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 31, (2019); Vanheel H., Vicario M., Boesmans W., Vanuytsel T., Salvo-Romero E., Tack J., Farre R., Activation of Eosinophils and Mast Cells in Functional Dyspepsia: An Ultrastructural Evaluation, Sci. Rep, 8, (2018); Giancola F., Volta U., Repossi R., Latorre R., Beeckmans D., Carbone F., Van den Houte K., Bianco F., Bonora E., Gori A., Et al., Mast cell-nerve interactions correlate with bloating and abdominal pain severity in patients with non-celiac gluten/wheat sensitivity, Neurogastroenterol. Motil, 5, (2020); Galli S.J., Tsai M., IgE and mast cells in allergic disease, Nat. Med, 18, pp. 693-704, (2012); Kinbara M., Bando K., Shiraishi D., Kuroishi T., Nagai Y., Ohtsu H., Takano-Yamamoto T., Sugawara S., Endo Y., Mast cell histamine-mediated transient inflammation following exposure to nickel promotes nickel allergy in mice, Exp. Dermatol, 25, pp. 466-471, (2016); Walsh M.L., Smith V.H., King C.M., Type 1 and type IV hypersensitivity to nickel, Australas. J. Dermatol, 51, pp. 285-286, (2010); Ishii N., Sugita Y., Nakajima H., Tanaka S., Askenase P.W., Elicitation of nickel sulfate (NiSO4)-specific delayed-type hypersensitivity requires early-occurring and early-acting, NiSO4-specific DTH-initiating cells with an unusual mixed phenotype for an antigen-specific cell, Cell Immunol, 161, pp. 244-255, (1995)^S. Miglietta; Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, 00161, Italy; email: selenia.miglietta@uniroma1.it; R. Borghini; Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, 00161, Italy; email: raffaele.borghini@uniroma1.it^^MDPI^^^^^^20734409^^^34685576.0^English^Cells^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85115852842
Russo F.; Riezzo G.; Linsalata M.; Orlando A.; Tutino V.; Prospero L.; D'Attoma B.; Giannelli G.^Russo, Francesco (59133987400); Riezzo, Giuseppe (7004144336); Linsalata, Michele (6603600075); Orlando, Antonella (23767683100); Tutino, Valeria (25646829800); Prospero, Laura (57207799778); D'Attoma, Benedetta (8554891800); Giannelli, Gianluigi (7005015716)^59133987400; 7004144336; 6603600075; 23767683100; 25646829800; 57207799778; 8554891800; 7005015716^Managing Symptom Profile of IBS-D Patients With Tritordeum-Based Foods: Results From a Pilot Study^2022^Frontiers in Nutrition^9.0^^797192^^^^8^10.3389/fnut.2022.797192^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125645014&doi=10.3389%2ffnut.2022.797192&partnerID=40&md5=0ad826c23ec8b6c80ff1eb4bc2b2daab^Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Scientific Direction, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy^Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Tutino V., Laboratory of Nutritional Biochemistry, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; D'Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; Giannelli G., Scientific Direction, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy^In the past few years, increasing attention has been given to the pathologic role of specific foods in IBS, like wheat and other cereals. Recent literature describes IBS patients who may experience gastrointestinal (GI) and extra-GI symptoms precipitated by the ingestion of cereals. Tritordeum is a cereal of Spanish origin derived from the hybridization of durum wheat and wild barley. It is different from classic wheat for its gluten protein composition, with fewer carbohydrates and fructans and a higher content of proteins, dietary fibers, and antioxidants. This pilot study aimed to investigate the effects of a 12-week diet with Tritordeum-based foods in substitution of other cereals on the profile of GI symptoms (evaluated by appropriate questionnaire) and the health of the GI barrier (assessed by sugar absorption test and different markers of integrity and functions) in 16 diarrhea-predominant IBS (IBS-D) patients. The diet with Tritordeum-based foods (bread, bakery products, and pasta) significantly reduced IBS-D patients' symptoms. This amelioration appears to occur through an overall improvement of the GI barrier, as demonstrated by the reduced intestinal permeability and the decreased levels of markers of intestinal mucosal integrity, mucosal inflammation, and fermentative dysbiosis. Copyright © 2022 Russo, Riezzo, Linsalata, Orlando, Tutino, Prospero, D'Attoma and Giannelli.^diet; dysbiosis; gastrointestinal symptoms; inflammation; intestinal permeability; irritable bowel syndrome; Tritordeum^^^^^^Italian Ministry of Health RC 2020^This work was supported by the Italian Ministry of Health RC 2020–2021, Prog. N. 16 (DDG n. 700/2020). Tritordeum bread, bakery products, and pasta were provided by Intini& C. SAS di Intini Bartolomeo, Putignano, Bari, Italy.^Chey W.D., Olden K., Carter E., Boyle J., Drossman D., Chang L., Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U, Am J Gastroenterol, 97, pp. 2803-2811, (2002); Schmulson M.J., Drossman D.A., What is new in Rome IV, J NeurogastroenterolMotil, 23, pp. 151-163, (2017); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Tuck C.J., Reed D.E., Muir J.G., Vanner S.J., Implementation of the low FODMAP diet in functional gastrointestinal symptoms: a real-world experience, NeurogastroenterolMotil, 32, (2020); Linsalata M., Riezzo G., Orlando A., D'attoma B., Prospero L., Tutino V., Et al., The relationship between low serum vitamin D levels and altered intestinal barrier function in patients with IBS diarrhoea undergoing a long-term low-FODMAP diet: novel observations from a clinical trial, Nutrients, 13, (2021); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Et al., Improved symptom profiles and minimal inflammation in IBS-D patients undergoing a long-term low-FODMAP diet: a lipidomic perspective, Nutrients, 12, (2020); RotondiAufiero V., Fasano A., Mazzarella G., Non-celiac gluten sensitivity: how its gut immune activation and potential dietary management differ from celiac disease, Mol Nutr Food Res, 62, (2018); Barmeyer C., Schumann M., Meyer T., Zielinski C., Zuberbier T., Siegmund B., Et al., Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome, Int J Colorectal Dis, 32, pp. 29-39, (2017); Aziz I., Trott N., Briggs R., North J.R., Hadjivassiliou M., Sanders D.S., Efficacy of a gluten- free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype, Clin Gastroenterol Hepatol, 14, pp. 696-703, (2016); Martin A., Alvarez J.B., Martin L.M., Barro F., Ballesteros J., The development of tritordeum: a novel cereal for food processing, J Cereal Sci, 30, pp. 85-95, (1999); Vaquero L., Comino I., Vivas S., Rodriguez-Martin L., Gimenez M.J., Pastor J., Et al., Tritordeum: a novel cereal for food processing with good acceptability and significant reduction in gluten immunogenic peptides in comparison with wheat, J Sci Food Agric, 98, pp. 2201-2209, (2018); Sanchez-Leon S., Haro C., Villatoro M., Vaquero L., Comino I., Gonzalez-Amigo A.B., Et al., Tritordeum breads are well tolerated with preference over gluten-free breads in non-celiac wheat-sensitive patients and its consumption induce changes in gut bacteria, J Sci Food Agric, 101, pp. 3508-3517, (2020); Cardoso-Silva D., Delbue D., Itzlinger A., Moerkens R., Withoff S., Branchi F., Et al., Intestinal barrier function in gluten-related disorders, Nutrients, 11, (2019); Linsalata M., Riezzo G., D'attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study, BMC Gastroenterol, 18, (2018); Linsalata M., Riezzo G., Clemente C., D'attoma B., Russo F., Noninvasive biomarkers of gut barrier function in patients suffering from diarrhea predominant-IBS: an update, Dis Markers, 2020, (2020); Leaky gut: mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Fasano A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer, Physiol Rev, 91, pp. 151-175, (2011); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clin Chim Acta, 352, pp. 15-35, (2005); Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Et al., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease, World J Gastroenterol, 15, pp. 3916-3919, (2009); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke, Am J Emerg Med, 33, pp. 867-871, (2015); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: the no man's land of gluten sensitivity, Am J Gastroenterol, 104, pp. 1587-1594, (2009); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment PharmacolTher, 44, pp. 693-703, (2016); Maagaard L., Ankersen D.V., Vegh Z., Burisch J., Jensen L., Pedersen N., Et al., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet, World J Gastroenterol, 22, pp. 4009-4019, (2016); Linsalata M., D'attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, pp. e61-e64, (2014); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease, Gastroenterology, 110, pp. 1395-1403, (1996); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Et al., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), Eur J Nutr, 58, pp. 2145-2156, (2019); Lombardi F., Fiasca F., Minelli M., Maio D., Mattei A., Vergallo I., Et al., The effects of low-nickel diet combined with oral administration of selected probiotics on patients with systemic nickel allergy syndrome (SNAS) and gut dysbiosis, Nutrients, 12, (2020); Drossman D.A., Chang L., Bellamy N., Gallo-Torres H.E., Lembo A., Mearin F., Et al., Severity in irritable bowel syndrome: a Rome Foundation Working Team report, Am J Gastroenterol, (2011); De Giorgio R., Volta U., Gibson P.R., Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?, Gut, 65, pp. 169-178, (2016); Catassi C., Bai J.C., Bonaz B., Bouma G., Calabro A., Carroccio A., Et al., Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders, Nutrients, 5, pp. 3839-3853, (2013); Dieterich W., Zopf Y., Gluten and FODMAPS-sense of a restriction/when is restriction necessary?, Nutrients, 11, (2019); Nilholm C., Larsson E., Roth B., Gustafsson R., Ohlsson B., Irregular dietary habits with a high intake of cereals and sweets are associated with more severe gastrointestinal symptoms in IBS patients, Nutrients, 11, (2019); Bohn L., Storsrud S., Liljebo T., Collin L., Lindfors P., Tornblom H., Et al., Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, pp. 1399-1407, (2015); Haro C., Villatoro M., Vaquero L., Pastor J., Gimenez M.J., Ozuna C.V., Et al., The dietary intervention of transgenic low-gliadin wheat bread in patients with non-celiac gluten sensitivity (NCGS) showed no differences with gluten free diet (GFD) but provides better gut microbiota profile, Nutrients, 10, (2018); Schwenk A., Eschner W., Kremer G., Ward L.C., Assessment of intracellular water by whole body bioelectrical impedance and total body potassium in HIV-positive patients, Clin Nutr, 19, pp. 109-113, (2000); Stapel S.N., Looijaard W., Dekker I.M., Girbes A.R.J., Weijs P.J.M., Oudemans-van Straaten H.M., Bioelectrical impedance analysis-derived phase angle at admission as a predictor of 90-day mortality in intensive care patients, Eur J Clin Nutr, 72, pp. 1019-1025, (2018); Ghosh S.S., Wang J., Yannie P.J., Ghosh S., Intestinal barrier dysfunction, LPS translocation, and disease development, J Endocr Soc, 4, (2020); Fritscher-Ravens A., Schuppan D., Ellrichmann M., Schoch S., Rocken C., Brasch J., Et al., Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome, Gastroenterology, 147, pp. 1012-1020, (2014); Wu R.L., Vazquez-Roque M.I., Carlson P., Burton D., Grover M., Camilleri M., Et al., Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression, Lab Invest, 97, pp. 14-23, (2017); Usai-Satta P., Bassotti G., Bellini M., Oppia F., Lai M., Cabras F., Irritable bowel syndrome and gluten-related disorders, Nutrients, 12, (2020); Elli L., Tomba C., Branchi F., Roncoroni L., Lombardo V., Bardella M.T., Et al., Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: results from a multicenter randomized double-blind placebo-controlled gluten challenge, Nutrients, 8, (2016)^F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, Italy; email: francesco.russo@irccsdebellis.it^^Frontiers Media S.A.^^^^^^2296861X^^^^English^Front. Nutr.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85125645014
Bonfrate L.; Di Palo D.M.; Celano G.; Albert A.; Vitellio P.; De Angelis M.; Gobbetti M.; Portincasa P.^Bonfrate, Leonilde (34871403600); Di Palo, Domenica M. (57201761977); Celano, Giuseppe (56347019400); Albert, Adelin (7202794939); Vitellio, Paola (57208562405); De Angelis, Maria (7102614438); Gobbetti, Marco (7005775302); Portincasa, Piero (7007157491)^34871403600; 57201761977; 56347019400; 7202794939; 57208562405; 7102614438; 7005775302; 7007157491^Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients^2020^European Journal of Clinical Investigation^50.0^3^e13201^^^^76^10.1111/eci.13201^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079394559&doi=10.1111%2feci.13201&partnerID=40&md5=2b2de29e7945d4007a6ba97f0bddc71c^Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy; Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Department of Biostatistics, University Hospital of Liège, Liège, Belgium; Faculty of Science and Technology, Free University of Bolzano, Bolzano, Italy^Bonfrate L., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy; Di Palo D.M., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy, Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Celano G., Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Albert A., Department of Biostatistics, University Hospital of Liège, Liège, Belgium; Vitellio P., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy, Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; De Angelis M., Department of Soil, Plant and Food Sciences, Università degli Studi di Bari Aldo Moro, Bari, Italy; Gobbetti M., Faculty of Science and Technology, Free University of Bolzano, Bolzano, Italy; Portincasa P., Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy^Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, which still lacks effective therapy. We aimed to investigate the effects of a novel formulation of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 with vitamin B6 (LBB) on symptoms, intestinal permeability, cultivable bacteria and metabolome in IBS subjects. Materials and methods: Twenty-five IBS patients (Rome IV criteria) (M:F = 8:17; age 48 years ± 11 SD) were randomized to treatment (LBB) or placebo (one month each) in a crossover randomized double-blind controlled trial. Symptoms, intestinal habits, disease severity, intestinal permeability and intestinal microbiota were analysed at 0, 30, 45 and 60 days. Results: Percentage decrease from baseline of abdominal pain (−48.8% vs −3.5%), bloating (−36.35% vs +7.35%) and severity of disease (−30.1% vs −0.4%) was significantly (P <.0001) greater with LBB than placebo, respectively. In IBS-D patients, the improvement from baseline of Bristol score was more consistent with LBB (from 6 ± 0.4 to 4.3 ± 1.1, P <.00001) than placebo (from 6.2 ± 0.7 to 5.3 ± 1.1, P =.04). In IBS-C patients, Bristol score tended to improve from baseline after LBB (2.6 ± 1.1 vs 3.2 ± 0.5, P =.06). LBB significantly improved the percentage of sucralose recovery (colonic permeability) (1.86 ± 0.1 vs 1.1 ± 0.2, P =.01). During treatment, presumptive lactic acid bacteria and bifidobacteria, relative abundance of propanoic, butanoic, pentanoic acids and hydrocarbons increased, while phenol decreased. Conclusions: The novel formulation of B. longum BB536 and L. rhamnosus HN001 with B6 vitamin improves symptoms and severity of disease, restores intestinal permeability and gut microbiota in IBS patients. © 2020 Stichting European Society for Clinical Investigation Journal Foundation^abdominal pain; bloating; functional gastrointestinal disorders; randomized placebo-controlled study^Adult; Bifidobacterium longum; Double-Blind Method; Female; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Lactobacillus rhamnosus; Male; Metabolome; Middle Aged; butyric acid; hydrocarbon; phenol; placebo; propionic acid; pyridoxine; sucralose; valeric acid derivative; abdominal pain; adult; Article; Bifidobacteriaceae; Bifidobacterium longum; bloating; clinical article; controlled study; crossover procedure; disease severity; female; human; intestine flora; intestine mucosa permeability; irritable colon; lactic acid bacterium; Lactobacillus rhamnosus; male; metabolome; middle aged; nonhuman; population abundance; priority journal; randomized controlled trial; double blind procedure; irritable colon; microbiology^^butyric acid, 107-92-6, 156-54-7, 461-55-2; phenol, 108-95-2, 3229-70-7; propionic acid, 72-03-7, 79-09-4; pyridoxine, 12001-77-3, 58-56-0, 65-23-6, 8059-24-3; sucralose, 56038-13-2^^^Alfasigma S.p.A.^Alfasigma S.p.A. (Milano, Italy) provided the packets containing Zircombi® (LBB) and placebo.^Lovell R.M., Ford A.C., Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis, Clin Gastroenterol Hepatol, 10, 7, pp. 712-721, (2012); Lacy B.E., Mearin F., Chang L., Et al., Bowel Disorders, Gastroenterology, 150, 6, pp. 1393-1407, (2016); Bonfrate L., Tack J., Grattagliano I., Cuomo R., Portincasa P., Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options, Scand J Gastroenterol, 48, 9, pp. 995-1009, (2013); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, 17, pp. 1626-1635, (2012); Hill C., Guarner F., Reid G., Et al., Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, 11, 8, (2014); Markowiak P., Slizewska K., Effects of probiotics, prebiotics, and synbiotics on human health, Nutrients, 9, 9, (2017); Milani C., Lugli G.A., Duranti S., Et al., Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut, Sci Rep, 5, (2015); Akatsu H., Iwabuchi N., Xiao J.Z., Et al., Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding, JPEN J Parenter Enteral Nutr, 37, 5, pp. 631-640, (2013); Falony G., Vlachou A., Verbrugghe K., De Vuyst L., Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose, Appl Environ Microbiol, 72, 12, pp. 7835-7841, (2006); Khailova L., Petrie B., Baird C.H., Dominguez Rieg J.A., Wischmeyer P.E., Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis, PLoS ONE, 9, 5, (2014); Toscano M., De Grandi R., Stronati L., De Vecchi E., Drago L., Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study, World J Gastroenterol, 23, 15, (2017); Parra M., Stahl S., Hellmann H., Vitamin B(6) and its role in cell metabolism and physiology, Cells, 7, 7, (2018); Qian B., Shen S., Zhang J., Jing P., Effects of vitamin B6 deficiency on the composition and functional potential of T cell populations, J Immunol Res, 2017, (2017); Bonfrate L., Krawczyk M., Lembo A., Grattagliano I., Lammert F., Portincasa P., Effects of dietary education, followed by a tailored fructose-restricted diet in adults with fructose malabsorption, Eur J Gastroenterol Hepatol, 27, 7, pp. 785-796, (2015); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); O'Donnell L.J., Virjee J., Heaton K.W., Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate, BMJ, 300, 6722, pp. 439-440, (1990); Sofi F., Macchi C., Abbate R., Gensini G.F., Casini A., Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score, Public Health Nutr, 17, 12, pp. 2769-2782, (2014); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); De Angelis M., Piccolo M., Vannini L., Et al., Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified, PLoS ONE, 8, 10, (2013); De Angelis M., Montemurno E., Vannini L., Et al., Effect of whole-grain barley on the human fecal microbiota and metabolome, Appl Environ Microbiol, 81, 22, pp. 7945-7956, (2015); Zak J., Willig M., Moorhead D., Wildman H., Functional diversity of microbial communities: A quantitative approach, Soil Biol Biochem, 26, 9, pp. 1101-1108, (1994); Hintze J., NCSS 10 Statistical Software, (2015); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 28, 8, pp. 994-1002, (2008); Bogovic Matijasic B., Obermajer T., Lipoglavsek L., Et al., Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial, J Dairy Sci, 99, 7, pp. 5008-5021, (2016); O'Sullivan M.A., O'Morain C.A., Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study, Dig Liver Dis, 32, 4, pp. 294-301, (2000); Whorwell P.J., Altringer L., Morel J., Et al., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol, 101, 7, pp. 1581-1590, (2006); Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S., The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review, Am J Gastroenterol, 104, 4, pp. 1033-1049, (2009); Giannetti E., Maglione M., Alessandrella A., Et al., A mixture of 3 bifidobacteria decreases abdominal pain and improves the quality of life in children with irritable bowel syndrome, J Clin Gastroenterol, 51, 1, pp. e5-e10, (2017); Irvine E.J., Tack J., Crowell M.D., Et al., Design of treatment trials for functional gastrointestinal disorders, Gastroenterology, 150, 6, pp. 1469-1480, (2016); Ringel Y., Carroll I.M., Alterations in the intestinal microbiota and functional bowel symptoms, Gastrointest Endosc Clin N Am, 19, 1, pp. 141-150, (2009); Piche T., Tight junctions and IBS–the link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterol Motil, 26, 3, pp. 296-302, (2014); Nebot-Vivinus M., Harkat C., Bzioueche H., Et al., Multispecies probiotic protects gut barrier function in experimental models, World J Gastroenterol, 20, 22, pp. 6832-6843, (2014); Agostini S., Goubern M., Tondereau V., Et al., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol Motil, 24, 4, (2012); Rosenberg J., Ischebeck T., Commichau F.M., Vitamin B6 metabolism in microbes and approaches for fermentative production, Biotechnol Adv, 35, 1, pp. 31-40, (2017); Pinto-Sanchez M.I., Hall G.B., Ghajar K., Et al., Probiotic bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome, Gastroenterology, 153, 2, pp. 448-459, (2017); Ahmed I., Greenwood R., Costello Bde L., Ratcliffe N.M., Probert C.S., An investigation of fecal volatile organic metabolites in irritable bowel syndrome, PLoS ONE, 8, 3, (2013); Portincasa P., Bonfrate L., de Bari O., Lembo A., Ballou S., Irritable bowel syndrome and diet, Gastroenterol Rep (Oxf), 5, 1, pp. 11-19, (2017); Duncan S.H., Louis P., Flint H.J., Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product, Appl Environ Microbiol, 70, 10, pp. 5810-5817, (2004); De Filippis F., Pellegrini N., Vannini L., Et al., High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome, Gut, 65, 11, pp. 1812-1821, (2016); Ahmed I., Greenwood R., Costello B., Ratcliffe N., Probert C.S., Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease, Aliment Pharmacol Ther, 43, 5, pp. 596-611, (2016)^P. Portincasa; Clinica Medica “A. Murri”, Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, Bari, Italy; email: piero.portincasa@uniba.it^^Blackwell Publishing Ltd^^^^^^00142972^^EJCIB^31960952.0^English^Eur. J. Clin. Invest.^Article^Final^^Scopus^2-s2.0-85079394559
Ma J.; Li J.; Qian M.; He N.; Cao Y.; Liu Y.; Wu K.; He S.^Ma, Jing (57738647200); Li, Jianhui (57606771600); Qian, Meirui (57201379135); He, Nan (57214454884); Cao, Ying (57751519100); Liu, Yaping (55985396400); Wu, Kaichun (8947728400); He, Shuixiang (7402691385)^57738647200; 57606771600; 57201379135; 57214454884; 57751519100; 55985396400; 8947728400; 7402691385^The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity^2019^FASEB Journal^33.0^12^^13560^13571^11.0^13^10.1096/fj.201901489R^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076123084&doi=10.1096%2ffj.201901489R&partnerID=40&md5=79a677dc4e779229391c697e7e816a8f^Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; School of Life Science, Northwest University, Xi'an, China^Ma J., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; Li J., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Department of Infectious Diseases, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China; Qian M., State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; He N., State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; Cao Y., School of Life Science, Northwest University, Xi'an, China; Liu Y., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Wu K., State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; He S., Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China^So far, a comprehensive animal model that can mimic both the central and peripheral pathophysiological changes of irritable bowel syndrome (IBS) is lacking. Here, we developed a novel IBS rat model combining trinitro-benzene-sulfonic acid (TNBS) and chronic unpredictable mild stress (CUMS) (designated as TC-IBS) and compared it with the TNBS-induced and CUMS-induced models. TC-IBS showed a pronounced depression phenotype with increased corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 expression at the frontal cortex and increased serum ACTH concentration. Visceral hypersensitivity (VH), as evidenced by colorectal distention (CRD) test, was highest in TC-IBS, accompanied by increased serum 5-hydroxytryptamine (5-HT) level and colonic 5-HT receptor 3A (5-HT3AR)/5-HT receptor 2B expression, impaired tight junction protein expression including occludin, zonula occludens-1, and phosphorylated myosin light chain. Palonosetron, a second generation of 5-HT3AR antagonist, alleviated VH significantly in TC-IBS. 16S rRNA sequencing showed that TNBS plus CUMS induced a significant disturbance of the gut microbiota. Cytokine profile analysis of TC-IBS model indicated an innate immune activation both in serum and colonic mucosa. Further, fecal microbiota transplantation improved VH and some pathophysiological changes in TC-IBS. In summary, we established a postinflammatory IBS model covering multifactorial pathophysiological changes, which may help to develop therapies that target specific IBS subtype.—Ma, J., Li, J., Qian, M., He, N., Cao, Y., Liu, Y., Wu, K., He, S. The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity. FASEB J. 33, 13560-13571 (2019). www.fasebj.org. © FASEB.^CUMS; fecal microbiota transplantation; intestinal permeability^Animals; Behavior, Animal; Depression; Disease Models, Animal; Gastrointestinal Microbiome; Hyperalgesia; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Stress, Physiological; Trinitrobenzenesulfonic Acid; Visceral Pain; corticotropin releasing factor receptor; corticotropin releasing factor receptor 1; corticotropin releasing factor receptor 2; trinitrobenzenesulfonic acid; animal; animal behavior; depression; disease model; genetics; hyperalgesia; intestine flora; intestine mucosa; irritable colon; male; metabolism; pathology; pathophysiology; physiological stress; rat; Sprague Dawley rat; visceral pain^^trinitrobenzenesulfonic acid, 16655-63-3, 2508-19-2; CRF receptor type 1, ; CRF receptor type 2, ; Receptors, Corticotropin-Releasing Hormone, ; Trinitrobenzenesulfonic Acid, ^^^State Key Laboratory of Cancer Biology; National Institute of Agrobiological Sciences, NIAS^Funding text 1: The authors thank Prof. Huang Niu and Dr. Zhou Yu (both from National Institute of Biological Sciences, Beijing, China) for developing the animal model. This study was funded by State Key Laboratory of Cancer Biology. The authors declare no conflicts of interest. ; Funding text 2: The authors thank Prof. Huang Niu and Dr. Zhou Yu (both from National Institute of Biological Sciences, Beijing, China) for developing the animal model. This study was funded by State Key Laboratory of Cancer Biology. The authors declare no conflicts of interest.^Spiller R., Clinical update: irritable bowel syndrome, Lancet, 369, pp. 1586-1588, (2007); Mayer E.A., Savidge T., Shulman R.J., Brain-gut microbiome interactions and functional bowel disorders, Gastroenterology, 146, pp. 1500-1512, (2014); Chang L., The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome, Gastroenterology, 140, pp. 761-765, (2011); Jones M.P., Tack J., Van Oudenhove L., Walker M.M., Holtmann G., Koloski N.A., Talley N.J., Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population, Clin. Gastroenterol. Hepatol., 15, pp. 1014-1020, (2017); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); Bhattarai Y., Muniz Pedrogo D.A., Kashyap P.C., Irritable bowel syndrome: a gut microbiota-related disorder?, Am. J. Physiol. Gastrointest. Liver Physiol., 312, pp. G52-G62, (2017); Saito Y.A., The role of genetics in IBS, Gastroenterol. Clin. North Am., 40, pp. 45-67, (2011); Holtmann G.J., Ford A.C., Talley N.J., Pathophysiology of irritable bowel syndrome, Lancet Gastroenterol. Hepatol., 1, pp. 133-146, (2016); Qin H.Y., Xiao H.T., Wu J.C., Berman B.M., Sung J.J., Bian Z.X., Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, World J. Gastroenterol., 18, pp. 2481-2492, (2012); Wu J., Cheng Y., Zhang R., Liu D., Luo Y.M., Chen K.L., Ren S., Zhang J., P2Y1R is involved in visceral hypersensitivity in rats with experimental irritable bowel syndrome, World J. Gastroenterol., 23, pp. 6339-6349, (2017); Williams C.L., Villar R.G., Peterson J.M., Burks T.F., Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome, Gastroenterology, 94, pp. 611-621, (1988); Szyf M., Weaver I., Meaney M., Maternal care, the epigenome and phenotypic differences in behavior, Reprod. Toxicol., 24, pp. 9-19, (2007); Mayer E.A., Collins S.M., Evolving pathophysiologic models of functional gastrointestinal disorders, Gastroenterology, 122, pp. 2032-2048, (2002); O'Mahony S.M., Tramullas M., Fitzgerald P., Cryan J.F., Rodent models of colorectal distension, Curr. Protoc. Neurosci., 9, (2012); Simpson J., Sundler F., Humes D.J., Jenkins D., Wakelin D., Scholefield J.H., Spiller R.C., Prolonged elevation of galanin and tachykinin expression in mucosal and myenteric enteric nerves in trinitrobenzene sulphonic acid colitis, Neurogastroenterol. Motil., 20, pp. 392-406, (2008); Sanovic S., Lamb D.P., Blennerhassett M.G., Damage to the enteric nervous system in experimental colitis, Am. J. Pathol., 155, pp. 1051-1057, (1999); Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci., 264, pp. 651-660, (2014); Traini C., Evangelista S., Girod V., Faussone-Pellegrini M.S., Vannucchi M.G., Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress, J. Cell. Mol. Med., 21, pp. 735-745, (2017); Overman E.L., Rivier J.E., Moeser A.J., CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-a, PLoS One, 7, (2012); Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F., Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development, Neuron, 20, pp. 1093-1102, (1998); Bale T.L., Picetti R., Contarino A., Koob G.F., Vale W.W., Lee K.F., Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior, J. Neurosci., 22, pp. 193-199, (2002); Simren M., Tornblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts, Gut, 67, pp. 255-262, (2018); Ritchie J., Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome, Gut, 14, pp. 125-132, (1973); Gershon M.D., Tack J., The serotonin signaling system: from basic understanding to drug development for functional GI disorders, Gastroenterology, 132, pp. 397-414, (2007); Shao Y.Y., Huang J., Ma Y.R., Han M., Ma K., Qin H.Y., Rao Z., Wu X.A., Serum serotonin reduced the expression of hepatic transporter Mrp2 and P-gp via regulating nuclear receptor CAR in PI-IBS rats, Can. J. Physiol. Pharmacol., 93, pp. 633-639, (2015); Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am. J. Gastroenterol., 104, pp. 1831-1843, (2009); Lin S.Y., Chang W.J., Lin C.S., Huang C.Y., Wang H.F., Sun W.H., Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia, J. Neurosci., 31, pp. 1410-1418, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 303, pp. G775-G785, (2012); Turner J.R., Rill B.K., Carlson S.L., Carnes D., Kerner R., Mrsny R.J., Madara J.L., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am. J. Physiol., 273, pp. C1378-C1385, (1997); Walsh S.V., Hopkins A.M., Chen J., Narumiya S., Parkos C.A., Nusrat A., Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia, Gastroenterology, 121, pp. 566-579, (2001); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., de Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am. J. Gastroenterol., 106, pp. 2165-2173, (2011); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Liebregts T., Adam B., Bredack C., Roith A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis, Neurogastroenterol. Motil., 26, pp. 1036-1048, (2014); Barbara G., Feinle-Bisset C., Ghoshal U.C., Quigley E.M., Santos J., Vanner S., Vergnolle N., Zoetendal E.G., The intestinal microenvironment and functional gastrointestinal disorders. [E-pub ahead of print], Gastroenterology, (2016); Bennet S.M., Ohman L., Simren M., Gut microbiota as potential orchestrators of irritable bowel syndrome, Gut Liver, 9, pp. 318-331, (2015); Kelly C.R., Kahn S., Kashyap P., Laine L., Rubin D., Atreja A., Moore T., Wu G., Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook, Gastroenterology, 149, pp. 223-237, (2015); Halkjaer S.I., Boolsen A.W., Gunther S., Christensen A.H., Petersen A.M., Can fecal microbiota transplantation cure irritable bowel syndrome?, World J. Gastroenterol., 23, pp. 4112-4120, (2017); Halkjaer S.I., Christensen A.H., Lo B.Z.S., Browne P.D., Gunther S., Hansen L.H., Petersen A.M., Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study, Gut, 67, pp. 2107-2115, (2018); Johnsen P.H., Hilpusch F., Cavanagh J.P., Leikanger I.S., Kolstad C., Valle P.C., Goll R., Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial, Lancet Gastroenterol. Hepatol., 3, pp. 17-24, (2018)^S. He; Department of Digestive Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; email: dyyyjxk@mail.xjtu.edu.cn; K. Wu; State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, Xi'an, China; email: kaicwu@fmmu.edu.cn^^John Wiley and Sons Inc^^^^^^08926638^^FAJOE^31570003.0^English^FASEB J.^Article^Final^^Scopus^2-s2.0-85076123084
Bahlouli W.; Breton J.; Lelouard M.; L'Huillier C.; Tirelle P.; Salameh E.; Amamou A.; Atmani K.; Goichon A.; Bôle-Feysot C.; Ducrotté P.; Ribet D.; Déchelotte P.; Coëffier M.^Bahlouli, Wafa (57191848794); Breton, Jonathan (13611261000); Lelouard, Mauranne (57216769729); L'Huillier, Clément (56177469400); Tirelle, Pauline (57216763674); Salameh, Emmeline (57202534256); Amamou, Asma (57209071590); Atmani, Karim (57950265700); Goichon, Alexis (46861122700); Bôle-Feysot, Christine (55881037400); Ducrotté, Philippe (7006732860); Ribet, David (6506850472); Déchelotte, Pierre (57201760610); Coëffier, Moïse (6603081357)^57191848794; 13611261000; 57216769729; 56177469400; 57216763674; 57202534256; 57209071590; 57950265700; 46861122700; 55881037400; 7006732860; 6506850472; 57201760610; 6603081357^Stress-induced intestinal barrier dysfunction is exacerbated during diet-induced obesity^2020^Journal of Nutritional Biochemistry^81.0^^108382^^^^10^10.1016/j.jnutbio.2020.108382^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084561213&doi=10.1016%2fj.jnutbio.2020.108382&partnerID=40&md5=501abba883a2fd234c63de5f501f8332^Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France; Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Department of Gastroenterology, Rouen University Hospital, Rouen, 76183, France; Department of Nutrition, Rouen University Hospital, Rouen, 76183, France^Bahlouli W., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Breton J., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Lelouard M., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; L'Huillier C., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Tirelle P., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Salameh E., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Amamou A., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Atmani K., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Goichon A., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Bôle-Feysot C., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Ducrotté P., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France, Department of Gastroenterology, Rouen University Hospital, Rouen, 76183, France; Ribet D., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France; Déchelotte P., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France, Department of Nutrition, Rouen University Hospital, Rouen, 76183, France; Coëffier M., Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France, Institute of Research and Innovation in Biomedicine (IRIB), UNIROUEN, Rouen, 76183, France, Department of Nutrition, Rouen University Hospital, Rouen, 76183, France^Obesity and irritable bowel syndrome (IBS) are two major public health issues. Interestingly previous data report a marked increase of IBS prevalence in morbid obese subjects compared with non-obese subjects but underlying mechanisms remain unknown. Obesity and IBS share common intestinal pathophysiological mechanisms such as gut dysbiosis, intestinal hyperpermeability and low-grade inflammatory response. We thus aimed to evaluate the link between obesity and IBS using different animal models. Male C57Bl/6 mice received high fat diet (HFD) for 12 weeks and were then submitted to water avoidance stress (WAS). In response to WAS, HFD mice exhibited higher intestinal permeability and plasma corticosterone concentration than non-obese mice. We were not able to reproduce a similar response both in ob/ob mice and in leptin-treated non-obese mice. In addition, metformin, a hypoglycemic agent, limited fasting glycaemia both in unstressed and WAS diet-induced obese mice but only partially restored colonic permeability in unstressed HFD mice. Metformin failed to improve intestinal permeability in WAS HFD mice. Finally, cecal microbiota transplantation from HFD mice in antibiotics-treated recipient mice did not reproduce the effects observed in stressed HFD mice. In conclusion, stress induced a more marked intestinal barrier dysfunction in diet-induced obese mice compared with non-obese mice that seems to be independent of leptin, glycaemia and gut microbiota. These data should be further confirmed and the role of the dietary composition should be studied. © 2020 Elsevier Inc.^Gut barrier; Gut microbiota; Irritable bowel syndrome; Leptin; Metformin; Morbid obesity^Animals; Cecum; Colon; Corticosterone; Diet, High-Fat; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Intestinal Mucosa; Irritable Bowel Syndrome; Leptin; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Permeability; Prevalence; Stress, Physiological; amphotericin B; ampicillin; claudin 1; corticosterone; genomic DNA; glucose; interleukin 1beta; leptin; messenger RNA; metformin; metronidazole; neomycin; occludin; vancomycin; antidiabetic agent; corticosterone; leptin; metformin; animal experiment; animal model; Article; cecum content; controlled study; corticosterone blood level; diet-induced obesity; disease exacerbation; dysbiosis; enteropathy; fasting; fecal microbiota transplantation; glucose blood level; intestine mucosa permeability; irritable colon; lipid diet; male; microbial community; mouse; nonhuman; obesity; stress; Western blotting; adverse event; animal; blood; C57BL mouse; cecum; colon; human; intestine flora; intestine mucosa; irritable colon; metabolism; microbiology; mouse mutant; obesity; permeability; physiological stress; prevalence^^amphotericin B, 1397-89-3, 30652-87-0; ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; claudin 1, 329338-06-9; corticosterone, 50-22-6; glucose, 50-99-7, 84778-64-3; metformin, 1115-70-4, 657-24-9; metronidazole, 39322-38-8, 443-48-1; neomycin, 11004-65-2, 1404-04-2, 1405-10-3, 8026-22-0; occludin, 176304-61-3; vancomycin, 1404-90-6, 1404-93-9; Corticosterone, ; Hypoglycemic Agents, ; Leptin, ; Metformin, ^^^European Union and Normandie Regional Council; Microbiome foundation; Roquette foundation for health; European Regional Development Fund, FEDER^Funding text 1: This work was co-supported by the Microbiome foundation, the Roquette foundation for health and by European Union and Normandie Regional Council (to W.B. and for equipment). Europe gets involved in Normandie with European Regional Development Fund (ERDF). These funders did not participate in the design, implementation, analysis, and interpretation of the data. ; Funding text 2: This work was co-supported by the Microbiome foundation, the Roquette foundation for health and by European Union and Normandie Regional Council (to W.B. and for equipment). Europe gets involved in Normandie with European Regional Development Fund (ERDF). These funders did not participate in the design, implementation, analysis, and interpretation of the data. WB, JB, ML, CL, PT, ES, AA, KA, AG, CBF and DR performed experiments and analyses. WB, PDu and MC designed experiments. WB, DR, PDe and MC interpreted the data. WB and MC wrote the main manuscript text and prepared figures. All authors reviewed the manuscript.^Gallus S., Lugo A., Murisic B., Bosetti C., Boffetta P., La Vecchia C., Overweight and obesity in 16 European countries, Eur J Nutr, 54, 5, pp. 679-689, (2015); Marques A., Peralta M., Naia A., Loureiro N., de Matos M.G., Prevalence of adult overweight and obesity in 20 European countries, 2014, Eur J Pub Health, 28, 2, pp. 295-300, (2018); Turnbaugh P.J., Backhed F., Fulton L., Gordon J.I., Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome, Cell Host Microbe, 3, 4, pp. 213-223, (2008); Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., Et al., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice, Diabetes, 57, 6, pp. 1470-1481, (2008); Teixeira T.F., Souza N.C., Chiarello P.G., Franceschini S.C., Bressan J., Ferreira C.L., Et al., Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors, Clin Nutr, 31, 5, pp. 735-740, (2012); Le Pluart D., Sabate J.M., Bouchoucha M., Hercberg S., Benamouzig R., Julia C., Functional gastrointestinal disorders in 35,447 adults and their association with body mass index, Aliment Pharmacol Ther, 41, 8, pp. 758-767, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable Bowel Syndrome, N Engl J Med, 376, 26, pp. 2566-2578, (2017); Bashashati M., Moossavi S., Cremon C., Barbaro M.R., Moraveji S., Talmon G., Et al., Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol Motil, 30, (2018); Menees S., Chey W., The gut microbiome and irritable bowel syndrome, F1000Res, (2018); Piche T., Barbara G., Aubert P., Bruley S., Varannes D., Dainese R., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Pickett-Blakely O., Obesity and irritable bowel syndrome: a comprehensive review, Gastroenterol Hepatol (N Y), 10, 7, pp. 411-416, (2014); Schneck A.S., Anty R., Tran A., Hastier A., Amor I.B., Gugenheim J., Et al., Increased Prevalence of Irritable Bowel Syndrome in a Cohort of French Morbidly Obese Patients Candidate for Bariatric Surgery, Obes Surg, 26, 7, pp. 1525-1530, (2016); Carter D., Beer-Gabel M., Tzur D., Levy G., Derazne E., Novis B., Et al., Predictive factors for the diagnosis of irritable bowel syndrome in a large cohort of 440,822 young adults, J Clin Gastroenterol, 49, 4, pp. 300-305, (2015); de La Serre C.B., Ellis C.L., Lee J., Hartman A.L., Rutledge J.C., Raybould H.E., Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation, Am J Physiol Gastrointest Liver Physiol, 299, 2, pp. G440-G448, (2010); Ghouzali I., Lemaitre C., Bahlouli W., Azhar S., Bole-Feysot C., Meleine M., Et al., Targeting immunoproteasome and glutamine supplementation prevent intestinal hyperpermeability, Biochim Biophys Acta, 1861, 1, pp. 3278-3288, (2017); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Pugliese G., Muscogiuri G., Barrea L., Laudisio D., Savastano S., Colao A., Irritable bowel syndrome: a new therapeutic target when treating obesity? Hormones (Athens), (2019); Le Drean G., Segain J.P., Connecting metabolism to intestinal barrier function: The role of leptin, Tissue Barriers, 2, 4, (2014); Thaiss C.A., Levy M., Grosheva I., Zheng D., Soffer E., Blacher E., Et al., Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection, Science, 359, 6382, pp. 1376-1383, (2018); Kilkenny C., Parsons N., Kadyszewski E., Festing M.F., Cuthill I.C., Fry D., Et al., Survey of the quality of experimental design, statistical analysis and reporting of research using animals, PLoS One, 4, 11, (2009); Goichon A., Bahlouli W., Ghouzali I., Chan P., Vaudry D., Dechelotte P., Et al., Colonic Proteome Signature in Immunoproteasome-Deficient Stressed Mice and Its Relevance for Irritable Bowel Syndrome, J Proteome Res, 18, 1, pp. 478-492, (2019); Maurya R., Bhattacharya P., Ismail N., Dagur P.K., Joshi A.B., Razdan K., Et al., Differential Role of Leptin as an Immunomodulator in Controlling Visceral Leishmaniasis in Normal and Leptin-Deficient Mice, Am J Trop Med Hyg, 95, 1, pp. 109-119, (2016); Zhou Z.Y., Ren L.W., Zhan P., Yang H.Y., Chai D.D., Yu Z.W., Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling, Acta Pharmacol Sin, 37, 8, pp. 1063-1075, (2016); Herrmann J.R., Turner J.R., Beyond Ussing's chambers: contemporary thoughts on integration of transepithelial transport, Am J Phys Cell Physiol, 310, 6, pp. C423-C431, (2016); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Et al., Increased Proteasome-Mediated Degradation of Occludin in Irritable Bowel Syndrome, Am J Gastroenterol, 105, 5, pp. 1181-1188, (2010); Costea P.I., Zeller G., Sunagawa S., Pelletier E., Alberti A., Levenez F., Et al., Towards standards for human fecal sample processing in metagenomic studies, Nat Biotechnol, 35, 11, pp. 1069-1076, (2017); Queipo-Ortuno M.I., Seoane L.M., Murri M., Pardo M., Gomez-Zumaquero J.M., Cardona F., Et al., Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels, PLoS One, 8, 5, (2013); Fierer N., Jackson J.A., Vilgalys R., Jackson R.B., Assessment of soil microbial community structure by use of taxon-specific quantitative PCR assays, Appl Environ Microbiol, 71, 7, pp. 4117-4120, (2005); Jesus P., Ouelaa W., Francois M., Riachy L., Guerin C., Aziz M., Et al., Alteration of intestinal barrier function during activity-based anorexia in mice, Clin Nutr, 33, pp. 1046-1053, (2014); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Et al., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, 6, pp. 996-1002, (2019); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, 5, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Annahazi A., Ferrier L., Bezirard V., Leveque M., Eutamene H., Ait-Belgnaoui A., Et al., Luminal Cysteine-Proteases Degrade Colonic Tight Junction Structure and Are Responsible for Abdominal Pain in Constipation-Predominant IBS, Am J Gastroenterol, 108, 8, pp. 1322-1331, (2013); Damms-Machado A., Louis S., Schnitzer A., Volynets V., Rings A., Basrai M., Et al., Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction, Am J Clin Nutr, 105, 1, pp. 127-135, (2017); Stenman L.K., Holma R., Gylling H., Korpela R., Genetically obese mice do not show increased gut permeability or faecal bile acid hydrophobicity, Br J Nutr, 110, 6, pp. 1157-1164, (2013); Nagpal R., Newman T.M., Wang S., Jain S., Lovato J.F., Yadav H., Obesity-Linked Gut Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal Cellular Homeostasis Independent of Diet, J Diabetes Res, 2018, (2018); Johnson A.M., Costanzo A., Gareau M.G., Armando A.M., Quehenberger O., Jameson J.M., Et al., High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability, PLoS One, 10, 4, (2015); Kim C.Y., Kim K.H., Curcumin prevents leptin-induced tight junction dysfunction in intestinal Caco-2 BBe cells, J Nutr Biochem, 25, 1, pp. 26-35, (2014); Le Drean G., Haure-Mirande V., Ferrier L., Bonnet C., Hulin P., de Coppet P., Et al., Visceral adipose tissue and leptin increase colonic epithelial tight junction permeability via a RhoA-ROCK-dependent pathway, FASEB J, 28, 3, pp. 1059-1070, (2014); Ye C., Wang R., Wang M., Huang Z., Tang C., Leptin alleviates intestinal mucosal barrier injury and inflammation in obese mice with acute pancreatitis, Int J Obes, 42, 8, pp. 1471-1479, (2018); Rena G., Hardie D.G., Pearson E.R., The mechanisms of action of metformin, Diabetologia, 60, 9, pp. 1577-1585, (2017); Zhou H.Y., Zhu H., Yao X.M., Qian J.P., Yang J., Pan X.D., Et al., Metformin regulates tight junction of intestinal epithelial cells via MLCK-MLC signaling pathway, Eur Rev Med Pharmacol Sci, 21, 22, pp. 5239-5246, (2017); Chen L., Wang J., You Q., He S., Meng Q., Gao J., Et al., Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin, Front Pharmacol, 9, (2018); Deng J., Zeng L., Lai X., Li J., Liu L., Lin Q., Et al., Metformin protects against intestinal barrier dysfunction via AMPKalpha1-dependent inhibition of JNK signalling activation, J Cell Mol Med, 22, 1, pp. 546-557, (2018); Nozu T., Miyagishi S., Kumei S., Nozu R., Takakusaki K., Okumura T., Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats, J Gastroenterol Hepatol, 34, 1, pp. 186-193, (2019); Li Y., Yang T., Yao Q., Li S., Fang E., Li Y., Et al., Metformin prevents colonic barrier dysfunction by inhibiting mast cell activation in maternal separation-induced IBS-like rats, Neurogastroenterol Motil, 31, 5, (2019); Cotillard A., Kennedy S.P., Kong L.C., Prifti E., Pons N., Le Chatelier E., Et al., Dietary intervention impact on gut microbial gene richness, Nature, 500, 7464, pp. 585-588, (2013); Aasbrenn M., Valeur J., Farup P.G., Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity, Scand J Clin Lab Invest, 78, 1-2, pp. 109-113, (2018); Francois M., Barde S., Legrand R., Lucas N., Azhar S., El Dhaybi M., Et al., High-fat diet increases ghrelin-expressing cells in stomach, contributing to obesity, Nutrition, 32, pp. 709-715, (2016); Gomez-Zorita S., Aguirre L., Milton-Laskibar I., Fernandez-Quintela A., Trepiana J., Kajarabille N., Et al., Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models, Nutrients, (2019); Zhao Y.J., Li J.H., Hu B., Wang Y., Chang X.F., Traub R.J., Et al., Extracellular signal-regulated kinase activation in the spinal cord contributes to visceral hypersensitivity induced by craniofacial injury followed by stress, Neurogastroenterol Motil, (2018); Agostini S., Goubern M., Tondereau V., Salvador-Cartier C., Bezirard V., Leveque M., Et al., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol Motil, 24, 4, pp. 376-e172, (2012); Miquel S., Martin R., Lashermes A., Gillet M., Meleine M., Gelot A., Et al., Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models, Sci Rep, 6, (2016); Yu Y., Wu S., Li J., Wang R., Xie X., Yu X., Et al., The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling, Metab Brain Dis, 30, 1, pp. 47-55, (2015)^M. Coëffier; Normandie University, UNIROUEN, INSERM UMR 1073 “Nutrition, inflammation and gut-brain axis”, Rouen, 76183, France; email: moise.coeffier@univ-rouen.fr^^Elsevier Inc.^^^^^^09552863^^JNBIE^32417626.0^English^J. Nutr. Biochem.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-85084561213
de los Ríos C.C.; Cabezudo M.A.; Vallés A.Z.; Díaz-Rubio E.R.^de los Ríos, Constanza Ciriza (6603114265); Cabezudo, Marta Aparicio (56562850800); Vallés, Ana Zaratain (57219449588); Díaz-Rubio, Enrique Rey (7103353498)^6603114265; 56562850800; 57219449588; 7103353498^Practical approach to irritable bowel syndrome-diarrhea beyond low-FODMAP diet^2022^Revista Espanola de Enfermedades Digestivas^114.0^^^^^^0^10.17235/reed.2022.8749/2022^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133880910&doi=10.17235%2freed.2022.8749%2f2022&partnerID=40&md5=3459863f60334eec7ee574685bf2678d^Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain^de los Ríos C.C., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Cabezudo M.A., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Vallés A.Z., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Díaz-Rubio E.R., Gastroenterology Department, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain^Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered defecation, usually accompanied by abdominal bloating or distension. The integrated model of bidirectional interaction between the central, autonomic, enteric nervous system, the microbiome, and the gut barrier allows a better understanding of the pathophysiology of IBS, as well as consideration of potential therapeutic strategies. IBS with predominant diarrhea (IBS-D) represents a therapeutic challenge. Dietary changes or restrictions are most commonly used by patients in an attempt at symptom control. Therefore, a number of diets, especially low-FODMAP diet, have increasingly gained interest as a therapy for IBS-D or mixed IBS. However, this kind of diet, while effective, is not exempt of problems. It is therefore necessary that other therapeutic options be considered while bearing pathophysiological mechanisms and general symptom management in mind. © 2022 ARAN Ediciones S.A.. All rights reserved.^Irritable bowel syndrome; Low-FODMAP diet; Microbiota; Mucoprotective drugs; Neuromodulators; Peppermint essential oil^cromoglycate disodium; ebastine; essential oil; fructan; histamine; hydrocortisone; ondansetron; peppermint; prebiotic agent; pregabalin; probiotic agent; ramosetron; rifaximin; saponin; abdominal distension; abdominal pain; Article; Bifidobacterium; bloating; cholecystectomy; colonoscopy; columnar epithelium; constipation; cytokine release; defecation; diarrhea; down regulation; extracellular matrix; fecal microbiota transplantation; feces microflora; gastrointestinal motility; gastrointestinal tract; health care utilization; human; immune response; intestine flora; intestine innervation; irritable colon; Lactobacillus; low FODMAP diet; mast cell; Mentha piperita; microbiome; nausea and vomiting; neuromuscular function; Parkinson disease; pathophysiology; quality of life; systematic review; upregulation; vomiting^^cromoglycate disodium, 15826-37-6, 16110-51-3, 93356-79-7, 93356-84-4; ebastine, 90729-43-4; fructan, 9037-90-5; histamine, 51-45-6, 56-92-8, 93443-21-1; hydrocortisone, 50-23-7; ondansetron, 103639-04-9, 116002-70-1, 99614-01-4; pregabalin, 148553-50-8; ramosetron, 132036-88-5, 132907-72-3; rifaximin, 80621-81-4, 88747-56-2; saponin, 8047-15-2^^^^^Ford AC, Lacy BE, Talley NJ., Irritable Bowel Syndrome, N Engl J Med, 376, 26, pp. 2566-2578, (2017); Black CJ, Ford AC., Global burden of irritable bowel syndrome: trends, predictions and risk factors, Nat Rev Gastroenterol Hepatol, 17, 8, pp. 473-486, (2020); Martin CR, Osadchiy V, Kalani A, Et al., The Brain-Gut-Microbiome Axis, Cellular and molecular gastroenterology and hepatology, 6, 2, pp. 133-148, (2018); Ford AC, Sperber AD, Corsetti M, Et al., Irritable bowel syndrome, Lancet, 396, 10263, pp. 1675-1688, (2020); Bohn L, Storsrud S, Tornblom H, Et al., Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life, Am J Gastroenterol, 108, 5, pp. 634-641, (2013); McKenzie YA, Bowyer RK, Leach H, Et al., British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update), J Hum Nutr Diet, 29, 5, pp. 549-575, (2016); Bellini M, Tonarelli S, Nagy AG, Et al., Low FODMAP Diet: Evidence, Doubts, and Hopes, Nutrients, 12, 1, (2020); Portincasa P, Bonfrate L, de Bari O, Et al., Irritable bowel syndrome and diet, Gastroenterol Rep (Oxf), 5, 1, pp. 11-19, (2017); Casellas F, Burgos R, Marcos A, Et al., Consensus document on exclusion diets in irritable bowel syndrome (IBS), Rev Esp Enferm Dig, 110, 12, pp. 806-824, (2018); Biesiekierski JR, Rosella O, Rose R, Et al., Quantification of fructans, galactooligosacharides and other short-chain carbohydrates in processed grains and cereals, J Hum Nutr Diet, 24, 2, pp. 154-176, (2011); Hahn J, Choi J, Chang MJ., Effect of Low FODMAPs Diet on Irritable Bowel Syndromes: A Systematic Review and Meta-Analysis of Clinical Trials, Nutrients, 13, 7, (2021); Vasant DH, Paine PA, Black CJ, Et al., British Society of Gastroenterology guidelines on the management of irritable bowel syndrome, Gut, 70, 7, pp. 1214-1240, (2021); Lacy BE, Pimentel M, Brenner DM, Et al., ACG Clinical Guideline: Management of Irritable Bowel Syndrome, Am J Gastroenterol, 116, 1, pp. 17-44, (2021); Ancona A, Petito C, Iavarone I, Et al., The gut-brain axis in irritable bowel syndrome and inflammatory bowel disease, Dig Liver Dis, 53, 3, pp. 298-305, (2021); Alonso-Cotoner C, Abril-Gil M, Albert-Bayo M, Et al., The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults, Adv Ther, 38, 5, pp. 2054-2076, (2021); Claesson MJ, Jeffery IB, Conde S, Et al., Gut microbiota composition correlates with diet and health in the elderly, Nature, 488, 7410, pp. 178-184, (2012); Mayer EA, Savidge T, Shulman RJ., Brain-gut microbiome interactions and functional bowel disorders, Gastroenterology, 146, 6, pp. 1500-1512, (2014); Gonzalez Olmo BM, Butler MJ, Barrientos RM., Evolution of the Human Diet and Its Impact on Gut Microbiota, Immune Responses, and Brain Health, Nutrients, 13, 1, (2021); O'Keeffe M, Jansen C, Martin L, Et al., Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome, Neurogastroenterol Motil, 30, 1, (2018); Marsh A, Eslick EM, Eslick GD., Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis, Eur J Nutr, 55, 3, pp. 897-906, (2016); Schumann D, Klose P, Lauche R, Et al., Low fermentable, oligo-, di-, monosaccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis, Nutrition, 45, pp. 24-31, (2018); Staudacher HM, Whelan K, Irving PM, Et al., Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome, J Hum Nutr Diet, 24, 5, pp. 487-495, (2011); Hill P, Muir JG, Gibson PR., Controversies and Recent Developments of the Low-FODMAP Diet, Gastroenterol Hepatol (NY), 13, 1, pp. 36-45, (2017); Black CJ, Staudacher HM, Ford AC., Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis, Gut, 71, 6, pp. 1117-1126, (2022); Dionne J, Ford AC, Yuan Y, Et al., A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome, Am J Gastroenterol, 113, 9, pp. 1290-1300, (2018); Skodje GI, Sarna VK, Minelle IH, Et al., Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity, Gastroenterology, 154, 3, pp. 529-539, (2018); Moshiree B, Zhou Q, Price DD, Et al., Central sensitisation in visceral pain disorders, Gut, 55, 7, pp. 905-908, (2006); Lambarth A, Zarate-Lopez N, Fayaz A., Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol Motil, 34, 1, (2022); Saito YA, Almazar AE, Tilkes KE, Et al., Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome, Aliment Pharmacol Ther, 49, 4, pp. 389-397, (2019); Edogawa S, Edwinson AL, Peters SA, Et al., Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS, Gut, 69, 1, pp. 62-73, (2020); Alexea O, Bacarea V, Pique N., The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial, United European Gastroenterol J, 4, 3, pp. 455-465, (2016); Trifan A, Burta O, Tiuca N, Et al., Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial, United European Gastroenterol J, 7, 8, pp. 1093-1101, (2019); Ciriza de Los Rios C, Falcon BS, Arguelles-Arias F, Et al., Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome, Therap Adv Gastroenterol, 14, (2021); Ford AC, Harris LA, Lacy BE, Et al., Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment Pharmacol Ther, 48, 10, pp. 1044-1060, (2018); Xu D, Chen VL, Steiner CA, Et al., Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis, Am J Gastroenterol, 114, 7, pp. 1043-1050, (2019); Ianiro G, Eusebi LH, Black CJ, Et al., Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome, Aliment Pharmacol Ther, 50, 3, pp. 240-248, (2019); Lembo A, Pimentel M, Rao SS, Et al., Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome, Gastroenterology, 151, 6, pp. 1113-1121, (2016); Alammar N, Wang L, Saberi B, Et al., The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data, BMC Complement Altern Med, 19, 1, (2019); Weerts Z, Masclee AAM, Witteman BJM, Et al., Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome, Gastroenterology, 158, 1, pp. 123-136, (2020); Hughes PA, Zola H, Penttila IA, Et al., Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?, Am J Gastroenterol, 108, 7, pp. 1066-1074, (2013); Wouters MM, Vicario M, Santos J., The role of mast cells in functional GI disorders, Gut, 65, 1, pp. 155-168, (2016); Barbara G, Stanghellini V, De Giorgio R, Et al., Functional gastrointestinal disorders and mast cells: implications for therapy, Neurogastroenterol Motil, 18, 1, pp. 6-17, (2006); Ciriza de Los Rios C, Castel de Lucas I, Canga Rodriguez-Valcarcel F, Et al., Irritable bowel syndrome and basal serum tryptase: correlation between subtype, severity, and comorbidities. A pilot study, Rev Esp Enferm Dig, 114, 1, pp. 22-27, (2022); Wouters MM, Balemans D, Van Wanrooy S, Et al., Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome, Gastroenterology, 150, 4, pp. 875-887, (2016); Lobo B, Ramos L, Martinez C, Et al., Downregulation of mucosal mast cell activation and immune response in diarrhoea-irritable bowel syndrome by oral disodium cromoglycate: A pilot study, United European Gastroenterol J, 5, 6, pp. 887-897, (2017); Barshop K, Staller K., Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy, Ther Adv Chronic Dis, 8, 11, pp. 153-160, (2017); Black CJ, Burr NE, Camilleri M, Et al., Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis, Gut, 69, 1, pp. 74-82, (2020); Cash BD, Lacy BE, Schoenfeld PS, Et al., Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea, Am J Gastroenterol, 112, 2, pp. 365-374, (2017); Brenner DM, Sayuk GS, Gutman CR, Et al., Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study, Am J Gastroenterol, 114, 9, pp. 1502-1511, (2019); Zheng Y, Yu T, Tang Y, Et al., Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials, PLoS One, 12, 3, (2017); Ford AC, Brandt LJ, Young C, Et al., Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis, Am J Gastroenterol, 104, 7, pp. 1831-1843, (2009); Lembo T, Wright RA, Bagby B, Et al., Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome, Am J Gastroenterol, 96, 9, pp. 2662-2670, (2001); Chang L, Chey WD, Harris L, Et al., Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data, Am J Gastroenterol, 101, 5, pp. 1069-1079, (2006); Garsed K, Chernova J, Hastings M, Et al., A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut, 63, 10, pp. 1617-1625, (2014); Plasse TF, Barton G, Davidson E, Et al., Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial, Am J Gastroenterol^C.C. de los Ríos; Servicio de Aparato Digestivo, Hospital Clínico San Carlos, Madrid, Calle del Profesor Martín Lagos, s/n, 28040, Spain; email: constanzacarpa@gmail.com^^ARAN Ediciones S.L^^^^^^11300108^^REDIE^35694883.0^English^Rev. Esp. Enferm. Dig.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85133880910
Yu L.-M.; Mao L.-Q.; Wu C.-Y.; Ye W.; Wang X.^Yu, Lei-Min (23037841100); Mao, Li-Qi (57211849788); Wu, Chun-Yan (57226128693); Ye, Wei (57219147042); Wang, Xi (56998855200)^23037841100; 57211849788; 57226128693; 57219147042; 56998855200^Chlorogenic acid improves intestinal barrier function by downregulating CD14 to inhibit the NF-κB signaling pathway^2021^Journal of Functional Foods^85.0^^104640^^^^20^10.1016/j.jff.2021.104640^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110520434&doi=10.1016%2fj.jff.2021.104640&partnerID=40&md5=66fe5354b289fa2054709f44f0f87f7d^Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Department of Gastroenterology, The First People's Hospital of Huzhou, The First Affiliated Hospital of Huzhou Teachers College, Huzhou, Zhejiang Province, China; Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China^Yu L.-M., Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Mao L.-Q., Department of Gastroenterology, The First People's Hospital of Huzhou, The First Affiliated Hospital of Huzhou Teachers College, Huzhou, Zhejiang Province, China; Wu C.-Y., Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Ye W., Department of Gastroenterology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China; Wang X., Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China^Chlorogenic acid (CGA) is a polyphenol compound present in plant foods. CGA is a differentially excreted gut microbial metabolite in fecal samples of irritable bowel syndrome model mice and normal control mice. Here, we aimed to clarify the protective effect of CGA on intestinal barrier function. We used Caco-2 cells to create an intestinal epithelial cell barrier model, and evaluated tight-junctional permeability with fluorescein isothiocyanate–dextran. We treated Caco-2 cells with lipopolysaccharide and CGA, and measured tight-junction protein expression, TLR4/NF-κB pathway activation, and proinflammatory cytokine levels. CGA blocked the NF-κB pathway by downregulating CD14 and p65, and preventing phospho-p65 from entering cell nuclei. CGA showed anti-inflammatory effects by suppressing tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production, and thereby restored intestinal epithelial tight-junction integrity. In conclusion, CGA was highly effective at preserving cell membrane integrity, and inhibited proinflammatory cytokine secretion by downregulating CD14 to block the NF-kB pathway. © 2021^CD14; Chlorogenic acid; Intestinal barrier; NF-κB; Pro-inflammatory cytokines^^^^^^Natural Science Foundation of Zhejiang Province, ZJNSF, (LY21H030002); Medical Scientific Research Foundation of Zhejiang Province, China, (2019RC229, 2019RC250, 2021KY917)^This study was supported by grants from Zhejiang Provincial Natural Science Foundation of China (no. LY21H030002) and the Medical Scientific Research Foundation of Zhejiang Province (nos. 2019RC250, 2021KY917, and 2019RC229).^Abreu M.T., Vora P., Faure E., Thomas L.S., Arnold E.T., Arditi M., Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide, J Immunol, 167, 3, pp. 1609-1616, (2001); Artursson P., Palm K., Luthman K., Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv Drug Deliv Rev, 46, pp. 27-43, (2001); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 303, 7, pp. G775-G785, (2012); Capaldo C.T., Nusrat A., Cytokine regulation of tight junctions, Biochim Biophys Acta, 1788, 4, pp. 864-871, (2009); Chen D., Pan D., Tang S., Tan Z., Zhang Y., Fu Y., Et al., Administration of chlorogenic acid alleviates spinal cord injury via TLR4/NF-κB and p38 signaling pathway anti-inflammatory activity, Mol Med Rep, (2018); Chen J., Yu B., Chen D., Huang Z., Mao X., Zheng P., Et al., Chlorogenic acid improves intestinal barrier functions by suppressing mucosa inflammation and improving antioxidant capacity in weaned pigs, J Nutr Biochem, 59, pp. 84-92, (2018); Chen L., Ilham S.J., Feng B., Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article, Anesth Pain Med, 7, (2017); Collins S.M., Piche T., Rampal P., The putative role of inflammation in the irritable bowel syndrome, Gut, 49, pp. 743-745, (2001); da Silva Correia J., Soldau K., Christen U., Tobias P.S., Ulevitch R.J., Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2, J Biol Chem, 276, 24, pp. 21129-21135, (2001); De Palma G., Lynch M.D.J., Lu J., Dang V.T., Deng Y., Jury J., Et al., Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice, Sci Transl Med, 9, 379, (2017); Fitzgerald K.A., Rowe D.C., Golenbock D.T., Endotoxin recognition and signal transduction by the TLR4/MD2-complex, Microbes Infect, 6, 15, pp. 1361-1367, (2004); Galvez-Llompart M., Recio M.C., Garcia-Domenech R., Topological virtual screening: A way to find new compounds active in ulcerative colitis by inhibiting NF-κB, Mol Divers, 15, 4, pp. 917-926, (2011); Gao K., Mu C.L., Farzi A., Zhu W.Y., Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain, Adv Nutr, 11, pp. 709-723, (2020); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Et al., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J Gastroenterol Hepatol, 32, 1, pp. 53-63, (2017); Guo S., Al-Sadi R., Said H.M., Ma T.Y., Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14, Am J Pathol, 182, pp. 375-387, (2013); Haziot A., Ferrero E., Kontgen F., Hijiya N., Yamamoto S., Silver J., Et al., Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice, Immunity, 4, 4, pp. 407-414, (1996); Li G.Z., Wang Z.H., Cui W., Fu J.L., Wang Y.R., Liu P., Tumor necrosis factor alpha increases intestinal permeability in mice with fulminant hepatic failure, World J Gastroenterol, 18, pp. 5042-5050, (2012); Liang N., Kitts D., Role of Chlorogenic Acids in Controlling Oxidative and Inflammatory Stress Conditions, Nutrients, 8, 1, (2015); Luissint A.-C., Parkos C.A., Nusrat A., Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair, Gastroenterology, 151, 4, pp. 616-632, (2016); Madden J.A., Hunter J.O., A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics, Br J Nutr, 88, pp. S67-S72, (2002); Mankertz J., Tavalali S., Schmitz H., Mankertz A., Riecken E.O., Fromm M., Et al., pp. 2085-2090, (2000); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J Inflamm Res, 11, pp. 345-349, (2018); Nicholson J.K., Holmes E., Wilson I.D., Gut microorganisms, mammalian metabolism and personalized health care, Nat Rev Microbiol, 3, 5, pp. 431-438, (2005); Noreen M., Shah M.A.A., Mall S.M., Choudhary S., Hussain T., Ahmed I., Et al., TLR4 polymorphisms and disease susceptibility, Inflamm Res, 61, 3, pp. 177-188, (2012); Plociennikowska A., Hromada-Judycka A., Borzecka K., Kwiatkowska K., Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling, Cell Mol Life Sci, 72, 3, pp. 557-581, (2015); Ponce de Leon-Rodriguez, Guyot J.P., Laurent-Babot C., Intestinal in vitro cell culture models and their potential to study the effect of food components on intestinal inflammation, Crit Rev Food Sci Nutr, 59, pp. 3648-3666, (2019); Ruan Z., Liu S., Zhou Y., Mi S., Liu G., Wu X., Et al., (2014); Ruan Z., Mi S., Zhou L., Zhou Y., Li J., Liu W., Et al., Chlorogenic acid enhances intestinal barrier by decreasing MLCK expression and promoting dynamic distribution of tight junction proteins in colitic rats, J Funct Foods, 26, pp. 698-708, (2016); Shariati A., Fallah F., Pormohammad A., Taghipour A., Safari H., chirani A.S., Et al., The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome, J Cell Physiol, 234, 6, pp. 8550-8569, (2019); Varadi J., Harazin A., Fenyvesi F., Reti-Nagy K., Gogolak P., Vamosi G., Et al., (2017); Vamadevan A.S., Fukata M., Arnold E.T., Thomas L.S., Hsu D., Abreu M.T., Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: A comprehensive analysis, Innate Immun, 16, 2, pp. 93-103, (2010); Van Spaendonk H., Ceuleers H., Witters L., Patteet E., Joossens J., Augustyns K., Et al., Regulation of intestinal permeability: The role of proteases, World J Gastroenterol, 23, 12, (2017); Volpe D.A., Permeability classification of representative fluoroquinolones by a cell culture method, Aaps j, 6, 2, pp. 1-6, (2004); Wang X., Lu B., Dai C., Fu Y., Hao K., Zhao B., Et al., (2020); Wullaert A., Role of NF-kappaB activation in intestinal immune homeostasis, Int J Med Microbiol, 300, pp. 49-56, (2010); Xavier R.J., Podolsky D.K., Unravelling the pathogenesis of inflammatory bowel disease, Nature, 448, 7152, pp. 427-434, (2007); Yu L.-M., Zhao K.-J., Wang S.-S., Wang X.I., Lu B., Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome, World J Gastroenterol, 24, 8, pp. 894-904, (2018); Zeber-Lubecka N., Kulecka M., Ambrozkiewicz F., Paziewska A., Goryca K., Karczmarski J., Et al., Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome, Gut Microbes, 7, 5, pp. 397-413, (2016); Zhang S., Xu W., Wang H., Cao M., Li M., Zhao J., Et al., Inhibition of CREB-mediated ZO-1 and activation of NF-κB-induced IL-6 by colonic epithelial MCT4 destroys intestinal barrier function, Cell Prolif, 52, 6, (2019); Zhang Z., Wu X., Cao S., Cromie M., Shen Y., Feng Y., Et al., Chlorogenic Acid Ameliorates Experimental Colitis by Promoting Growth of Akkermansia in Mice, Nutrients, 9, 7, (2017); Zhu S., Liu S., Li H., Zhang Z., Zhang Q., Chen L., Et al., (2019)^X. Wang; Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, Rm 20304, 20# Building, Binwen Campus, 548 Binwen Road, Binjiang District, 310053, China; email: wangxi@zcmu.edu.cn^^Elsevier Ltd^^^^^^17564646^^^^English^J. Funct. Foods^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85110520434
Linsalata M.; Riezzo G.; Clemente C.; D'Attoma B.; Russo F.^Linsalata, Michele (6603600075); Riezzo, Giuseppe (7004144336); Clemente, Caterina (7005101585); D'Attoma, Benedetta (8554891800); Russo, Francesco (59133987100)^6603600075; 7004144336; 7005101585; 8554891800; 59133987100^Noninvasive Biomarkers of Gut Barrier Function in Patients Suffering from Diarrhea Predominant-IBS: An Update^2020^Disease Markers^2020.0^^2886268^^^^22^10.1155/2020/2886268^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85094831821&doi=10.1155%2f2020%2f2886268&partnerID=40&md5=654e45ac8a2a8f1daab9a46103a39d6e^"Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy"^"Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; Clemente C., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; D'Attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy"^The intestinal barrier plays a crucial role in the absorption of nutrients and in preventing the entry of pathogenic microorganisms and toxic molecules. Several studies have shown a compromised intestinal barrier associated with low-grade inflammation in the small intestinal mucosa in celiac disease, inflammatory bowel disease, and irritable bowel syndrome (IBS), particularly in IBS with diarrhea (IBS-D). In light of these new data, IBS is no longer considered a functional disease but rather a heterogeneous syndrome that has yet to be carefully studied. Therefore, investigating the integrity and function of the intestinal barrier is now essential to improving knowledge of the pathophysiology of IBS-D and to improving the management of IBS-D patients. However, the study of the intestinal barrier must clarify some still unsolved methodological aspects and propose standardised assays before becoming a useful diagnostic tool. In this framework, this review will discuss data about the tests that noninvasively evaluate the integrity and functionality of the human intestinal barrier, paying particular attention to patients with IBS-D, in both clinical and research situations.  © 2020 Michele Linsalata et al.^^Amine Oxidase (Copper-Containing); Biomarkers; Diarrhea; Dysbiosis; Fatty Acid-Binding Proteins; Gastrointestinal Microbiome; Humans; Intestinal Absorption; Irritable Bowel Syndrome; amine oxidase (copper containing); biological marker; chromium 51; claudin 2; edetate chromium; fatty acid binding protein 2; indican; lactic acid; skatole; sugar; tight junction protein; unclassified drug; zonulin; amine oxidase (copper containing); biological marker; FABP2 protein, human; fatty acid binding protein; adult; Article; cell damage; diarrhea; dysbiosis; epithelium cell; follow up; human; intestine mucosa permeability; irritable colon; non invasive procedure; pathophysiology; diarrhea; dysbiosis; intestine absorption; intestine flora; irritable colon; pathophysiology^^amine oxidase (copper containing), 9001-53-0, 9014-75-9; chromium 51, 14392-02-0; indican, 1336-79-4, 487-94-5; lactic acid, 113-21-3, 50-21-5; skatole, 83-34-1; Amine Oxidase (Copper-Containing), ; Biomarkers, ; FABP2 protein, human, ; Fatty Acid-Binding Proteins, ^^^^^Camilleri M., Madsen K., Spiller R., Van Meerveld B.G., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterology and Motility, 24, 6, pp. 503-512, (2012); Galipeau H.J., Verdu E.F., The complex task of measuring intestinal permeability in basic and clinical science, Neurogastroenterology and Motility, 28, 7, pp. 957-965, (2016); Oshima T., Miwa H., Gastrointestinal mucosal barrier function and diseases, Journal of Gastroenterology, 51, 8, pp. 768-778, (2016); Fasano A., Zonulin, regulation of tight junctions, and autoimmune diseases, Annals of the New York Academy of Sciences, 1258, 1, pp. 25-33, (2012); Camilleri M., Leaky gut: Mechanisms, measurement and clinical implications in humans, Gut, 68, 8, pp. 1516-1526, (2019); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, 3, pp. 305-315, (2012); Canavan C., West J., Card T., The epidemiology of irritable bowel syndrome, Clinical Epidemiology, 6, pp. 71-80, (2014); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, American Journal of Physiology. Gastrointestinal and Liver Physiology, 303, 7, pp. G775-G785, (2012); Piche T., Tight junctions and IBS-The link between epithelial permeability, low-grade inflammation, and symptom generation?, Neurogastroenterology and Motility, 26, 3, pp. 296-302, (2014); Webb D.L., Tests of intestinal mucosal hyperpermeability: Many diseases, many biomarkers and a bright future, Best Practice & Research. Clinical Gastroenterology, (2019); Graziani C., Talocco C., De Sire R., Petito V., Lopetuso L.R., Gervasoni J., Persichilli S., Franceschi F., Ojetti V., Gasbarrini A., Scaldaferri F., Intestinal permeability in physiological and pathological conditions: Major determinants and assessment modalities, European Review for Medical and Pharmacological Sciences, 23, 2, pp. 795-810, (2019); Wang L., Llorente C., Hartmann P., Yang A.M., Chen P., Schnabl B., Methods to determine intestinal permeability and bacterial translocation during liver disease, Journal of Immunological Methods, 421, pp. 44-53, (2015); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Alonso-Cotoner C., Santos J., Vicario M., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, Journal of Gastroenterology and Hepatology, 32, 1, pp. 53-63, (2017); Pelsers M.M., Hermens W.T., Glatz J.F., Fatty acid-binding proteins as plasma markers of tissue injury, Clinica Chimica Acta, 352, 1-2, pp. 15-35, (2005); Peoc'h K., Nuzzo A., Guedj K., Paugam C., Corcos O., Diagnosis biomarkers in acute intestinal ischemic injury: So close, yet so far, Clinical Chemistry and Laboratory Medicine, 56, 3, pp. 373-385, (2018); Sun D.L., Cen Y.Y., Li S.M., Li W.M., Lu Q.P., Xu P.Y., Accuracy of the serum intestinal fatty-acid-binding protein for diagnosis of acute intestinal ischemia: A meta-analysis, Scientific Reports, 6, 1, (2016); Besnard P., Niot I., Poirier H., Clement L., Bernard A., New insights into the fatty acid-binding protein (FABP) family in the small intestine, Molecular and Cellular Biochemistry, 239, 1-2, pp. 139-147, (2002); Bodelier A.G., Pierik M.J., Lenaerts K., De Boer E., Olde Damink S.W., Hameeteman W.M., Masclee A.A., Jonkers D.M., Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients, European Journal of Gastroenterology & Hepatology, 28, 7, pp. 807-813, (2016); Sarikaya M., Ergul B., Dogan Z., Filik L., Can M., Arslan L., Intestinal fatty acid binding protein (I-FABP) as a promising test for Crohn's disease: A preliminary study, Clinical Laboratory, 61, pp. 87-91, (2015); Vogt A., Reuken P.A., Stengel S., Stallmach A., Bruns T., Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study, World Journal of Gastroenterology, 22, 11, pp. 3275-3284, (2016); Abu Faddan N.H., Sherif T.M., Mohammed O.A., Nasif K.A., El Gezawy E.M., Intestinal barrier integrity and function in infants with cholestasis, Intestinal Research, 15, 1, pp. 118-123, (2017); Adriaanse M.P., Tack G.J., Passos V.L., Damoiseaux J.G., Schreurs M.W., Van Wijck K., Riedl R.G., Masclee A.A., Buurman W.A., Mulder C.J., Vreugdenhil A.C., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Alimentary Pharmacology & Therapeutics, 37, 4, pp. 482-490, (2013); Adriaanse M.P., Leffler D.A., Kelly C.P., Schuppan D., Najarian R.M., Goldsmith J.D., Buurman W.A., Vreugdenhil A.C., Serum I-FABP detects gluten responsiveness in adult celiac disease patients on a short-term gluten challenge, The American Journal of Gastroenterology, 111, 7, pp. 1014-1022, (2016); Vreugdenhil A.C., Wolters V.M., Adriaanse M.P., Van Den Neucker A.M., Van Bijnen A.A., Houwen R., Buurman W.A., Additional value of serum I-FABP levels for evaluating celiac disease activity in children, Scandinavian Journal of Gastroenterology, 46, 12, pp. 1435-1441, (2011); Adriaanse M.P.M., Mubarak A., Riedl R.G., Ten Kate F.J.W., Damoiseaux J.G.M.C., Buurman W.A., Houwen R.H.J., Vreugdenhil A.C.E., Progress towards noninvasive diagnosis and follow-up of celiac disease in children; A prospective multicentre study to the usefulness of plasma I-FABP, Scientific Reports, 7, 1, (2017); Uhde M., Ajamian M., Caio G., De Giorgio R., Indart A., Green P.H., Verna E.C., Volta U., Alaedini A., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, 12, pp. 1930-1937, (2016); Shi H., Wan J., Liu W., Su B., An analysis for the clinical difference between post infectious irritable bowel syndrome and non post infectious irritable bowel syndrome, Zhonghua Nei Ke Za Zhi, 54, 4, pp. 326-329, (2015); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, Bmc Gastroenterology, 18, 1, (2018); Luk G.D., Bayless T.M., Baylin S.B., Diamine oxidase (histaminase). A circulating marker for rat intestinal mucosal maturation and integrity, The Journal of Clinical Investigation, 66, 1, pp. 66-70, (1980); Zhang L., Fan X., Zhong Z., Xu G., Shen J., Association of plasma diamine oxidase and intestinal fatty acid-binding protein with severity of disease in patient with heat stroke, The American Journal of Emergency Medicine, 33, 7, pp. 867-871, (2015); Meng Y., Zhang Y., Liu M., Kun Huang Y., Zhang J., Yao Q., Ling Zhao Y., Jing Xiong J., Evaluating intestinal permeability by measuring plasma endotoxin and diamine oxidase in children with acute lymphoblastic leukemia treated with high-dose methotrexate, Anti-Cancer Agents in Medicinal Chemistry, 16, 3, pp. 387-392, (2016); Gu J., Hu J., Qian H., Shi Y., Zhang E., Guo Y., Xiao Z., Fang Z., Zhong M., Zhang H., Meng W., Intestinal barrier dysfunction: A novel therapeutic target for inflammatory response in acute Stanford type A aortic dissection, Journal of Cardiovascular Pharmacology and Therapeutics, 21, 1, pp. 64-69, (2015); D'Agostino L., Daniele B., Pignata S., Greco L., Mazzacca G., Postheparin plasma diamine oxidase in subjects with small bowel disease. Diagnostic efficiency of a simplified test, Digestion, 41, 1, pp. 46-54, (1988); Forget P., Grandfils C., Van Cutsem J.L., Dandrifosse G., Diamine oxidase in serum and small intestinal biopsy tissue in childhood celiac disease, Journal of Pediatric Gastroenterology and Nutrition, 5, 3, pp. 379-383, (1986); Corazza G.R., Falasca A., Strocchi A., Rossi C.A., Gasbarrini G., Decreased plasma postheparin diamine oxidase levels in celiac disease, Digestive Diseases and Sciences, 33, 8, pp. 956-961, (1988); Corazza G.R., Ginaldi L., Falasca A., Strocchi A., Rossi C.A., Quaglino D., Gasbarrini G., Diamine oxidase plasma activities after treatment with heparin and jejunal morphometry in untreated coeliac disease, Journal of Clinical Pathology, 42, 11, pp. 1136-1139, (1989); Rokkas T., Vaja S., Murphy G.M., Dowling R.H., Postheparin plasma diamine oxidase in health and intestinal disease, Gastroenterology, 98, 6, pp. 1493-1501, (1990); Honzawa Y., Nakase H., Matsuura M., Chiba T., Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: Importance of evaluation of small intestinal permeability, Inflammatory Bowel Diseases, 17, 2, pp. E23-E25, (2011); Xu X.J., Zhang Y.L., Liu L., Pan L., Yao S.K., Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: A preliminary explorative study, Alimentary Pharmacology & Therapeutics, 45, 1, pp. 100-114, (2017); Assimakopoulos S.F., Papageorgiou I., Charonis A., Enterocytes' tight junctions: From molecules to diseases, World Journal of Gastrointestinal Pathophysiology, 2, 6, pp. 123-137, (2011); Liang G.H., Weber C.R., Molecular aspects of tight junction barrier function, Current Opinion in Pharmacology, 19, pp. 84-89, (2014); Lee S.H., Intestinal permeability regulation by tight junction: Implication on inflammatory bowel diseases, Intestinal Research, 13, 1, pp. 11-18, (2015); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, The American Journal of Gastroenterology, 106, 12, pp. 2165-2173, (2011); Wu R.L., Vazquez-Roque M.I., Carlson P., Burton D., Grover M., Camilleri M., Turner J.R., Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression, Laboratory Investigation, 97, 1, pp. 14-23, (2017); Saliminejad K., Khorram Khorshid H.R., Soleymani Fard S., Ghaffari S.H., An overview of microRNAs: Biology, functions, therapeutics, and analysis methods, Journal of Cellular Physiology, 234, 5, pp. 5451-5465, (2019); Vicario M., Martinez C., Santos J., Role of microRNA in IBS with increased gut permeability, Gut, 59, 6, pp. 710-712, (2010); Capaldo C.T., Nusrat A., Claudin switching: Physiological plasticity of the tight junction, Seminars in Cell & Developmental Biology, 42, pp. 22-29, (2015); Ishimoto H., Oshima T., Sei H., Yamasaki T., Kondo T., Tozawa K., Tomita T., Ohda Y., Fukui H., Watari J., Miwa H., Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients, Journal of Clinical Biochemistry and Nutrition, 60, 2, pp. 146-150, (2017); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., De Torres I., Gonzalez-Castro A.M., Pigrau M., Saperas E., Azpiroz F., Santos J., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, The American Journal of Gastroenterology, 107, 5, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., De Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, 8, pp. 1160-1168, (2013); Thuijls G., Derikx J.P., De Haan J.J., Grootjans J., De Bruine A., Masclee A.A., Heineman E., Buurman W.A., Urine-based detection of intestinal tight junction loss, Journal of Clinical Gastroenterology, 44, 1, pp. e14-e19, (2010); Thomson A., Smart K., Somerville M.S., Lauder S.N., Appanna G., Horwood J., Sunder Raj L., Srivastava B., Durai D., Scurr M.J., Keita A.V., Gallimore A.M., Godkin A., The Ussing chamber system for measuring intestinal permeability in health and disease, Bmc Gastroenterology, 19, 1, (2019); Schoultz I., Keita A.V., The intestinal barrier and current techniques for the assessment of gut permeability, Cells, 9, 8, (2020); Van Wijck K., Verlinden T.J., Van Eijk H.M., Dekker J., Buurman W.A., Dejong C.H., Lenaerts K., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: A randomized controlled crossover trial, Clinical Nutrition, 32, 2, pp. 245-251, (2013); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, 10, pp. 1512-1520, (2006); Denno D.M., VanBuskirk K., Nelson Z.C., Musser C.A., Hay Burgess D.C., Tarr P.I., Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: A systematic review, Clinical Infectious Diseases, 59, pp. S213-S219, (2014); Musa M.A., Kabir M., Hossain M.I., Ahmed E., Siddique A., Rashid H., Mahfuz M., Mondal D., Ahmed T., Petri W.A., Haque R., Measurement of intestinal permeability using lactulose and mannitol with conventional five hours and shortened two hours urine collection by two different methods: HPAE-PAD and LC-MSMS, PLoS One, 14, 8, (2019); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clinical Chemistry and Laboratory Medicine, 52, 4, pp. e61-e64, (2014); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Tilg H., Watson A., Wells J.M., Intestinal permeability-A new target for disease prevention and therapy, Bmc Gastroenterology, 14, 1, (2014); Konig J., Wells J., Cani P.D., Garcia-Rodenas C.L., Mac Donald T., Mercenier A., Whyte J., Troost F., Brummer R.J., Human intestinal barrier function in health and disease, Clinical and Translational Gastroenterology, 7, 10, (2016); Russo F., Chimienti G., Linsalata M., Clemente C., Orlando A., Riezzo G., The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals, European Journal of Gastroenterology & Hepatology, 29, 2, pp. 160-168, (2017); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Martino A.C., Patel N.S., Remaley A.T., Henderson W.A., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clinica Chimica Acta, 418, pp. 97-101, (2013); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Zinsmeister A.R., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, American Journal of Physiology. Gastrointestinal and Liver Physiology, 301, 5, pp. G919-G928, (2011); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Hanssen N.M., Conchillo J.M., Jonkers D.M., Masclee A.A., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Alimentary Pharmacology & Therapeutics, 40, 3, pp. 288-297, (2014); Wahnschaffe U., Schulzke J.D., Zeitz M., Ullrich R., Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome, Clinical Gastroenterology and Hepatology, 5, 7, pp. 844-850, (2007); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J.A., Marietta E., O'Neill J., Carlson P., Lamsam J., Janzow D., Eckert D., Burton D., Zinsmeister A.R., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterology, 144, 5, pp. 903e3-911e3, (2013); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J.A., O'Neill J., Carlson P., Lamsam J., Eckert D., Janzow D., Burton D., Ryks M., Rhoten D., Zinsmeister A.R., Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea, American Journal of Physiology. Gastrointestinal and Liver Physiology, 303, 11, pp. G1262-G1269, (2012); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, Journal of Gastroenterology, 49, 11, pp. 1467-1476, (2014); Zhou Q., Zhang B., Verne N.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1, pp. 41-46, (2009); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, 6, pp. 775-784, (2010); Li L., Xiong L., Yao J., Zhuang X., Zhang S., Yu Q., Xiao Y., Cui Y., Chen M., Increased small intestinal permeability and RNA expression profiles of mucosa from terminal ileum in patients with diarrhoea-predominant irritable bowel syndrome, Digestive and Liver Disease, 48, 8, pp. 880-887, (2016); Russo F., Chimienti G., Riezzo G., Linsalata M., D'Attoma B., Clemente C., Orlando A., Adipose tissue-derived biomarkers of intestinal barrier functions for the characterization of diarrhoea-predominant IBS, Disease Markers, 2018, (2018); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, 6, pp. 996-1002, (2019); Ohland C.L., MacNaughton W.K., Probiotic bacteria and intestinal epithelial barrier function, American Journal of Physiology Gastrointestinal and Liver Physiology, 298, 6, pp. G807-G819, (2010); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology & Therapeutics, 28, 8, pp. 994-1002, (2008); Bjarnason I., Peters T.J., Veall N., 51Cr-EDTA test for intestinal permeability, The Lancet, 324, 8401, (1984); Zuckerman M.J., Watts M.T., Bhatt B.D., Ho H., Intestinal permeability to [51Cr] EDTA in infectious diarrhea, Digestive Diseases and Sciences, 38, 9, pp. 1651-1657, (1993); Horton F., Wright J., Smith L., Hinton P.J., Robertson M.D., Increased intestinal permeability to oral chromium (51 Cr)-EDTA in human type 2 diabetes, Diabetic Medicine, 31, 5, pp. 559-563, (2014); Gecse K., Roka R., Sera T., Rosztoczy A., Annahazi A., Izbeki F., Nagy F., Molnar T., Szepes Z., Pavics L., Bueno L., Wittmann T., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, The American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Peled Y., Watz C., Gilat T., Measurement of intestinal permeability using 51Cr-EDTA, The American Journal of Gastroenterology, 80, 10, pp. 770-773, (1985); Sundqvist T., Magnusson K.E., Sjodahl R., Stjernstrom I., Tagesson C., Passage of molecules through the wall of the gastrointestinal tract. II. Application of low-molecular weight polyethyleneglycol and a deterministic mathematical model for determining intestinal permeability in man, Gut, 21, 3, pp. 208-214, (1980); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, 5, pp. 1566-1581, (1995); Parlesak A., Bode J.C., Bode C., Parallel determination of gut permeability in man with M <sub>r</sub>400, M <sub>r</sub>1500, M <sub>r</sub>4000 and M <sub>r</sub>10 000 polyethylene glycol, European Journal of Clinical Chemistry and Clinical Biochemistry, 32, 11, pp. 813-820, (1994); Magnusson K.E., Sundqvist T., Sjodahl R., Tagesson C., Altered intestinal permeability to low-molecular-weight polyethyleneglycols (PEG 400) in patients with Crohn's disease, Acta Chirurgica Scandinavica, 149, 3, pp. 323-327, (1983); Falth-Magnusson K., Kjellman N.I., Magnusson K.E., Sundqvist T., Intestinal permeability in healthy and allergic children before and after sodium-cromoglycate treatment assessed with different-sized polyethyleneglycols (PEG 400 and PEG 1000), Clinical Allergy, 14, 3, pp. 277-286, (1984); Falth-Magnusson K., Kjellman N.I., Odelram H., Sundqvist T., Magnusson K.E., Gastrointestinal permeability in children with cow's milk allergy: Effect of milk challenge and sodium cromoglycate as assessed with polyethyleneglycols (PEG 400 and PEG 1000), Clinical Allergy, 16, 6, pp. 543-551, (1986); Sundqvist T., Stenhammar L., Tjellstrom B., Magnusson K.E., Forslund T., Hogberg L., Oral immunoglobulin treatment improved intestinal permeability in children with active Crohn's disease, Acta Paediatrica, 106, 4, pp. 647-653, (2017); Van Wijck K., Bessems B.A., Van Eijk H.M., Buurman W.A., Dejong C.H., Lenaerts K., Polyethylene glycol versus dual sugar assay for gastrointestinal permeability analysis: Is it time to choose?, Clinical and Experimental Gastroenterology, 5, pp. 139-150, (2012); Stenhamma L., Falth-Magnusson K., Jansson G., Magnusson K.E., Sundqvist T., Intestinal permeability to inert sugars and different-sized polyethyleneglycols in children with celiac disease, Journal of Pediatric Gastroenterology and Nutrition, 9, 3, pp. 281-289, (1989); Kerckhoffs A.P., Akkermans L.M., De Smet M.B., Besselink M.G., Hietbrink F., Bartelink I.H., Busschers W.B., Samsom M., Renooij W., Intestinal permeability in irritable bowel syndrome patients: Effects of NSAIDs, Digestive Diseases and Sciences, 55, 3, pp. 716-723, (2010); Park J.H., Park D.I., Kim H.J., Cho Y.K., Sohn C.I., Jeon W.K., Kim B.I., Won K.H., Park S.M., The relationship between small-intestinal bacterial overgrowth and intestinal permeability in patients with irritable bowel syndrome, Gut Liver, 3, 3, pp. 174-179, (2009); Fasano A., Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications, Clinical Gastroenterology and Hepatology, 10, 10, pp. 1096-1100, (2012); Esnafoglu E., Cirrik S., Ayyildiz S.N., Erdil A., Erturk E.Y., Dagli A., Noyan T., Increased serum zonulin levels as an intestinal permeability marker in autistic subjects, The Journal of Pediatrics, 188, pp. 240-244, (2017); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Sapone A., De Magistris L., Pietzak M., Clemente M.G., Tripathi A., Cucca F., Lampis R., Kryszak D., Carteni M., Generoso M., Iafusco D., Prisco F., Laghi F., Riegler G., Carratu R., Counts D., Fasano A., Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives, Diabetes, 55, 5, pp. 1443-1449, (2006); Vorobjova T., Raikkerus H., Kadaja L., Talja I., Uibo O., Heilman K., Uibo R., Circulating zonulin correlates with density of enteroviruses and tolerogenic dendritic cells in the small bowel mucosa of celiac disease patients, Digestive Diseases and Sciences, 62, 2, pp. 358-371, (2017); Fasano A., Not T., Wang W., Uzzau S., Berti I., Tommasini A., Goldblum S.E., Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, The Lancet, 355, 9214, pp. 1518-1519, (2000); Khaleghi S., Ju J.M., Lamba A., Murray J.A., The potential utility of tight junction regulation in celiac disease: Focus on larazotide acetate, Therapeutic Advances in Gastroenterology, 9, 1, pp. 37-49, (2015); Duerksen D.R., Wilhelm-Boyles C., Veitch R., Kryszak D., Parry D.M., A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet, Digestive Diseases and Sciences, 55, 4, pp. 1026-1031, (2010); Barbaro M.R., Cremon C., Caio G., De Giorgio R., Volta U., Stanghellini V., Barbara G., Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 11, pp. 5072-5076, (2015); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United European Gastroenterology Journal, 7, 5, pp. 709-715, (2019); Bueno L., Protease activated receptor 2: A new target for IBS treatment, European Review for Medical and Pharmacological Sciences, 12, pp. 95-102, (2008); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annual Review of Pathology: Mechanisms of Disease, 5, 1, pp. 119-144, (2010); Moser A.M., Spindelboeck W., Halwachs B., Strohmaier H., Kump P., Gorkiewicz G., Hogenauer C., Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome, European Journal of Nutrition, 58, 7, pp. 2767-2778, (2018); Moreno-Navarrete J.M., Sabater M., Ortega F., Ricart W., Fernandez-Real J.M., Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance, PLoS One, 7, 5, (2012); Kume T., Acar S., Tuhan H., Catli G., Anik A., Gursoy Calan O., Bober E., Abaci A., The relationship between serum zonulin level and clinical and laboratory parameters of childhood obesity, Journal of Clinical Research in Pediatric Endocrinology, 9, 1, pp. 31-38, (2017); Takiishi T., Fenero C.I.M., Camara N.O.S., Intestinal barrier and gut microbiota: Shaping our immune responses throughout life, Tissue Barriers, 5, 4, (2017); Adike A., DiBaise J.K., Small intestinal bacterial overgrowth: Nutritional implications, diagnosis, and management, Gastroenterology Clinics of North America, 47, 1, pp. 193-208, (2018); Raj A.S., Shanahan E.R., Tran C.D., Bhat P., Fletcher L.M., Vesey D.A., MacDonald G.A., Dysbiosis of the duodenal mucosal microbiota is associated with increased small intestinal permeability in chronic liver disease, Clinical and Translational Gastroenterology, 10, 8, (2019); Hawrelak J.A., Myers S.P., The causes of intestinal dysbiosis: A review, Alternative Medicine Review, 9, 2, pp. 180-197, (2004); Hendrikx T., Schnabl B., Indoles: Metabolites produced by intestinal bacteria capable of controlling liver disease manifestation, Journal of Internal Medicine, 286, 1, pp. 32-40, (2019); Lord R.S., Bralley J.A., Clinical applications of urinary organic acids. Part 2. Dysbiosis markers, Alternative Medicine Review, 13, 4, pp. 292-306, (2008); Garcia Regueiro J.A., Rius M.A., Rapid determination of skatole and indole in pig back fat by normal-phase liquid chromatography, Journal of Chromatography. A, 809, 1-2, pp. 246-251, (1998); Cassani E., Barichella M., Cancello R., Cavanna F., Iorio L., Cereda E., Bolliri C., Zampella Maria P., Bianchi F., Cestaro B., Pezzoli G., Increased urinary indoxyl sulfate (indican): New insights into gut dysbiosis in Parkinson's disease, Parkinsonism & Related Disorders, 21, 4, pp. 389-393, (2015); Simeoni M., Citraro M.L., Cerantonio A., Deodato F., Provenzano M., Cianfrone P., Capria M., Corrado S., Libri E., Comi A., Pujia A., Abenavoli L., Andreucci M., Cocchi M., Montalcini T., Fuiano G., An open-label, randomized, placebo-controlled study on the effectiveness of a novel probiotics administration protocol (ProbiotiCKD) in patients with mild renal insufficiency (stage 3a of CKD), European Journal of Nutrition, 58, 5, pp. 2145-2156, (2019); Wang Z., Xu C.M., Liu Y.X., Wang X.Q., Zhang L., Li M., Zhu S.W., Xie Z.J., Wang P.H., Duan L.P., Zhu H.Q., Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome, Chinese Medical Journal, 132, 8, pp. 889-904, (2019); Cai J., Chen H., Weng M., Jiang S., Gao J., Diagnostic and clinical significance of serum levels of D-lactate and diamine oxidase in patients with Crohn's disease, Gastroenterology Research and Practice, 2019, (2019); Murray M.J., Barbose J.J., Cobb C.F., Serum D(-)-lactate levels as a predictor of acute intestinal ischemia in a rat model, The Journal of Surgical Research, 54, 5, pp. 507-509, (1993); Assadian A., Assadian O., Senekowitsch C., Rotter R., Bahrami S., Furst W., Jaksch W., Hagmuller G.W., Hubl W., Plasma D-lactate as a potential early marker for colon ischaemia after open aortic reconstruction, European Journal of Vascular and Endovascular Surgery, 31, 5, pp. 470-474, (2006); Sun X.Q., Fu X.B., Zhang R., Lu Y., Deng Q., Jiang X.G., Sheng Z.Y., Relationship between plasma D(-)-lactate and intestinal damage after severe injuries in rats, World Journal of Gastroenterology, 7, 4, pp. 555-558, (2001); Shi H., Wu B., Wan J., Liu W., Su B., The role of serum intestinal fatty acid binding protein levels and D-lactate levels in the diagnosis of acute intestinal ischemia, Clinics and Research in Hepatology and Gastroenterology, 39, 3, pp. 373-378, (2015); Song W.B., Lv Y.H., Zhang Z.S., Li Y.N., Xiao L.P., Yu X.P., Wang Y.Y., Ji H.L., Ma L., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease, World Journal of Gastroenterology, 15, 31, pp. 3916-3919, (2009); Xu X., Liu L., Yao S., Zhang Y., Visceral sensitivity, gut barrier function and autonomic nerve function in patients with diarrhea-predominant irritable bowel syndrome, Zhong Nan da Xue Xue Bao Yi Xue Ban, 42, 5, pp. 522-528, (2017)^"F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology, S. de Bellis"" Research Hospital, Castellana Grotte, I-70013, Italy; email: francesco.russo@irccsdebellis.it"^^Hindawi Limited^^^^^^02780240^^DMARD^33110455.0^English^Dis. Markers^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85094831821
Zhou Q.; Verne M.L.; Fields J.Z.; Lefante J.J.; Basra S.; Salameh H.; Verne G.N.^Zhou, QiQi (13404854200); Verne, Meghan L (57203725585); Fields, Jeremy Z (7103238507); Lefante, John J (6602087100); Basra, Sarpreet (55970998300); Salameh, Habeeb (36574126600); Verne, G Nicholas (7004085639)^13404854200; 57203725585; 7103238507; 6602087100; 55970998300; 36574126600; 7004085639^Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome^2019^Gut^68.0^6^^996^1002^6.0^114^10.1136/gutjnl-2017-315136^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052731357&doi=10.1136%2fgutjnl-2017-315136&partnerID=40&md5=3ec8f41a1a725b03c487ac6835e72b6b^Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States; Department of Veteran Affairs, Malcom Randall VAMC, Gainesville, FL, United States; Health Sciences, Texas AandM University, College Station, TX, United States; Department of Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States; Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States^Zhou Q., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States, Department of Veteran Affairs, Malcom Randall VAMC, Gainesville, FL, United States; Verne M.L., Health Sciences, Texas AandM University, College Station, TX, United States; Fields J.Z., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States; Lefante J.J., Department of Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States; Basra S., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States; Salameh H., Department of Medicine, University of Texas Medical Branch, Galveston, TX, United States; Verne G.N., Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, LA, United States^Background More effective treatments are needed for patients with postinfectious, diarrhoea-predominant, irritable bowel syndrome (IBS-D). Accordingly, we conducted a randomised, double-blind, placebo-controlled, 8-week-long trial to assess the efficacy and safety of oral glutamine therapy in patients who developed IBS-D with increased intestinal permeability following an enteric infection. Methods Eligible adults were randomised to glutamine (5 g/t.i.d.) or placebo for 8 weeks. The primary end point was a reduction of ≥50 points on the Irritable Bowel Syndrome Severity Scoring System (IBS-SS). Secondary endpoints included: raw IBS-SS scores, changes in daily bowel movement frequency, stool form (Bristol Stool Scale) and intestinal permeability. Results Fifty-four glutamine and 52 placebo subjects completed the 8-week study. The primary endpoint occurred in 43 (79.6%) in the glutamine group and 3 (5.8%) in the placebo group (a 14-fold difference). Glutamine also reduced all secondary endpoint means: IBS-SS score at 8 weeks (301 vs 181, p<0.0001), daily bowel movement frequency (5.4 vs 2.9±1.0, p<0.0001), Bristol Stool Scale (6.5 vs 3.9, p<0.0001) and intestinal permeability (0.11 vs 0.05; p<0.0001). 'Intestinal hyperpermeability' (elevated urinary lactulose/mannitol ratios) was normalised in the glutamine but not the control group. Adverse events and rates of study-drug discontinuation were low and similar in the two groups. No serious adverse events were observed. Conclusions In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints. Large randomised clinical trials (RCTs) should now be done to validate these findings, assess quality of life benefits and explore pharmacological mechanisms. Trial registration number NCT 1414244; Results. © Author(s) (or their employer(s)) 2019.^diarrhoea; enteric infections; intestinal permeability; irritable bowel syndrome^Administration, Oral; Adult; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enteritis; Female; Glutamine; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome; glutamine; lactulose; mannitol; placebo; glutamine; abdominal distension; abdominal pain; adult; Article; bloating; Bristol Stool Scale; clinical article; controlled study; diarrhea; digestive system disease assessment; digestive tract parameters; double blind procedure; drug efficacy; drug safety; female; human; intestine infection; intestine mucosa permeability; Irritable Bowel Syndrome Severity Scoring System; irritable colon; male; patient compliance; patient satisfaction; priority journal; quality of life; randomized controlled trial; urinary lactulose mannitol ratio; complication; dietary supplement; dose response; drug administration; drug effect; enteritis; intestine mucosa; irritable colon; microbiology; oral drug administration; reference value; risk assessment; severity of illness index; treatment outcome^^glutamine, 56-85-9, 6899-04-3; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; Glutamine, ^^^National Institutes of Health, NIH, (NCT1414244); National Institute of General Medical Sciences, NIGMS, (U54GM104940); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (DK099052); U.S. Department of Veterans Affairs, VA, (1 U54 gM104940, cX001477-01); National Center for Complementary and Integrative Health, NCCIH, (AT 005291); national, (at005291)^Funding text 1: Funding this study was supported by the national center for complementary and integrative Health (at005291); national institute of Diabetes and Digestive and Kidney Diseases (DK099052) and the Department of Veterans affairs (cX001477-01). Supported in part by 1 U54 gM104940 from the national institute of general Medical Sciences of the national institutes of Health, which funds the louisiana clinical and translational Science center. clinicaltrials.gov number, nct1414244. Competing interests none declared. Patient consent Obtained. ethics approval institutional review Board. Provenance and peer review not commissioned; externally peer reviewed.; Funding text 2: The authors would like to thank Wiley W Souba, MD, MBA, ScD, Professor of Surgery, Emeritus Dean, Dartmouth Geisel School of Medicine, Hanover, NH for help with the study design. This study was supported by the National Center for Complementary and Integrative Health (AT 005291); National Institute of Diabetes and Digestive and Kidney Diseases (DK099052) and the Department of Veterans Affairs (CX001477-01). Supported in part by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. ClinicalTrials. gov number, NCT1414244.^Enck P., Aziz Q., Barbara G., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Peery A.F., Dellon E.S., Lund J., Et al., Burden of gastrointestinal disease in the United States: 2012 update, Gastroenterology, 143, pp. 1179-1187, (2012); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, pp. 22-32, (2011); Lembo A.J., Lacy B.E., Zuckerman M.J., Et al., Eluxadoline for irritable bowel syndrome with diarrhea, N Engl J Med, 374, pp. 242-253, (2016); Chang L., Heitkemper M.M., Wiley J.W., Et al., Freston single topic conference: A renaissance in the understanding and management of irritable bowel syndrome, Gastroenterology, 2016, pp. e1-8, (2015); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Zhou Q., Souba W.W., Croce C.M., Et al., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Klimberg V.S., Souba W.W., The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness, Surg Annu, 22, pp. 61-76, (1990); Labow B.I., Souba W.W., Glutamine, World J Surg, 24, pp. 1503-1513, (2000); Zhou Q., Verne G.N., Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: Is there a place for glutamine supplementation?, Gastroenterology, 148, pp. 1080-1081, (2015); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Keshavarzian A., Fields J.Z., Vaeth J., Et al., The differing effects of acute and chronic alcohol on gastric and intestinal permeability, Am J Gastroenterol, 89, pp. 2205-2211, (1994); Rezaie A., Buresi M., Lembo A., Et al., Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus, Am J Gastroenterol, 112, pp. 775-784, (2017); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, pp. 395-402, (1997); Macdonald T.T., Monteleone G., Immunity, inflammation, and allergy in the gut, Science, 307, pp. 1920-1925, (2005); Zhou Q., Costinean S., Croce C., Et al., Targeted deletion of microRNA-29 reverses intestinal hyperpermeability, Gastroenterology, 148, pp. 158-169, (2015); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Maynard C.L., Elson C.O., Hatton R.D., Et al., Reciprocal interactions of the intestinal microbiota and immune system, Nature, 489, pp. 231-241, (2012); Heyland D., Muscedere J., Wischmeyer P.E., Et al., A randomized trial of glutamine and antioxidants in critically ill patients, N Engl J Med, 368, pp. 1489-1497, (2013); Yoshida S., Matsui M., Shirouzu Y., Et al., Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer, Ann Surg, 227, pp. 485-491, (1998); Sido B., Seel C., Hochlehnert A., Et al., Low intestinal glutamine level and low glutaminase activity in Crohn's disease: A rational for glutamine supplementation?, Dig Dis Sci, 51, pp. 2170-2179, (2006); Zhou Q., Verne G.N., New insights into visceral hypersensitivity-clinical implications in IBS, Nat Rev Gastroenterol Hepatol, 8, pp. 349-355, (2011); Hong S., Zheng G., Wiley J.W., Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system, Gastroenterology, 148, pp. 148-157, (2015); Ghishan F.K., Kiela P.R., Epithelial transport in inflammatory bowel diseases, Inflamm Bowel Dis, 20, pp. 1-109, (2014); Bertrand J., Ghouzali I., Guerin C., Et al., Glutamine restores tight junction protein Claudin-1 Expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome, J Parenter Enteral Nutr, 40, pp. 1170-1176, (2016)^G.N. Verne; Department of Medicine, Tulane University School of Medicine, New Orleans, 70112-2699, United States; email: gverne@tulane.edu^^BMJ Publishing Group^^^^^^00175749^^GUTTA^30108163.0^English^Gut^Article^Final^All Open Access; Green Open Access^Scopus^2-s2.0-85052731357
Caviglia G.P.; Tucci A.; Pellicano R.; Fagoonee S.; Rosso C.; Abate M.L.; Olivero A.; Armandi A.; Vanni E.; Saracco G.M.; Bugianesi E.; Astegiano M.; Ribaldone D.G.^Caviglia, Gian Paolo (24491739500); Tucci, Alessandra (56219805900); Pellicano, Rinaldo (7005853671); Fagoonee, Sharmila (6603221574); Rosso, Chiara (55613318800); Abate, Maria Lorena (7004963939); Olivero, Antonella (55369742700); Armandi, Angelo (57204445604); Vanni, Ester (6601986579); Saracco, Giorgio Maria (57205711772); Bugianesi, Elisabetta (6701433364); Astegiano, Marco (6701316557); Ribaldone, Davide Giuseppe (57195507877)^24491739500; 56219805900; 7005853671; 6603221574; 55613318800; 7004963939; 55369742700; 57204445604; 6601986579; 57205711772; 6701433364; 6701316557; 57195507877^Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with bifidobacterium longum es1 for 8 or 12 weeks: A preliminary report^2020^Journal of Clinical Medicine^9.0^8^2353^1^11^10.0^22^10.3390/jcm9082353^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85111770871&doi=10.3390%2fjcm9082353&partnerID=40&md5=221a59ad6ad0399edc19bc46e656c0ff^Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, Turin, 10126, Italy^Caviglia G.P., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Tucci A., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Pellicano R., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Fagoonee S., Institute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Centre, Turin, 10126, Italy; Rosso C., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Abate M.L., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Olivero A., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Armandi A., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Vanni E., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Saracco G.M., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Bugianesi E., Department of Medical Sciences, University of Turin, Turin, 10124, Italy; Astegiano M., Unit of Gastroenterology, Città della Salute e della Scienza di Torino—Molinette Hospital, Turin, 10126, Italy; Ribaldone D.G., Department of Medical Sciences, University of Turin, Turin, 10124, Italy^Bifidobacterium longum (B. longum) ES1 is a probiotic strain capable of modulating microbiome composition, anti-inflammatory activity and intestinal barrier function. We investigated the use of B. Longum ES1 in the treatment of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Sixteen patients were treated for 8 or 12 weeks with B. Longum ES1 (1 × 109 CFU/day). Serum zonulin and cytokines were measured at baseline (T0) and at the end of therapy (T1). Clinical response to therapy was assessed by IBS Severity Scoring System. Interleukin (IL)-6, IL-8, IL-12p70 and tumor necrosis factor (TNF) α levels decreased from T0 to T1, irrespective of treatment duration (p < 0.05), while zonulin levels diminished only in patients treated for 12 weeks (p = 0.036). Clinical response was observed in 5/16 patients (31%): 4/8 (50%) treated for 12 weeks and 1/8 (13%) treated for 8 weeks. Abdominal pain improved only in patients treated for 12 weeks (5/8 vs. 0/8, p = 0.025), while stool consistency improved regardless of therapy duration (p < 0.001). In conclusion, the results of this pilot study showed, in IBS-D patients treated for 12 weeks with B. longum ES1, a reduction in the levels of pro-inflammatory cytokines, and intestinal permeability as well as an improvement in gastrointestinal symptoms, but further studies including a placebo-control group are necessary to prove a causal link. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.^IBS; IL-12p70; IL-6; IL-8; Intestinal permeability; Zonulin^Bifidobacterium longum ES1; interleukin 12p70; interleukin 6; interleukin 8; probiotic agent; tumor necrosis factor; unclassified drug; zonulin; abdominal pain; adult; Article; Bifidobacterium longum; clinical article; clinical outcome; diarrhea; disease severity; Disorder Severity Index questionnaire; enzyme linked immunosorbent assay; female; human; irritable colon; male; pain intensity; quality control; quality of life; questionnaire; scoring system; treatment duration^^interleukin 8, 114308-91-7^^^^^Adriani A., Ribaldone D.G., Astegiano M., Durazzo M., Saracco G.M., Pellicano R., Irritable bowel syndrome: The clinical approach, Panminerva Med, 60, pp. 213-222, (2018); Gonzalez-Castro A.M., Martinez C., Salvo-Romero E., Fortea M., Pardo-Camacho C., Perez-Berezo T., Alonso-Cotoner C., Santos J., Vicario M., Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome, J. Gastroenterol. Hepatol, 32, pp. 53-63, (2017); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Barbara G., Wang B., Stanghellini V., de Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, (2016); Caviglia G.P., Rosso C., Ribaldone D.G., Dughera F., Fagoonee S., Asteigano M., Pellicano R., Physiopathology of intestinal barrier and the role of zonulin, Minerva Biotecnol, 31, pp. 83-92, (2019); Fasano A., All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000 Res, 9, (2020); Caviglia G.P., Dughera F., Ribaldone D.G., Rosso C., Abate M.L., Pellicano R., Bresso F., Smedile A., Saracco G.M., Astegiano M., Serum zonulin in patients with inflammatory bowel disease: A pilot study, Minerva Med, 110, pp. 95-100, (2019); Singh P., Silvester J., Chen X., Xu H., Sawhney V., Rangan V., Iturrino J., Nee J., Duerksen D.R., Lembo A., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United Eur. Gastroenterol. J, 7, pp. 709-715, (2019); Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., De Giorgio R., Corinaldesi R., Stanghellini V., The immune system in irritable bowel syndrome, J. Neurogastroenterol. Motil, 17, pp. 349-359, (2011); Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M., Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome, Gastroenterology, 156, pp. 46-58, (2019); Musch M.W., Clarke L.L., Mamah D., Gawenis L.R., Zhang Z., Ellsworth W., Shalowitz D., Mittal N., Efthimiou P., Alnadjim Z., Et al., T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase, J. Clin. Invest, 110, pp. 1739-1747, (2002); Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R., Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am. J. Pathol, 166, pp. 409-419, (2005); Parkes G.C., Rayment N.B., Hudspith B.N., Petrovska L., Lomer M.C., Brostoff J., Whelan K., Sanderson J.D., Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome, Neurogastroenterol. Motil, 24, pp. 31-39, (2012); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil, 24, pp. 521-530, (2012); Abrams G.D., Bauer H., Sprinz H., Influence of the normal flora on mucosal morphology and cellular renewal in the ileum. A comparison of germ-free and conventional mice, Lab. Invest, 12, pp. 355-364, (1963); Fan W.T., Ding C., Xu N.N., Zong S., Ma P., Gu B., Close association between intestinal microbiota and irritable bowel syndrome, Eur. J. Clin. Microbiol. Infect. Dis, 36, pp. 2303-2317, (2017); Tojo R., Suarez A., Clemente M.G., De Los Reyes-Gavilan C.G., Margolles A., Gueimonde M., Ruas-Madiedo P., Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis, World J. Gastroenterol, 20, pp. 15163-15176, (2014); Chenoll E., Codoner F., Silva A., Ibanez A., Martinez-Blanch J., Bollati-Fogolin M., Crispo M., Ramirez S., Sanz Y., Ramon D., Et al., Genomic Sequence and Pre-Clinical Safety Assessment of Bifidobacterium longum CECT 7347, a Probiotic able to Reduce the Toxicity and Inflammatory Potential of Gliadin-Derived Peptides, J. Probiotics Heal, pp. 1-6, (2013); Izquierdo E., Medina M., Ennahar S., Marchioni E., Sanz Y., Resistance to simulated gastrointestinal conditions and adhesion to mucus as probiotic criteria for Bifidobacterium longum strains, Curr. Microbiol, 56, pp. 613-618, (2008); Olivares M., Castillejo G., Varea V., Sanz Y., Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease, Br. J. Nutr, 112, pp. 30-40, (2014); Sultana R., McBain A.J., O'Neill C.A., Strain-dependent augmentation of tight-junction barrier function in human primary epidermal keratinocytes by Lactobacillus and Bifidobacterium lysates, Appl. Environ. Microbiol, 79, pp. 4887-4894, (2013); Takeda Y., Nakase H., Namba K., Inoue S., Ueno S., Uza N., Chiba T., Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis, Inflamm. Bowel Dis, 15, pp. 1617-1618, (2009); Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., Li Y., Effects of probiotic type, dose and treatmenty duration on irritable bowel syndrome diagnosed by Rome III criteria: A meta-analysis, BMC Gastroenterolol, 16, (2016); Ford A.C., Harris L.A., Lucy B.E., Quigley E.M.M., Moayyedi P., Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment. Pharmacol. Ther, 48, pp. 1044-1060, (2018); Ciacci C., Franceschi F., Purchiaroni F., Capone P., Buccelletti F., Iacomini P., Ranaudo A., Andreozzi P., Tondi P., Gentiloni Silveri N., Et al., Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS, Eur. Rev. Med. Pharmacol. Sci, 15, pp. 637-643, (2011); Spaguolo R., Cosco C., Mancina R.M., Ruggiero G., Garieri P., Cosco V., Doldo P., Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome, Eur. Rev. Med. Pharmacol. Sci, 21, pp. 102-107, (2017); Drossman D.A., Hasler W.L., Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction, Gastroenterology, 150, pp. 1257-1261, (2016); Drossman D.A., Li Z., Toner B.B., Diamant N.E., Creed F.H., Thompson D., Read N.W., Babbs C., Barreiro M., Bank L., Et al., Functional bowel disorders. A multicenter comparison of health status and development of illness severity index, Dig. Dis. Sci, 40, pp. 986-995, (1995); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Patrick D.L., Drossman D.A., Frederick I.O., Di Cesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure, Dig. Dis. Sci, 43, pp. 400-411, (1998); Caviglia G.P., Rosso C., Stalla F., Rizzo M., Massano A., Abate M.L., Olivero A., Armandi A., Vanni E., Younes R., Et al., On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Dis, J. Clin. Med, 9, (2020); Andresen V., Gschossmann J., Layer P., Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN–HI–001) in the treatment of irritable bowel syndrome: A multicentre, randomised, double-blind, placebo-controlled clinical trial, Lancet Gastroenterol. Hepatol, 5, pp. 658-666, (2020); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol, 32, pp. 920-924, (1997); Drossman D., Morris C.B., Hu Y., Toner B.B., Diamant N., Whitehead W.E., Dalton C.B., Leserman J., Patrick D.L., Bangdiwala S.I., Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment, Am. J. Gastroenterol, 102, pp. 1442-1453, (2007); Davis C., Bryan J., Hodgson J., Murphy K., Definition of the Mediterranean Diet; a Literature Review, Nutrients, 7, pp. 9139-9153, (2015); Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P., Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis, Am. J. Gastroenterol, 109, pp. 1547-1561, (2014); Duan R., Zhu S., Wang B., Duan L., Alterations of gut microbiota in patients with irritable bowel syndrome based on 16 rRNA-targeted sequencing: A systemic review, Clin. Gasteroenterol. Hepatol, 10, (2019); Pittayanon R., Lau J.T., Yuan Y., Leontiadis G.I., Tse F., Surette M., Moayyedi P., Gut microbiota in patients with irritable bowel syndrome—A systematic review, Gastroenterology, 157, pp. 97-108, (2019); Ki Cha B., Mun Jung S., Hwan Choi C., Song I.D., Woong Lee H., Joon Kim H., Hyuk J., Kyung Chang S., Kim K., Chung W.S., Et al., The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial, J. Clin. Gastroenterol, 46, pp. 220-227, (2012); Giannetti E., Maglione M., Alessandrella A., Strisciuglio C., De Giovanni D., Campanozzi A., Miele E., Staiano A., A Mixture of 3 Bifidobacteria Decreases Abdominal Pain and Improves the Quality of Life in Children With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial, J. Clin. Gastroenterol, 51, pp. e5-e10, (2017); Pinto-Sanchez M.I., Hall G.B., Ghajar K., Nardelli A., Bolino C., Lau J.T., Martin F.P., Cominetti O., Welsh C., Rieder A., Et al., Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome, Gastroenterology, 153, pp. 448-459, (2017); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51, pp. i41-i44, (2002); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments, J. Neurogastroenterol. Motil, 22, pp. 558-574, (2016); Song D.D., Li Y., Tang D., Huang L.Y., Yuan Y.Z., Neuron-glial communication mediated by TNF-alfa and glial activation in dorsal root ganglia in visceral inflammatory hypersensitivity, Am. J. Physiol. Gastrointest. Liver Physiol, 306, pp. G788-G795, (2014); Bashashati M., Moradi M., Sarosiek I., Interleukin-6 in irritable bowel syndrome: A systematic review and meta-analysis of IL-(-G174C) and circulating IL-6 levels, Cytokine, 99, pp. 132-138, (2017); Patel S.R., Singh A., Misra V., Misra S.P., Dwivedi M., Trivedi P., Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome, Indian J. Pathol. Microbiol, 60, pp. 385-389, (2017); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 26, pp. 1036-1048, (2014); Ng Q.X., Soh A.Y.S., Loke W., Lim D.Y., Yeo W.S., The role of inflammation in irritable bowel syndrome (IBS), J. Inflamm. Res, 11, pp. 345-349, (2018); Mujagic Z., Ludidi S., Keszthelyi D., Hesselink M.A., Kruimel J.W., Lenaerts K., Hanssen N.M., Conchillo J.M., Jonkers D.M., Masclee A.A., Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders, Aliment. Pharmacol. Ther, 40, pp. 288-297, (2014); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Wong B.S., Lamsam J., Singh R., Zinsmeister A.R., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am. J. Physiol. Gastrointest. Liver. Physiol, 301, pp. 919-928, (2011); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, BMC Gastroenterol, 18, (2018); Bonfrate L., Di Palo D.M., Celano G., Albert A., Vitellio P., De Angelis M., Gobbetti M., Portincasa P., Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients, Eur. J. Clin. Invest, 50, (2020)^G.P. Caviglia; Department of Medical Sciences, University of Turin, Turin, 10124, Italy; email: gianpaolo.caviglia@unito.it; D.G. Ribaldone; Department of Medical Sciences, University of Turin, Turin, 10124, Italy; email: davidegiuseppe.ribaldone@unito.it^^MDPI^^^^^^20770383^^^^English^J. Clin. Med.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85111770871
Lobo de Sá F.D.; Heimesaat M.M.; Bereswill S.; Nattramilarasu P.K.; Schulzke J.D.; Bücker R.^Lobo de Sá, F.D. (57211078887); Heimesaat, M.M. (6602258464); Bereswill, S. (7003804266); Nattramilarasu, P.K. (57192703302); Schulzke, J.D. (35502556700); Bücker, R. (10043068400)^57211078887; 6602258464; 7003804266; 57192703302; 35502556700; 10043068400^Resveratrol Prevents Campylobacter jejuni-Induced Leaky gut by Restoring Occludin and Claudin-5 in the Paracellular Leak Pathway^2021^Frontiers in Pharmacology^12.0^^640572^^^^20^10.3389/fphar.2021.640572^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104968577&doi=10.3389%2ffphar.2021.640572&partnerID=40&md5=4718299bda9abb66672a10fdcd867cbd^Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Institute of Microbiology, Infectious Diseases, and Immunology, Gastrointestinal Microbiology Research Group, Charité - Universitätsmedizin Berlin, Berlin, Germany^Lobo de Sá F.D., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Heimesaat M.M., Institute of Microbiology, Infectious Diseases, and Immunology, Gastrointestinal Microbiology Research Group, Charité - Universitätsmedizin Berlin, Berlin, Germany; Bereswill S., Institute of Microbiology, Infectious Diseases, and Immunology, Gastrointestinal Microbiology Research Group, Charité - Universitätsmedizin Berlin, Berlin, Germany; Nattramilarasu P.K., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Schulzke J.D., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; Bücker R., Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany^Campylobacter jejuni is a bacterial human pathogen causing gastroenteritis and sequelae like irritable bowel syndrome. Epidemiologists count the human campylobacteriosis by C. jejuni as the most common foodborne zoonosis and bacterial diarrheal disease worldwide. Based on bioinformatics predictions for potential protective compounds in campylobacteriosis, the question was raised whether the plant-based polyphenol resveratrol is sufficient to attenuate intestinal epithelial damage induced by C. jejuni. We investigated this by performing experimental infection studies in an epithelial cell culture and the secondary abiotic IL-10−/− mouse model. In C. jejuni-infected human colonic HT-29/B6 cell monolayers, transepithelial electrical resistance (TER) was decreased and the paracellular marker flux of fluorescein (332 Da) increased. Concomitantly, the tight junction (TJ) proteins occludin and claudin-5 were re-distributed off the tight junction domain. This was accompanied by an increased induction of epithelial apoptosis, both changes contributing to compromised barrier function and the opening of the leak pathway induced by C. jejuni. In parallel, the recovery experiments with the application of resveratrol revealed a functional improvement of the disturbed epithelial barrier in both models in vitro and in vivo. During treatment with resveratrol, TJ localization of occludin and claudin-5 was fully restored in the paracellular domain of HT-29/B6 cells. Moreover, resveratrol decreased the rate of epithelial apoptosis. These resveratrol-induced molecular and cellular effects would therefore be expected to improve epithelial barrier function, thereby minimizing the so-called leaky gut phenomenon. In conclusion, the induction of the leak pathway by C. jejuni and the restoration of barrier function by resveratrol demonstrates its effectiveness as a potential preventive or therapeutic method of mitigating the leaky gut associated with campylobacteriosis. © Copyright © 2021 Lobo de Sá, Heimesaat, Bereswill, Nattramilarasu, Schulzke and Bücker.^epithelial apoptosis; epithelial barrier; leak flux; leak pathway; leaky gut model; mucosal permeability; tight junction^claudin 5; fluorescein; gamma interferon; interleukin 10; interleukin 1beta; occludin; resveratrol; tumor necrosis factor; animal experiment; animal model; animal tissue; apoptosis; Article; bioinformatics; Campylobacter enteritis; cellular distribution; controlled study; cytokine production; cytokine release; drug mechanism; epithelium cell; experimental infection; HT-29 cell line; human; human cell; in vitro study; in vivo study; infection prevention; intestine epithelium; intestine injury; intestine mucosa permeability; mouse; nonhuman; permeability barrier; protein expression; protein localization; tight junction; transepithelial resistance^^fluorescein, 2321-07-5, 91316-42-6; gamma interferon, 82115-62-6; occludin, 176304-61-3; resveratrol, 501-36-0^^^German Federal Ministries of Economy and Energy, (ZF4117904 AJ8); University of Leeds; Deutsche Forschungsgemeinschaft, DFG; Bundesministerium für Bildung und Forschung, BMBF, (DFG Schu559/11-3, IP7/ 01KI1725D, IP8/01KI2007D); Charité – Universitätsmedizin Berlin^Funding text 1: We acknowledge support from the German Research Foundation and the Open Access Publication Fund of the Charité–Universitätsmedizin Berlin. This work was supported by the German Federal Ministry of Education and Research (BMBF) in frame of the zoonoses research consortium PAC-Campylobacter to RB and JDS (project IP8/01KI2007D) and to MMH and SB (IP7/ 01KI1725D). This work was supported by the German Research Foundation (DFG Schu559/11-3) to JDS. Furthermore, MMH and SB received support from the German Federal Ministries of Economy and Energy (ZIM; ZF4117904 AJ8).; Funding text 2: We acknowledge the excellent technical support of Anja Fromm and In-Fah Maria Lee. We wish to thank Professor Geoffrey Sandle (University of Leeds, United Kingdom) for proof reading and editing the manuscript.^Al-Salloom F., Mahmeed A.A., Ismaeel A., Botta G.A., Bakhiet M., Campylobacter-stimulated INT407 cells produce dissociated cytokine profiles, J. Infect, 47, 3, pp. 217-224, (2003); Amasheh M., Fromm A., Krug S.M., Amasheh S., Andres S., Zeitz M., Et al., TNFα-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFκB signaling, J. Cell Sci, 123, 23, pp. 4145-4155, (2010); Bereswill S., Munoz M., Fischer A., Plickert R., Haag L.-M., Otto B., Et al., Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation, PLoS One, 5, 12, (2010); Bergann T., Ploger S., Fromm A., Zeissig S., Borden S.A., Fromm M., Et al., A colonic mineralocorticoid receptor cell model expressing epithelial Na+ channels, Biochem. Biophys. Res. Comm, 381, 2, pp. 280-285, (2009); Berman A.Y., Motechin R.A., Wiesenfeld M.Y., Holz M.K., The therapeutic potential of resveratrol: a review of clinical trials, npj Precision Onc, 1, (2017); Black R.E., Levine M.M., Clements M.L., Hughes T.P., Blaser M.J., Experimental Campylobacter jejuni infection in humans, J. Infect. Dis, 157, 3, pp. 472-479, (1988); Bojarski C., Weiske J., Schoneberg T., Schroder W., Mankertz J., Schulzke J.D., Et al., The specific fates of tight junction proteins in apoptotic epithelial cells, J. Cell Sci, 117, 10, pp. 2097-2107, (2004); Bucker R., Krug S.M., Fromm A., Nielsen H.L., Fromm M., Nielsen H., Et al., Campylobacter fetusimpairs barrier function in HT-29/B6 cells through focal tight junction alterations and leaks, Ann. N.Y. Acad. Sci, 1405, 1, pp. 189-201, (2017); Bucker R., Krug S.M., Moos V., Bojarski C., Schweiger M.R., Kerick M., Et al., Erratum: Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon, Mucosal Immunol, 11, 2, pp. 575-577, (2018); Bucker R., Schulz E., Gunzel D., Bojarski C., Lee I.F.M., John L.J., Et al., α-Haemolysin ofEscherichia coliin IBD: a potentiator of inflammatory activity in the colon, Gut, 63, 12, pp. 1893-1901, (2014); Butkevych E., Lobo de Sa F.D., Nattramilarasu P.K., Bucker R., Contribution of epithelial apoptosis and subepithelial immune responses in Campylobacter jejuni-induced barrier disruption, Front. Microbiol, 11, (2020); Cao S., Shen Z., Wang C., Zhang Q., Hong Q., He Y., Et al., Resveratrol improves intestinal barrier function, alleviates mitochondrial dysfunction and induces mitophagy in diquat challenged piglets1, Food Funct, 10, 1, pp. 344-354, (2019); Carrasco-Pozo C., Morales P., Gotteland M., Polyphenols protect the epithelial barrier function of Caco-2 cells exposed to indomethacin through the modulation of occludin and zonula occludens-1 expression, J. Agric. Food Chem, 61, 22, pp. 5291-5297, (2013); Chen M.L., Ge Z., Fox J.G., Schauer D.B., Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni, Iai, 74, 12, pp. 6581-6589, (2006); Chudzinska M., Rogowicz D., Wolowiec L., Banach J., Sielski S., Bujak R., Et al., Resveratrol and cardiovascular system-the unfulfilled hopes, Ir J. Med. Sci, (2020); Dampf Stone A., Batie S.F., Sabir M.S., Jacobs E.T., Lee J.H., Whitfield G.K., Et al., Resveratrol potentiates vitamin D and nuclear receptor signaling, J. Cell. Biochem, 116, 6, pp. 1130-1143, (2015); Edwards L.A., Nistala K., Mills D.C., Stephenson H.N., Zilbauer M., Wren B.W., Et al., Delineation of the innate and adaptive T-cell immune outcome in the human host in response to Campylobacter jejuni infection, PLoS One, 5, 11, (2010); El-Kott A.F., Shati A.A., Ali Al-Kahtani M., Alharbi S.A., The apoptotic effect of resveratrol in ovarian cancer cells is associated with downregulation of galectin-3 and stimulating miR-424-3p transcription, J. Food Biochem, 43, 12, (2019); Feng L., Yasmeen R., Schoene N.W., Lei K.Y., Wang T.T.Y., Resveratrol differentially modulates immune responses in human THP-1 monocytes and macrophages, Nutr. Res, 72, pp. 57-69, (2019); Gao X., Xu Y.X., Janakiraman N., Chapman R.A., Gautam∗ S.C., Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production11Abbreviations: CTLs, cytotoxic T lymphocytes; LAK cells, lymphokine activated killer cells; IL-2, interleukin-2; IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-α NF-κB, nuclear factor kappa B; Con A, concanavalin A; HBSS, Hanks' balanced salt solution; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; RT-PCR, reverse transcription-polymerase chain reaction; LPS, lipopolysaccharide; and EMSA, electrophoretic mobility shift assay, Biochem. Pharmacol, 62, pp. 1299-1308, (2001); Golz G., Karadas G., Alutis M.E., Fischer A., Kuhl A.A., Breithaupt A., Et al., Arcobacter butzleri induce colonic, extra-intestinal and systemic inflammatory responses in Gnotobiotic IL-10 deficient mice in a strain-dependent manner, PLoS One, 10, 9, (2015); Haag L.-M., Fischer A., Otto B., Plickert R., Kuhl A.A., Gobel U.B., Et al., Campylobacter jejuni induces acute enterocolitis in Gnotobiotic IL-10−/− mice via toll-like-receptor-2 and -4 signaling, PLoS One, 7, 7, (2012); Harrer A., Bucker R., Boehm M., Zarzecka U., Tegtmeyer N., Sticht H., Et al., Campylobacter jejuni enters gut epithelial cells and impairs intestinal barrier function through cleavage of occludin by serine protease HtrA, Gut Pathog, 11, (2019); Heimesaat M.M., Escher U., Grunau A., Kuhl A.A., Bereswill S., Multidrug-resistant Pseudomonas aeruginosa accelerate intestinal, extra-intestinal, and systemic inflammatory responses in human microbiota-associated mice with subacute ileitis, Front. Immunol, 10, (2019); Heimesaat M.M., Mousavi S., Escher U., Lobo de Sa F.D., Peh E., Schulzke J.-D., Et al., Resveratrol alleviates acute Campylobacter jejuni induced enterocolitis in a preclinical murine intervention study, Microorganisms, 8, 12, (2020); Hollander D., Intestinal permeability, leaky gut, and intestinal disorders, Curr. Gastroenterol. Rep, 1, 5, pp. 410-416, (1999); Klancnik A., Sikic Pogacar M., Trost K., Tusek Znidaric M., Mozetic Vodopivec B., Smole Mozina S., Anti-Campylobacter activity of resveratrol and an extract from waste Pinot noir grape skins and seeds, and resistance of Camp. jejuni planktonic and biofilm cells, mediated via the CmeABC efflux pump, J. Appl. Microbiol, 122, 1, pp. 65-77, (2017); Koushki M., Amiri-Dashatan N., Ahmadi N., Abbaszadeh H.A., Rezaei-Tavirani M., Resveratrol: a miraculous natural compound for diseases treatment, Food Sci. Nutr, 6, 8, pp. 2473-2490, (2018); Koushki M., Dashatan N.A., Meshkani R., Effect of resveratrol supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials, Clin. Ther, 40, 7, pp. 1180-1192, (2018); Kundu J.K., Surh Y.-J., Molecular basis of chemoprevention by resveratrol: NF-κB and AP-1 as potential targets, Mutat. Research/Fundamental Mol. Mech. Mutagenesis, 555, 1-2, pp. 65-80, (2004); Ling K.-H., Wan M.L.Y., El-Nezami H., Wang M., Protective capacity of resveratrol, a natural polyphenolic compound, against deoxynivalenol-induced intestinal barrier dysfunction and bacterial translocation, Chem. Res. Toxicol, 29, 5, pp. 823-833, (2016); Liu J., Zhang X., Yan T., Wang F., Li J., Jia L., Et al., Screening of an endophyte transforming polydatin to resveratrol from Reynoutria japonica houtt and the optimization of its transformation parameters, Molecules, 25, 20, (2020); Lobo de Sa F.D., Butkevych E., Nattramilarasu P.K., Fromm A., Mousavi S., Moos V., Et al., Curcumin mitigates immune-induced epithelial barrier dysfunction by Campylobacter jejuni, Int. J. Mol. Sci, 20, 19, (2019); Lobo de Sa F.D., Schulzke J.D., Bucker R., Diarrheal mechanisms and the role of intestinal barrier dysfunction in Campylobacter infections, Curr. Top. Microbiol. Immunol, 431, pp. 203-231, (2021); Luettig J., Rosenthal R., Lee I.F.M., Krug S.M., Schulzke J.D., The ginger component 6-shogaol prevents TNF-α-induced barrier loss via inhibition of PI3K/Akt and NF-κB signaling, Mol. Nutr. Food Res, 60, 12, pp. 2576-2586, (2016); Mayangsari Y., Suzuki T., Resveratrol ameliorates intestinal barrier defects and inflammation in colitic mice and intestinal cells, J. Agric. Food Chem, 66, 48, pp. 12666-12674, (2018); Mousavi S., Bereswill S., Heimesaat M., Novel clinical Campylobacter jejuni infection models based on sensitization of mice to lipooligosaccharide, a major bacterial factor triggering innate immune responses in human campylobacteriosis, Microorganisms, 8, 4, (2020); Mousavi S., Lobo de Sa F.D., Schulzke J.-D., Bucker R., Bereswill S., Heimesaat M.M., Vitamin D in acute campylobacteriosis-results from an intervention study applying a clinical Campylobacter jejuni induced enterocolitis model, Front. Immunol, 10, (2019); Nielsen H.L., Engberg J., Ejlertsen T., Bucker R., Nielsen H., Short-term and medium-term clinical outcomes of Campylobacter concisus infection, Clin. Microbiol. Infect, 18, 11, pp. E459-E465, (2012); Otto B., Haag L.-M., Fischer A., Plickert R., Kuhl A.A., Gobel U.B., Et al., Campylobacter jejuniinduces extra-intestinal immune responses via toll-like-receptor-4 signaling in conventional IL-10 deficient mice with chronic colitis, Eur. J. Microbiol. Immunol. (Bp), 2, 3, pp. 210-219, (2012); Rees L.E.N., Cogan T.A., Dodson A.L., Birchall M.A., Bailey M., Humphrey T.J., Campylobacter and IFNγ interact to cause a rapid loss of epithelial barrier integrity, Inflamm. Bowel Dis, 14, 3, pp. 303-309, (2008); Rosenthal R., Luettig J., Hering N.A., Krug S.M., Albrecht U., Fromm M., Et al., Myrrh exerts barrier-stabilising and -protective effects in HT-29/B6 and Caco-2 intestinal epithelial cells, Int. J. Colorectal Dis, 32, 5, pp. 623-634, (2017); Salehi B., Mishra A., Nigam M., Sener B., Kilic M., Sharifi-Rad M., Et al., Resveratrol: a double-edged sword in health benefits, Biomedicines, 6, 3, (2018); Schulzke J.-D., Bojarski C., Zeissig S., Heller F., Gitter A.H., Fromm M., Disrupted barrier function through epithelial cell apoptosis, Ann. New York Acad. Sci, 1072, pp. 288-299, (2006); Shane S.M., The significance ofcampylobacter jejuniinfection in poultry: a review, Avian Pathol, 21, 2, pp. 189-213, (1992); Singh S.K., Banerjee S., Acosta E.P., Lillard J.W., Singh R., Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway, Oncotarget, 8, 10, pp. 17216-17228, (2017); Singh U.P., Singh N.P., Singh B., Hofseth L.J., Price R.L., Nagarkatti M., Et al., Resveratrol (Trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-κb activation to abrogate dextran sulfate sodium-induced colitis, J. Pharmacol. Exp. Ther, 332, 3, pp. 829-839, (2010); Stahl M., Ries J., Vermeulen J., Yang H., Sham H.P., Crowley S.M., Et al., A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for Toll-like receptor signaling during infection, Plos Pathog, 10, 7, (2014); Stahl M., Vallance B.A., Insights intoCampylobacter jejunicolonization of the mammalian intestinal tract using a novel mouse model of infection, Gut Microbes, 6, 2, pp. 143-148, (2015); Tsai S.H., Lin-Shiau S.Y., Lin J.K., Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol, Br. J. Pharmacol, 126, 3, pp. 673-680, (1999); Vandamme P., Falsen E., Rossau R., Hoste B., Segers P., Tytgat R., Et al., Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: emendation of generic descriptions and proposal of Arcobacter gen. nov, Int. J. Syst. Bacteriol, 41, 1, pp. 88-103, (1991); von Klitzing E., Ekmekciu I., Kuhl A.A., Bereswill S., Heimesaat M.M., Intestinal, extra-intestinal and systemic sequelae of Toxoplasma gondii induced acute ileitis in mice harboring a human gut microbiota, PLoS One, 12, 4, (2017); Wang N., Han Q., Wang G., Ma W.P., Wang J., Wu W.X., Et al., Resveratrol protects oxidative stress-induced intestinal epithelial barrier dysfunction by upregulating heme oxygenase-1 expression, Dig. Dis. Sci, 61, 9, pp. 2522-2534, (2016); Wassenaar T.M., Blaser M.J., Pathophysiology of Campylobacter jejuni infections of humans, Microbes Infect, 1, 12, pp. 1023-1033, (1999); Weiskirchen S., Weiskirchen R., Resveratrol: how much wine do you have to drink to stay healthy?, Adv. Nutr, 7, 4, pp. 706-718, (2016); Yao J., Wang J.Y., Liu L., Li Y.X., Xun A.Y., Zeng W.S., Et al., Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis, Arch. Med. Res, 41, 4, pp. 288-294, (2010); Yao J., Wei C., Wang J.Y., Zhang R., Li Y.X., Wang L.S., Effect of resveratrol on Treg/Th17 signaling and ulcerative colitis treatment in mice, Wjg, 21, 21, pp. 6572-6581, (2015); Zhang M., Xue Y., Chen H., Meng L., Chen B., Gong H., Et al., Resveratrol inhibits MMP3 and MMP9 expression and secretion by suppressing TLR4/NF-κB/STAT3 activation in ox-LDL-treated HUVECs, Oxid Med. Cell Longev, (2019); Zhao L., Lee J.Y., Hwang D.H., Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals, Nutr. Rev, 69, 6, pp. 310-320, (2011); Zhong M., Cheng G.F., Wang W.J., Guo Y., Zhu X.Y., Zhang J.T., Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice, Phytomedicine, 6, 2, pp. 79-84, (1999)^R. Bücker; Medical Department, Division of Gastroenterology, Infectious Diseases, Rheumatology, Nutritional Medicine/Clinical Physiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; email: roland-felix.buecker@charite.de; ^^Frontiers Media S.A.^^^^^^16639812^^^^English^Front. Pharmacol.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85104968577
Khoshbin K.; Khanna L.; Maselli D.; Atieh J.; Breen-Lyles M.; Arndt K.; Rhoten D.; Dyer R.B.; Singh R.J.; Nayar S.; Bjerkness S.; Harmsen W.S.; Busciglio I.; Camilleri M.^Khoshbin, Katayoun (57193934219); Khanna, Lehar (57220210306); Maselli, Daniel (57208710617); Atieh, Jessica (57217292842); Breen-Lyles, Margaret (57195807544); Arndt, Kayla (57215864406); Rhoten, Deborah (35765672600); Dyer, Roy B. (7202532150); Singh, Ravinder J. (55994265700); Nayar, Sunita (57194201242); Bjerkness, Sandra (14019050700); Harmsen, William S. (7005973985); Busciglio, Irene (17343569900); Camilleri, Michael (7102181053)^57193934219; 57220210306; 57208710617; 57217292842; 57195807544; 57215864406; 35765672600; 7202532150; 55994265700; 57194201242; 14019050700; 7005973985; 17343569900; 7102181053^Development and Validation of Test for “Leaky Gut” Small Intestinal and Colonic Permeability Using Sugars in Healthy Adults^2021^Gastroenterology^161.0^2^^463^475.e13^^30^10.1053/j.gastro.2021.04.020^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109077620&doi=10.1053%2fj.gastro.2021.04.020&partnerID=40&md5=196f24d5006757425023190c8436047d^Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Clinical Research and Trials Unit, Mayo Clinic, Rochester, MN, United States; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States^Khoshbin K., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Khanna L., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Maselli D., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Atieh J., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Breen-Lyles M., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Arndt K., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Rhoten D., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Dyer R.B., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Singh R.J., Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States; Nayar S., Clinical Research and Trials Unit, Mayo Clinic, Rochester, MN, United States; Bjerkness S., Clinical Research and Trials Unit, Mayo Clinic, Rochester, MN, United States; Harmsen W.S., Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States; Busciglio I., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States; Camilleri M., Clinical Enteric NeuroscienceTranslational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States^Background: Oral monosaccharides and disaccharides are used to measure in vivo human gut permeability through urinary excretion. Aims: The aims were as follows: (1) to obtain normative data on small intestinal and colonic permeability; (2) to assess variance on standard 16 g fiber diet performed twice; (3) to determine whether dietary fiber influences gut permeability measurements; and (4) to present pilot data using 2 selected probes in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: Sixty healthy female and male adults, age 18–70 years, participated in 3 randomized studies (2 studies on 16.25 g and 1 study on 32.5 g fiber) in otherwise standardized diets. At each test, the following sugars were ingested: 12C-mannitol, 13C-mannitol, rhamnose (monosaccharides), sucralose, and lactulose (disaccharides). Standardized meals were administered from 24 hours before and during 24 hours post-sugars with 3 urine collections: 0–2, 2–8, and 8–24 hours. Sugars were measured using high-performance liquid chromatography–tandem mass spectrometry. Eighteen patients with IBS-D underwent 24-hour excretion studies after oral 13C-mannitol and lactulose. Results: Baseline sugars (>3-fold above lower limits of quantitation) were identified in the 3 studies: 12C-mannitol in all participants; sucralose in 4–8, and rhamnose in 1–3. Median excretions/24 h (percentage of administered dose) for 13C-mannitol, rhamnose, lactulose, and sucralose were ∼30%, ∼15%, 0.32%, and 2.3%, respectively. 13C-mannitol and rhamnose reflected mainly small intestinal permeability. Intraindividual saccharide excretions were consistent, with minor differences with 16.25 g vs 32.5 g fiber diets. Median interindividual coefficient of variation was 76.5% (10–90 percentile: 34.6–111.0). There were no significant effects of sex, age, or body mass index on permeability measurements in health. 13C-mannitol measurements are feasible in IBS-D. Conclusions: Baseline 12C-mannitol excretion precludes its use; 13C-mannitol is the preferred probe for small intestinal permeability. © 2021 The Authors^Barrier; Lactulose; Mannitol; Sucralose^Administration, Oral; Adult; Aged; Biomarkers; Chromatography, High Pressure Liquid; Colon; Cross-Over Studies; Diagnostic Techniques, Digestive System; Diarrhea; Dietary Fiber; Disaccharides; Female; Healthy Volunteers; Humans; Intestinal Mucosa; Intestine, Small; Irritable Bowel Syndrome; Male; Middle Aged; Monosaccharides; Permeability; Pilot Projects; Predictive Value of Tests; Renal Elimination; Reproducibility of Results; Tandem Mass Spectrometry; Urinalysis; carbohydrate; lactulose; mannitol; rhamnose; sucralose; biological marker; disaccharide; monosaccharide; adult; age; aged; Article; body mass; clinical article; cohort analysis; colon; female; glucose urine level; high fiber diet; high performance liquid chromatography; human; human experiment; intestine mucosa permeability; irritable colon; male; normal human; pilot study; sex difference; small intestine; tandem mass spectrometry; urinary excretion; urine sampling; administration and dosage; colon; comparative study; complication; controlled study; crossover procedure; diarrhea; dietary fiber; digestive system examination; intestine mucosa; irritable colon; metabolism; middle aged; oral drug administration; permeability; predictive value; randomized controlled trial; reproducibility; small intestine; urinalysis; urine^^lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; rhamnose, 10485-94-6, 3615-41-6; sucralose, 56038-13-2; Biomarkers, ; Dietary Fiber, ; Disaccharides, ; Monosaccharides, ^^^Institute for the Advancement of Food and Nutrition Sciences; National Institutes of Health, NIH, (R01 DK115950); National Institutes of Health, NIH; National Center for Advancing Translational Sciences, NCATS, (UL1TR002377); National Center for Advancing Translational Sciences, NCATS^Funding text 1: Funding This work was supported by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) (through an ILSI North America Carbohydrate Committee grant). IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. ILSI North America receives support primarily from its industry membership. ILSI North America had no role in the design, analysis, interpretation, or presentation of the data and results. Dr Camilleri receives funding for studies on intestinal permeability in irritable bowel syndrome (unrelated to current project) from the National Institutes of Health (R01 DK115950). The study was conducted in the Mayo Clinic Clinical Research Trials Unit, supported in part by nursing, dietetic, physiology, and immunochemistry laboratory components, which are supported by grant number UL1-TR002377 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.; Funding text 2: Funding This work was supported by the Institute for the Advancement of Food and Nutrition Sciences (IAFNS) (through an ILSI North America Carbohydrate Committee grant). IAFNS is a nonprofit science organization that pools funding from industry and advances science through the in-kind and financial contributions from private and public sector members. ILSI North America receives support primarily from its industry membership. ILSI North America had no role in the design, analysis, interpretation, or presentation of the data and results. Dr Camilleri receives funding for studies on intestinal permeability in irritable bowel syndrome (unrelated to current project) from the National Institutes of Health (R01 DK115950). The study was conducted in the Mayo Clinic Clinical Research Trials Unit, supported in part by nursing, dietetic, physiology, and immunochemistry laboratory components, which are supported by grant number UL1-TR002377 from the National Center for Advancing Translational Sciences . Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. ^Odenwald M.A., Turner J.R., The intestinal epithelial barrier: a therapeutic target?, Nat Rev Gastroenterol Hepatol, 14, pp. 9-21, (2017); Quigley E.M., Leaky gut - concept or clinical entity?, Curr Opin Gastroenterol, 32, pp. 74-79, (2016); Camilleri M., Lyle B.J., Madsen K.L., Et al., Role for diet in normal gut barrier function: developing guidance within the framework of food labeling regulations, Am J Physiol, 317, pp. G17-G39, (2019); Camilleri M., Invited recent advances in basic science: the leaky gut: mechanisms, measurement and clinical implications in humans, Gut, 68, pp. 1516-1526, (2019); Guidance for Industry: Evidence-Based Review System for Scientific Evaluation of Health Claims (Online); Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act (Online); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol, 301, pp. G919-G928, (2011); Grover M., Camilleri M., Hines J., Et al., <sup>13</sup>C-mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol Motil, 28, pp. 1114-1119, (2016); Faubion W.A., Camilleri M., Murray J.A., Et al., Improving the detection of environmental enteric dysfunction: a lactulose, rhamnose assay of intestinal permeability in children aged under 5 years exposed to poor sanitation and hygiene, BMJ Glob Health, 1, (2016); Dwyer J., Picciano M.F., Raiten D.J., Estimation of usual intakes: what we eat in America-NHANES, J Nutr, 133, pp. 609S-623S, (2003); Talley N.J., Phillips S.F., Wiltgen C.M., Et al., Assessment of functional gastrointestinal disease: the bowel disease questionnaire, Mayo Clin Proc, 65, pp. 1456-1479, (1990); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Camilleri M., Nadeau A., Lamsam J., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol Motil, 22, pp. e15-e26, (2010); Lostia A.M., Lionetto L., Principessa L., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clin Biochem, 41, pp. 887-892, (2008); Bjarnason I., Scarpignato C., Holmgren E., Et al., Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs, Gastroenterology, 154, pp. 500-514, (2018); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Camilleri M., Nadeau A., Tremaine W.J., Et al., Measurement of serum 7α-hydroxy-4-cholesten-3-one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry, Neurogastroenterol Motil, 21, pp. 734-743, (2009); Donato L.J., Lueke A., Kenyon S.M., Et al., Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry, Clin Biochem, 52, pp. 106-111, (2018); Camilleri M., Busciglio I., Acosta A., Et al., Effect of increased bile acid synthesis or fecal excretion in irritable bowel syndrome-diarrhea, Am J Gastroenterol, 109, pp. 1621-1630, (2014); Meddings J., Gibbons I., Discrimination of site-specific alterations in gastrointestinal permeability in the rat, Gastroenterology, 114, pp. 83-92, (1998); Flint H.J., Scott K.P., Louis P., Et al., The role of the gut microbiota in nutrition and health, Nat Rev Gastroenterol Hepatol, 9, pp. 577-589, (2012); Sahota S.S., Bramley P.M., Menzies I.S., The fermentation of lactulose by colonic bacteria, J Gen Microbiol, 128, pp. 319-325, (1982); McOmber M.E., Ou C.-N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, J Pediatr Gastroenterol Nutr, 50, pp. 269-275, (2010); Karhu E., Forsgard R.A., Alanko L., Et al., Exercise and gastrointestinal symptoms: running-induced changes in intestinal permeability and markers of gastrointestinal function in asymptomatic and symptomatic runners, Eur J Appl Physiol, 117, pp. 2519-2526, (2017); Pires W., Veneroso C.E., Wanner S.P., Et al., Association between exercise-induced hyperthermia and intestinal permeability: a systematic review, Sports Med, 47, pp. 1389-1403, (2017); van Wijck K., Wijnands K.A., Meesters D.M., Et al., L-citrulline improves splanchnic perfusion and reduces gut injury during exercise, Med Sci Sports Exerc, 46, pp. 2039-2046, (2014); Man A.L., Bertelli E., Rentini S., Et al., Age-associated modifications of intestinal permeability and innate immunity in human small intestine, Clin Sci (Lond), 129, pp. 515-527, (2015); Bischoff S.C., Barbara G., Buurman W., Et al., Intestinal permeability--a new target for disease prevention and therapy, BMC Gastroenterol, 14, (2014)^M. Camilleri; Rochester, 200 First Street SW, Charlton Building, Room 8-110, 55905, United States; email: camilleri.michael@mayo.edu^^W.B. Saunders^^^^^^00165085^^GASTA^33865841.0^English^Gastroenterology^Article^Final^All Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85109077620
Meira de-Faria F.; Bednarska O.; Ström M.; Söderholm J.D.; Walter S.A.; Keita Å.V.^Meira de-Faria, Felipe (36450289100); Bednarska, Olga (55789563900); Ström, Magnus (7005995994); Söderholm, Johan D. (7004276501); Walter, Susanna A. (23053245700); Keita, Åsa V. (13104052600)^36450289100; 55789563900; 7005995994; 7004276501; 23053245700; 13104052600^Colonic paracellular permeability and circulating zonulin-related proteins^2021^Scandinavian Journal of Gastroenterology^56.0^4^^424^431^7.0^17^10.1080/00365521.2021.1879247^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100537095&doi=10.1080%2f00365521.2021.1879247&partnerID=40&md5=f3c51ec0cc51d7129d04066481bc1d62^Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Gastroenterology, Linköping University, Linköping, Sweden; Department of Surgery, Linköping University, Linköping, Sweden^Meira de-Faria F., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Bednarska O., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Ström M., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Söderholm J.D., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Surgery, Linköping University, Linköping, Sweden; Walter S.A., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden, Department of Gastroenterology, Linköping University, Linköping, Sweden; Keita Å.V., Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden^Objective: Irritable bowel syndrome (IBS) is a gut-brain disorder associated with increased gut permeability. Zonulin has been suggested to regulate the gut barrier and claimed to be pre-haptoglobin 2 (pre-HP2) and circulating zonulin is often used as a proxy for gastrointestinal permeability. This study investigated the correlation between colonic paracellular permeability and levels of circulating zonulin and pre-HP2. Materials and Methods: Colonic biopsies from 32 patients with IBS and 15 healthy controls (HC) were used to measure permeability in Ussing chambers and levels of zonulin (Cusabio ELISA). Zonulin was also measured in blood samples from 40 HC, 78 patients with IBS and 20 patients with celiac disease (CeD), before and after a gluten-free diet. In addition, we verified HP genotype and circulating pre-HP2 using a monoclonal pre-HP2 antibody (Bio-Rad) by ELISA. Results: Increased colonic paracellular permeability correlated positively with zonulin levels in IBS biopsies, but negatively with plasma zonulin. We found no agreement between circulating zonulin and pre-HP2. Genotyping revealed non-specificity of the zonulin kit, as all pre-HP2 non-producers presented detectable levels. Patients with CeD displayed higher pre-HP2 and zonulin levels compared to HC. A gluten-free diet in patients with CeD led to lower serum zonulin and pre-HP2 concentrations. Conclusions: Our study suggests that neither circulating zonulin nor pre-HP2 mirror colonic permeability. Our data corroborate previous reports showing the inability of the Cusabio zonulin kit to target zonulin and highlights that the results of studies using this kit must be re-examined with caution. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.^Colonic paracellular permeability; ELISA; irritable bowel syndrome; pre-haptoglobin 2; zonulin^Haptoglobins; Humans; Intestinal Mucosa; Permeability; Protein Precursors; DNA; genomic DNA; haptoglobin; nonsteroid antiinflammatory agent; unclassified drug; zonulin; haptoglobin; protein precursor; zonulin; adult; Article; blood sampling; celiac disease; clinical assessment; colon biopsy; colonic paracellular permeability; comparative study; concentration process; controlled study; correlation analysis; enzyme linked immunosorbent assay; female; genotype; gluten free diet; human; human tissue; intestine mucosa permeability; irritable colon; major clinical study; male; priority journal; protein blood level; protein expression; intestine mucosa; permeability^^DNA, 9007-49-2; haptoglobin, 9087-69-8; Haptoglobins, ; Protein Precursors, ; zonulin, ^Cusabio, Biotech, United States; QIAamp, Qiagen; Softmax pro 5, Molecular Devices; Thermal Cycler, Biorad^Biorad; Biotech, United States; Molecular Devices; Qiagen^^^Oswiecimska J., Szymlak A., Roczniak W., Et al., New insights into the pathogenesis and treatment of irritable bowel syndrome, Adv Med Sci, 62, 1, pp. 17-30, (2017); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol, 101, 6, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, 7, pp. 545-552, (2007); Del Valle-Pinero A.Y., Van Deventer H.E., Fourie N.H., Et al., Gastrointestinal permeability in patients with irritable bowel syndrome assessed using a four probe permeability solution, Clin Chim Acta, 418, pp. 97-101, (2013); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, 2, pp. 196-201, (2009); Quigley E., Gut permeability in irritable bowel syndrome: more leaks add to slightly inflamed bowel syndrome conspiracy theory, Gastroenterology, 137, 2, pp. 728-730, (2009); Turcotte J.F., Kao D., Mah S.J., Et al., Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos), Gastrointest Endosc, 77, 4, pp. 624-630, (2013); Bednarska O., Walter S.A., Casado-Bedmar M., Et al., Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome, Gastroenterology, 153, 4, pp. 948-960, (2017); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, 11-12, pp. 1317-1322, (2004); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, 6, pp. 804-811, (2000); Sturgeon C., Fasano A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases, Tissue Barriers, 4, 4, (2016); Fasano A., Intestinal zonulin: open sesame!, Gut, 49, 2, pp. 159-162, (2001); Suzuki T., Regulation of intestinal epithelial permeability by tight junctions, Cell Mol Life Sci, 70, 4, pp. 631-659, (2013); Stevens B.R., Goel R., Seungbum K., Et al., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, 8, pp. 1555-1557, (2018); Fasano A., Not T., Wang W., Et al., Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, Lancet, 355, 9214, pp. 1518-1519, (2000); El Asmar R., Panigrahi P., Bamford P., Et al., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, 5, pp. 1607-1615, (2002); Smecuol E., Sugai E., Niveloni S., Et al., Permeability, zonulin production, and enteropathy in dermatitis herpetiformis, Clin Gastroenterol Hepatol, 3, 4, pp. 335-341, (2005); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, 10, pp. 1512-1520, (2006); Tripathi A., Lammers K.M., Goldblum S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci USA, 106, 39, pp. 16799-16804, (2009); Koch W., Latz W., Eichinger M., Et al., Haptoglobin gene subtyping by restriction enzyme analysis, Clin Chem, 49, 11, pp. 1937-1940, (2003); Vanuytsel T., Vermeire S., Cleynen I., The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease, Tissue Barriers, 1, 5, (2013); Scheffler L., Crane A., Heyne H., Et al., Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family, Front Endocrinol, 9, (2018); Ajamian M., Steer D., Rosella G., Et al., Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems, PLoS One, 14, 1, (2019); Talley N.J., Holtmann G.J., Jones M., Et al., Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity, Gut, 69, 9, pp. 1-3, (2020); Witt S.T., Bednarska O., Keita A.V., Et al., Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome, Neuroimage Clin, 21, (2019); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, 5, pp. 1480-1491, (2006); Keita A.V., Gullberg E., Ericson A.C., Et al., Characterization of antigen and bacterial transport in the follicle-associated epithelium of human ileum, Lab Invest, 86, 5, pp. 504-516, (2006); Koch W., Latz W., Eichinger M., Et al., Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR, Clin Chem, 48, 9, pp. 1377-1382, (2002); Flanagan J.J., Arjomandi A., Delanoy M.L., Et al., Development of monoclonal antibodies to pre-haptoglobin 2 and their use in an enzyme-linked immunosorbent assay (ELISA), J Immunol Methods, 406, pp. 34-42, (2014); Duerksen D.R., Wilhelm-Boyles C., Veitch R., Et al., A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet, Dig Dis Sci, 55, 4, pp. 1026-1031, (2010); Fasano A., Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin, Ann NY Acad Sci, 915, pp. 214-222, (2000); Ganda Mall J.P., Ostlund-Lagerstrom L., Lindqvist C.M., Et al., Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress?, BMC Geriatr, 18, 1, (2018); Langlois M.R., Delanghe J.R., Biological and clinical significance of haptoglobin polymorphism in humans, Clin Chem, 42, 10, pp. 1589-1600, (1996); Wang W., Uzzau S., Goldblum S.E., Et al., Human zonulin, a potential modulator of intestinal tight junctions, J Cell Sci, 113, 24, pp. 4435-4440, (2000); Paterson B.M., Lammers K.M., Arrieta M.C., Et al., The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study, Aliment Pharmacol Ther, 26, 5, pp. 757-766, (2007); Clemente M.G., De Virgiliis S., Kang J.S., Et al., Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function, Gut, 52, 2, pp. 218-223, (2003); Barbaro M.R., Cremon C., Caio G., Et al., 247 zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, 4, (2015); Barbaro M.R., Cremon C., Morselli-Labate A.M., Et al., Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity, Gut, 69, 11, pp. 1966-1974, (2020); Fasano A., Uzzau S., Fiore C., Et al., The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway, Gastroenterology, 112, 3, pp. 839-846, (1997); Drago S., El Asmar R., Di Pierro M., Et al., Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines, Scand J Gastroenterol, 41, 4, pp. 408-419, (2006); Cenac N., Chin A.C., Garcia-Villar R., Et al., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and -independent pathways, J Physiol, 558, 3, pp. 913-925, (2004); Pontarollo G., Mann A., Brandao I., Et al., Protease-activated receptor signaling in intestinal permeability regulation, FEBS J, 287, 4, pp. 645-658, (2020); Fasano A., Shea-Donohue T., Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases, Nat Clin Pract Gastroenterol Hepatol, 2, 9, pp. 416-422, (2005); Leffler D.A., Kelly C.P., Abdallah H.Z., Et al., A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge, Am J Gastroenterol, 107, 10, pp. 1554-1562, (2012); Kelly C.P., Green P.H., Murray J.A., Et al., Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study, Aliment Pharmacol Ther, 37, 2, pp. 252-262, (2013); Tajik N., Frech M., Schulz O., Et al., Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis, Nat Commun, 11, 1, (2020)^^^Taylor and Francis Ltd.^^^^^^00365521^^SJGRA^33535002.0^English^Scand. J. Gastroenterol.^Article^Final^All Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85100537095
Dale H.F.; Johannessen J.C.H.; Brønstad I.; Lied G.A.^Dale, Hanna Fjeldheim (57202963187); Johannessen, Julianne C. H. (57369012400); Brønstad, Ingeborg (36449808400); Lied, Gülen Arslan (26030494000)^57202963187; 57369012400; 36449808400; 26030494000^Assessment of markers of gut integrity and inflammation in non-celiac gluten sensitivity after a gluten free-diet^2021^International Journal of General Medicine^14.0^^^9459^9470^11.0^1^10.2147/IJGM.S333078^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120965314&doi=10.2147%2fIJGM.S333078&partnerID=40&md5=b2cbf1fcb33fb76134174d0d9f103dd8^Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway; National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway^Dale H.F., Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway, Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway; Johannessen J.C.H., Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Brønstad I., Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway; Lied G.A., Centre for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, Norway, Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway, National Centre of Functional Gastrointestinal Disorders, Haukeland University Hospital, Bergen, Norway^Purpose: Markers for gut integrity and inflammation have received increasing interest as intestinal permeability and innate immune system activation are suggested as possible pathophysiological mechanisms in non-celiac gluten sensitivity (NCGS). We aimed to assess relevant biomarkers in NCGS by analyzing serum levels of gut integrity and permeability markers, pro-inflammatory cytokines and antigliadin IgG in patients with suspected NCGS on a gluten-free diet (GFD), and compare them to serum levels in patients with irritable bowel syndrome (IBS) and healthy controls (HC). Patients and Methods: Serum samples collected from patients with suspected NCGS on a GFD (n=20, 14 women, 21–62 years), IBS (n=20, 16 women, 24–67 years) and HC (n=20, 14 women, 21–54 years) were analyzed. IBS severity scoring system (IBS-SSS) was applied to evaluate gastrointestinal symptoms. Results: The IBS-SSS score was higher in subjects with suspected NCGS and IBS patients compared to HC (p<0.0001). No significant differences were found in the serum levels of any of the gut integrity and permeability markers, cytokines or antigliadin IgG antibodies between the three groups. However, positive correlations were observed between claudin-1 and i-FABP, and between claudin-1 and antigliadin IgG antibodies. Conclusion: No differences in serum levels of gut integrity and permeability markers, proinflammatory cytokines or antigliadin IgG antibodies were found among patients with suspected NCGS on a GFD, IBS and HC. © 2021 Dale et al.^Gluten; Irritable bowel syndrome; Permeability; Pro-inflammatory cytokines^claudin 1; cytokine; fatty acid binding protein 2; gliadin antibody; immunoglobulin G antibody; interleukin 8; lipopolysaccharide binding protein; membrane protein; occludin; unclassified drug; zonulin family peptide; adult; antibody blood level; Article; clinical article; controlled study; descriptive research; digestive system disease assessment; enteritis; female; gastrointestinal symptom; gluten free diet; gut integrity; human; intestine mucosa permeability; intestine parameters; Irritable Bowel Syndrome Quality of Life; Irritable Bowel Syndrome Severity Scoring System; irritable colon; male; non-celiac gluten sensitivity; population research; protein blood level^^claudin 1, 329338-06-9; interleukin 8, 114308-91-7; lipopolysaccharide binding protein, 203946-66-1; occludin, 176304-61-3^^^^^Catassi C, Elli L, Bonaz B, Et al., Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): the salerno experts’ criteria, Nutrients, 7, 6, pp. 4966-4977, (2015); Biesiekierski RJ, Newnham DE, Irving MP, Et al., Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial, Am J Gastroenterol, 106, 3, pp. 508-514, (2011); Volta U, Bardella MT, CalabrA A, Troncone R, Corazza GR., An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity, BMC Med, 12, 1, (2014); Junker Y, Zeissig S, Kim S-J, Et al., Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4, J Exp Med, 209, (2012); Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR., No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates, Gastroenterology, 145, 2, pp. 320-328, (2013); Pellegrina CD, Perbellini O, Scupoli MT, Et al., Effects of wheat germ agglutinin on human gastrointestinal epithelium: insights from an experimental model of immune/epithelial cell interaction, Toxicol Appl Pharmacol, 237, 2, pp. 146-153, (2009); Elli L, Roncoroni L, Bardella MT., Non-celiac gluten sensitivity: time for sifting the grain, World J Gastroenterol, 21, 27, (2015); Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG, Diet A., Low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, 1, pp. 67-75, (2014); Barrett JS, Gearry RB, Muir JG, Et al., Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. (Clinical report), Aliment Pharmacol Ther, 31, 8, (2010); Skodje GI, Sarna VK, Minelle IH, Et al., Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity, Gastroenterology, 154, 3, pp. 529-539, (2018); Dale HF, Hatlebakk JG, Hovdenak N, Ystad SO, Lied GA., The effect of a controlled gluten challenge in a group of patients with suspected noncoeliac gluten sensitivity: a randomized, double-blind placebo-controlled challenge, Neurogastroenterol Motility, 30, 8, (2018); Vazquez-Roque M, Oxentenko A., Nonceliac Gluten Sensitivity, Mayo Clin Proc, 90, 9, pp. 1272-1277, (2015); Carroccio A, Giannone G, Mansueto P, Et al., Duodenal and rectal mucosa inflammation in patients with non-celiac wheat sensitivity, Clin Gastroenterol Hepatol, 17, 4, pp. 682-690, (2019); Margit B, Ann-Christin RB, Stig T, Et al., Mucosal cytokine response after short-term gluten challenge in celiac disease and non-celiac gluten sensitivity, Am J Gastroenterol, 108, 5, (2013); Uhde M, Ajamian M, Caio G, Et al., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, 12, pp. 1930-1937, (2016); Fritscher-Ravens A, Pflaum T, Mosinger M, Et al., Many patients with irritable bowel syndrome have atypical food allergies not associated with immunoglobulin E, Gastroenterology, 157, 1, pp. 109-118, (2019); Barbaro M, Cremon C, Caio G, Et al., Zonulin serum levels are increased in non-celiac gluten sensitivity and irritable bowel syndrome with diarrhea, Gastroenterology, 148, 4, pp. S56-S56, (2015); Sapone A, Lammers K, Casolaro V, Et al., Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity, BMC Med, 9, (2011); Wang W, Uzzau S, Goldblum SE, Fasano A., Human zonulin, a potential modulator of intestinal tight junctions, J Cell Sci, 113, (2000); Lammers KM, Lu R, Brownley J, Et al., Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3, Gastroenterology, 135, 1, pp. 194-204, (2008); Fasano A., All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000Res, 9, (2020); Schumann RR., Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review, Res Immunol, 143, 1, pp. 11-15, (1992); Adriaanse MP, Tack GJ, Passos VL, Et al., Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies, Aliment Pharmacol Ther, 37, 4, pp. 482-490, (2013); Cardoso-Silva D, Delbue D, Itzlinger A, Et al., Intestinal barrier function in gluten-related disorders, Nutrients, 11, 10, (2019); Barmeyer C, Schulzke JD, Fromm M., Claudin-related intestinal diseases, Semin Cell Dev Biol, 42, pp. 30-38, (2015); Dale HF, Jensen C, Hausken T, Valeur J, Hoff DAL, Lied GA., Effects of a cod protein hydrolysate supplement on symptoms, gut integrity markers and fecal fermentation in patients with irritable bowel syndrome, Nutrients, 11, 7, (2019); Francis CY, Morris J, Whorwell PJ., The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress, Aliment Pharmacol Ther, 11, 2, pp. 395-402, (1997); Barbaro MR, Cremon C, Morselli-Labate AM, Et al., Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity, Gut, 69, 11, pp. 1966-1974, (2020); Vazquez-Roque MI, Camilleri M, Smyrk T, Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function, Gastroenterology, 144, 5, pp. 903-911, (2013); Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G., Cytokine levels in the serum of healthy subjects, Mediators Inflamm, 2013, (2013); Justin H, Elaine Leonard P, Bruce G, Eric G, Anthony G, Alessio F., Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity, Nutrients, 7, 3, pp. 1565-1576, (2015); Lau E, Marques C, Pestana D, Et al., The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity, Nutr Metab, 13, (2016); Molina-Infante J, Carroccio A., Suspected nonceliac gluten sensitivity confirmed in few patients after gluten challenge in double-blind, placebo-controlled trials, Clin Gastroenterol Hepatol, 15, 3, pp. 339-348, (2017)^H.F. Dale; Department of Clinical Medicine, University of Bergen, Bergen, Jonas Lies vei 65, 0521, Norway; email: hanna.dale@outlook.com^^Dove Medical Press Ltd^^^^^^11787074^^^^English^Int. J. Gen. Med.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85120965314
Barbaro M.R.; Cremon C.; Morselli-Labate A.M.; Di Sabatino A.; Giuffrida P.; Corazza G.R.; Di Stefano M.; Caio G.; Latella G.; Ciacci C.; Fuschi D.; Mastroroberto M.; Bellacosa L.; Stanghellini V.; Volta U.; Barbara G.^Barbaro, Maria Raffaella (56235164100); Cremon, Cesare (6507319921); Morselli-Labate, Antonio Maria (35458723700); Di Sabatino, Antonio (6603698114); Giuffrida, Paolo (55018594900); Corazza, Gino Roberto (57205413845); Di Stefano, Michele (7005484843); Caio, Giacomo (36005480000); Latella, Giovanni (6603914614); Ciacci, Carolina (7004873608); Fuschi, Daniele (57202989311); Mastroroberto, Marianna (54585720400); Bellacosa, Lara (34972669400); Stanghellini, Vincenzo (7006377452); Volta, Umberto (35780792400); Barbara, Giovanni (7004311418)^56235164100; 6507319921; 35458723700; 6603698114; 55018594900; 57205413845; 7005484843; 36005480000; 6603914614; 7004873608; 57202989311; 54585720400; 34972669400; 7006377452; 35780792400; 7004311418^Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity^2020^Gut^69.0^11^^1966^1974^8.0^51^10.1136/gutjnl-2019-319281^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85080046102&doi=10.1136%2fgutjnl-2019-319281&partnerID=40&md5=0ef4cc5278daf2a07e24ed8043c621ff^Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Department of Clinical Medicine Public Health Life Sciences and Environment, University of l'Aquila, L'Aquila, Abruzzo, Italy; Department of Medicine, Surgery, and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Campania, Italy^Barbaro M.R., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Cremon C., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Morselli-Labate A.M., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Di Sabatino A., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Giuffrida P., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Corazza G.R., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Di Stefano M., First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Lombardia, Italy; Caio G., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Latella G., Department of Clinical Medicine Public Health Life Sciences and Environment, University of l'Aquila, L'Aquila, Abruzzo, Italy; Ciacci C., Department of Medicine, Surgery, and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Campania, Italy; Fuschi D., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Mastroroberto M., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Bellacosa L., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Stanghellini V., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Volta U., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy; Barbara G., Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, 40138, Italy^Objective Non-coeliac gluten sensitivity (NCGS) is characterised by intestinal and extraintestinal symptoms related to the ingestion of gluten-containing foods, in the absence of coeliac disease (CD) and wheat allergy. No biomarkers are available to diagnose NCGS and the gold standard double-blind placebo-controlled gluten challenge is clinically impractical. The aim of our work was to investigate the role of serum zonulin as a diagnostic biomarker of NCGS and to develop a diagnostic algorithm. Design In a multicentre study, we enrolled 86 patients with either self-reported or double-blind confirmed NCGS, 59 patients with diarrhoea-predominant IBS (IBS-D), 15 patients with CD and 25 asymptomatic controls (AC). Zonulin serum levels were assessed and the associated diagnostic power calculated. Clinical and symptomatic data were recorded. The effect of diet on zonulin levels was evaluated in a subgroup of patients with NCGS. Results Compared with ACs, the NCGS, irrespective of modality of diagnosis, and patients with CD had significantly increased levels of zonulin, as did both NCGS and patients with CD compared with participants with IBS-D. Self-reported NCGS showed increased zonulin levels compared with double-blind confirmed and not-confirmed NCGS. Six-month wheat avoidance significantly reduced zonulin levels only in HLA-DQ2/8-positive participants with NCGS. The diagnostic accuracy of zonulin levels in distinguishing NCGS from IBS-D was 81%. After exclusion of CD, a diagnostic algorithm combining zonulin levels, symptoms and gender improved the accuracy to 89%. Conclusion Zonulin can be considered a diagnostic biomarker in NCGS and combined with demographic and clinical data differentiates NCGS from IBS-D with high accuracy. Wheat withdrawal was associated with a reduction in zonulin levels only in NCGS carrying HLA genotype.  © ^epithelial barrier; functional bowel disorder; irritable bowel syndrome; nutrition^Adult; Algorithms; Biomarkers; Case-Control Studies; Celiac Disease; Female; Glutens; Haptoglobins; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Predictive Value of Tests; Protein Precursors; ROC Curve; Wheat Hypersensitivity; HLA DQ2 antigen; HLA DQ8 antigen; HLA DQA1 antigen; HLA DQB1 antigen; membrane protein; unclassified drug; zonulin; biological marker; gluten; haptoglobin; protein precursor; zonulin; adult; Article; asymptomatic disease; celiac disease; controlled study; diagnostic accuracy; diagnostic value; diet; differential diagnosis; enzyme linked immunosorbent assay; female; gender; genotype; human; irritable colon; major clinical study; malabsorption; male; non celiac gluten sensitivity; nutritional intolerance; priority journal; protein blood level; receiver operating characteristic; self report; sensitivity and specificity; wheat; algorithm; blood; case control study; celiac disease; irritable colon; middle aged; predictive value; wheat allergy^^gluten, 8002-80-0; haptoglobin, 9087-69-8; Biomarkers, ; Glutens, ; Haptoglobins, ; Protein Precursors, ; zonulin, ^NanoDrop 2000, Thermo, Italy^Thermo, Italy^Fondazione del Monte di Bologna; University; Ministry of Education, MOE; Ministero dell’Istruzione, dell’Università e della Ricerca, MIUR; Fondazione del Monte di Bologna e Ravenna; Università di Bologna, UNIBO^Funding text 1: Funding The study was supported by the italian Ministry of education, University and research, the University of Bologna and Fondazione del Monte di Bologna e ravenna.; Funding text 2: The study was supported by the Italian Ministry of Education, University and Research, the University of Bologna and Fondazione del Monte di Bologna e Ravenna.^Catassi C., Elli L., Bonaz B., Et al., Diagnosis of non-celiac gluten sensitivity (NCGS): The Salerno experts' criteria, Nutrients, 7, pp. 4966-4977, (2015); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Volta U., Bardella M.T., Calabro A., Et al., An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity, BMC Med, 12, (2014); Carroccio A., D'Alcamo A., Cavataio F., Et al., High proportions of people with Nonceliac wheat sensitivity have autoimmune disease or antinuclear antibodies, Gastroenterology, 149, pp. 596-603, (2015); Hollon J., Puppa E.L., Greenwald B., Et al., Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity, Nutrients, 7, pp. 1565-1576, (2015); Wang W., Uzzau S., Goldblum S.E., Et al., Human zonulin, a potential modulator of intestinal tight junctions, J Cell Sci, 113, pp. 4435-4440, (2000); Tripathi A., Lammers K.M., Goldblum S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci U S A, 106, pp. 16799-16804, (2009); Sapone A., De Magistris L., Pietzak M., Et al., Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives, Diabetes, 55, pp. 1443-1449, (2006); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterology, 144, pp. 903-911, (2013); El Asmar R., Panigrahi P., Bamford P., Et al., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, pp. 1607-1615, (2002); Lammers K.M., Lu R., Brownley J., Et al., Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3, Gastroenterology, 135, pp. 194-204, (2008); Fasano A., Not T., Wang W., Et al., Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, The Lancet, 355, pp. 1518-1519, (2000); Caio G., Volta U., Tovoli F., Et al., Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity, BMC Gastroenterol, 14, (2014); Volta U., Caio G., De Giorgio R., Et al., Non-celiac gluten sensitivity: A work-in-progress entity in the spectrum of wheat-related disorders, Best Pract Res Clin Gastroenterol, 29, pp. 477-491, (2015); Di Sabatino A., Volta U., Salvatore C., Et al., Small amounts of gluten in subjects with suspected Nonceliac gluten sensitivity: A randomized, double-blind, placebo-controlled, cross-over trial, Clin Gastroenterol Hepatol, 13, pp. 1604-1612, (2015); Elli L., Tomba C., Branchi F., Et al., Evidence for the presence of non-celiac gluten sensitivity in patients with functional gastrointestinal symptoms: Results from a multicenter randomized double-blind placebo-controlled gluten challenge, Nutrients, 8, (2016); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Rubio-Tapia A., Hill I.D., Kelly C.P., Et al., ACG clinical guidelines: Diagnosis and management of celiac disease, Am J Gastroenterol, 108, pp. 656-676, (2013); Oberhuber G., Granditsch G., Vogelsang H., The histopathology of coeliac disease: Time for a standardized report scheme for pathologists, Eur J Gastroenterol Hepatol, 11, pp. 1185-1194, (1999); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barbaro M.R., Cremon C., Caio G., Et al., The role of zonulin in non-celiac gluten sensitivity and irritable bowel syndrome, United Eur Gastroenterol J, 3, (2015); Dupont W.D., Plummer W.D., PS: Power and Sample Size Calculation; Dupont W.D., Plummer W.D., Power and sample size calculations. A review and computer program, Control Clin Trials, 11, pp. 116-128, (1990); Dupont W.D., Plummer W.D., Power and sample size calculations for studies involving linear regression, Control Clin Trials, 19, pp. 589-601, (1998); Pezzilli R., Billi P., Miniero R., Et al., Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis. Comparison with serum C-reactive protein, Dig Dis Sci, 40, pp. 2341-2348, (1995); Uhde M., Ajamian M., Caio G., Et al., Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease, Gut, 65, pp. 1930-1937, (2016); De Punder K., Pruimboom L., The dietary intake of wheat and other cereal grains and their role in inflammation, Nutrients, 5, pp. 771-787, (2013); Skodje G.I., Sarna V.K., Minelle I.H., Et al., Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity, Gastroenterology, 154, pp. 529-539, (2018); Pinto-Sanchez M.I., Verdu E.F., Non-coeliac gluten sensitivity: Are we closer to separating the wheat from the chaff?, Gut, 65, pp. 1921-1922, (2016); Junker Y., Zeissig S., Kim S.-J., Et al., Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of Toll-like receptor 4, J Exp Med, 209, pp. 2395-2408, (2012); Singh P., Silvester J., Chen X., Et al., Serum zonulin is elevated in IBS and correlates with stool frequency in IBS-D, United European Gastroenterol J, 7, pp. 709-715, (2019); Zhou Q., Zhang B., Verne N.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Carroccio A., Mansueto P., Iacono G., Et al., Non-C eliac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity, Am J Gastroenterol, 107, pp. 1898-1906, (2012); Stevens B.R., Goel R., Seungbum K., Et al., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Perrier C., Corthesy B., Gut permeability and food allergies, Clin Exp Allergy, 41, pp. 20-28, (2011); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Volta U., Tovoli F., Cicola R., Et al., Serological tests in gluten sensitivity (nonceliac gluten intolerance), J Clin Gastroenterol, 46, pp. 680-685, (2012); Carroccio A., Giannone G., Mansueto P., Et al., Duodenal and rectal mucosa inflammation in patients with non-celiac wheat sensitivity, Clin Gastroenterol Hepatol, 17, pp. 682-690, (2019); Barbara G., IBS: Biomarkers for IBS: Ready for prime time?, Nat Rev Gastroenterol Hepatol, 12, pp. 9-10, (2015)^^^BMJ Publishing Group^^^^^^00175749^^GUTTA^32060130.0^English^Gut^Article^Final^^Scopus^2-s2.0-85080046102
Yin S.; Sun C.; Ji Y.; Abdolmaleky H.; Zhou J.-R.^Yin, Sheng (57218525830); Sun, Chao (57746230900); Ji, Yi (57208291852); Abdolmaleky, Hamid (8744606800); Zhou, Jin-Rong (7405549563)^57218525830; 57746230900; 57208291852; 8744606800; 7405549563^Herbal medicine WangShiBaoChiWan improves gastrointestinal health in mice via modulation of intestinal tight junctions and gut microbiota and inhibition of inflammation^2021^Biomedicine and Pharmacotherapy^138.0^^111426^^^^12^10.1016/j.biopha.2021.111426^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103005687&doi=10.1016%2fj.biopha.2021.111426&partnerID=40&md5=7cf23bef2e2ea6def52d869777d95367^Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States; Department of Acupuncture-Moxibustion and Tuina, Qilu Hospital of Shangdong University, Jinan, 250012, Shangdong, China; Department of Oncology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, China^Yin S., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States; Sun C., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States, Department of Acupuncture-Moxibustion and Tuina, Qilu Hospital of Shangdong University, Jinan, 250012, Shangdong, China; Ji Y., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States, Department of Oncology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, Jiangsu, China; Abdolmaleky H., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States; Zhou J.-R., Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, United States^WangShiBoChiWan (WSBCW) is a commonly used Chinese herbal medicine for the treatment of functional gastrointestinal disorders. However, its preclinical efficacy and the mechanisms of action have not been adequately studied. The goals of this study were to evaluate the effects of WSBCW on gastrointestinal health and modulation of related biomarkers. Female C57BL mice were randomly assigned into one of the experimental groups consisting of the control, drug controls, and WSBCW at 40, 120, and 360 mg/kg BW. Whole gut transit, small intestinal motility, and intestinal barrier permeability were determined. The castor oil-induced diarrhea mouse model was used to determine the effect of WSBCW on the diarrhea type of irritable bowel syndrome (IBS-D). WSBCW increased whole gut transit and intestinal motility, improved intestinal permeability in healthy animals and alleviated diarrhea symptoms in IBS-D mice. WSBCW upregulated intestinal junction proteins, increased the abundance of Bifidobacterium genus, Desulfovibrio genus and inhibited Bacteroides fragillis group in the gut microbiota, increased intestinal villi lengths, and decreased blood levels of inflammatory cytokines. Our study provided preclinical evidence to verify the effectiveness of WSBCW in gastrointestinal health and elucidate mechanistic insights. The results warrant further investigations to evaluate the therapeutic efficacy of WSBCW on gastrointestinal disorders, such as IBS and IBD. © 2021 The Authors^Gastrointestinal; Inflammation; Junction; Microbiota; Motility; Permeability^Animals; Diarrhea; Drugs, Chinese Herbal; Female; Gastrointestinal Microbiome; Gastrointestinal Motility; Gastrointestinal Tract; Herbal Medicine; Inflammation Mediators; Intestinal Mucosa; Irritable Bowel Syndrome; Mice; Mice, Inbred C57BL; Tight Junctions; agents used in inflammatory bowel disease; antidiarrheal agent; biological marker; Chinese drug; claudin; claudin 1; claudin 15; claudin 4; claudin 7; gamma interferon; genomic DNA; herbaceous agent; interleukin 12p40; interleukin 12p70; interleukin 6; junctional adhesion molecule; junctional adhesion molecule 4; junctional adhesion molecule A; linaclotide; loperamide; membrane protein; messenger RNA; monocyte chemotactic protein 1; protein ZO1; protein ZO2; protein ZO3; tumor necrosis factor; unclassified drug; uvomorulin; wangshibaochiwan; autacoid; herbaceous agent; adherens junction; adult; animal cell; animal experiment; animal model; animal tissue; antidiarrheal activity; Article; Atopobium; Bacteroides; Bacteroides fragilis; Bacteroides fragillis; Bifidobacterium; castor oil-induced diarrhea; Chinese medicine; Clostridium; Clostridium coccoides; Clostridium leptum; controlled study; Desulfovibrio; digestive system function disorder; DNA extraction; female; gastrointestinal tract function; gastrointestinal transit; inflammatory bowel disease; intestine flora; intestine motility; intestine mucosa permeability; intestine villus; irritable colon; Lactobacillus; mouse; mRNA expression level; nonhuman; Prevotella; priority journal; protein blood level; real time polymerase chain reaction; small intestine; tight junction; upregulation; animal; C57BL mouse; diarrhea; drug effect; gastrointestinal motility; gastrointestinal tract; herbal medicine; intestine mucosa; pathophysiology; physiology; procedures^^claudin 1, 329338-06-9; gamma interferon, 82115-62-6; linaclotide, 851199-59-2, 851199-60-5; loperamide, 34552-83-5, 53179-11-6; uvomorulin, 112956-45-3; Drugs, Chinese Herbal, ; Inflammation Mediators, ^^^Jinghua Pharmaceuticals Group^This research was funded by Beth Israel Deaconess Medical Center Research Project (#A10164) sponsored by Jinghua Pharmaceuticals Group, China.^Bischoff S.C., ‘Gut health’: a new objective in medicine?, BMC Med., 9, (2011); Noddin L., Callahan M., Lacy B.E., Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?, MedGenMed, 7, 3, (2005); Chogle A., Velasco-Benitez C.A., Koppen I.J., Moreno J.E., Ramirez Hernandez C.R., Saps M., A population-based study on the epidemiology of functional gastrointestinal disorders in young children, J. Pediatr., 179, pp. 139-143 e1, (2016); Boronat A.C., Ferreira-Maia A.P., Matijasevich A., Wang Y.P., Epidemiology of functional gastrointestinal disorders in children and adolescents: a systematic review, World J. Gastroenterol., 23, 21, pp. 3915-3927, (2017); Avramidou M., Angst F., Angst J., Aeschlimann A., Rossler W., Schnyder U., Epidemiology of gastrointestinal symptoms in young and middle-aged Swiss adults: prevalences and comorbidities in a longitudinal population cohort over 28 years, BMC Gastroenterol., 18, 1, (2018); Dale H.F., Rasmussen S.H., Asiller O.O., Lied G.A., Probiotics in irritable bowel syndrome: an up-to-date systematic review, Nutrients, 11, 9, (2019); Masuy I., Pannemans J., Tack J., Irritable bowel syndrome: diagnosis and management, Minerva Gastroenterol. Dietol., 66, 2, pp. 136-150, (2020); Vegh Z., Kurti Z., Lakatos P.L., Epidemiology of inflammatory bowel diseases from west to east, J. Dig. Dis., 18, 2, pp. 92-98, (2017); Hu S.Y., Ma R., Guang J.X., Feng Z.W., Xu H.F., Li X.M., Bai X.H., Ma Q.P., Xiang X.X., Zhu F.L., Li W.W., Liu P.D., Cai J.X., Zhang H., Treatment of functional dyspepsia in children with WangshiBaochi Pills: a randomized double-blind multicenter clinical trial, Chin. J. New Drugs, 28, pp. 179-183, (2019); He L.X., Abdolmaleky H.M., Yin S., Wang Y., Zhou J.R., Dietary fermented soy extract and oligo-lactic acid alleviate chronic kidney disease in mice via inhibition of inflammation and modulation of gut microbiota, Nutrients, 12, 8, (2020); Gunzel D., Yu A.S., Claudins and the modulation of tight junction permeability, Physiol. Rev., 93, 2, pp. 525-569, (2013); Lee S.H., Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases, Intest. Res., 13, 1, pp. 11-18, (2015); Luettig J., Rosenthal R., Barmeyer C., Schulzke J.D., Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation, Tissue Barriers, 3, 1-2, (2015); Tokuda S., Hirai T., Furuse M., Claudin-4 knockout by TALEN-mediated gene targeting in MDCK cells: Claudin-4 is dispensable for the permeability properties of tight junctions in wild-type MDCK cells, PLoS One, 12, 8, (2017); Nishiguchi Y., Fujiwara-Tani R., Sasaki T., Luo Y., Ohmori H., Kishi S., Mori S., Goto K., Yasui W., Sho M., Kuniyasu H., Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer, Oncotarget, 10, 22, pp. 2189-2202, (2019); Fujiwara-Tani R., Sasaki T., Luo Y., Goto K., Kawahara I., Nishiguchi Y., Kishi S., Mori S., Ohmori H., Kondoh M., Kuniyasu H., Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer, Oncotarget, 9, 100, pp. 37367-37378, (2018); Duarte G.M., Almeida N.R., Tocchet F., Espinola J., Barreto C.T.R., Pinto G.A., Soares F.A., Marshall P., Russano de Paiva Silva G., Claudin-4 expression is associated with disease-free survival in breast carcinoma-in-situ: mean follow-up of 8.2 years, Clin. Breast Cancer, 18, 5, pp. e1111-e1116, (2018); Martin de la Fuente L., Malander S., Hartman L., Jonsson J.M., Ebbesson A., Nilbert M., Masback A., Hedenfalk I., Claudin-4 expression is associated with survival in ovarian cancer but not with chemotherapy response, Int. J. Gynecol. Pathol., 37, 2, pp. 101-109, (2018); Breed C., Hicks D.A., Webb P.G., Galimanis C.E., Bitler B.G., Behbakht K., Baumgartner H.K., Ovarian tumor cell expression of claudin-4 reduces apoptotic response to paclitaxel, Mol. Cancer Res., 17, 3, pp. 741-750, (2019); Mehta S., Nijhuis A., Kumagai T., Lindsay J., Silver A., Defects in the adherens junction complex (E-cadherin/beta-catenin) in inflammatory bowel disease, Cell Tissue Res., 360, 3, pp. 749-760, (2015); Hermiston M.L., Gordon J.I., Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin, Science, 270, 5239, pp. 1203-1207, (1995); Satokari R., Modulation of gut microbiota for health by current and next-generation probiotics, Nutrients, 11, 8, (2019); Hirano A., Umeno J., Okamoto Y., Shibata H., Ogura Y., Moriyama T., Torisu T., Fujioka S., Fuyuno Y., Kawarabayasi Y., Matsumoto T., Kitazono T., Esaki M., Comparison of the microbial community structure between inflamed and non-inflamed sites in patients with ulcerative colitis, J. Gastroenterol. Hepatol., 33, pp. 1590-1597, (2018); Blandford L.E., Johnston E.L., Sanderson J.D., Wade W.G., Lax A.J., Promoter orientation of the immunomodulatory Bacteroides fragilis capsular polysaccharide A (PSA) is off in individuals with inflammatory bowel disease (IBD), Gut Microbes, 10, 5, pp. 569-577, (2019); Rashidan M., Azimirad M., Alebouyeh M., Ghobakhlou M., Asadzadeh Aghdaei H., Zali M.R., Detection of B. fragilis group and diversity of bft enterotoxin and antibiotic resistance markers cepA, cfiA and nim among intestinal Bacteroides fragilis strains in patients with inflammatory bowel disease, Anaerobe, 50, pp. 93-100, (2018); Aomatsu T., Imaeda H., Takahashi K., Fujimoto T., Kasumi E., Yoden A., Tamai H., Fujiyama Y., Andoh A., Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts, Int. J. Mol. Med., 30, 5, pp. 1152-1158, (2012); Mazzucchelli L., Hauser C., Zgraggen K., Wagner H.E., Hess M.W., Laissue J.A., Mueller C., Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease, J. Pathol., 178, 2, pp. 201-206, (1996); Spoettl T., Hausmann M., Herlyn M., Gunckel M., Dirmeier A., Falk W., Herfarth H., Schoelmerich J., Rogler G., Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes, Clin. Exp. Immunol., 145, 1, pp. 190-199, (2006); Neurath M.F., IL-23 in inflammatory bowel diseases and colon cancer, Cytokine Growth Factor Rev., 45, pp. 1-8, (2019); Shim H.H., Chan P.W., Chuah S.W., Schwender B.J., Kong S.C., Ling K.L., A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases, JGH Open, 2, 5, pp. 223-234, (2018)^J.-R. Zhou; Nutrition/Metabolism Laboratory, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ST-8M10D, 330 Brookline Avenue, 02215, United States; email: jrzhou@bidmc.harvard.edu^^Elsevier Masson s.r.l.^^^^^^07533322^^BIPHE^33762124.0^English^Biomed. Pharmacother.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85103005687
Palombo G.; Merone M.; Altomare A.; Gori M.; Terradura C.; Bacco L.; Del Chierico F.; Putignani L.; Cicala M.; Guarino M.P.L.; Piemonte V.^Palombo, Giovanni (56203913300); Merone, Mario (56102657200); Altomare, Annamaria (11539354000); Gori, Manuele (56284669400); Terradura, Carlotta (57224948092); Bacco, Luca (57220927387); Del Chierico, Federica (8976163900); Putignani, Lorenza (6603168130); Cicala, Michele (6701721784); Guarino, Michele Pier Luca (35901989300); Piemonte, Vincenzo (8706417000)^56203913300; 56102657200; 11539354000; 56284669400; 57224948092; 57220927387; 8976163900; 6603168130; 6701721784; 35901989300; 8706417000^The impact of the intestinal microbiota and the mucosal permeability on three different antibiotic drugs^2021^European Journal of Pharmaceutical Sciences^164.0^^105869^^^^3^10.1016/j.ejps.2021.105869^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108726646&doi=10.1016%2fj.ejps.2021.105869&partnerID=40&md5=71d385932adca8f55a79dbf095fd66a1^Unit of Chemical-physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Istituto di Analisi dei Sistemi ed Informatica “A. Ruberti”, IASI-CNR (National Research Council of Italy), Rome, Italy; Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Institute of Biochemistry and Cell Biology (IBBC) - National Research Council (CNR), Monterotondo Scalo, Rome, Italy; Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Department of Diagnostic and Laboratory Medicine, Unit of Parasitology and Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Istituto di Linguistica Computazionale “Antonio Zampolli” (IL-CNR), ItaliaNLP Lab, Pisa, Italy; SYSBIO/ISBE.IT, Centre of System Biology, Rome, Italy^Palombo G., Istituto di Analisi dei Sistemi ed Informatica “A. Ruberti”, IASI-CNR (National Research Council of Italy), Rome, Italy, SYSBIO/ISBE.IT, Centre of System Biology, Rome, Italy; Merone M., Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Altomare A., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Gori M., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy, Institute of Biochemistry and Cell Biology (IBBC) - National Research Council (CNR), Monterotondo Scalo, Rome, Italy; Terradura C., Unit of Chemical-physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Italy; Bacco L., Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy, Istituto di Linguistica Computazionale “Antonio Zampolli” (IL-CNR), ItaliaNLP Lab, Pisa, Italy; Del Chierico F., Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Putignani L., Department of Diagnostic and Laboratory Medicine, Unit of Parasitology and Multimodal Laboratory Medicine Research Area, Unit of Human Microbiome, Bambino Gesú Children's Hospital, IRCCS, Rome, Italy; Cicala M., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Guarino M.P.L., Unit of Gastroenterology Campus Bio-Medico University, Rome, Italy; Piemonte V., Unit of Chemical-physics Fundamentals in Chemical Engineering, Department of Engineering, University Campus Bio-Medico of Rome, Italy^BackgroundThe totality of bacteria, protozoa, viruses and fungi that lives in the human body is called microbiota. Human microbiota specifically colonizes the skin, the respiratory and urinary tract, the urogenital tract and the gastrointestinal system. This study focuses on the intestinal microbiota to explore the drug-microbiota relationship and, therefore, how the drug bioavailability changes in relation to the microbiota biodiversity to identify more personalized therapies, with the minimum risk of side effects. MethodsTo achieve this goal, we developed a new mathematical model with two compartments, the intestine and the blood, which takes into account the colonic mucosal permeability variation - measured by Ussing chamber system on human colonic mucosal biopsies - and the fecal microbiota composition, determined through microbiota 16S rRNA sequencing analysis. Both of the clinical parameters were evaluated in a group of Irritable Bowel Syndrome patients compared to a group of healthy controls. Key ResultsThe results show that plasma drug concentration increases as bacterial concentration decreases, while it decreases as intestinal length decreases too. ConclusionsThe study provides interesting data since in literature there are not yet mathematical models with these features, in which the importance of intestinal microbiota, the ”forgotten organ”, is considered both for the subject health state and in the nutrients and drugs metabolism. © 2021^Compartmental models; Drug bioavailability; Gut barrier function; Intestinal microbiota^Anti-Bacterial Agents; Feces; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Permeability; Pharmaceutical Preparations; RNA, Ribosomal, 16S; ampicillin; antibiotic agent; antihypertensive agent; beta adrenergic receptor blocking agent; ciprofloxacin; hydroxymethylglutaryl coenzyme A reductase inhibitor; RNA 16S; tetracycline; antiinfective agent; drug; RNA 16S; adult; Article; blood; clinical article; colon biopsy; colon mucosa; compartment model; computer simulation; controlled study; data analysis software; drug bioavailability; drug blood level; feces microflora; female; human; human tissue; intestine; intestine flora; intestine mucosa permeability; irritable colon; length; male; microbial diversity; nonhuman; prospective study; RNA sequencing; species composition; feces; genetics; intestine mucosa; permeability^^ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0; ciprofloxacin, 85721-33-1, 86393-32-0, 128074-72-6, 128074-76-0, 192934-52-4, 93107-08-5, 86483-48-9, 96186-80-0; tetracycline, 23843-90-5, 60-54-8, 64-75-5, 8021-86-1; Anti-Bacterial Agents, ; Pharmaceutical Preparations, ; RNA, Ribosomal, 16S, ^FastStart High Fidelity, Hoffmann La Roche, United States; GS sequencer software v.2.7, Hoffmann La Roche, Germany; Infinite M200-Pro, Tecan, Switzerland; QIAamp DNA Stool Mini Kit, Qiagen, Germany; QIIME 1.9.0; Quant-iT PicoGreen, Life Technologies, United States; Roche 454, Life Science^Hoffmann La Roche, Germany; Hoffmann La Roche, United States; Life Science; Life Technologies, United States; Qiagen, Germany; Tecan, Switzerland^^^Acetate G., Livertox: Clinical and Research Information on Drug-induced Liver Injury, (2012); Agoram B., Woltosz W.S., Bolger M.B., Predicting the impact of physiological and biochemical processes on oral drug bioavailability, Adv. Drug Deliv. Rev., 50, pp. S41-S67, (2001); Alegria A., Garcia-Llatas G., Cilla A., Static digestion models: general introduction, The impact of food bioactives on health, pp. 3-12, (2015); Altomare A., Gori M., Cocca S., Carotti S., Francesconi M., Ribolsi M., Emerenziani S., Perrone G., Morini S., Cicala M., Et al., Impaired colonic contractility and intestinal permeability in symptomatic uncomplicated diverticular disease, J. Neurogastroenterol. Motil., (2021); Anson N.M., Havenaar R., Bast A., Haenen G.R., Antioxidant and anti-inflammatory capacity of bioaccessible compounds from wheat fractions after gastrointestinal digestion, J. Cereal Sci., 51, 1, pp. 110-114, (2010); den Besten G., van Eunen K., Groen A.K., Venema K., Reijngoud D.-J., Bakker B.M., The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism, J. Lipid Research, 54, 9, pp. 2325-2340, (2013); Blaser J., Stone B.B., Groner M.C., Zinner S.H., Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to mic for bactericidal activity and emergence of resistance., Antimicrob. Agents Chemother., 31, 7, pp. 1054-1060, (1987); Bowker K., Wootton M., Rogers C., Lewis R., Holt H., MacGowan A., Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin, J. Antimicrob. Chemother., 44, 5, pp. 661-667, (1999); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Fierer N., Pena A.G., Goodrich J.K., Gordon J.I., Et al., Qiime allows analysis of high-throughput community sequencing data, Nat. Methods, 7, 5, (2010); Carabotti M., Scirocco A., Maselli M.A., Severi C., The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems, Ann. Gastroenterol., 28, 2, (2015); Carinci P., Marinozzi G., Gaudio E., Anatomia umana e istologia, (2015); Craig W.A., Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin. Infect. Dis., pp. 1-10, (1998); Dinan T., Borre Y., Cryan J., Genomics of schizophrenia: time to consider the gut microbiome?, Mol. Psychiatry, 19, 12, pp. 1252-1257, (2014); Dona D., Barbieri E., Daverio M., Lundin R., Giaquinto C., Zaoutis T., Sharland M., Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review, Antimicrob. Resist. Infect. Control, 9, 1, (2020); Dressman J., Amidon G., Fleisher D., Absorption potential: estimating the fraction absorbed for orally administered compounds, J. Pharm. Sci., 74, 5, pp. 588-589, (1985); Edgar R.C., Search and clustering orders of magnitude faster than blast, Bioinformatics, 26, 19, pp. 2460-2461, (2010); Ekmekcioglu C., A physiological approach for preparing and conducting intestinal bioavailability studies using experimental systems, Food Chem., 76, 2, pp. 225-230, (2002); Ercolini D., De Filippis F., La Storia A., Iacono M., “remake” by high-throughput sequencing of the microbiota involved in the production of water buffalo mozzarella cheese, Appl. Environ. Microbiol., 78, 22, pp. 8142-8145, (2012); (2016); Fasano A., All disease begins in the (leaky) gut: Role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases, F1000Research, 9, (2020); Fernandez-Garcia E., Carvajal-Lerida I., Perez-Galvez A., In vitro bioaccessibility assessment as a prediction tool of nutritional efficiency, Nutr. Res., 29, 11, pp. 751-760, (2009); Ferrua M.J., Singh R.P., Human gastric simulator (riddet model), The Impact of Food Bioactives on Health, pp. 61-71, (2015); Finnah A., Pineiro S., Reuss R., Sanders P.; Fouchecourt M.-O., Beliveau M., Krishnan K., Quantitative structure–pharmacokinetic relationship modelling, Sci. Total Environ., 274, 1-3, pp. 125-135, (2001); Guarino M.P.L., Altomare A., Stasi E., Marignani M., Severi C., Alloni R., Dicuonzo G., Morelli L., Coppola R., Cicala M., Effect of acute mucosal exposure to lactobacillus rhamnosus gg on human colonic smooth muscle cells, J. Clin. Gastroenterol., 42, pp. S185-S190, (2008); Haggard H.W., The absorption, distribution, and elimination of ethyl ether ii. analysis of the mechanism of absorption and elimination of such a gas or vapor as ethyl ether, J. Biol. Chem., 59, 3, pp. 753-770, (1924); Haggard H.W., The absorption, distribution, and elimination of ethyl ether. III. The relation of the concentration of ether, or any similar volatile substance, in the central nervous system to the concentration in the arterial blood, and the buffer action of the body, J. Biol. Chem., 59, 3, pp. 771-781, (1924); Hellstrom P.M., Benno P., The rome iv: irritable bowel syndrome-a functional disorder, Best Pract. Res. Clin. Gastroenterol., (2019); Hiippala K., Kainulainen V., Kalliomaki M., Arkkila P., Satokari R., Mucosal prevalence and interactions with the epithelium indicate commensalism of sutterella spp., Front. Microbiol., 7, (2016); Holz M., Fahr A., Compartment modeling, Adv. Drug Deliv. Rev., 48, 2-3, pp. 249-264, (2001); Jeffery I.B., O'toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, 7, pp. 997-1006, (2012); Kim S., Covington A., Pamer E.G., The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens, Immunol. Rev., 279, 1, pp. 90-105, (2017); Klinke R., Silbernagl S., Fisiologia, (1999); Kong F., Singh R.P., A human gastric simulator (HGS) to study food digestion in human stomach, J. Food Sci., 75, 9, pp. E627-E635, (2010); Labus J.S., Hollister E.B., Jacobs J., Kirbach K., Oezguen N., Gupta A., Acosta J., Luna R.A., Aagaard K., Versalovic J., Et al., Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome, Microbiome, 5, 1, (2017); Lacy B.E., Patel N.K., Rome criteria and a diagnostic approach to irritable bowel syndrome, J. Clin. Med., 6, 11, (2017); Larsson M., Minekus M., Havenaar R., Estimation of the bioavailability of iron and phosphorus in cereals using a dynamic in vitro gastrointestinal model, J. Sci. Food Agric., 74, 1, pp. 99-106, (1997); Lawrence X.Y., Crison J.R., Amidon G.L., Compartmental transit and dispersion model analysis of small intestinal transit flow in humans, Int. J. Pharm., 140, 1, pp. 111-118, (1996); Lennernas H., Human in vivo regional intestinal permeability: importance for pharmaceutical drug development, Mol. Pharm., 11, 1, pp. 12-23, (2014); Lin J.H., Sugiyama Y., Awazu S., Hanano M., In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models, J. Pharmacokinet. Biopharm., 10, 6, pp. 637-647, (1982); Lin L., Wong H., Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models, Pharmaceutics, 9, 4, (2017); Liu L., Pang K.S., An integrated approach to model hepatic drug clearance, Eur. J. Pharm. Sci., 29, 3-4, pp. 215-230, (2006); Lo Presti A., Zorzi F., Del Chierico F., Altomare A., Cocca S., Avola A., De Biasio F., Russo A., Cella E., Reddel S., Et al., Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease, Front. Microbiol., 10, (2019); Maier L., Pruteanu M., Kuhn M., Zeller G., Telzerow A., Anderson E.E., Brochado A.R., Fernandez K.C., Dose H., Mori H., Et al., Extensive impact of non-antibiotic drugs on human gut bacteria, Nature, 555, 7698, pp. 623-628, (2018); Mann J.C., Pygall S.R., A formulation case study comparing the dynamic gastric model with conventional dissolution methods, Dissolut. Technol., 19, 4, pp. 14-19, (2012); Menard O., Picque D., Dupont D., The didgi® system, The Impact of Food Bioactives on Health, pp. 73-81, (2015); Menees S., Chey W., The gut microbiome and irritable bowel syndrome, F1000Research, 7, (2018); Minekus M., The tno gastro-intestinal model (tim), The impact of food bioactives on health, pp. 37-46, (2015); Minekus M., Marteau P., Havenaar R., Et al., Multicompartmental dynamic computer-controlled model simulating the stomach and small intestine, Altern. Lab. Anim., (1995); Moreda-Pineiro J., Moreda-Pineiro A., Romaris-Hortas V., Moscoso-Perez C., Lopez-Mahia P., Muniategui-Lorenzo S., Bermejo-Barrera P., Prada-Rodriguez D., In-vivo and in-vitro testing to assess the bioaccessibility and the bioavailability of arsenic, selenium and mercury species in food samples, TrAC Trends Anal. Chem., 30, 2, pp. 324-345, (2011); Nestorov I., Whole body pharmacokinetic models, Clin. Pharmacokinet., 42, 10, pp. 883-908, (2003); Ohlsson A., Shah V.S., Intrapartum antibiotics for known maternal group b streptococcal colonization, Cochrane Database Syst. Rev., 6, (2014); Peng H., Cheung B., A Review on Pharmacokinetic Modeling and the Effects of Environmental Stressors on Pharmacokinetics for Operational Medicine: Operational Pharmacokinetics, Technical Report, (2009); Pompa M., Capocelli M., Piemonte V., A new gastro-intestinal mathematical model to study drug bioavailability, Med. Eng. Phys., 74, pp. 106-114, (2019); Recenti R., Il microbiota intestinale, Recenti Prog. Med., 107, 6, pp. 257-266, (2016); Reeder J., Knight R., Rapidly denoising pyrosequencing amplicon reads by exploiting rank-abundance distributions, Nat. Methods, 7, 9, pp. 668-669, (2010); Regoes R.R., Wiuff C., Zappala R.M., Garner K.N., Baquero F., Levin B.R., Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens, Antimicrob. Agents Chemother., 48, 10, pp. 3670-3676, (2004); Ruan W., Engevik M.A., Spinler J.K., Versalovic J., Healthy human gastrointestinal microbiome: composition and function after a decade of exploration, Digest. Dis. Sci., pp. 1-11, (2020); S Darwich A., Neuhoff S., Jamei M., Rostami-Hodjegan A., Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “advanced dissolution, absorption, metabolism (adam)- model, Curr. Drug Metab., 11, 9, pp. 716-729, (2010); Sanchez Navarro M.D., Sayalero Marinero M.L., Sanchez Navarro A., Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections, J. Antimicrob. Chemother., 50, 1, pp. 67-72, (2002); Sarkar S.R., Banerjee S., Gut microbiota in neurodegenerative disorders, J. Neuroimmunol., 328, pp. 98-104, (2019); Sjogren E., Westergren J., Grant I., Hanisch G., Lindfors L., Lennernas H., Abrahamsson B., Tannergren C., In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-SIM, Eur. J. Pharm. Sci., 49, 4, pp. 679-698, (2013); Steelant B., Farre R., Wawrzyniak P., Belmans J., Dekimpe E., Vanheel H., Van Gerven L., Krohn I.K., Bullens D.M., Ceuppens J.L., Et al., Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression, J. Allergy Clin. Immunol., 137, 4, pp. 1043-1053, (2016); Sugano K., Introduction to computational oral absorption simulation, Expert Opin. Drug Metab. Toxicol., 5, 3, pp. 259-293, (2009); Tang H., Mayersohn M., pp. 1297-1303, (2005); Teorell T., Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration, Arch. Internatl. Pharm.Ther., 57, pp. 205-225, (1937); Thelen K., Coboeken K., Willmann S., Burghaus R., Dressman J.B., Lippert J., Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions, J. Pharm. Sci., 100, 12, pp. 5324-5345, (2011); Thuenemann E.C., Mandalari G., Rich G.T., Faulks R.M., Dynamic gastric model (DGM), The impact of food bioactives on health, pp. 47-59, (2015); Ungell A.-L., Nylander S., Bergstrand S., Sjoberg A., Lennernas H., Membrane transport of drugs in different regions of the intestinal tract of the rat, J. Pharm. Sci., 87, 3, pp. 360-366, (1998); Unno T., Choi J.-H., Hur H.-G., Sadowsky M.J., Ahn Y.-T., Huh C.-S., Kim G.-B., Cha C.-J., Changes in human gut microbiota influenced by probiotic fermented milk ingestion, J. Dairy Sci., 98, 6, pp. 3568-3576, (2015); Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita A.V., Pardon N., Santos J., Soderholm J.D., Tack J., Et al., Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia, Gut, 63, 2, pp. 262-271, (2014); Wallon C., Braaf Y., Wolving M., Olaison G., Soderholm J.D., Endoscopic biopsies in ussing chambers evaluated for studies of macromolecular permeability in the human colon, Scand. J. Gastroenterol., 40, 5, pp. 586-595, (2005); Wickham M., Faulks R., Mann J., Mandalari G., The design, operation, and application of a dynamic gastric model, Dissolut. Technol., 19, 3, pp. 15-22, (2012); Wickham M., Faulks R., Mills C., In vitro digestion methods for assessing the effect of food structure on allergen breakdown, Mol. Nutr. Food Res., 53, 8, pp. 952-958, (2009); Williams L., Leggett R., Reference values for resting blood flow to organs of man, Clin. Phys. Physiol. Meas., 10, 3, (1989); Willmann S., Schmitt W., Keldenich J., Lippert J., Dressman J.B., A physiological model for the estimation of the fraction dose absorbed in humans, J. Med. Chem., 47, 16, pp. 4022-4031, (2004); Wu H., Tremaroli V., Backhed F., Linking microbiota to human diseases: a systems biology perspective, Trends Endocrinol. Metab., 26, 12, pp. 758-770, (2015); Yu L.C.-H., Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis, J. Biomed. Sci., 25, 1, pp. 1-14, (2018); Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L., Separating host and microbiome contributions to drug pharmacokinetics and toxicity, Science, 363, 6427, (2019)^M. Merone; Computer Systems and Bioinformatics Laboratory, Department of Engineering, University Campus Bio-Medico of Rome, Italy; email: m.merone@unicampus.it^^Elsevier B.V.^^^^^^09280987^^EPSCE^34020000.0^English^Eur. J. Pharm. Sci.^Article^Final^^Scopus^2-s2.0-85108726646
Prospero L.; Riezzo G.; Linsalata M.; Orlando A.; D’attoma B.; Russo F.^Prospero, Laura (57207799778); Riezzo, Giuseppe (7004144336); Linsalata, Michele (6603600075); Orlando, Antonella (23767683100); D’attoma, Benedetta (57205751185); Russo, Francesco (59133987400)^57207799778; 7004144336; 6603600075; 23767683100; 57205751185; 59133987400^Psychological and gastrointestinal symptoms of patients with irritable bowel syndrome undergoing a low-fodmap diet: The role of the intestinal barrier^2021^Nutrients^13.0^7^2469^^^^16^10.3390/nu13072469^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110358153&doi=10.3390%2fnu13072469&partnerID=40&md5=8e03f6f1717c1d7236329b434e4a02cc^Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy^Prospero L., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; D’attoma B., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy; Russo F., Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, BA, Castellana Grotte, 70013, Italy^A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (LFD) improves both gastrointestinal (GI) symptoms and the psychological profile of patients with irritable bowel syndrome with diarrhea (IBS-D). The effects of 12 weeks of LFD on GI symptom and psychological profiles in relation to inflammation and the involvement of the intestinal barrier were studied in twenty IBS-D patients. The IBS Severity Scoring System, the Symptom Checklist-90-Re-vised, the Italian version of the 36-Item Short-Form Health Survey, the IBS-Quality of Life (QoL) questionnaire, and the Psychophysiological questionnaire were administered. The GI barrier function was assessed by sugar absorption test, the serum and fecal zonulin levels, and the serum levels of intestinal fatty-acid binding protein and diamine oxidase. Interleukins (ILs) and lipopolysaccha-ride (LPS) serum levels were evaluated along with dysbiosis. At the end of LFD, GI symptoms, psychological state (mainly anxiety, somatization, psychoticism, and interpersonal sensitivity), and QoL significantly improved in these patients. Simultaneously, an improvement in small intestinal permeability and intestinal mucosal integrity occurred, while IL-6, Il-10, LPS, and fermentative dysbiosis significantly decreased. The LFD can modify the immune-inflammatory features and en-hance intestinal permeability and mucosal integrity, thus determining a concurrent improvement in the clinical and psychological conditions. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.^Gastrointestinal symptom profile; Intestinal barrier; Irritable bowel syndrome; Low FODMAP diet; Psychological profile^Adult; Diarrhea; Diet, Carbohydrate-Restricted; Disaccharides; Female; Fermentation; Gastrointestinal Tract; Humans; Inflammation; Intestinal Absorption; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Male; Mental Disorders; Middle Aged; Monosaccharides; Oligosaccharides; Polymers; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; amine oxidase (copper containing); fatty acid binding protein 2; indican; interleukin 10; interleukin 6; lipopolysaccharide; skatole; disaccharide; monosaccharide; oligosaccharide; polymer; polyol; abdominal circumference; abdominal distension; abdominal pain; adult; anxiety; arm circumference; Article; bacterial translocation; blood level; blood sampling; body mass; clinical article; controlled study; defecation habit; depression; digestive system disease assessment; disease severity assessment; dysbiosis; female; gastrointestinal symptom; hip circumference; human; intestine flora; intestine mucosa permeability; Irritable Bowel Syndrome Severity Scoring System; irritable colon; low FODMAP diet; male; mental disease; mental health; obsessive compulsive disorder; paranoia; phobia; physical activity; psychosis; quality of life; Short Form 36; shoulder; somatization; Symptom Checklist 90; urine level; urine sampling; waist circumference; diarrhea; fermentation; gastrointestinal tract; inflammation; intestine; intestine absorption; intestine mucosa; irritable colon; low carbohydrate diet; mental disease; middle aged; pathophysiology; physiology; psychology; questionnaire; severity of illness index^^amine oxidase (copper containing), 9001-53-0, 9014-75-9; indican, 1336-79-4, 487-94-5; skatole, 83-34-1; Disaccharides, ; Monosaccharides, ; Oligosaccharides, ; Polymers, ; polyol, ^^^Ministero della Salute, (RC 2020-2021); Ministero della Salute^Funding: The research was funded by the Italian Ministry of Health RC 2020-2021, Prog. N° 16 (D.D.G. n. 700/2020).^Chey W.D., Kurlander J., Eswaran S., Irritable bowel syndrome: A clinical review, JAMA, 313, pp. 949-958, (2015); Whitehead W.E., Palsson O., Jones K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?, Gastroenterology, 122, pp. 1140-1156, (2002); Hu Z., Li M., Yao L., Wang Y., Wang E., Yuan J., Wang F., Yang K., Bian Z., Zhong L.L.D., The level and prevalence of depression and anxiety among patients with different subtypes of irritable bowel syndrome: A network meta-analysis, BMC Gastroenterol, 21, pp. 1-18, (2021); Zamani M., Alizadeh-Tabari S., Zamani V., Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome, Aliment. Pharmacol. Ther, 50, pp. 132-143, (2019); Kabra N., Nadkarni A., Prevalence of depression and anxiety in irritable bowel syndrome: A clinic based study from India, Indian J. Psychiatry, 55, pp. 77-80, (2013); Tanaka Y., Kanazawa M., Fukudo S., Drossman D.A., Biopsychosocial model of irritable bowel syndrome, J. Neurogastroenterol. Motil, 17, pp. 131-139, (2011); Bai T., Xia J., Jiang Y., Cao H., Zhao Y., Zhang L., Wang H., Song J., Hou X., Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey, J. Gastroenterol. Hepatol, 32, pp. 1018-1025, (2017); Tornblom H., Van Oudenhove L., Sadik R., Abrahamsson H., Tack J., Simren M., Colonic transit time and IBS symptoms: what's the link?, Am. J. Gastroenterol, 107, pp. 754-760, (2012); Simren M., Tornblom H., Palsson O.S., van Tilburg M.A.L., Van Oudenhove L., Tack J., Whitehead W.E., Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: Consistent findings from five different patient cohorts, Gut, 67, pp. 255-262, (2018); Martinez C., Gonzalez-Castro A., Vicario M., Santos J., Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome, Gut Liver, 6, pp. 305-315, (2012); Martin-Vinas J.J., Quigley E.M., Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators, J. Dig. Dis, 17, pp. 572-581, (2016); Lee K.N., Lee O.Y., Intestinal microbiota in pathophysiology and management of irritable bowel syndrome, World J. Gastroenterol, 20, pp. 8886-8897, (2014); Powell N., Walker M.M., Talley N.J., The mucosal immune system: Master regulator of bidirectional gut-brain communications, Nat. Rev. Gastroenterol. Hepatol, 14, pp. 143-159, (2017); Mayer E.A., Gut feelings: The emerging biology of gut-brain communication, Nat. Rev. Neurosci, 12, pp. 453-466, (2011); Bashashati M., Rezaei N., Shafieyoun A., McKernan D.P., Chang L., Ohman L., Quigley E.M., Schmulson M., Sharkey K.A., Simren M., Cytokine imbalance in irritable bowel syndrome: A systematic review and meta-analysis, Neurogastroenterol. Motil, 26, pp. 1036-1048, (2014); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Orlando A., Tutino V., Notarnicola M., Riezzo G., Linsalata M., Clemente C., Prospero L., Martulli M., D'Attoma B., De Nunzio V., Et al., Improved Symptom Profiles and Minimal Inflammation in IBS-D Patients Undergoing a Long-Term Low-FODMAP Diet: A Lipidomic Perspective, Nutrients, 12, (2020); Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Meheust A., de Vos W.M., Et al., Homeostasis of the gut barrier and potential biomarkers, Am. J. Physiol.-Gastrointest. Liver Physiology, 312, pp. G171-G193, (2017); Hughes P.A., Zola H., Penttila I.A., Blackshaw L.A., Andrews J.M., Krumbiegel D., Immune activation in irritable bowel syndrome: Can neuroimmune interactions explain symptoms?, Am. J. Gastroenterol, 108, pp. 1066-1074, (2013); Linsalata M., Riezzo G., D'Attoma B., Clemente C., Orlando A., Russo F., Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study, BMC Gastroenterol, 18, (2018); Stevens B.R., Goel R., Seungbum K., Richards E.M., Holbert R.C., Pepine C.J., Raizada M.K., Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression, Gut, 67, pp. 1555-1557, (2018); Camilleri M., Lyle B.J., Madsen K.L., Sonnenburg J., Verbeke K., Wu G.D., Role for diet in normal gut barrier function: Developing guidance within the framework of food-labeling regulations, Am. J. Physiol.-Gastrointest. Liver Physiol, 317, pp. G17-G39, (2019); Tuck C.J., Reed D.E., Muir J.G., Vanner S.J., Implementation of the low FODMAP diet in functional gastrointestinal symptoms: A real-world experience, Neurogastroenterol. Motil, 32, (2020); Linsalata M., Riezzo G., Orlando A., D'Attoma B., Prospero L., Tutino V., Notarnicola M., Russo F., The Relationship between Low Serum Vitamin D Levels and Altered Intestinal Barrier Function in Patients with IBS Diarrhoea Undergoing a Long-Term Low-FODMAP Diet: Novel Observations from a Clinical Trial, Nutrients, 13, (2021); Kortlever T.L., Ten Bokkel Huinink S., Offereins M., Hebblethwaite C., O'Brien L., Leeper J., Mulder C.J.J., Barrett J.S., Gearry R.B., Low-FODMAP Diet Is Associated With Improved Quality of Life in IBS Patients-A Prospective Observational Study, Nutr. Clin. Pract, 34, pp. 623-630, (2019); Hayes P.A., Fraher M.H., Quigley E.M., Irritable bowel syndrome: The role of food in pathogenesis and management, Gastroenterol. Hepatol, 10, pp. 164-174, (2014); Mearin F., Lacy B.E., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel Disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Francis C.Y., Morris J., Whorwell P.J., The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress, Aliment. Pharmacol. Ther, 11, pp. 395-402, (1997); Miller L.E., Study design considerations for irritable bowel syndrome clinical trials, Ann. Gastroenterol, 27, pp. 338-345, (2014); Blake M.R., Raker J.M., Whelan K., Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther, 44, pp. 693-703, (2016); Derogatis L.R., Lipman R.S., Covi L., SCL-90: An outpatient psychiatric rating scale--preliminary report, Psychopharmacol. Bull, 9, pp. 13-28, (1973); Jensen H.H., Mortensen E.L., Lotz M., Scl-90-R symptom profiles and outcome of short-term psychodynamic group therapy, ISRN Psychiatry, 2013, (2013); Bertolotti G., Zotti A.M., Michielin P., Vidotto G., Sanavio E., A computerized approach to cognitive behavioural assessment: An introduction to CBA-2.0 primary scales, J. Behav. Ther. Exp. psychiatry, 21, pp. 21-27, (1990); Ware J.E., Sherbourne C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med. Care, 30, pp. 473-483, (1992); Patrick D.L., Drossman D.A., Frederick I.O., DiCesare J., Puder K.L., Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure, Dig. Dis. Sci, 43, pp. 400-411, (1998); Hilsden R.J., Meddings J.B., Sutherland L.R., Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease, Gastroenterology, 110, pp. 1395-1403, (1996); Hendrikx T., Schnabl B., Indoles: Metabolites produced by intestinal bacteria capable of controlling liver disease manifestation, J. Intern. Med, 286, pp. 32-40, (2019); Garcia Regueiro J.A., Rius M.A., Rapid determination of skatole and indole in pig back fat by normal-phase liquid chromatography, J. Chromatography. A, 809, pp. 246-251, (1998); Zhou Q., Verne M.L., Fields J.Z., Lefante J.J., Basra S., Salameh H., Verne G.N., Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome, Gut, 68, pp. 996-1002, (2019); Prospero L., Riezzo G., Linsalata M., Orlando A., D'Attoma B., Di Masi M., Martulli M., Russo F., Somatization in patients with predominant diarrhoea irritable bowel syndrome: The role of the intestinal barrier function and integrity, BMC Gastroenterol, 21, pp. 1-10, (2021); Cingolani A., Paduano D., Vecchiarelli V., Demelas M., Corrias P.T., Casula L., Usai P., Feasibility of Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and Polyol Diet and Its Effects on Quality of Life in an Italian Cohort, Nutrients, 12, (2020); Kumar S., Shukla R., Ranjan P., Kumar A., Interleukin-10: A Compelling Therapeutic Target in Patients With Irritable Bowel Syndrome, Clin. Ther, 39, pp. 632-643, (2017); Holzer P., Hassan A.M., Jain P., Reichmann F., Farzi A., Neuroimmune pharmacological approaches, Curr. Opin. Pharmacol, 25, pp. 13-22, (2015); Gonsalkorale W.M., Perrey C., Pravica V., Whorwell P.J., Hutchinson I.V., Interleukin 10 genotypes in irritable bowel syndrome: Evidence for an inflammatory component?, Gut, 52, pp. 91-93, (2003); Li C.C., Gan L., Tan Y., Yan M.Z., Liu X.M., Chang Q., Pan R.L., Chronic restraint stress induced changes in colonic homeostasis-related indexes and tryptophan-kynurenine metabolism in rats, J. Proteom, 240, (2021); Zhou S.Y., Gillilland M., Wu X., Leelasinjaroen P., Zhang G., Zhou H., Ye B., Lu Y., Owyang C., FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction, J. Clin. Investig, 128, pp. 267-280, (2018); Sperandeo P., Martorana A.M., Polissi A., Lipopolysaccharide Biosynthesis and Transport to the Outer Membrane of Gram-Negative Bacteria, Bact. Cell Walls Membr, 92, pp. 9-37, (2019); Wang Z., Xu C.M., Liu Y.X., Wang X.Q., Zhang L., Li M., Zhu S.W., Xie Z.J., Wang P.H., Duan L.P., Et al., Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome, Chin. Med. J, 132, pp. 889-904, (2019); Maes M., Kubera M., Leunis J.C., The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression, Neuroendocrinol. Lett, 29, pp. 117-124, (2008); Rogers G.B., Keating D.J., Young R.L., Wong M.L., Licinio J., Wesselingh S., From gut dysbiosis to altered brain function and mental illness: Mechanisms and pathways, Mol. Psychiatry, 21, pp. 738-748, (2016); Hollier J.M., van Tilburg M.A.L., Liu Y., Czyzewski D.I., Self M.M., Weidler E.M., Heitkemper M., Shulman R.J., Multiple psychological factors predict abdominal pain severity in children with irritable bowel syndrome, Neurogastroenterol. Motil, 31, (2019); Boem F., Amedei A., Healthy axis: Towards an integrated view of the gut-brain health, World J. Gastroenterol, 25, pp. 3838-3841, (2019); van Lanen A.S., de Bree A., Greyling A., Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: A systematic review and meta-analysis, Eur. J. Nutr, (2021)^F. Russo; Laboratory of Nutritional Pathophysiology, National Institute of Gastroenterology “S. de Bellis” Research Hospital, Castellana Grotte, BA, 70013, Italy; email: francesco.russo@irccsdebellis.it^^MDPI AG^^^^^^20726643^^^34371976.0^English^Nutrients^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85110358153
Beatty J.K.; Akierman S.V.; Motta J.-P.; Muise S.; Workentine M.L.; Harrison J.J.; Bhargava A.; Beck P.L.; Rioux K.P.; McKnight G.W.; Wallace J.L.; Buret A.G.^Beatty, Jennifer K. (37761071500); Akierman, Sarah V. (26646301000); Motta, Jean-Paul (36098189300); Muise, Stacy (54788177600); Workentine, Matthew L. (12788559500); Harrison, Joe J. (7402743258); Bhargava, Amol (55976378200); Beck, Paul L. (7201483589); Rioux, Kevin P. (6603085314); McKnight, Gordon Webb (7005826710); Wallace, John L. (55634626300); Buret, Andre G. (7007101465)^37761071500; 26646301000; 36098189300; 54788177600; 12788559500; 7402743258; 55976378200; 7201483589; 6603085314; 7005826710; 55634626300; 7007101465^Giardia duodenalis induces pathogenic dysbiosis of human intestinal microbiota biofilms^2017^International Journal for Parasitology^47.0^6^^311^326^15.0^115^10.1016/j.ijpara.2016.11.010^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014144288&doi=10.1016%2fj.ijpara.2016.11.010&partnerID=40&md5=b19e20b0c31176839ac3428ee5fbbc1a^Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Department of Medicine, Division of Gastroenterology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, L8S 4K1, Ontario, Canada^Beatty J.K., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Akierman S.V., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Motta J.-P., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada, Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Muise S., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Workentine M.L., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Harrison J.J., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Bhargava A., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada; Beck P.L., Department of Medicine, Division of Gastroenterology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Rioux K.P., Department of Medicine, Division of Gastroenterology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; McKnight G.W., Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, L8S 4K1, Ontario, Canada; Wallace J.L., Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada; Buret A.G., Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, T2N 4N1, Alberta, Canada, Department of Physiology & Pharmacology, University of Calgary, 3330 Hospital Drive NW, Calgary, T2N 4N1, Alberta, Canada^Giardia duodenalis is a prevalent cause of acute diarrheal disease worldwide. However, recent outbreaks in Italy and Norway have revealed a link between giardiasis and the subsequent development of chronic post-infectious irritable bowel syndrome. While the mechanisms underlying the causation of post-infectious irritable bowel syndrome remain obscure, recent findings suggest that alterations in gut microbiota communities are linked to the pathophysiology of irritable bowel syndrome. In the present study, we use a laboratory biofilm system to culture and enrich mucosal microbiota from human intestinal biopsies. Subsequently, we show that co-culture with Giardia induces disturbances in biofilm species composition and biofilm structure resulting in microbiota communities that are intrinsically dysbiotic – even after the clearance of Giardia. These microbiota abnormalities were mediated in part by secretory-excretory Giardia cysteine proteases. Using in vitro cell culture and germ-free murine infection models, we show that Giardia-induced disruptions of microbiota promote bacterial invasion, resulting in epithelial apoptosis, tight junctional disruption, and bacterial translocation across an intestinal epithelial barrier. Additionally, these dysbiotic microbiota communities resulted in increased activation of the Toll-like receptor 4 signalling pathway, and overproduction of the pro-inflammatory cytokine IL-1beta in humanized germ-free mice. Previous studies that have sought explanations and risk factors for the development of post-infectious irritable bowel syndrome have focused on features of enteropathogens and attributes of the infected host. We propose that polymicrobial interactions involving Giardia and gut microbiota may cause persistent dysbiosis, offering a new interpretation of the reasons why those afflicted with giardiasis are predisposed to gastrointestinal disorders post-infection. © 2017 The Author(s)^Biofilm; Gastrointestinal microbiome; Giardia duodenalis; Post-infectious irritable bowel syndrome^Animals; Apoptosis; Biofilms; Biopsy; Caco-2 Cells; Colon; Cysteine Proteases; Feces; Gastrointestinal Microbiome; Germ-Free Life; Giardia lamblia; Giardiasis; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Mice; Microscopy, Electron, Scanning; Rabbits; Rats; Symbiosis; Italy; Norway; Bacteria (microorganisms); Giardia; Giardia intestinalis; Murinae; Mus; toll like receptor 4; cysteine proteinase; biofilm; diarrheal disease; digestive system disorder; disease incidence; disease severity; infectivity; microbial community; parasite; pathology; physiology; adult; animal experiment; animal model; animal tissue; apoptosis; Article; bacterial translocation; biofilm; controlled study; culture medium; disease association; enzyme activation; Giardia intestinalis; giardiasis; human; human cell; human tissue; in vitro study; in vivo study; intestine epithelium cell; intestine flora; irritable colon; limit of detection; limit of quantitation; mouse; nonhuman; parasite clearance; pathophysiology; risk factor; signal transduction; tight junction; animal; biofilm; biopsy; Caco-2 cell line; colon; complication; enzymology; feces; germfree animal; giardiasis; growth, development and aging; intestine flora; intestine mucosa; irritable colon; Leporidae; metabolism; microbiology; parasitology; pathology; physiology; rat; scanning electron microscopy; symbiosis; ultrastructure^^toll like receptor 4, 203811-83-0; cysteine proteinase, 37353-41-6; Cysteine Proteases, ^^^^^Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function, Nature Rev. Immunol., 10, pp. 131-144, (2010); Amat C., Motta J.-P., Bhargava A., Chadee K., Buret A., Giardia duodenalis depletes goblet cell mucins and degrades MUC2, Facilitating bacterial translocation, FASEB J., 29, (2015); Abreu M.T., Arnold E.T., Thomas L.S., Gonsky R., Zhou Y., Hu B., Arditi M., TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells, J. Biol. Chem., 277, pp. 20431-20437, (2002); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51, pp. i41-i44, (2002); Barrett A.J., Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates, Biochem, J187, pp. 909-912, (1980); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype, PLoS ONE, 7, (2012); Bhargava A., Cotton J.A., Dixon B.R., Gedamu L., Yates R.M., Buret A.G., Giardia duodenalis Surface Cysteine Proteases Induce Cleavage of the Intestinal Epithelial Cytoskeletal Protein Villin via Myosin Light Chain Kinase, PLoS ONE, 10, (2015); Buret A.G., Mechanisms of epithelial dysfunction in giardiasis, Gut, 56, pp. 316-317, (2007); Buret A.G., Bhargava A., Modulatory mechanisms of enterocyte apoptosis by viral, bacterial and parasitic pathogens, Crit. Rev. Microbiol., 40, pp. 1-17, (2014); Cario E., Podolsky D.K., Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease, Infect. Immun., 68, pp. 7010-7017, (2000); Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., Ringel Y., Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome, Am. J. Physiol. Gastrointest. Liver Physiol., 301, pp. G799-G807, (2011); Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., Buret A., The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms, J. Clin. Microbiol., 37, pp. 1771-1776, (1999); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Chen J., Ng C.P., Tsang L.L., Ho L.S., Xu P.H., Rowlands D.K., Gao J.Y., Chung Y.W., Li T.Y., Chan H.C., Altered expression of inflammatory cytokine receptors in response to LPS challenge through interaction between intestinal epithelial cells and lymphocytes of Peyer's patch, Cell Biol. Int., 33, pp. 369-375, (2009); Chua S.L., Liu Y., Yam J.K., Chen Y., Vejborg R.M., Tan B.G., Kjelleberg S., Tolker-Nielsen T., Givskov M., Yang L., Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles, Nat. Commun., 5, (2014); Cotton J.A., Amat C.B., Buret A.G., Disruptions of Host Immunity and Inflammation by Giardia Duodenalis: Potential Consequences for Co-Infections in the Gastro-Intestinal Tract, Pathog, 4, pp. 764-792, (2015); Cotton J.A., Bhargava A., Ferraz J.G., Yates R.M., Beck P.L., Buret A.G., Giardia duodenalis cathepsin B proteases degrade intestinal epithelial interleukin-8 and attenuate interleukin-8-induced neutrophil chemotaxis, Infect. Immun., 82, pp. 2772-2787, (2014); Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R.F., De Giorgio R., Stanghellini V., Corinaldesi R., Barbara G., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am. J. Gastroenterol., 104, pp. 392-400, (2009); Cremon C., Stanghellini V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Labate A.M., Paccapelo A., Di Nardo G., Cogliandro R.F., De Giorgio R., Corinaldesi R., Barbara G., Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood, Gastroenterology, 147, pp. 69-77, (2014); David E.B., de Carvalho T.B., Oliveira C.M., Coradi S.T., Sforcin J.M., Guimaraes S., Characterisation of protease activity in extracellular products secreted by Giardia duodenalis trophozoites treated with propolis, Nat. Prod. Res., 26, pp. 370-374, (2012); Dongari-Bagtzoglou A., Pathogenesis of mucosal biofilm infections: challenges and progress, Expert Rev. Anti Infect. Ther., 6, pp. 201-208, (2008); DuBois K.N., Abodeely M., Sajid M., Engel J.C., McKerrow J.H., Giardia lamblia cysteine proteases, Parasitol. Res., 99, pp. 313-316, (2006); Edgar R.C., UPARSE: highly accurate OTU sequences from microbial amplicon reads, Nat. Methods, 10, pp. 996-998, (2013); Fahlgren A., Hammarstrom S., Danielsson A., Hammarstrom M.L., Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis, Clin. Exp. Immunol., 131, pp. 90-101, (2003); Gerbaba T.K., Gupta P., Rioux K., Hansen D., Buret A.G., Giardia duodenalis-induced alterations of commensal bacteria kill Caenorhabditis elegans: a new model to study microbial-microbial interactions in the gut, Am. J. Physiol. Gastrointest. Liver Physiol., 308, pp. G550-G561, (2015); Green M.R., Sambrook J., Molecular Cloning: A Laboratory Manual, (2012); Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., McKendrick M.W., Moochhala S.M., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Halliez M.C., Buret A.G., Extra-intestinal and long term consequences of Giardia duodenalis infections, World J. Gastroenterol., 19, pp. 8974-8985, (2013); Halliez M.C., Motta J.P., Feener T.D., Guerin G., LeGoff L., Francois A., Colasse E., Favennec L., Gargala G., Lapointe T.K., Altier C., Buret A.G., Giardia duodenalis induces para-cellular bacterial translocation and causes post-infectious visceral hypersensitivity, Am. J. Physiol. Gastrointest. Liver Physiol., 144, (2016); Hanevik K., Dizdar V., Langeland N., Hausken T., Development of functional gastrointestinal disorders after Giardia lamblia infection, BMC Gastroenterol., 9, (2009); Hare D.F., Jarroll E.L., Lindmark D.G., Giardia lamblia: characterization of proteinase activity in trophozoites, Exp. Parasitol., 68, pp. 168-175, (1989); Harrison J.J., Ceri H., Yerly J., Stremick C.A., Hu Y., Martinuzzi R., Turner R.J., The use of microscopy and three-dimensional visualization to evaluate the structure of microbial biofilms cultivated in the Calgary Biofilm Device, Biol. Proc. Online, 8, pp. 194-215, (2006); Harrison J.J., Stremick C.A., Turner R.J., Allan N.D., Olson M.E., Ceri H., Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening, Nat. Protoc., 5, pp. 1236-1254, (2010); Kalischuk L.D., Inglis G.D., Buret A.G., Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts, Gut Pathog, 1, (2009); Kalischuk L.D., Leggett F., Inglis G.D., Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells, Gut Pathog, 2, (2010); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Keselman A., Li E., Maloney J., Singer S.M., The microbiota contributes to CD8+ T cell activation and nutrient malabsorption following intestinal infection with giardia duodenalis, Infect. Immun., 84, pp. 2853-2860, (2016); Kleessen B., Blaut M., Modulation of gut mucosal biofilms, T Brit J Nutr, 93, pp. S35-S40, (2005); Klindworth A., Pruesse E., Schweer T., Peplies J., Quast C., Horn M., Glockner F.O., Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies, Nucleic Acids Res., 41, (2013); Konig J., Brummer R.J., Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome, Beneficial Microb., 3, pp. 1-15, (2014); Koster J., Rahmann S., Snakemake—a scalable bioinformatics workflow engine, Bioinformatics, 28, pp. 2520-2522, (2012); Kozlowski C., Jeet S., Beyer J., Guerrero S., Lesch J., Wang X., Devoss J., Diehl L., An entirely automated method to score DSS-induced colitis in mice by digital image analysis of pathology slides, Dis. Models Mech., 6, pp. 855-865, (2013); Lapointe T.K., Buret A.G., Interleukin-18 facilitates neutrophil transmigration via myosin light chain kinase-dependent disruption of occludin, without altering epithelial permeability, Am. J. Physiol. Gastrointest. Liver Physiol., 302, pp. G343-G351, (2012); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Love M.I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, (2014); Macfarlane G.T., Macfarlane S., Human colonic microbiota: ecology, physiology and metabolic potential of intestinal bacteria, Scand. J. Gastroenterol. Suppl., 222, pp. 3-9, (1997); Macfarlane S., Woodmansey E.J., Macfarlane G.T., Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system, Appl. Environ. Microbiol., 71, pp. 7483-7492, (2005); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery, Gut, 59, pp. 605-611, (2010); Mason K.L., Stepien T.A., Blum J.E., Holt J.F., Labbe N.H., Rush J.S., Raffa K.F., Handelsman J., From commensal to pathogen: translocation of Enterococcus faecalis from the midgut to the hemocoel of Manduca sexta, mBio, 2, (2011); McMurdie P.J., Holmes S., Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data, PLoS ONE, 8, (2013); McMurdie P.J., Holmes S., Waste not, want not: why rarefying microbiome data is inadmissible, PLoS Comput. Biol., 10, (2014); Noronha A.M., Liang Y., Hetzel J.T., Hasturk H., Kantarci A., Stucchi A., Zhang Y., Nikolajczyk B.S., Farraye F.A., Ganley-Leal L.M., Hyperactivated B cells in human inflammatory bowel disease, J. Leuk. Biol., 86, pp. 1007-1016, (2009); O'Hara J.R., Buret A.G., Mechanisms of intestinal tight junctional disruption during infection, Front. Biosci., 13, pp. 7008-7021, (2008); O'Neil D.A., Porter E.M., Elewaut D., Anderson G.M., Eckmann L., Ganz T., Kagnoff M.F., Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium, J. Immunol., 163, pp. 6718-6724, (1999); Ohman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Strid H., Sjovall H., Simren M., T-cell activation in patients with irritable bowel syndrome, Am. J. Gastroenterol., 104, pp. 1205-1212, (2009); Perez-Mendoza D., Coulthurst S.J., Sanjuan J., Salmond G.P., N-Acetylglucosamine-dependent biofilm formation in Pectobacterium atrosepticum is cryptic and activated by elevated c-di-GMP levels, Microbiology, 157, pp. 3340-3348, (2011); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Ramachandran A., Madesh M., Balasubramanian K.A., Apoptosis in the intestinal epithelium: its relevance in normal and pathophysiological conditions, J. Gastroenterol. Hepatol., 15, pp. 109-120, (2000); Reti K.L., Tymensen L.D., Davis S.P., Amrein M.W., Buret A.G., Campylobacter jejuni increases flagellar expression and adhesion of noninvasive Escherichia coli: effects on enterocytic Toll-like receptor 4 and CXCL-8 expression, Infect. Immun., 83, pp. 4571-4581, (2015); Roberts-Thomson I.C., Stevens D.P., Mahmoud A.A., Warren K.S., Giardiasis in the mouse: an animal model, Gastroenterology, 71, pp. 57-61, (1976); Rodriguez-Fuentes G.B., Cedillo-Rivera R., Fonseca-Linan R., Arguello-Garcia R., Munoz O., Ortega-Pierres G., Yepez-Mulia L., Giardia duodenalis: analysis of secreted proteases upon trophozoite-epithelial cell interaction in vitro, Mem. Inst. Oswaldo Cruz, 101, pp. 693-696, (2006); Roslev P., King G.M., Application of a tetrazolium salt with a water-soluble formazan as an indicator of viability in respiring bacteria, Appl. Environ. Microbiol., 59, pp. 2891-2896, (1993); Round J.L., Mazmanian S.K., The gut microbiota shapes intestinal immune responses during health and disease, Nat. Rev. Immunol., 9, pp. 313-323, (2009); Salonen A., de Vos W.M., Palva A., Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives, Microbiology, 156, pp. 3205-3215, (2010); Sambuy Y., De Angelis I., Ranaldi G., Scarino M.L., Stammati A., Zucco F., The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics, Cell Biol. Toxicol., 21, pp. 1-26, (2005); Sawada N., Tight junction-related human diseases, Pathol. Int., 63, pp. 1-12, (2013); Scully P., McKernan D.P., Keohane J., Groeger D., Shanahan F., Dinan T.G., Quigley E.M., Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity, Am. J. Gastroenterol., 105, pp. 2235-2243, (2010); Sepehri S., Kotlowski R., Bernstein C.N., Krause D.O., Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease, Inflamm. Bowel Dis., 13, pp. 675-683, (2007); Spiller R., Campbell E., Post-infectious irritable bowel syndrome, Curr. Opin. Gastroenterol., 22, pp. 13-17, (2006); Spiller R.C., Jenkins D., Thornley J.P., Hebden J.M., Wright T., Skinner M., Neal K.R., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Sproule-Willoughby K.M., Stanton M.M., Rioux K.P., McKay D.M., Buret A.G., Ceri H., In vitro anaerobic biofilms of human colonic microbiota, J. Microbiol. Methods, 83, pp. 296-301, (2010); Stevens D.P., Roberts-Thompson I.C., Animal model of human disease: giardiasis, Am. J. Pathol., 90, pp. 529-532, (1978); Sutherland I.W., The biofilm matrix–an immobilized but dynamic microbial environment, Trends Microbiol., 9, pp. 222-227, (2001); Tchoupe J.R., Moreau T., Gauthier F., Bieth J.G., Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group, Biochim. Biophys. Acta, 1076, pp. 149-151, (1991); Teoh D.A., Kamieniecki D., Pang G., Buret A.G., Giardia lamblia rearranges F-actin and alpha-actinin in human colonic and duodenal monolayers and reduces transepithelial electrical resistance, J. Parasitol., 86, pp. 800-806, (2000); Thabane M., Marshall J.K., Post-infectious irritable bowel syndrome, World J. Gastroenterol., 15, pp. 3591-3596, (2009); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Toyofuku M., Roschitzki B., Riedel K., Eberl L., Identification of proteins associated with the Pseudomonas aeruginosa biofilm extracellular matrix, J. Proteo Res., 11, pp. 4906-4915, (2012); von Rosenvinge E.C., O'May G.A., Macfarlane S., Macfarlane G.T., Shirtliff M.E., Microbial biofilms and gastrointestinal diseases, Pathog Dis., 67, pp. 25-38, (2013); Vora P., Youdim A., Thomas L.S., Fukata M., Tesfay S.Y., Lukasek K., Michelsen K.S., Wada A., Hirayama T., Arditi M., Abreu M.T., Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells, J. Immunol., 173, pp. 5398-5405, (2004); Wang D., Dubois R.N., Richmond A., The role of chemokines in intestinal inflammation and cancer, Curr. Opin. Pharmacol., 9, pp. 688-696, (2009); Wensaas K.A., Langeland N., Hanevik K., Morch K., Eide G.E., Rortveit G., Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study, Gut, 61, pp. 214-219, (2012); Williams A.G., Coombs G.H., Multiple protease activities in Giardia intestinalis trophozoites, Int. J. Parasitol., 25, pp. 771-778, (1995); Yu L.C., Flynn A.N., Turner J.R., Buret A.G., SGLT-1-mediated glucose uptake protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a novel cellular rescue mechanism?, FASEB J., 19, pp. 1822-1835, (2005); Zoetendal E.G., Rajilic-Stojanovic M., de Vos W.M., High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota, Gut, 57, pp. 1605-1615, (2008)^A.G. Buret; Department of Biological Sciences, Faculty of Sciences, University of Calgary, Calgary, 2500 University Drive NW, T2N 4N1, Canada; email: aburet@ucalgary.ca^^Elsevier Ltd^^^^^^00207519^^IJPYB^28237889.0^English^Int. J. Parasitol.^Article^Final^All Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85014144288
Barbaro M.R.; Fuschi D.; Cremon C.; Carapelle M.; Dino P.; Marcellini M.M.; Dothel G.; De Ponti F.; Stanghellini V.; Barbara G.^Barbaro, M.R. (56235164100); Fuschi, D. (57202989311); Cremon, C. (6507319921); Carapelle, M. (57202987898); Dino, P. (57189630336); Marcellini, M.M. (55358259100); Dothel, G. (37107414200); De Ponti, F. (55992097200); Stanghellini, V. (7006377452); Barbara, G. (7004311418)^56235164100; 57202989311; 6507319921; 57202987898; 57189630336; 55358259100; 37107414200; 55992097200; 7006377452; 7004311418^Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators^2018^Neurogastroenterology and Motility^30.0^8^e13388^^^^23^10.1111/nmo.13388^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050077165&doi=10.1111%2fnmo.13388&partnerID=40&md5=e123a1cd2fed989ed8d1ef61d9a1f1f9^Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy^Barbaro M.R., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Fuschi D., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Cremon C., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Carapelle M., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Dino P., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Marcellini M.M., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Dothel G., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; De Ponti F., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Stanghellini V., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; Barbara G., Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy^Background: Intestinal permeability is altered in a subgroup of irritable bowel syndrome (IBS) patients and may contribute to symptom development. The aim of this study was to evaluate the in vitro effect of the probiotic Escherichia coli Nissle 1917 (EcN) on Caco-2 permeability alterations induced by mediators released by IBS mucosal biopsies compared to asymptomatic controls (AC). Methods: Caco-2 cells were used as an in vitro model of intestinal permeability. Seven AC and 28 well-phenotyped IBS (9 IBS-D, 8 IBS-C, and 11 IBS-M) patients were enrolled. Mucosal mediators spontaneously released (SUP) by IBS and AC biopsies were collected. Two concentrations of EcN (108 and 106) were applied to Caco-2 with or without SUP or SLIGRL (a protease-activated receptor-2 activating peptide), tumor necrosis factor-α, and interferon-γ. Paracellular permeability was assessed by evaluating the flow of sulfonic-acid conjugated to fluorescein through Caco-2 monolayer. Key Results: EcN 108 significantly reinforced Caco-2 monolayer compared to cells incubated with medium alone. IBS SUP induced a significant increase in paracellular permeability compared to AC SUP, independently of IBS bowel habit. EcN 108 induced a significant recovery of permeability rate compared to IBS SUP. Permeability increase induced by IBS SUP significantly correlated with severity and frequency of abdominal pain and abdominal distension. The co-incubation of EcN and IBS SUP abolished the above significant correlations. Conclusions and Inferences: EcN reinforces the integrity of Caco-2 monolayer and reverts the increase of permeability induced by mediators released by IBS biopsies. Future studies should investigate EcN therapeutic potentials in IBS. © 2018 John Wiley & Sons Ltd^Escherichia coli Nissle 1917; irritable bowel syndrome; permeability; probiotics^fluorescein; gamma interferon; probiotic agent; proteinase activated receptor 2; sligrl protein; sup protein; tumor necrosis factor; unclassified drug; adult; aged; Article; Caco-2 cell line; cell membrane permeability; clinical article; controlled study; epithelium cell; Escherichia coli; Escherichia coli nissle 1917; female; human; human cell; human tissue; in vitro study; intestine biopsy; irritable colon; male; nonhuman; oral biopsy; phenotype; priority journal^^fluorescein, 2321-07-5, 91316-42-6; gamma interferon, 82115-62-6^^^Ministero dell’Istruzione, dell’Università e della Ricerca, MIUR; Fondazione del Monte di Bologna e Ravenna; Università di Bologna, UNIBO^The study was supported in part by the Italian Ministry of Education, University and Research and funds from the University of Bologna RFO to GB. GB is a recipient of an educational grant from Fondazione del Monte di Bologna e Ravenna, Bologna, Italy. GB is recipient of a research support from Ca.Di.Group S.r.l., Rome, Italy.^Mearin F., Lacy B.E., Chang L., Et al., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Ford A.C., Lacy B.E., Talley N.J., Irritable bowel syndrome, N Engl J Med, 376, pp. 2566-2578, (2017); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Cremon C., Carini G., Wang B., Et al., Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome, Am J Gastroenterol, 106, pp. 1290-1298, (2011); Barbara G., Wang B., Stanghellini V., Et al., Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome, Gastroenterology, 132, pp. 26-37, (2007); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Vivinus-Nebot M., Dainese R., Anty R., Et al., Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells, Am J Gastroenterol, 107, pp. 75-81, (2012); Simren M., Barbara G., Flint H.J., Et al., Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, pp. G851-G857, (2000); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Curr Opin Cell Biol, 11, pp. 628-633, (1999); Cunningham K.E., Turner J.R., Myosin light chain kinase: pulling the strings of epithelial tight junction function, Ann N Y Acad Sci, 1258, pp. 34-42, (2012); Coeffier M., Claeyssens S., Bensifi M., Et al., Influence of leucine on protein metabolism, phosphokinase expression, and cell proliferation in human duodenum1,3, Am J Clin Nutr, 93, pp. 1255-1262, (2011); Hill C., Guarner F., Reid G., Et al., Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, 11, pp. 506-514, (2014); Kumar M., Nagpal R., Verma V., Et al., Probiotic metabolites as epigenetic targets in the prevention of colon cancer, Nutr Rev, 71, pp. 23-34, (2013); Reid G., Younes J.A., Van der Mei H.C., Gloor G.B., Knight R., Busscher H.J., Microbiota restoration: natural and supplemented recovery of human microbial communities, Nat Rev Microbiol, 9, pp. 27-38, (2011); Ukena S.N., Singh A., Dringenberg U., Et al., Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity, PLoS ONE, 2, (2007); Mennigen R., Nolte K., Rijcken E., Et al., Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis, Am J Physiol Gastrointest Liver Physiol, 296, pp. G1140-G1149, (2009); Llopis M., Antolin M., Carol M., Et al., Lactobacillus casei downregulates commensals’ inflammatory signals in Crohn’s disease mucosa, Inflamm Bowel Dis, 15, pp. 275-283, (2009); Patzer S.I., Baquero M.R., Bravo D., Moreno F., Hantke K., The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN, Microbiology, 149, pp. 2557-2570, (2003); Altenhoefer A., Oswald S., Sonnenborn U., Et al., The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens, FEMS Immunol Med Microbiol, 40, pp. 223-229, (2004); Lodinova-Zadnikova R., Sonnenborn U., Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants, Biol Neonate, 71, pp. 224-232, (1997); Wehkamp J., Harder J., Wehkamp K., Et al., NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium, Infect Immun, 72, pp. 5750-5758, (2004); Westendorf A.M., Gunzer F., Deppenmeier S., Et al., Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules, FEMS Immunol Med Microbiol, 43, pp. 373-384, (2005); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-816, (2007); Kruis W., Schutz E., Fric P., Fixa B., Judmaier G., Stolte M., Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis, Aliment Pharmacol Ther, 11, pp. 853-858, (1997); Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T., Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial, Lancet, 354, pp. 635-639, (1999); Dignass A., Lindsay J.O., Sturm A., Et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohns Colitis, 6, pp. 991-1030, (2012); Talley N.J., Phillips S.F., Melton J., Wiltgen C., Zinsmeister A.R., A patient questionnaire to identify bowel disease, Ann Intern Med, 111, pp. 671-674, (1989); Moayyedi P., Ford A.C., Talley N.J., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review, Gut, 59, pp. 325-332, (2010); Ford A.C., Quigley E.M., Lacy B.E., Et al., Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis, Am J Gastroenterol, 109, pp. 1547-1561, (2014); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Wang H., Bastian S.E., Cheah K.Y., Lawrence A., Howarth G.S., Escherichia coli Nissle 1917-derived factors reduce cell death and late apoptosis and increase transepithelial electrical resistance in a model of 5-fluorouracil-induced intestinal epithelial cell damage, Cancer Biol Ther, 15, pp. 560-569, (2014); Veltman K., Hummel S., Cichon C., Sonnenborn U., Schmidt M.A., Identification of specific miRNAs targeting proteins of the apical junctional complex that simulate the probiotic effect of E. coli Nissle 1917 on T84 epithelial cells, Int J Biochem Cell Biol, 2012, 44, pp. 341-349, (1917); Kruis W., Chrubasik S., Boehm S., Stange C., Schulze J., A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome, Int J Colorectal Dis, 27, pp. 467-474, (2012); Faghihi A.H., Agah S., Masoudi M., Ghafoori S.M., Eshraghi A., Efficacy of probiotic Escherichia coli Nissle 1917 in patients with irritable bowel syndrome: a double blind placebo-controlled randomized trial, Acta Med Indones, 47, pp. 201-208, (2015); Nasser Y., Boeckxstaens G.E., Wouters M.M., Schemann M., Vanner S., Using human intestinal biopsies to study the pathogenesis of irritable bowel syndrome, Neurogastroenterol Motil, 26, pp. 455-469, (2014); Coelho A.M., Vergnolle N., Guiard B., Fioramonti J., Bueno L., Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats, Gastroenterology, 122, pp. 1035-1047, (2002); Jacob C., Yang P.C., Darmoul D., Et al., Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins, J Biol Chem, 280, pp. 31936-31948, (2005); Wang F., Graham W.V., Wang Y., Witkowski E.D., Schwarz B.T., Turner J.R., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Utech M., Ivanov A.I., Samarin S.N., Et al., Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane, Mol Biol Cell, 16, pp. 5040-5052, (2005); Gecse K., Roka R., Ferrier L., Et al., Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Hughes P.A., Harrington A.M., Castro J., Et al., Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes, Gut, 62, pp. 1456-1465, (2013); Bashashati M., Rezaei N., Shafieyoun A., Et al., Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis, Neurogastroenterol Motil, 26, pp. 1036-1048, (2014); Barbaro M.R., Di Sabatino A., Cremon C., Et al., Interferon-gamma is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism, Am J Physiol Gastrointest Liver Physiol, 310, pp. G439-G447, (2016); O'Neill L.A., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress, Immunol Rev, 226, pp. 10-18, (2008); Dlugosz A., Zakikhany K., Acevedo N., D'Amato M., Lindberg G., Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome, Biomed Res Int, 2017, (2017); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Ohman L., Isaksson S., Lindmark A.C., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Muller S., Seibold F., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Langhorst J., Junge A., Rueffer A., Et al., Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 404-410, (2009); Hafez M., Hayes K., Goldrick M., Grencis R.K., Roberts I.S., The K5 capsule of Escherichia coli strain Nissle 1917 is important in stimulating expression of Toll-like receptor 5, CD14, MyD88, and TRIF together with the induction of interleukin-8 expression via the mitogen-activated protein kinase pathway in epithelial cells, Infect Immun, 78, pp. 2153-2162, (2010); Cross M.L., Ganner A., Teilab D., Fray L.M., Patterns of cytokine induction by gram-positive and gram-negative probiotic bacteria, FEMS Immunol Med Microbiol, 42, pp. 173-180, (2004); Ukena S.N., Westendorf A.M., Hansen W., Et al., The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1, BMC Med Genet, 6, (2005); Sturm A., Rilling K., Baumgart D.C., Et al., Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling, Infect Immun, 73, pp. 1452-1465, (2005); Perez-Berezo T., Pujo J., Martin P., Et al., Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917, Nat Commun, 8, (2017); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013)^G. Barbara; Department of Medical and Surgical Sciences (DIMEC), Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum - University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy; email: giovanni.barbara@unibo.it^^Blackwell Publishing Ltd^^^^^^13501925^^NMOTE^^English^Neurogastroenterol. Motil.^Article^Final^^Scopus^2-s2.0-85050077165
Shulman R.J.; Hollister E.B.; Cain K.; Czyzewski D.I.; Self M.M.; Weidler E.M.; Devaraj S.; Luna R.A.; Versalovic J.; Heitkemper M.^Shulman, Robert J. (56961627200); Hollister, Emily B. (35224866500); Cain, Kevin (7103341073); Czyzewski, Danita I. (6701585207); Self, Mariella M. (55695874800); Weidler, Erica M. (26424158700); Devaraj, Sridevi (7004533440); Luna, Ruth Ann (15019309900); Versalovic, James (7003744341); Heitkemper, Margaret (7005514887)^56961627200; 35224866500; 7103341073; 6701585207; 55695874800; 26424158700; 7004533440; 15019309900; 7003744341; 7005514887^Psyllium Fiber Reduces Abdominal Pain in Children With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial^2017^Clinical Gastroenterology and Hepatology^15.0^5^^712^719.e4^^72^10.1016/j.cgh.2016.03.045^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994662238&doi=10.1016%2fj.cgh.2016.03.045&partnerID=40&md5=05c2286a7f26652e01ae7b698229cea7^Department of Pediatrics, Baylor College of Medicine, United States; Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States; Department of Pathology and Immunology, Baylor College of Medicine, United States; Children's Nutrition Research Center, United States; Department of Pathology, Texas Children's Hospital, United States; Texas Children's Hospital, United States; Texas Children's Microbiome Center, United States; Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, Washington, United States; Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, Washington, United States^Shulman R.J., Department of Pediatrics, Baylor College of Medicine, United States, Children's Nutrition Research Center, United States, Texas Children's Hospital, United States; Hollister E.B., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Cain K., Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, Washington, United States; Czyzewski D.I., Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States, Texas Children's Hospital, United States; Self M.M., Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, United States, Texas Children's Hospital, United States; Weidler E.M., Department of Pediatrics, Baylor College of Medicine, United States, Children's Nutrition Research Center, United States, Texas Children's Hospital, United States; Devaraj S., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Luna R.A., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Versalovic J., Department of Pathology and Immunology, Baylor College of Medicine, United States, Department of Pathology, Texas Children's Hospital, United States, Texas Children's Hospital, United States, Texas Children's Microbiome Center, United States; Heitkemper M., Department of Biobehavioral Nursing and Health Systems, University of Washington, Seattle, Washington, United States^Background & Aims We sought to determine the efficacy of psyllium fiber treatment on abdominal pain and stool patterns in children with irritable bowel syndrome (IBS). We evaluated effects on breath hydrogen and methane production, gut permeability, and microbiome composition. We also investigated whether psychological characteristics of children or parents affected the response to treatment. Methods We performed a randomized, double-blind trial of 103 children (mean age, 13 ± 3 y) with IBS seen at primary or tertiary care settings. After 2 weeks on their habitual diet, children began an 8-day diet excluding carbohydrates thought to cause symptoms of IBS. Children with ≥75% improvement in abdominal pain were excluded (n = 17). Children were assigned randomly to groups given psyllium (n = 37) or placebo (maltodextrin, n = 47) for 6 weeks. Two-week pain and stool diaries were compared at baseline and during the final 2 weeks of treatment. We assessed breath hydrogen and methane production, intestinal permeability, and the composition of the microbiome before and after administration of psyllium or placebo. Psychological characteristics of children were measured at baseline. Results Children in the psyllium group had a greater reduction in the mean number of pain episodes than children in the placebo group (mean reduction of 8.2 ± 1.2 after receiving psyllium vs mean reduction of 4.1 ± 1.3 after receiving placebo; P = .03); the level of pain intensity did not differ between the groups. Psychological characteristics were not associated with response. At the end of the study period, the percentage of stools that were normal (Bristol scale scores, 3–5), breath hydrogen or methane production, intestinal permeability, and microbiome composition were similar between groups. Conclusions Psyllium fiber reduced the number of abdominal pain episodes in children with IBS, independent of psychological factors. Psyllium did not alter breath hydrogen or methane production, gut permeability, or microbiome composition. ClinicalTrials.gov no: NCT00526903. © 2017 AGA Institute^Abdominal Pain; Fiber; Irritable Bowel Syndrome; Microbiome; Psyllium^Abdominal Pain; Adolescent; Breath Tests; Child; Dietary Fiber; Double-Blind Method; Female; Humans; Irritable Bowel Syndrome; Male; Placebos; Psyllium; Treatment Outcome; carbohydrate; hydrogen; ispagula; maltodextrin; methane; placebo; ispagula; placebo; abdominal pain; adolescent; adult; Article; Bristol scale score; child; controlled study; dietary intake; double blind procedure; feces analysis; feeding behavior; female; human; hydrogen breath test; intestine flora; intestine mucosa permeability; irritable colon; major clinical study; male; nonhuman; outcome assessment; pain intensity; preschool child; psychological aspect; randomized controlled trial; rating scale; school child; scoring system; species composition; tertiary health care; treatment duration; treatment response; abdominal pain; administration and dosage; breath analysis; dietary fiber; irritable colon; treatment outcome^^hydrogen, 12385-13-6, 1333-74-0; ispagula, 77462-61-4, 8063-16-9; maltodextrin, 9050-36-6; methane, 74-82-8; Dietary Fiber, ; Placebos, ; Psyllium, ^^^National Institute of Nursing Research, NINR, (R01NR005337); National Institute of Nursing Research, NINR^^Saps M., Seshadri R., Sztainberg M., Et al., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, pp. 322-326, (2009); Mobley A.R., Jones J.M., Rodriguez J., Et al., Identifying practical solutions to meet America's fiber needs: proceedings from the Food & Fiber Summit, Nutrients, 6, pp. 2540-2551, (2014); Moayyedi P., Quigley E.M., Lacy B.E., Et al., The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis, Am J Gastroenterol, 109, pp. 1367-1374, (2014); Ruepert L., Quartero A.O., de Wit N.J., Et al., Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome, Cochrane Database Syst Rev, 8, (2011); Czyzewski D.I., Lane M.M., Weidler E.M., Et al., The interpretation of Rome III criteria and method of assessment affect the irritable bowel syndrome classification of children, Aliment Pharmacol Ther, 33, pp. 403-411, (2011); Barrett J.S., Gibson P.R., Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals?, Therap Adv Gastroenterol, 5, pp. 261-268, (2012); Clemens R., Kranz S., Mobley A.R., Et al., Filling America's fiber intake gap: summary of a roundtable to probe realistic solutions with a focus on grain-based foods, J Nutr, 142, pp. 1390S-1401S, (2012); Von Baeyer C.L., Spagrud L.J., McCormick J.C., Et al., Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children's self-reports of pain intensity, Pain, 143, pp. 223-227, (2009); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand J Gastroenterol, 32, pp. 920-924, (1997); Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Niu H.C., Schoeller D.A., Klein P.D., Improved gas chromatographic quantitation of breath hydrogen by normalization to respiratory carbon dioxide, J Lab Clin Med, 94, pp. 755-763, (1979); McOmber M.E., Ou C.N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, J Pediatr Gastroenterol Nutr, 50, pp. 269-275, (2010); Reynolds C.R., Kamphaus R.W., Behavior assessment system for children, (2004); Walker L.S., Garber J., Greene J.W., Somatization symptoms in pediatric abdominal pain patients: relation to chronicity of abdominal pain and parent somatization, J Abnorm Child Psychol, 19, pp. 379-394, (1991); Van Slyke D.A., Walker L.S., Mothers' responses to children's pain, Clin J Pain, 22, pp. 387-391, (2006); Walker L.S., Smith C.A., Garber J., Et al., Testing a model of pain appraisal and coping in children with chronic abdominal pain, Health Psychol, 24, pp. 364-374, (2005); Varni J.W., Bendo C.B., Denham J., Et al., PedsQL Gastrointestinal Symptoms Scales and Gastrointestinal Worry Scales in pediatric patients with functional and organic gastrointestinal diseases in comparison to healthy controls, Qual Life Res, 24, pp. 363-378, (2015); Derogatis L.R., Lipman R.S., Covi L., SLC-90: an outpatient psychiatric rating scale–preliminary report, Psychopharmacol Bull, 9, pp. 13-28, (1973); Aagaard K., Petrosino J., Keitel W., Et al., The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters, FASEB J, 27, pp. 1012-1022, (2013); Caporaso J.G., Kuczynski J., Stombaugh J., Et al., QIIME allows analysis of high-throughput community sequencing data, Nat Methods, 7, pp. 335-336, (2010); Edgar R.C., Search and clustering orders of magnitude faster than BLAST, Bioinformatics, 26, pp. 2460-2461, (2010); DeSantis T.Z., Hugenholtz P., Larsen N., Et al., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Appl Environ Microbiol, 72, pp. 5069-5072, (2006); Haas B.J., Gevers D., Earl A.M., Et al., Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons, Genome Res, 21, pp. 494-504, (2011); Carlson M.J., Moore C.E., Tsai C.M., Et al., Child and parent perceived food-induced gastrointestinal symptoms and quality of life in children with functional gastrointestinal disorders, J Acad Nutr Diet, 114, pp. 403-413, (2014); Feldman W., McGrath P., Hodgson C., Et al., The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent abdominal pain. Results in a prospective, double-blind, randomized, controlled trial, Am J Dis Child, 139, pp. 1216-1218, (1985); Ford A.C., Talley N.J., Spiegel B.M., Et al., Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis, BMJ, 337, (2008); Christensen M.F., Recurrent abdominal pain and dietary fiber, Am J Dis Child, 140, pp. 738-739, (1986); Huertas-Ceballos A.A., Logan S., Bennett C., Et al., Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database Syst Rev, 2, (2014); Marlett J.A., Fischer M.H., The active fraction of psyllium seed husk, Proc Nutr Soc, 62, pp. 207-209, (2003); Marteau P., Flourie B., Cherbut C., Et al., Digestibility and bulking effect of ispaghula husks in healthy humans, Gut, 35, pp. 1747-1752, (1994); Elli M., Cattivelli D., Soldi S., Et al., Evaluation of prebiotic potential of refined psyllium (Plantago ovata) fiber in healthy women, J Clin Gastroenterol, 42, pp. S174-S176, (2008); Shulman R.J., Eakin M.N., Czyzewski D.I., Et al., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Kim H., Bartley G.E., Young S.A., Et al., Altered hepatic gene expression profiles associated with improved fatty liver, insulin resistance, and intestinal permeability after hydroxypropyl methylcellulose (HPMC) supplementation in diet-induced obese mice, J Agric Food Chem, 61, pp. 6404-6411, (2013); van Tilburg M.A., Levy R.L., Walker L.S., Et al., Psychosocial mechanisms for the transmission of somatic symptoms from parents to children, World J Gastroenterol, 21, pp. 5532-5541, (2015); Fales J.L., Essner B.S., Harris M.A., Et al., When helping hurts: miscarried helping in families of youth with chronic pain, J Pediatr Psychol, 39, pp. 427-437, (2014); Rao S.S., Yu S., Fedewa A., Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome, Aliment Pharmacol Ther, 41, pp. 1256-1270, (2015); Shulman R.J., Kerzner B., Sloan H.R., Et al., Absorption and oxidation of glucose polymers of different lengths in young infants, Pediatr Res, 20, pp. 740-743, (1986); Shulman R.J., Feste A., Ou C., Absorption of lactose, glucose polymers, or combination in premature infants, J Pediatr, 127, pp. 626-631, (1995); Varni J.W., Shulman R.J., Self M.M., Et al., Symptom profiles in patients with irritable bowel syndrome or functional abdominal pain compared with healthy controls, J Pediatr Gastroenterol Nutr, 61, pp. 323-329, (2015); Cain K.C., Headstrom P., Jarrett M.E., Et al., Abdominal pain impacts quality of life in women with irritable bowel syndrome, Am J Gastroenterol, 101, pp. 124-132, (2006)^R.J. Shulman; Children's Nutrition Research Center, Houston, 1100 Bates Avenue, Room 8072, 77030, United States; email: rshulman@bcm.edu^^W.B. Saunders^^^^^^15423565^^CGHLA^27080737.0^English^Clin. Gastroenterol. Hepatol.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-84994662238
De Palma G.; Lynch M.D.J.; Lu J.; Dang V.T.; Deng Y.; Jury J.; Umeh G.; Miranda P.M.; Pastor M.P.; Sidani S.; Pinto-Sanchez M.I.; Philip V.; McLean P.G.; Hagelsieb M.-G.; Surette M.G.; Bergonzelli G.E.; Verdu E.F.; Britz-McKibbin P.; Neufeld J.D.; Collins S.M.; Bercik P.^De Palma, Giada (26029304200); Lynch, Michael D.J. (57202459599); Lu, Jun (57199237883); Dang, Vi T. (57191579889); Deng, Yikang (7401531040); Jury, Jennifer (7004287397); Umeh, Genevieve (55931080300); Miranda, Pedro M. (57193534210); Pastor, Marc Pigrau (57193537742); Sidani, Sacha (57206175564); Pinto-Sanchez, Maria Ines (26649598100); Philip, Vivek (57204255186); McLean, Peter G. (57206423778); Hagelsieb, Moreno-Gabriel (57193533839); Surette, Michael G. (7006624110); Bergonzelli, Gabriela E. (6602847479); Verdu, Elena F. (8109011300); Britz-McKibbin, Philip (57203382441); Neufeld, Josh D. (7005470596); Collins, Stephen M. (57203291674); Bercik, Premysl (6602481586)^26029304200; 57202459599; 57199237883; 57191579889; 7401531040; 7004287397; 55931080300; 57193534210; 57193537742; 57206175564; 26649598100; 57204255186; 57206423778; 57193533839; 7006624110; 6602847479; 8109011300; 57203382441; 7005470596; 57203291674; 6602481586^Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice^2017^Science Translational Medicine^9.0^379^eaaf6397^^^^374^10.1126/scitranslmed.aaf6397^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014649400&doi=10.1126%2fscitranslmed.aaf6397&partnerID=40&md5=00bf204efe04fccd7c283fba44abc4fa^Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Biology, University of Waterloo, Waterloo, ON, Canada; Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada; Nestlé Research Center, Lausanne, Switzerland; Department of Biology, Wilfrid Laurier University, Waterloo, ON, Canada^De Palma G., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Lynch M.D.J., Department of Biology, University of Waterloo, Waterloo, ON, Canada; Lu J., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Dang V.T., Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada; Deng Y., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Jury J., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Umeh G., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Miranda P.M., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Pastor M.P., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Sidani S., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Pinto-Sanchez M.I., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Philip V., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; McLean P.G., Nestlé Research Center, Lausanne, Switzerland; Hagelsieb M.-G., Department of Biology, Wilfrid Laurier University, Waterloo, ON, Canada; Surette M.G., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Bergonzelli G.E., Nestlé Research Center, Lausanne, Switzerland; Verdu E.F., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Britz-McKibbin P., Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada; Neufeld J.D., Department of Biology, University of Waterloo, Waterloo, ON, Canada; Collins S.M., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada; Bercik P., Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, ON, Canada^Irritable bowel syndrome (IBS) is a common disorder characterized by altered gut function and often is accompanied by comorbid anxiety. Although changes in the gut microbiota have been documented, their relevance to the clinical expression of IBS is unknown. To evaluate a functional role for commensal gut bacteria in IBS, we colonized germ-free mice with the fecal microbiota from healthy control individuals or IBS patients with diarrhea (IBS-D), with or without anxiety, and monitored gut function and behavior in the transplanted mice. Microbiota profiles in recipient mice clustered according to the microbiota profiles of the human donors. Mice receiving the IBS-D fecal microbiota showed a taxonomically similar microbial composition to that of mice receiving the healthy control fecal microbiota. However, IBS-D mice showed different serum metabolomic profiles. Mice receiving the IBS-D fecal microbiota, but not the healthy control fecal microbiota, exhibited faster gastrointestinal transit, intestinal barrier dysfunction, innate immune activation, and anxiety-like behavior. These results indicate the potential of the gut microbiota to contribute to both intestinal and behavioral manifestations of IBS-D and suggest the potential value of microbiota-directed therapies in IBS patients. © 2017 The Authors, some rights reserved.^^Adult; Animals; Anxiety; Behavior, Animal; Case-Control Studies; Colon; Fecal Microbiota Transplantation; Feces; Female; Gastrointestinal Microbiome; Gastrointestinal Tract; Gastrointestinal Transit; Germ-Free Life; Humans; Irritable Bowel Syndrome; Male; Metabolomics; Mice; Tissue Donors; beta defensin 3; C reactive protein; chemokine receptor CCR2; chemokine receptor CXCR3; chemokine receptor CXCR4; complement component C3; gamma interferon; glucocorticoid receptor; glycerophosphorylcholine; immunoglobulin enhancer binding protein; interleukin 10; interleukin 1beta; interleukin 2; interleukin 6; interleukin 8; lysophosphatidylcholine; mitogen activated protein kinase p38; monocyte chemotactic protein 1; oleic acid; palmitic acid; pattern recognition receptor; phosphatidylserine; stearic acid; tumor necrosis factor; adult; animal experiment; animal tissue; anxiety; Article; CD3+ T lymphocyte; clinical article; controlled study; diarrhea; fecal microbiota transplantation; female; gastrointestinal transit; gene expression regulation; germfree mouse; human; innate immunity; intestine function; intestine motility; intestine mucosa permeability; irritable colon; lymphocyte count; male; mouse; nonhuman; recipient; Swiss Webster mouse; upregulation; animal; animal behavior; anxiety; blood; case control study; colon; donor; feces; gastrointestinal tract; germfree animal; immunology; intestine flora; irritable colon; metabolism; metabolomics; microbiology; pathophysiology^^C reactive protein, 9007-41-4; chemokine receptor CXCR4, 188900-71-2; complement component C3, 80295-41-6; gamma interferon, 82115-62-6; glycerophosphorylcholine, 4217-84-9, 563-24-6; interleukin 2, 85898-30-2; interleukin 8, 114308-91-7; lysophosphatidylcholine, 93794-93-5; oleic acid, 112-80-1, 115-06-0; palmitic acid, 57-10-3; stearic acid, 57-11-4, 646-29-7^^^Canadian Institutes of Health Research, IRSC; Canadian Association of Gastroenterology, CAG^This study was supported by grants from Canadian Institutes of Health Research (CIHR) and Nestlé Switzerland. P.B. is a recipient of a Hamilton Health Sciences Early Career Research Award. G.D.P. is a recipient of a CIHR-Canadian Association of Gastroenterology Postdoctoral Fellowship.^Sekirov I., Russell S.L., Antunes L.C.M., Finlay B.B., Gut microbiota in health and disease, Physiol. Rev., 90, pp. 859-904, (2010); Hooper L.V., Littman D.R., Macpherson A.J., Interactions between the microbiota and the immune system, Science, 336, pp. 1268-1273, (2012); Husebye E., Hellstrom P.M., Sundler F., Chen J., Midtvedt T., Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats, Am. J. Physiol. Gastrointest. Liver Physiol., 280, pp. G368-G380, (2001); Ridaura V.K., Faith J.J., Rey F.E., Cheng J., Duncan A.E., Kau A.L., Griffin N.W., Lombard V., Henrissat B., Bain J.R., Muehlbauer M.J., Ilkayeva O., Semenkovich C.F., Funai K., Hayashi D.K., Lyle B.J., Martini M.C., Ursell L.K., Clemente J.C., Van Treuren W., Walters W.A., Knight R., Newgard C.B., Heath A.C., Gordon J.I., Gut microbiota from twins discordant for obesity modulate metabolism in mice, Science, 341, (2013); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Nieuwdorp M., Gilijamse P.W., Pai N., Kaplan L.M., Role of the microbiome in energy regulation and metabolism, Gastroenterology, 146, pp. 1525-1533, (2014); Schnabl B., Brenner D.A., Interactions between the intestinal microbiome and liver diseases, Gastroenterology, 146, pp. 1513-1524, (2014); Amaral F.A., Sachs D., Costa V.V., Fagundes C.T., Cisalpino D., Cunha T.M., Ferreira S.H., Cunha F.Q., Silva T.A., Nicoli J.R., Vieira L.Q., Souza D.G., Teixeira M.M., Commensal microbiota is fundamental for the development of inflammatory pain, Proc. Natl. Acad. Sci. U.S.A., 105, pp. 2193-2197, (2008); Heijtz R.D., Wang S., Anuar F., Qian Y., Bjorkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S., Normal gut microbiota modulates brain development and behavior, Proc. Natl. Acad. Sci. U.S.A., 108, pp. 3047-3052, (2011); Bercik P., Denou E., Collins J., Jackson W., Lu J., Jury J., Deng Y., Blennerhassett P., Macri J., McCoy K.D., Verdu E.F., Collins S.M., The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice, Gastroenterology, 141, pp. 599-609e3, (2011); Gareau M.G., Wine E., Rodrigues D.M., Cho J.H., Whary M.T., Philpott D.J., Macqueen G., Sherman P.M., Bacterial infection causes stress-induced memory dysfunction in mice, Gut, 60, pp. 307-317, (2011); Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F., Ingestion of lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve, Proc. Natl. Acad. Sci. U.S.A., 108, pp. 16050-16055, (2011); Collins S.M., Surette M., Bercik P., The interplay between the intestinal microbiota and the brain, Nat. Rev. Microbiol., 10, pp. 735-742, (2012); Peterson D.A., Frank D.N., Pace N.R., Gordon J.I., Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases, Cell Host Microbe, 3, pp. 417-427, (2008); Bhargava P., Mowry E.M., Gut microbiome and multiple sclerosis, Curr. Neurol. Neurosci. Rep., 14, (2014); Mulle J.G., Sharp W.G., Cubells J.F., The gut microbiome: A new frontier in autism research, Curr. Psychiatry Rep., 15, (2013); Hanage W.P., Microbiology: Microbiome science needs a healthy dose of scepticism, Nature, 512, pp. 247-248, (2014); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., Roger M., Tamouza R., Leboyer M., Boyer L., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): A systematic review and meta-analysis, Eur. Arch. Psychiatry Clin. Neurosci., 264, pp. 651-660, (2014); Simren M., Barbara G., Flint H.J., Spiegel B.M.R., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G., Intestinal microbiota in functional bowel disorders: A Rome foundation report, Gut, 62, pp. 159-176, (2013); Matto J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A., Saarela M., Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - A longitudinal study in IBS and control subjects, FEMS Immunol. Med. Microbiol., 43, pp. 213-222, (2005); Tana Y.C., Umesaki A., Imaoka T., Handa M., Kanazawa S., Fukudo, altered profiles of intestinal microbiota and organic acids May be the origin of symptoms in irritable bowel syndrome, Neurogastroenterol. Motil., 22, pp. 512-519, (2010); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, pp. 521-530e248, (2012); Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., Makivuokko H., Kajander K., Palva A., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol., 9, (2009); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Villarreal A.A., Aberger F.J., Benrud R., Gundrum J.D., Use of broad-spectrum antibiotics and the development of irritable bowel syndrome, WMJ, 111, pp. 17-20, (2012); El-Salhy M., Ostgaard H., Gundersen D., Hatlebakk J.G., Hausken T., The role of diet in the pathogenesis and management of irritable bowel syndrome (Review), Int. J. Mol. Med., 29, pp. 723-731, (2012); Dunlop S.P., Coleman N.S., Blackshaw E., Perkins A.C., Singh G., Marsden C.A., Spiller R.C., Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 3, pp. 349-357, (2005); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J. Gastroenterol., 46, pp. 421-431, (2011); Liebregts T., Adam B., Bredack C., Roth A., Heinzel S., Lester S., Downie-Doyle S., Smith E., Drew P., Talley N.J., Holtmann G., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Reed D.E., Pigrau M., Lu J., Mayyedi P., Collins S.M., Bercik P., Beads study: A novel method to measure gastrointestinal transit in mice, Neurogastroenterol. Motil., 26, pp. 1663-1668, (2014); Talley N.J., Functional gastrointestinal disorders in 2007 and Rome III: Something new, something borrowed, something objective, Rev. Gastroenterol. Disord., 7, pp. 97-105, (2007); Whitehead W.E., Palsson O., Jones K.R., Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?, Gastroenterology, 122, pp. 1140-1156, (2002); Voss E., Wehkamp J., Wehkamp K., Stange E.F., Schroder J.M., Harder J., NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2, J. Biol. Chem., 281, pp. 2005-2011, (2006); Wehkamp J., Fellermann K., Herrlinger K.R., Baxmann S., Schmidt K., Schwind B., Duchrow M., Wohlschlager C., Feller A.C., Stange E.F., Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease, Eur. J. Gastroenterol. Hepatol., 14, pp. 745-752, (2002); Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., Musial F., Dobos G.J., Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am. J. Gastroenterol., 104, pp. 404-410, (2009); Cohen S.B., Maurer K.J., Egan C.E., Oghumu S., Satoskar A.R., Denkers E.Y., CXCR3-dependent CD4<sup>+</sup> T cells are required to activate inflammatory monocytes for defense against intestinal infection, PLOS Pathog., 9, (2013); Ostvik A.E., Granlund A.V., Bugge M., Nilsen N.J., Torp S.H., Waldum H.L., Damas J.K., Espevik T., Sandvik A.K., Enhanced expression of CXCL10 in inflammatory bowel disease: Potential role of mucosal toll-like receptor 3 stimulation, Inflamm. Bowel Dis., 19, pp. 265-274, (2013); Moloney G., Fanning A., Sharry J.M., Craig O.F., Edelstein E., Dinan T.G., Cryan J.F., Shanahan F., Quigley E.M., Melgar S., Nally K., Evidence of on-going activation of the CXCR3 chemokine system in irritable bowel syndrome (IBS), Gastroenterology, 146, pp. S530-S531, (2014); Salonen A., De Vos W.M., Palva A., Gastrointestinal microbiota in irritable bowel syndrome: Present state and perspectives, Microbiology, 156, pp. 3205-3215, (2010); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Sanchez A., Guilarte M., Antolin M., De Torres I., Gonzalez-Castro A.M., Pigrau M., Saperas E., Azpiroz F., Santos J., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol., 107, pp. 736-746, (2012); Bercik P., Verdu E.F., Foster J.A., Macri J., Potter M., Huang X., Malinowski P., Jackson W., Blennerhassett P., Neufeld K.A., Lu J., Khan W.I., Corthesy-Theulaz I., Cherbut C., Bergonzelli G.E., Collins S.M., Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice, Gastroenterology, 139, pp. 2102-2112e1, (2010); Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., Guyonnet D., Legrain-Raspaud S., Trotin B., Naliboff B., Mayer E.A., Consumption of fermented milk product with probiotic modulates brain activity, Gastroenterology, 144, pp. 1394-1401e4, (2013); Pinto-Sanchez M.I., Hall G., Gajar K., Nardelli A., Bolino C., Welch C., Rieder A., Traynor J., Gregory C., Lau J., Ford A.C., Bergonzelli G., Surette M.G., Collins S.M., Moayyedi P., Bercik P., Bifidobacterium longum NCC3001 improves depression scores and alters brain activity in patients with irritable bowel syndrome: A randomized, double blind, placebo-controlled trial, UEG Proc. J., 3, (2015); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N. Engl. J. Med., 367, pp. 1626-1635, (2012); Radojevic N., McKay D.M., Merger M., Vallance B.A., Collins S.M., Croitoru K., Characterization of enteric functional changes evoked by in vivo anti-CD3 T cell activation, Am. J. Physiol., 276, pp. R715-R723, (1999); Ibeakanma C., Ochoa-Cortes F., Miranda-Morales M., McDonald T., Spreadbury I., Cenac N., Cattaruzza F., Hurlbut D., Vanner S., Bunnett N., Vergnolle N., Vanner S., Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome, Gastroenterology, 141, pp. 2098-2108e5, (2011); Tran L., Chaloner A., Sawalha A.H., Greenwood Van-Meerveld B., Importance of epigenetic mechanisms in visceral pain induced by chronic water avoidance stress, Psychoneuroendocrinology, 38, pp. 898-906, (2013); Rohrl J., Yang D., Oppenheim J.J., Hehlgans T., Human β-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2, J. Immunol., 184, pp. 6688-6694, (2010); Oeckinghaus A., Hayden M.S., Ghosh S., Crosstalk in NF-κB signaling pathways, Nat. Immunol., 12, pp. 695-708, (2011); Avula L.R., Knapen D., Buckinx R., Vergauwen L., Adriaensen D., Van Nassauw L., Timmermans J.-P., Whole-genome microarray analysis and functional characterization reveal distinct gene expression profiles and patterns in two mouse models of ileal inflammation, BMC Genomics, 13, (2012); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Salvioli B., Corinaldesi R., New pathophysiological mechanisms in irritable bowel syndrome, Aliment. Pharmacol. Ther., 20, pp. 1-9, (2004); Al-Sadi R., Guo S., Ye D., Dokladny K., Alhmoud T., Ereifej L., Said H.M., Ma T.Y., Mechanism of IL-1β modulation of intestinal epithelial barrier involves p38 kinase and activating transcription factor-2 activation, J. Immunol., 190, pp. 6596-6606, (2013); Sano R., Reed J.C., ER stress-induced cell death mechanisms, Biochim. Biophys. Acta, 1833, pp. 3460-3470, (2013); Wohleb E.S., Powell N.D., Godbout J.P., Sheridan J.F., Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior, J. Neurosci., 33, pp. 13820-13833, (2013); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., De Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Saulnier D.M., Riehle K., Mistretta T.-A., Diaz M.-A., Mandal D., Raza S., Weidler E.M., Qin X., Coarfa C., Milosavljevic A., Petrosino J.F., Highlander S., Gibbs R., Lynch S.V., Shulman R.J., Versalovic J., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Fuchs B., Muller K., Paasch U., Schiller J., Lysophospholipids: Potential markers of diseases and infertility?, Mini Rev. Med. Chem., 12, pp. 74-86, (2012); Fan H., Zingarelli B., Harris V., Tempel G.E., Halushka P.V., Cook J.A., Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: Potential anti-inflammatory signaling pathways, Mol. Med., 14, pp. 422-428, (2008); Frey B., Gaipl U.S., The immune functions of phosphatidylserine in membranes of dying cells and microvesicles, Semin. Immunopathol., 33, pp. 497-516, (2011); Hellhammer J., Fries E., Buss C., Engert V., Tuch A., Rutenberg D., Hellhammer D., Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress, Stress, 7, pp. 119-126, (2004); Funfgeld E.W., Baggen M., Nedwidek P., Richstein B., Mistlberger G., Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer's type (SDAT), Prog. Clin. Biol. Res., 317, pp. 1235-1246, (1989); Castilho J.C., Perry J.C., Andreatini R., Vital M.A.B.F., Phosphatidylserine: An antidepressive or a cognitive enhancer?, Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, pp. 731-738, (2004); Brambilla F., Maggioni M., Blood levels of cytokines in elderly patients with major depressive disorder, Acta Psychiatr. Scand., 97, pp. 309-313, (1998); Vanotti A., Osio M., Mailland E., Nascimbene C., Capiluppi E., Mariani C., Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies, CNS Drugs, 21, pp. 3-12, (2007); Pettegrew J.W., Levine J., McClure R.J., Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression, Mol. Psychiatry, 5, pp. 616-632, (2000); Benoit S.C., Kemp C.J., Elias C.F., Abplanalp W., Herman J.P., Migrenne S., Lefevre A.-L., Cruciani-Guglielmacci C., Magnan C., Yu F., Niswender K., Irani B.G., Holland W.L., Clegg D.J., Palmitic acid mediates hypothalamic insulin resistance by altering PKC-θ subcellular localization in rodents, J. Clin. Invest., 119, pp. 2577-2589, (2009); De Jesus Moreno Moreno M., Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial, Clin. Ther., 25, pp. 178-193, (2003); Parnetti L., Mignini F., Tomassoni D., Traini E., Amenta F., Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?, J. Neurol. Sci., 257, pp. 264-269, (2007); Bailey M.T., Dowd S.E., Parry N.M.A., Galley J.D., Schauer D.B., Lyte M., Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by citrobacter rodentium, Infect. Immun., 78, pp. 1509-1519, (2010); Park A.J., Collins J., Blennerhassett P.A., Ghia J.E., Verdu E.F., Bercik P., Collins S.M., Altered colonic function and microbiota profile in a mouse model of chronic depression, Neurogastroenterol. Motil., 25, pp. 733-1575, (2013); Anisman H., Hayley S., Kelly O., Borowski T., Merali Z., Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: Mouse strain-dependent outcomes, Behav. Neurosci., 115, pp. 443-454, (2001); Bourin M., Hascoet M., The mouse light/dark box test, Eur. J. Pharmacol., 463, pp. 55-65, (2003); Sakic B., Szechtman H., Talangbayan H., Denburg S.D., Carbotte R.M., Denburg J.A., Disturbed emotionality in autoimmune MRL-lpr mice, Physiol. Behav., 56, pp. 609-617, (1994); Galipeau H.J., Rulli N.E., Jury J., Huang X., Araya R., Murray J.A., David C.S., Chirdo F.G., McCoy K.D., Verdu E.F., Sensitization to gliadin induces moderate enteropathy and insulitis in nonobese diabetic-DQ8 mice, J. Immunol., 187, pp. 4338-4346, (2011); Kennedy K., Hall M.W., Lynch M.D.J., Moreno-Hagelsieb G., Neufeld J.D., Evaluating bias of illumina-based bacterial 16S rRNA gene profiles, Appl. Environ. Microbiol., 80, pp. 5717-5722, (2014); Bartram A.K., Lynch M.D.J., Stearns J.C., Moreno-Hagelsieb G., Neufeld J.D., Generation of multimillion-sequence 16S rRNA gene libraries from complex microbial communities by assembling paired-end illumina reads, Appl. Environ. Microbiol., 77, pp. 3846-3852, (2011); Lynch M.D.J., Masella A.P., Hall M.W., Bartram A.K., Neufeld J.D., AXIOME: Automated exploration of microbial diversity, GigaScience, 2, (2013); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Fierer N., Pena A.G., Goodrich J.K., Gordon J.I., Huttley G.A., Kelley S.T., Knights D., Koenig J.E., Ley R.E., Lozupone C.A., McDonald D., Muegge B.D., Pirrung M., Reeder J., Sevinsky J.R., Turnbaugh P.J., Walters W.A., Widmann J., Yatsunenko T., Zaneveld J., Knight R., QIIME allows analysis of high-throughput community sequencing data, Nat. Methods, 7, pp. 335-336, (2010); Masella A.P., Bartram A.K., Truszkowski J.M., Brown D.G., Neufeld J.D., PANDAseq: Paired-end assembler for illumina sequences, BMC Bioinformatics, 13, (2012); Edgar R.C., UPARSE: Highly accurate OTU sequences from microbial amplicon reads, Nat. Methods, 10, pp. 996-998, (2013); Wang Q., Garrity G.M., Tiedje J.M., Cole J.R., Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy, Appl. Environ. Microbiol., 73, pp. 5261-5267, (2007); DeSantis T.Z., Hugenholtz P., Larsen N., Rojas M., Brodie E.L., Keller K., Huber T., Dalevi D., Hu P., Andersen G.L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Appl. Environ. Microbiol., 72, pp. 5069-5072, (2006); McDonald D., Price M.N., Goodrich J., Nawrocki E.P., DeSantis T.Z., Probst A., Andersen G.L., Knight R., Hugenholtz P., An improved greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea, ISME J., 6, pp. 610-618, (2012); Edgar R.C., Haas B.J., Clemente J.C., Quince C., Knight R., UCHIME improves sensitivity and speed of chimera detection, Bioinformatics, 27, pp. 2194-2200, (2011); Mielke P.W., Meteorological applications of permutation techniques based on distance function, Handbook of Statistics, 4, pp. 813-830, (1984); Lozupone C., Knight R., UniFrac: A new phylogenetic method for comparing microbial communities, Appl. Environ. Microbiol., 71, pp. 8228-8235, (2005); Price M.N., Dehal P.S., Arkin A.P., FastTree 2-approximately maximum-likelihood trees for large alignments, PLOS ONE, 5, (2010); Price M.N., Dehal P.S., Arkin A.P., FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix, Mol. Biol. Evol., 26, pp. 1641-1650, (2009); Caporaso J.G., Bittinger K., Bushman F.D., DeSantis T.Z., Andersen G.L., Knight R., PyNAST: A flexible tool for aligning sequences to a template alignment, Bioinformatics, 26, pp. 266-267, (2010); Dufrene M., Legendre P., Species assemblages and indicator species: The need for a flexible asymmetrical approach, Ecol. Monogr., 67, pp. 345-366, (1997); Walter J., Tannock G.W., Tilsala-Timisjarvi A., Rodtong S., Loach D.M., Munro K., Alatossava T., Detection and identification of gastrointestinal lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers, Appl. Environ. Microbiol., 66, pp. 297-303, (2000); Chalcraft K.R., McCarry B.E., Tandem LC columns for the simultaneous retention of polar and nonpolar molecules in comprehensive metabolomics analysis, J. Sep. Sci., 36, pp. 3478-3485, (2013); Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G., XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification, Anal. Chem., 78, pp. 779-787, (2006)^P. Bercik; Farncombe Family Digestive Health Research Institute, Department of Medicine, McMaster University, Hamilton, Canada; email: bercikp@mcmaster.ca^^American Association for the Advancement of Science^^^^^^19466234^^^28251905.0^English^Sci. Transl. Med.^Article^Final^^Scopus^2-s2.0-85014649400
Fukui H.; Oshima T.; Tanaka Y.; Oikawa Y.; Makizaki Y.; Ohno H.; Tomita T.; Watari J.; Miwa H.^Fukui, Hirokazu (7202565238); Oshima, Tadayuki (7401663152); Tanaka, Yoshiki (57206614122); Oikawa, Yosuke (57193748394); Makizaki, Yutaka (57193749174); Ohno, Hiroshi (59065099100); Tomita, Toshihiko (7403059566); Watari, Jiro (56682679100); Miwa, Hiroto (56921458500)^7202565238; 7401663152; 57206614122; 57193748394; 57193749174; 59065099100; 7403059566; 56682679100; 56921458500^Effect of probiotic Bifidobacterium bifidum G9-1 on the relationship between gut microbiota profile and stress sensitivity in maternally separated rats^2018^Scientific Reports^8.0^1^12384^^^^58^10.1038/s41598-018-30943-3^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85051757460&doi=10.1038%2fs41598-018-30943-3&partnerID=40&md5=20daa26723279863940e8b0c52ff7480^Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Medical Science Department, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan^Fukui H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Oshima T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Tanaka Y., R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Oikawa Y., R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Makizaki Y., Medical Science Department, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Ohno H., R&D Center, Biofermin Pharmaceutical Co., Ltd, Kobe, Japan; Tomita T., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Watari J., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; Miwa H., Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan^Although gut microbiota and early life events are likely involved in the development of irritable bowel syndrome (IBS), it remains unclear how these factors interact in the pathophysiology of IBS. In the present study, using rats subjected to maternal separation (MS) as a model of IBS, we investigated interrelationships among gut microbiota, stress susceptibility and intestinal permeability, and examined the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on those interrelationships. When compared with the controls at postnatal day 20, MS rats showed hypercorticosteronemia, enhanced intestinal permeability and changes in gut microbiota structure. All of these changes in MS rats were prevented by treatment with BBG9-1. Although the gut microbiota profile and basal serum corticosterone level did not differ between MS and control rats at postnatal day 56, MS rats showed hypersensitivity to restraint stress in terms of serum corticosterone level and fecal frequency. However, such hypersensitivity was not observed in MS rats treated with BBG9-1. These findings suggest that MS initiates the link between gut microbiota alteration and hypersensitivity to stress and that the triggering of this process can be prevented by the treatment with the probiotic BBG9-1. © 2018, The Author(s).^^Animals; Bifidobacterium bifidum; Biodiversity; Biomarkers; Body Weight; Corticosterone; Gastrointestinal Microbiome; Intestinal Mucosa; Permeability; Probiotics; Rats; Stress, Physiological; biological marker; corticosterone; probiotic agent; animal; Bifidobacterium bifidum; biodiversity; blood; body weight; intestine flora; intestine mucosa; metabolism; microbiology; permeability; physiological stress; rat^^corticosterone, 50-22-6; Biomarkers, ; Corticosterone, ^^^Biofermin Pharmaceutical Co., Ltd.; Japan Society for the Promotion of Science, JSPS, (17K09363); Japan Society for the Promotion of Science, JSPS; Ministry of Education, Culture, Sports, Science and Technology, MEXT^This work was supported in part by Grants-in-aid for Scientific Research 17K09363 (H.F) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. This work was also funded by Biofermin Pharmaceutical Co., Ltd. This funder provided support in the form of salaries for Y.T., Y.O., Y.M. and H.O.^Longstreth G.F., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 480-1491, (2006); Enck P., Et al., Irritable bowel syndrome, Nat Rev Dis Primers, 2, (2016); Simren M., Et al., Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Barbara G., Et al., Interactions between commensal bacteria and gut sensorimotor function in health and disease, Am J Gastroenterol, 100, pp. 2560-2568, (2005); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Ford A.C., Et al., Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis, Am J Gastroenterol, 109, pp. 1547-1561, (2014); Mazurak N., Broelz E., Storr M., Enck P., Probiotic therapy in the irritable bowel syndrome — why is the evidence for clinical efficacy still poor and what can be done about it?, J Neurogastroeterol Motil, 21, pp. 471-485, (2015); Didari T., Mozaffari S., Nikfar S., Abdollahi M., Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis, World J Gastroenterol, 21, pp. 3072-3084, (2015); Brenner D.M., Moeller M.J., Chey W.D., Schoenfeld P.S., The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review, Am J Gastroenterol, 104, pp. 1033-1049, (2009); Moayyedi P., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review, Gut, 59, pp. 325-332, (2010); Kawahara T., Et al., Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors, PLoS One, 12, (2017); Kato S., Et al., Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses, Clin Exp Pharmacol Physiol, 44, pp. 1017-1025, (2017); Coutinho S.V., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, pp. G307-G316, (2002); Rosztoczy A., Et al., Influence of sex and experimental protocol on the effect of maternal deprivation on rectal sensitivity to distension in the adult rat, Neurogastroenterol Motil, 15, pp. 679-686, (2003); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, pp. 240-245, (2007); Oshima T., Fukui H., Watari J., Miwa H., Childhood abuse history is associated with the development of dyspepsia: a population-based survey in Japan, J Gastroenterol, 50, pp. 744-750, (2015); Delvaux M., Denis P., Allemand H., Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry, French club of digestive motility. Eur J Gastroenterol Hepatol, 9, pp. 345-352, (1997); Gareau M.G., Jury J., MacQueen G., Sherman P.M., Perdue M.H., Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation, Gut, 56, pp. 1522-1528, (2007); Matsuki T., Et al., Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria, Appl Environ Microbiol, 70, pp. 167-173, (2004); Fadrosh D.W., Et al., An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform, Microbiome, 2, (2014); Caporaso J.G., Et al., QIIME allows analysis of high-throughput community sequencing data, Nat Methods, 27, pp. 335-336, (2010); Lozupone C., Knight R., UniFrac: a new phylogenetic method for comparing microbial communities, Appl Environ Microbiol, 71, pp. 8228-8235, (2005); Moussaoui N., Et al., Changes in intestinal glucocorticoid sensitivity in early life shape the risk of epithelial barrier defect in maternal-deprived rats, PLoS One, 9, (2014); Lehmann J., Russig H., Feldon J., Pryce C.R., Effect of a single maternal separation at different pup ages on the corticosterone stress response in adult and aged rats, Pharmacol Biochem Behav, 73, pp. 141-145, (2002); R: A language and environment for statistical computing, R Foundation for Statistical Computing, (2016); Sekirov I., Russell S.L., Antunes L.C., Finlay B.B., Gut microbiota in health and disease, Physiol Rev, 90, pp. 859-904, (2010); Schroeder B.O., Backhed F., Signals from the gut microbiota to distant organs in physiology and disease, Nat Med, 22, pp. 1079-1089, (2016); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Matricon J., Et al., Associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment Pharmacol Ther, 36, pp. 1009-1031, (2012); Rajilic-Stojanovic M., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Crost E.H., Et al., Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent, PLoS One, 8, (2013); Takeshita K., Et al., A single species of Clostridium subcluster XIVa decreased in ulcerative colitis patients, Inflamm Bowel Dis, 22, pp. 2802-2810, (2016); Ostuka Y., Et al., Effect of Bifidobacterium breve on inflammatory gene expression I neonatal and weaning rat intestine, Pediatr Res, 71, pp. 46-53, (2012); Jalanka-Tuovinen J., Et al., Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome, Gut, 63, pp. 1737-1745, (2014); Pozuelo M., Et al., Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome, Sci Rep, 5, (2015); Tap J., Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2017); Shade A., Et al., Fundamentals of microbial community resistance and resilience, Front Microbiol, 3, (2012); David L.A., Et al., Diet rapidly and reproducibly alters the human gut microbiome, Nature, 505, pp. 559-563, (2014); Dethlefsen L., Relman D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proc Natl Acad Sci USA, 108, pp. 4554-4561, (2011); Barouei J., Moussavi M., Hodgson D.M., Effect of maternal probiotic intervention on HPA axis, immunity and gutmicrobiota in a rat mode of irritable bowel syndrome, PLoS One, 7, (2012); De Palma G., Et al., Microbiota and host determinants of behavioural phenotype in maternally separated mice, Nat Commun, 6, (2015); Lehmann J., Feldon J., Long-term biobehavioral effects of maternal separation in the rat: consistent or confusing?, Rev Neurosci, 11, pp. 383-408, (2000)^H. Fukui; Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan; email: hfukui@hyo-med.ac.jp^^Nature Publishing Group^^^^^^20452322^^^30120330.0^English^Sci. Rep.^Article^Final^All Open Access; Gold Open Access^Scopus^2-s2.0-85051757460
Ohlsson B.; Orho-Melander M.; Nilsson P.M.^Ohlsson, Bodil (7005252394); Orho-Melander, Marju (6701619781); Nilsson, Peter M. (56388244600)^7005252394; 6701619781; 56388244600^Higher levels of serum zonulin may rather be associated with increased risk of obesity and hyperlipidemia, than with gastrointestinal symptoms or disease manifestations^2017^International Journal of Molecular Sciences^18.0^3^582^^^^94^10.3390/ijms18030582^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014830587&doi=10.3390%2fijms18030582&partnerID=40&md5=acb0c22940705da2c5fe11e2e6d13141^Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden; Genetic Epidemiology, Diabetes and Cardiovascular Disease, Lund University, Malmö, 205 02, Sweden^Ohlsson B., Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden; Orho-Melander M., Genetic Epidemiology, Diabetes and Cardiovascular Disease, Lund University, Malmö, 205 02, Sweden; Nilsson P.M., Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden^Zonulin is considered a biomarker of increased intestinal permeability, and elevated levels have been found in celiac disease. The primary aim of this study was to examine the association between serum zonulin levels and gastrointestinal (GI) symptoms, and secondarily, between zonulin levels and anthropometric and metabolic factors. The offspring (n = 363) of the participants of the Malmö Diet and Cancer cardiovascular cohort (MDC-CV) were invited to an anthropometric and clinical examination, where fasting plasma glucose levels were measured. Questionnaires about lifestyle factors and medical history were completed along with the Visual Analog Scale for Irritable Bowel Syndrome (VAS-IBS). Zonulin levels were measured in serum by ELISA. Neither GI symptoms nor GI diseases had any influence on zonulin levels. Higher zonulin levels were associated with higher waist circumference (p = 0.003), diastolic blood pressure (p = 0.003), and glucose levels (p = 0.036). Higher zonulin levels were associated with increased risk of overweight (p < 0.001), obesity (p = 0.047), and hyperlipidemia (p = 0.048). We cannot detect altered zonulin levels among individuals reporting GI symptoms or GI diseases, but higher zonulin levels are associated with higher waist circumference, diastolic blood pressure, fasting glucose, and increased risk of metabolic diseases. © 2017 by the authors. Licensee MDPI, Basel, Switzerland.^Blood pressure; Gastrointestinal disorders; Gastrointestinal symptoms; Hyperlipidemia; Obesity; Overweight; Zonulin^Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Weights and Measures; Cholera Toxin; Female; Gastrointestinal Diseases; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Phenotype; Population Surveillance; Risk; regulator protein; unclassified drug; zonulin; biological marker; cholera toxin; glucose blood level; zonulin; adult; age; Article; blood level; body height; controlled study; diabetes mellitus; diastolic blood pressure; enzyme linked immunosorbent assay; female; gastrointestinal disease; gastrointestinal symptom; gender; glucose blood level; human; hyperlipidemia; hypertension; irritable colon; major clinical study; male; middle aged; obesity; observational study; prospective study; questionnaire; visual analog scale; waist circumference; blood; blood pressure; Gastrointestinal Diseases; health survey; Hyperlipidemias; morphometry; obesity; phenotype; risk^^Biomarkers, ; Blood Glucose, ; Cholera Toxin, ; zonulin, ^^^^^Chiba H., Osanai M., Murata M., Kojima T., Sawada N., Transmembrane proteins of tight junctions, Biochim. Biophys. Acta, 1778, pp. 588-600, (2008); Fasano A., Intestinal permeability and its regulation by zonulin: Diagnostic and therapeutic implications, Ann. N. Y. Acad. Sci, 1258, pp. 25-33, (2012); Sapone A., De Magistris L., Pietzak M., Clemente M.G., Tripathi A., Cucca F., Lampis R., Kryszak D., Carteni M., Generoso M., Et al., Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives, Diabetes, 55, pp. 1443-1449, (2006); Fasano A., Regulation of intercellular tight junctions by zonula occludens toxin and its eujaryotic analogue zonulin, Ann. N. Y. Acad. Sci, 915, pp. 214-222, (2000); Tripathi A., Lammers K.M., Goldblum S., Shea-Donohue T., Netzel-Arnett S., Buzza M.S., Antalis T.M., Vogel S.N., Zhao A., Yang S., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc. Natl. Acad. Sci. USA, 106, pp. 16799-16804, (2009); Wang W., Uzzau S., Goldblum S.E., Fasano A., Human zonulin, a potential modulator of intestinal tight junctions, J. Cell Sci, 113, pp. 4435-4440, (2000); Vanuytsel T., Vermeire S., Cleynen I., The role of haptoglobin and its related protein, zonulin, in inflammatory bowel disease, Tissue Barriers, 1, (2013); El Asmar R., Panigrahi P., Bamford P., Berti I., Not T., Coppa G.V., Catassi C., Fasano A., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, pp. 1607-1615, (2002); Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R., Bowel disorders, Gastroenterology, 150, pp. 1393-1407, (2016); Walsham N.E., Sherwood R.A., Fecal calprotectin in inflammatory bowel disease. Clin. Exp, Gastroenterol, 9, pp. 21-29, (2016); Zhou Q., Souba W.W., Croce C., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiol. Rev, 91, pp. 151-175, (2011); Zak-Golab A., Kocelak P., Aptekorz M., Zientara M., Juszczyk L., Martirosian G., Chudek J., Olszanecka-Glinianowicz M., Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects, Int. J. Endocrinol, 2013, (2013); Zhang D., Zhang L., Zheng Y., Yue F., Russell R.D., Zeng Y., Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients, Diabetes Res. Clin. Pract, 106, pp. 312-318, (2014); Ohlsson B., Darwiche G., Roth B., Hoglund P., Two meals with different carbohydrate-, fat-, and protein contents render equivalent postprandial plasma levels of calprotectin, cortisol, triglycerides, and zonulin, Int. J. Food Sci. Nutr, 67, pp. 872-880, (2016); Pacifico L., Bonci E., Marandola L., Romaggioli S., Bascetta S., Chiesa C., Increased circulating zonuln in children with biopsy-proven nonalcoholoic fatty liver disease, World J. Gastroenterol, 20, pp. 17107-17114, (2014); Ohlsson B., Roth B., Larsson E., Hoglund P., Calprotectin in serum and zonulin in serum and feces are elevated after introduction of a diet with lower carbohydrate content and higher fiber, fat and protein contents, Biomed. Rep, (2017); Levy A.P., Asleh R., Blum S., Levy N.S., Miller-Lotan R., Kalet-Litman S., Anbinder Y., Lache O., Nakhoul F.M., Asaf R., Et al., Haptoglobin: Basic and clinical aspects, Antioxid. Redox Signal, 12, pp. 293-304, (2010); Quaye I.K., Haptoglobin, inflammation and disease, Trans. R. Soc. Trop. Med. Hyg, 12, pp. 735-742, (2008); Malyszko J., Koc-Zorawska E., Levin-Laina N., Malyszko J., Zonulin, iron status, and anemia in kidney transplant recipients: Are they related?, Transplant. Proc, 46, pp. 2644-2646, (2014); Chiellini C., Santini F., Marsili A., Berti P., Bertacca A., Pelosini C., Scartabelli G., Pardini E., Lopez-Soriano J., Centoni R., Et al., Serum haptoglobin: A novel marker of adiposity in humans, J. Clin. Endocrinol. Metab, 89, pp. 2678-2683, (2004); Hamalainen P., Saltevo J., Kautiainen H., Mantyselka P., Vanhala M., Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: A case control study, Cardiovasc. Diabetol, 11, (2012); Qi L., Hu F.B., Dietary glycemic load, whole grains, and systemic inflammation in diabetes: The epidemiological evidence, Curr. Opin. Lipidol, 18, pp. 3-8, (2007); Rittirsch D., Flieri M.A., Nadeau B.A., Day D.E., Huber-Lang M.S., Grailer J.J., Zetoune F.S., Andjelkovic A.V., Fasano A., Ward P.A., Zonulin as prehaptoglobin-2 regulates lung permeability and activates the complement system, Am. J. Physiol. Lung Cell. Mol. Physiol, 304, pp. L863-L872, (2013); Chagnac A., Weinstein T., Herman M., Hirsh J., Gafter U., Ori Y., The effects of weight loss on renal function in patients with severe obesity, J. Am. Soc. Nephrol, 14, pp. 1480-1486, (2003); Visser J.T., Lammers K., Hoogendijk A., Boer M.W., Brugman S., Beijer-Liefers S., Zandvoort A., Harmsen H., Welling G., Stellaard F., Et al., Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat, Diabetologia, 53, pp. 2621-2628, (2010); Madara J.L., Stafford J., Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers, J. Clin. Investig, 83, pp. 724-727, (1989); Skardelly M., Armbruster F.P., Meixensberger J., Hilbig H., Expression of zonulin, c-kit, and glial fibrillary acidic protein in human gliomas, Transl. Oncol, 2, pp. 117-120, (2009); Giacco F., Brownlee M., Oxidative stress and diabetic complications, Circ. Res, 107, pp. 1058-1070, (2010); Griendling K.K., Fitzgerald G., Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS, Circulation, 108, pp. 1912-1916, (2003); Casas R., Sacanella E., Estruch R., The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases, Endocr. Metab. Immune Disord. Drug Targets, 14, pp. 245-254, (2014); Manjer J., Carlsson S., Elmstahl S., Gullberg B., Janzon L., Lindstrom M., Mattisson I., Berglund G., The Malmö Diet and Cancer Study: Representativity, cancer incidence and mortality in participants and non-participants, Eur. J. Cancer Prev, 10, pp. 489-499, (2001); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the visual analogue scale for irritable bowel syndrome (VAS-IBS), BMC Gastroenterol, 7, (2007); Bengtsson M., Persson J., Sjolund K., Ohlsson B., Further validation of the visual analogue scale for irritable bowel syndrome after use in clinical practice, Gastroenterol. Nurs, 36, pp. 188-198, (2013); Global Database on Body Mass Index, (2015); Bengtsson M., Hammar O., Mandl T., Ohlsson B., Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS), BMC Gastroenterol, 11, (2011)^B. Ohlsson; Department of Internal Medicine, Skane University Hospital, Lund University, Malmö, 205 02, Sweden; email: bodil.ohlsson@med.lu.se^^MDPI AG^^^^^^16616596^^^28282855.0^English^Int. J. Mol. Sci.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85014830587
Rizzi A.; Nucera E.; Laterza L.; Gaetani E.; Valenza V.; Corbo G.M.; Inchingolo R.; Buonomo A.; Schiavino D.; Gasbarrini A.^Rizzi, Angela (24537318700); Nucera, Eleonora (57192332998); Laterza, Lucrezia (55428675300); Gaetani, Eleonora (7003631094); Valenza, Venanzio (7004161175); Corbo, Giuseppe M (7005355725); Inchingolo, Riccardo (57837086500); Buonomo, Alessandro (7004415698); Schiavino, Domenico (7004829829); Gasbarrini, Antonio (58589716200)^24537318700; 57192332998; 55428675300; 7003631094; 7004161175; 7005355725; 57837086500; 7004415698; 7004829829; 58589716200^Irritable bowel syndrome and nickel allergy: What is the role of the low nickel diet?^2017^Journal of Neurogastroenterology and Motility^23.0^1^^101^108^7.0^31^10.5056/jnm16027^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010402999&doi=10.5056%2fjnm16027&partnerID=40&md5=58021232b8b5dc827300278019939a62^Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Department of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy^Rizzi A., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Nucera E., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Laterza L., Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Gaetani E., Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Valenza V., Department of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Corbo G.M., Department of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Inchingolo R., Department of Pulmonary Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Buonomo A., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Schiavino D., Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy; Gasbarrini A., Division of Gastroenterology, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy^Background/Aims Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain or discomfort accompanied by abnormal bowel movements. In sensitized subjects, ingested nickel (Ni) may induce gastrointestinal symptoms similar to IBS, in addition to typical systemic cutaneous lesions (systemic nickel allergy syndrome [SNAS]). A low nickel diet could improve the systemic manifestations. We evaluated prevalence of nickel allergy in IBS and effects of low Ni diet on (1) gastrointestinal symptoms control, (2) intestinal barrier function, (3) quality of life, and (4) psychological status of patients with IBS and Ni-sensitized patients. Methods Twenty consecutive patients affected by IBS and suspected SNAS underwent intestinal permeability tests. Gastrointestinal symptoms were evaluated using the visual analogue scale before and after 3 months low Ni diet. Subjects with increased intestinal permeability at baseline repeated nuclear examination after the diet. Results The most frequent profile was diarrhea-predominant IBS (8/20). The low Ni diet induced a significant and constant improvement of gastrointestinal symptoms and an equally significant improvement of visual analogue scale. Mean urinary output of 51Chromium ethylene-diamine-tetra-acetate (51Cr-EDTA) was 5.91%/24 hr (± 2.08), significantly different from the control group (2.20%/24 hr ± 0.60, P < 0.0001). Conclusion This pilot study shows that low Ni diet improves gastrointestinal symptoms in patients with IBS and SNAS. © 2017 The Korean Society of Neurogastroenterology and Motility.^Diet; Hypersensitivity; Irritable bowel syndrome; Nickel; Permeability^edetate chromium cr 51; adult; Article; clinical article; controlled clinical trial; controlled study; diarrhea; diet; female; gastrointestinal symptom; human; intestine barrier; intestine function; intestine mucosa permeability; irritable colon; low nickel diet; male; nickel hypersensitivity; permeability barrier; pilot study; prevalence; prospective study; quality of life; systemic nickel allergy syndrome; urine volume; visual analog scale^^edetate chromium cr 51, 11063-42-6^^^^^Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Oshima T., Miwa H., Epidemiology of functional gastrointestinal disorders in Japan and in the world, J Neurogastroenterol Motil, 21, pp. 320-329, (2015); Lackner J.M., Gudleski G.D., Thakur E.R., Stewart T.J., Iacobucci G.J., Spiegel B.M., The impact of physical complaints, social environment, and psychological functioning on IBS patients' health perceptions: looking beyond GI symptom severity, Am J Gastroenterol, 109, pp. 224-233, (2014); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat Rev Gastroenterol Hepatol, 7, pp. 163-173, (2010); Falagiani P., Di Gioacchino M., Ricciardi L., Et al., Systemic nickel allergy syndrome (SNAS): a review, Rev Port Imunoalergologia, 16, pp. 135-147, (2008); Pizzutelli S., Systemic nickel hypersensitivity and diet: myth or reality?, Eur Ann Allergy Clin Immunol, 43, pp. 5-18, (2011); Veien N.K., Menne T., Nickel contact allergy and a nickel-restricted diet, Semin Dermatol, 9, pp. 197-205, (1990); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Di Gioacchino M., Masci S., Cavallucci E., Et al., [Immunohistopathologic changes in the gastrointestinal mucosa in patients with nickel contact allergy.], G Ital Med Lav, 17, (1995); Minelli M., Schiavino D., Musca F., Et al., Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome, Int J Immunopathol Pharmacol, 23, pp. 193-201, (2010); Drossman D.A., The functional Gastrointestinal Disorders and the Rome III process, Gastroenterology, 130, pp. 1377-1390, (2006); Calnan C.D., Fregert S., Magnusson B., The international contact dermatitis research group, Cutis, 18, pp. 708-710, (1976); Spiewak R., Patch Testing for contact allergy and allergic contact dermatitis, Open Allergy Journal, 1, pp. 42-51, (2008); Braga M., Quecchia C., Perotta C., Et al., Systemic nickel allergy syndrome: nosologic framework and diet regimen, Int J Immunopathol Pharmacol, 26, pp. 707-716, (2013); Bengtsson M., Ohlsson B., Ulander K., Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VASIBS), BMC Gastroenterol, 7, (2007); Ware J.E., Sherbourne C.D., The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, pp. 473-483, (1992); Dupy H., The psychological general well-being (PGWB) index, Assessment of quality of life in clinical trials of cardiovascular therapies, (1984); Butcher J.N., Dahlstrom W.G., Graham J.R., Tellegen A., Kaemmer B., MMPI-2: manual for administration and scoring, (1989); Balimane P.V., Chong S., Morrison R.A., Current methodologies used for the evaluation of the intestinal permeability and absorption, J Pharmacol Toxicol Methods, 44, pp. 301-312, (2000); Rossi M., Sganga G., Mazzone M., Et al., Cardiopulmonary bypass in man: role of the intestine in a self-limiting inflammatory response with demonstrable bacterial translocation, Ann Thorac Surg, 77, pp. 612-618, (2004); Perino A., Nickel and food, Int J Immunopathol Pharmacol, 18, 4, pp. 15-17, (2005); Simren M., Mansson A., Langkilde A.M., Et al., Food-related gastrointestinal symptoms in the irritable bowel syndrome, Digestion, 63, pp. 108-115, (2001); Lovell R.M., Ford A.C., Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis, Am J Gastroenterol, 107, pp. 991-1000, (2012); Hayes P.A., Fraher M.H., Quigley E.M., Irritable bowel syndrome: the role of food in pathogenesis and management, Gastroenterol Hepatol (NY), 10, pp. 164-174, (2014); Iacovou M., Tan V., Muir J.G., Gibson P.R., The Low FODMAP diet and its application in east and southeast Asia, J Neurogastroenterol Motil, 21, pp. 459-470, (2015); Staudacher H.M., Whelan K., Irving P.M., Lomer M.C., Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome, J Hum Nutr Diet, 24, pp. 487-495, (2011); Bohn L., Storsrud S., Liljebo T., Et al., Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial, Gastroenterology, 149, pp. 1399.e2-1407.e2, (2015); McKenzie Y.A., Alder A., Anderson W., Et al., British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults, J Hum Nutr Diet, 25, pp. 260-274, (2012); Cazzato I.A., Vadrucci E., Cammarota G., Minelli M., Gasbarrini A., Lactose intolerance in systemic nickel allergy syndrome, Int J Immunopathol Pharmacol, 24, pp. 535-537, (2011); Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G.N., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Lackner J.M., Ma C.X., Keefer L., Et al., Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome, Clin Gastroenterol Hepatol, 11, pp. 1147-1157, (2013); Folks D.G., The interface of psychiatry and irritable bowel syndrome, Curr Psychiatry Rep, 6, pp. 210-215, (2004)^A. Rizzi; Department of Rheumatology, Immunology, Dermatology and Uro-Nefrological Sciences, Allergy Unit, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Largo A. Gemelli 8, 00168, Italy; email: angelarizzi81@gmail.com^^Journal of Neurogastroenterology and Motility^^^^^^20930879^^^^English^J. Neurogastroenterology Motil.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85010402999
Wu R.L.; Vazquez-Roque M.I.; Carlson P.; Burton D.; Grover M.; Camilleri M.; Turner J.R.^Wu, Richard L (57192836146); Vazquez-Roque, Maria I (8983380500); Carlson, Paula (7103028430); Burton, Duane (35453351900); Grover, Madhusudan (23012057300); Camilleri, Michael (7102181053); Turner, Jerrold R. (7404249336)^57192836146; 8983380500; 7103028430; 35453351900; 23012057300; 7102181053; 7404249336^Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression^2017^Laboratory Investigation^97.0^1^^14^23^9.0^42^10.1038/labinvest.2016.118^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85008311673&doi=10.1038%2flabinvest.2016.118&partnerID=40&md5=8930e090192f8b975a3b3f2e6d1b0652^Department of Pathology, University of Chicago, Chicago, IL, United States; Department of Pathology and Laboratory Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, United States; Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Departments of Pathology and Medicine (GI), Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, TH1428, Boston, 02115, MA, United States^Wu R.L., Department of Pathology, University of Chicago, Chicago, IL, United States, Department of Pathology and Laboratory Medicine, Jackson Memorial Hospital, University of Miami, Miami, FL, United States; Vazquez-Roque M.I., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Carlson P., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Burton D., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Grover M., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Camilleri M., Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN, United States; Turner J.R., Department of Pathology, University of Chicago, Chicago, IL, United States, Departments of Pathology and Medicine (GI), Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, TH1428, Boston, 02115, MA, United States^The mechanisms underlying diarrhea-predominant irritable bowel syndrome (IBS-D) are poorly understood, but increased intestinal permeability is thought to contribute to symptoms. A recent clinical trial of gluten-free diet (GFD) demonstrated symptomatic improvement, relative to gluten-containing diet (GCD), which was associated with reduced intestinal permeability in non-celiac disease IBS-D patients. The aim of this study was to characterize intestinal epithelial tight junction composition in IBS-D before and after dietary gluten challenge. Biopsies from 27 IBS-D patients (13 GFD and 14 GCD) were examined by H&E staining and semiquantitative immunohistochemistry for phosphorylated myosin II regulatory light chain (MLC), MLC kinase, claudin-2, claudin-8 and claudin-15. Diet-induced changes were assessed and correlated with urinary mannitol excretion (after oral administration). In the small intestine, epithelial MLC phosphorylation was increased or decreased by GCD or GFD, respectively, and this correlated with increased intestinal permeability (P<0.03). Colonocyte expression of the paracellular Na + channel claudin-15 was also markedly augmented following GCD challenge (P<0.05). Conversely, colonic claudin-2 expression correlated with reduced intestinal permeability (P<0.03). Claudin-8 expression was not affected by dietary challenge. These data show that alterations in MLC phosphorylation and claudin-15 and claudin-2 expression are associated with gluten-induced symptomatology and intestinal permeability changes in IBS-D. The results provide new insight into IBS-D mechanisms and can explain permeability responses to gluten challenge in these patients. © 2017 USCAP, Inc All rights reserved.^^Adult; Claudin-2; Claudins; Colon; Diarrhea; Diet, Gluten-Free; Female; Glutens; Humans; Immunohistochemistry; Intestines; Irritable Bowel Syndrome; Male; Middle Aged; Myosin Light Chains; Myosin-Light-Chain Kinase; Permeability; Phosphorylation; Tight Junctions; claudin; claudin 15; claudin 2; claudin 8; gluten; myosin II; myosin light chain kinase; sodium channel; unclassified drug; claudin; claudin 15; claudin 2; claudin 8; gluten; myosin light chain; myosin light chain kinase; Article; body mass; clinical article; colon biopsy; colon cell; controlled study; diarrhea; double blind procedure; duodenum biopsy; enzyme phosphorylation; human; immunohistochemistry; intestine cell; irritable colon; priority journal; protein analysis; protein expression; protein function; randomized controlled trial; tight junction; adult; colon; diarrhea; drug effects; female; gluten free diet; intestine; Irritable Bowel Syndrome; male; metabolism; middle aged; pathology; permeability; phosphorylation^^gluten, 8002-80-0; myosin light chain kinase, 51845-53-5; claudin 15, ; claudin 8, ; Claudin-2, ; Claudins, ; Glutens, ; Myosin Light Chains, ; Myosin-Light-Chain Kinase, ^^^National Institutes of Health, NIH, (R01DK61931, R01DK68271, R24DK099803); National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (R01DK092179); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK^ACKNOWLEDGMENTS This study was supported by National Institute of Health Grants R01DK61931 (JRT); R01DK68271 (JRT); R24DK099803 (JRT); and R01DK092179 (MC).^Drossman D.A., Chang L., Bellamy N., Et al., Severity in irritable bowel syndrome: A Rome Foundation Working Team report, Am J Gastroenterol, 106, pp. 1749-1759, (2011); Sood R., Law G.R., Ford A.C., Diagnosis of IBS: Symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?, Nat Rev Gastroenterol Hepatol, 11, (2014); Peery A.F., Dellon E.S., Lund J., Et al., Burden of gastrointestinal disease in the United States: 2012 update, Gastroenterol, 143, pp. 1179-1187, (2012); Camilleri M., Katzka D.A., Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome, Am J Physiol Gastrointest Liver Physiol, 302, pp. G1075-G1084, (2012); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., Association of HLA-DQ gene with bowel transit, barrier function, and inflammation in irritable bowel syndrome with diarrhea, Am J Physiol Gastrointest Liver Physiol, 303, pp. G1262-G1269, (2012); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Marchiando A.M., Shen L., Graham W.V., Et al., Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo, J Cell Biol, 189, pp. 111-126, (2010); Saitou M., Furuse M., Sasaki H., Et al., Complex phenotype of mice lacking occludin, a component of tight junction strands, Mol Biol Cell, 11, pp. 4131-4142, (2000); Schulzke J.D., Gitter A.H., Mankertz J., Et al., Epithelial transport and barrier function in occludin-deficient mice, Biochim Biophys Acta, 1669, pp. 34-42, (2005); Marchiando A.M., Graham W.V., Turner J.R., Epithelial barriers in homeostasis and disease, Annu Rev Pathol, 5, pp. 119-144, (2010); Muto S., Hata M., Taniguchi J., Et al., Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules, Proc Natl Acad Sci USA, 107, pp. 8011-8016, (2010); Tamura A., Hayashi H., Imasato M., Et al., Loss of claudin-15, but not claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestine, Gastroenterol, 140, pp. 913-923, (2011); Tamura A., Kitano Y., Hata M., Et al., Megaintestine in claudin-15-deficient mice, Gastroenterol, 134, pp. 523-534, (2008); Bagherie-Lachidan M., Wright S.I., Kelly S.P., Claudin-8 and -27 tight junction proteins in puffer fish Tetraodon nigroviridis acclimated to freshwater and seawater, J Comp Physiol B, 179, pp. 419-431, (2009); Hou J., Renigunta A., Yang J., Et al., Claudin-4 forms paracellular chloride channel in the kidney and requires claudin-8 for tight junction localization, Proc Natl Acad Sci USA, 107, pp. 18010-18015, (2010); Wada M., Tamura A., Takahashi N., Et al., Loss of claudins 2 and 15 from mice causes defects in paracellular Na+ flow and nutrient transport in gut and leads to death from malnutrition, Gastroenterol, 144, pp. 369-380, (2013); Clayburgh D.R., Musch M.W., Leitges M., Et al., Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo, J Clin Invest, 116, pp. 2682-2694, (2006); Vazquez-Roque M.I., Camilleri M., Smyrk T., Et al., A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function, Gastroenterol, 144, pp. 903-911, (2013); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, pp. G919-G928, (2011); Blair S.A., Kane S.V., Clayburgh D.R., Et al., Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease, Lab Invest, 86, pp. 191-201, (2006); Weber C.R., Nalle S.C., Tretiakova M., Et al., Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation, Lab Invest, 88, pp. 1110-1120, (2008); Russo J.M., Florian P., Shen L., Et al., Distinct temporal-spatial roles for rho kinase and myosin light chain kinase in epithelial purse-string wound closure, Gastroenterol, 128, pp. 987-1001, (2005); Clayburgh D.R., Rosen S., Witkowski E.D., Et al., A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability, J Biol Chem, 279, pp. 55506-55513, (2004); Clayburgh D.R., Barrett T.A., Tang Y., Et al., Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo, J Clin Invest, 115, pp. 2702-2715, (2005); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Van Itallie C.M., Holmes J., Bridges A., Et al., The density of small tight junction pores varies among cell types and is increased by expression of claudin-2, J Cell Sci, 121, pp. 298-305, (2008); Li J., Zhuo M., Pei L., Et al., Comprehensive cysteine-scanning mutagenesis reveals claudin-2 pore-lining residues with different intrapore locations, J Biol Chem, 289, pp. 6475-6484, (2014); Yu A.S., Cheng M.H., Angelow S., Et al., Molecular basis for cation selectivity in claudin-2-based paracellular pores: Identification of an electrostatic interaction site, J Gen Physiol, 133, pp. 111-127, (2009); Weber C.R., Liang G.H., Wang Y., Et al., Claudin-2-dependent paracellular channels are dynamically gated, ELife, 4, (2015); Angelow S., Schneeberger E.E., Yu A.S., Claudin-8 expression in renal epithelial cells augments the paracellular barrier by replacing endogenous claudin-2, J Membr Biol, 215, pp. 147-159, (2007); Angelow S., Kim K.J., Yu A.S., Claudin-8 modulates paracellular permeability to acidic and basic ions in MDCK II cells, J Physiol, 571, pp. 15-26, (2006); Yu A.S., Enck A.H., Lencer W.I., Et al., Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation, J Biol Chem, 278, pp. 17350-17359, (2003); Colegio O.R., Van Itallie C., Rahner C., Et al., Claudin extracellular domains determine paracellular charge selectivity and resistance but not tight junction fibril architecture, Am J Physiol Cell Physiol, 284, pp. C1346-C1354, (2003); Capaldo C.T., Farkas A.E., Hilgarth R.S., Et al., Proinflammatory cytokine-induced tight junction remodeling through dynamic self-assembly of claudins, Mol Biol Cell, 25, pp. 2710-2719, (2014); Szakal D.N., Gyorffy H., Arato A., Et al., Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease, Virchows Arch, 456, pp. 245-250, (2010); Zeissig S., Burgel N., Gunzel D., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Heller F., Florian P., Bojarski C., Et al., Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterol, 129, pp. 550-564, (2005); Su L., Nalle S.C., Shen L., Et al., TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis, Gastroenterol, 145, pp. 407-415, (2013); Suzuki H., Nishizawa T., Tani K., Et al., Crystal structure of a claudin provides insight into the architecture of tight junctions, Science, 344, pp. 304-307, (2014); Abiko Y., Kojima T., Murata M., Et al., Changes of tight junction protein claudins in small intestine and kidney tissues of mice fed a DDC diet, J Toxicol Pathol, 26, pp. 433-438, (2013); Arimura Y., Nagaishi K., Hosokawa M., Dynamics of claudins expression in colitis and colitis-associated cancer in rat, Methods Mol Biol, 762, pp. 409-425, (2011); Darsigny M., Babeu J.P., Dupuis A.A., Et al., Loss of hepatocyte-nuclear-factor-4alpha affects colonic ion transport and causes chronic inflammation resembling inflammatory bowel disease in mice, PLoS One, 4, (2009); Tipsmark C.K., Sorensen K.J., Madsen S.S., Aquaporin expression dynamics in osmoregulatory tissues of Atlantic salmon during smoltification and seawater acclimation, J Exp Biol, 213, pp. 368-379, (2010); Holmes J.L., Van Itallie C.M., Rasmussen J.E., Et al., Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns, Gene Expr Patterns, 6, pp. 581-588, (2006); Turner J.R., De C., Mrsny R.J., Et al., Noninvasive in vivo analysis of human small intestinal paracellular absorption: Regulation by Na +-glucose cotransport, Dig Dis Sci, 45, pp. 2122-2126, (2000); Rosenthal R., Gunzel D., Krug S.M., Et al., Claudin-2-mediated cation and water transport share a common pore, Acta Physiol (Oxf), (2016); Amasheh S., Meiri N., Gitter A.H., Et al., Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells, J Cell Sci, 115, pp. 4969-4976, (2002); Turner J.R., Buschmann M.M., Romero-Calvo I., Et al., The role of molecular remodeling in differential regulation of tight junction permeability, Semin Cell Dev Biol, 36, pp. 204-212, (2014); Edelblum K.L., Shen L., Weber C.R., Et al., Dynamic migration of gammadelta intraepithelial lymphocytes requires occludin, Proc Natl Acad Sci USA, 109, pp. 7097-7102, (2012); Edelblum K.L., Singh G., Ma O., Et al., Gammadelta intraepithelial lymphocyte migration limits transepithelial pathogen invasion and systemic disease in mice, Gastroenterol, 148, pp. 1417-1426, (2015); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Cheng P., Yao J., Wang C., Et al., Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome, Mol Med Rep, 12, pp. 3257-3264, (2015); Furuse M., Hata M., Furuse K., Et al., Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice, J Cell Biol, 156, pp. 1099-1111, (2002); Saeedi B.J., Kao D.J., Kitzenberg D.A., Et al., HIF-dependent regulation of claudin-1 is central to intestinal epithelial tight junction integrity, Mol Biol Cell, 26, pp. 2252-2262, (2015); Martinez C., Lobo B., Pigrau M., Et al., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Bertrand J., Ghouzali I., Guerin C., Et al., Glutamine restores tight junction protein claudin-1 expression in colonic mucosa of patients with diarrhea-predominant irritable bowel syndrome, J Parenter Enteral Nutr, (2015); Umeda K., Ikenouchi J., Katahira-Tayama S., Et al., ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation, Cell, 126, pp. 741-754, (2006); Wilcz-Villega E., McClean S., O'Sullivan M., Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS, Neurogastroenterol Motil, 26, pp. 316-325, (2014); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Nalle S.C., Turner J.R., Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease, Mucosal Immunol, 8, pp. 720-730, (2015); Turner J.R., Madara J.L., Physiological regulation of tight junction permeability by Na+-nutrient cotransport, Tight Junctions, pp. 333-347, (2001); Turner J.R., Rill B.K., Carlson S.L., Et al., Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation, Am J Physiol-Cell Physiol, 273, pp. C1378-C1385, (1997); Atisook K., Carlson S., Madara J.L., Effects of phlorizin and sodium on glucose-elicited alterations of cell junctions in intestinal epithelia, Am J Physiol, 258, pp. C77-C85, (1990); Zolotarevsky Y., Hecht G., Koutsouris A., Et al., A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease, Gastroenterol, 123, pp. 163-172, (2002); Berglund J.J., Riegler M., Zolotarevsky Y., Et al., Regulation of human jejunal transmucosal resistance and MLC phosphorylation by Na<sup>+</sup>-glucose cotransport, Am J Physiol Gastrointest Liver Physiol, 281, pp. G1487-G1493, (2001); Shen L., Black E.D., Witkowski E.D., Et al., Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure, J Cell Sci, 119, pp. 2095-2106, (2006); Su L., Shen L., Clayburgh D.R., Et al., Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis, Gastroenterol, 136, pp. 551-563, (2009); Wang F., Graham W.V., Wang Y., Et al., Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression, Am J Pathol, 166, pp. 409-419, (2005); Graham W.V., Wang F., Clayburgh D.R., Et al., Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter, J Biol Chem, 281, pp. 26205-26215, (2006); Wang F., Schwarz B.T., Graham W.V., Et al., IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction, Gastroenterol, 131, pp. 1153-1163, (2006); Rosenthal R., Milatz S., Krug S.M., Et al., Claudin-2, a component of the tight junction, forms a paracellular water channel, J Cell Sci, 123, pp. 1913-1921, (2010); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Anderson J.M., Van Itallie C.M., Physiology and function of the tight junction, Cold Spring Harb Perspect Biol, 1, (2009); Weber C.R., Raleigh D.R., Su L., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J Biol Chem, 285, pp. 12037-12046, (2010); Marciani L., Cox E.F., Hoad C.L., Et al., Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome, Gastroenterol, 138, pp. 469-477, (2010); Wilcz-Villega E.M., McClean S., Ma O., Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: Implications for the mechanisms of barrier dysfunction in irritable bowel syndrome, Am J Gastroenterol, 108, pp. 1140-1151, (2013); Vetrano S., Rescigno M., Cera M.R., Et al., Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease, Gastroenterol, 135, pp. 173-184, (2008); Swan C., Duroudier N.P., Campbell E., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha, Gut, 62, pp. 985-994, (2013)^J.R. Turner; Departments of Pathology and Medicine (GI), Brigham and Women's Hospital, Harvard Medical School, Boston, 20 Shattuck Street, TH1428, 02115, United States; email: jrturner@bwh.harvard.edu^^Nature Publishing Group^^^^^^00236837^^LAINA^27869798.0^English^Lab. Investig.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-85008311673
Valentin N.; Camilleri M.; Carlson P.; Harrington S.C.; Eckert D.; O'Neill J.; Burton D.; Chen J.; Shaw A.L.; Acosta A.^Valentin, Nelson (56644402100); Camilleri, Michael (7102181053); Carlson, Paula (7103028430); Harrington, Sean C. (12770653200); Eckert, Deborah (25121346500); O'Neill, Jessica (9043435800); Burton, Duane (35453351900); Chen, Jun (56640742100); Shaw, Audrey L. (7402249214); Acosta, Andres (55844615900)^56644402100; 7102181053; 7103028430; 12770653200; 25121346500; 9043435800; 35453351900; 56640742100; 7402249214; 55844615900^Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome^2017^Physiological Reports^5.0^5^e13170^^^^20^10.14814/phy2.13170^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015177828&doi=10.14814%2fphy2.13170&partnerID=40&md5=8aa584af02a499f180bb31b0494dcf07^Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Entera Health Inc., Cary, NC, United States^Valentin N., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Camilleri M., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Carlson P., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Harrington S.C., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Eckert D., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; O'Neill J., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Burton D., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Chen J., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States; Shaw A.L., Entera Health Inc., Cary, NC, United States; Acosta A., Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, United States^Serum-derived bovine immunoglobulin/protein isolate (SBI), an oral nutritional therapy, is efficacious in diverse diarrheal diseases. In an open-label study in 15 patients with irritable bowel syndrome-diarrhea (IBS-D), we evaluated effects of SBI (5.0 g, twice a day) for 8 weeks on safety, on bowel function and abdominal pain, tryptophan metabolism (K:T ratio), intestinal permeability (13C-mannitol and lactulose excretion), bile acid synthesis (fasting serum FGF-19 and C4), duodenal and stool microbiome, and the expression of 90 genes related to inflammation, immune function, and tight junctions in duodenal mucosa. Statistical analysis (paired tests, baseline vs. treatment) was based on intention to treat (ITT) principles. One of 15 Caucasian patients (13F, 2M, age 40.3 ± 2.3y, BMI 34.3 ± 3.0 kg/m2) withdrew without completing studies. There were improvements in stools/day (decrease, P < 0.001), ease of passage (P = 0.035), and evacuation (P = 0.004) with SBI therapy. Worst pain severity was numerically reduced in last 2 weeks' treatment (P = 0.078). Duodenal mucosal mRNA expression; serum C4, FGF-19, and KT ratio; small bowel or colon permeability; and stool microbiome were not significantly different after SBI therapy, compared to baseline. In duodenal brushings, there was considerable microbiota structure difference (β diversity analysis P = 0.072, UniFrac) and, on taxonomic analysis, increased abundance of Proteobacteria Burkholderiales, Firmicutes Catonella, and unclassified genus organisms with SBI therapy. Thus, SBI therapy for 8 weeks in IBS-D patients is associated with improved bowel function; the mechanism of benefit is unclear, though there were microbiota structure differences in duodenal brushings. Further studies in patients with low-grade inflammation and intestinal barrier dysfunction at baseline are indicated. © 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.^Bile acids; gene expression; permeability; tryptophan^Abdominal Pain; Adult; Animals; Cattle; Diarrhea; Female; Humans; Immunoglobulins; Intestinal Mucosa; Intestine, Small; Irritable Bowel Syndrome; Male; Pain Measurement; Permeability; Treatment Outcome; bovine immunoglobulin; chemokine; complement component C4; fibroblast growth factor 19; lactulose; mannitol; tight junction protein; immunoglobulin; abdominal pain; adult; aged; anastomosis leakage; Article; backache; bacterium isolation; bile acid synthesis; bloating; clinical article; clinical trial; defecation habit; diarrhea; drug withdrawal; duodenum biopsy; enzyme linked immunosorbent assay; feces analysis; female; Firmicutes; gastroesophageal reflux; gastrointestinal endoscopy; gene expression; headache; high performance liquid chromatography; human; human tissue; inflammation; influenza; intestine flora; intestine function; intestine mucosa permeability; irritable colon; liquid chromatography-mass spectrometry; male; meteorism; molecular therapy; mouth pain; muscle cramp; nausea; nonhuman; pain severity; patient compliance; protein expression; protein isolate therapy; Proteobacteria; real time polymerase chain reaction; taste disorder; taxonomy; tryptophan metabolism; abdominal pain; animal; bovine; diarrhea; intestine mucosa; irritable colon; metabolism; pain measurement; permeability; small intestine; treatment outcome^^complement component C4, 80295-48-3, 80295-71-2; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; immunoglobulin, 9007-83-4; Immunoglobulins, ^^^Department of Bioengineering; EnteraHealth, (R01-DK92179, UL1-TR000135); National Institutes of Health, NIH; National Center for Advancing Translational Sciences, NCATS; University of California, San Francisco, UCSF, (CA 94143)^Funding Information This study was supported by a research grant from EnteraHealth. Dr. Camilleri is supported by NIH grant R01-DK92179. The study was made possible by CCaTS grant UL1-TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. We thank Mrs. Cindy Stanislav for excellent secretarial assistance. K/T analyses were conducted by a contract lab (Dr. Yong Huang at the University of California, San Francisco Drug Studies Unit, Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, UCSF, CA 94143).^Asmuth D.M., Ma Z.M., Albanese A., Sandler N.G., Devaraj S., Knight T.H., Et al., Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy, AIDS, 27, pp. 2207-2217, (2013); Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J.D., Serino M., Et al., Intestinal permeability–a new target for disease prevention and therapy, BMC Gastroenterol., 14, (2014); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N. Engl. J. Med., 367, pp. 1626-1635, (2012); Camilleri M., Katzka D.A., Invited Review. irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome, Am. J. Physiol., 302, pp. G1075-G1084, (2012); Camilleri M., Nadeau A., Tremaine W.J., Lamsam J., Burton D., Odunsi S., Et al., Measurement of serum 7 α -hydroxy-4-cholesten-3-one (or 7 α C4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry, Neurogastroenterol. Motil., 21, pp. 734-743, (2009); Camilleri M., Nadeau A., Lamsam J., Nord S.L., Ryks M., Burton D., Et al., Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion, Neurogastroenterol. Motil., 22, pp. e15-e26, (2010); Camilleri M., Acosta A., Busciglio I., Boldingh A., Dyer R.B., Zinsmeister A.R., Et al., Effect of colesevelam on fecal bile acids and bowel functions in diarrhea-predominant irritable bowel syndrome, Aliment. Pharmacol. Ther., 41, pp. 438-448, (2015); Camilleri M., Carlson P., Acosta A., Busciglio I., Colonic mucosal gene expression and genotype in irritable bowel syndrome with normal or elevated fecal bile acid excretion, Am. J. Physiol. Gastrointest. Liver Physiol., 309, pp. G10-G20, (2015); Camilleri M., Carlson P., Valentin N., Acosta A., O'Neill J., Eckert D., Et al., Pilot study of small mucosal gene expression in patients with irritable bowel syndrome and diarrhea, Am. J. Physiol., 311, pp. G365-G376, (2016); Camilleri M., Oduyebo I., Halawi H., Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges and unanswered questions, Am. J. Physiol. Gastrointest. Liver Physiol., 311, pp. G777-G784, (2016); Campbell J.M., Polo J., Russell L.E., Crenshaw J.D., Review of spray-dried plasma's impact on intestinal barrier function, Livestock. Sci., 133, pp. 239-241, (2010); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Et al., QIIME allows analysis of high-throughput community sequencing data, Nat. Methods, 7, pp. 335-336, (2010); Caporaso J.G., Lauber C.L., Walters W.A., Berg-Lyons D., Huntley J., Fierer N., Et al., Ultra-high-throughput microbial community analysis on the Illumina HiSeq platforms, ISME J., 6, pp. 1621-1624, (2012); Carretti N., Florio P., Bertolin A., Costa C.V., Allegri G., Zilli G., Serum fluctuations of total and free tryptophan levels during the menstrual cycle are related to gonadotrophins and reflect brain serotonin utilization, Hum. Reprod., 20, pp. 1548-1553, (2005); Clarke G., Fitzgerald P., Cryan J.F., Cassidy E.M., Quigley E.M., Dinan T.G., Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort, BMC Gastroenterol., 9, (2009); Crawford C., Panas R., Post-infectious irritable bowel syndrome with functional diarrhea following C. difficile infections: case studies of responses using serum-derived bovine immunoglobulin, J. Gastroenterol. Hepatol. Res., 4, pp. 1577-1581, (2015); Dawson J., Hodgson H.J., Pepys M.B., Peters T.J., Chadwick V.S., Immunodeficiency, malabsorption and secretory diarrhea a new syndrome, Am. J. Med., 67, pp. 540-546, (1979); Dethlefsen L., Relman D.A., Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation, Proc. Natl Acad. Sci. USA, 108, pp. 4554-4561, (2011); Dethlefsen L., Huse S., Sogin M.L., Relman D.A., The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing, PLoS Biol., 6, (2008); Detzel C.J., Horgan A., Henderson A.L., Petschow B.W., Warner C.D., Maas K.J., Et al., Bovine immunoglobulin/protein isolate binds pro-inflammatory bacterial compounds and prevents immune activation in an intestinal co-culture model, PLoS ONE, 10, (2015); Gohl D.M., Vangay P., Garbe J., MacLean A., Hauge A., Becker A., Et al., Systematic improvement of amplicon marker gene methods for increased accuracy in microbiome studies, Nat. Biotechnol., 34, pp. 942-949, (2016); Good L., Rosario R., Panas R., New therapeutic option for irritable bowel syndrome: serum-derived bovine immunoglobulin, World J. Gastroenterol., 21, pp. 3361-3366, (2015); Grover M., Camilleri M., Hines J., Burton D., Ryks M., Wadhwa A., Et al.,            <sup>13</sup>C mannitol as a novel biomarker for measurement of intestinal permeability, Neurogastroenterol. Motil., 28, pp. 1114-1119, (2016); Huang Y., Louie A., Yang Q., Massenkoff N., Xu C., Hunt P.W., Et al., A simple LC-MS/MS method for determination of kynurenine and tryptophan concentrations in human plasma from HIV-infected patients, Bioanalysis, 5, pp. 1397-1407, (2013); Jatoi A., Anti-inflammatory therapy: exploring exercise, serum-derived bovine immunoglobulin/protein isolates, and ruxolitinib for the cancer-associated weight loss syndrome, Curr. Opin. Support Palliat. Care., 7, pp. 339-341, (2013); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Jenabian M.A., El-Far M., Vyboh K., Kema I., Costiniuk C.T., Thomas R., Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection, J. Infect. Dis., 212, pp. 355-366, (2015); Jeraldo P., Kalari K., Chen X., Bhavsar J., Mangalam A., White B., Et al., IM-TORNADO: a tool for comparison of 16S reads from paired-end libraries, PLoS ONE, 9, (2014); Kuchibhatla R., Petschow B.W., Odle J., Weaver E.M., Nutritional impact of dietary plasma proteins in animals undergoing experimental challenge and implications for patients with inflammatory bowel disorders: a meta-analysis, Adv. Nutr., 6, pp. 541-551, (2015); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scand. J. Gastroenterol., 32, pp. 920-924, (1997); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Lostia A.M., Lionetto L., Principessa L., Evangelisti M., Gamba A., Villa M.P., Et al., A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability, Clin. Biochem., 41, pp. 887-892, (2008); Martinez C., Vicario M., Ramos L., Lobo B., Mosquera J.L., Alonso C., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am. J. Gastroenterol., 107, pp. 736-746, (2012); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Et al., Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Moreto M., Perez-Bosque A., Dietary plasma proteins, the intestinal immune system, and the barrier functions of the intestinal mucosa, J. Anim. Sci., 87, 14, pp. E92-E100, (2009); Navarro A., Eslava C., de Garcia la Torre G., Leon L.A., Licona D., Leon L., Zarco L.A., Cravioto A., Common epitopes in LPS of different Enterobacteriaceae are associated with an immune response against Escherichia coli O157 in bovine serum samples, J Med Microbiol, 56, pp. 1447-1454, (2007); Ohman L., Simren M., Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions, Nat. Rev. Gastroenterol. Hepatol., 7, pp. 163-173, (2010); Perez-Bosque A., Miro L., Maijo M., Polo J., Campbell J., Russell L., Et al., Dietary intervention with serum-derived bovine immunoglobulins protects barrier function in a mouse model of colitis, Am. J. Physiol. Gastrointest. Liver Physiol., 308, pp. G1012-G1018, (2015); Perez-Pantoja D., Donoso R., Agullo L., Cordova M., Seeger M., Pieper D.H., Et al., Genomic analysis of the potential for aromatic compounds biodegradation in Burkholderiales, Environ. Microbiol., 14, pp. 1091-1117, (2012); Rao A.S., Camilleri M., Eckert D.J., Busciglio I., Burton D.D., Ryks M., Et al., Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am. J. Physiol., 301, pp. G919-G928, (2011); Shafran I., Burgunder P., Wei D., Young H.E., Klein G., Burnett B.P., Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin, Therap. Adv. Gastroenterol., 8, pp. 331-339, (2015); Simren M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., Et al., Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report, Gut, 62, pp. 159-176, (2013); Teahon K., Smethurst P., Pearson M., Levi A.J., Bjarnason I., The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease, Gastroenterology, 101, pp. 84-89, (1991); Tomita G.M., Todhunter D.A., Hogan J.S., Smith K.L., Antigenic crossreactivity and lipopolysaccharide neutralization properties of bovine immunoglobulin G, J. Dairy Sci., 78, pp. 2745-2752, (1995); Torrallardona D., Spray dried animal plasma as an alternative to antibiotics in weanling pigs – A review, Asian-Aust. J. Anim. Sci., 23, pp. 131-148, (2010); Torres M.I., Lopez-Casado M.A., Lorite P., Rios A., Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease, Clin. Exp. Immunol., 148, pp. 419-424, (2007); Valentin N., Camilleri M., Altayar O., Vijayvargiya P., Acosta A., Nelson A.D., Et al., Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis, Gut, 65, pp. 1951-1959, (2016); Vazquez-Roque M.I., Camilleri M., Smyrk T., Murray J.A., O'Neill J., Carlson P., Et al., Association of HLA-DQ gene with bowel transit, barrier function and inflammation in irritable bowel syndrome with diarrhea, Am. J. Physiol., 303, pp. G1262-G1269, (2012); Wilson D., Evans M.D., Weaver E., Shaw A.L., Klein G.L., Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome, Clin. Med. Insights Gastroenterol., 6, pp. 49-60, (2013); Yu Z., Morrison M., Comparisons of different hypervariable regions of rrs genes for use in fingerprinting of microbial communities by PCR-denaturing gradient gel electrophoresis, Appl. Environ. Microbiol., 70, pp. 4800-4806, (2004)^M. Camilleri; Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, United States; email: camilleri.michael@mayo.edu^^American Physiological Society^^^^^^2051817X^^^28275113.0^English^Physiol. Rep.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85015177828
Zhou S.-Y.; Gillilland M., III; Wu X.; Leelasinjaroen P.; Zhang G.; Zhou H.; Ye B.; Lu Y.; Owyang C.^Zhou, Shi-Yi (38062671900); Gillilland, Merritt (6603428978); Wu, Xiaoyin (7407063918); Leelasinjaroen, Pornchai (55697991200); Zhang, Guanpo (56023790100); Zhou, Hui (57215083667); Ye, Bo (57200207528); Lu, Yuanxu (7405480526); Owyang, Chung (7102742637)^38062671900; 6603428978; 7407063918; 55697991200; 56023790100; 57215083667; 57200207528; 7405480526; 7102742637^FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction^2018^Journal of Clinical Investigation^128.0^1^^267^280^13.0^143^10.1172/JCI92390^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040180220&doi=10.1172%2fJCI92390&partnerID=40&md5=6862ed490e58e9f2526747d28fd4cc0b^Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; 3912 Taubman Center, SPC 5362, Ann Arbor, 48109, MI, United States^Zhou S.-Y., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Gillilland M., III, Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Wu X., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Leelasinjaroen P., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Zhang G., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Zhou H., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Ye B., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Lu Y., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States; Owyang C., Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, United States, 3912 Taubman Center, SPC 5362, Ann Arbor, 48109, MI, United States^Foods high in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism of action is unknown. We hypothesized that a high-FODMAP (HFM) diet increases visceral nociception by inducing dysbiosis and that the FODMAP-altered gut microbial community leads to intestinal pathology. We fed rats an HFM and showed that HFM increases rat fecal Gram-negative bacteria, elevates lipopolysaccharides (LPS), and induces intestinal pathology, as indicated by inflammation, barrier dysfunction, and visceral hypersensitivity (VH). These manifestations were prevented by antibiotics and reversed by low-FODMAP (LFM) diet. Additionally, intracolonic administration of LPS or fecal supernatant (FS) from HFM-fed rats caused intestinal barrier dysfunction and VH, which were blocked by the LPS antagonist LPS-RS or by TLR4 knockdown. Fecal LPS was higher in IBS patients than in healthy subjects (HS), and IBS patients on a 4-week LFM diet had improved IBS symptoms and reduced fecal LPS levels. Intracolonic administration of FS from IBS patients, but not FS from HS or LFM-treated IBS patients, induced VH in rats, which was ameliorated by LPS-RS. Our findings indicate that HFM-associated gut dysbiosis and elevated fecal LPS levels induce intestinal pathology, thereby modulating visceral nociception and IBS symptomatology, and might provide an explanation for the success of LFM diet in IBS patients.^^Animals; Dietary Carbohydrates; Dysbiosis; Gastrointestinal Microbiome; Gene Knockdown Techniques; Intestines; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Nociception; Rats; Rats, Wistar; Toll-Like Receptor 4; antibiotic agent; disaccharide; endotoxin; fluorescein isothiocyanate dextran; gamma interferon; genomic DNA; interleukin 17; interleukin 1beta; interleukin 6; lipopolysaccharide; messenger RNA; monosaccharide; occludin; oligosaccharide; polyol; protein ZO1; rifaximin; small interfering RNA; toll like receptor 4; tumor necrosis factor; lipopolysaccharide; Tlr4 protein, mouse; toll like receptor 4; abdominal pain; animal experiment; animal model; Article; ascending colon; Bacteroidetes; bloating; colon epithelium; colon mucosa; colon tissue; controlled study; diet; diet therapy; DNA isolation; dysbiosis; endotoxemia; enteritis; ex vivo study; fecal supernatant; feces; Firmicutes; FODMAP diet; gene expression; Gram negative bacterium; Gram positive bacterium; high FODMAP diet; histology; human; human cell; hyperalgesia; hypersensitivity; immobilization stress; intestine cell; intestine flora; intestine mucosa permeability; intracolonic drug administration; irritable colon; lamina propria; low FODMAP diet; mast cell; microbial community; mononuclear cell; neutrophil; nociception; nonhuman; priority journal; Proteobacteria; quantitative analysis; rat; real time polymerase chain reaction; supernatant; tight junction; Verrucomicrobia; visceral hyperalgesia; visceral hypersensitivity; Western blotting; Wistar rat; animal; carbohydrate diet; chemically induced; dysbiosis; gene knockdown; genetics; intestine; intestine flora; irritable colon; male; metabolism; microbiology; pharmacology^^fluorescein isothiocyanate dextran, 60842-46-8; gamma interferon, 82115-62-6; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2; toll like receptor 4, 203811-83-0; Dietary Carbohydrates, ; Lipopolysaccharides, ; Tlr4 protein, mouse, ; Toll-Like Receptor 4, ^^^National Institutes of Health, NIH, (R01DK058913); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30DK034933)^The studies were supported by NIH grants R01DK058913 and P30DK34933.^Shepherd S.J., Lomer M.C., Gibson P.R., Short-chain carbohydrates and functional gastrointestinal disorders, Am J Gastroenterol, 108, 5, pp. 707-717, (2013); Ong D.K., Et al., Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome, JGastroenterolHepatol, 25, 8, pp. 1366-1373, (2010); Shepherd S.J., Parker F.C., Muir J.G., Gibson P.R., Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled evidence, Clin Gastroenterol Hepatol, 6, 7, pp. 765-771, (2008); Staudacher H.M., Et al., Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome, JNutr, 142, 8, pp. 1510-1518, (2012); Staudacher H.M., Whelan K., Irving P.M., Lomer M.C., Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome, J Hum Nutr Diet, 24, 5, pp. 487-495, (2011); Halmos E.P., Power V.A., Shepherd S.J., Gibson P.R., Muir J.G., A diet low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, 1, pp. 67-75, (2014); Raetz C.R., Whitfield C., Lipopolysaccharide endotoxins, Annu Rev Biochem, 71, pp. 635-700, (2002); Pastor Rojo O., Lopez San Roman A., Albeniz Arbizu E., de la Hera Martinez A., Ripoll Sevillano E., Albillos Martinez A., Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease, Inflamm Bowel Dis, 13, 3, pp. 269-277, (2007); van Deventer S.J., Buller H.R., Ten Cate J.W., Aarden L.A., Hack C.E., Sturk A., Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways, Blood, 76, 12, pp. 2520-2526, (1990); Dlugosz A., Et al., Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome, NeurogastroenterolMotil, 27, 12, pp. 1747-1754, (2015); Jalanka-Tuovinen J., Et al., Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome, Gut, 63, 11, pp. 1737-1745, (2014); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, 2, pp. 131-144, (2010); Bhattacharyya S., Dudeja P.K., Tobacman J.K., Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells, Am J Physiol Gas-Trointest Liver Physiol, 295, 4, pp. G784-G790, (2008); Lenoir C., Et al., MD-2 controls bacterial lipopolysaccharide hyporesponsiveness in human intestinal epithelial cells, Life Sci, 82, 9-10, pp. 519-528, (2008); Guo S., Al-Sadi R., Said H.M., Ma T.Y., Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14, Am J Pathol, 182, 2, pp. 375-387, (2013); Xu D., Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, 2, (2014); Symons P., Jones M.P., Kellow J.E., Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol, Scand J Gastroenterol, 27, 11, pp. 940-944, (1992); Ravich W.J., Bayless T.M., Carbohydrate absorption and malabsorption, Clin Gastroenterol, 12, 2, pp. 335-356, (1983); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, JGastroenterol, 46, 4, pp. 421-431, (2011); Dunlop S.P., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Bertiaux-Vandaele N., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, 12, pp. 2165-2173, (2011); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, 1-2, pp. 141-147, (2005); Ludidi S., Et al., The intestinal barrier in irritable bowel syndrome: Subtype-specific effects of the systemic compartment in an in vitro model, PLoS ONE, 10, 5, (2015); Neuman M.G., Immune dysfunction in inflammatory bowel disease, TranslRes, 149, 4, pp. 173-186, (2007); van Deventer S.J., Ten Cate J.W., Tytgat G.N., Intestinal endotoxemia. Clinical significance, Gastroenterology, 94, 3, pp. 825-831, (1988); Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G., Diets that differ in their FODMAP content alter the colonic luminal microenvironment, Gut, 64, 1, pp. 93-100, (2015); Derrien M., Vaughan E.E., Plugge C.M., De Vos W.M., Akkermansia muciniphila gen. Nov., sp. Nov., a human intestinal mucin-degrading bacterium, Int JSystEvolMicrobiol, 54, pp. 1469-1476, (2004); Collado M.C., Derrien M., Isolauri E., De Vos W.M., Salminen S., Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly, Appl Environ Microbiol, 73, 23, pp. 7767-7770, (2007); Everard A., Et al., Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice, Diabetes, 60, 11, pp. 2775-2786, (2011); Kang C.S., Et al., Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis, PLoS ONE, 8, 10, (2013); Vatanen T., Et al., Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans, Cell, 165, 6, (2016); Saulnier D.M., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1782-1791, (2011); Rajilic-Stojanovic M., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Nahid M.A., Satoh M., Chan E.K., MicroRNA in TLR signaling and endotoxin tolerance, CellMol Immunol, 8, 5, pp. 388-403, (2011); Kang D.J., Et al., Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition, Clin Transl Gastroenterol, 7, 8, (2016); Bailey M.T., Dowd S.E., Parry N.M., Galley J.D., Schauer D.B., Lyte M., Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by Citrobacter rodentium, Infect Immun, 78, 4, pp. 1509-1519, (2010); Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodu-lation, Brain Behav Immun, 25, 3, pp. 397-407, (2011); Soderholm J.D., Et al., Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine, Gastroenterology, 123, 4, pp. 1099-1108, (2002); Bhunia A., Mohanram H., Domadia P.N., Torres J., Bhattacharjya S., Designed beta-boomerang antiendotoxic and antimicrobial peptides: Structures and activities in lipopolysaccharide, JBiol Chem, 284, 33, pp. 21991-22004, (2009); El Asmar R., Et al., Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure, Gastroenterology, 123, 5, pp. 1607-1615, (2002); Tripathi A., Et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proc Natl Acad Sci USA, 106, 39, pp. 16799-16804, (2009); Buzza M.S., Et al., Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine, Proc Natl Acad Sci U S A, 107, 9, pp. 4200-4205, (2010); Coutinho S.V., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastroin-Test Liver Physiol, 282, 2, pp. G307-G316, (2002); Chen S.L., Et al., Subdiaphragmatic vagal afferent nerves modulate visceral pain, Am J Physiol Gastro-Intest Liver Physiol, 294, 6, pp. G1441-G1449, (2008); Bradesi S., Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastro-Intest Liver Physiol, 289, 1, pp. G42-G53, (2005); Dabek M., Et al., Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: Role of cathepsin G and protease-activated receptor-4, InflammBowelDis, 17, 6, pp. 1409-1414, (2011); Zhang Y., Et al., Engineering mucosal RNA interference in vivo, MolTher, 14, 3, pp. 336-342, (2006); Palliser D., Et al., An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection, Nature, 439, 7072, pp. 89-94, (2006); Sato T., Et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche, Nature, 459, 7244, pp. 262-265, (2009); Jung P., Et al., Isolation and in vitro expansion of human colonic stem cells, Nat Med, 17, 10, pp. 1225-1227, (2011); Leslie J.L., Et al., Persistence and toxin production by Clostridium difficile within human intestinal organoids result in disruption of epithelial paracellular barrier function, Infect Immun, 83, 1, pp. 138-145, (2015)^C. Owyang; Division of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, United States; email: cowyang@med.umich.edu^^American Society for Clinical Investigation^^^^^^00219738^^JCINA^29202473.0^English^J. Clin. Invest.^Article^Final^All Open Access; Bronze Open Access; Green Open Access^Scopus^2-s2.0-85040180220
Russo F.; Chimienti G.; Linsalata M.; Clemente C.; Orlando A.; Riezzo G.^Russo, Francesco (59133987400); Chimienti, Guglielmina (57210207419); Linsalata, Michele (6603600075); Clemente, Caterina (7005101585); Orlando, Antonella (23767683100); Riezzo, Giuseppe (7004144336)^59133987400; 57210207419; 6603600075; 7005101585; 23767683100; 7004144336^The obestatin/ghrelin ratio and ghrelin genetics in adult celiac patients before and after a gluten-free diet, in irritable bowel syndrome patients and healthy individuals^2017^European Journal of Gastroenterology and Hepatology^29.0^2^^160^168^8.0^9^10.1097/MEG.0000000000000760^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991454129&doi=10.1097%2fMEG.0000000000000760&partnerID=40&md5=32daad7904fb78112eddea5ddd815962^Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy^Russo F., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Chimienti G., Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy; Linsalata M., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Clemente C., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Orlando A., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy; Riezzo G., Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Via Turi 27, Castellana Grotte, Bari, I-70013, Italy^Background: Ghrelin levels and obestatin/ghrelin ratio have been proposed as activity markers in ulcerative colitis, but no data are available in celiac disease (CD) and irritable bowel syndrome (IBS). Our aims were as follows: (a) to assess obestatin and ghrelin concentrations in adult active CD patients, diarrhea-predominant IBS (IBS-d), and healthy controls (HC) in relation to intestinal permeability; (b) to evaluate the ghrelin-obestatin profile in CD patients after a 1-year gluten-free diet (GFD); and (c) to establish the impact of ghrelin genetics. Methods: The study included 31 CD patients, 28 IBS-d patients, and 19 HC. Intestinal permeability, assayed by highperformance liquid chromatography determination of urinary lactulose (La)/mannitol (Ma), and circulating concentrations of obestatin, ghrelin, and their ratio were evaluated at enrollment and after GFD. The ghrelin single nucleotide polymorphisms Arg51Gln (rs34911341), Leu72Met (rs696217), and Gln90Leu (rs4684677) were analyzed. Results: Intestinal permeability was impaired in CD patients and ameliorated after GFD. Ghrelin was significantly (P =0.048) higher and the obestatin/ghrelin ratio was significantly (P= 0.034) lower in CD patients compared with both IBS-d and HC, and GFD reduced the peptide levels, but without reaching the concentrations in HC. Significant differences (P< 0.05) were found in the Leu72Met polymorphism among groups, with the reduction of the GT genotype and the T allele in both CD and IBS-d patients compared with HC. Conclusion: Intestinal permeability is altered in CD, but not in IBS-d patients, and ghrelin levels increase in CD patients as observed in other inflammatory conditions. Moreover, a role for ghrelin genetics is hypothesized in sustaining the many pathogenetic components of these different pathologies, but with a similar symptom profile. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.^Celiac disease; Ghrelin; GHRL; Gluten-free diet; Irritable bowel syndrome; Obestatin^Adult; Celiac Disease; Diarrhea; Diet, Gluten-Free; Female; Genetic Predisposition to Disease; Genotype; Ghrelin; Healthy Volunteers; Humans; Intestines; Irritable Bowel Syndrome; Lactulose; Male; Mannitol; Permeability; Polymorphism, Single Nucleotide; ghrelin; obestatin; sugar; ghrelin; lactulose; mannitol; obestatin, human; absorption; adult; allele; Article; celiac disease; clinical article; dietary compliance; female; genotype; gluten free diet; high performance liquid chromatography; human; intestine mucosa permeability; irritable colon; male; priority journal; sample size; single nucleotide polymorphism; blood; celiac disease; diarrhea; diet therapy; genetic predisposition; genetics; gluten free diet; intestine; irritable colon; metabolism; normal human; permeability; urine^^ghrelin, 304853-26-7; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; Ghrelin, ; Lactulose, ; Mannitol, ; obestatin, human, ^^^^^Gujral N., Freeman H.J., Thomson A.B., Celiac disease: Prevalence, diagnosis, pathogenesis and treatment, World J Gastroenterol, 18, pp. 6036-6059, (2012); Shahbazkhani B., Forootan M., Merat S., Akbari M.R., Nasserimoghadam S., Vahedi H., Et al., Coeliac disease presenting with symptoms of irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 231-235, (2003); Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., Et al., Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome, J Clin Gastroenterol, 46, pp. S52-S55, (2012); Russo F., Chimienti G., Clemente C., D'Attoma B., Linsalata M., Orlando A., Et al., Adipokine profile in celiac patients: Differences in comparison with patients suffering from diarrhea-predominant IBS and healthy subjects, Scand J Gastroenterol, 48, pp. 1377-1385, (2013); El-Salhy M., Seim I., Chopin L., Gundersen D., Hatlebakk J.G., Hausken T., Irritable bowel syndrome: The role of gut neuroendocrine peptides, Front Biosci (Elite Ed), 4, pp. 2783-2800, (2012); Lanzini A., Magni P., Petroni M.L., Motta M., Lanzarotto F., Villanacci V., Et al., Circulating ghrelin level is increased in coeliac disease as in functional dyspepsia and reverts to normal during gluten-free diet, Aliment Pharmacol Ther, 23, pp. 907-913, (2006); Capristo E., Farnetti S., Mingrone G., Certo M., Greco A.V., Addolorato G., Et al., Reduced plasma ghrelin concentration in celiac disease after gluten-free diet treatment, Scand J Gastroentero, 40, pp. 430-436, (2005); Otto B., Spranger J., Benoit S.C., Clegg D.J., Tschop M.H., The many faces of ghrelin: New perspectives for nutrition research?, Br J Nutr, 93, pp. 765-771, (2005); Eissa N., Ghia J.E., Immunomodulatory effect of ghrelin in the intestinal mucosa, Neurogastroent Motil, 27, pp. 1519-1527, (2015); Jung J.Y., Jeong J.B., Kim J.W., Kim S.H., Koh S.J., Kim B.G., Et al., Circulating ghrelin levels and obestatin/ghrelin ratio as a marker of activity in ulcerative colitis, Intest Res, 13, pp. 68-73, (2015); Russo F., Linsalata M., Clemente C., D'Attoma B., Orlando A., Campanella G., Et al., The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: An observational study, BMC Cancer, 13, (2013); Pamukcu O., Kumral Z.N., Ercan F., Yegen B.C., Ertem D., Antiinflammatory effect of obestatin and ghrelin in dextran sulfate sodiuminduced colitis in rats, J Pediatr Gastroenterol Nutr, 57, pp. 211-218, (2013); Nikoukar L.R., Nabavizadeh F., Mohamadi S.M., Moslehi A., Hassanzadeh G., Nahrevanian H., Et al., Protective effect of ghrelin in a rat model of celiac disease, Acta Physiol Hung, 101, pp. 438-447, (2014); Seim I., Walpole C., Amorim L., Josh P., Herington A., Chopin L., The expanding roles of the ghrelin-gene derived peptide obestatin in health and disease, Mol Cell Endocrinol, 340, pp. 111-117, (2011); Ghalandari H., Hosseini-Esfahani F., Mirmiran P., The association of polymorphisms in leptin/leptin receptor genes and ghrelin/ghrelin receptor genes with overweight/obesity and the related metabolic disturbances: A review, Int J Endocrinol Metab, 13, (2015); Futagami S., Shimpuku M., Kawagoe T., Izumi N., Ohishi N., Yamawaki H., Et al., The preproghrelin 3056 TT genotype is associated with the feeling of hunger and low acylated ghrelin levels in Japanese patients with Helicobacter pylori-negative functional dyspepsia, Internal Med, 52, pp. 1155-1163, (2013); Pabalan N.A., Seim I., Jarjanazi H., Chopin L.K., Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: A meta-analysis, BMC Genet, 15, (2014); Yamawaki H., Futagami S., Shimpuku M., Shindo T., Maruki Y., Nagoya H., Et al., Leu72Met408 polymorphism of the ghrelin gene is associated with early phase of gastric emptying in the patients with functional dyspepsia in Japan, J Neurogastroenterol Motil, 21, pp. 93-102, (2015); Hassouna R., Zizzari P., Tolle V., The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake, J Neuroendocrinol, 22, pp. 793-804, (2010); Trovato L., Gallo D., Settanni F., Gesmundo I., Ghigo E., Granata R., Obestatin: Is it really doing something?, Front Horm Res, 42, pp. 175-185, (2014); Ates Y., Degertekin B., Erdil A., Yaman H., Dagalp K., Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status, Digest Dis Sci, 53, pp. 2215-2221, (2008); Schmulson M., Lee O.Y., Chang L., Naliboff B., Mayer E.A., Symptom differences in moderate to severe IBS patients based on predominant bowel habit, Am J Gastroenterol, 94, pp. 2929-2935, (1999); Svedlund J., Sjodin I., Dotevall G., GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, pp. 129-134, (1988); Verdu E.F., Armstrong D., Murray J.A., Between celiac disease and irritable bowel syndrome: The 'no man's land' of gluten sensitivity, Am J Gastroenterol, 104, pp. 1587-1594, (2009); El-Salhy M., Hatlebakk J.G., Gilja O.H., Hausken T., The relation between celiac disease, nonceliac gluten sensitivity and irritable bowel syndrome, Nutr J, 14, (2015); Antonioli D.A., Celiac disease: A progress report, Mod Pathol, 16, pp. 342-346, (2003); Ozgen M., Koca S.S., Etem E.O., Yuce H., Aydin S., Isik A., Ghrelin gene polymorphisms in rheumatoid arthritis, Joint Bone Spine, 78, pp. 368-373, (2011); Linsalata M., D'Attoma B., Orlando A., Guerra V., Russo F., Comparison of an enzymatic assay with liquid chromatography-pulsed amperometric detection for the determination of lactulose and mannitol in urine of healthy subjects and patients with active celiac disease, Clin Chem Lab Med, 52, pp. E61-E64, (2014); Gaunt T.R., Rodriguez S., Day I.N.M., Cubic exact solutions for the estimation of pairwise haplotype frequencies: Implications for linkage disequilibrium analyses and a web tool 'CubeX, BMC Bioinformatics, 8, (2007); Mearin F., Balboa A., Badia X., Baro E., Caldwell E., Cucala M., Et al., Irritable bowel syndrome subtypes according to bowel habit: Revisiting the alternating subtype, Eur J Gastroenterol Hepatol, 15, pp. 165-172, (2003); Spiller R., Lam C., The shifting interface between IBS and IBD, Curr Opin Pharmacol, 11, pp. 586-592, (2011); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Kempinski R., Demissie M., Jasinska M., Paradowski L., Plasma ghrelin concentration in celiac patients, Gastroenterol Pol, 15, pp. 375-377, (2008); Janas R.M., Rybak A., Wierzbicka-Rucinska A., Socha P., Nitko R., Szaflarska-Poplawska A., Et al., Serum concentrations of insulin, ghrelin, adiponectin, leptin, leptin receptor and lipocalin-2 in children with celiac disease who do and do not adhere to a gluten-free diet, Gut Liver, 10, pp. 587-594, (2016); Manavalan J.S., Hernandez L., Shah J.G., Konikkara J., Naiyer A.J., Lee A.R., Et al., Serum cytokine elevations in celiac disease: Association with disease presentation, Hum Immunol, 71, pp. 50-57, (2010); Cheung C.K., Wu J.C.Y., Role of ghrelin in the pathophysiology of gastrointestinal disease, Gut Liver, 7, pp. 505-512, (2013); Sung E.Z., Da Silva N.F., Goodyear S., McTernan P.G., Sanger G.J., Nwokolo C.U., Increased plasma ghrelin following infliximab in Crohn's disease, Aliment Pharmacol Ther, 29, pp. 83-89, (2009); Hosomi S., Oshitani N., Kamata N., Sogawa M., Yamagami H., Watanabe K., Et al., Phenotypical and functional study of ghrelin and its receptor in the pathogenesis of Crohn's disease, Inflamm Bowel Dis, 14, pp. 1205-1213, (2008); Poykko S.M., Kellokoski E., Horkko S., Kauma H., Kesaniemi Y.A., Ukkola O., Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes, Diabetes, 52, pp. 2546-2553, (2003); Zhang X.L., Zhai L.M., Rong C.Z., Qin X., Li S., Association of ghrelin gene polymorphisms and serum ghrelin levels with the risk of hepatitis B virus-related liver diseases in a Chinese population, PLoS One, 10, (2015); Mora M., Adam V., Palomera E., Blesa S., Diaz G., Buquet X., Et al., Ghrelin gene variants influence on metabolic syndrome components in aged Spanish population, PLoS One, 10, (2015); Ukkola O., Genetic variants of ghrelin in metabolic disorders, Peptides, 32, pp. 2319-2322, (2011)^F. Russo; Laboratory of Nutritional Pathophysiology, Department of Clinical Pathology, National Institute of Digestive Diseases, IRCCS Saverio de Bellis, Castellana Grotte, Bari, Via Turi 27, I-70013, Italy; email: francesco.russo@irccsdebellis.it^^Lippincott Williams and Wilkins^^^^^^0954691X^^EJGHE^27750262.0^English^Eur. J. Gastroenterol. Hepatol.^Article^Final^^Scopus^2-s2.0-84991454129
Heitkemper M.M.; Cain K.C.; Shulman R.J.; Burr R.L.; Ko C.; Hollister E.B.; Callen N.; Zia J.; Han C.J.; Jarrett M.E.^Heitkemper, M.M. (7005514887); Cain, K.C. (7103341073); Shulman, R.J. (56961627200); Burr, R.L. (7005552308); Ko, C. (7202596492); Hollister, E.B. (35224866500); Callen, N. (57201998997); Zia, J. (6507732284); Han, C.J. (56493706700); Jarrett, M.E. (59045458700)^7005514887; 7103341073; 56961627200; 7005552308; 7202596492; 35224866500; 57201998997; 6507732284; 56493706700; 59045458700^Stool and urine trefoil factor 3 levels: Associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome^2018^Beneficial Microbes^9.0^3^^345^355^10.0^12^10.3920/bm2017.0059^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046725288&doi=10.3920%2fbm2017.0059&partnerID=40&md5=f7f8daa3dd294b9aa8c0d021597da56e^Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Department of Biostatistics and Office of Nursing Research, University of Washington, 1959 NE Pacific Street, Seattle, WA, United States; Children's Nutrition Research Center, Baylor College of Medicine, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; University of Washington Medical Center, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Department of Pathology and Immunology, Baylor College of Medicine, Texas Children's Microbiome Center, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; Department of Family and Child Nursing, University of Washington, 1959 NE Pacific Street, Seattle, 98195, WA, United States^Heitkemper M.M., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Cain K.C., Department of Biostatistics and Office of Nursing Research, University of Washington, 1959 NE Pacific Street, Seattle, WA, United States; Shulman R.J., Children's Nutrition Research Center, Baylor College of Medicine, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; Burr R.L., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Ko C., University of Washington Medical Center, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Hollister E.B., Department of Pathology and Immunology, Baylor College of Medicine, Texas Children's Microbiome Center, Texas Children's Hospital, 6621 Fannin Street, Houston, 77030, TX, United States; Callen N., Department of Family and Child Nursing, University of Washington, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Zia J., University of Washington Medical Center, 1959 NE Pacific Street, Seattle, 98195, WA, United States; Han C.J., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States; Jarrett M.E., Department of Biobehavioral Nursing and Health Informatics, University of Washington, 1959 NE Pacific Street, Seattle, 98195-7266, WA, United States^Previously we showed that urine trefoil factor 3 (TFF3) levels were higher in females with irritable bowel syndrome (IBS) compared to non-IBS females. To assess if TFF3 is associated with symptoms and/or reflect alterations in gastrointestinal permeability and gut microbiota in an IBS population, we correlated stool and urine TFF3 levels with IBS symptoms, intestinal permeability, stool microbial diversity and relative abundance of predominant bacterial families and genera. We also tested the relationship of stool TFF3 to urine TFF3, and compared results based on hormone contraception use. Samples were obtained from 93 females meeting Rome III IBS criteria and completing 4-week symptom diaries. TFF3 levels were measured by ELISA. Permeability was assessed with the urine lactulose/mannitol (L/M) ratio. Stool microbiota was assessed using 16S rRNA. Stool TFF3, but not urine TFF3, was associated positively with diarrhoea and loose stool consistency. Higher stool TFF3 was also associated with lower L/M ratio and microbial diversity. Of the 20 most abundant bacterial families Mogibacteriaceae and Christensenellaceae were inversely related to stool TFF3, with only Christensenellaceae remaining significant after multiple comparison adjustment. There were no significant relationships between stool or urine TFF3 levels and other symptoms, nor between stool and urine levels. In premenopausal females, urine TFF3 levels were higher in those reporting hormone contraception. Collectively these results suggest that higher stool TFF3 levels are associated with IBS symptoms (loose/diarrhoeal stools), lower gut permeability, and altered stool bacteria composition (decreased diversity and decreased Christensenellaceae), which further suggests that TFF3 may be an important marker of host-bacteria interaction. © 2018 Wageningen Academic Publishers.^Anti-microbial peptide; Christensenellaceae; Diarrhoea; Hormone contraception^Adult; Aged; DNA, Bacterial; DNA, Ribosomal; Enzyme-Linked Immunosorbent Assay; Feces; Female; Gastrointestinal Microbiome; Humans; Irritable Bowel Syndrome; Microbiota; Middle Aged; Permeability; Phylogeny; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Trefoil Factor-3; Urine; Young Adult; lactulose; mannitol; RNA 16S; trefoil factor 3; bacterial DNA; ribosome DNA; RNA 16S; TFF3 protein, human; trefoil factor 3; abdominal pain; adult; aged; Article; behavior therapy; Christensenellaceae; constipation; controlled study; diarrhea; disease association; disease severity; enzyme linked immunosorbent assay; feces analysis; female; gastrointestinal tract; genetic variability; Gram negative bacterium; human; intestine flora; intestine mucosa permeability; irritable colon; major clinical study; microbial diversity; Mogibacteriaceae; randomized controlled trial; symptomatology; urinalysis; chemistry; DNA sequence; feces; genetics; intestine flora; irritable colon; microflora; middle aged; pathology; permeability; phylogeny; urine; young adult^^lactulose, 4618-18-2, 58166-24-8; mannitol, 69-65-8, 87-78-5; DNA, Bacterial, ; DNA, Ribosomal, ; RNA, Ribosomal, 16S, ; TFF3 protein, human, ; Trefoil Factor-3, ^^^National Institutes of Health, NIH; National Institute of Nursing Research, NINR, (R21NR014331); National Institute of Nursing Research, NINR^Work was supported by a grant from the National Institute of Nursing Research, National Institutes of Health R21NR014331.^Aagaard K., Petrosino J., Keitel W., Watson M., Katancik J., Garcia N., Patel S., Cutting M., Madden T., Hamilton H., Harris E., Gevers D., Simone G., McInnes P., Versalovic J., The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters, FASEB Journal, 27, pp. 1012-1022, (2013); Aronesty E., Command-line tools for processing biological sequencing data, (2011); Beck P.L., Ihara E., Hirota S.A., MacDonald J.A., Meng D., Nanthakumar N.N., Podolsky D.K., Xavier R.J., Exploring the interplay of barrier function and leukocyte recruitment in intestinal inflammation by targeting fucosyltransferase VII and trefoil factor 3, American Journal of Physiology, Gastrointestinal and Liver Physiology, 299, pp. G43-53, (2010); Bennet S.M., Polster A., Tornblom H., Isaksson S., Capronnier S., Tessier A., Le Neve B., Simren M., Ohman L., Global cytokine profiles and association with clinical characteristics in patients with irritable bowel syndrome, American Journal of Gastroenterology, 111, pp. 1165-1176, (2016); Biagi E., Franceschi C., Rampelli S., Severgnini M., Ostan R., Turroni S., Consolandi C., Quercia S., Scurti M., Monti D., Capri M., Brigidi P., Candela M., Gut microbiota and extreme longevity, Current Biology, 26, pp. 1480-1485, (2016); Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry, 72, pp. 248-254, (1976); Buda A., Jepson M.A., Pignatelli M., Regulatory function of trefoil peptides (TFF) on intestinal cell junctional complexes, Cell Communication and Adhesion, 19, pp. 63-68, (2012); Camilleri M., Lasch K., Zhou W., Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome, American Journal of Physiology, Gastrointestinal and Liver Physiology, 303, pp. G775-G785, (2012); Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., Costello E.K., Fierer N., Pena A.G., Goodrich J.K., Gordon J.I., Huttley G.A., Kelley S.T., Knights D., Koenig J.E., Ley R.E., Lozupone C.A., McDonald D., Muegge B.D., Pirrung M., Reeder J., Sevinsky J.R., Turnbaugh P.J., Walters W.A., Widmann J., Yatsunenko T., Zaneveld J., Knight R., QIIME allows analysis of high-throughput community sequencing data, Nature Methods, 7, pp. 335-336, (2010); Caporaso J.G., Lauber C.L., Walters W.A., Berg-Lyons D., Lozupone C.A., Turnbaugh P.J., Fierer N., Knight R., Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample, Proceedings of the National Academy of Sciences of the USA, 108, pp. 4516-4522, (2011); Catassi C., Pierani P., Natalini G., Gabrielli O., Coppa G.V., Giorgi P.L., Clinical application of a simple HPLC method for the sugar intestinal permeability test, Journal of Pediatric Gastroenterology and Nutrition, 12, pp. 209-212, (1991); Chaiyarit P., Chayasadom A., Wara-Aswapati N., Hormdee D., Sittisomwong S., Nakaresisoon S., Samson M.H., Pitiphat W., Giraud A.S., Trefoil factors in saliva and gingival tissues of patients with chronic periodontitis, Journal of Periodontology, 83, pp. 1129-1138, (2012); Chang R., Wang Y., Chang J., Wen L., Jiang Z., Yang T., Yu K., LPS preconditioning ameliorates intestinal injury in a rat model of hemorrhagic shock, Inflammation Research, 63, pp. 675-682, (2014); Comelli E.M., Simmering R., Faure M., Donnicola D., Mansourian R., Rochat F., Corthesy-Theulaz I., Cherbut C., Multifaceted transcriptional regulation of the murine intestinal mucus layer by endogenous microbiota, Genomics, 91, pp. 70-77, (2008); DeSantis T.Z., Hugenholtz P., Larsen N., Rojas M., Brodie E.L., Keller K., Huber T., Dalevi D., Hu P., Andersen G.L., Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB, Applied and Environmental Microbiology, 72, pp. 5069-5072, (2006); Drossman D.A., Dumitrascu D.L., Rome III: new standard for functional gastrointestinal disorders, Journal of Gastrointestinal and Liver Diseases, 15, pp. 237-241, (2006); Edgar R.C., Search and clustering orders of magnitude faster than BLAST, Bioinformatics, 26, pp. 2460-2461, (2010); Edgar R.C., UPARSE: highly accurate OTU sequences from microbial amplicon reads, Nature Methods, 10, pp. 996-998, (2013); Ek M., Roth B., Ekstrom P., Valentin L., Bengtsson M., Ohlsson B., Gastrointestinal symptoms among endometriosis patients - a case-cohort study, BMC Women's Health, 15, (2015); Fu T., Znalesniak E.B., Kalinski T., Mohle L., Biswas A., Salm F., Dunay I.R., Hoffmann W., TFF peptides play a role in the immune response following oral infection of mice with Toxoplasma gondii, European Journal of Microbiology and Immunology, 5, pp. 221-231, (2015); Goo Y.A., Cain K., Jarrett M., Smith L., Voss J., Tolentino E., Tsuji J., Tsai Y.S., Panchaud A., Goodlett D.R., Shulman R.J., Heitkemper M., Urinary proteome analysis of irritable bowel syndrome (IBS) symptom subgroups, Journal of Proteome Research, 11, pp. 5650-5662, (2012); Gronbaek H., Vestergaard E.M., Hey H., Nielsen J.N., Nexo E., Serum trefoil factors in patients with inflammatory bowel disease, Digestion, 74, pp. 33-39, (2006); Haas B.J., Gevers D., Earl A.M., Feldgarden M., Ward D.V., Giannoukos G., Ciulla D., Tabbaa D., Highlander S.K., Sodergren E., Methe B., DeSantis T.Z., Petrosino J.F., Knight R., Birren B.W., Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons, Genome Research, 21, pp. 494-504, (2011); Henze D., Doecke W.D., Hornung D., Agueusop I., Von Ahsen O., Machens K., Schmitz A.A., Gashaw I., Endometriosis leads to an increased trefoil factor 3 concentration in the peritoneal cavity but does not alter systemic levels, Reproductive Sciences, 24, pp. 258-267, (2016); Hildebrand F., Tadeo R., Voigt A.Y., Bork P., Raes J., LotuS: an efficient and user-friendly OTU processing pipeline, Microbiome, 2, (2014); Jarrett M.E., Cain K.C., Barney P.G., Burr R.L., Naliboff B.D., Shulman R., Zia J., Heitkemper M.M., Balance of autonomic nervous system predicts who benefits from a self-management intervention program for irritable bowel syndrome, Journal of Neurogastroenterology and Motility, 22, pp. 102-111, (2016); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Quigley E.M., Simren M., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Johansson P.A., Farup P.G., Bracco A., Vandvik P.O., How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice, BMC Gastroenterology, 10, (2010); Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H., Tameda M., Shiraki K., Ito M., Takei Y., Takase K., Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing, BMC Gastroenterology, 15, (2015); Khailova L., Dvorak K., Arganbright K.M., Halpern M.D., Kinouchi T., Yajima M., Dvorak B., Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis, American Journal of Physiology, Gastrointestinal and Liver Physiology, 297, pp. G940-G949, (2009); May F.E., Westley B.R., TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer, Endocrine-Related Cancer, 22, pp. 465-479, (2015); McOmber M.E., Ou C.N., Shulman R.J., Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults, Journal of Pediatric Gastroenterology and Nutrition, 50, pp. 269-275, (2010); Mhawech-Fauceglia P., Wang D., Samrao D., Liu S., DuPont N.C., Pejovic T., Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma, Gynecologic Oncology, 130, pp. 174-180, (2013); Morotomi M., Nagai F., Watanabe Y., Description of Christensenella minuta gen. nov., sp. nov., isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of Christensenellaceae fam. nov., International Journal of Systematic and Evolutionary Microbiology, 62, pp. 144-149, (2012); Podolsky D.K., Gerken G., Eyking A., Cario E., Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency, Gastroenterology, 137, pp. 209-220, (2009); Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., Guarner F., Azpiroz F., Manichanh C., Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome, Scientific Reports, 5, (2015); Renes I.B., Verburg M., Van Nispen D.J., Taminiau J.A., Buller H.A., Dekker J., Einerhand A.W., Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression, International Journal of Colorectal Disease, 17, pp. 317-326, (2002); Ritari J., Salojarvi J., Lahti L., De Vos W.M., Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database, BMC Genomics, 16, (2015); Rognes T., Flouri T., Nichols B., Quince C., Mahe F., VSEARCH: a versatile open source tool for metagenomics, PeerJ, 4, (2016); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Raza S., Weidler E.M., Qin X., Coarfa C., Milosavljevic A., Petrosino J.F., Highlander S., Gibbs R., Lynch S.V., Shulman R.J., Versalovic J., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E., Heitkemper M.M., Associations among gut permeability, inflammatory markers and symptoms in patients with irritable bowel syndrome, Journal of Gastroenterology, 49, pp. 1467-1476, (2014); Shulman R.J., Jarrett M.E., Cain K.C., Broussard E.K., Heitkemper M.M., Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome, Journal of Gastroenterology, 49, pp. 1467-1476, (2014); Shulman R.J., Schanler R.J., Lau C., Heitkemper M., Ou C.N., Smith E.O., Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants, Pediatric Research, 44, pp. 519-523, (1998); Srivastava S., Kedia S., Kumar S., Pratap Mouli V., Dhingra R., Sachdev V., Tiwari V., Kurrey L., Pradhan R., Ahuja V., Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity, Journal of Crohn's and Colitis, 9, pp. 575-579, (2015); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Storsrud S., Le Neve B., Ohman L., Simren M., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome, Gastroenterology, 152, pp. 111-123, (2016); Taupin D., Podolsky D.K., Trefoil factors: initiators of mucosal healing, Nature Reviews, Molecular Cell Biology, 4, pp. 721-732, (2003); Thim L., Madsen F., Poulsen S.S., Effect of trefoil factors on the viscoelastic properties of mucus gels, European Journal of Clinical Investigation, 32, pp. 519-527, (2002); Verey F., Nexo E., Greenwood R., Berry M., Corfield A.P., Trefoil factor family peptides are increased in the saliva of children with mucositis, Clinical Chemistry and Laboratory Medicine, 49, pp. 2051-2055, (2011)^M.M. Heitkemper; Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, 1959 NE Pacific Street, 98195-7266, United States; email: heit@uw.edu^^Wageningen Academic Publishers^^^^^^18762883^^^29633639.0^English^Benefic. Microbes^Article^Final^All Open Access; Green Open Access^Scopus^2-s2.0-85046725288
Bertrand J.; Ghouzali I.; Guérin C.; Bôle-Feysot C.; Gouteux M.; Déchelotte P.; Ducrotté P.; Coëffier M.^Bertrand, Julien (57198107366); Ghouzali, Ibtissem (55534510300); Guérin, Charlène (55319308600); Bôle-Feysot, Christine (55881037400); Gouteux, Mélodie (57191954126); Déchelotte, Pierre (57201760610); Ducrotté, Philippe (7006732860); Coëffier, Moïse (6603081357)^57198107366; 55534510300; 55319308600; 55881037400; 57191954126; 57201760610; 7006732860; 6603081357^Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients with Diarrhea-Predominant Irritable Bowel Syndrome^2016^Journal of Parenteral and Enteral Nutrition^40.0^8^^1170^1176^6.0^36^10.1177/0148607115587330^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84995387494&doi=10.1177%2f0148607115587330&partnerID=40&md5=baaf2170f8882c3a995153148d17eaf6^INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France; Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Department of Nutrition, Rouen University Hospital, Rouen, France; Department of Gastroenterology, Rouen University Hospital, Rouen, France^Bertrand J., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Ghouzali I., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Guérin C., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Bôle-Feysot C., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Gouteux M., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France; Déchelotte P., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France, Department of Nutrition, Rouen University Hospital, Rouen, France; Ducrotté P., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Department of Gastroenterology, Rouen University Hospital, Rouen, France; Coëffier M., INSERM UMR1073, University of Rouen, 22 boulevard Gambetta, Rouen Cedex 1, 76183, France, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Rouen, France, Department of Nutrition, Rouen University Hospital, Rouen, France^Background:Recent studies showed that patients with diarrhea-predominant irritable bowel syndrome (IBS-D) had an increased intestinal permeability as well as a decreased expression of tight junctions. Glutamine, the major substrate of rapidly dividing cells, is able to modulate intestinal permeability and tight junction expression in other diseases. We aimed to evaluate, ex vivo, glutamine effects on tight junction proteins, claudin-1 and occludin, in the colonic mucosa of patients with IBS-D. Materials and Methods: Twelve patients with IBS-D, diagnosed with the Rome III criteria, were included (8 women/4 men, aged 40.7 ± 6.9 years). Colonic biopsy specimens were collected and immediately incubated for 18 hours in culture media with increasing concentrations of glutamine from 0.6-10 mmol/L. Claudin-1 and occludin expression was then measured by immunoblot, and concentrations of cytokines were assessed by multiplex technology. Claudin-1 expression was affected by glutamine (P <.05, analysis of variance). In particularly, 10 mmol/L glutamine increased claudin-1 expression compared with 0.6 mmol/L glutamine (0.47 ± 0.04 vs 0.33 ± 0.03, P <.05). In contrast, occludin expression was not significantly modified by glutamine. Interestingly, glutamine effect was negatively correlated to claudin-1 (Pearson r = -0.83, P <.001) or occludin basal expression (Pearson r = -0.84, P <.001), suggesting that glutamine had more marked effects when tight junction protein expression was altered. Cytokine concentrations in culture media were not modified by glutamine treatment. Conclusion: Glutamine increased claudin-1 expression in the colonic mucosa of patients with IBS-D. In addition, glutamine effect seems to be dependent on basal expression of tight junction proteins. © 2015 The American Society for Parenteral and Enteral Nutrition.^claudin; diarrhea; glutamine; irritable bowel syndrome; occludin; tight junctions^Adult; Claudin-1; Diarrhea; Female; Glutamine; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; Occludin; Permeability; claudin 1; glutamine; occludin; tight junction protein; claudin 1; glutamine; occludin; adult; Article; clinical article; colon biopsy; colon mucosa; culture medium; cytokine production; diarrhea; drug effect; ex vivo study; female; human; human tissue; immunoblotting; incubation time; intestine mucosa permeability; irritable colon; male; pilot study; priority journal; protein expression; diarrhea; genetics; intestine mucosa; irritable colon; metabolism; middle aged; permeability^^claudin 1, 329338-06-9; glutamine, 56-85-9, 6899-04-3; occludin, 176304-61-3; Claudin-1, ; Glutamine, ; Occludin, ^^^^^"Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Muller-Lissner S.A., Functional bowel disorders and functional abdominal pain, Gut, 45, pp. II43-II47, (1999); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, pp. 2108-2131, (2002); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Bertiaux-Vandaele N., Beutheu Youmba S., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 166, pp. 2165-2173, (2011); Coeffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Martinez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Sido B., Seel C., Hochlehnert A., Breitkreutz R., Droge W., Low intestinal glutamine level and low glutaminase activity in Crohn's disease: A rational for glutamine supplementation?, Dig Dis Sci, 51, pp. 2170-2179, (2006); De-Souza D.A., Greene L.J., Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine, Crit Care Med, 33, pp. 1125-1135, (2005); Boukhettala N., Claeyssens S., Bensifi M., Et al., Effects of essential amino acids or glutamine deprivation on intestinal permeability and protein synthesis in HCT-8 cells: Involvement of GCN2 and mTOR pathways, Amino Acids, 42, pp. 375-383, (2012); Le Bacquer O., Laboisse C., Darmaun D., Glutamine preserves protein synthesis and paracellular permeability in Caco-2 cells submitted to ""luminal fasting., Am J Physiol Gastrointest Liver Physiol, 285, pp. G128-G136, (2003); Li N., Lewis P., Samuelson D., Liboni K., Neu J., Glutamine regulates Caco-2 cell tight junction proteins, Am J Physiol Gastrointest Liver Physiol, 287, pp. G726-G733, (2004); Beutheu S., Ghouzali I., Galas L., Dechelotte P., Coeffier M., Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells, Clin Nutr, 32, pp. 863-869, (2013); Beutheu S., Ouelaa W., Guerin C., Et al., Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-induced intestinal mucositis in rats, Clin Nutr, 33, pp. 694-701, (2014); Choi K., Lee S.S., Oh S.J., Et al., The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test, Clin Nutr, 26, pp. 57-62, (2007); Daniele B., Perrone F., Gallo C., Et al., Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: A double blind, placebo controlled, randomised trial, Gut, 48, pp. 28-33, (2001); Coeffier M., Dechelotte P., Ducrotte P., Intestinal permeability in patients with diarrhea predominant irritable bowel syndrome: Is there a place for glutamine supplementation?, Gastroenterology, 148, 5, pp. 1079-1080, (2015); Coeffier M., Marion R., Ducrotte P., Dechelotte P., Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut, Clin Nutr, 22, pp. 407-413, (2003); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Et al., Role of Toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal Biochem, 72, pp. 248-254, (1976); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Costinean S., Croce C.M., Et al., MicroRNA 29 targets nuclear factor-kappaB-repressing factor and claudin 1 to increase intestinal permeability, Gastroenterology, 148, pp. 158-169, (2015); Smith M.W., James P.S., Amino acid transport by the helicoidal colon of the new-born pig, Biochim Biophys Acta, 419, pp. 391-394, (1976); Blachier F., Boutry C., Bos C., Tome D., Metabolism and functions of L-glutamate in the epithelial cells of the small and large intestines, Am J Clin Nutr, 90, pp. 814S-821S, (2009); Bertrand J., Marion-Letellier R., Et al., Glutamine enema regulates colonic ubiquitinated-proteins but not proteasome activities during TNBS-induced colitis leading to increased mitochondrial activity, Proteomics, (2015); Kretzmann N.A., Fillmann H., Mauriz J.L., Et al., Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis, Inflamm Bowel Dis, 14, pp. 1504-1513, (2008); Wischmeyer P., Pemberton J.H., Phillips S.F., Chronic pouchitis after ileal pouch-anal anastomosis: Responses to butyrate and glutamine suppositories in a pilot study, Mayo Clin Proc, 68, pp. 978-981, (1993); Coeffier M., Marion-Letellier R., Dechelotte P., Potential for amino acids supplementation during inflammatory bowel diseases, Inflamm Bowel Dis, 16, pp. 518-524, (2010); Darcy-Vrillon B., Morel M.T., Cherbuy C., Et al., Metabolic characteristics of pig colonocytes after adaptation to a high fiber diet, J Nutr, 123, pp. 234-243, (1993); Vermeulen M.A., De Jong J., Vaessen M.J., Van Leeuwen P.A., Houdijk A.P., Glutamate reduces experimental intestinal hyperpermeability and facilitates glutamine support of gut integrity, World J Gastroenterol, 17, pp. 1569-1573, (2011); Seth A., Basuroy S., Sheth P., Rao R.K., L-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer, Am J Physiol Gastrointest Liver Physiol, 287, pp. G510-G517, (2004); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barkhordari E., Rezaei N., Mahmoudi M., Et al., T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome, Inflammation, 33, pp. 281-286, (2010); O'Loughlin E.V., Pang G.P., Noltorp R., Koina C., Batey R., Clancy R., Interleukin 2 modulates ion secretion and cell proliferation in cultured human small intestinal enterocytes, Gut, 49, pp. 636-643, (2001); Epple H.J., Schneider T., Troeger H., Et al., Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients, Gut, 58, pp. 220-227, (2009)"^M. Coëffier; INSERM UMR1073, University of Rouen, Rouen Cedex 1, 22 boulevard Gambetta, 76183, France; email: moise.coeffier@univ-rouen.fr^^SAGE Publications Inc.^^^^^^01486071^^JPEND^25972430.0^English^J. Parenter. Enter. Nutr.^Article^Final^^Scopus^2-s2.0-84995387494
Bücker R.; Krug S.M.; Moos V.; Bojarski C.; Schweiger M.R.; Kerick M.; Fromm A.; Janßen S.; Fromm M.; Hering N.A.; Siegmund B.; Schneider T.; Barmeyer C.; Schulzke J.D.^Bücker, R. (10043068400); Krug, S.M. (25641099900); Moos, V. (6602224334); Bojarski, C. (8764110100); Schweiger, M.R. (9240082000); Kerick, M. (26632263800); Fromm, A. (13106110800); Janßen, S. (57201777066); Fromm, M. (55605772841); Hering, N.A. (35332178600); Siegmund, B. (7006254804); Schneider, T. (56835063000); Barmeyer, C. (6506742657); Schulzke, J.D. (35502556700)^10043068400; 25641099900; 6602224334; 8764110100; 9240082000; 26632263800; 13106110800; 57201777066; 55605772841; 35332178600; 7006254804; 56835063000; 6506742657; 35502556700^Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon^2018^Mucosal Immunology^11.0^2^^474^485^11.0^30^10.1038/mi.2017.66^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046102198&doi=10.1038%2fmi.2017.66&partnerID=40&md5=8c939468424e149a2bf017b6220145fc^Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Laboratory of Functional Epigenomics, Functional Epigenomics, CCG, University Hospital of Cologne, Cologne, Germany; Department of General, Visceral and Vascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany^Bücker R., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Krug S.M., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Moos V., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Bojarski C., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Schweiger M.R., Laboratory of Functional Epigenomics, Functional Epigenomics, CCG, University Hospital of Cologne, Cologne, Germany; Kerick M., Laboratory of Functional Epigenomics, Functional Epigenomics, CCG, University Hospital of Cologne, Cologne, Germany; Fromm A., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Janßen S., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Fromm M., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; Hering N.A., Department of General, Visceral and Vascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany; Siegmund B., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Schneider T., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Barmeyer C., Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Schulzke J.D., Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany^Campylobacter jejuni is the most prevalent cause of foodborne bacterial enteritis worldwide. Patients present with diarrhea and immune responses lead to complications like arthritis and irritable bowel syndrome. Although studies exist in animal and cell models, we aimed at a functional and structural characterization of intestinal dysfunction and the involved regulatory mechanisms in human colon. First, in patients' colonic biopsies, sodium malabsorption was identified as an important diarrheal mechanism resulting from hampered epithelial ion transport via impaired epithelial sodium channel (ENaC) β- and γ-subunit. In addition, barrier dysfunction from disrupted epithelial tight junction proteins (claudin-1, -3, -4, -5, and -8), epithelial apoptosis, and appearance of lesions was detected, which cause leak-flux diarrhea and can perpetuate immune responses. Importantly, these effects in human biopsies either represent direct action of Campylobacter jejuni (ENaC impairment) or are caused by proinflammatory signaling (barrier dysfunction). This was revealed by regulator analysis from RNA-sequencing (cytometric bead array-checked) and confirmed in cell models, which identified interferon-γ, TNFα, IL-13, and IL-1β. Finally, bioinformatics' predictions yielded additional information on protective influences like vitamin D, which was confirmed in cell models. Thus, these are candidates for intervention strategies against C. jejuni infection and post-infectious sequelae, which result from the permissive barrier defect along the leaky gut. © 2018 Nature Publishing Group. All rights reserved.^^Adult; Apoptosis; Campylobacter Infections; Campylobacter jejuni; Cells, Cultured; Colon; Computational Biology; Cytokines; Enteritis; Epithelial Sodium Channels; Female; Humans; Inflammation Mediators; Intestinal Mucosa; Ion Transport; Malabsorption Syndromes; Male; Middle Aged; Signal Transduction; Sodium; Tight Junction Proteins; Vitamin D; claudin 1; claudin 3; claudin 4; claudin 5; claudin 8; epithelial sodium channel; gamma interferon; interleukin 13; interleukin 1beta; tumor necrosis factor; autacoid; cytokine; epithelial sodium channel; sodium; tight junction protein; vitamin D; adult; apoptosis; Article; Campylobacter jejuni; campylobacteriosis; clinical article; colon biopsy; controlled study; cytokine release; diarrhea; female; human; human cell; immune response; in vitro study; ion transport; male; nonhuman; pathogenesis; priority journal; protein localization; regulatory mechanism; RNA sequence; signal transduction; sodium transport; biology; Campylobacter jejuni; campylobacteriosis; cell culture; colon; enteritis; genetics; immunology; intestine mucosa; malabsorption; metabolism; microbiology; middle aged; pathology; physiology^^claudin 1, 329338-06-9; gamma interferon, 82115-62-6; interleukin 13, 148157-34-0; sodium, 7440-23-5; Cytokines, ; Epithelial Sodium Channels, ; Inflammation Mediators, ; Sodium, ; Tight Junction Proteins, ; Vitamin D, ^^^Deutsche Forschungsgemeinschaft, DFG, (DFG Schu559/11)^In-Fah Maria Lee and Diana Bösel are gratefully acknowledged for their technical support. Funding for this study was supported by the Deutsche Forschungsgemeinschaft (DFG Schu559/11) to J.D.S; the Volkswagen Foundation (Lichtenberg program) to M.R.S. and the German Federal Ministry of Education and Research (BMBF) PAC-CAMPY consortium (IP8) to R.B. and J.D.S.^Blaser M.J., Et al., Experimental Campylobacter jejuni infection of adult mice, Infect. Immun, 39, pp. 908-916, (1983); Russell R.G., Et al., Experimental Campylobacter jejuni infection in Macaca nemestrina, Infect. Immun, 57, pp. 1438-1444, (1989); Fox J.G., Et al., Gastroenteritis in NF-kappaB-deficient mice is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains, Infect. Immun, 72, pp. 1116-1125, (2004); Hickey T.E., Et al., Intracellular survival of Campylobacter jejuni in human monocytic cells and induction of apoptotic death by cytholethal distending toxin, Infect. Immun, 73, pp. 5194-5197, (2005); Elmi A., Et al., Campylobacter jejuni outer membrane vesicles play an important role in bacterial interactions with human intestinal epithelial cells, Infect. Immun, 80, pp. 4089-4098, (2012); Black R.E., Et al., Experimental Campylobacter jejuni infection in humans, J. Infect. Dis, 157, pp. 472-479, (1988); Spiller R.C., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Van Spreeuwel J.P., Et al., Campylobacter colitis: Histological immunohistochemical and ultrastructural findings, Gut, 26, pp. 945-951, (1985); Boehm M., Et al., Rapid paracellular transmigration of Campylobacter jejuni across polarized epithelial cells without affecting TER: Role of proteolyticactive HtrA cleaving E-cadherin but not fibronectin, Gut Pathog, 4, (2012); Backert S., Et al., Transmigration route of Campylobacter jejuni across polarized intestinal epithelial cells: Paracellular, transcellular or both?, Cell Commun. Signal, 11, (2013); Chen M.L., Et al., Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni, Infect. Immun, 74, pp. 6581-6589, (2006); Lamb-Rosteski J.M., Et al., Epidermal growth factor inhibits Campylobacter jejuni-induced claudin-4 disruption, loss of epithelial barrier function, and Escherichia coli translocation, Infect. Immun, 76, pp. 3390-3398, (2008); Rees L.E., Et al., Campylobacter and IFNgamma interact to cause a rapid loss of epithelial barrier integrity, Inflamm. Bowel Dis, 14, pp. 303-309, (2008); Soler A.P., Et al., Activation of NF-kappaB is necessary for the restoration of the barrier function of an epithelium undergoing TNF-alpha-induced apoptosis, Eur. J. Cell Biol, 78, pp. 56-66, (1999); Negoro S., Et al., Campylobacter jejuni infection suppressed Cl- secretion induced by CFTR activation in T-84 cells, J. Infect. Chemother, 20, pp. 682-688, (2014); Zeissig S., Et al., Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease, Gut, 56, pp. 61-72, (2007); Bergann T., Et al., Glucocorticoid receptor is indispensable for physiological responses to aldosterone in epithelial Na+ channel induction via the mineralocorticoid receptor in a human colonic cell line, Eur. J. Cell Biol, 90, pp. 432-439, (2011); Kreusel K.M., Et al., Cl- secretion in epithelial monolayers of mucusforming human colon cells (HT-29/B6), Am. J. Physiol, 261, pp. C574-C582, (1991); Dames P., Et al., Interleukin-13 affects the epithelial sodium channel in the intestine by coordinated modulation of STAT6 and p38 MAPK activity, J. Physiol, 593, pp. 5269-5282, (2015); Lissner D., Et al., Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD, Inflamm. Bowel Dis, 21, pp. 1297-1305, (2015); Barmeyer C., Et al., ENaC dysregulation through activation of MEK1/2 contributes to impaired Na+ absorption in lymphocytic colitis, Inflamm. Bowel Dis, 22, pp. 539-547, (2016); Barmeyer C., Et al., IL-1beta and TNFalpha regulate sodium absorption in rat distal colon, Biochem. Biophys. Res. Commun, 317, pp. 500-507, (2004); Marchelletta R.R., Et al., Altered expression and localization of ion transporters contribute to diarrhea in mice with Salmonella-induced enteritis, Gastroenterology, 145, pp. 1358-1368, (2013); Bachmann O., Seidler U., News from the end of the gut - How the highly segmental pattern of colonic HCO- transport relates to absorptive function and mucosal integrity, Biol. Pharm. Bull, 34, pp. 794-802, (2011); Bucker R., Et al., Arcobacter butzleri induces barrier dysfunction in intestinal HT-29/B6 cells, J. Infect. Dis, 200, pp. 756-764, (2009); Nielsen H.L., Et al., Oral and fecal Campylobacter concisus strains perturb barrier function by apoptosis induction in HT-29/B6 intestinal epithelial cells, PLoS ONE, 6, (2011); Amasheh M., Et al., TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling, J. Cell. Sci, 123, pp. 4145-4155, (2010); Weber C.R., Et al., Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation, Lab. Invest, 88, pp. 1110-1120, (2008); Poritz L.S., Et al., Increase in the tight junction protein claudin-1 in intestinal inflammation, Dig. Dis. Sci, 56, pp. 2802-2809, (2011); Mankertz J., Et al., TNFalpha up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling, Cell. Tissue Res, 336, pp. 67-77, (2009); Bojarski C., Et al., Apoptosis and intestinal barrier function, Ann. N.Y. Acad. Sci, 915, pp. 270-274, (2000); Bojarski C., Et al., Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis, J. Physiol, 535, pp. 541-552, (2001); Troeger H., Et al., Effect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum, Gut, 56, pp. 328-335, (2007); Troeger H., Et al., Structural and functional changes of the duodenum in human norovirus infection, Gut, 58, pp. 1070-1077, (2009); Weber C.R., Et al., Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity, J. Biol. Chem, 285, pp. 12037-12046, (2010); Heller F., Et al., Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: Effect of pro-inflammatory interleukin-13 on epithelial cell function, Mucosal Immunol, 1, pp. S58-S61, (2008); Suzuki T., Et al., Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium, J. Biol. Chem, 286, pp. 31263-31271, (2011); Bucker R., Et al., A-Haemolysin of Escherichia coli in IBD: A potentiator of inflammatory activity in the colon, Gut, 63, pp. 1893-1901, (2014); Amasheh M., Et al., Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells, J. Nutr, 138, pp. 1067-1073, (2008); Sun X., Et al., Campylobacter jejuni induces colitis through activation of mammalian target of rapamycin signaling, Gastroenterology, 142, pp. 86-95, (2012); Daniel C., Et al., Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile, J. Pharmacol. Exp. Ther, 324, pp. 23-33, (2008); De Haes P., Et al., Molecular pathways involved in the anti-apoptotic effect of 1, 25-dihydroxyvitamin D3 in primary human keratinocytes, J. Cell Biochem, 93, pp. 951-967, (2004); Stio M., Et al., Vitamin D regulates the tight-junction protein expression in active ulcerative colitis, Scand. J. Gastroenterol, 20, pp. 1-7, (2016); Burgel N., Et al., Mechanisms of diarrhea in collagenous colitis, Gastroenterology, 123, pp. 433-443, (2002); Dobin A., Et al., STAR: Ultrafast universal RNA-seq aligner, Bioinformatics, 29, pp. 15-21, (2013); Schneider T., Et al., Increased immunoglobulin G production by short term cultured duodenal biopsy samples from HIV infected patients, Gut, 42, pp. 357-361, (1998)^J.D. Schulzke; Institute of Clinical Physiology, Nutritional Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany; email: joerg.schulzke@charite.de^^Nature Publishing Group^^^^^^19330219^^^28766554.0^English^Mucosal Immunol.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-85046102198
Pereira M.T.; Malik M.; Nostro J.A.; Mahler G.J.; Musselman L.P.^Pereira, Matthew T. (57205378239); Malik, Mridu (57205380237); Nostro, Jillian A. (57205379350); Mahler, Gretchen J. (24544410300); Musselman, Laura Palanker (54584141300)^57205378239; 57205380237; 57205379350; 24544410300; 54584141300^Effect of dietary additives on intestinal permeability in both Drosophila and a human cell co-culture^2018^DMM Disease Models and Mechanisms^11.0^12^dmm034520^^^^32^10.1242/dmm.034520^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059811172&doi=10.1242%2fdmm.034520&partnerID=40&md5=46405a89180361ded4a18245b90c2f78^Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States; Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, NY, United States^Pereira M.T., Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States; Malik M., Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, NY, United States; Nostro J.A., Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States; Mahler G.J., Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, NY, United States; Musselman L.P., Department of Biological Sciences, Binghamton University, Binghamton, 13902, NY, United States^Increased intestinal barrier permeability has been correlated with aging and disease, including type 2 diabetes, Crohn’s disease, celiac disease, multiple sclerosis and irritable bowel syndrome. The prevalence of these ailments has risen together with an increase in industrial food processing and food additive consumption. Additives, including sugar, metal oxide nanoparticles, surfactants and sodium chloride, have all been suggested to increase intestinal permeability. We used two complementary model systems to examine the effects of food additives on gut barrier function: a Drosophila in vivo model and an in vitro human cell co-culture model. Of the additives tested, intestinal permeability was increased most dramatically by high sugar. High sugar also increased feeding but reduced gut and overall animal size. We also examined how food additives affected the activity of a gut mucosal defense factor, intestinal alkaline phosphatase (IAP), which fluctuates with bacterial load and affects intestinal permeability. We found that high sugar reduced IAP activity in both models. Artificial manipulation of the microbiome influenced gut permeability in both models, revealing a complex relationship between the two. This study extends previous work in flies and humans showing that diet can play a role in the health of the gut barrier. Moreover, simple models can be used to study mechanisms underlying the effects of diet on gut permeability and function. © 2018. Published by The Company of Biologists Ltd.^Alkaline phosphatase; Drosophila; Gut barrier function; Intestinal permeability^Alkaline Phosphatase; Animals; Cell Line; Coculture Techniques; Diet; Dietary Sugars; Drosophila melanogaster; Drosophila Proteins; Food Additives; Humans; Intestines; Microbiota; Permeability; Phenotype; Polysorbates; Sodium Chloride, Dietary; Sugars; Ubiquitin-Protein Ligases; alkaline phosphatase; food additive; alkaline phosphatase; carbohydrate; Drosophila protein; food additive; polysorbate; Smurf protein, Drosophila; ubiquitin protein ligase; animal tissue; Article; bacterial load; Caco-2 cell line; coculture; controlled study; Drosophila; human; human cell; human cell culture; intestine flora; intestine mucosa permeability; nonhuman; priority journal; animal; cell line; coculture; cytology; diet; Drosophila melanogaster; drug effect; intestine; metabolism; microbiology; microflora; permeability; pharmacology; phenotype; salt intake; sugar intake^^alkaline phosphatase, 9001-78-9; polysorbate, 9005-63-4; ubiquitin protein ligase, 134549-57-8; Alkaline Phosphatase, ; Dietary Sugars, ; Drosophila Proteins, ; Food Additives, ; Polysorbates, ; Smurf protein, Drosophila, ; Sodium Chloride, Dietary, ; Sugars, ; Ubiquitin-Protein Ligases, ^^^National Institutes of Health, NIH; National Institute of Environmental Health Sciences, NIEHS, (R15ES022828); State University of New York, SUNY^We thank Thécla Lesuffleur for the HT29-MTX intestinal epithelial cell line, the Vienna Drosophila Resource Center for the flies, and Paul Pereira for technical support. Funding for this work was provided by the National Institutes of Health (1R15 ES022828) and the Research Foundation of the State University of New York through a Transdisciplinary Area of Excellence Award.^Akiba Y., Mizumori M., Guth P.H., Engel E., Kaunitz J.D., Duodenal brush border intestinal alkaline phosphatase activity affects bicarbonate secretion in rats, Am. J. Physiol. Gastrointest. Liver Physiol., 293, pp. G1223-G1233, (2007); Al-Saraf A., Holm R., Nielsen C.U., Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo, Int. J. Pharm., 498, pp. 66-69, (2016); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, pp. 1512-1520, (2006); Bamba T., Vaja S., Murphy G.M., Dowling R.H., Effect of fasting and feeding on polyamines and related enzymes along the villus: Crypt axis, Digestion, 46, pp. 424-429, (1990); Barone S., Fussell S.L., Singh A.K., Lucas F., Xu J., Kim C., Wu X., Yu Y., Amlal H., Seidler U., Et al., Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension, J. Biol. Chem., 284, pp. 5056-5066, (2009); Bettini S., Boutet-Robinet E., Cartier C., Comera C., Gaultier E., Dupuy J., Naud N., Tache S., Grysan P., Reguer S., Et al., Food-grade TiO2 impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon, Sci. Rep., 7, (2017); Beumer C., Wulferink M., Raaben W., Fiechter D., Brands R., Seinen W., Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets, J. Pharmacol. Exp. Ther., 307, (2003); Biteau B., Hochmuth C.E., Jasper H., JNK activity in somatic stem cells causes loss of tissue homeostasis in the aging drosophila gut, Cell Stem Cell, 3, pp. 442-455, (2008); Brummel T., Ching A., Seroude L., Simon A.F., Benzer S., Drosophila lifespan enhancement by exogenous bacteria, Proc. Natl. Acad. Sci. USA, 101, pp. 12974-12979, (2004); Brun E., Barreau F., Veronesi G., Fayard B., Sorieul S., Chaneac C., Carapito C., Rabilloud T., Mabondzo A., Herlin-Boime N., Et al., Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia, Part. Fibre Toxicol., 11, (2014); Buchon N., Osman D., All for one and one for all: Regionalization of the Drosophila intestine, Insect Biochem. Mol. Biol., 67, pp. 2-8, (2015); Cheng J., Palva A.M., De Vos W.M., Satokari R., Contribution of the intestinal microbiota to human health: From birth to 100 years of age, Curr. Top. Microbiol. Immunol., 358, pp. 323-346, (2013); Chiba H., Osanai M., Murata M., Kojima T., Sawada N., Transmembrane proteins of tight junctions, Biochim. Biophys. Acta, 1778, pp. 588-600, (2007); Choi N.-H., Kim J.-G., Yang D.-J., Kim Y.-S., Yoo M.-A., Age-related changes in Drosophila midgut are associated with PVF2, a PDGF/VEGF-like growth factor, Aging Cell, 7, pp. 318-334, (2008); Chung H.Y., Cesari M., Anton S., Marzetti E., Giovannini S., Seo A.Y., Carter C., Yu B.P., Leeuwenburgh C., Molecular inflammation: Underpinnings of aging and age-related diseases, Ageing Res. Rev., 8, pp. 18-30, (2009); Clark R.I., Salazar A., Yamada R., Fitz-Gibbon S., Morselli M., Alcaraz J., Rana A., Rera M., Pellegrini M., Ja W.W., Et al., Distinct shifts in microbiota composition during drosophila aging impair intestinal function and drive mortality, Cell Rep, 12, pp. 1656-1667, (2015); Dambroise E., Monnier L., Ruisheng L., Aguilaniu H., Joly J.-S., Tricoire H., Rera M., Two phases of aging separated by the Smurf transition as a public path to death, Nat. Publ. Gr., 6, (2016); Das S., Chaudhury A., Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery, AAPS PharmSciTech, 12, pp. 62-76, (2011); De Lisle R.C., Mueller R., Boyd M., Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse, J. Pediatr. Gastroenterol. Nutr., 53, pp. 371-379, (2011); DeSesso J.M., Jacobson C.F., Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats, Food Chem. Toxicol., 39, pp. 209-228, (2001); Deshpande G., Mapanga R.F., Essop M.F., Frequent sugar-sweetened beverage consumption and the onset of cardiometabolic diseases: Cause for concern?, J. Endocr. Soc., 1, pp. 1372-1385, (2017); D'Souza V.M., Shertzer H.G., Menon A.G., Pauletti G.M., High glucose concentration in isotonic media alters Caco-2 cell permeability, AAPS PharmSci, 5, pp. 17-25, (2003); Dus M., Ai M., Suh G.S.B., Taste-independent nutrient selection is mediated by a brain-specific Na+ /solute co-transporter in Drosophila, Nat. Neurosci., 16, pp. 526-528, (2013); Economopoulos K.P., Ward N.L., Phillips C.D., Teshager A., Patel P., Mohamed M.M., Hakimian S., Cox S.B., Ahmed R., Moaven O., Et al., Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase, Diabetes Obes. Metab., 18, pp. 519-527, (2016); Eliakim R., DeSchryver-Kecskemeti K., Nogee L., Stenson W.F., Alpers D.H., Isolation and characterization of a small intestinal surfactant-like particle containing alkaline phosphatase and other digestive enzymes, J. Biol. Chem., 264, pp. 20614-20619, (1989); Engle M.J., Mahmood A., Alpers D.H., Regulation of surfactant-like particle secretion by Caco-2 cells, Biochim. Biophys. Acta Biomembr., 1511, pp. 369-380, (2001); Farhadi A., Banan A., Fields J., Keshavarzian A., Intestinal barrier: An interface between health and disease, J. Gastroenterol. Hepatol., 18, pp. 479-497, (2003); Fasano A., Shea-Donohue T., Mechanisms of disease: The role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases, Nat. Clin. Pract. Gastroenterol. Hepatol., 2, pp. 416-422, (2005); Faust J.J., Doudrick K., Yang Y., Westerhoff P., Capco D.G., Food grade titanium dioxide disrupts intestinal brush border microvilli in vitro independent of sedimentation, Cell Biol. Toxicol., 30, pp. 169-188, (2014); Fihn B.M., Sjoqvist A., Jodal M., Permeability of the rat small intestinal epithelium along the villus-crypt axis: Effects of glucose transport, Gastroenterology, 119, pp. 1029-1036, (2000); Francavilla R., Miniello V., Magista A.M., De Canio A., Bucci N., Gagliardi F., Lionetti E., Castellaneta S., Polimeno L., Peccarisi L., Et al., A randomized controlled trial of lactobacillus GG in children with functional abdominal pain, Pediatrics, 126, pp. e1445-e1452, (2010); Glahn R.P., Lee O.A., Yeung A., Goldman M.I., Miller D.D., Caco-2 cell ferritin formation predicts nonradiolabeled food iron availability in an in vitro digestion/Caco-2 cell culture model, J. Nutr., 128, pp. 1555-1561, (1998); Goldberg R.F., Austen W.G., Zhang X., Munene G., Mostafa G., Biswas S., McCormack M., Eberlin K.R., Nguyen J.T., Tatlidede H.S., Et al., Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition, Proc. Natl. Acad. Sci. USA, 105, pp. 3551-3556, (2008); Gouyon F., Caillaud L., Carriere V., Klein C., Dalet V., Citadelle D., Kellett G.L., Thorens B., Leturque A., Brot-Laroche E., Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: A study in GLUT2-null mice, J. Physiol., 552, pp. 823-832, (2003); Guan G., Wang H., Chen S., Liu G., Xiong X., Tan B., Duraipandiyan V., Al-Dhabi N.A., Fang J., Dietary chitosan supplementation increases microbial diversity and attenuates the severity of citrobacter rodentium infection in mice, Mediators Inflamm, 2016, (2016); Guo Z., Martucci N.J., Moreno-Olivas F., Tako E., Mahler G.J., Titanium dioxide nanoparticle ingestion alters nutrient absorption in an in vitro model of the small intestine, NanoImpact, 5, pp. 70-82, (2017); Guo Z., Martucci N.J., Liu Y., Yoo E., Tako E., Mahler G.J., Silicon dioxide nanoparticle exposure affects small intestine function in an in vitro model, Nanotoxicology, 12, pp. 485-508, (2018); Guthmann F., Maehl P., Preiss J., Kolleck I., Rustow B., Ectoprotein kinase-mediated phosphorylation of FAT/CD36 regulates palmitate uptake by human platelets, Cell. Mol. Life Sci., 59, pp. 1999-2003, (2002); Hamid K.A., Katsumi H., Sakane T., Yamamoto A., The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats, Int. J. Pharm., 379, pp. 100-108, (2009); Han G., Lee H.J., Jeong S.E., Jeon C.O., Hyun S., Comparative analysis of Drosophila Melanogaster gut microbiota with respect to host strain, sex, and age, Microb. Ecol., 74, pp. 207-216, (2017); Hansen G.H., Niels-Christiansen L.-L., Immerdal L., Nystrom B.T., Danielsen E.M., Intestinal alkaline phosphatase: Selective endocytosis from the enterocyte brush border during fat absorption, AJP Gastrointest. Liver Physiol., 293, pp. G1325-G1332, (2007); Harris C.E., Griffiths R.D., Freestone N., Billington D., Atherton S.T., Macmillan R.R., Intestinal permeability in the critically ill, Intensive Care Med, 18, pp. 38-41, (1992); Hidalgo I.J., Raub T.J., Borchardt R.T., Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability, Gastroenterology, 96, pp. 736-749, (1989); Hopfer U., Nelson K., Perrotto J., Isselbacher K.J., Glucose transport in isolated brush border membrane from rat small intestine, J. Biol. Chem., 248, pp. 25-32, (1973); Huygelen V., De Vos M., Willemen S., Fransen E., Casteleyn C., Van Cruchten S., Van Ginneken C., Age-related differences in mucosal barrier function and morphology of the small intestine in low and normal birth weight piglets, J. Anim. Sci., 92, pp. 3398-3406, (2014); Izumi Y., Furuse M., Molecular organization and function of invertebrate occluding junctions, Semin. Cell Dev. Biol., 36, pp. 186-193, (2014); Jang I., Jung K., Cho J., Influence of age on duodenal brush border membrane and specific activities of brush border membrane enzymes in wistar rats, Exp. Anim, 49, pp. 281-287, (2000); Jonusaite S., Donini A., Kelly S.P., Occluding junctions of invertebrate epithelia, J. Comp. Physiol. B, 186, pp. 17-43, (2016); Kabeerdoss J., Shobana Devi R., Regina Mary R., Ramakrishna B.S., Faecal microbiota composition in vegetarians: Comparison with omnivores in a cohort of young women in southern India, Br. J. Nutr., 108, pp. 953-957, (2012); Kaliannan K., Hamarneh S.R., Economopoulos K.P., Nasrin Alam S., Moaven O., Patel P., Malo N.S., Ray M., Abtahi S.M., Muhammad N., Et al., Intestinal alkaline phosphatase prevents metabolic syndrome in mice, Proc. Natl. Acad. Sci. USA, 110, pp. 7003-7008, (2013); Kang M.J., Kim H.S., Jeon H.S., Park J.H., Lee B.S., Ahn B.K., Moon K.Y., Choi Y.W., In situ intestinal permeability and in vivo absorption characteristics of olmesartan medoxomil in self-microemulsifying drug delivery system, Drug Dev. Ind. Pharm., 38, pp. 587-596, (2012); Katz D., Hollander D., Said H.M., Dadufalza V., Aging-associated increase in intestinal permeability to polyethylene glycol 900, Dig. Dis. Sci., 32, pp. 285-288, (1987); Katzenberger R.J., Chtarbanova S., Rimkus S.A., Fischer J.A., Kaur G., Seppala J.M., Swanson L.C., Zajac J.E., Ganetzky B., Wassarman D.A., Death following traumatic brain injury in Drosophila is associated with intestinal barrier dysfunction, Elife, 4, (2015); Kayanos T., Burants C.F., Fukumotoq H., Gouldll G.W., Fanll Y.-S., Eddy R.L., Byersii M.G., Shows T.B., Seinos S., Bell G.I., Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like, J. Biol. Chem., 265, pp. 13276-13282, (1990); Kellett G.L., Brot-Laroche E., Apical GLUT2: A major pathway of intestinal sugar absorption, Diabetes, 54, pp. 3056-3062, (2005); Kirkwood T.B.L., Intrinsic ageing of gut epithelial stem cells, Mech. Ageing Dev., 125, pp. 911-915, (2004); Kuraishi T., Binggeli O., Opota O., Buchon N., Lemaitre B., Genetic evidence for a protective role of the peritrophic matrix against intestinal bacterial infection in Drosophila melanogaster, Proc. Natl. Acad. Sci. USA, 108, pp. 15966-15971, (2011); Landis G.N., Abdueva D., Skvortsov D., Yang J., Rabin B.E., Carrick J., Tavare S., Tower J., Similar gene expression patterns characterize aging and oxidative stress in Drosophila melanogaster, Proc. Natl. Acad. Sci. USA, 101, pp. 7663-7668, (2004); Lane E.R., Zisman T.L., Suskind D.L., The microbiota in inflammatory bowel disease: Current and therapeutic insights, J. Inflamm. Res., 10, pp. 63-73, (2017); Lesuffleur T., Barbat A., Dussaulx E., Zweibaum A., Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells, Cancer Res, 50, pp. 6334-6343, (1990); Lesuffleur T., Roche F., Hill A.S., Lacasa M., Fox M., Swallow D.M., Zweibaum A., Real F.X., Characterization of a mucin cDNA clone isolated from HT-29 mucus-secreting cells. The 3’ end of MUC5AC?, J. Biol. Chem., 270, pp. 13665-13673, (1995); Liu W., Hu D., Huo H., Zhang W., Adiliaghdam F., Morrison S., Ramirez J.M., Gul S.S., Hamarneh S.R., Hodin R.A., Intestinal alkaline phosphatase regulates tight junction protein levels, J. Am. Coll. Surg., 222, pp. 1009-1017, (2016); Lo Y., Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines, J. Control. Release, 90, pp. 37-48, (2003); Loo Y., Grigsby C.L., Yamanaka Y.J., Chellappan M.K., Jiang X., Mao H.-Q., Leong K.W., Comparative study of nanoparticle-mediated transfection in different GI epithelium co-culture models, J. Control. Release, 160, pp. 48-56, (2012); Lopez-Otin C., Blasco M.A., Partridge L., Serrano M., Kroemer G., The hallmarks of aging Europe PMC funders group, Cell June, 6, pp. 1194-121705, (2013); Lushchak V.I., Dissection of the hormetic curve: Analysis of components and mechanisms, Dose-Response, 12, pp. 466-479, (2014); Lusis A.J., Attie A.D., Reue K., Metabolic syndrome: From epidemiology to systems biology, Nat. Rev. Genet., 9, pp. 819-830, (2008); Lv L.-Z., Tong C.-Q., Yu J., Han M., Gao J.-Q., Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles, Int. J. Nanomedicine, 8, pp. 2709-2717, (2013); Ma T.Y., Anderson J.M., Tight junctions and the intestinal barrier, Physiology of The Gastrointestinal Tract, pp. 1559-1594, (2006); MacMillan H.A., Yerushalmi G.Y., Jonusaite S., Kelly S.P., Donini A., Thermal acclimation mitigates cold-induced paracellular leak from the Drosophila gut, Sci. Rep., 7, (2017); Madara J.L., Carlson S., Supraphysiologic L-tryptophan elicits cytoskeletal and macromolecular permeability alterations in hamster small intestinal epithelium in vitro, J. Clin. Invest., 87, pp. 454-462, (1991); Madara J.L., Pappenheimer J.R., Structural basis for physiological regulation of paracellular pathways in intestinal epithelia, J. Membr. Biol., 100, pp. 149-164, (1987); Madara J.L., Moore R., Carlson S., Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction, Am. J. Physiol., 253, pp. C854-C861, (1987); Madara J.L., Carlson S., Anderson J.M., ZO-1 maintains its spatial distribution but dissociates from junctional fibrils during tight junction regulation, Am. J. Physiol., 264, pp. C1096-C1101, (1993); Mahler G.J., Shuler M.L., Glahn R.P., Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability, J. Nutr. Biochem., 20, pp. 494-502, (2009); Mahler G.J., Esch M.B., Tako E., Southard T.L., Archer S.D., Glahn R.P., Shuler M.L., Oral exposure to polystyrene nanoparticles affects iron absorption, Nat. Nanotechnol., 7, pp. 264-271, (2012); Manzel A., Muller D.N., Hafler D.A., Erdman S.E., Linker R.A., Kleinewietfeld M., Role of “Western Diet” in inflammatory autoimmune diseases, Curr. Allergy Asthma Rep., 14, (2014); Matijasic B.B., Obermajer T., Lipoglavsek L., Grabnar I., Avgustin G., Rogelj I., Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia, Eur. J. Nutr., 53, pp. 1051-1064, (2014); Micchelli C.A., Perrimon N., Evidence that stem cells reside in the adult Drosophila midgut epithelium, Nature, 439, pp. 475-479, (2006); Mine Y., Zhang J.W., Surfactants enhance the tight-junction permeability of food allergens in human intestinal epithelial Caco-2 cells, Int. Arch. Allergy Immunol., 130, pp. 135-142, (2003); Mizumori M., Ham M., Guth P.H., Engel E., Kaunitz J.D., Akiba Y., Intestinal alkaline phosphatase regulates protective surface microclimate pH in rat duodenum, J. Physiol., 587, pp. 3651-3663, (2009); Molnar K., Vannay A., Sziksz E., Banki N.F., Gyo rffy H., Arato A., Dezso fi A., Veres G., Decreased mucosal expression of intestinal alkaline phosphatase in children with coeliac disease, Virchows Arch, 460, pp. 157-161, (2012); Montoya C.A., Leterme P., Lalles J.-P., A protein-free diet alters small intestinal architecture and digestive enzyme activities in rats, Reprod. Nutr. Dev., 46, pp. 49-56, (2006); Morley J.E., Decreased food intake with aging, J. Gerontol. Ser. A Biol. Sci. Med. Sci., 56, pp. 81-88, (2001); Morris S.N.S., Coogan C., Chamseddin K., Fernandez-Kim S.O., Kolli S., Keller J.N., Bauer J.H., Development of diet-induced insulin resistance in adult Drosophila melanogaster, Biochim. Biophys. Acta. Mol. Basis Dis., 1822, pp. 1230-1237, (2012); Moskalev A., Shaposhnikov M., Proshkina E., Belyi A., Fedintsev A., Zhikrivetskaya S., Guvatova Z., Sadritdinova A., Snezhkina A., Krasnov G., Et al., The influence of pro-longevity gene Gclc overexpression on the age-dependent changes in Drosophila transcriptome and biological functions, BMC Genomics, 17, (2016); Musselman L.P., Fink J.L., Narzinski K., Ramachandran P.V., Hathiramani S.S., Cagan R.L., Baranski T.J., A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila, Dis. Model. Mech., 4, pp. 842-849, (2011); Na J., Musselman L.P., Pendse J., Baranski T.J., Bodmer R., Ocorr K., Cagan R., A drosophila model of high sugar diet-induced cardiomyopathy, PLoS Genet, 9, (2013); Narisawa S., Huang L., Iwasaki A., Hasegawa H., Alpers D.H., Millan J.L., Accelerated fat absorption in intestinal alkaline phosphatase knockout mice, Mol. Cell. Biol., 23, pp. 7525-7530, (2003); Narisawa S., Hoylaerts M.F., Doctor K.S., Fukuda M.N., Alpers D.H., Millan J.L., A novel phosphatase upregulated in Akp3 knockout mice, Am. J. Physiol. Gastrointest. Liver Physiol., 293, pp. G1068-G1077, (2007); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am. J. Physiol. Gastrointest. Liver Physiol., 279, pp. G851-G857, (2000); O'Flaherty S., Klaenhammer T.R., Influence of exposure time on gene expression by human intestinal epithelial cells exposed to Lactobacillus acidophilus, Appl. Environ. Microbiol., 78, pp. 5028-5032, (2012); Pappenheimer J.R., Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters, J. Membr. Biol., 100, pp. 137-148, (1987); Pappenheimer J.R., Reiss K.Z., Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat, J. Membr. Biol., 100, pp. 123-136, (1987); Pappenheimer J.R., Volpp K., Transmucosal impedance of small intestine: Correlation with transport of sugars and amino acids, Am. J. Physiol., 263, pp. C480-C493, (1992); Park J.-S., Kim Y.-S., Yoo M.-A., The role of p38b MAPK in age-related modulation of intestinal stem cell proliferation and differentiation in Drosophila, Aging (Albany. NY), 1, pp. 637-651, (2009); Pletcher S.D., Macdonald S.J., Marguerie R., Certa U., Stearns S.C., Goldstein D.B., Partridge L., Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster, Curr. Biol., 12, pp. 712-723, (2002); Poelstra K., Bakker W.W., Klok P.A., Kamps J.A.A.M., Hardonk M.J., Meijer D.K.F., Dephosphorylation of endotoxin by alkaline phosphatase in vivo, Am. J. Pathol., 151, pp. 1163-1169, (1997); Pueyo J.I., Magny E.G., Sampson C.J., Amin U., Evans I.R., Bishop S.A., Couso J.P., Hemotin, a regulator of phagocytosis encoded by a small ORF and conserved across metazoans, PLoS Biol, 14, (2016); Rapin J.R., Wiernsperger N., Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine, Clinics, 65, pp. 635-643, (2010); Regan J.C., Khericha M., Dobson A.J., Bolukbasi E., Rattanavirotkul N., Partridge L., Sex difference in pathology of the ageing gut mediates the greater response of female lifespan to dietary restriction, Elife, 5, (2016); Ren C., Webster P., Finkel S.E., Tower J., Increased internal and external bacterial load during drosophila aging without life-span trade-off, Cell Metab, 6, pp. 144-152, (2007); Rera M., Bahadorani S., Cho J., Koehler C.L., Ulgherait M., Hur J.H., Ansari W.S., Lo T., Jones D.L., Walker D.W., Modulation of longevity and tissue homeostasis by the drosophila PGC-1 homolog, Cell Metab, 14, pp. 623-634, (2011); Rera M., Clark R.I., Walker D.W., Intestinal barrier dysfunction links metabolic and inflammatory markers of aging to death in Drosophila, Proc. Natl. Acad. Sci. USA, 109, pp. 21528-21533, (2012); Richter J.W., Shull G.M., Fountain J.H., Guo Z., Musselman L.P., Fiumera A.C., Mahler G.J., Titanium dioxide nanoparticle exposure alters metabolic homeostasis in a cell culture model of the intestinal epithelium and drosophila melanogaster, Nanotoxicology, 12, pp. 390-406, (2018); Roder P.V., Geillinger K.E., Zietek T.S., Thorens B., Koepsell H., Daniel H., The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing, PLoS ONE, 9, (2014); Liu R., Drug delivery applications, Water-Insoluble Drug Formulation, pp. 293-295, (2008); Round J.L., Mazmanian S.K., The gut microbiota shapes intestinal immune responses during health and disease, Nat. Rev. Immunol., 9, pp. 313-323, (2009); Sadowski D.C., Meddings J.B., Luminal nutrients alter tight-junction permeability in the rat jejunum: An in vivo perfusion model, Can. J. Physiol. Pharmacol., 71, pp. 835-839, (1993); Sandek A., Rauchhaus M., Anker S.D., Von Haehling S., The emerging role of the gut in chronic heart failure, Curr. Opin. Clin. Nutr. Metab. Care, 11, pp. 632-639, (2008); Saremi S., Dinarvand R., Kebriaeezadeh A., Ostad S.N., Atyabi F., Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: Preparation, in vitro and in vivo studies, Biomed Res. Int., 2013, (2013); Selmi C., The worldwide gradient of autoimmune conditions, Autoimmun. Rev., 9, pp. A247-A250, (2010); Sha X., Yan G., Wu Y., Li J., Fang X., Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells, Eur. J. Pharm. Sci., 24, pp. 477-486, (2005); Shanbhag S., Tripathi S., Electrogenic H+ transport and pH gradients generated by a V-H+-ATPase in the isolated perfused larval drosophila midgut, J. Membr. Biol., 206, pp. 61-72, (2005); Singh G.M., Micha R., Khatibzadeh S., Lim S., Ezzati M., Mozaffarian D., Estimated global, regional, and national disease burdens related to sugar-sweetened beverage consumption in 2010CLINICAL PERSPECTIVE, Circulation, 132, pp. 639-666, (2015); Sogabe N., Mizoi L., Asahi K., Ezawa I., Goseki-Sone M., Enhancement by lactose of intestinal alkaline phosphatase expression in rats, Bone, 35, pp. 249-255, (2004); Sogabe N., Maruyama R., Hosori T., Goseki-Sone M., Enhancement effects of vitamin K1 (phylloquinone) or vitamin K2 (menaquinone-4) on intestinal alkaline phosphatase activity in rats, J. Nutr. Sci. Vitaminol., 53, pp. 219-224, (2007); Stergiopoulos K., Cabrero P., Davies S.-A., Dow J.A.T., Salty dog, an SLC5 symporter, modulates Drosophila response to salt stress, Physiol. Genomics, 37, pp. 1-11, (2009); Strand M., Micchelli C.A., Regional control of Drosophila gut stem cell proliferation: EGF establishes GSSC proliferative set point controls emergence from quiescence, PLoS ONE, 8, (2013); Thaiss C.A., Levy M., Grosheva I., Zheng D., Soffer E., Blacher E., Braverman S., Tengeler A.C., Barak O., Elazar M., Et al., Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection, Science, 359, pp. 1376-1383, (2018); Tricoire H., Rera M., A new, discontinuous 2 phases of aging model: Lessons from Drosophila melanogaster, PLoS ONE, 10, (2015); Turner J.R., Cohen D.E., Mrsny R.J., Madara J.L., Noninvasive in vivo analysis of human small intestinal paracellular absorption: Regulation by Na+-glucose cotransport, Dig. Dis. Sci., 45, pp. 2122-2126, (2000); Uhing M.R., Kimura R.E., Active transport of 3-O-methyl-glucose by the small intestine in chronically catheterized rats, J. Clin. Invest., 95, pp. 2799-2805, (1995); CFR - Code of Federal Regulations Title 21, (2017); Ventura E.E., Davis J.N., Goran M.I., Sugar content of popular sweetened beverages based on objective laboratory analysis: Focus on fructose content, Obesity, 19, pp. 868-874, (2011); Wang W., Chen S.W., Zhu J., Zuo S., Ma Y.Y., Chen Z.Y., Zhang J.L., Chen G.W., Liu Y.C., Wang P.Y., Intestinal alkaline phosphatase inhibits the translocation of bacteria of gut-origin in mice with peritonitis: Mechanism of action, PLoS ONE, 10, (2015); Watts T., Berti I., Sapone A., Gerarduzzi T., Not T., Zielke R., Fasano A., Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats, Proc. Natl. Acad. Sci. USA, 102, pp. 2916-2921, (2005); Webster J.L., Dunford E.K., Neal B.C., A systematic survey of the sodium contents of processed foods, Am. J. Clin. Nutr., 91, pp. 413-420, (2010); Weir A., Westerhoff P., Fabricius L., Hristovski K., Von Goetz N., Titanium dioxide nanoparticles in food and personal care products, Environ. Sci. Technol., 46, pp. 2242-2250, (2012); Welsh J.D., Stevenson D.E., Poley J.R., Walker A.W., Intestinal alkaline phosphatase activity in relation to age in humans, J. Pediatr. Gastroenterol. Nutr., 4, pp. 954-959, (1985); Welsh J.A., Sharma A.J., Grellinger L., Vos M.B., Consumption of added sugars is decreasing in the United States, Am. J. Clin. Nutr., 94, pp. 726-734, (2011); Wong R., Piper M.D.W., Wertheim B., Partridge L., Quantification of food intake in Drosophila, PLoS ONE, 4, (2009); Wray L., The diabetic patient and dental treatment: An update, Br. Dent. J., 211, pp. 209-215, (2011); Yu Q., Wang Z., Li P., Yang Q., The effect of various absorption enhancers on tight junction in the human intestinal Caco-2 cell line, Drug Dev. Ind. Pharm., 39, pp. 587-592, (2013); Zackular J.P., Moore J.L., Jordan A.T., Juttukonda L.J., Noto M.J., Nicholson M.R., Crews J.D., Semler M.W., Zhang Y., Ware L.B., Et al., Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection, Nat. Med., 22, pp. 1330-1334, (2016); Zhang L., Li N., Des Robert C., Fang M., Liboni K., McMahon R., Caicedo R.A., Neu J., Lactobacillus rhamnosus GG decreases lipopolysaccharide-induced systemic inflammation in a gastrostomy-fed infant rat model, J. Pediatr. Gastroenterol. Nutr., 42, pp. 545-552, (2006); Zhang J., Zhu X., Jin Y., Shan W., Huang Y., Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles, Mol. Pharm., 11, pp. 1520-1532, (2014); Zhang X., Jin Q., Jin L.H., High sugar diet disrupts gut homeostasis though JNK and STAT pathways in Drosophila, Biochem. Biophys. Res. Commun., 487, pp. 910-916, (2017); Zhao H., Zhao C., Dong Y., Zhang M., Wang Y., Li F., Li X., McClain C., Yang S., Feng W., Inhibition of miR122a by Lactobacillus rhamnosus GG culture supernatant increases intestinal occludin expression and protects mice from alcoholic liver disease, Toxicol. Lett., 234, pp. 194-200, (2015)^G.J. Mahler; Department of Biomedical Engineering, Binghamton University, Binghamton, 13902, United States; email: gmahler@binghamton.edu^^Company of Biologists Ltd^^^^^^17548403^^^30504122.0^English^DNM Dis. Models Mech.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-85059811172
Jin Y.; Ren X.; Li G.; Li Y.; Zhang L.; Wang H.; Qian W.; Hou X.^Jin, Yu (56727028600); Ren, Xiaoyang (57200383199); Li, Gangping (56726862100); Li, Ying (57872790600); Zhang, Lei (56562609800); Wang, Huan (53986862000); Qian, Wei (35238189900); Hou, Xiaohua (7402838898)^56727028600; 57200383199; 56726862100; 57872790600; 56562609800; 53986862000; 35238189900; 7402838898^Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota^2018^Journal of Gastroenterology and Hepatology (Australia)^33.0^2^^443^452^9.0^34^10.1111/jgh.13841^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041079292&doi=10.1111%2fjgh.13841&partnerID=40&md5=ba9d4895b7e1dffb5e4f097d1de3ec51^Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China^Jin Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Ren X., The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; Li G., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Li Y., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Zhang L., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Wang H., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Qian W., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hou X., Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China^Background and Aims: Rifaximin is a minimally absorbed antibiotic, which has shown efficacy in irritable bowel syndrome (IBS) patients. However, the mechanism on how it effects in IBS is still incompletely defined. In this study, Trichinella spiralis-infected post-infectious (PI) IBS mouse model was used, to assess the action of rifaximin on visceral hypersensitivity, barrier function, gut inflammation, and microbiota. Methods: Post-infectious IBS model was established by T. spiralis infection in mice. Rifaximin were administered to PI-IBS mice for seven consecutive days. The abdominal withdrawal reflex and threshold of colorectal distention were employed to evaluate visceral sensitivity. Smooth muscle contractile response was recorded in the organ bath. Intestinal permeability was measured by Ussing chamber. Expression of tight junction protein and cytokines were measured by Western blotting. Ilumina miseq platform was used to analyze bacterial 16S ribosomal RNA. Results: Post-infectious IBS mice treated with rifaximin exhibited decreased abdominal withdrawal reflex score, increased threshold, reduced contractile response, and intestinal permeability. Rifaximin also suppressed the expression of interleukin-12 and interleukin-17 and promoted the expression of the major tight junction protein occludin. Furthermore, rifaximin did not change the composition and diversity, and the study reavealed that rifaximin had a tiny effect on the relative abundance of Lactobacillus and Bifidobacterium in this PI-IBS model. Conclusions: Rifaximin alleviated visceral hypersensitivity, recovered intestinal barrier function, and inhibited low-grade inflammation in colon and ileum of PI-IBS mouse model. Moreover, rifaximin exerts anti-inflammatory effects with only a minimal effect on the overall composition and diversity of the gut microbiota in this model. © 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd^anti-inflammatory effect; barrier function; gut microbiota; irritable bowel syndrome; rifaximin^Animals; Anti-Infective Agents; Bifidobacterium; Disease Models, Animal; Gastrointestinal Microbiome; Interleukin-12; Interleukin-17; Irritable Bowel Syndrome; Lactobacillus; Male; Mice; Occludin; Rifamycins; Trichinella spiralis; Trichinellosis; claudin 1; gamma interferon; interleukin 12; interleukin 17; interleukin 22; occludin; rifaximin; tight junction protein; antiinfective agent; interleukin 12; interleukin 17; occludin; rifamycin; rifaximin; abdominal wall; animal experiment; animal model; Article; colonic muscle; controlled study; down regulation; intestine flora; intestine infection; intestine mucosa; irritable colon; male; mouse; nonhuman; pain threshold; priority journal; protein expression; surface property; transepithelial resistance; Trichinella spiralis; trichinosis; upregulation; animal; Bifidobacterium; complication; disease model; irritable colon; Lactobacillus; metabolism; microbiology; Trichinella spiralis; trichinosis^^claudin 1, 329338-06-9; gamma interferon, 82115-62-6; interleukin 12, 138415-13-1; interleukin 22, 457106-70-6, 478219-35-1, 554460-75-2; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2; rifamycin, 6998-60-3, 14897-39-3, 15105-92-7; Anti-Infective Agents, ; Interleukin-12, ; Interleukin-17, ; Occludin, ; Rifamycins, ; rifaximin, ^^^^^Weber H.C., New treatment options for irritable bowel syndrome with predominant diarrhea, Curr. Opin. Endocrinol. Diabetes Obes., 24, pp. 25-30, (2016); Pimentel M., Park S., Mirocha J., Kane S.V., Kong Y., The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial, Ann. Intern. Med., 145, pp. 557-563, (2006); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N. Engl. J. Med., 364, pp. 22-32, (2011); Meyrat P., Safroneeva E., Schoepfer A.M., Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months, Aliment. Pharmacol. Ther., 36, pp. 1084-1093, (2012); Pimentel M., Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea, Aliment. Pharmacol. Ther., 43, pp. 37-49, (2016); Sharara A.I., Aoun E., Abdul-Baki H., Mounzer R., Sidani S., Elhajj I., A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence, Am. J. Gastroenterol., 101, pp. 326-333, (2006); Pistiki A., Galani I., Pyleris E., Barbatzas C., Pimentel M., Giamarellos-Bourboulis E.J., In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth, Int. J. Antimicrob. Agents, 43, pp. 236-241, (2014); Di Stefano M., Malservisi S., Veneto G., Ferrieri A., Corazza G.R., Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth, Aliment. Pharmacol. Ther., 14, pp. 551-556, (2000); Jeffery I.B., O'Toole P.W., Ohman L., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Adachi J.A., DuPont H.L., Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders, Clin. Infect. Dis., 42, pp. 541-547, (2006); DuPont H.L., Jiang Z.D., Okhuysen P.C., Et al., A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea, Ann. Intern. Med., 142, pp. 805-812, (2005); Calanni F., Renzulli C., Barbanti M., Viscomi G.C., Rifaximin: beyond the traditional antibiotic activity, J. Antibiot., 67, pp. 667-670, (2014); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Raskov H., Burcharth J., Pommergaard H.C., Rosenberg J., Irritable bowel syndrome, the microbiota and the gut-brain axis, Gut Microbes, 29, pp. 1-19, (2016); Long Y., Wang W., Wang H., Hao L., Qian W., Hou X., Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome, J. Gastroenterol. Hepatol., 27, pp. 935-944, (2012); Fu Y., Wang W., Tong J., Et al., Th17: a new participant in gut dysfunction in mice infected with Trichinella spiralis, Mediat. Inflamm., 2009, pp. 1-7, (2009); Wang H., Gong J., Wang W., Et al., Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?, PLoS One, 9, (2014); Castro G.A., Fairbairn D., Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro, J. Parasitol., 55, pp. 51-58, (1969); Jones Iii R.C.W., Otsuka E., Wagstrom E., Jensen C.S., Price M.P., Gebhart G.F., Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse, Gastroenterology, 133, pp. 184-194, (2007); Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome, Neurogastroenterol. Motil., 24, pp. 521-530, (2012); Quast C., Pruesse E., Yilmaz P., Et al., The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res., 41, pp. D590-D596, (2013); Xu D., Gao J., Gillilland M., Et al., Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats, Gastroenterology, 146, pp. 484-496, (2014); Akiho H., Deng Y., Blennerhassett P., Kanbayashi H., Collins S.M., Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction, Gastroenterology, 129, pp. 131-141, (2005); Bercik P., Wang L., Verdu E.F., Et al., Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction, Gastroenterology, 127, pp. 179-187, (2004); Qin H.Y., Wu J.C., Tong X.D., Sung J.J., Xu H.X., Bian Z.X., Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome, J. Gastroenterol., 46, pp. 164-174, (2011); Talley N.J., Spiller R., Irritable bowel syndrome: a little understood organic bowel disease?, Lancet, 360, pp. 555-564, (2002); Ludidi S., Conchillo J.M., Keszthelyi D., Et al., Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff, Neurogastroenterol. Motil., 24, pp. 729-733, (2012); Barbara G., Cremon C., De Giorgio R., Et al., Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome, Curr. Gastroenterol. Rep., 13, pp. 308-315, (2011); Farzaei M.H., Bahramsoltani R., Abdollahi M., Rahimi R., The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments, J. Neurogastroenterol. Motil., 22, pp. 558-574, (2016); Lee H., Park J.H., Park D.I., Et al., Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome, J. Neurogastroenterol. Motil., 19, pp. 244-250, (2013); Matricon J., Meleine M., Gelot A., Et al., Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome, Aliment. Pharmacol. Ther., 36, pp. 1009-1031, (2012); Spiller R., Lam C., An update on post-infectious irritable bowel syndrome: Role of genetics, immune activation, serotonin and altered microbiome, J. Neurogastroenterol. Motil., 18, pp. 258-268, (2012); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review, J. Gastroenterol., 46, pp. 421-431, (2011); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Zhou Q., Zhang B., Nicholas V.G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Wullaert A., Heyninck K., Beyaert R., Mechanisms of crosstalk between TNF-induced NF-κB and JNK activation in hepatocytes, Biochem. Pharmacol., 72, pp. 1090-1101, (2006); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Elsenbruch S., Holtmann G., Oezcan D., Et al., Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome?, Am. J. Gastroenterol., 99, pp. 703-710, (2004); Liebregts T., Adam B., Bredack C., Et al., Immune activation in patients with irritable bowel syndrome, Gastroenterology, 132, pp. 913-920, (2007); Blaschitz C., Raffatellu M., Th17 cytokines and the gut mucosal barrier, J. Clin. Immunol., 30, pp. 196-203, (2010); Guslandi M., Rifaximin in the treatment of inflammatory bowel disease, World J Gastroenterol: WJG, 17, pp. 4643-4646, (2011); Bajaj J.S., Hylemon P.B., Ridlon J.M., Et al., Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation, Am. J. Physiol. Gastrointest. Liver Physiol., 303, pp. G675-G685, (2012); Cheng J., Shah Y.M., Gonzalez F.J., Pregnane X receptor as a target for treatment of inflammatory bowel disorders, Trends Pharmacol. Sci., 33, pp. 323-330, (2012); Cheng J., Shah Y.M., Ma X., Et al., Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation, J. Pharmacol. Exp. Ther., 335, pp. 32-41, (2010)^X. Hou; Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; email: houxh@medmail.com.cn^^Blackwell Publishing^^^^^^08159319^^JGHEE^28573746.0^English^J. Gastroenterol. Hepatol.^Article^Final^^Scopus^2-s2.0-85041079292
Zhang J.; Song L.; Wang Y.; Liu C.; Zhang L.; Zhu S.; Liu S.; Duan L.^Zhang, Jindong (57205127895); Song, Lijin (57200651228); Wang, Yujing (57201739138); Liu, Chang (57203359455); Zhang, Lu (15040157300); Zhu, Shiwei (57205130831); Liu, Shuangjiang (7409461413); Duan, Liping (10539575000)^57205127895; 57200651228; 57201739138; 57203359455; 15040157300; 57205130831; 7409461413; 10539575000^Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats^2019^Journal of Gastroenterology and Hepatology (Australia)^34.0^8^^1368^1376^8.0^179^10.1111/jgh.14536^https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058708876&doi=10.1111%2fjgh.14536&partnerID=40&md5=07b6758174e4ac7483a6bff73613c78c^Department of Gastroenterology, Peking University Third Hospital, Beijing, China; State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China^Zhang J., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Song L., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Wang Y., State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Liu C., State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Zhang L., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Zhu S., Department of Gastroenterology, Peking University Third Hospital, Beijing, China; Liu S., State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China; Duan L., Department of Gastroenterology, Peking University Third Hospital, Beijing, China^Background and Aim: Emerging evidence indicates that psychological stress is involved in the pathogenesis of irritable bowel syndrome, which is characterized by visceral hypersensitivity and may be accompanied by gut dysbiosis. However, how such stress contributes to the development of visceral hypersensitivity is incompletely understood. Here, we aimed to investigate the influence that stress-induced microbial changes exert on visceral sensitivity, as well as the possible underlying mechanisms associated with this effect. Methods: Male Sprague–Dawley rats underwent chronic water avoidance stress (WAS) to induce visceral hypersensitivity. Visceral sensitivity, colonic tight junction protein expression, and short-chain fatty acids of cecal contents were measured. Fecal samples were collected to characterize microbiota profiles. In a separate study, oral gavage of Roseburia in WAS rats was conducted to verify its potential role in the effectiveness on visceral hypersensitivity. Results: Repeated WAS caused visceral hypersensitivity, altered fecal microbiota composition and function, and decreased occludin expression in the colon. Stressed rats exhibited reduced representation of pathways involved in the metabolism of butyrate and reduced abundance of several operational taxonomic units associated with butyrate-producing bacteria, such as Lachnospiraceae. Consistently, supplementation with Roseburia hominis, a species belonging to Lachnospiraceae, significantly increased cecal butyrate content. Moreover, Roseburia supplementation alleviated visceral hypersensitivity and prevented the decreased expression of occludin. Conclusions: Reduction in the abundance of butyrate-producing Lachnospiraceae, which is beneficial for the intestinal barrier, was involved in the formation of visceral hypersensitivity. R. hominis is a potential probiotic for treating stress-induced visceral hypersensitivity. © 2018 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd^butyrate; intestinal barrier; microbiota; stress; visceral hypersensitivity^Animals; Butyrates; Clostridiales; Colon; Disease Models, Animal; Feces; Gastrointestinal Microbiome; Hyperalgesia; Male; Occludin; Pain Perception; Pain Threshold; Probiotics; Rats, Sprague-Dawley; Stress, Psychological; Tight Junctions; Visceral Pain; beta actin; butyric acid; complementary DNA; corticotropin releasing factor; occludin; probiotic agent; RNA 16S; short chain fatty acid; butyric acid derivative; occludin; Ocln protein, rat; probiotic agent; animal experiment; animal model; Article; avoidance behavior; drug efficacy; feces microflora; hypersensitivity; male; mental stress; nonhuman; priority journal; protein blood level; protein expression; rat; Roseburia; Roseburia hominis; animal; Clostridiales; colon; complication; disease model; feces; hyperalgesia; intestine flora; mental stress; metabolism; microbiology; nociception; pain threshold; pathophysiology; Sprague Dawley rat; tight junction; visceral pain^^butyric acid, 107-92-6, 156-54-7, 461-55-2; corticotropin releasing factor, 9015-71-8, 178359-01-8, 79804-71-0, 86297-72-5, 86784-80-7; occludin, 176304-61-3; Butyrates, ; Occludin, ; Ocln protein, rat, ^^^Capital’s Funds for Health Improvement and Research, (2016-2-4093); Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences; National Natural Science Foundation of China, NSFC, (81670491)^Funding text 1: We are greatly thankful for the support of Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences, as well as Metabolomics Facility at Technology Center for Protein Sciences in Tsinghua University.; Funding text 2: disclosed no financial relationships relevant to this publication. Financial support: This work was supported by the National Natural Science Foundation of China (grant number 81670491) and Capital’s Funds for Health Improvement and Research (grant number 2016-2-4093).^Liu Y., Zhang L., Wang X., Et al., Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression, Clin. Gastroenterol. Hepatol., 14, pp. 1602-1611, (2016); Tap J., Derrien M., Tornblom H., Brazeilles R., Cools-Portier S., Dore J., Et al., Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology, (2016); Luczynski P., Tramullas M., Viola M., Et al., Microbiota regulates visceral pain in the mouse, Elife, 6, (2017); O'Mahony S.M., Felice V.D., Nally K., Et al., Disturbance of the gut microbiota in early-life selectively affects visceral pain in adulthood without impacting cognitive or anxiety-related behaviors in male rats, Neuroscience, 277, pp. 885-901, (2014); Sisson G., Ayis S., Sherwood R.A., Bjarnason I., Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—a 12 week double-blind study, Aliment Pharmacol. Ther., 40, pp. 51-62, (2014); Acosta A., Camilleri M., Shin A., Et al., Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome, Clin. Transl. Gastroenterol., 7, (2016); Bailey M.T., Dowd S.E., Galley J.D., Hufnagle A.R., Allen R.G., Lyte M., Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation, Brain Behav. Immun., 25, pp. 397-407, (2011); Bharwani A., Mian M.F., Foster J.A., Surette M.G., Bienenstock J., Forsythe P., Structural & functional consequences of chronic psychosocial stress on the microbiome & host, Psychoneuroendocrinology, 63, pp. 217-227, (2016); Szyszkowicz J.K., Wong A., Anisman H., Merali Z., Audet M.C., Implications of the gut microbiota in vulnerability to the social avoidance effects of chronic social defeat in male mice, Brain Behav. Immun., 66, pp. 45-55, (2017); de Theije C.G., Wopereis H., Ramadan M., Et al., Altered gut microbiota and activity in a murine model of autism spectrum disorders, Brain Behav. Immun., 37, pp. 197-206, (2014); Tan J., McKenzie C., Potamitis M., Thorburn A.N., Mackay C.R., Macia L., The role of short-chain fatty acids in health and disease, Adv. Immunol., 121, pp. 91-119, (2014); Kannampalli P., Shaker R., Sengupta J.N., Colonic butyrate- algesic or analgesic?, Neurogastroenterol. Motil., 23, pp. 975-979, (2011); Farup P.G., Rudi K., Hestad K., Fecal short-chain fatty acids—a diagnostic biomarker for irritable bowel syndrome?, BMC Gastroenterol, 16, (2016); Gil D.W., Wang J., Gu C., Donello J.E., Cabrera S., Al-Chaer E.D., Role of sympathetic nervous system in rat model of chronic visceral pain, Neurogastroenterol. Motil., 28, pp. 423-431, (2016); Hong S., Fan J., Kemmerer E.S., Evans S., Li Y., Wiley J.W., Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat, Gut, 58, pp. 202-210, (2009); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, pp. 1276-1285, (2000); Langille M.G.I., Zaneveld J., Caporaso J.G., McDonald D., Knights D., Reyes J.A., Et al., Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences, Nat. Biotechnol., 31, pp. 814-821, (2013); Han J., Lin K., Sequeira C., Borchers C.H., An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry, Anal. Chim. Acta., 854, pp. 86-94, (2015); Chung C.S., Chang P.F., Liao C.H., Et al., Differences of microbiota in small bowel and faeces between irritable bowel syndrome patients and healthy subjects, Scand. J. Gastroenterol., 51, pp. 410-419, (2016); Elinav E., Strowig T., Kau A.L., Et al., NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis, Cell, 145, pp. 745-757, (2011); Chen W., Liu F., Ling Z., Tong X., Xiang C., Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer, PLoS One, 7, (2012); Harmsen H.J.M., Wildeboer-Veloo A.C.M., Grijpstra J., Knol J., Degener J.E., Welling G.W., Development of 16S rRNA-based probes for the Coriobacterium group and the Atopobium cluster and their application for enumeration of Coriobacteriaceae in human feces from volunteers of different age groups, Appl. Environ. Microbiol., 66, pp. 4523-4527, (2000); Bangsgaard Bendtsen K.M., Krych L., Sorensen D.B., Et al., Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse, PLoS One, 7, (2012); Flint H.J., Duncan S.H., Scott K.P., Louis P., Links between diet, gut microbiota composition and gut metabolism, Proc Nutr Soc, 74, pp. 13-22, (2015); Dehingia M., Devi K.T., Talukdar N.C., Et al., Gut bacterial diversity of the tribes of India and comparison with the worldwide data, Sci. Rep., 5, (2015); Tamanai-Shacoori Z., Smida I., Bousarghin L., Et al., Roseburia spp.: a marker of health?, Future Microbiol., 12, pp. 157-170, (2017); Kumari R., Ahuja V., Paul J., Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India, World J. Gastroenterol., 19, pp. 3404-3414, (2013); Machiels K., Joossens M., Sabino J., Et al., A decrease of the butyrate-producing species Roseburia hominis and Fecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis, Gut, 63, pp. 1275-1283, (2014); Chassard C., Dapoigny M., Scott K.P., Et al., Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome, Aliment Pharm. Ther., 35, pp. 828-838, (2012); Wang T.T., Cai G.X., Qiu Y.P., Et al., Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers, ISME J, 6, pp. 320-329, (2012); Takahashi K., Nishida A., Fujimoto T., Et al., Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease, Digestion, 93, pp. 59-65, (2016); Undseth R., Jakobsdottir G., Nyman M., Berstad A., Valeur J., Low serum levels of short-chain fatty acids after lactulose ingestion may indicate impaired colonic fermentation in patients with irritable bowel syndrome, Clin. Exp. Gastroenterol., 8, pp. 303-308, (2015); Banasiewicz T., Krokowicz L., Stojcev Z., Et al., Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome, Colorectal Dis., 15, pp. 204-209, (2013); Vanhoutvin S.A., Troost F.J., The effects of butyrate enemas on visceral perception in healthy volunteers, Neurogastroenterol. Motil., 21, pp. 952-e76, (2009); Treem W.R., Ahsan N., Kastoff G., Hyams J.S., Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation, J. Pediatr. Gastroenterol. Nutr., 23, pp. 280-286, (1996); Bourdu S., Dapoigny M., Chapuy E., Et al., Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats, Gastroenterology, 128, pp. 1996-2008, (2005); Long X., Li M., Li L.X., Et al., Butyrate promotes visceral hypersensitivity in an IBS-like model via enteric glial cell-derived nerve growth factor, Neurogastroenterol. Motil., 30, (2018); Ringel-Kulka T., Choi C.H., Temas D., Et al., Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome, Am. J. Gastroenterol., 110, pp. 1339-1346, (2015); Patterson A.M., Mulder I.E., Travis A.J., Et al., Human gut symbiont Roseburia hominis promotes and regulates innate immunity, Front. Immunol., 8, (2017); Burger-van Paassen N., Vincent A., Puiman P.J., Et al., The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection, Biochem. J., 420, pp. 211-219, (2009); Peng L., Li Z.R., Green R.S., Holzman I.R., Lin J., Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers, J. Nutr., 139, pp. 1619-1625, (2009)^L. Duan; Department of Gastroenterology, Peking University Third Hospital, Beijing, China; email: duanlp@bjmu.edu.cn^^Blackwell Publishing^^^^^^08159319^^JGHEE^30402954.0^English^J. Gastroenterol. Hepatol.^Article^Final^All Open Access; Green Open Access; Hybrid Gold Open Access^Scopus^2-s2.0-85058708876
Barbara G.; Zecchi L.; Barbaro R.; Cremon C.; Bellacosa L.; Marcellini M.; De Giorgio R.; Corinaldesi R.; Stanghellini V.^Barbara, Giovanni (7004311418); Zecchi, Lisa (36098678300); Barbaro, Raffaella (56235164100); Cremon, Cesare (6507319921); Bellacosa, Lara (34972669400); Marcellini, Marco (55358259100); De Giorgio, Roberto (7005471207); Corinaldesi, Roberto (7004571215); Stanghellini, Vincenzo (7006377452)^7004311418; 36098678300; 56235164100; 6507319921; 34972669400; 55358259100; 7005471207; 7004571215; 7006377452^Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome^2012^Journal of Clinical Gastroenterology^46.0^SUPPL. 1^^S52^S55^3.0^84^10.1097/MCG.0b013e318264e918^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84866264998&doi=10.1097%2fMCG.0b013e318264e918&partnerID=40&md5=eb69ab61d42c096a9356fb82a0d5958c^Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy^Barbara G., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Zecchi L., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Barbaro R., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Cremon C., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Bellacosa L., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Marcellini M., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; De Giorgio R., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Corinaldesi R., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy; Stanghellini V., Department of Clinical Medicine, Centre for Applied Biomedical Research, University of Bologna, Bologna, Italy^There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in postinfectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future. © 2012 by Lippincott Williams & Wilkins.^abdominal pain; immune activation; irritable bowel syndrome; mast cells; mucosal barrier^Abdominal Pain; Bifidobacterium; Gastrointestinal Tract; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Lactobacillus; Mast Cells; Permeability; Probiotics; Randomized Controlled Trials as Topic; beta defensin 2; immunoglobulin A; ketotifen; mesalazine; messenger RNA; mucin 1; mucin 2; mucin 3; probiotic agent; protein ZO1; RNA 16S; abdominal pain; antiinflammatory activity; article; Bifidobacterium breve; Bifidobacterium longum infantis; disease severity; drug safety; feces microflora; human; hypersensitivity; immune response; intestine flora; intestine mucosa permeability; irritable colon; Lactobacillus rhamnosus; Lactobacillus salivarius; mast cell; pathophysiology; priority journal; quality of life; symptom^^ketotifen, 34580-13-7; mesalazine, 89-57-6; mucin 1, 212255-06-6; mucin 3, 199543-31-2^^^^^Longstreth G.F., Thompson W.G., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Barbara G., De Giorgio R., Stanghellini V., Cremon C., Salvioli B., Corinaldesi R., New pathophysiological mechanisms in irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 20, SUPPL.2, pp. 1-9, (2004); Barbara G., Stanghellini V., Biomarkers in IBS: When will they replace symptoms for diagnosis and management?, Gut, 58, pp. 1571-1575, (2009); Barbara G., Stanghellini V., Cremon C., Et al., Probiotics and irritable bowel syndrome: Rationale and clinical evidence for their use, J Clin Gastroenterol, 42, SUPPL. 3, (2008); Turner J.R., Intestinal mucosal barrier function in health and disease, Nat Rev Immunol, 9, pp. 799-809, (2009); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions IV Regulation of tight junctions by extracellular stimuli: Nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, American Journal of Gastroenterology, 101, 6, pp. 1295-1298, (2006); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Rao A.S., Camilleri M., Eckert D.J., Et al., Urine sugars for in vivo gut permeability: Validation and comparisons in irritable bowel syndrome-diarrhea and controls, Am J Physiol Gastrointest Liver Physiol, 301, (2011); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Martnez C., Vicario M., Ramos L., Et al., The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations, Am J Gastroenterol, 107, pp. 736-746, (2012); Coe Ffier M., Gloro R., Boukhettala N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Bertiaux-Vandaelse N., Youmba S.B., Et al., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Lee J.W., Park J.H., Park D.I., Et al., Subjects with diarrheapredominant IBS have increased rectal permeability responsive to tryptase, Dig Dis Sci, 55, pp. 2922-2928, (2010); Barbara G., Cremon C., Carini G., Et al., The immune system in irritable bowel syndrome, J Neurogastroenterol Motil, 17, pp. 349-359, (2011); Chadwick V.S., Chen W., Shu D., Paulus B., Bethwaite P., Tie A., Wilson I., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, 7, pp. 1778-1783, (2002); Guilarte M., Santos J., De Torres I., Et al., Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum, Gut, 56, pp. 203-209, (2007); Weston A.P., Biddle W.L., Bhatia P.S., Miner Jr. P.B., Terminal ileal mucosal mast cells in irritable bowel syndrome, Digestive Diseases and Sciences, 38, 9, pp. 1590-1595, (1993); Walker M.M., Talley N.J., Prabhakar M., Et al., Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia, Aliment Pharmacol Ther, 29, pp. 765-773, (2009); Barbara G., Stanghellini V., De Giorgio R., Cremon C., Cottrell G.S., Santini D., Pasquinelli G., Morselli-Labate A.M., Grady E.F., Bunnett N.W., Collins S.M., Corinaldesi R., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, 3, pp. 693-702, (2004); Piche T., Saint-Paul M.C., Dainese R., Marine-Barjoan E., Iannelli A., Montoya M.L., Peyron J.F., Czerucka D., Cherikh F., Filippi J., Tran A., Hebuterne X., Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome, Gut, 57, 4, pp. 468-473, (2008); Cremon C., Gargano L., Morselli-Labate A.M., Et al., Mucosal immune activation in irritable bowel syndrome: Genderdependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G.P., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, Journal of Clinical Investigation, 117, 3, pp. 636-647, (2007); Barbara G., Wang B., Stanghellini V., De Giorgio R., Cremon C., Di Nardo G., Trevisani M., Campi B., Geppetti P., Tonini M., Bunnett N.W., Grundy D., Corinaldesi R., Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome, Gastroenterology, 132, 1, pp. 26-37, (2007); MacSharry J., O'mahony L., Fanning A., Et al., Mucosal cytokine imbalance in irritable bowel syndrome, Scand J Gastroenterol, 43, pp. 1467-1476, (2008); Buhner S., Li Q., Vignali S., Et al., Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome, Gastroenterology, 137, pp. 1425-1434, (2009); Salim S.Y., So Derholm J.D., Importance of disrupted intestinal barrier in inflammatory bowel diseases, Inflamm Bowel Dis, 17, pp. 362-381, (2011); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Et al., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Preidis G.A., Versalovic J., Targeting the human microbiome with antibiotics, probiotics, and prebiotics: Gastroenterology enters the metagenomics era, Gastroenterology, 136, pp. 2015-2031, (2009); Moayyedi P., Ford A.C., Talley N.J., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review, Gut, 59, pp. 325-332, (2010); Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, pp. 22-32, (2011); Lyra A., Rinttila T., Nikkila J., Et al., Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification, World J Gastroenterol, 15, pp. 5936-5945, (2009); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Malinen E., Rinttila T., Kajander K., Matto J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, American Journal of Gastroenterology, 100, 2, pp. 373-382, (2005); Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., Lochs H., Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease, Journal of Clinical Microbiology, 43, 7, pp. 3380-3389, (2005); Langhorst J., Junge A., Rueffer A., Et al., Elevated human betadefensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 404-410, (2009); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Ohman L., Isaksson S., Lindmark A.C., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Corinaldesi R., Stanghellini V., Cremon C., Et al., Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: A randomized controlled proof-of-concept study, Aliment Pharmacol Ther, 30, pp. 245-252, (2009); Lunardi C., Bambara L.M., Biasi D., Et al., Double-blind crossover trial of oral sodium cromoglycate in patients with irritable bowel syndrome due to food intolerance, Clin Exp Allergy, 21, pp. 569-572, (1991); Stefanini G.F., Saggioro A., Alvisi V., Et al., Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type: Multicenter study of 428 patients, Scand J Gastroenterol, 30, pp. 535-541, (1995); Klooker T.K., Braak B., Koopman K.E., Et al., The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome, Gut, 59, pp. 1213-1221, (2010); Ohland C.L., MacNaughton W.K., Probiotic bacteria and intestinal epithelial barrier function, Am J Physiol Gastrointest Liver Physiol, 298, (2010); Lyra A., Krogius-Kurikka L., Nikkila J., Et al., Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes, BMC Gastroenterol, 10, pp. 110-119, (2010); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Halpern G.M., Prindiville T., Blankenburg M., Hsia T., Gershwin M.E., Treatment of irritable bowel syndrome with lacteol fort: A randomized, double-blind, cross-over trial, American Journal of Gastroenterology, 91, 8, pp. 1579-1585, (1996); Nobaek S., Johansson M.-L., Molin G., Ahrne S., Jeppsson B., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, American Journal of Gastroenterology, 95, 5, pp. 1231-1238, (2000); O'sullivan M.A., O'morain C.A., Bacterial supplementation in the irritable bowel syndrome; A randomised double blind placebo-controlled crossover study, Dig Liver Dis, 32, pp. 294-301, (2000); Niedzielin K., Kordecki H., Birkenfeld B., A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, European Journal of Gastroenterology and Hepatology, 13, 10, pp. 1143-1147, (2001); Sen S., Mullan M.M., Parker T.J., Woolner J.T., Tarry S.A., Hunter J.O., Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome, Digestive Diseases and Sciences, 47, 11, pp. 2615-2620, (2002); Niv E., Naftali T., Hallak R., Vaisman N., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study, Clinical Nutrition, 24, 6, pp. 925-931, (2005); Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley E.M.M., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, American Journal of Gastroenterology, 101, 7, pp. 1581-1590, (2006); Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.-H., Matuchansky C., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial, Alimentary Pharmacology and Therapeutics, 26, 3, pp. 475-486, (2007); Spiller R., Review article: Probiotics and prebiotics in irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 28, 4, pp. 385-396, (2008); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003); Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Kajander K., Hatakka K., Poussa T., Farkkila M., Korpela R., A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: A controlled 6-month intervention, Alimentary Pharmacology and Therapeutics, 22, 5, pp. 387-394, (2005)^G. Barbara; Department of Clinical Medicine, University of Bologna, S. Orsola-Malpighi Hospital, I-40138 Bologna, Via Massarenti 9, Italy; email: giovanni.barbara@unibo.it^^^^^^^^15392031^^JCGAD^22955358.0^English^J. Clin. Gastroenterol.^Article^Final^^Scopus^2-s2.0-84866264998
Brown D.^Brown, Donald (55738763900)^55738763900^Probiotics effectively treat irritable bowel syndrome in children^2011^Alternative Medicine Alert^14.0^3^^28^30^2.0^0^^https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955911537&partnerID=40&md5=04d7d20b62f6a1d2f4c0c54324d53b5a^Natural Products Research Consultants, Seattle, WA, United States^Brown D., Natural Products Research Consultants, Seattle, WA, United States^Results of this 8-week clinical trial demonstrated the efficacy of Lactobacillus rhamnosus strain GG (LGG) in reducing the frequency and severity of pain in children with irritable bowel syndrome or functional abdominal pain. Benefits persisted for 8 weeks after cessation of treatment. Additionally, small intestinal permeability was decreased in children with IBS treated with LGG.^^^^^^^^^Saps M., Et al., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, pp. 322-326, (2009); Rasquin A., Et al., Childhood functional gastrointestinal disorders :child/adolescent, Gastroenterology, 130, pp. 1527-1537, (2006); Hoveyda N., Et al., A systematic review and metaanalysis: Probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterol, 9, (2009); Mertz H.R., Iritable bowel syndrome, N Engl J Med, 349, pp. 2136-2146, (2003); Everheart J.E., Et al., Irritable bowel syndrome in office-based practice in the United States, Gastroenterol, 100, pp. 998-1005, (1991); Weydert J.A., Et al., Systematic review of treatments for recurrent abdominal pain, Pediatrics, 111, (2003); Baussermann M., Et al., The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial, J Pediatr, 147, pp. 197-201, (2005); Gawronska A., Dziechciarz P., Horvath A., Szajewska H., A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children, Alimentary Pharmacology and Therapeutics, 25, 2, pp. 177-184, (2007); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Stratiki Z., Costalos C., Sevastiadou S., Kastanidou O., Skouroliakou M., Giakoumatou A., Petrohilou V., The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants, Early Human Development, 83, 9, pp. 575-579, (2007); Mohammad M., Hussein L., Yamamah G., Rawi S., The impact of probiotic and/or honey supplements on gut permeability among Egyptian children, Journal of Nutritional and Environmental Medicine, 16, 1, pp. 10-15, (2007); Shulman R.J., Et al., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, pp. 646-650, (2008); Lin H.C., Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome, Journal of the American Medical Association, 292, 7, pp. 852-858, (2004)^^^^^^^^^1096942X^^^^English^Altern.Med. Alert^Article^Final^^Scopus^2-s2.0-79955911537
Ghoshal U.C.; Ranjan P.^Ghoshal, Uday C. (7005966711); Ranjan, Prabhat (57200595370)^7005966711; 57200595370^Post-infectious irritable bowel syndrome: The past, the present and the future^2011^Journal of Gastroenterology and Hepatology (Australia)^26.0^SUPPL. 3^^94^101^7.0^64^10.1111/j.1440-1746.2011.06643.x^https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953093222&doi=10.1111%2fj.1440-1746.2011.06643.x&partnerID=40&md5=e0166dce0ee13a7971e78966354dd5bc^Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India^Ghoshal U.C., Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India; Ranjan P., Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India^Background: Irritable bowel syndrome (IBS), once thought to be a psychosomatic disease, is being considered to be more organic. Post-infectious IBS (PI-IBS), defined as acute onset IBS (by Rome criteria) after gastrointestinal infection in an individual without prior IBS with two or more of the followings: fever, vomiting, diarrhea, a positive stool culture. The recent and old literature of PI-IBS will be reviewed. Future directions for research will be presented. Methods: Literature on PI-IBS was reviewed by electronic search and cross references of these papers. Results: Interest in studies on PI-IBS, which was described five to six decades ago, re-surfaced recently. 3.6 to 32% patients with acute gastroenteritis develop PI-IBS during 3-12 month follow-up. PI-IBS is commonly diarrhea predominant. Factors implicated in development include nature of pathogens, duration and severity of diarrhea, younger age, female gender and psychological co-morbidities like anxiety and depression. The pathogenesis of PI-IBS is largely related to continuing gut inflammation due to inability of the host to contain the inflammatory reaction, altered gut microbiota, increased intestinal permeability, muscle hyper-contractility and visceral hypersensitivity. There could be an overlap between PI-IBS and post-infectious malabsorption syndrome (PI-MAS), popularly known as tropical sprue. Conclusions: Development of IBS in a subset of patients with acute gastroenteritis is uncontested. This is expected to open a paradigm shift in understanding the pathogenesis of IBS. Future studies should address the issue of overlap of PI-IBS and PI-MAS. Exploring the molecular mechanisms of pathogenesis of PI-IBS may help to design preventive and therapeutic strategies. © 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.^Chronic diarrhea; Dysentery; Functional bowel disease; Gastroenteritis; Tropical sprue^toll like receptor 9; acute gastroenteritis; anxiety; article; bacterial flora; comorbidity; depression; diarrhea; disease severity; DNA polymorphism; enteritis; follow up; groups by age; Helicobacter pylori; human; innate immunity; irritable colon; malabsorption; membrane permeability; microflora; muscle contraction; pathogenesis; post infection irritable bowel syndrome; post infection malabsorption syndrome; priority journal; psychological aspect; risk factor; sex difference^^toll like receptor 9, 352486-49-8, 390883-32-6^^^^^"Gwee K.A., Lu C.L., Ghoshal U.C., Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed, J. Gastroenterol. Hepatol., 24, pp. 1601-1607, (2009); Ghoshal U.C., Park H., Gwee K.A., Bugs and irritable bowel syndrome: the good, the bad and the ugly, J. Gastroenterol. Hepatol., 25, pp. 244-251, (2010); Collins S., Verdu E., Denou E., Bercik P., The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome, Dig. Dis., 27, SUPPL. 1, pp. 85-89, (2009); Cuomo R., Savarese M.F., Gargano R., Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues, Dig. Dis., 25, pp. 241-244, (2007); Spiller R.C., Infection, immune function, and functional gut disorders, Clin. Gastroenterol. Hepatol., 2, pp. 445-455, (2004); Spiller R.C., Overlap between irritable bowel syndrome and inflammatory bowel disease, Dig. Dis., 27, SUPPL. 1, pp. 48-54, (2009); Stewart G.T., Post-dysenteric colitis, Br. Med. J., 1, pp. 405-409, (1950); Chaudhary N.A., Truelove S.C., The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases, Q. J. Med., 31, pp. 307-322, (1962); Mathan V.I., Baker S.J., Epidemic tropical sprue and other epidemics of diarrhea in South Indian villages, Am. J. Clin. Nutr., 21, pp. 1077-1087, (1968); Montgomery R.D., Shearer A.C., The cell population of the upper jejunal mucosa in tropical sprue and postinfective malabsorption, Gut, 15, pp. 387-391, (1974); Lindenbaum J., Malabsorption during and after recovery from acute intestinal infection, Br. Med. J., 2, pp. 326-329, (1965); Ramakrishna B.S., Venkataraman S., Mukhopadhya A., Tropical malabsorption, Postgrad. Med. J., 82, pp. 779-787, (2006); Gwee K.A., Graham J.C., McKendrick M.W., Et al., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); McKendrick M.W., Read N.W., Irritable bowel syndrome-post salmonella infection, J. Infect., 29, pp. 1-3, (1994); Neal K.R., Hebden J., Spiller R., Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients, BMJ, 314, pp. 779-782, (1997); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study, BMJ, 318, pp. 565-566, (1999); Mearin F., Badia X., Balboa A., Et al., Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population, Scand. J. Gastroenterol., 36, pp. 1155-1161, (2001); Ilnyckyj A., Balachandra B., Elliott L., Choudhri S., Duerksen D.R., Post-traveler's diarrhea irritable bowel syndrome: a prospective study, Am. J. Gastroenterol., 98, pp. 596-599, (2003); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, Am. J. Gastroenterol., 98, pp. 1578-1583, (2003); Parry S.D., Stansfield R., Jelley D., Et al., Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study, Am. J. Gastroenterol., 98, pp. 1970-1975, (2003); Wang L.H., Fang X.C., Pan G.Z., Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis, Gut, 53, pp. 1096-1101, (2004); Okhuysen P.C., Jiang Z.D., Carlin L., Forbes C., DuPont H.L., Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico, Am. J. Gastroenterol., 99, pp. 1774-1778, (2004); Ji S., Park H., Lee D., Song Y.K., Choi J.P., Lee S.I., Post-infectious irritable bowel syndrome in patients with Shigella infection, J. Gastroenterol. Hepatol., 20, pp. 381-386, (2005); Kim H.S., Kim M.S., Ji S.W., Park H., The development of irritable bowel syndrome after Shigella infection: 3year follow-up study, Korean J. Gastroenterol., 47, pp. 300-305, (2006); Jung I.S., Kim H.S., Park H., Lee S.I., The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study, J. Clin. Gastroenterol., 43, pp. 534-540, (2009); Marshall J.K., Thabane M., Garg A.X., Clark W.F., Salvadori M., Collins S.M., Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery, Gastroenterology, 131, pp. 445-450, (2006); Borgaonkar M.R., Ford D.C., Marshall J.K., Churchill E., Collins S.M., The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection, Dig. Dis. Sci., 51, pp. 1026-1032, (2006); Moss-Morris R., Spence M., To ""lump"" or to ""split"" the functional somatic syndromes: can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?, Psychosom. Med., 68, pp. 463-469, (2006); Stermer E., Lubezky A., Potasman I., Paster E., Lavy A., Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study, Clin. Infect. Dis., 43, pp. 898-901, (2006); Marshall J.K., Thabane M., Borgaonkar M.R., James C., Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen, Clin. Gastroenterol. Hepatol., 5, pp. 457-460, (2007); Spence M.J., Moss-Morris R., The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis, Gut, 56, pp. 1066-1071, (2007); Hanevik K., Dizdar V., Langeland N., Hausken T., Development of functional gastrointestinal disorders after Giardia lamblia infection, BMC Gastroenterol., 9, (2009); Haagsma J.A., Siersema P.D., De Wit N.J., Havelaar A.H., Disease burden of post-infectious irritable bowel syndrome in The Netherlands, Epidemiol. Infect., 138, pp. 1650-1656, (2010); Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome, Aliment. Pharmacol. Ther., 26, pp. 535-544, (2007); Halvorson H.A., Schlett C.D., Riddle M.S., Postinfectious irritable bowel syndrome-a meta-analysis, Am. J. Gastroenterol., 101, pp. 1894-1899, (2006); Grazioli B., Matera G., Laratta C., Et al., Giardia lamblia infection in patients with irritable bowel syndrome and dyspepsia: a prospective study, World J. Gastroenterol., 12, pp. 1941-1944, (2006); D'Anchino M., Orlando D., De Feudis L., Giardia lamblia infections become clinically evident by eliciting symptoms of irritable bowel syndrome, J. Infect., 45, pp. 169-172, (2002); Sinha P., Ghoshal U.C., Choudhuri G., Naik S., Ayyagari A., Naik S.R., Does Entamoeba histolytica cause irritable bowel syndrome?, Indian J. Gastroenterol., 16, pp. 130-133, (1997); Anand A.C., Reddy P.S., Saiprasad G.S., Kher S.K., Does non-dysenteric intestinal amoebiasis exist?, Lancet, 349, pp. 89-92, (1997); Pan G., Lu S., Ke M., Han S., Guo H., Fang X., Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling, Chin. Med. J. (Engl.), 113, pp. 35-39, (2000); Tuteja A.K., Talley N.J., Gelman S.S., Et al., Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA, Dig. Dis. Sci., 53, pp. 271-276, (2008); Sykes M.A., Blanchard E.B., Lackner J., Keefer L., Krasner S., Psychopathology in irritable bowel syndrome: support for a psychophysiological model, J. Behav. Med., 26, pp. 361-372, (2003); Thabane M., Simunovic M., Akhtar-Danesh N., Marshall J.K., Development and validation of a risk score for post-infectious irritable bowel syndrome, Am. J. Gastroenterol., 104, pp. 2267-2274, (2009); Xiong L.S., Chen M.H., Chen H.X., Xu A.G., Wang W.A., Hu P.J., A population-based epidemiologic study of irritable bowel syndrome in Guangdong province, Zhonghua Yi Xue Za Zhi, 84, pp. 278-281, (2004); Xiong L.S., Chen M.H., Chen H.X., Xu A.G., Wang W.A., Hu P.J., A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling, Aliment. Pharmacol. Ther., 19, pp. 1217-1224, (2004); Park K.S., Ahn S.H., Hwang J.S., Et al., A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients, Dig. Dis. Sci., 53, pp. 704-711, (2008); Ghoshal U.C., Abraham P., Bhatt C., Et al., Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian society of gastroenterology task force, Indian J. Gastroenterol., 27, pp. 22-28, (2008); Danivat D., Tankeyoon M., Sriratanaban A., Prevalence of irritable bowel syndrome in a non-Western population, Br. Med. J. (Clin. Res. Ed), 296, (1988); Masud M.A., Hasan M., Khan A.K., Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior, Am. J. Gastroenterol., 96, pp. 1547-1552, (2001); Husain N., Chaudhry I.B., Jafri F., Niaz S.K., Tomenson B., Creed F., A population-based study of irritable bowel syndrome in a non-Western population, Neurogastroenterol. Motil., 20, pp. 1022-1029, (2008); Pearce E.J., M Kane C., Sun J., J Taylor J., McKee A.S., Cervi L., Th2 response polarization during infection with the helminth parasite Schistosoma mansoni, Immunol. Rev., 201, pp. 117-126, (2004); Baker S.J., Mathan V.I., An epidemic of tropical sprue in southern India. II. Epidemiology, Ann. Trop. Med. Parasitol., 64, pp. 453-467, (1970); Mathan V.I., Baker S.J., An epidemic of tropical sprue in southern India. I. Clinical features, Ann. Trop. Med. Parasitol., 64, pp. 439-451, (1970); Sheeby T.W., Digestive disease as a national problem. VI. Enteric disease among United States troops in Vietnam, Gastroenterology, 55, pp. 105-112, (1968); Lim M.L., A perspective on tropical sprue, Curr. Gastroenterol. Rep., 3, pp. 322-327, (2001); Ghoshal U.C., Ghoshal U., Ayyagari A., Et al., Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time, J. Gastroenterol. Hepatol., 18, pp. 540-547, (2003); Gorbach S.L., Mitra R., Jacobs B., Banwell J.G., Chatterjee B.D., Mazumder D.N., Bacterial contamination of the upper small bowel in tropical sprue, Lancet, 1, pp. 74-77, (1969); Rana S.V., Sinha S.K., Sikander A., Bhasin D.K., Singh K., Study of small intestinal bacterial overgrowth in North Indian patients with irritable bowel syndrome: a case control study, Trop. Gastroenterol., 29, pp. 23-25, (2008); Gupta D., Ghoshal U.C., Misra A., Choudhuri G., Singh K., Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study, J. Gastroenterol. Hepatol., 22, pp. 2261-2265, (2007); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Ghoshal U.C., Kumar S., Mehrotra M., Lakshmi C., Misra A., Frequency of small intestinal bacterial overgrowth in patients with irritable bowel syndrome and chronic non-specific diarrhea, J. Neurogastroenterol. Motil., 16, pp. 40-46, (2010); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am. J. Gastroenterol., 101, pp. 1288-1294, (2006); Kumar S., Ghoshal U.C., Jayalakshmi K., Roy R., Misra A., Khetrapal C.L., Abnormal small intestinal permeability in patients with idiopathic malabsorption in tropics (tropical Sprue) does not change even after successful treatment, Dig. Dis. Sci., 56, pp. 161-169, (2011); Gorbach S.L., Neale G., Levitan R., Hepner G.W., Alterations in human intestinal microflora during experimental diarrhoea, Gut, 11, pp. 1-6, (1970); Malinen E., Rinttila T., Kajander K., Et al., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am. J. Gastroenterol., 100, pp. 373-382, (2005); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol., 9, (2009); Malinen E., Krogius-Kurikka L., Lyra A., Et al., Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome, World J. Gastroenterol., 16, pp. 4532-4540, (2010); Pimentel M., Chatterjee S., Chang C., Et al., A new rat model links two contemporary theories in irritable bowel syndrome, Dig. Dis. Sci., 53, pp. 982-989, (2008); Pimentel M., Mayer A.G., Park S., Chow E.J., Hasan A., Kong Y., Methane production during lactulose breath test is associated with gastrointestinal disease presentation, Dig. Dis. Sci., 48, pp. 86-92, (2003); Rana S.V., Sharma S., Sinha S.K., Kaur H., Sikander A., Singh K., Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from North India, Dig. Dis. Sci., 54, pp. 132-135, (2009); Kumar S., Misra A., Ghoshal U.C., Patients with irritable bowel syndrome exhale more hydrogen than healthy subjects in fasting state, J. Neurogastroenterol. Motil., 16, pp. 299-305, (2010); Austin G.L., Dalton C.B., Hu Y., Et al., A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome, Clin. Gastroenterol. Hepatol., 7, (2009); Goldstein R., Braverman D., Stankiewicz H., Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints, Isr. Med. Assoc. J., 2, pp. 583-587, (2000); Haderstorfer B., Psycholgin D., Whitehead W.E., Schuster M.M., Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome, Am. J. Gastroenterol., 84, pp. 375-378, (1989); Afdhal N.H., Piggott C., Long A.A., O'Donoghue D.P., Carbohydrate handling by colonic flora-is it pathogenic in the irritable bowel syndrome?, Ir. J. Med. Sci., 155, pp. 197-201, (1986); Mortensen P.B., Andersen J.R., Arffmann S., Krag E., Short-chain fatty acids and the irritable bowel syndrome: the effect of wheat bran, Scand. J. Gastroenterol., 22, pp. 185-192, (1987); Treem W.R., Ahsan N., Kastoff G., Hyams J.S., Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation, J. Pediatr. Gastroenterol. Nutr., 23, pp. 280-286, (1996); Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment. Pharmacol. Ther., 20, pp. 1317-1322, (2004); Gwee K.A., Collins S.M., Read N.W., Et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Dumoulin V., Moro F., Barcelo A., Dakka T., Cuber J.C., Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum, Endocrinology, 139, pp. 3780-3786, (1998); Cherbut C., Aube A.C., Blottiere H.M., Galmiche J.P., Effects of short-chain fatty acids on gastrointestinal motility, Scand. J. Gastroenterol. Suppl., 222, pp. 58-61, (1997); Akiho H., Deng Y., Blennerhassett P., Kanbayashi H., Collins S.M., Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction, Gastroenterology, 129, pp. 131-141, (2005); Long Y.Q., Tong J.J., Qian W., Hou X.H., Altered expression of intestinal cytokines in development of postinfectious irritable bowel syndrome mouse model, Zhonghua Yi Xue Za Zhi, 90, pp. 2415-2419, (2010); Dunlop S.P., Jenkins D., Neal K.R., Spiller R.C., Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS, Gastroenterology, 125, pp. 1651-1659, (2003); Villani A.C., Lemire M., Thabane M., Et al., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010)"^U.C. Ghoshal; Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India; email: udayghoshal@gmail.com^^Blackwell Publishing^^^^^^08159319^^JGHEE^^English^J. Gastroenterol. Hepatol.^Article^Final^^Scopus^2-s2.0-79953093222
Lin H.C.; Pimentel M.^Lin, Henry C. (56919981500); Pimentel, Mark (7006799213)^56919981500; 7006799213^Bacterial concepts in irritable bowel syndrome^2005^Reviews in Gastroenterological Disorders^5.0^SUPPL. 3^^S3^S9^6.0^20^^https://www.scopus.com/inward/record.uri?eid=2-s2.0-31144467842&partnerID=40&md5=d0e3d42a3dba284763525522c7f9f152^Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Gastrointestinal Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, United States^Lin H.C., Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Pimentel M., Gastrointestinal Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, United States^An overlap of symptoms in irritable bowel syndrome (IBS) exists across subtype groups. Symptoms include intestinal gas, diarrhea, dyspepsia, bloating, abdominal pain, and constipation. The unifying symptom may be excessive intestinal gas as a by-product of intestinal microbial fermentation. Abnormal fermentation of food takes place when gut microbes expand proximally into the small intestine instead of being confined predominantly to the colon. Such proximal expansion of indigenous gut microbes or small intestinal bacterial overgrowth (SIBO) may lead to activation of host mucosal immunity and an increase in intestinal permeability to result in flu-like extra-intestinal symptoms that accompany the classic IBS symptoms of altered bowels. The presence of methane on lactulose breath testing is associated with constipation-predominant IBS. Antibiotic therapy may be appropriate to treat underlying SIBO in IBS patients. Seventy-five percent improvement of IBS symptoms was reported in a double-blind, placebo-controlled study once antibiotics succeeded in treating bacterial overgrowth. Once a good clinical response and normalization of the lactulose breath test are achieved, a prokinetic agent may be used to stimulate phase III of interdigestive motility to delay relapse of bacterial overgrowth. © 2005 MedReviews, LLC.^Constipation; Diarrhea; Gut microbes; Intestinal gas; Irritable bowel syndrome^Anti-Bacterial Agents; Bacteria; Humans; Intestine, Small; Irritable Bowel Syndrome; Prognosis; erythromycin; lactulose; methane; tegaserod; article; bacterial overgrowth; breath analysis; host pathogen interaction; host resistance; host susceptibility; human; immunological tolerance; infection prevention; intestine flora; intestine motility; irritable colon; mucosal immunity; small intestine; symptomatology^^erythromycin, 114-07-8, 70536-18-4; lactulose, 4618-18-2; methane, 74-82-8; tegaserod, 145158-71-0, 189188-57-6; Anti-Bacterial Agents, ^^^^^Thompson W.G., Creed F.H., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gastroenterol Int., 5, pp. 75-91, (1992); Thompson W.G., Longstretch G.F., Drossman D.A., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. II, pp. 1143-1147, (1999); Locke G.R., Zinsmeister A.R., Fett S., Et al., Overlap of gastrointestinal symptom complexes in a US community, Neurogastroenterol Motil., 17, pp. 29-34, (2005); Chami T.N., Schuster M.M., Bohlman M.E., Et al., A simple radiologic method to estimate the quantity of bowel gas, Am J Gastroenterol., 86, pp. 599-602, (1991); Dotevall G., Svedlund J., Sjodin I., Symptoms in irritable bowel syndrome, Scand J Gastroenterol Suppl., 79, pp. 16-19, (1982); Lin H.C., Small intestinal bacterial overgrowth: A framework for understanding IBS, JAMA, 292, pp. 852-858, (2004); Lasser R.B., Bond J.H., Levitt M.D., The role of intestinal gas in functional abdominal pain, N Engl J Med., 293, pp. 524-525, (1975); Serra J., Azpiroz F., Malagelada J.R., Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome, Gut, 48, pp. 14-19, (2001); Lea R., Houghton L.A., Reilly B., Whorwell P.J., Abdominal distension in irritable bowel syndrome (IBS): Is there a relationship to visceral sensitivity, Gastroenterology, 124, (2003); Koide A., Yamaguchi T., Odaka T., Et al., Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome, Am J Gastroenterol., 95, pp. 735-741, (2000); King T.S., Ekua M., Hunter J.O., Abnormal colonic fermentation in irritable bowel syndrome, Lancet, 352, pp. 1187-1189, (1998); Levitt M.D., Production and excretion of hydrogen gas in man, N Engl J Med., 281, pp. 122-127, (1969); Strocchi A., Furne J., Ellis C., Levitt M.D., Methanogens outcompetes sulphate reducing bacteria for H2 in the human colon, Gut, 35, pp. 1098-1101, (1994); Eckburg P.B., Bik E.M., Bernstein C.N., Et al., Diversity of the human intestinal microbial flora, Science, 308, pp. 1635-1638, (2005); Brandtzaeg P., History of oral tolerance and mucosal immunity, Ann NY Acad Sci., 778, pp. 1-27, (1996); Gorbach S.L., Intestinal microflora, Gastroenterology, 60, pp. 1110-1129, (1971); Plaut A.G., Gorbach S.L., Nahas L., Et al., Intestinal microflora. 3. The microbial flora of human small intestinal mucosa, Gastroenterology, 53, pp. 868-873, (1967); Dear K.L., Elia M., Hunter J.O., Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?, Dig Dis Sci., 50, pp. 758-766, (2005); Riordan S.M., McIver C.J., Thomas D.H., Et al., Luminal bacteria and small intestinal permeability, Scand J Gastroenterol Suppl., 32, pp. 556-563, (1997); Woodcock N.P., Robertson J., Morgan D.R., Et al., Bacterial translocation and immunohistochemical measurement of gut immune function, J Clin Pathol., 54, pp. 619-623, (2001); Gwee K.A., Collins S.M., Read N.W., Et al., Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome, Gut, 52, pp. 523-526, (2003); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of post-infective bowel syndrome, Am J Gastroenterol., 98, pp. 1578-1583, (2003); O'Sullivan M., Clayton N., Breslin N.P., Et al., Increased mast cells in the irritable bowel syndrome, Neurogastroenterol Motil., 12, pp. 449-457, (2000); Spiller R.C., Jenkins D., Thomley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-811, (2000); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-1979, (2002); Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B.J., Terminal ileal mucosal mast cells in irritable bowel syndrome, Dig Dis Sci., 38, pp. 1590-1595, (1993); Chadwick V., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Marshall J.K., Thabane M., Meddings J., Et al., Increased intestinal permeability (IP) in subjects with irritable bowel syndrome (IBS) two years after the Walkerton outbreak of waterborne gastroenteritis, Gastroenterology, 126, (2004); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom response and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-551, (2005); Van der Veek P., DeKoon Y., Van den Berg M., Et al., Tumor necrosis factor alpha and interleukin 10 gene polymorphisms in irritable bowel syndrome, Gastroenterology, 126, (2004); Toskes P.P., Small intestinal bacterial overgrowth, Sleisinger and Fortran Textbook of Gastroenterology, (1989); Matsuo K., Ota H., Akamatsu T., Et al., Histochemistry of the surface mucous gel layer of the human colon, Gut, 40, pp. 782-789, (1997); Levitt M.D., Donaldson R.M., Use of respiratory hydrogen (H2) excretion to detect carbohydrate malabsorption, J Lab Clin Med., 75, pp. 937-945, (1970); Riordan S.M., McIver C.J., Walker B.M., Et al., The lactulose breath hydrogen test and small intestinal bacterial overgrowth, Am J Gastroenterol., 91, pp. 1795-1803, (1996); Galatola G., Grosso M., Barlotta A., Et al., Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinal diseases, Minerva Gastroenterol Dietol., 37, pp. 169-175, (1991); Pimentel M., Chow E.J., Lin H.C., Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study, Am J Gastroenterol., 98, pp. 412-419, (2003); Nucera G., Gabrielli M., Lupascu A., Et al., Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth, Aliment Pharmacol Ther., 21, pp. 1391-1395, (2005); Walters B., Vanner S.J., Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14C-D-xylose and healthy controls, Am J Gastroenterol., 100, pp. 1566-1570, (2005); Lupascu A., Lauritano C., Gabrielli M., Et al., Small intestinal bacterial overgrowth prevalence in irritable bowel syndrome, Gastroenterology, 128, (2005); McCallum R., Schultz C., Sostarich S., Evaluating the role of small intestinal bacterial overgrowth (sibo) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (gbt), Gastroenterology, 128, (2005); Simren M., Ringstrom G., Agerforz P., Et al., Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome, Gastroenterology, 124, (2003); Robson K.M., Kakullavarapu J., Lembo T., Bacterial overgrowth and irritable bowel syndrome: A look at prevalence, symptoms and quality of life, Am J Gastroenterol., 98, (2003); Pimentel M., Park S., Kong Y., Et al., Rifaximin, a non-absorbable antibiotic, improves the symptoms of irritable bowel syndrome: A double-blind randomized controlled study, Am J Gastroenterol., 100, 9, (2005); Vantrappen G., Jannssen J., Hellemans J., Ghoos Y., The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine, J Clin Invest., 59, pp. 1158-1166, (1977); Pimentel M., Soffer E.E., Chow E.J., Lin H.C., Lower frequency of MMC is found in IBS subjects with abnormal breath test suggesting bacterial overgrowth, Dig Dis Sci., 47, pp. 2639-2643, (2002); Pimentel M., Mayer A.G., Park S., Et al., Methane production during lactulose breath test is associated with gastrointestinal disease presentation, Dig Dis Sci., 48, pp. 86-92, (2003); Lin H.C., Pimentel M., Chen J.H., Intestinal transit is slowed by luminal methane, Neurogastroenterol Motil., 4, (2002); Pimentel M., Chatterjee S., Chow E.J., Et al., Neomycin improves C-IBS in a fashion that is dependent on the presence of methane gas: Sub-analysis of a double-blind randomized controlled study, Am J Gastroenterol^^^^^^^^^1533001X^^RGDEA^17713456.0^English^Rev. Gastroenterol. Disord.^Article^Final^^Scopus^2-s2.0-31144467842
Daguet D.; Pinheiro I.; Verhelst A.; Possemiers S.; Marzorati M.^Daguet, David (6506368748); Pinheiro, Iris (56441265800); Verhelst, An (6602779093); Possemiers, Sam (6506792414); Marzorati, Massimo (12545508300)^6506368748; 56441265800; 6602779093; 6506792414; 12545508300^Acacia gum improves the gut barrier functionality in vitro^2015^Agro Food Industry Hi-Tech^26.0^4^^29^33^4.0^4^^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943802525&partnerID=40&md5=4efd1d1c445e09f6deda5ca15dcf8106^NEXIRA SAS, 129 Chemin de Croisset, BP 4151, Rouen Cedex 3, 76723, France; ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Laboratory of Microbial Ecology and Technology (LabMET), Ghent University, Coupure Links 653, Ghent, 9000, Belgium^Daguet D., NEXIRA SAS, 129 Chemin de Croisset, BP 4151, Rouen Cedex 3, 76723, France; Pinheiro I., ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Verhelst A., ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Possemiers S., ProDigest BVBA, Technologiepark 4, Ghent, 9052, Belgium; Marzorati M., Laboratory of Microbial Ecology and Technology (LabMET), Ghent University, Coupure Links 653, Ghent, 9000, Belgium^The Leaky Gut Syndrome - impairment of the gut wall functionality - is involved in many inflammatory diseases, among them IBS. The aim of this work was to evaluate the effect of arabinogalactan (AG) and fructo-oligosaccharides (FOS) on gut wall modulation using a Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) - inoculated with faecal material from an IBS donor - coupled with co-cultures of enterocytes and macrophages (transwell approach using Caco-2 and THP1 cells). AG and FOS showed a different fermentation profile (more proximal for FOS and distal for AG) and both fibres exerted a potential positive effect on gut barrier (increased TEER parameter) and inflammation (modulation of cytokines IL-8, IL-6, IL-10 and NF-κB) in their main area of fermentation. AG could be an interesting nutritional supplement for the treatment of those conditions characterized by inflammation and increased permeability in the distal colon.^Colonic fermentation; Fibregum; Gut inflammation; Gut permeability; IBS; SHIME®^Fermentation; Modulation; Pathology; Arabinogalactan; Fibregum; Fructo-oligosaccharides; Gut inflammation; IBS; Inflammatory disease; Microbial eco system; Nutritional supplements; Food additives^^^^^^^"Chey W.D., Maneerattaporn M., Saad R., Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome, Gut and Liver, 5, 3, pp. 253-266, (2011); Heitkemper M., Jarrett M., Jun S.E., Update on irritable bowel syndrome program of research, Journal of Korean Academy of Nursing, 43, 5, pp. 579-586, (2013); Guarner F., Casellas F., Borruel N., Et al., Role of microecology in chronic inflammatory bowel diseases, European Journal of Clinical Nutrition, 56, pp. S34-S38, (2002); Rescigno M., The intestinal epithelial barrier in the control of homeostasis and immunity, Trends Immunol, 32, 6, pp. 256-264, (2011); Gecse K., Roka R., Sera T., Et al., Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis, Digestion, 85, 1, pp. 40-46, (2012); Groschwitz K.R., Hogan S.P., Intestinal barrier function: Molecular regulation and disease pathogenesis, Journal of Allergy and Clinical Immunology, 124, 1, pp. 3-20, (2009); Maes M., Wisk F T., Chronic Fatigue Syndrome: La bete noire of the Belgian Health Care System, Neuroendocrinology Letters, 30, 3, pp. 300-311, (2009); Fasano A., Zonulin and its regulation of intestinal barrier function: The biological door to inflammation, autoimmunity, and cancer, Physiological Reviews, 91, 1, pp. 151-175, (2011); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterology and Motility, 24, 6, pp. 503-512, (2012); Vaarala O., Atkinson M.A., Neu J., The ""perfect storm"" for type 1 diabetes - The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity, Diabetes, 57, 10, pp. 2555-2562, (2008); Hartmann P., Chen P., Wang H.J., Et al., Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice, Hepatology, 58, 1, pp. 108-119, (2013); Fasano A., Leaky gut and autoimmune diseases, Clinical Reviews in Allergy & Immunology, 42, 1, pp. 71-78, (2012); Zhang Y.Z., Li Y.Y., Inflammatory bowel disease: Pathogenesis, World Journal of Gastroenterology, 20, 1, pp. 91-99, (2014); Major G., Spiller R., Irritable bowel syndrome, inflammatory bowel disease and the microbiome, Current Opinion in Endocrinology Diabetes and Obesity, 21, 1, pp. 15-21, (2014); Terpend K., Possemiers S., Daguet D., Et al., Arabinogalactan and fructo-oligosaccharides have a different fermentation profile in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME), Environmental Microbiology Reports, 5, 4, pp. 595-603, (2013); Marzorati M., Qin B., Hildebrand F., Et al., Addition of acacia gum to a FOS/inulin blend improves its fermentation profile in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), J Funct Food, 16, pp. 211-222, (2015); Possemiers S., Pinheiro I., Verhelst A., Et al., A Dried Yeast Fermentate Selectively Modulates both the Luminal and Mucosal Gut Microbiota and Protects against Inflammation, As Studied in an Integrated in Vitro Approach, Journal of Agricultural and Food Chemistry, 61, 39, pp. 9380-9392, (2013); Menzies A.R., Osman M.E., Malik A.A., Et al., A comparison of the physicochemical and immunological properties of the plant gum exudates of Acacia Senegal (gum Arabic) and Acacia seyal (gum tahla), Food Additives and Contaminants, 13, 8, pp. 991-999, (1996); Van De Wiel E.T., Boon N., Possemiers S., Et al., Prebiotic effects of chicory inulin in the simulator of the human intestinal microbial ecosystem, FEMS Microbiology Ecology, 51, pp. 143-153, (2004); Tsuchiya S., Kobayashi Y., Goto Y., Et al., Induction of Maturation in Cultured Human Monocytic Leukemia-Cells by a Phorbol Diester, Cancer Research, 42, 4, pp. 1530-1536, (1982); Schwende H., Fitzke E., Ambs P., Et al., Differences in the state of differentiation of THP-1 cells induced by phorbol ester and 1,25-dihydroxyvitamin D-3, Journal of Leukocyte Biology, 59, 4, pp. 555-561, (1996); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Wullaert A., Bonnet M.C., Pasparakis M., NF-kappa B in the regulation of epithelial homeostasis and inflammation, Cell Research, 21, 1, pp. 146-158, (2011); Pasparakis M., IKK/NF-kappa B signaling in intestinal epithelial cells controls immune homeostasis in the gut, Mucosal Immunology, 1, pp. S54-S57, (2008); Wong J.M.W., De Souza R., Kendall C.W.C., Et al., Colonic health: Fermentation and short chain fatty acids, Journal of Clinical Gastroenterology, 40, 3, pp. 235-243, (2006); Vinolo M.A.R., Rodrigues H.G., Nachbar R.T., Et al., Regulation of inflammation by short chain fatty acids, Nutrients, 3, 10, pp. 858-876, (2011); Puertollano E., Kolida S., Yaqoob P., Biological significance of shortchain fatty acid metabolism by the intestinal microbiome, Curr Opin Clin Nutr Metab Care, 17, 2, pp. 139-144, (2014)"^^^TeknoScienze^^^^^^17226996^^^^English^Agro Food Ind. Hi-Tech^Article^Final^^Scopus^2-s2.0-84943802525
Martín R.; Chain F.; Miquel S.; Natividad J.M.; Sokol H.; Verdu E.F.; Langella P.; Bermúdez-Humarán L.G.^Martín, Rebeca (24179115600); Chain, Florian (15070399500); Miquel, Sylvie (23009469300); Natividad, Jane M. (23470366600); Sokol, Harry (14421842400); Verdu, Elena F. (8109011300); Langella, Philippe (7003598187); Bermúdez-Humarán, Luis G. (6602243913)^24179115600; 15070399500; 23009469300; 23470366600; 14421842400; 8109011300; 7003598187; 6602243913^Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation^2014^Human Vaccines and Immunotherapeutics^10.0^6^^1611^1621^10.0^68^10.4161/hv.28549^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899876481&doi=10.4161%2fhv.28549&partnerID=40&md5=5ba60f9be4eef23f300f1b567ab9c6ce^INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France; AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada; Department of Gastroenterology and Nutrition, Hôpital Saint-Antoine F-75012, UPMC Univ Paris, Paris, France; INSERM, Equipe AVENIR U1057, UMR CNRS 7203, Paris, France^Martín R., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Chain F., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Miquel S., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Natividad J.M., Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada; Sokol H., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France, Department of Gastroenterology and Nutrition, Hôpital Saint-Antoine F-75012, UPMC Univ Paris, Paris, France, INSERM, Equipe AVENIR U1057, UMR CNRS 7203, Paris, France; Verdu E.F., Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada; Langella P., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France; Bermúdez-Humarán L.G., INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France, AgroParisTech, UMR1319 Micalis, Jouy-en-Josas, France^"Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic abdominal pain, discomfort, and bloating. Interestingly, there is now evidence of the presence of a low-grade inflammatory status in many IBS patients, including histopathological and mucosal cytokine levels in the colon, as well as the presence of IBS-like symptoms in quiescent inflammatory bowel disease (IBD). The use of a genetically engineered food-grade bacterium, such as Lactococcus lactis, secreting the anti-inflammatory cytokine IL-10 has been proven by many pre-clinical studies to be a successful therapy to treat colon inflammation. In this study, we first reproduced the recovery-recurrence periods observed in IBS-patients in a new chronic model characterized by 2 episodes of DiNitro-BenzeneSulfonic-acid (DNBS)-challenge and we tested the effects of a recombinant strain of L. lactis secreting IL-10 under a Stress-Inducible Controlled Expression (SICE) system. In vivo gut permeability, colonic serotonin levels, cytokine profiles, and spleen cell populations were then measured as readouts of a low-grade inflammation. In addition, since there is increasing evidence that gut microbiota tightly regulates gut barrier function, tight junction proteins were also measured by qRT-PCR after administration of recombinant L. lactis in DNBS-treated mice. Strikingly, oral administration of L. lactis secreting active IL-10 in mice resulted in significant protective effects in terms of permeability, immune activation, and gut-function parameters. Although genetically engineered bacteria are, for now, used only as a ""proof-of-concept,"" our study validates the interest in the use of the novel SICE system in L. lactis to express therapeutic molecules, such as IL-10, locally at mucosal surfaces. © 2014 Landes Bioscience."^Genetically engineered bacteria; Gut hyperpermeability; IBS; IL-10; Lactococcis lactis; Probiotic^Animals; Biological Therapy; Colitis; Cytokines; Disease Models, Animal; Gene Expression Profiling; Humans; Immunologic Factors; Immunotherapy; Interleukin-10; Lactococcus lactis; Male; Mice, Inbred C57BL; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Serotonin; Spleen; Treatment Outcome; claudin 4; interleukin 10; occludin; protein ZO1; serotonin; tight junction protein; uvomorulin; cytokine; immunologic factor; interleukin 10; recombinant protein; serotonin; animal cell; animal experiment; animal model; animal tissue; article; bacterial strain; cell population; colitis; controlled study; cytokine production; drug effect; immunostimulation; in vivo study; intestine mucosa permeability; Lactococcus lactis; male; mouse; nonhuman; nucleotide sequence; quantitative analysis; reverse transcription polymerase chain reaction; spleen cell; animal; biological therapy; C57BL mouse; colitis; disease model; gene expression profiling; genetics; growth, development and aging; human; immunology; immunotherapy; Lactococcus lactis; metabolism; pathology; procedures; real time polymerase chain reaction; spleen; treatment outcome^GENBANK: NM_008084, NM_008756, NM_009864, NM_009902, NM_009903, NM_013805, NM_016674, NM_016675, NM_021719, NM_172647^occludin, 176304-61-3; serotonin, 50-67-9; uvomorulin, 112956-45-3; Cytokines, ; Immunologic Factors, ; Interleukin-10, ; Recombinant Proteins, ; Serotonin, ^^^Merck Médication Familiale; Saint Etienne de Chomeil; Vitagora Competitive Cluster; Crohn's and Colitis Foundation of Canada, CCFC; Fonds Unique Interministériel, FUI, (F1010012D); Fonds Unique Interministériel, FUI; European Regional Development Fund, ERDF, (34606); European Regional Development Fund, ERDF^This study was a part of FPARIS collaborative project selected and supported by the Vitagora Competitive Cluster and funded by the French FUI (Fond Unique Interministériel; FUI: n°F1010012D), the FEDER (Fonds Européen de Développement Régional; Bourgogne: 34606), the Burgundy Region, the Conseil Général 21, and the Grand Dijon. This work was also supported by Merck Médication Familiale (Dijon, France) and Biovitis (Saint Etienne de Chomeil, France). R.M. receives a salary from the same grants. E.F.V. holds a Canada Research Chair. The work was partially funded by a CCFC grant to P.L. and E.F.V. Authors would like to thank Jean Jacques Gratadoux and all UEAR personal for their technical help.^Collins S.M., Is the irritable gut an inflamed gut?, Scand J Gastroenterol Suppl, 192, pp. 102-105, (1992); Khan S., Chang L., Diagnosis and management of IBS, Nat Rev Gastroenterol Hepatol, 7, pp. 565-581, (2010); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Ohman L., Simren M., New insights into the pathogenesis and pathophysiology of irritable bowel syndrome, Dig Liver Dis, 39, pp. 201-215, (2007); Marshall J.K., Thabane M., Garg A.X., Clark W., Meddings J., Collins S.M., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Akiho H., Ihara E., Nakamura K., Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome, World J Gastrointest Pathophysiol, 1, pp. 97-105, (2010); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., Et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, (2013); Halpin S.J., Ford A.C., Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: Systematic review and meta-analysis, Am J Gastroenterol, 107, pp. 1474-1482, (2012); Simren M., Axelsson J., Gillberg R., Abrahamsson H., Svedlund J., Bjornsson E.S., Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors, Am J Gastroenterol, 97, pp. 389-396, (2002); Bermudez-Humaran L.G., Aubry C., Motta J.P., Deraison C., Steidler L., Vergnolle N., Chatel J.M., Langella P., Engineering lactococci and lactobacilli for human health, Curr Opin Microbiol, 16, pp. 278-283, (2013); Seegers J.F., Lactobacilli as live vaccine delivery vectors: Progress and prospects, Trends Biotechnol, 20, pp. 508-515, (2002); Lee S.F., Halperin S.A., Salloum D.F., MacMillan A., Morris A., Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein, Infect Immun, 71, pp. 2272-2275, (2003); Cortes-Perez N.G., Bermudez-Humaran L.G., Le Loir Y., Rodriguez-Padilla C., Gruss A., Saucedo-Cardenas O., Langella P., Montes-de-Oca-Luna R., Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein, FEMS Microbiol Lett, 229, pp. 37-42, (2003); Bermudez-Humaran L.G., Langella P., Cortes-Perez N.G., Gruss A., Tamez-Guerra R.S., Oliveira S.C., Saucedo-Cardenas O., Montes De Oca-Luna R., Le Loir Y., Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production, Infect Immun, 71, pp. 1887-1896, (2003); Bermudez-Humaran L.G., Cortes-Perez N.G., Le Loir Y., Alcocer-Gonzalez J.M., Tamez-Guerra R.S., De Oca-Luna R.M., Langella P., An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci, J Med Microbiol, 53, pp. 427-433, (2004); Grangette C., Muller-Alouf H., Goudercourt D., Geoffroy M.C., Turneer M., Mercenier A., Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum, Infect Immun, 69, pp. 1547-1553, (2001); Kruger C., Hu Y., Pan Q., Marcotte H., Hultberg A., Delwar D., Van Dalen P.J., Pouwels P.H., Leer R.J., Kelly C.G., Et al., In situ delivery of passive immunity by lactobacilli producing single-chain antibodies, Nat Biotechnol, 20, pp. 702-706, (2002); Robinson K., Chamberlain L.M., Schofield K.M., Wells J.M., Le Page R.W., Oral vaccination of mice against tetanus with recombinant Lactococcus lactis, Nat Biotechnol, 15, pp. 653-657, (1997); Steidler L., Neirynck S., Huyghebaert N., Snoeck V., Vermeire A., Goddeeris B., Cox E., Remon J.P., Remaut E., Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10, Nat Biotechnol, 21, pp. 785-789, (2003); Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., Fiers W., Remaut E., Treatment of murine colitis by Lactococcus lactis secreting interleukin-10, Science, 289, pp. 1352-1355, (2000); Schotte L., Steidler L., Vandekerckhove J., Remaut E., Secretion of biologically active murine interleukin-10 by Lactococcus lactis, Enzyme Microb Technol, 27, pp. 761-765, (2000); Benbouziane B., Ribelles P., Aubry C., Martin R., Kharrat P., Riazi A., Langella P., Bermudez-Humaran L.G., Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces, J Biotechnol, 168, pp. 120-129, (2013); Martin R., Chain F., Miquel S., Lu J., Gratadoux J.J., Sokol H., Verdu E.F., Bercik P., Bermudez-Humaran L.G., Langella P., The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models, Inflamm Bowel Dis, 20, pp. 417-430, (2014); Martin R., Miquel S., Ulmer J., Kechaou N., Langella P., Bermudez-Humaran L.G., Role of commensal and probiotic bacteria in human health: A focus on inflammatory bowel disease, Microb Cell Fact, 12, (2013); Motta J.P., Bermudez-Humaran L.G., Deraison C., Martin L., Rolland C., Rousset P., Boue J., Dietrich G., Chapman K., Kharrat P., Et al., Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis, Sci Transl Med, 4, (2012); Galipeau H.J., Wiepjes M., Motta J.P., Schulz J.D., Jury J., Natividad J.M., Pinto-Sanchez I., Sinclair D., Rousset P., Martin-Rosique R., Et al., Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders, Am J Gastroenterol, (2014); Foligne B., Dessein R., Marceau M., Poiret S., Chamaillard M., Pot B., Simonet M., Daniel C., Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein, Gastroenterology, 133, pp. 862-874, (2007); Smelt M.J., De Haan B.J., Bron P.A., Van Swam I., Meijerink M., Wells J.M., Faas M.M., De Vos P., L. Plantarum, L. Salivarius, and L. Lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner, PLoS One, 7, (2012); Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., Gratadoux J.J., Rodriguez-Padilla C., Tamez-Guerra R.S., Corthier G., Et al., A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors, J Immunol, 175, pp. 7297-7302, (2005); Shashidharamurthy R., Machiah D., Aitken J.D., Putty K., Srinivasan G., Chassaing B., Parkos C.A., Selvaraj P., Vijay-Kumar M., Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice, Arthritis Rheum, 65, pp. 1064-1073, (2013); Vijay-Kumar M., Wu H., Jones R., Grant G., Babbin B., King T.P., Kelly D., Gewirtz A.T., Neish A.S., Flagellin suppresses epithelial apoptosis and limits disease during enteric infection, Am J Pathol, 169, pp. 1686-1700, (2006); Miyauchi E.M.H., Morita H., Tanabe S., Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo, J Dairy Sci, 92, pp. 2400-2408, (2009); Mennigen R.N.K., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., Bruewer M., Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis, Am J Physiol Gastrointest Liver Physiol, 296, (2009); Coates M.D., Johnson A.C., Greenwood-Van Meerveld B., Mawe G.M., Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse, Neurogastroenterol Motil, 18, pp. 464-471, (2006); Khan W.I., Ghia J.E., Gut hormones: Emerging role in immune activation and inflammation, Clin Exp Immunol, 161, pp. 19-27, (2010); Bertrand P.P., Barajas-Espinosa A., Neshat S., Bertrand R.L., Lomax A.E., Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse, Am J Physiol Gastrointest Liver Physiol, 298, (2010); Qin H.Y., Xiao H.T., Wu J.C., Berman B.M., Sung J.J., Bian Z.X., Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats, World J Gastroenterol, 18, pp. 2481-2492, (2012); Wallace J.L., Le T., Carter L., Appleyard C.B., Beck P.L., Hapten-induced chronic colitis in the rat: Alternatives to trinitrobenzene sulfonic acid, J Pharmacol Toxicol Methods, 33, pp. 237-239, (1995); Appleyard C.B., Wallace J.L., Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs, Am J Physiol, 269, (1995); Qiu B.S., Vallance B.A., Blennerhassett P.A., Collins S.M., The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis, Nat Med, 5, pp. 1178-1182, (1999); Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis, Lab Invest, 69, pp. 238-249, (1993); Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G., Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker, J Invest Dermatol, 78, pp. 206-209, (1982); Tambuwala M.M., Cummins E.P., Lenihan C.R., Kiss J., Stauch M., Scholz C.C., Fraisl P., Lasitschka F., Mollenhauer M., Saunders S.P., Et al., Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function, Gastroenterology, 139, pp. 2093-2101, (2010)^L.G. Bermúdez-Humarán; INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, Jouy-en-Josas, France; email: luis.bermudez@jouy.inra.fr^^Landes Bioscience^^^^^^21645515^^^24732667.0^English^Hum. Vaccines Immunother.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-84899876481
Ko S.J.; Ryu B.; Kim J.; Hong B.G.; Yeo I.; Lee B.J.; Lee J.M.; Park J.W.^Ko, Seok-Jae (52363719300); Ryu, Bongha (36444287400); Kim, Jinsung (57203251776); Hong, Beom-Gi (52363710000); Yeo, Inkwon (8209765300); Lee, Beom-Joon (35299944200); Lee, Jin-Moo (54792039400); Park, Jae-Woo (57193414960)^52363719300; 36444287400; 57203251776; 52363710000; 8209765300; 35299944200; 54792039400; 57193414960^Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: study protocol for a randomized controlled trial.^2011^Trials^12.0^^219^219^^^18^10.1186/1745-6215-12-219^https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053532829&doi=10.1186%2f1745-6215-12-219&partnerID=40&md5=2c054747cf3c9a7bf0b7a89bbeea16d6^Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.^Ko S.J., Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, Seoul, Republic of Korea.; Ryu B.; Kim J.; Hong B.G.; Yeo I.; Lee B.J.; Lee J.M.; Park J.W.^Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by abdominal pain and change of bowel habits without organic disease. Many patients seek alternative IBS treatments because of the limitations of conventional treatments. Gwakhyangjeonggisan (GJS), a herbal formula, has long been used for alleviating diarrhea-predominant IBS (D-IBS) in traditional medicine. Duolac7S, which comprises 7 bacterial species as probiotics, has been frequently used for D-IBS. Although GJS and Duolac7S have been administered simultaneously in many D-IBS patients, no study has investigated the effects of GJS and Duolac7S combination therapy on D-IBS. The current trial is a randomized, double-blinded, placebo-controlled, 4-arm study. After a 2-week run-in period, 60 patients with D-IBS will be randomly assigned to one of the 4 combination groups consisting of GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day) or their placebos and followed up for 2 weeks. The assigned treatments will last for 8 weeks. The primary outcomes are adequate relief of IBS pain and discomfort and the proportion of responders (on a weekly basis). The secondary outcomes are visual analog scale for IBS symptoms (on a daily basis), quality of life (at 0, 8, and 10 weeks), intestinal permeability, and composition of intestinal microbiota (at 0 and 8 weeks). The present study is designed to examine the safety and efficacy of GJS and Duolac7S combination therapy on D-IBS. Our study provides the clinical evidence of a new therapeutic strategy for D-IBS.^^Adolescent; Adult; Aged; Clinical Protocols; Diarrhea; Double-Blind Method; Humans; Intestines; Irritable Bowel Syndrome; Middle Aged; Outcome Assessment (Health Care); Permeability; Plant Extracts; Probiotics; plant extract; probiotic agent; MLCS; MLOWN; adolescent; adult; aged; article; clinical protocol; clinical trial; controlled clinical trial; controlled study; diarrhea; double blind procedure; human; intestine; irritable colon; metabolism; microbiology; middle aged; outcome assessment; permeability; randomized controlled trial^^Plant Extracts, ^^^Cell Biotech Co., Ltd., (2011CBT-001)^The study was sponsored by Cell Biotech Co., Ltd., Seoul, Korea (2011CBT-001).^^^^^^^^^^17456215^^^21978382.0^English^Trials^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-80053532829
Jalanka-Tuovinen J.; Salojärvi J.; Salonen A.; Immonen O.; Garsed K.; Kelly F.M.; Zaitoun A.; Palva A.; Spiller R.C.; De Vos W.M.^Jalanka-Tuovinen, Jonna (56502248200); Salojärvi, Jarkko (12140977600); Salonen, Anne (22935234500); Immonen, Outi (36193970000); Garsed, Klara (15845718400); Kelly, Fiona M. (14830570700); Zaitoun, Abed (35497124700); Palva, Airi (7005149835); Spiller, Robin C. (7005287882); De Vos, Willem M. (35495729400)^56502248200; 12140977600; 22935234500; 36193970000; 15845718400; 14830570700; 35497124700; 7005149835; 7005287882; 35495729400^Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome^2014^Gut^63.0^11^^1737^1745^8.0^252^10.1136/gutjnl-2013-305994^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890985732&doi=10.1136%2fgutjnl-2013-305994&partnerID=40&md5=34b859625838f56aaaa35f2cd26d7a13^Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; GSK Research and Development Ltd., GlaxoSmithKline, Stevenage, United Kingdom; Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands^Jalanka-Tuovinen J., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Salojärvi J., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Salonen A., Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; Immonen O., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Garsed K., NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; Kelly F.M., GSK Research and Development Ltd., GlaxoSmithKline, Stevenage, United Kingdom; Zaitoun A., NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; Palva A., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland; Spiller R.C., NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom; De Vos W.M., Department of Veterinary Biosciences, Microbiology, University of Helsinki, PO Box 66, Helsinki, FI-00014, Finland, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland, Laboratory of Microbiology, Wageningen University, Wageningen, Netherlands^Results Microbiota analysis revealed a bacterial profile of 27 genus-like groups, providing an Index of Microbial Dysbiosis (IMD), which significantly separated patient groups and controls. Within this profile, several members of Bacteroidetes phylum were increased 12-fold in patients, while healthy controls had 35-fold more uncultured Clostridia. We showed correlations between the IMD and expression of several host gene pathways, including amino acid synthesis, cell junction integrity and inflammatory response, suggesting an impaired epithelial barrier function in IBS.; Background About 10% of patients with IBS report the start of the syndrome after infectious enteritis. The clinical features of postinfectious IBS (PI-IBS) resemble those of diarrhoea-predominant IBS (IBS-D). While altered faecal microbiota has been identified in other IBS subtypes, composition of the microbiota in patients with PI-IBS remains uncharacterised.; Objective To characterise the microbial composition of patients with PI-IBS, and to examine the associations between the faecal microbiota and a patient's clinical features.; Design Using a phylogenetic microarray and selected qPCR assays, we analysed differences in the faecal microbiota of 57 subjects from five study groups: patients with diagnosed PI-IBS, patients who 6 months after gastroenteritis had either persisting bowel dysfunction or no IBS symptoms, benchmarked against patients with IBS-D and healthy controls. In addition, the associations between the faecal microbiota and health were investigated by correlating the microbial profiles to immunological markers, quality of life indicators and host gene expression in rectal biopsies.; Conclusions The faecal microbiota of patients with PI-IBS differs from that of healthy controls and resembles that of patients with IBS-D, suggesting a common pathophysiology. Moreover, our analysis suggests a variety of host-microbe associations that may underlie intestinal symptoms, initiated by gastroenteritis.^^Adult; Feces; Female; Gastroenteritis; Gene Expression Profiling; Humans; Irritable Bowel Syndrome; Male; Microbiota; Middle Aged; Receptor Cross-Talk; adult; feces; female; gastroenteritis; gene expression profiling; human; Irritable Bowel Syndrome; male; microbiology; microflora; middle aged; pathophysiology; physiology; signal transduction^^^^^GlaxoSmithKline; Suomen Akatemia, (1141130, 118602, 137389, 141140)^^Spiller R., Aziz Q., Creed F., Et al., Guidelines on the irritable bowel syndrome: Mechanisms and practical management, Gut, 56, pp. 1770-1798, (2007); Camilleri M., Peripheral mechanisms in irritable bowel syndrome, N Engl J Med, 367, pp. 1626-1635, (2012); Saito Y.A., Mitra N., Mayer E.A., Genetic approaches to functional gastrointestinal disorders, Gastroenterology, 138, pp. 1276-1285, (2010); Koloski N.A., Jones M., Kalantar J., Et al., The brain-gut pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective population-based study, Gut, 61, pp. 1284-1290, (2012); Rodriguez L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, BMJ, 318, pp. 565-566, (1999); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Lupp C., Robertson M.L., Wickham M.E., Et al., Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae, Cell Host Microbe, 2, pp. 119-129, (2007); Rao S.S., Edwards C.A., Austen C.J., Et al., Impaired colonic fermentation of carbohydrate after ampicillin, Gastroenterology, 94, pp. 928-932, (1988); Dunlop S.P., Jenkins D., Neal K.R., Et al., Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS, Gastroenterology, 125, pp. 1651-1659, (2003); Neal K.R., Barker L., Spiller R.C., Prognosis in post-infective irritable bowel syndrome: A six year follow up study, Gut, 51, pp. 410-413, (2002); Salonen A., De Vos W.M., Palva A., Gastrointestinal microbiota in irritable bowel syndrome: Present state and perspectives, Microbiology, 156, pp. 3205-3215, (2010); Jeffery I.B., O'toole P.W., Ohman L., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Swan C., Duroudier N.P., Campbell E., Et al., Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFalpha, Gut, 62, pp. 985-994, (2013); Melzack R., The McGill Pain Questionnaire: Major properties and scoring methods, Pain, 1, pp. 277-299, (1975); Zigmond A.S., Snaith R.P., The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Spiller R.C., Humes D.J., Campbell E., Et al., The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease, Aliment Pharmacol Ther, 32, pp. 811-820, (2010); Talley N.J., Phillips S.F., Melton J., Et al., A patient questionnaire to identify bowel disease, Ann Intern Med, 111, pp. 671-674, (1989); Irizarry R.A., Bolstad B.M., Collin F., Et al., Summaries of Affymetrix GeneChip probe level data, Nucleic Acids Res, 31, (2003); Dai M., Wang P., Boyd A.D., Et al., Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data, Nucleic Acids Res, 33, (2005); Salonen A., Nikkila J., Jalanka-Tuovinen J., Et al., Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis, J Microbiol Methods, 81, pp. 127-134, (2010); Rajilic-Stojanovic M., Heilig H.G., Molenaar D., Et al., Development and application of the human intestinal tract chip, a phylogenetic microarray: Analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults, Environ Microbiol, 11, pp. 1736-1751, (2009); Jalanka-Tuovinen J., Salonen A., Nikkila J., Et al., Intestinal microbiota in healthy adults: Temporal analysis reveals individual and common core and relation to intestinal symptoms, PLoS ONE, 6, (2011); Claesson M.J., O'sullivan O., Wang Q., Et al., Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine, PLoS ONE, 4, (2009); Ufnar J.A., Wang S.Y., Christiansen J.M., Et al., Detection of the nifH gene of Methanobrevibacter smithii: A potential tool to identify sewage pollution in recreational waters, J Appl Microbiol, 101, pp. 44-52, (2006); Rinttila T., Kassinen A., Malinen E., Et al., Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR, J Appl Microbiol, 97, pp. 1166-1177, (2004); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Development C.T., R: A language and environment for statistical computing, Vienna Austria: R Foundation for Statistical Computing, (2012); Efron B., Tibshirani R., Improvements on cross-validation: The .632+ bootstrap method, J Am Stat Assoc, 92, pp. 548-560, (1997); Lozupone C., Knight R., UniFrac: A new phylogenetic method for comparing microbial communities, Appl Environ Microbiol, 71, pp. 8228-8235, (2005); Efron B., Tibshirani R., On testing the significance of sets of genes, Ann Appl Stat, 1, pp. 107-129, (2007); Subramanian A., Tamayo P., Mootha V.K., Et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci USA, 102, pp. 15545-15550, (2005); Caldas J., Gehlenborg N., Faisal A., Et al., Probabilistic retrieval and visualization of biologically relevant microarray experiments, Bioinformatics, 25, pp. i145-i153, (2009); Hansson G.C., Role of mucus layers in gut infection and inflammation, Curr Opin Microbiol, 15, pp. 57-62, (2012); Cunningham K.E., Turner J.R., Myosin light chain kinase: Pulling the strings of epithelial tight junction function, Ann N y Acad Sci, 1258, pp. 34-42, (2012); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Kashyap P.C., Marcobal A., Ursell L.K., Et al., Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice, Gastroenterology, 144, pp. 967-977, (2013); Kunkel D., Basseri R.J., Makhani M.D., Et al., Methane on breath testing is associated with constipation: A systematic review, Dig Dis Sci, 56, pp. 1612-1618, (2011); Ponnusamy K., Choi J.N., Kim J., Et al., Microbial community and metabolomic comparison of irritable bowel syndrome faeces, J Med Microbiol, 60, pp. 817-827, (2011); Parkes G.C., Rayment N.B., Hudspith B.N., Et al., Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome, Neurogastroenterol Motil, 24, pp. 31-39, (2012); Manichanh C., Eck A., Varela E., Et al., Anal gas evacuation and colonic microbiota in patients with flatulence: Effect of diet, Gut, 63, pp. 401-408, (2014); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Krogius-Kurikka L., Lyra A., Malinen E., Et al., Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers, BMC Gastroenterol, 9, (2009); Malinen E., Krogius-Kurikka L., Lyra A., Et al., Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome, World J Gastroenterol, 16, pp. 4532-4540, (2010); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1778-1783, (2002); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Mudter J., Neurath M.F., Apoptosis of T cells and the control of inflammatory bowel disease: Therapeutic implications, Gut, 56, pp. 293-303, (2007); Faure M., Moennoz D., Montigon F., Et al., Dietary threonine restriction specifically reduces intestinal mucin synthesis in rats, J Nutr, 135, pp. 486-491, (2005); Wrzosek L., Miquel S., Noordine M.L., Et al., Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent, BMC Biology, 11, (2013); Manning A.P., Thompson W.G., Heaton K.W., Et al., Towards positive diagnosis of the irritable bowel, Br Med J, 2, pp. 653-654, (1978); O'malley D., Julio-Pieper M., Gibney S.M., Et al., Distinct alterations in colonic morphology and physiology in two rat models of enhanced stress-induced anxiety and depression-like behaviour, Stress, 13, pp. 114-122, (2010)^^^BMJ Publishing Group^^^^^^00175749^^GUTTA^24310267.0^English^Gut^Article^Final^^Scopus^2-s2.0-84890985732
Hyland N.P.; Quigley E.M.M.; Brint E.^Hyland, Niall P. (15762604000); Quigley, Eamonn M.M. (7103105068); Brint, Elizabeth (6507920898)^15762604000; 7103105068; 6507920898^Microbiota-host interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions^2014^World Journal of Gastroenterology^^27^^8859^8866^7.0^87^10.3748/wjg.v20.i27.8859^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905376185&doi=10.3748%2fwjg.v20.i27.8859&partnerID=40&md5=7b84ead0284004de556b3a44e5204758^Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, 30, Ireland; Houston Methodist Hospital, Houston, 77030, TX, United States; Department of Pathology, University College Cork, Coláiste Na Hollscoile, Bóthar an Choláiste, Co. Corcaigh, Cork, 30, Ireland^Hyland N.P., Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland, Department of Pharmacology and Therapeutics, University College Cork, Cork, 30, Ireland; Quigley E.M.M., Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland, Houston Methodist Hospital, Houston, 77030, TX, United States; Brint E., Alimentary Pharmabiotic Centre, University College Cork, Cork, 30, Ireland, Department of Pathology, University College Cork, Coláiste Na Hollscoile, Bóthar an Choláiste, Co. Corcaigh, Cork, 30, Ireland^Irritable bowel syndrome (IBS) is a common, sometimes debilitating, gastrointestinal disorder worldwide. While altered gut motility and sensation, as well as aberrant brain perception of visceral events, are thought to contribute to the genesis of symptoms in IBS, a search for an underlying aetiology has, to date, proven unsuccessful. Recently, attention has been focused on the microbiota as a possible factor in the pathogenesis of IBS. Prompted by a number of clinical observations, such as the recognition of the de novo development of IBS following enteric infections, as well as descriptions of changes in colonic bacterial populations in IBS and supported by clinical responses to interventions, such as antibiotics and probiotics, that modify the microbiota, various approaches have been taken to investigating the microbiota-host response in IBS, as well as in animal models thereof. From such studies a considerable body of evidence has accumulated to indicate the activation or upregulation of both factors involved in bacterial engagement with the host as well host defence mechanisms against bacteria. Alterations in gut barrier function, occurring in response, or in parallel, to changes in the microbiota, have also been widely described and can be seen to play a pivotal role in generating and sustaining host immune responses both within and beyond the gut. In this manner a plausible hypothesis, based on an altered microbiota and/or an aberrant host response, for the pathogenesis, of at least some instances of IBS, can be generated. © 2014 Baishideng Publishing Group Inc. All rights reserved.^Epithelial barrier; Gut-brain axis; Irritable bowel syndrome; Microbiota; Toll-like receptor^Animals; Bacteria; Brain; Host-Pathogen Interactions; Humans; Immunity, Mucosal; Intestinal Mucosa; Intestines; Irritable Bowel Syndrome; Microbiota; Permeability; Signal Transduction; G protein coupled receptor; G protein coupled receptor 41; G protein coupled receptor 43; interleukin 10; interleukin 12; short chain fatty acid; toll like receptor; toll like receptor 2; toll like receptor 4; unclassified drug; uvomorulin; Article; commensal ; host pathogen interaction ; host resistance ; immune response ; immunological tolerance ; immunoregulation ; intestine epithelium cell ; intestine innervation ; irritable colon ; mucosal immunity ; nerve cell plasticity ; neuromuscular function ; nonhuman; upregulation ; animal; Bacteria; brain; host pathogen interaction; human; immunology; innervation; intestine; intestine mucosa; irritable colon; metabolism; microbiology; microflora; mucosal immunity; pathophysiology; permeability; signal transduction^^interleukin 12, 138415-13-1; toll like receptor, 409141-78-2; toll like receptor 2, 203811-81-8; toll like receptor 4, 203811-83-0; uvomorulin, 112956-45-3^^^^^Guarner F., Malagelada J.R., Gut flora in health and disease, Lancet, 361, pp. 512-519, (2003); Codling C., O'Mahony L., Shanahan F., Quigley E.M., Marchesi J.R., A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome, Dig Dis Sci, 55, pp. 392-397, (2010); Jeffery I.B., Quigley E.M., Ohman L., Simren M., O'Toole P.W., The microbiota link to irritable bowel syndrome: An emerging story, Gut Microbes, 3, pp. 572-576, (2012); Quigley E.M., Therapies aimed at the gut microbiota and inflammation: Antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies, Gastroenterol Clin North Am, 40, pp. 207-222, (2011); Choung R.S., Locke G.R., Epidemiology of IBS, Gastroenterol Clin North Am, 40, pp. 1-10, (2011); Clarke G., Quigley E.M., Cryan J.F., Dinan T.G., Irritable bowel syndrome: Towards biomarker identification, Trends Mol Med, 15, pp. 478-489, (2009); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Quigley E.M., Abdel-Hamid H., Barbara G., Bhatia S.J., Boeckxstaens G., De Giorgio R., Delvaux M., Drossman D.A., Foxx-Orenstein A.E., Guarner F., Gwee K.A., Harris L.A., Hungin A.P., Hunt R.H., Kellow J.E., Khalif I.L., Kruis W., Lindberg G., Olano C., Moraes-Filho J.P., Schiller L.R., Schmulson M., Simren M., Tzeuton C., A global perspective on irritable bowel syndrome: A consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome, J Clin Gastroenterol, 46, pp. 356-366, (2012); Quigley E.M., Bugs on the brain; brain in the gut - Seeking explanations for common gastrointestinal symptoms, Ir J Med Sci, 182, pp. 1-6, (2013); Thabane M., Kottachchi D.T., Marshall J.K., Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 26, pp. 535-544, (2007); Farhadi A., Banan A., Fields J., Keshavarzian A., Intestinal barrier: An interface between health and disease, J Gastroenterol Hepatol, 18, pp. 479-497, (2003); Goto Y., Ivanov I.I., Intestinal epithelial cells as mediators of the commensal-host immune crosstalk, Immunol Cell Biol, 91, pp. 204-214, (2013); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-816, (2007); Ulluwishewa D., Anderson R.C., McNabb W.C., Moughan P.J., Wells J.M., Roy N.C., Regulation of tight junction permeability by intestinal bacteria and dietary components, J Nutr, 141, pp. 769-776, (2011); Petersson J., Schreiber O., Hansson G.C., Gendler S.J., Velcich A., Lundberg J.O., Roos S., Holm L., Phillipson M., Importance and regulation of the colonic mucus barrier in a mouse model of colitis, Am J Physiol Gastrointest Liver Physiol, 300, pp. G327-G333, (2011); Ohland C.L., Macnaughton W.K., Probiotic bacteria and intestinal epithelial barrier function, Am J Physiol Gastrointest Liver Physiol, 298, pp. G807-G819, (2010); Natividad J.M., Verdu E.F., Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications, Pharmacol Res, 69, pp. 42-51, (2013); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Frese S.A., Benson A.K., Tannock G.W., Loach D.M., Kim J., Zhang M., Oh P.L., Heng N.C., Patil P.B., Juge N., Mackenzie D.A., Pearson B.M., Lapidus A., Dalin E., Tice H., Goltsman E., Land M., Hauser L., Ivanova N., Kyrpides N.C., Walter J., The evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri, PLoS Genet, 7, (2011); Bertiaux-Vandaele N., Youmba S.B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., Leroi A.M., Dechelotte P., Menard J.F., Ducrotte P., Coeffier M., The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype, Am J Gastroenterol, 106, pp. 2165-2173, (2011); Martinez C., Lobo B., Pigrau M., Ramos L., Gonzalez-Castro A.M., Alonso C., Guilarte M., Guila M., De Torres I., Azpiroz F., Santos J., Vicario M., Diarrhoea-predominant irritable bowel syndrome: An organic disorder with structural abnormalities in the jejunal epithelial barrier, Gut, 62, pp. 1160-1168, (2013); Villani A.C., Lemire M., Thabane M., Belisle A., Geneau G., Garg A.X., Clark W.F., Moayyedi P., Collins S.M., Franchimont D., Marshall J.K., Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis, Gastroenterology, 138, pp. 1502-1513, (2010); Nicholson J.K., Holmes E., Lindon J.C., Wilson I.D., The challenges of modeling mammalian biocomplexity, Nat Biotechnol, 22, pp. 1268-1274, (2004); Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., Liu C.H., Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 28, pp. 994-1002, (2008); Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., Filippi J., Saint-Paul M.C., Tulic M.K., Verhasselt V., Hebuterne X., Piche T., Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation, Gut, 63, pp. 744-752, (2014); Magalhaes J.G., Tattoli I., Girardin S.E., The intestinal epithelial barrier: How to distinguish between the microbial flora and pathogens, Semin Immunol, 19, pp. 106-115, (2007); Medzhitov R., Origin and physiological roles of inflammation, Nature, 454, pp. 428-435, (2008); O'Hara A.M., Shanahan F., Gut microbiota: Mining for therapeutic potential, Clin Gastroenterol Hepatol, 5, pp. 274-284, (2007); Thomas C.M., Versalovic J., Probiotics-host communication: Modulation of signaling pathways in the intestine, Gut Microbes, 1, pp. 148-163, (2010); Lyons A., O'Mahony D., O'Brien F., MacSharry J., Sheil B., Ceddia M., Russell W.M., Forsythe P., Bienenstock J., Kiely B., Shanahan F., O'Mahony L., Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models, Clin Exp Allergy, 40, pp. 811-819, (2010); Sibartie S., O'Hara A.M., Ryan J., Fanning A., O'Mahony J., O'Neill S., Sheil B., O'Mahony L., Shanahan F., Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria, BMC Immunol, 10, (2009); McCarthy J., O'Mahony L., O'Callaghan L., Sheil B., Vaughan E.E., Fitzsimons N., Fitzgibbon J., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance, Gut, 52, pp. 975-980, (2003); Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., Raz E., Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis, Gastroenterology, 126, pp. 520-528, (2004); Jijon H., Backer J., Diaz H., Yeung H., Thiel D., McKaigney C., De Simone C., Madsen K., DNA from probiotic bacteria modulates murine and human epithelial and immune function, Gastroenterology, 126, pp. 1358-1373, (2004); Sheil B., McCarthy J., O'Mahony L., Bennett M.W., Ryan P., Fitzgibbon J.J., Kiely B., Collins J.K., Shanahan F., Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis, Gut, 53, pp. 694-700, (2004); O'Mahony L., O'Callaghan L., McCarthy J., Shilling D., Scully P., Sibartie S., Kavanagh E., Kirwan W.O., Redmond H.P., Collins J.K., Shanahan F., Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans, Am J Physiol Gastrointest Liver Physiol, 290, pp. G839-G845, (2006); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: How bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, pp. 131-144, (2010); Kamdar K., Nguyen V., DePaolo R.W., Toll-like receptor signaling and regulation of intestinal immunity, Virulence, 4, pp. 207-212, (2013); Neish A.S., Gewirtz A.T., Zeng H., Young A.N., Hobert M.E., Karmali V., Rao A.S., Madara J.L., Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination, Science, 289, pp. 1560-1563, (2000); Round J.L., Lee S.M., Li J., Tran G., Jabri B., Chatila T.A., Mazmanian S.K., The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota, Science, 332, pp. 974-977, (2011); Wang Y., Devkota S., Musch M.W., Jabri B., Nagler C., Antonopoulos D.A., Chervonsky A., Chang E.B., Regional mucosaassociated microbiota determine physiological expression of TLR2 and TLR4 in murine colon, PLoS One, 5, (2010); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); McKernan D.P., Nolan A., Brint E.K., O'Mahony S.M., Hyland N.P., Cryan J.F., Dinan T.G., Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome, PLoS One, 4, (2009); Tattoli I., Petitta C., Scirocco A., Ammoscato F., Cicenia A., Severi C., Microbiota, innate immune system, and gastrointestinal muscle: Ongoing studies, J Clin Gastroenterol, 46, pp. S6-S11, (2012); Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., Fulmer A., Kiely B., Dinan T.G., Shanahan F., Quigley E.M., Mucosal cytokine imbalance in irritable bowel syndrome, Scand J Gastroenterol, 43, pp. 1467-1476, (2008); Lee B.J., Bak Y.T., Irritable bowel syndrome, gut microbiota and probiotics, J Neurogastroenterol Motil, 17, pp. 252-266, (2011); Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., Ouwehand A., Leyer G., Carcano D., Colombel J.F., Ardid D., Desreumaux P., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, pp. 35-37, (2007); Kuhn K.A., Stappenbeck T.S., Peripheral education of the immune system by the colonic microbiota, Semin Immunol, 25, pp. 364-369, (2013); Falk P.G., Hooper L.V., Midtvedt T., Gordon J.I., Creating and maintaining the gastrointestinal ecosystem: What we know and need to know from gnotobiology, Microbiol Mol Biol Rev, 62, pp. 1157-1170, (1998); O'Mahony C., Scully P., O'Mahony D., Murphy S., O'Brien F., Lyons A., Sherlock G., MacSharry J., Kiely B., Shanahan F., O'Mahony L., Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation, PLoS Pathog, 4, (2008); Ochoa-Reparaz J., Mielcarz D.W., Ditrio L.E., Burroughs A.R., Begum-Haque S., Dasgupta S., Kasper D.L., Kasper L.H., Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression, J Immunol, 185, pp. 4101-4108, (2010); Corr S.C., Li Y., Riedel C.U., O'Toole P.W., Hill C., Gahan C.G., Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118, Proc Natl Acad Sci USA, 104, pp. 7617-7621, (2007); Rea M.C., Sit C.S., Clayton E., O'Connor P.M., Whittal R.M., Zheng J., Vederas J.C., Ross R.P., Hill C., Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile, Proc Natl Acad Sci USA, 107, pp. 9352-9357, (2010); Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., Pothoulakis C., Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa, Infect Immun, 67, pp. 302-307, (1999); Ohman L., Lindmark A.C., Isaksson S., Posserud I., Strid H., Sjovall H., Simren M., B-cell activation in patients with irritable bowel syndrome (IBS), Neurogastroenterol Motil, 21, pp. 644-650, (2009); Ohman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Strid H., Sjovall H., Simren M., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Cremon C., Pallotti F., Bacchilega M., Stanghellini V., Corinaldesi R., Barbara G., Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis, Expert Rev Gastroenterol Hepatol, 2, pp. 735-740, (2008); Schoepfer A.M., Schaffer T., Seibold-Schmid B., Muller S., Seibold F., Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients, Neurogastroenterol Motil, 20, pp. 1110-1118, (2008); Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., Musial F., Dobos G.J., Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 404-410, (2009); O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M., Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-551, (2005); Diaz Heijtz R., Wang S., Anuar F., Qian Y., Bjorkholm B., Samuelsson A., Hibberd M.L., Forssberg H., Pettersson S., Normal gut microbiota modulates brain development and behavior, Proc Natl Acad Sci USA, 108, pp. 3047-3052, (2011); Neufeld K.M., Kang N., Bienenstock J., Foster J.A., Reduced anxiety-like behavior and central neurochemical change in germ-free mice, Neurogastroenterol Motil, 23, pp. 255-264, (2011); Cryan J.F., O'Mahony S.M., The microbiome-gut-brain axis: From bowel to behavior, Neurogastroenterol Motil, 23, pp. 187-192, (2011); Fleshner M., The gut microbiota: A new player in the innate immune stress response?, Brain Behav Immun, 25, pp. 395-396, (2011); Wang S.X., Wu W.C., Effects of psychological stress on small intestinal motility and bacteria and mucosa in mice, World J Gastroenterol, 11, pp. 2016-2021, (2005); Cryan J.F., Dinan T.G., Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour, Nat Rev Neurosci, 13, pp. 701-712, (2012); Desbonnet L., Garrett L., Clarke G., Kiely B., Cryan J.F., Dinan T.G., Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression, Neuroscience, 170, pp. 1179-1188, (2010); Bravo J.A., Forsythe P., Chew M.V., Escaravage E., Savignac H.M., Dinan T.G., Bienenstock J., Cryan J.F., Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve, Proc Natl Acad Sci USA, 108, pp. 16050-16055, (2011); Clarke G., Grenham S., Scully P., Fitzgerald P., Moloney R.D., Shanahan F., Dinan T.G., Cryan J.F., The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner, Mol Psychiatry, 18, pp. 666-673, (2013); Tillisch K., Labus J., Kilpatrick L., Jiang Z., Stains J., Ebrat B., Guyonnet D., Legrain-Raspaud S., Trotin B., Naliboff B., Mayer E.A., Consumption of fermented milk product with probiotic modulates brain activity, Gastroenterology, 144, pp. 1394-1401, (2013); Barajon I., Serrao G., Arnaboldi F., Opizzi E., Ripamonti G., Balsari A., Rumio C., Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia, J Histochem Cytochem, 57, pp. 1013-1023, (2009); Scirocco A., Matarrese P., Petitta C., Cicenia A., Ascione B., Mannironi C., Ammoscato F., Cardi M., Fanello G., Guarino M.P., Malorni W., Severi C., Exposure of Toll-like receptors 4 to bacterial lipopolysaccharide (LPS) impairs human colonic smooth muscle cell function, J Cell Physiol, 223, pp. 442-450, (2010); Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., Gordon J.I., Molecular analysis of commensal host-microbial relationships in the intestine, Science, 291, pp. 881-884, (2001); Verdu E.F., Bercik P., Bergonzelli G.E., Huang X.X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corthesy-Theulaz I., Collins S.M., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, pp. 826-837, (2004); Husebye E., Hellstrom P.M., Sundler F., Chen J., Midtvedt T., Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats, Am J Physiol Gastrointest Liver Physiol, 280, pp. G368-G380, (2001); Kim G., Deepinder F., Morales W., Hwang L., Weitsman S., Chang C., Gunsalus R., Pimentel M., Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath, Dig Dis Sci, 57, pp. 3213-3218, (2012); Pimentel M., Lin H.C., Enayati P., Van Den Burg B., Lee H.R., Chen J.H., Park S., Kong Y., Conklin J., Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity, Am J Physiol Gastrointest Liver Physiol, 290, pp. G1089-G1095, (2006); Lee H.R., Pimentel M., Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth, Curr Gastroenterol Rep, 8, pp. 305-311, (2006); Linden D.R., Levitt M.D., Farrugia G., Szurszewski J.H., Endogenous production of H2S in the gastrointestinal tract: Still in search of a physiologic function, Antioxid Redox Signal, 12, pp. 1135-1146, (2010); Fiorucci S., Distrutti E., Cirino G., Wallace J.L., The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver, Gastroenterology, 131, pp. 259-271, (2006); Carbonero F., Benefiel A.C., Gaskins H.R., Contributions of the microbial hydrogen economy to colonic homeostasis, Nat Rev Gastroenterol Hepatol, 9, pp. 504-518, (2012); Teague B., Asiedu S., Moore P.K., The smooth muscle relaxant effect of hydrogen sulphide in vitro: Evidence for a physiological role to control intestinal contractility, Br J Pharmacol, 137, pp. 139-145, (2002); Gallego D., Clave P., Donovan J., Rahmati R., Grundy D., Jimenez M., Beyak M.J., The gaseous mediator, hydrogen sulphide, inhibits in vitro motor patterns in the human, rat and mouse colon and jejunum, Neurogastroenterol Motil, 20, pp. 1306-1316, (2008); Salminen S., Bouley C., Boutron-Ruault M.C., Cummings J.H., Franck A., Gibson G.R., Isolauri E., Moreau M.C., Roberfroid M., Rowland I., Functional food science and gastrointestinal physiology and function, Br J Nutr, 80, pp. S147-S171, (1998); Thompson J.S., Quigley E.M., Adrian T.E., Qualitative changes in enteric flora and short-chain fatty acids after intestinal resection, Dig Dis Sci, 43, pp. 624-631, (1998); Canani R.B., Costanzo M.D., Leone L., Pedata M., Meli R., Calignano A., Potential beneficial effects of butyrate in intestinal and extraintestinal diseases, World J Gastroenterol, 17, pp. 1519-1528, (2011); Treem W.R., Ahsan N., Kastoff G., Hyams J.S., Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: In vitro studies of carbohydrate fermentation, J Pediatr Gastroenterol Nutr, 23, pp. 280-286, (1996); Soret R., Chevalier J., De Coppet P., Poupeau G., Derkinderen P., Segain J.P., Neunlist M., Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats, Gastroenterology, 138, pp. 1772-1782, (2010); Haschke G., Schafer H., Diener M., Effect of butyrate on membrane potential, ionic currents and intracellular Ca2+ concentration in cultured rat myenteric neurones, Neurogastroenterol Motil, 14, pp. 133-142, (2002); Tazoe H., Otomo Y., Kaji I., Tanaka R., Karaki S.I., Kuwahara A., Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions, J Physiol Pharmacol, 59, pp. 251-262, (2008); Lesniewska V., Rowland I., Laerke H.N., Grant G., Naughton P.J., Relationship between dietary-induced changes in intestinal commensal microflora and duodenojejunal myoelectric activity monitored by radiotelemetry in the rat in vivo, Exp Physiol, 91, pp. 229-237, (2006); Durban A., Abellan J.J., Jimenez-Hernandez N., Artacho A., Garrigues V., Ortiz V., Ponce J., Latorre A., Moya A., Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome, FEMS Microbiol Ecol, 86, pp. 581-589, (2013)^^^WJG Press^^^^^^10079327^^WJGAF^25083059.0^English^World J. Gastroenterol.^Article^Final^^Scopus^2-s2.0-84905376185
Nébot-Vivinus M.; Harkat C.; Bzioueche H.; Cartier C.; Plichon-Dainese R.; Moussa L.; Eutamene H.; Pishvaie D.; Holowacz S.; Seyrig C.; Piche T.; Theodorou V.^Nébot-Vivinus, Mylene (57217982819); Harkat, Cherryl (56199620800); Bzioueche, Hanene (55810625700); Cartier, Christel (24079526500); Plichon-Dainese, Raffaella (56199913100); Moussa, Lara (55255554900); Eutamene, Helene (55926684800); Pishvaie, Dorsa (56201065700); Holowacz, Sophie (56200615700); Seyrig, Christian (15833116800); Piche, Thierry (7004658977); Theodorou, Vassilia (55410684700)^57217982819; 56199620800; 55810625700; 24079526500; 56199913100; 55255554900; 55926684800; 56201065700; 56200615700; 15833116800; 7004658977; 55410684700^Multispecies probiotic protects gut barrier function in experimental models^2014^World Journal of Gastroenterology^20.0^22^^6832^6843^11.0^52^10.3748/wjg.v20.i22.6832^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84902182868&doi=10.3748%2fwjg.v20.i22.6832&partnerID=40&md5=b1376f860bff1b2d9b3d2ffab57f8774^Department of Immunology Pole of Biology, CHU de Nice, 06103 Nice, France; EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France; Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Groupe PiLeJe, 75015 Paris Cedex 15, 37 Quai de Grenelle, France^Nébot-Vivinus M., Department of Immunology Pole of Biology, CHU de Nice, 06103 Nice, France, EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France; Harkat C., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Bzioueche H., Department of Immunology Pole of Biology, CHU de Nice, 06103 Nice, France, EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France; Cartier C., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Plichon-Dainese R., EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France, Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Moussa L., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Eutamene H., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France; Pishvaie D., Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Holowacz S., Groupe PiLeJe, 75015 Paris Cedex 15, 37 Quai de Grenelle, France; Seyrig C., Groupe PiLeJe, 75015 Paris Cedex 15, 37 Quai de Grenelle, France; Piche T., EA 6302 'Tolérance immunitaire', Université de Nice Sophia Antipolis, 06103 Nice, France, Department of Gastroenterology, CHU de Nice, 06103 Nice, France; Theodorou V., Neuro-Gastroenterology and Nutrition Group, Toxalim UMR 1331 INRA/INPT/UPS, F-31027 Toulouse, France^Aim: To investigate the effect of the probiotic combination Lactibiane Tolerance® (LT) on epithelial barrier function in vitro and in vivo Methods: The effect of the multispecies probiotic LT was assessed on several models of epithelial barrier function both in vitro (in basal and inflammatory conditions) and in vivo [visceral hypersensitivity induced by chronic stress or by colonic perfusion of a fecal supernatant (FSN) from patients with irritable bowel syndrome (IBS)]. In vitro, we measured the permeability of confluent T84 cell monolayers incubated with or without LT by evaluating the paracellular flux of macromolecules, in basal conditions and after stimulation with lipopolysaccharide (LPS) or with conditioned medium of colonic biopsies from IBS patients (IBS-CM). In vivo, male C57/Bl6 mice received orally NaCl or LT for 15 d and were submitted to water avoidance stress (WAS) before evaluating visceral sensitivity by measuring the myoelectrical activity of the abdominal muscle and the paracellular permeability with 51Cr-EDTA. Permeability and sensitivity were also measured after colonic instillation of FSN. Tight-junctions were assessed by immunoblotting and TLR-4 expression was evaluated by immunohistochemistry Results: Incubation of T84 cell monolayers with LT in basal conditions had no significant effect on permeability (P > 0.05 vs culture medium). By contrast, addition of LT bacterial bodies (LT) completely prevented the LPS-induced increase in paracellular permeability (P < 0.01 vs LPS 10 ng/mL (LPS 10); P < 0.01 vs LPS 100 ng/mL (LPS 100), P > 0.05 vs culture medium). The effect was dose dependent as addition of 109 LT bacterial bodies induced a stronger decrease in absorbance than 106 LT (109 LT + LPS 10: -20.1% ± 13.4, P < 0.01 vs LPS 10; 106 LT + LPS 10: -11.6% ± 6.2, P < 0.01 vs LPS 10; 109 LT + LPS 100: -14.4% ± 5.5, P < 0.01 vs LPS 100; 106 LT + LPS 100: -11.6% ± 7.3, P < 0.05 vs LPS 100). Moreover, the increase in paracellular permeability induced by culturing T84 cells with conditioned medium of colonic biopsies from IBS patients (IBS-CM) was completely inhibited in the presence of 109 LT (P< 0.01 vs IBS-CM). LT also significantly prevented the epithelial disruption induced by intracolonic infusion of fecal supernatant from IBS patients (P < 0.01 vs IBS FSN) or water avoidance stress P < 0.01 vs WAS) in C57/Bl6 mice and increased the expression of occludin in vitro and in vivo, as assessed by immnunoblotting. The WAS-induced effect on visceral sensitivity was prevented by LT treatment since values obtained for all steps of colorectal distension were significantly (P < 0.01) different from the WAS group. Finally, LT downregulated the response mediated through TLR-4 in vitro (decrease in tumor necrosis factor α secretion in response to LPS: -65.8% for 109 LT and -52.5% for 106 LT, P < 0.01 vs LPS) and in vivo (inhibition of WAS induced an increase in TLR-4 expression in the LT treated mice colon, P < 0.01 vs WAS). Conclusion: The probiotic LT mix prevented the disruption to the epithelial barrier induced by LPS, stress or colonic soluble factors from IBS patients and prevented visceral hypersensitivity. © 2014 Baishideng Publishing Group Inc. All rights reserved.^Hypersensitivity; Intestinal epithelial barrier permeability; Irritable bowel syndrome; Probiotic^Animals; Cell Line; Colon; Culture Media, Conditioned; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Feces; Humans; Hyperalgesia; Inflammation Mediators; Intestinal Mucosa; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Mice, Inbred C57BL; Permeability; Probiotics; Tight Junction Proteins; Tight Junctions; Time Factors; Tissue Culture Techniques; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Visceral Pain; Lactibiane Tolerance; lipopolysaccharide; occludin; probiotic agent; protein ZO1; toll like receptor 4; tumor necrosis factor alpha; unclassified drug; autacoid; culture medium; lipopolysaccharide; probiotic agent; tight junction protein; Tlr4 protein, mouse; toll like receptor 4; tumor necrosis factor alpha; article; cell culture; cell membrane permeability; clinical assessment; colon biopsy; controlled study; feces analysis; human; human cell; hypersensitivity; immunoblotting; immunohistochemistry; intestine epithelium; intestine flora; irritable colon; myoelectric control; pathophysiology; permeability barrier; protein expression; quantitative assay; treatment outcome; animal; C57BL mouse; cell line; colon; culture medium; disease model; dose response; drug effects; epithelium cell; feces; hyperalgesia; intestine mucosa; Irritable Bowel Syndrome; male; metabolism; microbiology; permeability; tight junction; time; tissue culture technique; visceral pain^^occludin, 176304-61-3; toll like receptor 4, 203811-83-0; Culture Media, Conditioned, ; Inflammation Mediators, ; Lipopolysaccharides, ; Tight Junction Proteins, ; Tlr4 protein, mouse, ; Toll-Like Receptor 4, ; Tumor Necrosis Factor-alpha, ^Lactibiane Tolerance^^^^Brint E.K., McSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2011); Belmonte L., Beutheu Youmba S., Bertiaux-Vandaele N., Antonietti M., Lecleire S., Zalar A., Gourcerol G., Leroi A.M., Dechelotte P., Coeffier M., Ducrotte P., Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype, PLoS One, 7, (2012); Dai C., Zheng C.Q., Jiang M., Ma X.Y., Jiang L.J., Probiotics and irritable bowel syndrome, World J Gastroenterol, 19, pp. 5973-5980, (2013); Simren M., Barbara G., Flint H.J., Spiegel B.M., Spiller R.C., Vanner S., Verdu E.F., Whorwell P.J., Zoetendal E.G., Intestinal microbiota in functional bowel disorders: A Rome foundation report, Gut, 62, pp. 159-176, (2013); Sanders M.E., Guarner F., Guerrant R., Holt P.R., Quigley E.M., Sartor R.B., Sherman P.M., Mayer E.A., An update on the use and investigation of probiotics in health and disease, Gut, 62, pp. 787-796, (2013); Zareie M., Johnson-Henry K., Jury J., Yang P.C., Ngan B.Y., McKay D.M., Soderholm J.D., Perdue M.H., Sherman P.M., Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress, Gut, 55, pp. 1553-1560, (2006); Ait-Belgnaoui A., Durand H., Cartier C., Chaumaz G., Eutamene H., Ferrier L., Houdeau E., Fioramonti J., Bueno L., Theodorou V., Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats, Psychoneuroendocrinology, 37, pp. 1885-1895, (2012); Ait-Belgnaoui A., Han W., Lamine F., Eutamene H., Fioramonti J., Bueno L., Theodorou V., Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: A possible action through interaction with epithelial cell cytoskeleton contraction, Gut, 55, pp. 1090-1094, (2006); Eutamene H., Lamine F., Chabo C., Theodorou V., Rochat F., Bergonzelli G.E., Corthesy-Theulaz I., Fioramonti J., Bueno L., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); Ki Cha B., Mun Jung S., Hwan Choi C., Song I.D., Woong Lee H., Joon Kim H., Hyuk J., Kyung Chang S., Kim K., Chung W.S., Seo J.G., The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebocontrolled trial, J Clin Gastroenterol, 46, pp. 220-227, (2012); Lyra A., Krogius-Kurikka L., Nikkila J., Malinen E., Kajander K., Kurikka K., Korpela R., Palva A., Effect of a multispecies probiotic supplement on quantity of irritable bowel syndromerelated intestinal microbial phylotypes, BMC Gastroenterol, 10, (2010); Drouault-Holowacz S., Foligne B., Dennin V., Goudercourt D., Terpend K., Burckel A., Pot B., Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: In vitro and in vivo considerations, Clin Nutr, 25, pp. 994-1003, (2006); Hayasaka D., Maeda K., Ennis F.A., Terajima M., Increased permeability of human endothelial cell line EA. hy926 induced by hantavirus-specific cytotoxic T lymphocytes, Virus Res, 123, pp. 120-127, (2007); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Cremon C., Stanghellini V., De Giorgio R., Galmiche J.P., Neunlist M., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Larauche M., Bradesi S., Million M., McLean P., Tache Y., Mayer E.A., McRoberts J.A., Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats, Am J Physiol Gastrointest Liver Physiol, 294, (2008); Bjarnason I., Peters T.J., Veall N., 51Cr-EDTA test for intestinal permeability, Lancet, 2, (1984); Mangell P., Nejdfors P., Wang M., Ahrne S., Westrom B., Thorlacius H., Jeppsson B., Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability, Dig Dis Sci, 47, pp. 511-516, (2002); Behzadian M.A., Windsor L.J., Ghaly N., Liou G., Tsai N.T., Caldwell R.B., VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor, FASEB J, 17, pp. 752-754, (2003); Traweger A., Fang D., Liu Y.C., Stelzhammer W., Krizbai I.A., Fresser F., Bauer H.C., Bauer H., The tight junction-specific protein occludin is a functional target of the E3 ubiquitinprotein ligase itch, J Biol Chem, 277, pp. 10201-10208, (2002); Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L., Increased faecal serine protease activity in diarrhoeic IBS patients: A colonic lumenal factor impairing colonic permeability and sensitivity, Gut, 57, pp. 591-599, (2008); Silva M.A., Porras M., Jury J., Vergara P., Perdue M.H., Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation, Inflamm Bowel Dis, 12, pp. 457-470, (2006); Annahazi A., Gecse K., Dabek M., Ait-Belgnaoui A., Rosztoczy A., Roka R., Molnar T., Theodorou V., Wittmann T., Bueno L., Eutamene H., Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice, Pain, 144, pp. 209-217, (2009); Cenac N., Andrews C.N., Holzhausen M., Chapman K., Cottrell G., Andrade-Gordon P., Steinhoff M., Barbara G., Beck P., Bunnett N.W., Sharkey K.A., Ferraz J.G., Shaffer E., Vergnolle N., Role for protease activity in visceral pain in irritable bowel syndrome, J Clin Invest, 117, pp. 636-647, (2007); Cenac N., Chin A.C., Garcia-Villar R., Salvador-Cartier C., Ferrier L., Vergnolle N., Buret A.G., Fioramonti J., Bueno L., PAR2 activation alters colonic paracellular permeability in mice via IFN-gamma-dependent and-independent pathways, J Physiol, 558, pp. 913-925, (2004); Roka R., Demaude J., Cenac N., Ferrier L., Salvador-Cartier C., Garcia-Villar R., Fioramonti J., Bueno L., Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice, Neurogastroenterol Motil, 19, pp. 57-65, (2007); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., de Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Anderson R.C., Cookson A.L., McNabb W.C., Park Z., McCann M.J., Kelly W.J., Roy N.C., Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation, BMC Microbiol, 10, (2010); Iemoli E., Trabattoni D., Parisotto S., Borgonovo L., Toscano M., Rizzardini G., Clerici M., Ricci E., Fusi A., De Vecchi E., Piconi S., Drago L., Probiotics reduce gut microbial translocation and improve adult atopic dermatitis, J Clin Gastroenterol, 46, SUPPL., (2012); Paturi G., Phillips M., Kailasapathy K., Effect of probiotic strains Lactobacillus acidophilus LAFTI L10 and Lactobacillus paracasei LAFTI L26 on systemic immune functions and bacterial translocation in mice, J Food Prot, 71, pp. 796-801, (2008); Agostini S., Goubern M., Tondereau V., Salvador-Cartier C., Bezirard V., Leveque M., Keranen H., Theodorou V., Bourdu-Naturel S., Goupil-Feuillerat N., Legrain-Raspaud S., Eutamene H., A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats, Neurogastroenterol Motil, 24, (2012)^T. Piche; Department of Gastroenterology, CHU de Nice, 06103 Nice, Hôpital Archet 2, France; email: piche.t@chu-nice.fr^^Baishideng Publishing Group Co^^^^^^10079327^^WJGAF^24944474.0^English^World J. Gastroenterol.^Article^Final^All Open Access; Green Open Access^Scopus^2-s2.0-84902182868
Belmonte L.; Beutheu Youmba S.; Bertiaux-Vandaële N.; Antonietti M.; Lecleire S.; Zalar A.; Gourcerol G.; Leroi A.-M.; Déchelotte P.; Coëffier M.; Ducrotté P.^Belmonte, Liliana (6602674697); Beutheu Youmba, Stéphanie (55152209200); Bertiaux-Vandaële, Nathalie (53363278400); Antonietti, Michel (7103185148); Lecleire, Stéphane (6602495158); Zalar, Alberto (7005655226); Gourcerol, Guillaume (6506887187); Leroi, Anne-Marie (16555385000); Déchelotte, Pierre (57201760610); Coëffier, Moïse (6603081357); Ducrotté, Philippe (7006732860)^6602674697; 55152209200; 53363278400; 7103185148; 6602495158; 7005655226; 6506887187; 16555385000; 57201760610; 6603081357; 7006732860^Role of toll like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype^2012^PLoS ONE^7.0^8^e42777^^^^120^10.1371/journal.pone.0042777^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865066764&doi=10.1371%2fjournal.pone.0042777&partnerID=40&md5=3e940dfa54f78eda58039c2c321f700f^INSERM Unit U1073, Rouen University, Rouen, France; Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France; Laboratory of Immunology, IIHema, Consejo Nacional de Investigaciones Científicas y Técnicas, Academy National of Medicine, Buenos Aires, Argentina; Gastroenterology Department, Rouen University Hospital, Rouen, France; Physiology Department, Rouen University Hospital, Rouen, France; Nutrition Unit, Rouen University Hospital, Rouen, France^Belmonte L., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Laboratory of Immunology, IIHema, Consejo Nacional de Investigaciones Científicas y Técnicas, Academy National of Medicine, Buenos Aires, Argentina; Beutheu Youmba S., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France; Bertiaux-Vandaële N., Gastroenterology Department, Rouen University Hospital, Rouen, France; Antonietti M., Gastroenterology Department, Rouen University Hospital, Rouen, France; Lecleire S., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Gastroenterology Department, Rouen University Hospital, Rouen, France; Zalar A., Gastroenterology Department, Rouen University Hospital, Rouen, France; Gourcerol G., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Physiology Department, Rouen University Hospital, Rouen, France; Leroi A.-M., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Physiology Department, Rouen University Hospital, Rouen, France; Déchelotte P., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Nutrition Unit, Rouen University Hospital, Rouen, France; Coëffier M., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Nutrition Unit, Rouen University Hospital, Rouen, France; Ducrotté P., INSERM Unit U1073, Rouen University, Rouen, France, Institute for Research and Innovation in Biomedicine, Rouen University, Rouen, France, Gastroenterology Department, Rouen University Hospital, Rouen, France^Background: The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose pathogenesis is not completely understood. Its high prevalence and the considerable effects on quality of life make IBS a disease with high social cost. Recent studies suggest that low grade mucosal immune activation, increased intestinal permeability and the altered host-microbiota interactions that modulate innate immune response, contribute to the pathophysiology of IBS. However, the understanding of the precise molecular pathophysiology remains largely unknown. Methodology and Findings: In this study our objective was to evaluate the TLR expression as a key player in the innate immune response, in the colonic mucosa of IBS patients classified into the three main subtypes (with constipation, with diarrhea or mixed). TLR2 and TLR4 mRNA expression was assessed by real time RT-PCR while TLRs protein expression in intestinal epithelial cells was specifically assessed by flow cytometry and immunofluorescence. Mucosal inflammatory cytokine production was investigated by the multiplex technology. Here we report that the IBS-Mixed subgroup displayed a significant up-regulation of TLR2 and TLR4 in the colonic mucosa. Furthermore, these expressions were localized in the epithelial cells, opening new perspectives for a potential role of epithelial cells in host-immune interactions in IBS. In addition, the increased TLR expression in IBS-M patients elicited intracellular signaling pathways resulting in increased expression of the mucosal proinflammatory cytokines IL-8 and IL1β. Conclusions: Our results provide the first evidence of differential expression of TLR in IBS patients according to the disease subtype. These results offer further support that microflora plays a central role in the complex pathophysiology of IBS providing novel pharmacological targets for this chronic gastrointestinal disorder according to bowel habits. © 2012 Belmonte et al.^^Adult; Aged; Antigens, CD14; Case-Control Studies; Colon; Cytokines; Female; Gene Expression; Humans; Inflammation Mediators; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Middle Aged; PPAR gamma; RNA, Messenger; Toll-Like Receptor 2; Toll-Like Receptor 4; Up-Regulation; gamma interferon; interleukin 1beta; interleukin 6; interleukin 8; messenger RNA; peroxisome proliferator activated receptor gamma; toll like receptor; toll like receptor 2; toll like receptor 4; tumor necrosis factor alpha; adult; aged; article; cellular distribution; clinical article; colon mucosa; constipation; controlled study; cytokine production; diarrhea; female; flow cytometry; human; human cell; human tissue; immunofluorescence test; immunostimulation; inflammation; innate immunity; intestine epithelium cell; irritable colon; male; pathophysiology; protein expression; protein function; protein localization; real time polymerase chain reaction; reverse transcription polymerase chain reaction; signal transduction; upregulation^^gamma interferon, 82115-62-6; interleukin 8, 114308-91-7; toll like receptor, 409141-78-2; toll like receptor 2, 203811-81-8; toll like receptor 4, 203811-83-0; Antigens, CD14, ; Cytokines, ; Inflammation Mediators, ; PPAR gamma, ; RNA, Messenger, ; TLR2 protein, human, ; TLR4 protein, human, ; Toll-Like Receptor 2, ; Toll-Like Receptor 4, ^^^^^Thompson W.G., Longstreth G.F., Drossman D.A., Heaton K.W., Irvine E.J., Et al., Functional bowel disorders and functional abdominal pain, Gut, 45, SUPPL. 2, (1999); Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Ohman L., Isaksson S., Lindmark A.C., Posserud I., Stotzer P.O., Et al., T-cell activation in patients with irritable bowel syndrome, Am J Gastroenterol, 104, pp. 1205-1212, (2009); Cremon C., Gargano L., Morselli-Labate A.M., Santini D., Cogliandro R.F., Et al., Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms, Am J Gastroenterol, 104, pp. 392-400, (2009); Barbara G., de Giorgio R., Stanghellini V., Cremon C., Corinaldesi R., A role for inflammation in irritable bowel syndrome?, Gut, 51, SUPPL. 1, (2002); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterol Motil, 19, pp. 545-552, (2007); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Srikanth C.V., McCormick B.A., Interactions of the intestinal epithelium with the pathogen and the indigenous microbiota: a three-way crosstalk, Interdiscip Perspect Infect Dis, 2008, (2008); Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Et al., Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components, Immunity, 11, pp. 443-451, (1999); Medzhitov R., Toll-like receptors and innate immunity, Nat Rev Immunol, 1, pp. 135-145, (2001); Takeda K., Kaisho T., Akira S., Toll-like receptors, Annu Rev Immunol, 21, pp. 335-376, (2003); Gribar S.C., Richardson W.M., Sodhi C.P., Hackam D.J., No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammation, Mol Med, 14, pp. 645-659, (2008); Lien E., Sellati T.J., Yoshimura A., Flo T.H., Rawadi G., Et al., Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products, J Biol Chem, 274, pp. 33419-33425, (1999); Kawai T., Akira S., TLR signaling, Cell Death Differ, 13, pp. 816-825, (2006); Podolsky D.K., Inflammatory bowel disease, N Engl J Med, 347, pp. 417-429, (2002); Hausmann M., Kiessling S., Mestermann S., Webb G., Spottl T., Et al., Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation, Gastroenterology, 122, pp. 1987-2000, (2002); Cario E., Podolsky D.K., Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease, Infect Immun, 68, pp. 7010-7017, (2000); Szebeni B., Veres G., Dezsofi A., Rusai K., Vannay A., Et al., Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease, J Pediatr Gastroenterol Nutr, 45, pp. 187-193, (2007); Shibolet O., Podolsky D.K., TLRs in the Gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction, Am J Physiol Gastrointest Liver Physiol, 292, (2007); Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Et al., A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response, J Clin Invest, 104, pp. 383-389, (1999); Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Et al., Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis, Gastroenterology, 124, pp. 1265-1276, (2003); Coeffier M., Claeyssens S., Hecketsweiler B., Lavoinne A., Ducrotte P., Et al., Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa, Am J Physiol Gastrointest Liver Physiol, 285, (2003); Zalar A., Figueroa M.I., Ruibal-Ares B., Bare P., Cahn P., Et al., Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART, Antiviral Res, 87, pp. 269-271, (2010); Lecleire S., Hassan A., Marion-Letellier R., Antonietti M., Savoye G., Et al., Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways, J Nutr, 138, pp. 2481-2486, (2008); Frolova L., Drastich P., Rossmann P., Klimesova K., Tlaskalova-Hogenova H., Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis, J Histochem Cytochem, 56, pp. 267-274, (2008); Brint E.K., MacSharry J., Fanning A., Shanahan F., Quigley E.M., Differential expression of toll-like receptors in patients with irritable bowel syndrome, Am J Gastroenterol, 106, pp. 329-336, (2010); McKernan D.P., Gaszner G., Quigley E.M., Cryan J.F., Dinan T.G., Altered peripheral toll-like receptor responses in the irritable bowel syndrome, Aliment Pharmacol Ther, 33, pp. 1045-1052, (2011); Sato S., Nomura F., Kawai T., Takeuchi O., Muhlradt P.F., Et al., Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways, J Immunol, 165, pp. 7096-7101, (2000); Jung H.C., Eckmann L., Yang S.K., Panja A., Fierer J., Et al., A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion, J Clin Invest, 95, pp. 55-65, (1995); Drossman D.A., Morris C.B., Hu Y., Toner B.B., Diamant N., Et al., A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator, Gastroenterology, 128, pp. 580-589, (2005); O'Hara A.M., Shanahan F., The gut flora as a forgotten organ, EMBO Rep, 7, pp. 688-693, (2006)^L. Belmonte; INSERM Unit U1073, Rouen University, Rouen, France; email: liliana.belmonte-zalar@inv.univ-rouen.fr^^^^^^^^19326203^^^23028414.0^English^PLoS ONE^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-84865066764
Xu D.; Gao J.; Gillilland III M.; Wu X.; Song I.; Kao J.Y.; Owyang C.^Xu, Dabo (55856882500); Gao, Jun (58834228300); Gillilland III, Merritt (6603428978); Wu, Xiaoyin (7407063918); Song, Il (57217272417); Kao, John Y. (55383842700); Owyang, Chung (7102742637)^55856882500; 58834228300; 6603428978; 7407063918; 57217272417; 55383842700; 7102742637^Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats^2014^Gastroenterology^146.0^2^^484^496.e4^^233^10.1053/j.gastro.2013.10.026^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892825869&doi=10.1053%2fj.gastro.2013.10.026&partnerID=40&md5=2d76559b3e6bd1a63cc2770f86698883^Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States^Xu D., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Gao J., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Gillilland III M., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Wu X., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Song I., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Kao J.Y., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; Owyang C., Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States^Background & Aims Rifaximin is used to treat patients with functional gastrointestinal disorders, but little is known about its therapeutic mechanism. We propose that rifaximin modulates the ileal bacterial community, reduces subclinical inflammation of the intestinal mucosa, and improves gut barrier function to reduce visceral hypersensitivity. Methods We induced visceral hyperalgesia in rats, via chronic water avoidance or repeat restraint stressors, and investigated whether rifaximin altered the gut microbiota, prevented intestinal inflammation, and improved gut barrier function. Quantitative polymerase chain reaction (PCR) and 454 pyrosequencing were used to analyze bacterial 16S ribosomal RNA in ileal contents from the rats. Reverse transcription, immunoblot, and histologic analyses were used to evaluate levels of cytokines, the tight junction protein occludin, and mucosal inflammation, respectively. Intestinal permeability and rectal sensitivity were measured. Results Water avoidance and repeat restraint stress each led to visceral hyperalgesia, accompanied by mucosal inflammation and impaired mucosal barrier function. Oral rifaximin altered the composition of bacterial communities in the ileum (Lactobacillus species became the most abundant) and prevented mucosal inflammation, impairment to intestinal barrier function, and visceral hyperalgesia in response to chronic stress. Neomycin also changed the composition of the ileal bacterial community (Proteobacteria became the most abundant species). Neomycin did not prevent intestinal inflammation or induction of visceral hyperalgesia induced by water avoidance stress. Conclusions Rifaximin alters the bacterial population in the ileum of rats, leading to a relative abundance of Lactobacillus. These changes prevent intestinal abnormalities and visceral hyperalgesia in response to chronic psychological stress. © 2014 by the AGA Institute.^Antibiotic; Gut Flora; Intestine; Irritable Bowel Syndrome^Administration, Oral; Animals; Biological Markers; Blotting, Western; Cytokines; DNA, Bacterial; Drug Administration Schedule; Gastrointestinal Agents; Hyperalgesia; Ileitis; Ileum; Immunohistochemistry; Intestinal Mucosa; Male; Microbiota; Neomycin; Occludin; Rats; Rats, Wistar; Restraint, Physical; Reverse Transcriptase Polymerase Chain Reaction; Rifamycins; Sequence Analysis, DNA; Stress, Psychological; Antibiotic; colorectal distention; CRD; electromyographic; EMG; Gut Flora; IBS; IFN-gamma; IL; interferon-gamma; interleukin; Intestine; irritable bowel syndrome; Irritable Bowel Syndrome; PCR; polymerase chain reaction; pregnane X receptor; PXR; RF; ribosomal RNA; rifaximin; rRNA; TNF-α; tumor necrosis factor-α; visceromotor response; VMR; WAS; water avoidance stress; interleukin 10; interleukin 17; interleukin 6; neomycin; occludin; rifaximin; RNA 16S; tight junction protein; tumor necrosis factor alpha; animal experiment; animal model; animal tissue; article; avoidance behavior; chronic stress; controlled study; enteritis; immobilization stress; immunoblotting; intestine flora; intestine mucosa; Lactobacillus; male; microbial community; nonhuman; polymerase chain reaction; priority journal; pyrosequencing; rat; reverse transcription; visceral pain^^neomycin, 11004-65-2, 1404-04-2, 1405-10-3, 8026-22-0; occludin, 176304-61-3; rifaximin, 80621-81-4, 88747-56-2^^^National Institutes of Health, NIH, (R01DK058913); National Institutes of Health, NIH; National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, (P30DK034933); National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK^Funding The studies were supported by the National Institutes of Health grants R01DK058913 and P30DK34933 . ^Pimentel M., Lembo A., Chey W.D., Et al., Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, pp. 22-32, (2011); Menees S.B., Maneerattannaporn M., Kim H.M., Et al., The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis, Am J Gastroenterol, 107, pp. 28-35, (2012); Pimentel M., Park S., Mirocha J., Et al., The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial, Ann Intern Med, 145, pp. 557-563, (2006); Ford A.C., Talley N.J., Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review, J Gastroenterol, 46, pp. 421-431, (2011); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Lauritano E.C., Valenza V., Sparano L., Et al., Small intestinal bacterial overgrowth and intestinal permeability, Scand J Gastroenterol, 45, pp. 1131-1132, (2010); Camilleri M., Madsen K., Spiller R., Et al., Intestinal barrier function in health and gastrointestinal disease, Neurogastroenterol Motil, 24, pp. 503-512, (2012); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-1322, (2004); Nobaek S., Johansson M.L., Molin G., Et al., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroenterol, 95, pp. 1231-1238, (2000); Bennett E.J., Tennant C.C., Piesse C., Et al., Level of chronic life stress predicts clinical outcome in irritable bowel syndrome, Gut, pp. 256-261, (1998); Gwee K.A., Leong Y.L., Graham C., Et al., The role of psychological and biological factors in postinfective gut dysfunction, Gut, 44, pp. 400-406, (1999); Elenkov I.J., Chrousos G.P., Stress system - Organization, physiology and immunoregulation, Neuroimmunomodulation, 13, pp. 257-267, (2006); Coutinho S.V., Plotsky P.M., Sablad M., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, (2002); Bradesi S., Schwetz I., Ennes H.S., Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, (2005); Eutamene H., Lamine F., Chabo C., Et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); O'Mahony S.M., Marchesi J.R., Scully P., Et al., Early life stress alters behavior, immunity, and microbiota in rats: Implications for irritable bowel syndrome and psychiatric illnesses, Biol Psychiatry, 65, pp. 263-267, (2009); Bailey M.T., Dowd S.E., Parry N.M., Et al., Stressor exposure disrupts commensal microbial populations in the intestines and leads to increased colonization by Citrobacter rodentium, Infect Immunity, 78, pp. 1509-1519, (2010); Scarpignato C., Pelosini I., Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic, Digestion, 73, SUPPL. 1, pp. 13-27, (2006); Jahraus C.D., Schemera B., Rynders P., Et al., Rifaximin diminishes neutropenia following potentially lethal whole-body radiation, Exp Biol Med (Maywood), 235, pp. 900-905, (2010); Zelena D., Mergl Z., Foldes A., Et al., Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint, Am J Physiol Endocrin Metab, 285, (2003); Schloss P.D., Westcott S.L., Ryabin T., Et al., Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities, Appl Environ Microbiol, 75, pp. 7537-7541, (2009); Wang Q., Fang C.H., Hasselgren P.O., Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice, Am J Physiol Regul Integr Comp Physiol, 281, (2001); Brun P., Castagliuolo I., Di Leo V., Et al., Increased intestinal permeability in obese mice: New evidence in the pathogenesis of nonalcoholic steatohepatitis, Am J Physiol Gastrointest Liver Physiol, 292, (2007); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Et al., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: Role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Grabauskas G., Xu D., Wu X., Et al., HCN2 ion channel in dorsal root ganglion neurons is responsible for visceral hypersensitivity in chronically stressed rat, Gastroenterology, 142, SUPPL. 1, (2012); Grabauskas G., Xu D., Song I., Et al., PGE<sub>2</sub> which activates HCN2 ion channel in dorsal root ganglia mediates visceral hypersensitivity in chronically stressed rats, Gastroenterology, 144, SUPPL. 1, (2013); Bailey M.T., Dowd S.E., Galley J.D., Et al., Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation, Brain Behav Immunity, 25, pp. 397-407, (2011); Hooper L.V., Wong M.H., Thelin A., Et al., Molecular analysis of commensal host-microbial relationships in the intestine, Science, 291, pp. 881-884, (2001); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Malinen E., Rinttila T., Kajander K., Et al., Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR, Am J Gastroenterol, 100, pp. 373-382, (2005); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Jeffery I.B., O'Toole P.W., Ohman L., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Collins S.M., Bercik P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease, Gastroenterology, 136, pp. 2003-2014, (2009); Zareie M., Johnson-Henry K., Jury J., Et al., Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress, Gut, 55, pp. 1553-1560, (2006); Borruel N., Carol M., Casellas F., Et al., Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria, Gut, 51, pp. 659-664, (2002); Llopis M., Antolin M., Carol M., Et al., Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa, Inflamm Bowel Dis, 15, pp. 275-283, (2009); Verdu E.F., Bercik P., Verma-Gandhu M., Et al., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, pp. 182-190, (2006); Mencarelli A., Renga B., Palladino G., Et al., Inhibition of NF-Κβ by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells, Eur J Pharmacol, 668, pp. 317-324, (2011); Jones S.A., Moore L.B., Shenk J.L., Et al., The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution, Mol Endocrinol, 14, pp. 27-39, (2000); Sharara A.I., Aoun E., Abdul-Baki H., Et al., A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence, Am J Gastroenterol, 101, pp. 326-333, (2006); Lembo A., Zakko S.F., Ferreira N.L., Et al., Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: Short-term treatment leading to long-term sustained response, Gastroenterology, 134, SUPPL. 1, (2008); Tsiotsias A., Voidarou C., Skoufos J., Et al., Stress-induced alterations in intestinal microflora, Microb Ecol Health Dis, 16, pp. 28-31, (2004); Zelena D., Mergl Z., Foldes A., Et al., Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint, Am J Physiol Endocrinol Metab, 285, (2003); Schloss P.D., Westcott S.L., Ryabin T., Et al., Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities, Appl Environ Microbiol, 75, pp. 7537-7541, (2009); Mayer E.A., The neurobiology of stress and gastrointestinal disease, Gut, 47, pp. 861-869, (2000); Coutinho S.V., Plotsky P.M., Sablad M., Et al., Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat, Am J Physiol Gastrointest Liver Physiol, 282, (2002); Bradesi S., Schwetz I., Ennes H.S., Et al., Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia, Am J Physiol Gastrointest Liver Physiol, 289, (2005)^C. Owyang; Gastroenterology Research Unit, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, 3912 Taubman Center, SPC 5362, United States; email: cowyang@med.umich.edu^^W.B. Saunders^^^^^^00165085^^GASTA^24161699.0^English^Gastroenterology^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-84892825869
Ko S.-J.; Han G.; Kim S.-K.; Seo J.-G.; Chung W.-S.; Ryu B.; Kim J.; Yeo I.; Lee B.-J.; Lee J.-M.; Park J.-W.^Ko, Seok-Jae (52363719300); Han, Gajin (36443612500); Kim, Seul-Ki (55551947100); Seo, Jae-Gu (7401784267); Chung, Won-Seok (54416964300); Ryu, Bongha (36444287400); Kim, Jinsung (57203251776); Yeo, Inkwon (8209765300); Lee, Beom-Joon (35299944200); Lee, Jin-Moo (54792039400); Park, Jae-Woo (57193414960)^52363719300; 36443612500; 55551947100; 7401784267; 54416964300; 36444287400; 57203251776; 8209765300; 35299944200; 54792039400; 57193414960^Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: A double-blind, randomized, placebo-controlled trial^2013^Evidence-based Complementary and Alternative Medicine^2013.0^^824605^^^^50^10.1155/2013/824605^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893753857&doi=10.1155%2f2013%2f824605&partnerID=40&md5=aa816b5d9fc88d4cca2a26fd98da7622^College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Cell Biotech, Co., Ltd., Gyeonggi-do, Gimpo-si 415-871, Gaegok-Ri, Wolgot-myeon, South Korea; College of Sookmyung Women's University, Yongsan-gu, Seoul 140-742, Cheongpa-dong 2-ga, South Korea; Kangnam Korean Hospital, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea^Ko S.-J., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Han G., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Kim S.-K., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Seo J.-G., Cell Biotech, Co., Ltd., Gyeonggi-do, Gimpo-si 415-871, Gaegok-Ri, Wolgot-myeon, South Korea; Chung W.-S., Cell Biotech, Co., Ltd., Gyeonggi-do, Gimpo-si 415-871, Gaegok-Ri, Wolgot-myeon, South Korea; Ryu B., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Kim J., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Yeo I., College of Sookmyung Women's University, Yongsan-gu, Seoul 140-742, Cheongpa-dong 2-ga, South Korea; Lee B.-J., Kangnam Korean Hospital, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Lee J.-M., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; Park J.-W., College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea^Introduction. Although combination therapy with herbal medicine and probiotics is gaining popularity for controlling diarrhea-dominant irritable bowel syndrome (D-IBS) symptoms, few studies have investigated its clinical effects. Materials and Methods. Fifty-three patients with D-IBS were randomly allocated into 1 of the following 4 groups: herbal medicine (Gwakhyangjeonggisan; GJS) plus probiotics (Duolac7S; DUO), GJS plus placebo DUO, placebo GJS plus DUO, and placebo GJS plus placebo DUO. The study period consisted of a 2-week run-in, 8 weeks of administration, and 2 weeks of follow-up. The primary outcomes were weekly adequate relief (AR) of overall IBS symptoms and the proportion of responders (PR) during the administration period. The secondary outcomes included individual IBS symptoms, stool assessment, and quality of life. Changes of intestinal microbiota and intestinal permeability were also analyzed. Results and Discussion. Weekly AR was not different among the 4 groups throughout the treatment period. However, the 3 treatment groups exhibited significant improvements in PR compared to the findings in the placebo group. In the intestinal microbiota assessment, herbal medicine and probiotics synergistically increased beneficial bacteria counts. Conclusion. Combination therapy with herbal medicine and probiotics appears to relieve overall IBS symptoms by synergistically increasing beneficial intestinal microbe counts. © 2013 Seok-Jae Ko et al.^^^^^^^^^Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, 5, pp. 1480-1491, (2006); Chang F.Y., The current prevalence of irritable bowel syndrome in Asia, Journal of Neurogastroenterology and Motility, 16, 4, pp. 389-400, (2010); Duracinsky M., Chassany O., How can an effective drug to treat irritable bowel syndrome be successfully developed?, Gastroenterologie Clinique et Biologique, 33, 1, (2009); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., De Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Dunlop S.P., Hebden J., Campbell E., Naesdal J., Olbe L., Perkins A.C., Spiller R.C., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, American Journal of Gastroenterology, 101, 6, pp. 1288-1294, (2006); Wu J.C.Y., Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: Facts or myths?, Gastroenterology and Hepatology, 6, 11, pp. 705-711, (2010); Kim Y.B., Kim J.H., Chae B.Y., Effects on Koakhyangieonggisan and Gamikoahyangieonggisan on the digestive and anti-allergic function, Journal of Korean Medical Society, 10, pp. 11-23, (1993); Ryu K.W., Ryu B.H., Yun H.S., Park D.W., Experimental comparative studies on the effects of Kwakhyangjeonggisan and Souminkwakhyang-jeonggisan, Journal of Korean Medical College of KyungHee University, 21, (1998); Han J.H., Kim G.B., Han I.S., Shim Y.S., Kim E.G., A clinical report of chronic diarrhea treated with GwakHyang-JungGiSan, Journal of Korean Internal Medicine, 26, pp. 889-896, (2005); Liu J.P., Yang M., Liu Y.X., Wei M.L., Grimsgaard S., Herbal medicines for treatment of irritable bowel syndrome, Cochrane Database of Systematic Reviews, 1, (2006); Cha B.K., Jung S.M., Choi C.H., Song I.-D., Lee H.W., Kim H.J., Hyuk J., Chang S.K., Kim K., Chung W.-S., Seo J.-G., The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial, Journal of Clinical Gastroenterology, 46, 3, pp. 220-227, (2012); Herbal Formula and Lactic Acid Bacteria; Ko S.-J., Ryu B., Kim J., Hong B.-G., Yeo I., Lee B.-J., Lee J.-M., Park J.-W., Effect of herbal extract granules combined with probiotic mixture on irritable bowel syndrome with diarrhea: Study protocol for a randomized controlled trial, Trials, (2011); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003); Vejdani R., Shalmani H.R.M., Mir-Fattahi M., Sajed-Nia F., Abdollahi M., Zali M.R., Alizadeh A.H.M., Bahari A., Amin G., The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: A pilot study, Digestive Diseases and Sciences, 51, 8, pp. 1501-1507, (2006); Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Lewis S.J., Heaton K.W., Stool form scale as a useful guide to intestinal transit time, Scandinavian Journal of Gastroenterology, 32, 9, pp. 920-924, (1997); Coulie B., Szarka L.A., Camilleri M., Burton D.D., McKinzie S., Stambler N., Cedarbaum J.M., Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans, Gastroenterology, 119, 1, pp. 41-50, (2000); Drossman D.A., Patrick D.L., Whitehead W.E., Toner B.B., Diamant N.E., Hu Y., Jia H., Bangdiwala S.I., Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire, American Journal of Gastroenterology, 95, 4, pp. 999-1007, (2000); Park J.M., Choi M.-G., Oh J.H., Cho Y.K., Lee I.S., Kim S.W., Choi K.Y., Chung I.-S., Cross-cultural validation of irritable bowel syndrome quality of life in Korea, Digestive Diseases and Sciences, 51, 8, pp. 1478-1484, (2006); Zhou Q., Zhang B., Nicholas Verne G., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, 1-2, pp. 41-46, (2009); Hollander D., Intestinal permeability, leaky gut, and intestinal disorders, Current Gastroenterology Reports, 1, 5, pp. 410-416, (1999); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Malinen E., Krogius-Kurikka L., Lyra A., Nikkila J., Jaaskelainen A., Rinttila T., Vilpponen-Salmela T., Von Wright A.J., Palva A., Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome, World Journal of Gastroenterology, 16, 36, pp. 4532-4540, (2010); Wang C., Nishino N., Presence of sourdough lactic acid bacteria in commercial total mixed ration silage as revealed by denaturing gradient gel electrophoresis analysis, Letters in Applied Microbiology, 51, 4, pp. 436-442, (2010); Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Glasziou P., A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterology, 915, (2009); Rahimi R., Abdollahi M., Herbal medicines for the management of irritable bowel syndrome: A comprehensive review, World Journal of Gastroenterology, 18, 7, pp. 589-600, (2012); Leung W.K., Wu J.C.Y., Liang S.M., Chan L.S., Chan F.K.L., Xie H., Fung S.S.L., Hui A.J., Wong V.W.S., Che C.-T., Sung J.J.Y., Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: A randomized placebo-controlled trial, American Journal of Gastroenterology, 101, 7, pp. 1574-1580, (2006); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Camilleri M., Is there a role for probiotics in irritable bowel syndrome?, Digestive and Liver Disease, 38, SUPPL. 2, (2006); Pathmakanthan S., Li C.K.F., Cowie J., Hawkey C.J., Lactobacillus plantarum 299: Beneficial in vitro immunomodulation in cells extracted from inflamed human colon, Journal of Gastroenterology and Hepatology, 19, 2, pp. 166-173, (2004); Menard S., Candalh C., Bambou J.C., Terpend K., Cerf-Bensussan N., Heyman M., Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport, Gut, 53, 6, pp. 821-828, (2004); Chapman C.M.C., Gibson G.R., Rowland I., Health benefits of probiotics: Are mixtures more effective than single strains?, European Journal of Nutrition, 50, 1, pp. 1-17, (2011); Enck P., Zimmermann K., Menke G., Muller-Lissner S., Martens U., Klosterhalfen S., A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians, Neurogastroenterology and Motility, 20, 10, pp. 1103-1109, (2008); Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley E.M.M., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, American Journal of Gastroenterology, 101, 7, pp. 1581-1590, (2006); Niv E., Naftali T., Hallak R., Vaisman N., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study, Clinical Nutrition, 24, 6, pp. 925-931, (2005); O'Sullivan M.A., O'Morain C.A., Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study, Digestive and Liver Disease, 32, 4, pp. 294-301, (2000); Madisch A., Holtmann G., Plein K., Hotz J., Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multi-centre trial, Alimentary Pharmacology and Therapeutics, 19, 3, pp. 271-279, (2004); Wang G., Li T.-Q., Wang L., Xia Q., Chang J., Zhang Y., Wan M.-H., Guo J., Cheng Y., Huang X., Zhang R.-M., Tong-xie-ning, a Chinese herbal formula, in treatment of diarrhea-predominant irritable bowel syndrome: A prospective, randomized, double-blind, placebo-controlled trial, Chinese Medical Journal, 119, 24, pp. 2114-2119, (2006); Pan F., Zhang T., Zhang Y.-H., Xu J.-J., Chen F.-M., Effect of Tongxie Yaofang granule in treating diarrhea-predominate irritable bowel syndrome, Chinese Journal of Integrative Medicine, 15, 3, pp. 216-219, (2009); Si J.-M., Yu Y.-C., Fan Y.-J., Chen S.-J., Intestinal microecology and quality of life in irritable bowel syndrome patients, World Journal of Gastroenterology, 10, 12, pp. 1802-1805, (2004); Kassinen A., Krogius-Kurikka L., Makivuokko H., Rinttila T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A., The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly From That of Healthy Subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Fan Y.-J., Chen S.-J., Yu Y.-C., Si J.-M., Liu B., A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial, Journal of Zhejiang University Science B, 7, 12, pp. 987-991, (2006); Rajilic-Stojanovic M., Biagi E., Heilig H.G.H.J., Kajander K., Kekkonen R.A., Tims S., De Vos W.M., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, 5, pp. 1792-1801, (2011); Di Leo V., D'Inca R., Diaz-Granado N., Fries W., Venturi C., D'Odorico A., Martines D., Sturniolo G.C., Lactulose/Mannitol Test Has High Efficacy for Excluding Organic Causes of Chronic Diarrhea, American Journal of Gastroenterology, 98, 10, pp. 2245-2252, (2003); Xie Y.-C., Tang F., Experimental study on protecting intestinal barrier function of Huoxiang Zhengqi soft capsule, Zhongguo Zhong Yao Za Zhi, 29, 5, pp. 456-458, (2004)^J.-W. Park; College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, 26 Kyungheedae-ro, South Korea; email: pjw2907@khu.ac.kr^^^^^^^^17414288^^^^English^Evid.-Based Complement. Altern. Med.^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-84893753857
Mbodji K.; Torre S.; Haas V.; Déchelotte P.; Marion-Letellier R.^Mbodji, Khaly (36572131900); Torre, Stéphanie (54394666300); Haas, Verena (9737047300); Déchelotte, Pierre (57201760610); Marion-Letellier, Rachel (22951234400)^36572131900; 54394666300; 9737047300; 57201760610; 22951234400^Alanyl-glutamine restores maternal deprivation-induced TLR4 levels in a rat neonatal model^2011^Clinical Nutrition^30.0^5^^672^677^5.0^13^10.1016/j.clnu.2011.04.002^https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053629198&doi=10.1016%2fj.clnu.2011.04.002&partnerID=40&md5=36bdaf7c717c2f26a7995224f6125bc9^Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France; Department of Neonatal Medicine, Rouen University Hospital, 76000 Rouen, 1 rue de Germont, France; 10117 Berlin, Charitéplatz 1, Germany; Nutrition Unit, Rouen University Hospital, 76031 Rouen cedex, 1 rue de Germont, France^Mbodji K., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France; Torre S., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France, Department of Neonatal Medicine, Rouen University Hospital, 76000 Rouen, 1 rue de Germont, France; Haas V., 10117 Berlin, Charitéplatz 1, Germany; Déchelotte P., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France, Nutrition Unit, Rouen University Hospital, 76031 Rouen cedex, 1 rue de Germont, France; Marion-Letellier R., Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France^Background & aims: Increased intestinal permeability of Irritable bowel syndrome (IBS) patients has been recently associated with a decreased level of glutamine synthetase. Neonatal maternal deprivation (NMD) is considered as an IBS-like model. The aim of our study was to investigate whether early nutritional intervention with glutamine may attenuate the deleterious impact of early life stress on gut barrier function in NMD. Methods: 124 rat pups were separated from their dam 3 h daily during postnatal days 2-14, or left undisturbed (NS). Separated rats received by gavage either with alanyl-glutamine (GLN), an isonitrogenous amino acid mix (AA, control) or an equal amount of drinking water (H2O). Production of cytokines was measured by multiplex, expression of COX-2, PPARγ, tight junction proteins and TLR4 by western blot. Intestinal permeability was studied by Lactulose/Mannitol test. Results: Treatment of pups with GLN or AA abolished the decrease in body weight observed in NMD. Treatment with GLN decreased in the colon (i) TLR4 expression at D20, (ii) IL-2 and -10 productions at D60 (iii) protein expression of occludin at D20 compared to AA. GLN also decreased colon expression of COX2 and PPARγ at D60 compared to NS. Colon production of IFNγ is significantly reduced by GLN compared to H2O. No significant change in intestinal permeability was observed. Conclusions: These results showed that an early nutritional intervention with alanyl-glutamine specifically abolished the up-regulation of TLR4 expression in NMD. Glutamine may be evaluated as a potential treatment for IBS patients. © 2011 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.^Alanyl-glutamine; Irritable bowel syndrome; Maternal deprivation; Toll-like receptor^alanylglutamine; amino acid; claudin 1; cyclooxygenase 2; cytokine; interleukin 10; interleukin 2; lactulose; mannitol; occludin; peroxisome proliferator activated receptor gamma; toll like receptor 4; animal cell; animal experiment; animal tissue; article; controlled study; cytokine production; early intervention; early life stress; female; intestine mucosa permeability; maternal deprivation; maternal nutrition; newborn; nonhuman; protein expression; protein function; protein localization; pup (rodent); rat; Western blotting^^alanylglutamine, 39537-23-0; amino acid, 65072-01-7; claudin 1, 329338-06-9; interleukin 2, 85898-30-2; lactulose, 4618-18-2; mannitol, 69-65-8, 87-78-5; occludin, 176304-61-3; toll like receptor 4, 203811-83-0^^^^^Dapoigny M., Bellanger J., Bonaz B., Bruley des Varannes S., Bueno L., Coffin B., Et al., Irritable bowel syndrome in France: a common, debilitating and costly disorder, Eur J Gastroenterol Hepatol, 16, pp. 995-1001, (2004); Marion R., Baishanbo A., Gargala G., Francois A., Ducrotte P., Duclos C., Et al., Transient neonatal Cryptosporidium parvum infection triggers long-term jejunal hypersensitivity to distension in immunocompetent rats, Infect Immun, 74, pp. 4387-4389, (2006); Barreau F., Ferrier L., Fioramonti J., Bueno L., New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models, Pediatr Res, 62, pp. 240-245, (2007); Soderholm J.D., Yates D.A., Gareau M.G., Yang P.C., MacQueen G., Perdue M.H., Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress, Am J Physiol Gastrointest Liver Physiol, 283, (2002); Gareau M.G., Jury J., Perdue M.H., Neonatal maternal separation of rat pups results in abnormal cholinergic regulation of epithelial permeability, Am J Physiol Gastrointest Liver Physiol, 293, (2007); McKernan D.P., Nolan A., Brint E.K., O'Mahony S.M., Hyland N.P., Cryan J.F., Et al., Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models Relevant to irritable bowel syndrome, PLoS ONE, 4, (2009); Le Mandat Schultz A., Bonnard A., Barreau F., Aigrain Y., Pierre-Louis C., Berrebi D., Et al., Expression of TLR-2, TLR-4, NOD2 and pNF-kappaB in a neonatal rat model of necrotizing enterocolitis, PLoS ONE, 2, (2007); Jilling T., Simon D., Lu J., Meng F.J., Li D., Schy R., Et al., The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis, J Immunol, 177, pp. 3273-3282, (2006); Zhou Q., Souba W.W., Croce C.M., Verne G.N., MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome, Gut, 59, pp. 775-784, (2010); Klimberg V.S., Souba W.W., The importance of intestinal glutamine metabolism in maintaining a healthy gastrointestinal tract and supporting the body's response to injury and illness, Surg Annu, 22, pp. 61-76, (1990); Souba W.W., Klimberg V.S., Plumley D.A., Salloum R.M., Flynn T.C., Bland K.I., Et al., The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection, J Surg Res, 48, pp. 383-391, (1990); Lacey J.M., Wilmore D.W., Is glutamine a conditionally essential amino acid?, Nutr Rev, 48, pp. 297-309, (1990); DeMarco V.G., Li N., Thomas J., West C.M., Neu J., Glutamine and barrier function in cultured Caco-2 epithelial cell monolayers, J Nutr, 133, pp. 2176-2179, (2003); Coeffier M., Marion-Letellier R., Dechelotte P., Potential for amino acids supplementation during inflammatory bowel diseases, Inflamm Bowel Dis, 16, pp. 518-524, (2010); Clark E.C., Patel S.D., Chadwick P.R., Warhurst G., Curry A., Carlson G.L., Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate, Gut, 52, pp. 224-230, (2003); Coeffier M., Marion R., Ducrotte P., Dechelotte P., Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut, Clin Nutr, 22, pp. 407-413, (2003); Coeffier M., Marion R., Leplingard A., Lerebours E., Ducrotte P., Dechelotte P., Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro, Cytokine, 18, pp. 92-97, (2002); Marion R., Coeffier M.M., Gargala G., Ducrotte P., Dechelotte P.P., Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells, Clin Nutr, 23, pp. 579-585, (2004); Barreau F., Ferrier L., Fioramonti J., Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, pp. 501-506, (2004); Garcia-Rodenas C.L., Bergonzelli G.E., Nutten S., Schumann A., Cherbut C., Turini M., Et al., Nutritional approach to restore impaired intestinal barrier function and growth after neonatal stress in rats, J Pediatr Gastroenterol Nutr, 43, pp. 16-24, (2006); Gareau M.G., Jury J., MacQueen G., Sherman P.M., Perdue M.H., Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation, Gut, 56, pp. 1522-1528, (2007); Eutamene H., Lamine F., Chabo C., Theodorou V., Rochat F., Bergonzelli G.E., Et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); Gareau M.G., Jury J., Yang P.C., MacQueen G., Perdue M.H., Neonatal maternal separation causes colonic dysfunction in rat pups including impaired host resistance, Pediatr Res, 59, pp. 83-88, (2006); Cario E., Podolsky D.K., Toll-like receptor signaling and its relevance to intestinal inflammation, Ann N Y Acad Sci, 1072, pp. 332-338, (2006); Kessel A., Toubi E., Pavlotzky E., Mogilner J., Coran A.G., Lurie M., Et al., Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat, Clin Exp Immunol, 151, pp. 341-347, (2008); Asehnoune K., Strassheim D., Mitra S., Kim J.Y., Abraham E., Involvement of reactive oxygen species in Toll-like receptor 4-Dependent activation of NF-{kappa}B, J Immunol, 172, pp. 2522-2529, (2004); Abreu M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function, Nat Rev Immunol, 10, pp. 131-144, (2010); Coeffier M., Gloro R., Boukhettala N., Aziz M., Lecleire S., Vandaele N., Et al., Increased proteasome-mediated degradation of occludin in irritable bowel syndrome, Am J Gastroenterol, 105, pp. 1181-1188, (2010); Piche T., Barbara G., Aubert P., Bruley des Varannes S., Dainese R., Nano J.L., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Li N., Lassman B.J., Liu Z., Liboni K., Neu J., Effects of protein deprivation on growth and small intestine morphology are not improved by glutamine or glutamate in gastrostomy-fed rat pups, J Pediatr Gastroenterol Nutr, 39, pp. 28-33, (2004); Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Colombel J.F., Et al., Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis, Gastroenterology, 124, pp. 1265-1276, (2003); Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., Et al., PPARgamma as a new therapeutic target in inflammatory bowel diseases, Gut, 55, pp. 1341-1349, (2006); Marion-Letellier R., Dechelotte P., Iacucci M., Ghosh S., Dietary modulation of peroxisome proliferator-activated receptor gamma, Gut, 58, pp. 586-593, (2009); Sato N., Moore F.A., Kone B.C., Zou L., Smith M.A., Childs M.A., Et al., Differential induction of PPAR-{gamma} by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel, Am J Physiol Gastrointest Liver Physiol, 290, (2006); Ponferrada A., Caso J.R., Alou L., Colon A., Sevillano D., Moro M.A., Et al., The role of PPAR[gamma] on restoration of colonic Homeostasis after experimental stress-induced inflammation and dysfunction, Gastroenterology, 132, pp. 1791-1803, (2007); Fiatte C., Huin C., Collet P., Plenat F., Dauca M., Schohn H., Expression of PPARgamma is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells, Int J Mol Med, 22, pp. 825-832, (2008); Anderson L., Seilhamer J., A comparison of selected mRNA and protein abundances in human liver, Electrophoresis, 18, pp. 533-537, (1997); Durand M., Sarrieau A., Aguerre S., Mormede P., Chaouloff F., Differential effects of neonatal handling on anxiety, corticosterone response to stress, and hippocampal, glucocorticoid and serotonin (5HT)2A receptors in Lewis rats, Psychoneuroendocrinology, 23, pp. 323-335, (1998); Yamasu K., Shimada Y., Sakaizumi M., Soma G., Mizuno D., Activation of the systemic production of tumor necrosis factor after exposure to acute stress, Eur Cytokine Netw, 3, pp. 391-398, (1992); Arrieta M.C., Bistritz L., Meddings J.B., Alterations in intestinal permeability, Gut, 55, pp. 1512-1520, (2006); Sodhi C.P., Shi X.H., Richardson W.M., Grant Z.S., Shapiro R.A., Prindle T., Et al., Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis, Gastroenterology, 138, pp. 185-196, (2010); Kul M., Vurucu S., Demirkaya E., Tunc T., Aydinoz S., Meral C., Et al., Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine, J Pediatr Gastroenterol Nutr, 49, pp. 85-89, (2009); Akisu M., Baka M., Huseyinov A., Kultursay N., The role of dietary supplementation with L-glutamine in inflammatory mediator release and intestinal injury in hypoxia/reoxygenation-induced experimental necrotizing enterocolitis, Ann Nutr Metab, 47, pp. 262-266, (2003)^R. Marion-Letellier; Appareil Digestif Environnement Nutrition (ADEN EA 4311), University of Rouen, I.F.R. 23, Institute of Biomedical Research, 76183 Rouen cedex, 22, boulevard Gambetta, France; email: marion_rachel@hotmail.com^^Churchill Livingstone^^^^^^02615614^^CLNUD^21570752.0^English^Clin. Nutr.^Article^Final^^Scopus^2-s2.0-80053629198
Francavilla R.; Miniello V.; Magistà A.M.; De Canio A.; Bucci N.; Gagliardi F.; Lionetti E.; Castellaneta S.; Polimeno L.; Peccarisi L.; Indrio F.; Cavallo L.^Francavilla, Ruggiero (7003676833); Miniello, Vito (6602500979); Magistà, Anna Maria (6507379244); De Canio, Angela (23970240100); Bucci, Nunzia (23969840700); Gagliardi, Francesca (7005612084); Lionetti, Elena (9247230200); Castellaneta, Stefania (6506514036); Polimeno, Lorenzo (6603697344); Peccarisi, Lucia (6505945818); Indrio, Flavia (6507823589); Cavallo, Luciano (35562814400)^7003676833; 6602500979; 6507379244; 23970240100; 23969840700; 7005612084; 9247230200; 6506514036; 6603697344; 6505945818; 6507823589; 35562814400^A randomized controlled trial of lactobacillus GG in children with functional abdominal pain^2010^Pediatrics^126.0^6^^e1445^e1452^7.0^186^10.1542/peds.2010-0467^https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649684470&doi=10.1542%2fpeds.2010-0467&partnerID=40&md5=a287c2586d1ac6fa9f93ef0f2f6aa0e5^Department of Developmental Biomedicine, University of Bari, Bari, Italy; Department of Emergency and Organ Transplantation, Gastroenterology Section, University of Bari, Bari, Italy; Department of Pediatrics, University of Catania, Catania, Italy; Department of Pediatrics, San Paolo Hospital, Bari, Italy; ASL-Bari, Bari, Italy^Francavilla R., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Miniello V., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Magistà A.M., Department of Developmental Biomedicine, University of Bari, Bari, Italy; De Canio A., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Bucci N., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Gagliardi F., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Lionetti E., Department of Pediatrics, University of Catania, Catania, Italy; Castellaneta S., Department of Pediatrics, San Paolo Hospital, Bari, Italy; Polimeno L., Department of Emergency and Organ Transplantation, Gastroenterology Section, University of Bari, Bari, Italy; Peccarisi L., ASL-Bari, Bari, Italy; Indrio F., Department of Developmental Biomedicine, University of Bari, Bari, Italy; Cavallo L., Department of Developmental Biomedicine, University of Bari, Bari, Italy^OBJECTIVE: Our aim was to determine whether Lactobacillus rhamnosus GG (LGG) relieves symptoms in children with recurrent abdominal pain. PATIENTS AND METHODS: A total of 141 children with irritable bowel syndrome (IBS) or functional pain were enrolled in 9 primary care sites and a referral center. Children entered a randomized, double-blind, placebo-controlled trial and received LGG or placebo for 8 weeks and entered follow-up for 8 weeks. The primary outcome was overall pain at the end of the intervention period. At entry and at the end of the trial, children underwent a double-sugar intestinal permeability test. RESULTS: Compared with baseline, LGG, but not placebo, caused a significant reduction of both frequency (P < .01) and severity (P < .01) of abdominal pain. These differences still were significant at the end of follow-up (P < .02 and P < .001, respectively). At week 12, treatment success was achieved in 48 children in the LGG group compared with 37 children in the placebo group (P < .03); this difference still was present at the end of follow-up (P < .03). At entry, 59% of the children had abnormal results from the intestinal permeability test; LGG, but not placebo, determined a significant decrease in the number of patients with abnormal results from the intestinal permeability testing (P < .03). These effects mainly were in children with IBS. CONCLUSIONS: LGG significantly reduces the frequency and severity of abdominal pain in children with IBS; this effect is sustained and may be secondary to improvement of the gut barrier. Copyright © 2010 by the American Academy of Pediatrics.^Abdominal pain; Intestinal barrier function; Lactobacillus rhamnosus GG; Pediatric gastroenterology; Probiotics^Abdominal Pain; Adolescent; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Irritable Bowel Syndrome; Lactobacillus rhamnosus; Male; Probiotics; Retrospective Studies; Treatment Outcome; placebo; probiotic agent; sugar; abdominal pain; article; child; clinical trial; controlled clinical trial; controlled study; disease severity; double blind procedure; drug effect; female; follow up; human; intestine mucosa permeability; irritable colon; Lactobacillus rhamnosus; major clinical study; male; priority journal; randomized controlled trial; recurrent disease^^^^^^^Scharff L., Recurrent abdominal pain in children: A review of psychological factors and treatment, Clinical Psychology Review, 17, 2, pp. 145-166, (1997); Saps M., Seshadri R., Sztainberg M., Schaffer G., Marshall B.M., Di Lorenzo C., A prospective school-based study of abdominal pain and other common somatic complaints in children, J Pediatr, 154, 3, pp. 322-326, (2009); Rasquin A., Di Lorenzo C., Forbes D., Et al., Childhood functional gastrointestinal disorders: Child/adolescent, Gastroenterology, 130, 5, pp. 1527-1537, (2006); Sanders M.R., Shepherd R.W., Cleghorn G., Woolford H., The treatment of recurrent abdominal pain in children: A controlled comparison of cognitive-behavioral family intervention and standard pediatric care, J Consult Clin Psychol, 62, 2, pp. 306-314, (1994); Weydert J.A., Ball T.M., Davis M.F., Systematic review of treatments for recurrent abdominal pain, Pediatrics, 111, 1, (2003); Huertas-Ceballos A., Logan S., Bennett C., Macarthur C., Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database Syst Rev, 1, (2008); Huertas-Ceballos A.A., Logan S., Bennett C., Macarthur C., Dietaryinterventionsforrecurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database Syst Rev, 21, (2009); Saps M., Youssef N., Miranda A., Et al., Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders, Gastroenterology, 137, 4, pp. 1261-1269, (2009); Walker W.A., Goulet O., Morelli L., Antoine J.-M., Progress in the science of probiotics: From cellular microbiology and applied immunology to clinical nutrition, European Journal of Nutrition, 45, SUPPL. 9, pp. 1-18, (2006); Brown A.C., Valiere A., Probiotics and medical nutrition therapy, Nutr Clin Care, 7, 2, pp. 56-68, (2004); Lemberg D.A., Ooi C.Y., Day A.S., Probiotics in paediatric gastrointestinal diseases, J Paediatr Child Health, 43, 5, pp. 331-336, (2007); Silva M., Jacobus N.V., Deneke C., Gorbach S.L., Antimicrobial substance from a human Lactobacillus strain, Antimicrob Agents Chemother, 31, 8, pp. 1311-2233, (1987); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 415-551, (2005); Doron S., Snydman D.R., Gorbach L., Lactobacillus GG: Bacteriology and clinical applications, Gastroenterol Clin N Am, 34, 3, pp. 483-498, (2005); Bausserman M., Michail S., The use of Lactobacillus GG in irritable bowel syndrome in children: A double-blind randomized control trial, J Pediatr, 147, 2, pp. 197-201, (2005); Gawronska A., Dziechciarz P., Horvath A., Szajewska H., A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children, Aliment Pharmacol Ther, 25, 2, pp. 177-184, (2007); Corazziari E., Bytzer P., Delvauz M., Et al., Consensus report: Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome, Aliment Pharmcol Ther, 18, 6, pp. 569-580, (2003); Rasquin-Weber A., Hyman P.E., Cucchiara S., Et al., Childhood functional gastrointestinal disorder, Gut, 45, SUPPL. 2, (1999); McGrath P.A., Seifert C.E., Speechley K.N., Booth J.C., Stitt L., Gibson M.C., A new analogue scale for assessing children's pain: An initial validation study, Pain, 64, 3, pp. 435-443, (1996); Von Baeyer C.L., Children's self-reports of pain intensity: Scale selection, limitations and interpretation, Pain Res Manag. Autumn, 11, 3, pp. 157-162, (2006); Generoso M., De Rosa M., De Rosa R., De Magistris L., Secondulfo M., Fiandra R., Carratu R., Carteni M., Cellobiose and lactulose coupled with mannitol and determined using ion-exchange chromatography with pulsed amperometric detection, are reliable probes for investigation of intestinal permeability, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 783, 2, pp. 349-357, (2003); Secondulfo M., Iafusco D., Carratu R., Et al., Ultrastructural mucosal alterations and increased intestinal permeability in nonceliac, type 1 diabetic patients, Digest Liver Dis, 36, 1, pp. 35-45, (2004); Barbara G., Stanghellini V., Cremon C., Et al., Probiotics and irritable bowel syndrome: Rationale and clinical evidence for their use, J Clin Gastroenterol, 42, SUPPL. 3, (2008); Jarrett M., Heitkemper M., Czyzewski D.I., Shulman R., Recurrent abdominal pain in children: Forerunner to adult irritable bowel syndrome?, J Soc Pediatr Nurs, 8, 3, pp. 81-89, (2003); Hotopf M., Carr S., Mayou R., Wadsworth M., Wessely S., Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study, BMJ, 316, 7139, pp. 1196-2000, (1998); Di Lorenzo C., Youssef N.N., Sigurdsson L., Scharff L., Griffiths J., Wald A., Visceral hyperalgesia in children with functional abdominal pain, Journal of Pediatrics, 139, 6, pp. 838-843, (2001); Wyatt G.M., Bayliss C.E., Lakey A.F., Bradley H.K., Hunter J.O., Jones V.A., The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptomprovoking foods, J Med Microbiol, 26, 4, pp. 295-299, (1988); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 1, pp. 24-33, (2007); Matto J., Maunuksela L., Kajander K., Palva A., Riitta K., Anna K., Saarela M., Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome - A longitudinal study in IBS and control subjects, FEMS Immunology and Medical Microbiology, 43, 2, pp. 213-222, (2005); Lammers K.M., Brigidi P., Vitali B., Gionchetti P., Rizzello F., Caramelli E., Matteuzzi D., Campieri M., Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells, FEMS Immunology and Medical Microbiology, 38, 2, pp. 165-172, (2003); Chen C.C., Louie S., Shi H.N., Walker W.A., Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis, Pediatr Res, 58, 6, pp. 1185-1191, (2005); Rousseaux C., Thuru X., Gelot A., Et al., Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors, Nat Med, 13, 1, pp. 35-37, (2007); Berger M.J., Gieteling M.J., Benninga M.A., Chronic abdominal pain in children, BMJ, 334, 7601, pp. 997-1002, (2007); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, 6, pp. 1288-1294, (2006); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, 11-12, pp. 1317-1322, (2004); Camilleri M., Gorman H., Intestinal permeability and irritable bowel syndrome, Neurogastroenterology and Motility, 19, 7, pp. 545-552, (2007); Shulman R.J., Eakin M.N., Czyzewski D.I., Jarrett M., Ou C.N., Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome, J Pediatr, 153, 5, pp. 646-650, (2008); Johnson-Henry K.C., Donato K.A., Shen-Tu G., Gordanpour M., Sherman P.M., Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function, Infection and Immunity, 76, 4, pp. 1340-1348, (2008); Seth A., Yan F., Polk D.B., Rao R.K., Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism, Am J Physiol Gastrointest Liver Physiol, 294, 4, (2008); Isolauri E., Majamaa H., Arvola T., Rantala I., Virtanen E., Arvilommi H., Lactobacillus casei strain GGreversesincreasedintestinal permeability induced by cow milk in suckling rats, Gastroenterology, 105, 6, pp. 1643-1650, (1993); Forsyth C.B., Farhadi A., Jakate S.M., Tang Y., Shaikh M., Keshavarzian A., Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis, Alcohol, 43, 2, pp. 163-172, (2009); Madsen K., Cornish A., Soper P., Et al., Probiotic bacteria enhance murine and human intestinal epithelial barrier function, Gastroenterology, 121, 3, pp. 580-591, (2001); Preidis G.A., Versalovic J., Targeting the human microbiome with antibiotics, probiotics, and prebiotics: Gastroenterology enters the metagenomics era, Gastroenterology, 136, 6, pp. 2015-2031, (2009)^R. Francavilla; Clinica Pediatrica B. Trambusti, 11-Policlinico, Bari, Piazza Giulio Cesare, Italy; email: rfrancavilla@libero.it^^^^^^^^10984275^^PEDIA^21078735.0^English^Pediatrics^Article^Final^^Scopus^2-s2.0-78649684470
Wang H.; Gong J.; Wang W.; Long Y.; Fu X.; Fu Y.; Qian W.; Hou X.^Wang, Huan (53986862000); Gong, Jing (57037621500); Wang, Wenfeng (35239196900); Long, Yanqin (15846348900); Fu, Xiaochao (57219232777); Fu, Yu (55227977000); Qian, Wei (35238189900); Hou, Xiaohua (7402838898)^53986862000; 57037621500; 35239196900; 15846348900; 57219232777; 55227977000; 35238189900; 7402838898^Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?^2014^PLoS ONE^9.0^3^e90153^^^^95^10.1371/journal.pone.0090153^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896918001&doi=10.1371%2fjournal.pone.0090153&partnerID=40&md5=2762c7e02c8a556af1eaeb3d70c9526e^Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Division of Gastroenterology, Hospital of Dongfeng Motor Company of Hubei University of Medicine, Shiyan, Hubei, China; Division of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China; Division of Culture Collection, Hubei Center of Industrial Culture Collection and Research, Wuhan, Hubei, China^Wang H., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Gong J., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Wang W., Division of Gastroenterology, Hospital of Dongfeng Motor Company of Hubei University of Medicine, Shiyan, Hubei, China; Long Y., Division of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China; Fu X., Division of Culture Collection, Hubei Center of Industrial Culture Collection and Research, Wuhan, Hubei, China; Fu Y., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Qian W., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Hou X., Division of Gastroenterology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China^Background and Aims: Research has increasingly suggested that gut flora plays an important role in the development of post-infectious irritable bowel syndrome (PI-IBS). Studies of the curative effect of probiotics for IBS have usually been positive but not always. However, the differences of treatment effects and mechanisms among probiotic stains, or mixture of them, are not clear. In this study, we compared the effects of different probiotics (Befidobacterium, Lactobacillus, Streptococcus or mixture of the three) on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model. Methods: PI-IBS model was induced by Trichinella spiralis infection in mice. Different probiotics were administered to mice after 8 weeks infection. Visceral sensitivity was measured by scores of abdominal withdrawal reflex (AWR) and the threshold intensity of colorectal distention. Colonic smooth muscle contractile response was assessed by contraction of the longitudinal muscle strips. Plasma diamine oxidase (DAO) and d-lactate were determined by an enzymatic spectrophotometry. Expression of tight junction proteins and cytokines in ileum were measured by Western blotting. Results: Compared to control mice, PI-IBS mice treated either alone with Befidobacterium or Lactobacillus (but not Streptococcus), or the mixture of the three exhibited not only decreased AWR score and contractile response, but also reduced plasma DAO and D-lactate. These probiotic treatments also suppressed the expression of proinflammatory cytokine IL-6 and IL-17 and promoted the expression of major tight junction proteins claudin-1 and occludin. The mixture of the three probiotic strains performed better than the individual in up-regulating these tight junction proteins and suppressing IL-17 expression. Conclusions: Bifidobacterium and Lactobacillus, but not Streptococcus, alleviated visceral hypersensitivity and recovered intestinal barrier function as well as inflammation in PI-IBS mouse model, which correlated with an increase of major tight junction proteins. In addition, Mixture of three species was indicated to be superior to a single one. © 2014 Wang et al.^^Animals; Bifidobacterium; Blotting, Western; Cytokines; Intestinal Mucosa; Intestines; Lactobacillus; Mice; Permeability; Probiotics; Species Specificity; Streptococcus; amine oxidase (copper containing); claudin 1; interleukin 17; interleukin 6; lactic acid; occludin; probiotic agent; cytokine; probiotic agent; animal experiment; animal model; animal tissue; article; Bifidobacterium; colon motility; controlled study; drug effect; enzyme blood level; ileum; intestine distension; intestine mucosa permeability; irritable colon; lactate blood level; Lactobacillus; male; mouse; mucosal immunity; nonhuman; protein expression; Streptococcus; trichinosis; upregulation; withdrawal reflex; animal; immunology; intestine; intestine mucosa; metabolism; permeability; physiology; species difference; Western blotting^^amine oxidase (copper containing), 9001-53-0, 9014-75-9; claudin 1, 329338-06-9; lactic acid, 113-21-3, 50-21-5; occludin, 176304-61-3; Cytokines, ^^^^^Wilson S., Roberts L., Roalfe A., Bridge P., Singh S., Prevalence of irritable bowel syndrome: A community survey, British Journal of General Practice, 54, 504, pp. 495-502, (2004); Gwee K.-A., Wee S., Wong M.-L., Png D.J.C., The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community, American Journal of Gastroenterology, 99, 5, pp. 924-931, (2004); Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E., AGA technical review on irritable bowel syndrome, Gastroenterology, 123, 6, pp. 2108-2131, (2002); Gwee K.A., Graham J.C., McKendrick M.W., Collins S.M., Marshall J.S., Walters S.J., Read N.W., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, 8995, pp. 150-153, (1996); Garcia R.L.A., Ruigomez A., Increased risk of irritable bowel syndrome after bacterial gastroenteritis: Cohort study, British Medical Journal, 318, 7183, pp. 565-566, (1999); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome, American Journal of Gastroenterology, 98, 7, pp. 1578-1583, (2003); Spiller R., Garsed K., Postinfectious irritable bowel syndrome, Gastroenterology, 136, pp. 1979-1988, (2009); Saulnier D.M., Riehle K., Mistretta T.A., Diaz M.A., Mandal D., Et al., Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1782-1791, (2011); Jeffery I.B., O'Toole P.W., Ohman L., Claesson M.J., Deane J., Et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota, Gut, 61, pp. 997-1006, (2012); Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Et al., Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, Gastroenterology, 141, pp. 1792-1801, (2011); Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Et al., The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review, Gut, 59, pp. 325-332, (2010); Whelan K., Probiotics and prebiotics in the management of irritable bowel syndrome: A review of recent clinical trials and systematic reviews, Curr Opin Clin Nutr Metab Care, 14, pp. 581-587, (2011); Clarke G., Cryan J.F., Dinan T.G., Quigley E.M., Review article: Probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria, Aliment Pharmacol Ther, 35, pp. 403-413, (2012); Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Et al., A systematic review and meta-analysis: Probiotics in the treatment of irritable bowel syndrome, BMC Gastroenterol, 9, (2009); McFarland L.V., Dublin S., Meta-analysis of probiotics for the treatment of irritable bowel syndrome, World J Gastroenterol, 14, pp. 2650-2661, (2008); Ortiz-Lucas M., Tobias A., Saz P., Sebastian J.J., Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis, Rev Esp Enferm Dig, 105, pp. 19-36, (2013); Niedzielin K., Kordecki H., Birkenfeld B., A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, European Journal of Gastroenterology and Hepatology, 13, 10, pp. 1143-1147, (2001); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Nobaek S., Johansson M.-L., Molin G., Ahrne S., Jeppsson B., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, American Journal of Gastroenterology, 95, 5, pp. 1231-1238, (2000); Niv E., Naftali T., Hallak R., Vaisman N., The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - A double blind, placebo-controlled, randomized study, Clinical Nutrition, 24, 6, pp. 925-931, (2005); Bixquert Jimenez M., Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?, Rev Esp Enferm Dig, 101, pp. 553-564, (2009); Verdu E.F., Bercik P., Bergonzelli G.E., Huang X.-X., Blennerhasset P., Rochat F., Fiaux M., Mansourian R., Corthesy-Theulaz I., Collins S.M., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, 3, pp. 826-837, (2004); Distrutti E., Cipriani S., Mencarelli A., Renga B., Fiorucci S., Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome, PLoS ONE, 8, (2013); Fu Y., Wang W., Tong J., Pan Q., Long Y., Et al., Th17: A New Participant in Gut Dysfunction in Mice Infected with Trichinella spiralis, Mediators of Inflammation, 2009, pp. 1-7, (2009); Long Y., Wang W., Wang H., Hao L., Qian W., Et al., Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome, J Gastroenterol Hepatol, 27, pp. 935-944, (2012); Castro G.A., Fairbairn D., Carbohydrates and lipids in Trichinella spiralis larvae and their utilization in vitro, J Parasitol, 55, pp. 51-58, (1969); Wolvekamp M.C., De Bruin R.W., Diamine oxidase: An overview of historical, biochemical and functional aspects, Dig Dis, 12, pp. 2-14, (1994); Nakayama M., Yajima M., Hatano S., Yajima T., Kuwata T., Intestinal adherent bacteria and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infection, Pediatric Research, 54, 3, pp. 364-371, (2003); Ewaschuk J.B., Naylor J.M., Palmer R., Whiting S.J., Zello G.A., D-lactate production and excretion in diarrheic calves, Journal of Veterinary Internal Medicine, 18, 5, pp. 744-747, (2004); Anderson J.M., Van Itallie C.M., Tight junctions and the molecular basis for regulation of paracellular permeability, Am J Physiol, 269, (1995); Jones III R.C.W., Otsuka E., Wagstrom E., Jensen C.S., Price M.P., Gebhart G.F., Short-Term Sensitization of Colon Mechanoreceptors Is Associated With Long-Term Hypersensitivity to Colon Distention in the Mouse, Gastroenterology, 133, 1, pp. 184-194, (2007); Li J.-Y., Lu Y., Hu S., Sun D., Yao Y.-M., Preventive effect of glutamine on intestinal barrier dysfunction induced by severe trauma, World Journal of Gastroenterology, 8, 1, pp. 168-171, (2002); Brandt R.B., Siegel S.A., Waters M.G., Bloch M.H., Spectrophotometric assay for D-(-)-lactate in plasma, Analytical Biochemistry, 102, 1, pp. 39-46, (1980); Singh N., Arioli S., Wang A., Villa C.R., Jahani R., Et al., Impact of Bifidobacterium bifidum MIMBb75 on mouse intestinal microorganisms, FEMS Microbiol Ecol, 85, pp. 369-375, (2013); Matsuki T., Pedron T., Regnault B., Mulet C., Hara T., Et al., Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breve, PLoS ONE, 8, (2013); Fanning S., Hall L.J., Cronin M., Zomer A., MacSharry J., Et al., Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection, Proc Natl Acad Sci U S a, 109, pp. 2108-2113, (2012); Brenner D.M., Chey W.D., Bifidobacterium infantis 35624: A novel probiotic for the treatment of irritable bowel syndrome, Rev Gastroenterol Disord, 9, pp. 7-15, (2009); Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C.-H., Matuchansky C., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial, Alimentary Pharmacology and Therapeutics, 26, 3, pp. 475-486, (2007); Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley E.M.M., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, American Journal of Gastroenterology, 101, 7, pp. 1581-1590, (2006); Vanderhoof J.A., Probiotics: Future directions, Am J Clin Nutr, 73, (2001); Martens U., Enck P., Zieseniss E., Probiotic treatment of irritable bowel syndrome in children, Ger Med Sci, 8, (2010); Enck P., Zimmermann K., Menke G., Muller-Lissner S., Martens U., Et al., A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians, Neurogastroenterol Motil, 20, pp. 1103-1109, (2008); Kim H.J., Vazquez R.M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Guandalini S., Magazzu G., Chiaro A., La Balestra V., Di Nardo G., Et al., VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study, J Pediatr Gastroenterol Nutr, 51, pp. 24-30, (2010); Michail S., Kenche H., Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome, Probiotics Antimicrob Proteins, 3, pp. 1-7, (2011); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003)^^^Public Library of Science^^^^^^19326203^^POLNC^24595218.0^English^PLoS ONE^Article^Final^All Open Access; Gold Open Access; Green Open Access^Scopus^2-s2.0-84896918001
Dai C.; Guandalini S.; Zhao D.-H.; Jiang M.^Dai, Cong (53663341300); Guandalini, Stefano (7006380751); Zhao, De-Hui (55475700100); Jiang, Min (34971185300)^53663341300; 7006380751; 55475700100; 34971185300^Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: A possible action through nitric oxide pathway and enhance barrier function^2012^Molecular and Cellular Biochemistry^362.0^1-2^^43^53^10.0^57^10.1007/s11010-011-1126-5^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857062675&doi=10.1007%2fs11010-011-1126-5&partnerID=40&md5=cc5de969fa95df8ea5dfd2abc10e3959^Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; Section of Gastroenterology, Celiac Disease Center, University of Chicago Comer Children's Hospital, Chicago, United States^Dai C., Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; Guandalini S., Section of Gastroenterology, Celiac Disease Center, University of Chicago Comer Children's Hospital, Chicago, United States; Zhao D.-H., Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; Jiang M., Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China^Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by visceral hypersensitivity and altered bowel function. There are increasing evidences suggested that VSL#3 probiotics therapy has been recognized as an effective method to relieve IBS-induced symptoms. The aim of this study was to examine the effects of VSL#3 probiotics on visceral hypersensitivity (VH), nitric oxide (NO), fecal character, colonic epithelium permeability, and tight junction protein expression. IBS model was induced by intracolonic instillation of 4% acetic acid and restraint stress in rats. After subsidence of inflammation on the seventh experimental day, the rats were subjected to rectal distension, and then the abdominal withdrawal reflex and the number of fecal output were measured, respectively. Also, colonic permeability to Evans blue was measured in vivo, and tight junction protein expression was studied by immunohistochemistry and immunoblotting method. Rats had been pretreated with VSL#3 or aminoguanidine (NOS inhibitor) or VSL#3? aminoguanidine before measurements. The rats at placebo group showed hypersensitive response to rectal distension (P<0.05) and defecated more stools than control rats (P<0.05), whereas VSL#3 treatment significantly attenuated VH and effectively reduced defecation. Aminoguanidine reduced the protective effects of VSL#3 on VH. A pronounced increase in epithelial permeability and decreased expression of tight junction proteins (occludin, ZO-1) in placebo group were prevented by VSL#3, but not aminoguanidine. VSL#3 treatment reduce the hypersensitivity, defecation, colonic permeability and increase the expression of tight junction proteins (occludin, ZO-1). As the part of this effect was lowered by NOS inhibitor, NO might play a role in the protective effect of VSL#3 to some extent. © 2011 Springer Science+Business Media, LLC.^Intestinal barrier; Irritable bowel syndrome; Nitric oxide; Probiotic; Tight junction; Visceral hypersensitivity; VSL#3^Animals; Biological Transport; Colon; Defecation; Guanidines; Intestinal Mucosa; Irritable Bowel Syndrome; Male; Membrane Proteins; Nitric Oxide; Pain Management; Permeability; Phosphoproteins; Probiotics; Rats; Rats, Wistar; Tight Junctions; Rattus; Rattus; aminoguanidine; nitric oxide; occludin; protein ZO1; VSL3; acetic acid; aminoguanidine; Evans blue; nitric oxide; occludin; placebo; protein ZO1; VSL3; analgesic activity; animal cell; animal experiment; animal model; animal tissue; antinociception; article; colon dilatation; colon mucosa; controlled study; drug effect; drug efficacy; drug inhibition; feces analysis; immobilization stress; immunoblotting; immunohistochemistry; in vivo study; intestine mucosa permeability; irritable colon; male; nonhuman; protein expression; rat; rectal distension; tight junction; treatment response; visceral hypersensitivity; visceral pain; defecation; experimental animal; hypersensitivity reaction; inflammation; intestine distension; irritable colon; withdrawal reflex^^aminoguanidine, 1068-42-4, 2582-30-1, 79-17-4; nitric oxide, 10102-43-9; occludin, 176304-61-3; Evans blue, 314-13-6; acetic acid, 127-08-2, 127-09-3, 64-19-7, 71-50-1; Guanidines, ; Membrane Proteins, ; Nitric Oxide, 10102-43-9; Phosphoproteins, ; occludin, ; pimagedine, 79-17-4; zonula occludens-1 protein, ^^^^^Quigley E.M.M., Flourie B., Probiotics and irritable bowel syndrome: A rationale for their use and an assessment of the evidence to date, Neurogastroenterology and Motility, 19, 3, pp. 166-172, (2007); McCarthy J., O'Mahony L., O'Callaghan L., Sheil B., Vaughan E.E., Fitzsimons N., Fitzgibbon J., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance, Gut, 52, 7, pp. 975-980, (2003); O'Mahony L., Mccarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M.M., Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, 3, pp. 541-551, (2005); Verdu E.F., Bercik P., Verma-Gandhu M., Huang X.-X., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins S.M., Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice, Gut, 55, 2, pp. 182-190, (2006); Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T.R., Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial, Lancet, 354, 9179, pp. 635-639, (1999); Gionchetti P., Rizzello F., Venturi A., Campieri M., Probiotics in infective diarrhoea and inflammatory bowel diseases, Journal of Gastroenterology and Hepatology, 15, 5, pp. 489-493, (2000); Sullivan A., Nord C.E., Probiotics and gastrointestinal diseases, Journal of Internal Medicine, 257, 1, pp. 78-92, (2005); Lamine F., Fioramonti J., Bueno L., Nepveu F., Cauquil E., Lobysheva I., Eutamene H., Theodorou V., Nitric Oxide Released by Lactobacillus farciminis Improves TNBS-induced Colitis in Rats, Scandinavian Journal of Gastroenterology, 39, 1, pp. 37-45, (2004); Isolauri E., Majamaa H., Arvola T., Rantala I., Virtanen E., Arvilommi H., Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats, Gastroenterology, 105, 6, pp. 1643-1650, (1993); Salminen S., Clinical uses of probiotics for stabilizing the gut mucosal barrier: Successful strains and future challenges, Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology, 70, 2-4, pp. 347-358, (1996); Lu L., Walker W.A., Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium, American Journal of Clinical Nutrition, 73, 6, (2001); Resta-Lenert S., Barrett K.E., Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC), Gut, 52, 7, pp. 988-997, (2003); Montalto M., Maggiano N., Ricci R., Curigliano V., Santoro L., Di Nicuolo F., Vecchio F.M., Gasbarrini A., Gasbarrini G., Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells, Digestion, 69, 4, pp. 225-228, (2004); Gaudier E., Michel C., Segain J.-P., Cherbut C., Hoebler C., The VSL# 3 probiotic mixture modifies microflora but does not heal chronic dextran-sodium sulfate-induced colitis or reinforce the mucus barrier in mice, Journal of Nutrition, 135, 12, pp. 2753-2761, (2005); Mennigen R., Nolte K., Rijcken E., Utech M., Loeffler B., Senninger N., Bruewer M., Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis, Am J Physiol Gastrointest Liver Physiol, 296, 5, (2009); Kim H.J., Camilleri M., McKinzie S., Lempke M.B., Burton D.D., Thomforde G.M., Zinsmeister A.R., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 17, 7, pp. 895-904, (2003); Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., Burton D.D., Baxter K., Thomforde G., Zinsmeister A.R., A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterology and Motility, 17, 5, pp. 687-696, (2005); Guandalini S., Magazzu G., Chiaro A., La Balestra V., Di Nardo G., Gopalan S., Sibal A., Romano C., Canani R.B., Lionetti P., Setty M., VSL#3 improves symptoms in children with irritable bowel syndrome: A multicenter, randomized, placebo-controlled, double-blind, crossover study, J Pediatr Gastroenterol Nutr, 51, 1, pp. 24-30, (2010); Camilleri M., Heading R.C., Thompson W.G., Consensus report: Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome, Alimentary Pharmacology and Therapeutics, 16, 8, pp. 1407-1430, (2002); Alaradi O., Barkin J.S., Irritable bowel syndrome: Update on pathogenesis and management, Medical Principles and Practice, 11, 1, pp. 2-17, (2002); Frieling T., Functional and inflammatory bowel disorders, Med Klin (Munich), 101, SUPPL. 1, pp. 139-142, (2006); Crentsil V., Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?, Medical Hypotheses, 65, 1, pp. 97-102, (2005); Kuiken S.D., Klooker T.K., Tytgat G.N., Lei A., Boeckxstaens G.E., Possible role of nitric oxide in visceral hypersensitivity in patients with irritable bowel syndrome, Neurogastroenterol Motil, 18, 2, pp. 115-122, (2006); Delvaux M., Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome, Gut, 51, SUPPL. 1, (2002); Coutinho S.V., Urban M.O., Gebhart G.F., Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia, Pain, 78, 1, pp. 59-69, (1998); Coutinho S.V., Gebhart G.F., A role for spinal nitric oxide in mediating visceral hyperalgesia in the rat, Gastroenterology, 116, 6, pp. 1399-1408, (1999); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, American Journal of Gastroenterology, 101, 6, pp. 1295-1298, (2006); Barbara G., Cremon C., Pallotti F., De Giorgio R., Stanghellini V., Corinaldesi R., Postinfectious irritable bowel syndrome, J Pediatr Gastroenterol Nutr, 48, SUPPL. 2, (2009); Fanning A.S., Jameson B.J., Jesaitis L.A., Anderson J.M., The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton, Journal of Biological Chemistry, 273, 45, pp. 29745-29753, (1998); Gonzalez-Mariscal L., Betanzos A., Nava P., Jaramillo B.E., Tight junction proteins, Progress in Biophysics and Molecular Biology, 81, 1, pp. 1-44, (2003); Brookes S.J.H., Classes of enteric nerve cells in the guinea-pig small intestine, Anatomical Record, 262, 1, pp. 58-70, (2001); La Kim J.H.T.W., Sung T.S., Kang J.W., Kim H.J., Yang I.S., Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis, World J Gastroenterol, 9, 12, pp. 2791-2795, (2003); Al-Chaer E.D., Kawasaki M., Pasricha P.J., A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development, Gastroenterology, 119, 5, pp. 1276-1285, (2000); Kitajima S., Takuma S., Morimoto M., Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium, Experimental Animals, 48, 3, pp. 137-143, (1999); Ukena S.N., Singh A., Dringenberg U., Engelhardt R., Seidler U., Hansen W., Bleich A., Bruder D., Franzke A., Rogler G., Suerbaum S., Buer J., Gunzer F., Westendorf A.M., Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity, PLoS One, 2, 12, (2007); Kreiss C., Toegel S., Bauer A.J., α<sub>2</sub>-adrenergic regulation of NO production alters postoperative intestinal smooth muscle dysfunction in rodents, American Journal of Physiology - Gastrointestinal and Liver Physiology, 287, 3, (2004); Hierholzer C., Kalff J.C., Billiar T.R., Bauer A.J., Tweardy D.J., Harbrecht B.G., Induced nitric oxide promotes intestinal inflammation following hemorrhagic shock, American Journal of Physiology - Gastrointestinal and Liver Physiology, 286, 2, (2004); Garthwaite J., Charles S.L., Chess-Williams R., Endothelium- derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain, Nature, 336, 6197, pp. 385-388, (1988); Fritz E., Hammer J., Schmidt B., Eherer A.J., Hammer H.F., Stimulation of the Nitric Oxide-Guanosine 3′, 5′-Cyclic Monophosphate Pathway by Sildenafil: Effect on Rectal Muscle Tone, Distensibility, and Perception in Health and in Irritable Bowel Syndrome, American Journal of Gastroenterology, 98, 10, pp. 2253-2260, (2003); Kuiken S.D., Vergeer M., Heisterkamp S.H., Tytgat G.N.J., Boeckxstaens G.E.E., Role of nitric oxide in gastric motor and sensory functions in healthy subjects, Gut, 51, 2, pp. 212-218, (2002); Rodella L., Rezzani R., Agostini C., Bianchi R., Induction of NADPH-diaphorase activity in the rat periaqueductal gray matter after nociceptive visceral stimulation, Brain Research, 793, 1-2, pp. 333-336, (1998); Vizzard M.A., Erdman S.L., De Groat W.C., Increased expression of neuronal nitric oxide synthase (NOS) in visceral neurons after nerve injury, J Neurosci, 15, 5 PART 2, pp. 4033-4045, (1995); Bonaz B., Visceral sensitivity perturbation integration in the brain-gut axis in functional digestive disorders, J Physiol Pharmacol, 54, SUPPL. 4, pp. 27-42, (2003); Fooks L.J., Gibson G.R., Probiotics as modulators of the gut flora, British Journal of Nutrition, 88, SUPPL. 1, (2002); Verdu E.F., Bercik P., Collins S.M., Effect of probiotics on gastrointestinal function: Evidence from animal models, Therap Adv Gastroenterol, 2, 4, pp. 31-35, (2009); Matsuo K., Zhang X., Ono Y., Nagatomi R., Acute stressinduced colonic tissue HSP70 expression requires commensal bacterial components and intrinsic glucocorticoid, Brain Behav Immun, 23, 1, pp. 108-115, (2009)^M. Jiang; Department of Gastroenterology, First Affiliated Hospital, Medical University, Shenyang City, Liaoning Province, China; email: congdai2006@126.com^^Kluwer Academic Publishers^^^^^^03008177^^MCBIB^22020749.0^English^Mol. Cell. Biochem.^Article^Final^^Scopus^2-s2.0-84857062675
Zeng J.; Li Y.-Q.; Zuo X.-L.; Zhen Y.-B.; Yang J.; Liu C.-H.^Zeng, J. (58337271600); Li, Y.-Q. (57210136710); Zuo, X.-L. (13908131900); Zhen, Y.-B. (24391635600); Yang, J. (58372820400); Liu, C.-H. (7409787404)^58337271600; 57210136710; 13908131900; 24391635600; 58372820400; 7409787404^Clinical trial: Effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome^2008^Alimentary Pharmacology and Therapeutics^28.0^8^^994^1002^8.0^171^10.1111/j.1365-2036.2008.03818.x^https://www.scopus.com/inward/record.uri?eid=2-s2.0-52149114013&doi=10.1111%2fj.1365-2036.2008.03818.x&partnerID=40&md5=320ccc4954080106b25448d38fb3cdc4^Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Center of Medical Molecular Biology, Shandong University School of Medicine, Jinan, Shandong Province, China; Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province 250012, No. 107, Wenhua Xi Road, China^Zeng J., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Li Y.-Q., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China, Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province 250012, No. 107, Wenhua Xi Road, China; Zuo X.-L., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Zhen Y.-B., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Yang J., Department of Gastroenterology, Qilu Hospital, Shandong University School of Medicine, Jinan, Shandong Province, China; Liu C.-H., Center of Medical Molecular Biology, Shandong University School of Medicine, Jinan, Shandong Province, China^Background: The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS). Aim: To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS. Methods: Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment. Results: Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics treatment, small bowel permeability decreased significantly from 0.038 (0.024) at baseline to 0.023 (0.020) (P = 0.004), the proportion of patients with increased small bowel permeability was lower than baseline (28.6% vs. 64.3%, P = 0.023). However, colonic permeability improved neither in the probiotics group nor in the placebo group at week 4. Treatment with probiotics significantly decreased the mean global IBS scores compared with the baseline scores (9.62 ± 1.05 vs. 7.64 ± 1.24, P < 0.001). Conclusion: Short-term active lactic acid bacteria treatment for D-IBS improved mucosal barrier function. © 2008 The Authors.^^Adult; Bifidobacterium; Diarrhea; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Lactobacillus; Male; Middle Aged; Mucous Membrane; Probiotics; Single-Blind Method; Streptococcus thermophilus; ab100 jianneng; dudu; lactulose; placebo; probiotic agent; sucralose; unclassified drug; article; beverage; Bifidobacterium longum; clinical article; clinical trial; controlled clinical trial; controlled study; diarrhea; fermented product; human; intestine mucosa; intestine mucosa permeability; irritable colon; lactic acid bacterium; Lactobacillus acidophilus; lactobacillus bulgaricus; milk; nonhuman; priority journal; randomized controlled trial; scoring system; single blind procedure; small intestine; Streptococcus thermophilus; symptomatology; treatment response^^lactulose, 4618-18-2; sucralose, 56038-13-2^ab100 jianneng, Bright Dairy, China; dudu, Bright Dairy, China^Bright Dairy, China; Bright Dairy, China^^^Spiller R.C., Jenkins D., Thornley J.P., Et al., Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome, Gut, 47, pp. 804-11, (2000); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-94, (2006); Marshall J.K., Thabane M., Garg A.X., Et al., Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario, Aliment Pharmacol Ther, 20, pp. 1317-22, (2004); Barbara G., Mucosal barrier defects in irritable bowel syndrome. Who left the door open?, Am J Gastroenterol, 101, pp. 1295-8, (2006); Chadwick V.S., Chen W., Shu D., Et al., Activation of the mucosal immune system in irritable bowel syndrome, Gastroenterology, 122, pp. 1178-83, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Tornblom H., Lindberg G., Nyberg B., Veress B., Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome, Gastroenterology, 123, pp. 1972-9, (2002); Dunlop S.P., Jenkins D., Spiller R.C., Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS, Gastroenterology, 122, (2002); Barbara G., Stanghellini V., De Giorgio R., Et al., Functional gastrointestinal disorders and mast cells: Implications for therapy, Neurogastroenterol Motil, 18, pp. 6-17, (2006); Denker B.M., Nigam S.K., Molecular structure and assembly of the tight junction, Am J Physiol, 274, (1998); Stevenson B.R., Understanding tight junction clinical physiology at the molecular level, J Clin Invest, 104, pp. 3-4, (1999); Dunlop S.P., Jenkins D., Neal K.R., Et al., Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome, Aliment Pharmacol Ther, 18, pp. 77-84, (2003); Lilly D.M., Stillwell R.H., Probiotics: Growth promoting factors produced by microorganisms, Science, 147, pp. 747-8, (1965); Gill H.S., Guarner F., Probiotics and human health: A clinical perspective, Postgrad Med J, 80, pp. 516-26, (2004); Rolfe R.D., The role of probiotic cultures in the control of gastrointestinal health, J Nutr, 130, (2000); Borowiec A.M., Fedorak R.N., The role of probiotics in management of irritable bowel syndrome, Curr Gastroenterol Rep, 9, pp. 393-400, (2007); Kim H.J., Camilleri M., McKinzie S., Et al., A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 17, pp. 895-904, (2003); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-51, (2005); Guyonnet D., Chassany O., Ducrotte P., Et al., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial, Aliment Pharmacol Ther, 26, pp. 475-86, (2007); Kajander K., Myllyluoma E., Rajilic-Stojanovic M., Et al., Clinical trial: Multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota, Aliment Pharmacol Ther, 27, pp. 48-57, (2008); Svedlund J., Sjodin I., Dotevall G., GSRS - A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease, Dig Dis Sci, 33, pp. 129-34, (1988); Smecuol E., Bai J.C., Sugai E., Et al., Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs, Gut, 49, pp. 650-5, (2001); Celli M., D'Eufemia P., Dommarco R., Et al., Rapid gas-chromatographic assay of lactulose and mannitol for estimating intestinal permeability, Clin Chem, 41, pp. 752-6, (1995); Farhadi A., Keshavarzian A., Holmes E.W., Fields J., Zhang L., Banan A., Gas chromatographic method for detection of urinary sucralose: Application to the assessment of intestinal permeability, J Chromatogr B Analyt Technol Biomed Life Sci, 784, pp. 145-54, (2003); Abe T., Sugano E., Saigo Y., Tamai M., Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): Aberrant expression of junctional complex molecules, Invest Ophthalmol Vis Sci, 44, pp. 4097-104, (2003); Galante N.Z., Camara N.O., Kallas E.G., Salomao R., Pacheco-Silva A., Medina-Pestana J.O., Noninvasive immune monitoring assessed by flow cytometry and real time RT-PCR in urine of renal transplantation recipients, Transpl Immunol, 16, pp. 73-80, (2006); Kennedy R.J., The Effect of Lactobacillus Plantarum Species 299 on Intestinal Inflammation and Associated Gut Mucosal Barrier Dysfunction., (2000); Madsen K., Cornish A., Soper P., Et al., Probiotic bacteria enhance murine and human intestinal epithelial barrier function, Gastroenterology, 121, pp. 580-91, (2001); Furrie E., Is Bifidobacterium a more effective probiotic therapy than Lactobacillus for patients with irritable bowel syndrome?, Nat Clin Pract Gastroenterol Hepatol, 2, pp. 304-5, (2005); Luyer M.D., Buurman W.A., Hadfoune M., Et al., Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock, Infect Immun, 73, pp. 3686-92, (2005); Jain P.K., McNaught C.E., Anderson A.D., MacFie J., Mitchell C.J., Influence of symbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: A randomized controlled trial, Clin Nutr, 23, pp. 467-75, (2004); McNaught C.E., Woodcock N.P., Anderson A.D., MacFie J., A prospective randomized trial of probiotics in critically ill patients, Clin Nutr, 24, pp. 211-9, (2005); Caballero-Franco C., Keller K., De Simone C., Chadee K., The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells, Am J Physiol Gastrointest Liver Physiol, 292, (2007); MacK D.R., Ahrne S., Hyde L., Wei S., Hollingsworth M.A., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro, Gut, 52, pp. 827-33, (2003); Zyrek A.A., Cichon C., Helms S., Enders C., Sonnenborn U., Schmidt M.A., Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair, Cell Microbiol, 9, pp. 804-16, (2007); Ukena S.N., Singh A., Dringenberg U., Et al., Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity, PLoS ONE, 2, (2007); Hebden J.M., Erah P.O., Blackshaw P.E., Perkins A.C., Spiller R.C., Increased small bowel but not colonic permeability in post-infectious irritable bowel syndrome, Gastroenterology, 114, (1998); Gassler N., Rohr C., Schneider A., Et al., Inflammatory bowel disease is associated with changes of enterocytic junctions, Am J Physiol Gastrointest Liver Physiol, 281, (2001)^Y.-Q. Li; Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong Province 250012, No. 107, Wenhua Xi Road, China; email: liyanqing@sdu.edu.cn^^^^^^^^13652036^^APTHE^18671775.0^English^Aliment. Pharmacol. Ther.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-52149114013
Agostini S.; Goubern M.; Tondereau V.; Salvador-Cartier C.; Bezirard V.; Lévèque M.; Keränen H.; Theodorou V.; Bourdu-Naturel S.; Goupil-Feuillerat N.; Legrain-Raspaud S.; Eutamene H.^Agostini, S. (9244386700); Goubern, M. (7004069256); Tondereau, V. (8399121800); Salvador-Cartier, C. (8399122000); Bezirard, V. (8935204200); Lévèque, M. (16047756000); Keränen, H. (57224298846); Theodorou, V. (55410684700); Bourdu-Naturel, S. (26425020400); Goupil-Feuillerat, N. (6507037312); Legrain-Raspaud, S. (26534380300); Eutamene, H. (55926684800)^9244386700; 7004069256; 8399121800; 8399122000; 8935204200; 16047756000; 57224298846; 55410684700; 26425020400; 6507037312; 26534380300; 55926684800^A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats^2012^Neurogastroenterology and Motility^24.0^4^^376^e172^-204.0^91^10.1111/j.1365-2982.2011.01865.x^https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858290900&doi=10.1111%2fj.1365-2982.2011.01865.x&partnerID=40&md5=ed6d82de1a136b405ca0468db04e2441^Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Danone Research Centre Carasso, Palaiseau, France; Medical Nutrition Physiology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland^Agostini S., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Goubern M., Danone Research Centre Carasso, Palaiseau, France; Tondereau V., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Salvador-Cartier C., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Bezirard V., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Lévèque M., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Keränen H., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France, Medical Nutrition Physiology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland; Theodorou V., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France; Bourdu-Naturel S., Danone Research Centre Carasso, Palaiseau, France; Goupil-Feuillerat N., Danone Research Centre Carasso, Palaiseau, France; Legrain-Raspaud S., Danone Research Centre Carasso, Palaiseau, France; Eutamene H., Neuro-Gastroenterology and Nutrition Unit, Toxalim, UMR 1331, Toulouse, France^Background Fermented milk (FM) containing Bifidobacterium lactis CNCM I-2494 and yogurt strains improves irritable bowel syndrome (IBS) symptoms in constipated IBS patients. In rats, stressful events exacerbate IBS symptoms and result in the alteration of gut sensitivity and permeability via epithelial cell cytoskeleton contraction. In a stress model, we aimed at evaluating the effect of B. lactis CNCM I-2494 as a pure strain or contained in an FM product on visceral sensitivity and the impact of this FM on intestinal barrier integrity. Methods Visceral sensitivity was analyzed in rats subjected to partial restraint stress (PRS). Rats received during 15days the B. lactis as a pure strain (10 6 to 10 10CFUmL -1), B. lactis in an FM product (10 8CFUg -1, diluted or not), or a control product. Gut paracellular permeability, colonic occluding and Jam-A proteins, and blood endotoxin levels were determined in rats receiving B. lactis in an FM product submitted or not to a PRS. Key Results The FM product showed a dose-dependent inhibitory effect on stress-induced visceral hypersensitivity. A similar antihyperalgesic effect was observed at 10 10CFUmL -1 of pure B. lactis administration. The FM product prevented the increase in intestinal permeability induced by PRS and restored occludin and JAM-A expressions to control levels. The FM product abolished the increase concentration of blood endotoxin induced by PRS. Conclusions & Inferences This study illustrates that a probiotic food containing B. lactis CNCM I-2494 strain reduces visceral hypersensitivity associated with acute stress by normalizing intestinal epithelial barrier via a synergistic interplay with the different probiotic strains and/or metabolites contained in this product. © 2012 Blackwell Publishing Ltd.^Fermented milk; Gut barrier; Irritable bowel syndrome; Pain; Probiotics^Animals; Bifidobacterium; Colon; Cultured Milk Products; Disease Models, Animal; Female; Hyperesthesia; Immobilization; Intestinal Mucosa; Irritable Bowel Syndrome; Pain Threshold; Probiotics; Rats; Rats, Wistar; Stress, Psychological; endotoxin; junctional adhesion molecule A; occludin; probiotic agent; acute stress; analgesia; animal cell; animal experiment; animal tissue; article; bacterial strain; Bifidobacterium animalis; colony forming unit; controlled study; dairy product; dose response; female; fermented product; hyperalgesia; immobilization stress; intestinal dysmotility; intestine mucosa permeability; nonhuman; permeability barrier; priority journal; protein expression; rat^^occludin, 176304-61-3^^^^^Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006); Whitehead W.E., Psychosocial aspects of functional gastrointestinal disorders, Gastroenterol Clin North Am, 25, pp. 21-34, (1996); Piche T., Barbara G., Aubert P., Et al., Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators, Gut, 58, pp. 196-201, (2009); Zhou Q., Zhang B., Verne G.N., Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome, Pain, 146, pp. 41-46, (2009); Dunlop S.P., Hebden J., Campbell E., Et al., Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes, Am J Gastroenterol, 101, pp. 1288-1294, (2006); Ait-Belgnaoui A., Bradesi S., Fioramonti J., Theodorou V., Bueno L., Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase, Pain, 113, pp. 141-147, (2005); Tsukita S., Furuse M., Itoh M., Structural and signalling molecules come together at tight junctions, Curr Opin Cell Biol, 11, pp. 628-633, (1999); Nusrat A., Turner J.R., Madara J.L., Molecular physiology and pathophysiology of tight junctions IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells, Am J Physiol Gastrointest Liver Physiol, 279, (2000); Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003); Shanahan F., Irritable bowel syndrome: shifting the focus toward the gut microbiota, Gastroenterology, 133, pp. 340-342, (2007); Rhee S.H., Pothoulakis C., Mayer E.A., Principles and clinical implications of the brain-gut-enteric microbiota axis, Nat Rev Gastroenterol Hepatol, 6, pp. 306-314, (2009); Kassinen A., Krogius-Kurikka L., Makivuokko H., Et al., The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, pp. 24-33, (2007); Spiller R.C., Potential biomarkers, Gastroenterol Clin North Am, 40, pp. 121-139, (2011); Fuller R., Probiotics in human medicine, Gut, 32, pp. 439-442, (1991); Mack D.R., Lebel S., Role of probiotics in the modulation of intestinal infections and inflammation, Curr Opin Gastroenterol, 20, pp. 22-26, (2004); Gionchetti P., Rizzello F., Helwig U., Et al., Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial, Gastroenterology, 124, pp. 1202-1209, (2003); Mimura T., Rizzello F., Helwig U., Et al., Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis, Gut, 53, pp. 108-114, (2004); Quigley E.M., Flourie B., Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date, Neurogastroenterol Motil, 19, pp. 166-172, (2007); Parkes G.C., Brostoff J., Whelan K., Sanderson J.D., Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment, Am J Gastroenterol, 103, pp. 1557-1567, (2008); Eutamene H., Lamine F., Chabo C., Et al., Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats, J Nutr, 137, pp. 1901-1907, (2007); O'Mahony L., McCarthy J., Kelly P., Et al., Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles, Gastroenterology, 128, pp. 541-551, (2005); Whorwell P.J., Altringer L., Morel J., Et al., Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol, 101, pp. 1581-1590, (2006); Agrawal A., Houghton L.A., Morris J., Et al., Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 29, pp. 104-114, (2009); Marteau P., Cuillerier E., Meance S., Et al., Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study, Aliment Pharmacol Ther, 16, pp. 587-593, (2002); Guyonnet D., Chassany O., Ducrotte P., Et al., Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial, Aliment Pharmacol Ther, 26, pp. 475-486, (2007); Guyonnet D., Schlumberger A., Mhamdi L., Jakob S., Chassany O., Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study, Br J Nutr, 102, pp. 1654-1662, (2009); Williams C.L., Peterson J.M., Villar R.G., Burks T.F., Corticotropin-releasing factor directly mediates colonic responses to stress, Am J Physiol, 253, (1987); Morteau O., Hachet T., Caussette M., Bueno L., Experimental colitis alters visceromotor response to colorectal distension in awake rats, Dig Dis Sci, 39, pp. 1239-1248, (1994); Bjarnason I., MacPherson A., Hollander D., Intestinal permeability: an overview, Gastroenterology, 108, pp. 1566-1581, (1995); Agrawal A., Houghton L.A., Reilly B., Morris J., Whorwell P.J., Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit, Am J Gastroenterol, 104, pp. 1998-2004, (2009); Houghton L.A., Whorwell P.J., Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders, Neurogastroenterol Motil, 17, pp. 500-511, (2005); Verdu E.F., Bercik P., Bergonzelli G.E., Et al., Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction, Gastroenterology, 127, pp. 826-837, (2004); Kamiya T., Wang L., Forsythe P., Et al., Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats, Gut, 55, pp. 191-196, (2006); Donnet-Hughes A., Rochat F., Serrant P., Aeschlimann J.M., Schiffrin E.J., Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose, J Dairy Sci, 82, pp. 863-869, (1999); Sharp M.D., McMahon D.J., Broadbent J.R., Comparative evaluation of yogurt and low-fat cheddar cheese as delivery media for probiotic Lactobacillus casei, J Food Sci, 73, (2008); Saxelin M., Lassig A., Karjalainen H., Et al., Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese, Int J Food Microbiol, 144, pp. 293-300, (2010); Pochart P., Marteau P., Bouhnik Y., Goderel I., Bourlioux P., Rambaud J.C., Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion, Am J Clin Nutr, 55, pp. 78-80, (1992); Rochet V., Rigottier-Gois L., Ledaire A., Et al., Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults, J Mol Microbiol Biotechnol, 14, pp. 128-136, (2008); Berrada N., Lemeland J.F., Laroche G., Thouvenot P., Piaia M., Bifidobacterium from fermented milks: survival during gastric transit, J Dairy Sci, 74, pp. 409-413, (1991); Resta-Lenert S., Barrett K.E., Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC), Gut, 52, pp. 988-997, (2003); Ferrier L., Mazelin L., Cenac N., Et al., Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice, Gastroenterology, 125, pp. 795-804, (2003); Barbara G., Stanghellini V., De Giorgio R., Et al., Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome, Gastroenterology, 126, pp. 693-702, (2004); Barreau F., Ferrier L., Fioramonti J., Bueno L., Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats, Gut, 53, pp. 501-506, (2004)^H. Eutamene; Toxalim UMR 1331, Neuro-Gastroenterology and Nutrition Group, Toulouse 31027, 180 chemin de Tournefeuille, France; email: heutamen@toulouse.inra.fr^^^^^^^^13652982^^NMOTE^22272920.0^English^Neurogastroenterol. Motil.^Article^Final^^Scopus^2-s2.0-84858290900
Dainese R.; Galliani E.A.; De Lazzari F.; Di Leo V.; Naccarato R.^Dainese, Raffaella (23479438000); Galliani, Ermenegildo A. (35481544600); De Lazzari, Franca (6701728949); Di Leo, Vincenza (6603861235); Naccarato, Remo (36047524800)^23479438000; 35481544600; 6701728949; 6603861235; 36047524800^Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients^1999^American Journal of Gastroenterology^94.0^7^^1892^1897^5.0^129^10.1111/j.1572-0241.1999.01226.x^https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033051598&doi=10.1111%2fj.1572-0241.1999.01226.x&partnerID=40&md5=617eb574a70661ad798fe80cf87685d7^Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy^Dainese R., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; Galliani E.A., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; De Lazzari F., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; Di Leo V., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy; Naccarato R., Gastroenterology Unit, Dept. Surg. Gastroenterological S., Padua, Italy^OBJECTIVE: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with clinical signs typical of 'intestinal' food allergies or intolerance. The aim of this study was to characterize the clinical features of IBS patients suspected of suffering from adverse reactions to food. METHODS: The study involved 128 consecutive IBS patients divided into four groups according to their main symptom on presentation at our outpatient clinic. A detailed medical history was recorded, paying particular attention to any allergies and reported intolerance to food. Each patient was screened for allergies; intestinal permeability tests was performed in randomly selected patients from different groups. Findings were analyzed using the X2 test. RESULTS: Adverse reactions to one or more foods were reported by 80 patients (62.5%); skin prick tests (SPT) were positive in 67 patients (52.3%) with no significant differences between patients complaining of different symptoms. Patients who reported a food intolerance had more positive SPTs than those who did not (47 of 80 [58.7%] vs 20 of 48 [41.7%]); this difference was not statistically significant, although it suggests a trend (p < 0.0610). There was little consistency between the specific foods reported to cause intolerance and those resulting from the tests (11 of 80 patients, 13.7%). The intestinal permeability test was normal in 29 of 33 patients (87.9%). CONCLUSIONS: More than 50% of IBS patients were found sensitized to some food or inhalant without any typical clinical signs. Patients were unable to identify potentially offending foods. The lack of a correlation between SPT results and reported food allergies needs further investigation to clarify the pathophysiology and improve the diagnosis of intestinal food allergies.^^Adolescent; Adult; Aged; Allergens; Colonic Diseases, Functional; Female; Food; Food Hypersensitivity; Humans; Intestinal Absorption; Male; Middle Aged; Sensitivity and Specificity; Skin Tests; adolescent; adult; aged; anamnesis; article; clinical examination; female; food allergy; gastrointestinal symptom; human; irritable colon; major clinical study; male; nutritional intolerance; priority journal; skin test; statistical analysis^^Allergens, ^^^^^Thompson W.G., Symptomatic presentations of the irritable bowel syndrome, Gastroenterol Clin North Am, 20, pp. 235-247, (1991); Thompson W.G., Irritable bowel syndrome: Pathogenesis and management, Lancet, 341, pp. 1569-1572, (1993); Moreno-Osset E., Calvo B., Tomas-Ridocci M., Et al., The irritable bowel syndrome: Diagnostic strategies, Ital J Gastroenterol, 23, SUPPL. 1, pp. 41-47, (1991); Barbara I., Baldi F., Longanesi A., Pathogenesis of irritable bowel syndrome, Ital J Gastroenterol, 23, SUPPL. 1, pp. 36-38, (1991); Addolorato G., Gasbarrini G., Marsigli L., Et al., Irritable bowel syndrome and food allergy: An association via anxiety-depression?, Gastroenterology, 11, pp. 833-834, (1996); Alun Jones V., Shorthouse M., McLaughlan P., Et al., Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome, Lancet, 1, pp. 1115-1117, (1982); Bentley S.J., Pearson D.J., Rix K.J., Food hypersensitivity in irritable bowel syndrome, Lancet, 2, pp. 295-297, (1983); Petitpierre M., Gumowski P., Girard J.P., Irritable bowel syndrome and hypersensitivity to food, Ann Allergy, 54, pp. 538-540, (1985); Zwetchkenbaum J.F., Burakoff R., Food allergy and the irritable bowel syndrome, Am J Gastroenterol, 83, pp. 901-904, (1988); Bayliss C.E., Bradley H.K., Alun Jones V., Et al., Some aspects of colonic microbial activity in irritable bowel syndrome associated with food intolerance, Ann Ist Super Sanita, 22, pp. 959-963, (1986); Hunter J.O., Food allergy or enterometabolic disorder?, Lancet, 338, pp. 495-496, (1991); McKee A.M., Prior A., Whorwell P.J., Exclusion diets in irritable bowel syndrome: Are they worthwhile?, J Clin Gastroenterol, 9, pp. 526-528, (1987); Nanda R., James R., Smith H., Et al., Food intolerance and the irritable bowel syndrome, Gut, 30, pp. 1099-1104, (1989); Schmidt M., Floch M.H., Food hypersensitivity and the irritable bowel syndrome, Am J Gastroenterol, 87, pp. 18-19, (1992); Edwards A.M., Food allergic disease, Clin Exp Allergy, 25, SUPPL. 1, pp. 16-19, (1995); Stefanini G.F., Prati E., Albini M.C., Et al., Oral disodium cromoglycate treatment on irritable bowel syndrome: An open study on 101 subjects with diarrheic type, Am J Gastroenterol, 87, pp. 55-57, (1992); Stefanini G.F., Saggioro A., Alvisi V., Et al., Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type, Scan J Gastroenterol, 30, pp. 535-541, (1995); Bischoff S.C., Mayer J., Wedemeyer J., Et al., Colonoscopic allergen provocation (COLAP): A new diagnosic approach for gastrointestinal food allergy, Gut, 40, pp. 745-753, (1997); Bruijnzeel-Koomen C., Ortolani C., Aas K., Et al., Adverse reactions to food, Allergy, 50, pp. 623-635, (1995); Shanahan F., Food allergy: Fact, fiction, and fatality, Gastroenterology, 104, pp. 1229-1231, (1993); Young E., Stoneham M.D., Petruckevitch A., Et al., A population study of food intolerance, Lancet, 343, pp. 1127-1130, (1994); Bischoff S.C., Herrmann A., Manns M.P., Prevalence of adverse reactions to food in patients with gastrointestinal disease, Allergy, 51, pp. 811-818, (1996); Talley N.J., Zinsmeister A.R., Van Dyke C., Et al., Epidemiology of colonic symptoms and the irritable bowel syndrome, Gastroenterology, 101, pp. 927-934, (1991); King T.S., Elia M., Hunter J.O., Rapid colonic fermentation associated with symptoms in irritable bowel syndrome is corrected by exclusion diet, Gastroenterology, 112, (1997); Majamaa H., Isolauri E., Probiotics: A novel approach in the management of food allergy, J Allergy Clin Immunol, 1, pp. 1-8, (1997); Farah D.A., Calder I., Benson L., Et al., Specific food intolerance: Its place as a cause of gastrointestinal symptoms, Gut, 26, pp. 164-168, (1985); Gwee K.A., Graham J.C., Mckendrick M.W., Et al., Psychometric scores and persistence of irritable bowel after infectious diarrhoea, Lancet, 347, pp. 150-153, (1996); Farthing M.J.G., Irritable bowel, irritable body, or irritable brain?, BMJ, 310, pp. 171-175, (1995); Aziz Q., Thompson D.G., Brain-gut axis in health and disease, Gastroenterology, 114, pp. 559-578, (1998); Frieling T., Strohmeyer G., Neuroimmune Interaktionen im Gastrointestinaltrakt, Z Gastroenterol, 33, pp. 219-224, (1995); Bjarnason I., Macpherson A., Hollander D., Intestinal permeability: An overview, Gastroenterology, 108, pp. 1556-1581, (1995); Crowe S.E., Perdue M.H., Gastrointestinal food hypersensitivity: Basic mechanism of pathophysiology, Gastroenterology, 103, pp. 1075-1095, (1992); Bischoff S.C., Mucosal allergy: Role of mast cells and eosinophil granulocytes in the gut, Baillières Clin Gastroenterol, 10, pp. 443-459, (1996); Andre C., Andre A., Colin L., Et al., IgE in stools as indicator of food sensitization, Allergy, 50, pp. 328-333, (1995); Bischoff S.C., Grabowsky J., Manns M.P., Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls, Dig Dis Sci, 42, pp. 394-403, (1997); Talley N.J., Butterfield J.H., Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome, Am J Gastroenterol, 91, pp. 1675-1676, (1996); Baentkler H.W., Lux G., Antigen-induced histamine release from duodenal biopsy in gastrointestinal food allergy, Ann Allergy, 62, pp. 449-452, (1989); De Lazzari F., Venturi C., Fregona I., Et al., Ige Specifiche Nella Mucosa Gastrica e Duodenale. Minerva Gastroenterol Dietol, 40, pp. 1-9, (1994); Horauf A.M., Matek M., Raithel M., Et al., Histamine release from human colonic mucosa in response to anti-IgE, Agents Actions, 27, pp. 89-91, (1989); Raithel M., Matek M., Baennkler H.W., Et al., Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy, Int Arch Allergy Immunol, 108, pp. 127-133, (1995)^^^^^^^^^00029270^^AJGAA^10406255.0^English^Am. J. Gastroenterol.^Article^Final^^Scopus^2-s2.0-0033051598
Barau E.; Dupont C.^Barau, Edith (6603210881); Dupont, Christophe (35986193400)^6603210881; 35986193400^Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome^1990^Journal of Pediatric Gastroenterology and Nutrition^11.0^1^^72^77^5.0^64^10.1097/00005176-199007000-00015^https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025371557&doi=10.1097%2f00005176-199007000-00015&partnerID=40&md5=da7248dcf0bbcdf895995286cd6f580c^Hôpital Saint-Vincent de Paul, Paris, France^Barau E., Hôpital Saint-Vincent de Paul, Paris, France; Dupont C., Hôpital Saint-Vincent de Paul, Paris, France^An intestinal permeability test analyzing the differential urinary elimination of lactulose and mannitol orally ingested at the same dosage was carried out first in fasting condition, then combined with specific food ingestion, in 17 children with clinical symptoms of irritable bowel syndrome (IBS). Foods were selected based on a suggestive clinical history or on a positive radioaller-gosorbent or prick test. Comparison of the results with those of a control population reported in a previous study showed that in nine IBS patients, specific food ingestion was associated with a modification of intestinal permeability. The nine children all had a personal and/or familial history of allergy and/or raised total IgE. The symptoms disappeared in the nine patients after food exclusion either alone (seven patients) or together with further treatment by cromolyn (two patients). We conclude that, at least in some children, symptoms of IBS may be related to food hypersensitivity. © 1990 Raven Press, Ltd., New York.^Food allergy; Intestinal permeability; Irritable bowel syndrome^Adolescent; Child; Child, Preschool; Colonic Diseases, Functional; Diet; Female; Food Hypersensitivity; Human; Intestinal Absorption; Lactulose; Male; Mannitol; lactulose; mannitol; article; child; clinical article; female; food; food allergy; human; intestine absorption; intestine function; intestine mucosa permeability; male; oral drug administration; priority journal; urinary excretion^^Lactulose, 4618-18-2; Mannitol, 69-65-8^duphalac, duphar, France^duphar, France^^^Dupont C., Barau E., Molkhou P., Barbet J.P., Dehennin L., Food-induced alterations of intestinal permeability in children with cow’s milk sensitive enteropathy and atopic dermatitis, J Pediatr Gastroenterol Nutr, 8, pp. 459-465, (1989); Walker-Smith J.A., Ford R.P., Philips A.D., The spectrum of gastrointestinal allergies to food, Ann Allergy, 53, pp. 629-636, (1984); Davidson M., Wasserman R., The irritable colon of childhood (Chronic non specific diarrhea syndrome), J Pediatr, 69, pp. 1027-1038, (1986); Snape W.J., Carlson G.M., Matarazzo S.A., Cohen S., Evidence that abdominal myoelectrical activity produces colonic motor dysfunction in the irritable bowel syndrome, Gastroen-Terology, 72, pp. 383-387, (1977); Cohen S.A., Hendricks K.M., Mathis R.K., Laramee S., Walker W.A., Chronic non specific diarrhea: Dietary relationships, Pediatrics, 64, pp. 402-407, (1979); Ghisolfi J., Olives J.P., Familiades J., Rives J.J., Rives-Tocaven M., Diarchies chroniques des colopathies non spécifiques de l’enfant. Essai de déemembrement étiologique, Arch Fr Pediatr, 40, pp. 531-536, (1983); Chang E.B., Fedorak R.N., Prostaglandins in diarrheal disease, J Pediatr Gastroenterol Nutr, 4, pp. 341-344, (1985); Jonas A., Diver-Haber A., Stool output and composition in the chronic non-specific diarrhoea syndrome, Arch Dis Child, 57, pp. 35-39, (1982); Alun Jones V., Me Laughlan P., Shorthouse M., Workman E., Hunter J.O., Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome, Lancet, 2, pp. 1115-1117, (1982); Bentley S.J., Pearson D.J., Rix K.G., Food hypersensitivity in irritable bowel syndrome, Lancet, 2, pp. 295-297, (1983); Petitpierre M., Gumowski P., Girard J.P., Irritable bowel syndrome and hypersensitivity to food, Ann Allergy, 54, pp. 538-540, (1985); Savilahti E., Simell O., Chronic non-specific diarrhoea, Arch Dis Child, 60, pp. 452-456, (1985); Cohen S.A., Hendricks K.M., Eastham E.J., Mathis R.K., Walker W.A., Chronic nonspecific diarrhea. A complication of dietary fat restriction, Am J Dis Child, 133, pp. 490-492, (1979); Lloyd-Still J.D., Chronic diarrhea of childhood and the misuse of elimination diets, J Pediatr, 95, pp. 10-13, (1979); Juby L.D., Rothwell J., Axon A., Lactulose/mannitol test: An ideal screen for celiac disease, Gastroenterology, 96, pp. 79-85, (1989); Dupont C., Dehennin L., Navarro J., Canlorbe P., Identification des syndromes de malabsorption par mesure de la per-m£abilit£ intestinale. Son application k la maladie coeliaque de l’enfant, Presse Med, 16, pp. 777-778, (1987); Fenton T.R., The irritable bowel syndrome: A paediatric entity, Disorders of Gastrointestinal Motility in Childhood, pp. 101-109, (1988)^^^^^^^^^02772116^^^2117653.0^English^J. Pediatr. Gastroenterol. Nutr.^Article^Final^All Open Access; Bronze Open Access^Scopus^2-s2.0-0025371557
Strobel S.; Brydon W.G.; Ferguson A.^Strobel, S. (57208158895); Brydon, W.G. (57201271435); Ferguson, A. (16050168700)^57208158895; 57201271435; 16050168700^Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum^1984^Gut^25.0^11^^1241^1246^5.0^111^10.1136/gut.25.11.1241^https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021723161&doi=10.1136%2fgut.25.11.1241&partnerID=40&md5=b6043f3fffabff2b86d25605b8b1cf3e^United Kingdom^Strobel S., United Kingdom; Brydon W.G., United Kingdom; Ferguson A., United Kingdom^Intestinal permeability to probe molecules has been shown to correlate closely with the presence or absence of villous atrophy in a jejunal biopsy. The purpose of this study was to establish if there exist groups of patients with functional derangement of intestinal permeability but normal histopathology of the small bowel mucosa. In 135 patients a cellobiose/mannitol permeability test was performed at the same time as jejunal biopsy. Diagnosis included coeliac disease, Crohn's disease, irritable bowel syndrome, idiopathic diarrhoea, self diagnosed food allergy, atrophic eczema and postinfectious malabsorption. The value of the cellobiose/mannitol test in identifying patients with abnormal jejunal biopsy histopathology was confirmed. The permeability test was abnormal in all 28 patients with partial or subtotal villous atrophy, and also in all 10 in whom there was a high intraepithelial lymphocyte count despite normal villi and crypts. Functional abnormality of the small intestine has not previously been reported in patients with this jejunal biopsy abnormality. Abnormalities of permeability were also found in patients with idiopathic diarrhoea, folate deficiency, postinfectious or traveller's diarrhoea, small bowel Crohn's disease, and atopic eczema. These results show that sugar permeability tests have more potential in clinical investigation that merely serving as screening tests before jejunal biopsy. There are groups of patients without morphological changes in the small bowel in whom intestinal permeability is abnormal.^^biopsy; controlled study; diagnosis; histology; histopathology; human; intestine villus atrophy; jejunum; jejunum biopsy; major clinical study; priority journal; small intestine^^^^^^^^^^^^^^^^00175749^^GUTTA^6437913.0^English^GUT^Article^Final^All Open Access; Bronze Open Access; Green Open Access^Scopus^2-s2.0-0021723161
